disorder_id,orpha_code,name,disorder_type,disorder_group,prevalence_type,prevalence_qualification,prevalence_class,val_moy,prevalence_geographic,prevalence_validation_status,source
17601,166024,Multiple epiphyseal dysplasia-macrocephaly-facial dysmorphism syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,11389160[PMID]_9689990[PMID]_ [EXPERT]
17601,166024,Multiple epiphyseal dysplasia-macrocephaly-facial dysmorphism syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11389160[PMID]_9689990[PMID]
2,58,Alexander disease,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.037,Japan,Validated,21533827[PMID]_[EXPERT]
2,58,Alexander disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
17603,166032,Multiple epiphyseal dysplasia-miniepiphyses syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,15523498[PMID]
17603,166032,Multiple epiphyseal dysplasia-miniepiphyses syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15523498[PMID]
3,61,Alpha-mannosidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,European Medicines Agency 2005[INST]
3,61,Alpha-mannosidosis,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.09,Australia,Validated,9918480[PMID]
3,61,Alpha-mannosidosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.13,Norway,Not yet validated,7900112[PMID]
3,61,Alpha-mannosidosis,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.09,Netherlands,Validated,10480370[PMID]
3,61,Alpha-mannosidosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.12,Portugal,Validated,14685153[PMID]
3,61,Alpha-mannosidosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.38,Czech Republic,Validated,20490927[PMID]
3,61,Alpha-mannosidosis,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.07,Sweden,Validated,25274184[PMID]
17602,166029,Multiple epiphyseal dysplasia-severe proximal femoral dysplasia syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,15523498[PMID]
17602,166029,Multiple epiphyseal dysplasia-severe proximal femoral dysplasia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15523498[PMID]
17605,166038,"Metaphyseal chondrodysplasia, Kaitila type",Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,6979929[PMID]
17605,166038,"Metaphyseal chondrodysplasia, Kaitila type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6979929[PMID]
5,93,Aspartylglucosaminuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.2,Australia,Validated,9918480[PMID]
5,93,Aspartylglucosaminuria,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
5,93,Aspartylglucosaminuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.62,Sweden,Validated,25274184[PMID]
5,93,Aspartylglucosaminuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.35,Finland,Validated,27906067[PMID]
17604,166035,Brachydactyly-short stature-retinitis pigmentosa syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,7252997[PMID]_28285769[PMID]
17604,166035,Brachydactyly-short stature-retinitis pigmentosa syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7252997[PMID]_28285769[PMID]
6,585,Multiple sulfatase deficiency,Disease,Disorder,Cases/families,Case(s),,154.0,Worldwide,Validated,36980153[PMID]_37732042[PMID]_ORPHANET
6,585,Multiple sulfatase deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2,Worldwide,Validated,33144036[PMID]
7,118,Beta-mannosidosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.14,Europe,Validated,14685153[PMID]_10480370[PMID]_20490927[PMID]
7,118,Beta-mannosidosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.16,Czech Republic,Validated,20490927[PMID]
7,118,Beta-mannosidosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.13,Netherlands,Validated,10480370[PMID]
7,118,Beta-mannosidosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.12,Portugal,Validated,14685153[PMID]
7,118,Beta-mannosidosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
8,141,Canavan disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8,141,Canavan disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,7.0,Specific population,Validated,20301412[PMID]_ORPHANET
8,141,Canavan disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Worldwide,Validated,[EXPERT]
17608,166063,Pontocerebellar hypoplasia type 4,Malformation syndrome,Disorder,Cases/families,Family(ies),,10.0,Worldwide,Validated,[EXPERT]
17608,166063,Pontocerebellar hypoplasia type 4,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20952379[PMID]
17611,166078,Von Willebrand disease type 1,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET
17610,166073,Pontocerebellar hypoplasia type 6,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,25809939[PMID]
17610,166073,Pontocerebellar hypoplasia type 6,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25809939[PMID]
11,213,Cystinosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.75,Worldwide,Validated,12110740[PMID]_18008091[PMID]_11562417[PMID]
11,213,Cystinosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,[EXPERT]
11,213,Cystinosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.31,France,Validated,1018302[PMID]
11,213,Cystinosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.59,Germany,Validated,3921756[PMID]
11,213,Cystinosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.1,United Kingdom,Validated,9610798[PMID]
11,213,Cystinosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.52,Australia,Validated,9918480[PMID]
11,213,Cystinosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.5,Europe,Validated,European Medicines Agency 2014[INST]
11,213,Cystinosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.87,Denmark,Validated,975942[PMID]_27102039[PMID]
11,213,Cystinosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.38,Sweden,Validated,25274184[PMID]_27102039[PMID]
11,213,Cystinosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.6,Specific population,Validated,1937486[PMID]_25274184[PMID]
17613,166084,Von Willebrand disease type 2A,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12,333,Farber disease,Disease,Disorder,Cases/families,Case(s),,96.0,Worldwide,Validated,29048419[PMID]
12,333,Farber disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29048419[PMID]
17612,166081,Von Willebrand disease type 2,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 1 000 000,0.935,Worldwide,Validated,PMID: 30306084
13,349,Fucosidosis,Disease,Disorder,Cases/families,Case(s),,161.0,Worldwide,Validated,36082656[PMID]
13,349,Fucosidosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,36082656[PMID]_ORPHANET
13,349,Fucosidosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.1,Sweden,Validated,25274184[PMID]
13,349,Fucosidosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.63,Cuba,Validated,27706744[PMID]
17615,166090,Von Willebrand disease type 2M,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14,365,Glycogen storage disease due to acid maltase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.8,Europe,Not yet validated,ORPHANET
14,365,Glycogen storage disease due to acid maltase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.17,Portugal,Validated,14685153[PMID]
14,365,Glycogen storage disease due to acid maltase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.83,Italy,Validated,11953730[PMID]
14,365,Glycogen storage disease due to acid maltase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.25,Netherlands,Validated,10480370[PMID]_10482961[PMID]
14,365,Glycogen storage disease due to acid maltase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.37,Czech Republic,Validated,20490927[PMID]
14,365,Glycogen storage disease due to acid maltase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.5,Austria,Validated,22133539[PMID]
14,365,Glycogen storage disease due to acid maltase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.5,United States,Validated,9738873[PMID]
14,365,Glycogen storage disease due to acid maltase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.68,Australia,Validated,9918480[PMID]
14,365,Glycogen storage disease due to acid maltase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.0,China,Validated,3106710[PMID]
14,365,Glycogen storage disease due to acid maltase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14,365,Glycogen storage disease due to acid maltase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.72,Sweden,Validated,25274184[PMID]
14,365,Glycogen storage disease due to acid maltase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.3,Israel,Validated,33239050[PMID]
14,365,Glycogen storage disease due to acid maltase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.8,Specific population,Validated,33239050[PMID]
14,365,Glycogen storage disease due to acid maltase deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.0,Europe,Validated,European Medicines Agency 2018[INST]
17614,166087,Von Willebrand disease type 2B,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
15,366,Glycogen storage disease due to glycogen debranching enzyme deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,United States,Validated,9412782[PMID]
15,366,Glycogen storage disease due to glycogen debranching enzyme deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
17616,166093,Von Willebrand disease type 2N,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
17,368,Glycogen storage disease due to muscle glycogen phosphorylase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
17617,166096,Von Willebrand disease type 3,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1865,Worldwide,Validated,30306084[PMID]_33780098[PMID]_ORPHANET
17617,166096,Von Willebrand disease type 3,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.037,Austria,Validated,PMID: 6609712
17617,166096,Von Willebrand disease type 3,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.24,Finland,Validated,PMID: 6609712
17617,166096,Von Willebrand disease type 3,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.016,France,Validated,PMID: 6609712
17617,166096,Von Willebrand disease type 3,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.044,Greece,Validated,PMID: 6609712
17617,166096,Von Willebrand disease type 3,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.16,Israel,Validated,PMID: 6609712
17617,166096,Von Willebrand disease type 3,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.055,Italy,Validated,PMID: 6609712
17617,166096,Von Willebrand disease type 3,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.037,Netherlands,Validated,PMID: 6609712
17617,166096,Von Willebrand disease type 3,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.25,Norway,Validated,PMID: 6609712
17617,166096,Von Willebrand disease type 3,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.022,Portugal,Validated,PMID: 6609712
17617,166096,Von Willebrand disease type 3,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.011,Spain,Validated,PMID: 6609712
17617,166096,Von Willebrand disease type 3,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.312,Sweden,Validated,PMID: 6609712
17617,166096,Von Willebrand disease type 3,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.027,United Kingdom,Validated,PMID: 6609712
16,367,Glycogen storage disease due to glycogen branching enzyme deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.1,Worldwide,Not yet validated,23285490[PMID]
16,367,Glycogen storage disease due to glycogen branching enzyme deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19,371,Glycogen storage disease due to muscle phosphofructokinase deficiency,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,18421897[PMID]
19,371,Glycogen storage disease due to muscle phosphofructokinase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18421897[PMID]
17619,166105,FASTKD2-related infantile mitochondrial encephalomyopathy,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,18771761[PMID]_28499982[PMID]
17619,166105,FASTKD2-related infantile mitochondrial encephalomyopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18771761[PMID]_28499982[PMID]
18,369,Glycogen storage disease due to liver glycogen phosphorylase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18,369,Glycogen storage disease due to liver glycogen phosphorylase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.3,Israel,Validated,33239050[PMID]
18,369,Glycogen storage disease due to liver glycogen phosphorylase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.8,Specific population,Validated,33239050[PMID]
21,447,Paroxysmal nocturnal hemoglobinuria,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.35,United Kingdom,Validated,34060690[PMID]
21,447,Paroxysmal nocturnal hemoglobinuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.81,United Kingdom,Validated,34060690[PMID]
21,447,Paroxysmal nocturnal hemoglobinuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Europe,Validated,European Medicines Agency 2016[INST]
17620,166108,Birk-Barel syndrome,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,18678320[PMID]
17620,166108,Birk-Barel syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18678320[PMID]
17621,166113,Bazex syndrome,Disease,Disorder,Cases/families,Case(s),,145.0,Worldwide,Validated,18775590[PMID]
17621,166113,Bazex syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18775590[PMID]
23,535,Rare cutaneous lupus erythematosus,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,50.0,Europe,Validated,European Medicines Agency 2007[INST]
23,535,Rare cutaneous lupus erythematosus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.3,United States,Validated,19289752[PMID]
23,535,Rare cutaneous lupus erythematosus,Clinical group,Group of disorders,Point prevalence,Value and class,6-9 / 10 000,73.0,United States,Validated,19289752[PMID]
23,535,Rare cutaneous lupus erythematosus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.0,Sweden,Validated,21574972[PMID]
17622,166119,Isolated osteopoikilosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Worldwide,Validated,31129707[PMID]
17622,166119,Isolated osteopoikilosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.0,Worldwide,Validated,31129707[PMID]
22,487,Krabbe disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.327,United States,Validated,22991292[PMID]_26795590[PMID]
22,487,Krabbe disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,[EXPERT]
22,487,Krabbe disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.7,Worldwide,Validated,[EXPERT]
22,487,Krabbe disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Europe,Not yet validated,20301416[PMID]
22,487,Krabbe disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.7,France,Validated,[EXPERT]
22,487,Krabbe disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.71,Australia,Validated,9918480[PMID]
22,487,Krabbe disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.35,Netherlands,Validated,10480370[PMID]
22,487,Krabbe disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.21,Portugal,Validated,14685153[PMID]
22,487,Krabbe disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.6,Germany,Validated,9286459[PMID]
22,487,Krabbe disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Turkey,Validated,20490927[PMID]
22,487,Krabbe disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.4,Czech Republic,Validated,20490927[PMID]
22,487,Krabbe disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.9,Sweden,Validated,5409293[PMID]
17624,166260,Dentinogenesis imperfecta type 2,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-5 / 10 000,14.6,Europe,Validated,[EXPERT]
17625,166265,Dentinogenesis imperfecta type 3,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.16,Europe,Not yet validated,ORPHANET
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.23,Germany,Validated,16435194[PMID]
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.15,Netherlands,Validated,10480370[PMID]
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.42,Portugal,Validated,14685153[PMID]
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.23,Sweden,Validated,18681890[PMID]_25274184[PMID]
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.3,Sweden,Validated,18681890[PMID]
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.07,Norway,Validated,18681890[PMID]
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.2,Norway,Validated,18681890[PMID]
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.05,Denmark,Validated,18681890[PMID]
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.7,Denmark,Validated,18681890[PMID]
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.05,Czech Republic,Validated,20490927[PMID]
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.37,Australia,Validated,16600651[PMID]_14608657[PMID]
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.1,Canada,Validated,10617747[PMID]
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.14,"Taiwan, Province of China",Validated,19396827[PMID]
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.27,Estonia,Validated,22480138[PMID]
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.059,Colombia,Validated,22550061[PMID]
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.16,Europe,Validated,European Medicines Agency 2001[INST]
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.3,Turkey,Validated,16435194[PMID]
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.0132,Poland,Validated,25472774[PMID]
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.85,Saudi Arabia,Validated,20622343[PMID]
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.28,Brazil,Validated,PMID: 31926052
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.03,Japan,Validated,28595941[PMID]
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.11,Switzerland,Validated,28595941[PMID]
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.3,Tunisia,Validated,20209839[PMID]
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.019,"Korea, Republic of",Validated,25364648[PMID]
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.04,United States,Validated,34051828[PMID]
24,583,Mucopolysaccharidosis type 6,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.011,United States,Validated,34051828[PMID]
17626,166272,Odontochondrodysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,18241073[PMID]
17626,166272,Odontochondrodysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18241073[PMID]
27,576,Mucolipidosis type II,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.34,Europe,Validated,10480370[PMID]_14685153[PMID]_ 25274184[PMID]_ORPHANET
27,576,Mucolipidosis type II,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,ORPHANET
27,576,Mucolipidosis type II,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.81,Portugal,Validated,14685153[PMID]
27,576,Mucolipidosis type II,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.16,Netherlands,Validated,10480370[PMID]
27,576,Mucolipidosis type II,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,16.2,Specific population,Validated,18190596[PMID]_1937486[PMID]
27,576,Mucolipidosis type II,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.05,Sweden,Validated,25274184[PMID]
17627,166277,Wormian bone-multiple fractures-dentinogenesis imperfecta-skeletal dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,10544232[PMID]
17627,166277,Wormian bone-multiple fractures-dentinogenesis imperfecta-skeletal dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10544232[PMID]
26,812,Sialidosis type 1,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,ORPHANET
26,812,Sialidosis type 1,Disease,Disorder,Prevalence at birth,Class only,<1 / 1 000 000,0.0,Europe,Validated,ORPHANET
17628,166282,Familial sick sinus syndrome,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,ORPHANET
17628,166282,Familial sick sinus syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
29,578,Mucolipidosis type IV,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
29,578,Mucolipidosis type IV,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.1,Sweden,Validated,25274184[PMID]
29,578,Mucolipidosis type IV,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.5,Specific population,Validated,20159435[PMID]_16287144[PMID]_16645217[PMID]
17629,166286,Porokeratotic eccrine ostial and dermal duct nevus,Disease,Disorder,Cases/families,Case(s),,45.0,Worldwide,Validated,21393947[PMID]
17629,166286,Porokeratotic eccrine ostial and dermal duct nevus,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21393947[PMID]
28,577,Mucolipidosis type III,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.985,Europe,Validated,10480370[PMID]_ 14685153[PMID]_ ORPHANET
28,577,Mucolipidosis type III,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.08,Netherlands,Validated,10480370[PMID]
28,577,Mucolipidosis type III,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,1.68,Portugal,Validated,14685153[PMID]
28,577,Mucolipidosis type III,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,29.55,Europe,Validated,ORPHANET
28,577,Mucolipidosis type III,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.4,Netherlands,Validated,ORPHANET
28,577,Mucolipidosis type III,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,50.4,Portugal,Validated,ORPHANET
17630,166291,Dirofilariasis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
17635,166308,Benign infantile focal epilepsy with midline spikes and waves during sleep,Disease,Disorder,Cases/families,Case(s),,36.0,Worldwide,Validated,20822975[PMID]
17635,166308,Benign infantile focal epilepsy with midline spikes and waves during sleep,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20822975[PMID]
17634,166305,Benign infantile seizures associated with mild gastroenteritis,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,24125788[PMID]
17634,166305,Benign infantile seizures associated with mild gastroenteritis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24125788[PMID]
32,2912,Poliomyelitis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
32,2912,Poliomyelitis,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,European Centre for Disease prevention and Control 2011[INST]
38,796,Sandhoff disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.49,Portugal,Validated,14685153[PMID]
38,796,Sandhoff disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.34,Netherlands,Validated,10480370[PMID]
38,796,Sandhoff disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.19,Czech Republic,Validated,20490927[PMID]
38,796,Sandhoff disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.26,Australia,Validated,9918480[PMID]
38,796,Sandhoff disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.95,Turkey,Validated,15275696[PMID]
38,796,Sandhoff disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.3,United States,Validated,2955697[PMID]
38,796,Sandhoff disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.67,Europe,Validated,[EXPERT]
38,796,Sandhoff disease,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
38,796,Sandhoff disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.38,Sweden,Validated,25274184[PMID]
39,801,Scleroderma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.41,Worldwide,Validated,[EXPERT]
39,801,Scleroderma,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,42.0,Worldwide,Validated,[EXPERT]
39,801,Scleroderma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.5,Australia,Validated,11456035[PMID]
39,801,Scleroderma,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,23.0,Australia,Validated,11456035[PMID]
39,801,Scleroderma,Clinical group,Group of disorders,Point prevalence,Value and class,>1 / 1000,469.0,Specific population,Validated,8702445[PMID]
42,461,Recessive X-linked ichthyosis,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,15.0,Europe,Validated,ORPHANET
42,461,Recessive X-linked ichthyosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,16.6,Europe,Validated,ORPHANET
42,461,Recessive X-linked ichthyosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,9.9,Italy,Not yet validated,12920363[PMID]_ORPHANET
40,584,Mucopolysaccharidosis type 7,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.01,Europe,Validated,European Medicines Agency 2012[INST]
40,584,Mucopolysaccharidosis type 7,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.24,Netherlands,Validated,10480370[PMID]
40,584,Mucopolysaccharidosis type 7,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.02,Brazil,Validated,PMID: 31926052
40,584,Mucopolysaccharidosis type 7,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.02,Czech Republic,Validated,25060283[PMID]
40,584,Mucopolysaccharidosis type 7,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.02,Japan,Validated,28595941[PMID]
40,584,Mucopolysaccharidosis type 7,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.038,Switzerland,Validated,28595941[PMID]
40,584,Mucopolysaccharidosis type 7,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.047,Australia,Validated,9918480[PMID]
40,584,Mucopolysaccharidosis type 7,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.007,United States,Validated,34051828[PMID]
40,584,Mucopolysaccharidosis type 7,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.027,United States,Validated,34051828[PMID]
40,584,Mucopolysaccharidosis type 7,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.29,Canada,Validated,28595941[PMID]
44,881,Turner syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.5,Europe,Validated,EUROCAT European surveillance of congenital anomalies 1985-2010[REG]
44,881,Turner syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.5,Austria,Validated,EUROCAT European surveillance of congenital anomalies 1985-2009[REG]
44,881,Turner syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.9,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 1980-2010[REG]
44,881,Turner syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,10.5,Bulgaria,Validated,EUROCAT European surveillance of congenital anomalies 1996-1999[REG]
44,881,Turner syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.6,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 1983-2010[REG]
44,881,Turner syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,10.4,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 1980-2010[REG]
44,881,Turner syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.1,France,Validated,EUROCAT European surveillance of congenital anomalies 1980-2010[REG]
44,881,Turner syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,8.0,Germany,Validated,EUROCAT European surveillance of congenital anomalies 1987-2010[REG]
44,881,Turner syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.2,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 1998-2010[REG]
44,881,Turner syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.1,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 1980-2010[REG]
44,881,Turner syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.4,Italy,Validated,EUROCAT European surveillance of congenital anomalies 1980-2010[REG]
44,881,Turner syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.1,Malta,Validated,EUROCAT European surveillance of congenital anomalies 1986-2009[REG]
44,881,Turner syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,14.0,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 1981-2010[REG]
44,881,Turner syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.2,Norway,Validated,EUROCAT European surveillance of congenital anomalies 1999-2010[REG]
44,881,Turner syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.6,Poland,Validated,EUROCAT European surveillance of congenital anomalies 1999-2010[REG]
44,881,Turner syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.8,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 1990-2010[REG]
44,881,Turner syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.8,Spain,Validated,EUROCAT European surveillance of congenital anomalies 1980-2009[REG]
44,881,Turner syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,22.4,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 1989-2010[REG]
44,881,Turner syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,10.1,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 1980-2010[REG]
44,881,Turner syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.3,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2005-2010[REG]
44,881,Turner syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,70.0,Japan,Not yet validated,ISBN:444897208[OTHER]
44,881,Turner syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,42.5,Singapore,Validated,19551311[PMID]
44,881,Turner syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET
45,95,Friedreich ataxia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Europe,Validated,20301458[PMID]_23859338[PMID]
45,95,Friedreich ataxia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.3,France,Validated,9207112 [PMID]_23859338[PMID]
45,95,Friedreich ataxia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.8,Italy,Validated,2225525[PMID]_7793232[PMID]
45,95,Friedreich ataxia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.1,Italy,Validated,2225525[PMID]_7793232[PMID]
45,95,Friedreich ataxia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.2,Spain,Validated,2043954[PMID]_7898602[PMID]
45,95,Friedreich ataxia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.3,Spain,Not yet validated,2043954[PMID]_7898602[PMID]
45,95,Friedreich ataxia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Finland,Validated,11810294[PMID]
45,95,Friedreich ataxia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.13,Finland,Validated,11810294[PMID]_23859338[PMID]
45,95,Friedreich ataxia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.7,Denmark,Not yet validated,2096315[PMID]
45,95,Friedreich ataxia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.9,Portugal,Validated,23609960[PMID]
45,95,Friedreich ataxia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.8,United Kingdom,Validated,19347027[PMID]
45,95,Friedreich ataxia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.9,Greece,Validated,24209901[PMID]
45,95,Friedreich ataxia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Norway,Validated,1126051[PMID]
45,95,Friedreich ataxia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.1,Germany,Validated,9187683[PMID]_23859338[PMID]
45,95,Friedreich ataxia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.24,Sweden,Validated,11810294[PMID]_23859338[PMID]
45,95,Friedreich ataxia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.27,Czech Republic,Validated,15726025[PMID]_23859338[PMID]
45,95,Friedreich ataxia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.03,Russian Federation,Validated,15559155[PMID]_23859338[PMID]
51,848,Beta-thalassemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.0,Worldwide,Validated,[EXPERT]
51,848,Beta-thalassemia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,France,Validated,[EXPERT]
51,848,Beta-thalassemia,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,10.0,Europe,Validated,[EXPERT]
51,848,Beta-thalassemia,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
50,846,Alpha-thalassemia,Disease,Disorder,Prevalence at birth,Class only,Unknown,0.0,Europe,Validated,ORPHANET
50,846,Alpha-thalassemia,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,10.3,United States,Validated,19061217[PMID]_22766612[PMID]
50,846,Alpha-thalassemia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,25390741[PMID]_ORPHANET
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,19.3912,Europe,Validated,ORPHANET
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,11.1319,Europe,Validated,ORPHANET
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,28.5714,Austria,Validated,18442953[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.39,Austria,Validated,18442953[PMID]_ORPHANET
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,35.0877,Belgium,Validated,30335254[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.1429,Belgium,Validated,30335254[PMID]_ORPHANET
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,40.0,Bulgaria,Validated,18442953 [PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.26,Bulgaria,Validated,18442953 [PMID]_ORPHANET
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,12.6358,Cyprus,Validated,18442953[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.35,Cyprus,Validated,18442953[PMID]_ORPHANET
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,15.29,Czech Republic,Validated,31241292[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.7775,Czech Republic,Validated,31241292[PMID]_ORPHANET
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,17.41,Denmark,Validated,31682332[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,9.9946,Denmark,Validated,31682332[PMID]_ORPHANET
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,22.2222,Estonia,Validated,18442953[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.18,Estonia,Validated,18442953[PMID]_ORPHANET
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.0,Finland,Validated,16051530[PMID]_18442953[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.1027,Finland,Validated,18442953[PMID]_ORPHANET
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,21.15,France,Validated,25122143[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,12.1416,France,Validated,25122143[PMID]_ORPHANET
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,19.5017,Germany,Validated,25914230[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,11.1954,Germany,Validated,25914230[PMID]_ORPHANET
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,28.5714,Greece,Validated,18442953[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.21,Greece,Validated,18442953[PMID]_ORPHANET
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Class only,Unknown,0.0,Hungary,Validated,18442953[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.09,Hungary,Validated,18442953[PMID]_ORPHANET
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,36.36,Ireland,Validated,32483343[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.8733,Ireland,Validated,32483343[PMID]_ORPHANET
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,17.809,Italy,Validated,31005549[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.2236,Italy,Validated,31005549[PMID]_ORPHANET
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Class only,Unknown,0.0,Latvia,Validated,18442953[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.04,Latvia,Validated,18442953[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Class only,Unknown,0.0,Lithuania,Validated,18442953[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.3,Lithuania,Validated,18442953[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Class only,Unknown,0.0,Luxembourg,Validated,18442953[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.31,Luxembourg,Validated,18442953[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Class only,Unknown,0.0,Malta,Validated,18442953[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.79,Malta,Validated,18442953[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,16.58,Netherlands,Validated,30146269[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,9.5181,Netherlands,Validated,30146269[PMID]_ORPHANET
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.5474,Norway,Validated,26795017[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.629,Norway,Validated,26795017[PMID]_ORPHANET
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,17.4881,Poland,Validated,22892530[PMID]_ORPHANET
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0394,Poland,Validated,22892530[PMID]_ORPHANET
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,12.549,Portugal,Validated,33072945[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.204,Portugal,Validated,33072945[PMID]_ORPHANET
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,48.6381,Romania,Validated,18442953[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.06,Romania,Validated,18442953[PMID]_ORPHANET
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.7119,Russian Federation,Validated,ECFS Neonatal Screening Working Group
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.5753,Russian Federation,Validated,ECFS Neonatal Screening Working Group
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,15.38,Slovakia,Validated,28544683[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.8292,Slovakia,Validated,28544683[PMID]_ORPHANET
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,33.3333,Slovenia,Validated,18442953[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.28,Slovenia,Validated,18442953[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,16.5048,Spain,Validated,25680858[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,9.4749,Spain,Validated,25680858[PMID]_ORPHANET
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,17.9285,Sweden,Validated,12243313[PMID]_18442953[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.2922,Sweden,Validated,12243313[PMID]_18442953[PMID]_ORPHANET
49,586,Cystic fibrosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,41.9991,United Kingdom,Validated,18442953[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,13.7,United Kingdom,Validated,18442953[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,13.1995,Brazil,Validated,35209917[PMID]
49,586,Cystic fibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.7786,China,Validated,35313924[PMID]
55,262,Duchenne and Becker muscular dystrophy,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.23,United Kingdom,Validated,19767415[PMID]
55,262,Duchenne and Becker muscular dystrophy,Clinical group,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
55,262,Duchenne and Becker muscular dystrophy,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,United States,Validated,25687144[PMID]
59,261,Emery-Dreifuss muscular dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.3,Europe,Validated,[EXPERT]
63,550,MELAS,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.18,Japan,Validated,21443929[PMID]
63,550,MELAS,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
63,550,MELAS,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.6,Europe,Validated,European Medicines Agency 2015[INST]
63,550,MELAS,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.63,Finland,Validated,9371917[PMID]
63,550,MELAS,Disease,Disorder,Point prevalence,Value and class,>1 / 1000,236.0,Specific population,Validated,17300999[PMID]
62,269,Facioscapulohumeral dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.5,Europe,Validated,19320656[PMID]_22217918[PMID]_19767415[PMID]_[EXPERT]_ORPHANET
62,269,Facioscapulohumeral dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.4,Italy,Validated,19320656[PMID]
62,269,Facioscapulohumeral dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.95,United Kingdom,Validated,19767415[PMID]
62,269,Facioscapulohumeral dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Japan,Validated,1745328[PMID]
62,269,Facioscapulohumeral dystrophy,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,12.0,Netherlands,Validated,25122204[PMID]
62,269,Facioscapulohumeral dystrophy,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.3,Netherlands,Validated,25122204[PMID]
61,480,Kearns-Sayre syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Europe,Validated,[EXPERT]_17886296[PMID]
61,480,Kearns-Sayre syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.8,Finland,Validated,15781811[PMID]
61,480,Kearns-Sayre syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,United Kingdom,Validated,17886296[PMID]
61,480,Kearns-Sayre syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.3,Israel,Validated,33239050[PMID]
68,593,Myofibrillar myopathy,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
64,551,MERRF,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.494,Sweden,Validated,11261513[PMID]
64,551,MERRF,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
65,597,Central core disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.4,United Kingdom,Validated,19767415[PMID]
65,597,Central core disease,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
66,607,Nemaline myopathy,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,2.0,Europe,Validated,ORPHANET_15221447[PMID]
66,607,Nemaline myopathy,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.2,United Kingdom,Validated,19767415[PMID]
17538,163746,Peripheral demyelinating neuropathy-central dysmyelinating leukodystrophy-Waardenburg syndrome-Hirschsprung disease,Disease,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,Dr Véronique PINGAULT[EXPERT]
17538,163746,Peripheral demyelinating neuropathy-central dysmyelinating leukodystrophy-Waardenburg syndrome-Hirschsprung disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
76,684,Paramyotonia congenita of Von Eulenburg,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
76,684,Paramyotonia congenita of Von Eulenburg,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.17,United Kingdom,Validated,23516313[PMID]
76,684,Paramyotonia congenita of Von Eulenburg,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.94,Netherlands,Validated,29606556[PMID]
76,684,Paramyotonia congenita of Von Eulenburg,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,ORPHANET_23516313[PMID]_29606556[PMID]
77,273,Steinert myotonic dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.0,Europe,Validated,[EXPERT]
77,273,Steinert myotonic dystrophy,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,12.5,Worldwide,Not yet validated,ISBN:702021520[OTHER]_21364698[PMID]
77,273,Steinert myotonic dystrophy,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.4,United Kingdom,Validated,19767415[PMID]
77,273,Steinert myotonic dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.9,Iceland,Validated,16264243[PMID]
77,273,Steinert myotonic dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.3,Serbia,Validated,16713671[PMID]_21364698[PMID]
77,273,Steinert myotonic dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,9.13,Japan,Validated,1745328[PMID]
77,273,Steinert myotonic dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.46,"Taiwan, Province of China",Validated,12902623[PMID]_21364698[PMID]
77,273,Steinert myotonic dystrophy,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,14.3,South Africa,Validated,3992413[PMID]
77,273,Steinert myotonic dystrophy,Disease,Disorder,Point prevalence,Value and class,6-9 / 10 000,76.3,Specific population,Validated,4973215[PMID]
77,273,Steinert myotonic dystrophy,Disease,Disorder,Point prevalence,Value and class,>1 / 1000,210.5,Specific population,Validated,2924205[PMID]_21364698[PMID]
77,273,Steinert myotonic dystrophy,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.2,Serbia,Validated,16713671[PMID]
77,273,Steinert myotonic dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,9.31,Italy,Validated,11359466[PMID]_21364698[PMID]
77,273,Steinert myotonic dystrophy,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,11.95,Ireland,Validated,14960839[PMID]_21364698[PMID]
77,273,Steinert myotonic dystrophy,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.0,Specific population,Validated,12784291[PMID]_21364698[PMID]
77,273,Steinert myotonic dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.7,Specific population,Validated,12784291[PMID]_21364698[PMID]
77,273,Steinert myotonic dystrophy,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,18.1,Croatia,Validated,9088385[PMID]_21364698[PMID]
17551,163937,"X-linked intellectual disability, Najm type",Disease,Disorder,Cases/families,Family(ies),,35.0,Worldwide,Validated,ORPHANET
17551,163937,"X-linked intellectual disability, Najm type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
17550,163934,Atopic keratoconjunctivitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,15.0,Europe,Validated,European Medicines Agency 2009[INST]
75,614,Thomsen and Becker disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Worldwide,Validated,1822774[PMID]
75,614,Thomsen and Becker disease,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET
75,614,Thomsen and Becker disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.3,Finland,Validated,9598722[PMID]
75,614,Thomsen and Becker disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.9,Italy,Validated,7161034[PMID]
75,614,Thomsen and Becker disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.52,United Kingdom,Validated,23516313[PMID]
75,614,Thomsen and Becker disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.75,Netherlands,Validated,29606556[PMID]
17546,163921,Posttransplant acute limbic encephalitis,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
17556,163966,"X-linked dominant chondrodysplasia, Chassaing-Lacombe type",Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,16001442[PMID]_[EXPERT]
17556,163966,"X-linked dominant chondrodysplasia, Chassaing-Lacombe type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
17557,163971,"X-linked intellectual disability, Cilliers type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17369115[PMID]
17557,163971,"X-linked intellectual disability, Cilliers type",Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,17369115[PMID]
17558,163976,"X-linked intellectual disability, Van Esch type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16053905[PMID]
17558,163976,"X-linked intellectual disability, Van Esch type",Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,16053905[PMID]
17559,163979,X-linked intellectual disability-craniofacioskeletal syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17853486[PMID]
17559,163979,X-linked intellectual disability-craniofacioskeletal syndrome,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,17853486[PMID]
17554,163956,"X-linked intellectual disability, Nascimento type",Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,20412111[PMID]
17554,163956,"X-linked intellectual disability, Nascimento type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20412111[PMID]
17555,163961,X-linked cerebral-cerebellar-coloboma syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15887274[PMID]
17555,163961,X-linked cerebral-cerebellar-coloboma syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,15887274[PMID]
94,324,Fabry disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,6.66,Worldwide,Validated,ORPHANET
94,324,Fabry disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,6.96,Australia,Validated,35024668[PMID]
94,324,Fabry disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.21,Netherlands,Validated,10480370[PMID]
94,324,Fabry disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.12,Portugal,Validated,14685153[PMID]
94,324,Fabry disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.52,Czech Republic,Validated,20490927[PMID]
94,324,Fabry disease,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.015,Turkey,Validated,15275696[PMID]
94,324,Fabry disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.15,United Kingdom,Validated,11732485[PMID]
94,324,Fabry disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.25,Japan,Validated,22790789[PMID]
94,324,Fabry disease,Disease,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET
94,324,Fabry disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.11,Sweden,Validated,25274184[PMID]
94,324,Fabry disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.118,China,Validated,34103049[PMID]
17561,163985,Hyperekplexia-epilepsy syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,30078784[PMID]
17561,163985,Hyperekplexia-epilepsy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30078784[PMID]
91,778,Rett syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.0,Europe,Not yet validated,12378695[PMID]_21878110[PMID]
91,778,Rett syndrome,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,Europe,Validated,European Medicines Agency 2019[INST]
91,778,Rett syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,France,Not yet validated,16647997[PMID]_ORPHANET
91,778,Rett syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Worldwide,Not yet validated,ORPHANET
91,778,Rett syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.0,Sweden,Not yet validated,3571139[PMID]_ORPHANET
91,778,Rett syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Japan,Not yet validated,2803793[PMID]
91,778,Rett syndrome,Disease,Disorder,Prevalence at birth,Class only,1-9 / 100 000,0.0,United States,Not yet validated,2063900[PMID]
91,778,Rett syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.6,United Kingdom,Validated,National Congenital Anomaly and Rare Disease Registration Service 2017[INST]_3087206[PMID]
91,778,Rett syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.05,Australia,Not yet validated,21587099[PMID]_ORPHANET
91,778,Rett syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Australia,Not yet validated,21587099[PMID]
91,778,Rett syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Hong Kong,Not yet validated,18174559[PMID]
90,72,Angelman syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.5,Worldwide,Validated,20301323[PMID]_21587322[PMID]_[EXPERT]_ORPHANET
90,72,Angelman syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.3,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
90,72,Angelman syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2009[REG]
90,72,Angelman syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.5,Australia,Validated,16492624[PMID]
90,72,Angelman syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Australia,Not yet validated,16492624[PMID]
90,72,Angelman syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.0,Spain,Validated,12373673[PMID]
90,72,Angelman syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.3,Spain,Validated,12373673[PMID]
90,72,Angelman syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.8,Estonia,Validated,16906556[PMID]
90,72,Angelman syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Estonia,Not yet validated,16906556[PMID]
90,72,Angelman syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,Denmark,Validated,7573182[PMID]
90,72,Angelman syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Denmark,Validated,23913711[PMID]
90,72,Angelman syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.0,United Kingdom,Validated,21152085[PMID]
102,307,Juvenile myoclonic epilepsy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
101,1941,Juvenile absence epilepsy,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,7.5,Europe,Validated,8275976[PMID]_ORPHANET
101,1941,Juvenile absence epilepsy,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET_Dr Gabrielle Rudolf[EXPERT]
99,892,Von Hippel-Lindau disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.3,United Kingdom,Validated,20082463[PMID]_[EXPERT]
99,892,Von Hippel-Lindau disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.1,United Kingdom,Validated,20082463[PMID]_[EXPERT]
99,892,Von Hippel-Lindau disease,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
99,892,Von Hippel-Lindau disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.13,Denmark,Validated,27966541[PMID]
99,892,Von Hippel-Lindau disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.66,Denmark,Validated,27966541[PMID]
97,731,Autosomal recessive polycystic kidney disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.0,Germany,Validated,[EXPERT]_9511976[PMID]
97,731,Autosomal recessive polycystic kidney disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
110,138,CHARGE syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.5,Canada,Validated,15637722[PMID]
110,138,CHARGE syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.5,Worldwide,Not yet validated,16959034[PMID]
110,138,CHARGE syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
110,138,CHARGE syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,9.0,Europe,Validated,European Medicines Agency 2019[INST]
109,558,Marfan syndrome,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,25.0,Europe,Not yet validated,16325700[PMID]_ORPHANET
109,558,Marfan syndrome,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,15.0,Worldwide,Not yet validated,20301510[PMID]
109,558,Marfan syndrome,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.0,Europe,Validated,[EXPERT]
109,558,Marfan syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,10.2,United Kingdom,Validated,8151638[PMID]
109,558,Marfan syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.0,United Kingdom,Validated,8151638[PMID]
109,558,Marfan syndrome,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,United States,Validated,3788757[PMID]
17579,165805,Familial mesial temporal lobe epilepsy with febrile seizures,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,21922598[PMID]
17579,165805,Familial mesial temporal lobe epilepsy with febrile seizures,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21922598[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.2,Europe,Validated,19710046[PMID]_[EXPERT]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.2,Europe,Validated,19192301[PMID]_[EXPERT]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.85,Worldwide,Not yet validated,21665992[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.35,Worldwide,Not yet validated,21665992[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.06,United Kingdom,Validated,17898523[PMID]_17219036[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.9,United Kingdom,Validated,17898523[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.1,Ireland,Validated,10025778[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.7,Ireland,Validated,10025778[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.4,Finland,Validated,6601351[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.4,Finland,Validated,6601351[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.0,Canada,Not yet validated,3762972[PMID]_19494548[PMID]_ ORPHANET
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.9,Canada,Validated,3762972[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.46,United States,Validated,25298019[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.37,Uruguay,Validated,18334826[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.9,Uruguay,Validated,18334826[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.4,Denmark,Validated,2786160[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.1,Denmark,Validated,2786160[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.0,Italy,Validated,19237701[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.9,Italy,Not yet validated,19237701[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.0,France,Validated,19452307[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.4,Spain,Validated,23286747[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.4,Spain,Validated,23286747[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.2,Norway,Validated,21860251[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.0,Norway,Validated,21860251[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.51,"Taiwan, Province of China",Validated,DOI:10.1016/j.jfma.2013.01.008[OTHER]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.97,"Taiwan, Province of China",Validated,DOI:10.1016/j.jfma.2013.01.008[OTHER]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.6,Faroe Islands,Validated,22034926[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.42,"Iran, Islamic Republic of",Validated,20214678[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.57,"Iran, Islamic Republic of",Validated,20214678[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.5,Specific population,Validated,23052600[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.8,Specific population,Validated,23052600[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.4,Specific population,Validated,22409362[PMID]
106,803,Amyotrophic lateral sclerosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.0,Specific population,Validated,22409362[PMID]
104,100,Ataxia-telangiectasia,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,10.0,Norway,Validated,19339254[PMID]
104,100,Ataxia-telangiectasia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.4,Norway,Validated,19339254[PMID]
104,100,Ataxia-telangiectasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.7,United States,Validated,20301790[PMID]_21569628[PMID]
104,100,Ataxia-telangiectasia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.49,Europe,Validated,ORPHANET_19339254[PMID]_23609960[PMID]_19440741[PMID]_1512613[PMID]
104,100,Ataxia-telangiectasia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.15,Portugal,Validated,23609960[PMID]
104,100,Ataxia-telangiectasia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.25,France,Validated,19440741[PMID]
104,100,Ataxia-telangiectasia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.25,United Kingdom,Not yet validated,Ataxia Telangiectasia Society 2014[OTHER]
104,100,Ataxia-telangiectasia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.19,Italy,Validated,1512613[PMID]
105,733,Familial adenomatous polyposis,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Worldwide,Not yet validated,ORPHANET
105,733,Familial adenomatous polyposis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.0,Europe,Validated,European Medicines Agency 2011[INST]
105,733,Familial adenomatous polyposis,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,19.0,Denmark,Validated,12692062[PMID]
105,733,Familial adenomatous polyposis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.65,Denmark,Validated,12692062[PMID]
105,733,Familial adenomatous polyposis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,8.6,Sweden,Validated,10636071[PMID]
105,733,Familial adenomatous polyposis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.2,Sweden,Validated,10636071[PMID]
105,733,Familial adenomatous polyposis,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,15.8,Finland,Validated,1314763[PMID]
105,733,Familial adenomatous polyposis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.63,Finland,Validated,1314763[PMID]
105,733,Familial adenomatous polyposis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.6,United Kingdom,Validated,20082463[PMID]
105,733,Familial adenomatous polyposis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.3,United Kingdom,Validated,20082463[PMID]
105,733,Familial adenomatous polyposis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.24,Australia,Validated,2556632[PMID]
105,733,Familial adenomatous polyposis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.8,Australia,Validated,2556632[PMID]
118,399,Huntington disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.0,Greece,Validated,21166788[PMID]
118,399,Huntington disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.38,Worldwide,Validated,22692795[PMID]
118,399,Huntington disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.7,Worldwide,Validated,22692795[PMID]
118,399,Huntington disease,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,12.0,Europe,Validated,European Medicines Agency 2019[INST]
118,399,Huntington disease,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.6,Ireland,Validated,20880124[PMID]
118,399,Huntington disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.61,United Kingdom,Not yet validated,22133668[PMID]_ORPHANET
118,399,Huntington disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.4,United Kingdom,Not yet validated,22133668[PMID]_21088431[PMID]_7994530[PMID]_9231935[PMID]
118,399,Huntington disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.11,Italy,Validated,2151397[PMID]
118,399,Huntington disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.35,Italy,Not yet validated,2151397[PMID]_25689972[PMID]
118,399,Huntington disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.69,Canada,Validated,11595021[PMID]
118,399,Huntington disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.3,United States,Validated,8018043[PMID]
118,399,Huntington disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.9,United States,Validated,8018043[PMID]
118,399,Huntington disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.65,Japan,Validated,8700304[PMID]
118,399,Huntington disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.65,Australia,Validated,11008591[PMID]
118,399,Huntington disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.3,Australia,Validated,11008591[PMID]
118,399,Huntington disease,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.046,China,Validated,7586664[PMID]
118,399,Huntington disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.37,China,Validated,7586664[PMID]
118,399,Huntington disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.2,Slovenia,Validated,18976322[PMID]
118,399,Huntington disease,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.08,"Taiwan, Province of China",Validated,7586664[PMID]
118,399,Huntington disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.42,"Taiwan, Province of China",Validated,7586664[PMID]
118,399,Huntington disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.14,Iceland,Validated,22722209[PMID]
118,399,Huntington disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Iceland,Validated,22722209[PMID]
118,399,Huntington disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.7,Norway,Validated,2938203[PMID]
118,399,Huntington disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.7,Sweden,Validated,22722209[PMID]
118,399,Huntington disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.33,Greece,Validated,21166788[PMID]
118,399,Huntington disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Finland,Validated,2889026[PMID]
118,399,Huntington disease,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,21.0,Egypt,Validated,7969703[PMID]
118,399,Huntington disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.64,Cyprus,Validated,29105741[PMID]
118,399,Huntington disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Cyprus,Validated,29105741[PMID]
118,399,Huntington disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.8,Denmark,Validated,28155235[PMID]
118,399,Huntington disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.94,Spain,Validated,33568143[PMID]
118,399,Huntington disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.35,Spain,Validated,33568143[PMID]
117,501,Lafora disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,France,Validated,[EXPERT]
117,501,Lafora disease,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
117,501,Lafora disease,Disease,Disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,25217339[PMID]
117,501,Lafora disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_25217339[PMID]
116,870,Down syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,95.0,Worldwide,Validated,World Health Organization[INST]
116,870,Down syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Worldwide,Validated,World Health Organization[INST]
116,870,Down syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,>1 / 1000,101.0,Europe,Validated,33130823[PMID]
116,870,Down syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,57.0,Europe,Validated,33130823[PMID]
116,870,Down syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,63.7,France,Validated,Institut de Veille Sanitaire 2011[INST]
116,870,Down syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,98.3,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
116,870,Down syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,70.0,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
116,870,Down syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,74.0,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
116,870,Down syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,91.2,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
116,870,Down syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,>1 / 1000,110.0,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
116,870,Down syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,69.0,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
116,870,Down syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,38.0,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
116,870,Down syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,91.6,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
116,870,Down syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,98.0,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
116,870,Down syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,66.0,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
116,870,Down syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,59.0,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
116,870,Down syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,44.0,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
116,870,Down syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,75.0,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
116,870,Down syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,>1 / 1000,235.0,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
116,870,Down syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,>1 / 1000,100.0,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
116,870,Down syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,>1 / 1000,174.0,Japan,Validated,18412274[PMID]
116,870,Down syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,6-9 / 10 000,66.0,United Kingdom,Validated,23321618[PMID]
116,870,Down syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,>1 / 1000,126.0,United States,Validated,25822844[PMID]
116,870,Down syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,>1 / 1000,130.0,South Africa,Validated,9373864[PMID]
112,512,Metachromatic leukodystrophy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.47,Europe,Validated,21496291[PMID]_[EXPERT]_European Medicines Agency 2010[INST]
112,512,Metachromatic leukodystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,21496291[PMID]_[EXPERT]_European Medicines Agency 2010[INST]
112,512,Metachromatic leukodystrophy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.42,Netherlands,Validated,10480370[PMID]
112,512,Metachromatic leukodystrophy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.85,Portugal,Validated,14685153[PMID]
112,512,Metachromatic leukodystrophy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.6,Germany,Validated,9286459[PMID]
112,512,Metachromatic leukodystrophy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.43,Turkey,Validated,20490927[PMID]
112,512,Metachromatic leukodystrophy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.09,Australia,Validated,9918480[PMID]
112,512,Metachromatic leukodystrophy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.69,Czech Republic,Validated,20490927[PMID]
112,512,Metachromatic leukodystrophy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.38,Poland,Validated,21695197[PMID]
112,512,Metachromatic leukodystrophy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.5,United States,Validated,19380076[PMID]
112,512,Metachromatic leukodystrophy,Disease,Disorder,Prevalence at birth,Class only,1-9 / 100 000,0.0,Worldwide,Validated,ORPHANET_21695197[PMID]_20490927[PMID]_19380076[PMID]_9918480[PMID]_9286459[PMID]_14685153[PMID]_10480370[PMID]
112,512,Metachromatic leukodystrophy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.73,Sweden,Validated,25274184[PMID]
126,567,22q11.2 deletion syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.6,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
126,567,22q11.2 deletion syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,10.3,France,Not yet validated,8863171[PMID]
126,567,22q11.2 deletion syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,37.5,Worldwide,Not yet validated,21570089[PMID]_ORPHANET
126,567,22q11.2 deletion syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,16.8,United States,Validated,12837874[PMID]
126,567,22q11.2 deletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
126,567,22q11.2 deletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Validated,European Medicines Agency 2019[INST]
17599,166016,"Multiple epiphyseal dysplasia, Lowry type",Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8723087[PMID]
17599,166016,"Multiple epiphyseal dysplasia, Lowry type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8723087[PMID]
125,232,Sickle cell anemia,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,42.0,France,Validated,Institut de Veille Sanitaire 2010[INST]
125,232,Sickle cell anemia,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,25.0,Germany,Validated,24398797[PMID]
125,232,Sickle cell anemia,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,30.0,United States,Validated,20331952[PMID]_Center for Diseases Control and Prevention[INST]
125,232,Sickle cell anemia,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,47.5,Belgium,Validated,10321364[PMID]
125,232,Sickle cell anemia,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,41.7,United Kingdom,Not yet validated,Sickle Cell Society 2008[OTHER]
125,232,Sickle cell anemia,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,Europe,Validated,European Medicines Agency 2019[INST]
125,232,Sickle cell anemia,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,32.8,United States,Validated,17183567[PMID]
125,232,Sickle cell anemia,Disease,Disorder,Prevalence at birth,Value and class,>1 / 1000,344.8,Guadeloupe,Not yet validated,Institut de Veille Sanitaire 2015[INST]
125,232,Sickle cell anemia,Disease,Disorder,Prevalence at birth,Value and class,>1 / 1000,248.75,Martinique,Not yet validated,Institut de Veille Sanitaire 2015[INST]
125,232,Sickle cell anemia,Disease,Disorder,Prevalence at birth,Value and class,>1 / 1000,467.3,Guyana,Not yet validated,Institut de Veille Sanitaire 2015[INST]
125,232,Sickle cell anemia,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,20.15,Reunion,Not yet validated,Institut de Veille Sanitaire 2015[INST]
125,232,Sickle cell anemia,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,21.6262,Brazil,Validated,35209917[PMID]
124,536,Systemic lupus erythematosus,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,47.0,France,Validated,25172239[PMID]_28968809[PMID]
124,536,Systemic lupus erythematosus,Disease,Disorder,Point prevalence,Value and class,6-9 / 10 000,64.2,Martinique,Validated,11859691[PMID]_28968809[PMID]
124,536,Systemic lupus erythematosus,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,14.7,New Zealand,Validated,6929995[PMID]_28968809[PMID]
124,536,Systemic lupus erythematosus,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.6,"Korea, Republic of",Validated,24322455[PMID]_28968809[PMID]
124,536,Systemic lupus erythematosus,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,53.6,United States,Validated,15333286[PMID]_28968809[PMID]
124,536,Systemic lupus erythematosus,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,37.0,"Taiwan, Province of China",Validated,22899470[PMID]_28968809[PMID]
124,536,Systemic lupus erythematosus,Disease,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Validated,ORPHANET
124,536,Systemic lupus erythematosus,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,28.0,Finland,Validated,4001877[PMID]_28968809[PMID]
124,536,Systemic lupus erythematosus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.14,Worldwide,Validated,36241363[PMID]
124,536,Systemic lupus erythematosus,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,43.7,Worldwide,Validated,36241363[PMID]
124,536,Systemic lupus erythematosus,Disease,Disorder,Annual incidence,Value and class,6-9 / 10 000,81.84,Poland,Validated,36241363[PMID]
123,534,Oculocerebrorenal syndrome of Lowe,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2,Worldwide,Not yet validated,16722554[PMID]
123,534,Oculocerebrorenal syndrome of Lowe,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2,Europe,Validated,16722554[PMID]_[EXPERT]
123,534,Oculocerebrorenal syndrome of Lowe,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2,United Kingdom,Validated,21152085[PMID]
122,790,Retinoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.05,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
122,790,Retinoblastoma,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.6,"Taiwan, Province of China",Validated,19373260[PMID]
122,790,Retinoblastoma,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.9,"Korea, Republic of",Validated,24692122[PMID]
122,790,Retinoblastoma,Disease,Disorder,Lifetime Prevalence,Value and class,1-9 / 100 000,1.05,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
122,790,Retinoblastoma,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.0,Worldwide,Validated,22414599[PMID]_19704035[PMID]_ [EXPERT]
122,790,Retinoblastoma,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.05,Japan,Validated,1513060[PMID]
122,790,Retinoblastoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
122,790,Retinoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.018,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
122,790,Retinoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.073,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
122,790,Retinoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.035,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
122,790,Retinoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.04,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
122,790,Retinoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.018,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
122,790,Retinoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.053,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
122,790,Retinoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.033,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
122,790,Retinoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.043,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
122,790,Retinoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.071,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
122,790,Retinoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.045,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
122,790,Retinoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.016,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
122,790,Retinoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.017,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
122,790,Retinoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.094,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
122,790,Retinoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.071,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
122,790,Retinoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.038,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
122,790,Retinoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.047,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
122,790,Retinoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.042,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
122,790,Retinoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.038,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
122,790,Retinoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.048,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
122,790,Retinoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.039,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
122,790,Retinoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.071,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
122,790,Retinoblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.107,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
121,652,Multiple endocrine neoplasia type 1,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.3,Europe,Validated,20301710[PMID]_17014705[PMID]_ [EXPERT]
120,908,Fragile X syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,32.5,Worldwide,Validated,18413371[PMID]_[EXPERT]_ ORPHANET
120,908,Fragile X syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.0,Europe,Validated,European Medicines Agency 2018[INST]
120,908,Fragile X syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.7,United States,Validated,19804849[PMID]_23765048[PMID]
120,908,Fragile X syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.3,France,Validated,22925539[PMID]
120,908,Fragile X syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,19.0,Spain,Validated,19460941[PMID]
120,908,Fragile X syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,16.11,Canada,Validated,19863547[PMID]
120,908,Fragile X syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.4,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
137,3099,Rheumatic fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.0,Europe,Validated,21386976[PMID]_[EXPERT]
137,3099,Rheumatic fever,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,12.5,Canada,Validated,21386976[PMID]_[EXPERT]_ ORPHANET
137,3099,Rheumatic fever,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,12.5,Spain,Validated,21386976[PMID]_[EXPERT]_ ORPHANET
137,3099,Rheumatic fever,Disease,Disorder,Annual incidence,Value and class,>1 / 1000,100.0,Australia,Validated,21386976[PMID]_[EXPERT]
137,3099,Rheumatic fever,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,30.0,India,Validated,21386976[PMID]_[EXPERT]_ ORPHANET
137,3099,Rheumatic fever,Disease,Disorder,Annual incidence,Value and class,>1 / 1000,100.0,Mexico,Validated,21386976[PMID]_[EXPERT]
137,3099,Rheumatic fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.0,Latin America,Validated,21386976[PMID]_[EXPERT]
137,3099,Rheumatic fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,7.6,New Zealand,Validated,23254495[PMID]_21386976[PMID]_ [EXPERT]
137,3099,Rheumatic fever,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
139,739,Prader-Willi syndrome,Disease,Disorder,Prevalence at birth,Class only,1-9 / 100 000,0.0,Worldwide,Not yet validated,ORPHANET
139,739,Prader-Willi syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Worldwide,Not yet validated,ORPHANET
139,739,Prader-Willi syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.1,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
139,739,Prader-Willi syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET_EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
139,739,Prader-Willi syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.7,Belgium,Validated,14679397[PMID]
139,739,Prader-Willi syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.3,Belgium,Validated,14679397[PMID]
139,739,Prader-Willi syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.4,United Kingdom,Validated,11732491[PMID]
139,739,Prader-Willi syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.9,United Kingdom,Validated,11732491[PMID]
139,739,Prader-Willi syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.6,Japan,Validated,8579217[PMID]
139,739,Prader-Willi syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Japan,Validated,8579217[PMID]
139,739,Prader-Willi syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.0,Australia,Validated,12598399[PMID]
139,739,Prader-Willi syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Australia,Validated,12598399[PMID]
139,739,Prader-Willi syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.2,United States,Validated,2240051[PMID]
139,739,Prader-Willi syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,United States,Validated,2240051[PMID]
139,739,Prader-Willi syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.76,France,Validated,28659150[PMID]
139,739,Prader-Willi syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.229,China,Validated,34103049[PMID]
142,47,X-linked agammaglobulinemia,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Europe,Not yet validated,19419768[PMID]
142,47,X-linked agammaglobulinemia,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.22,Worldwide,Validated,[EXPERT]
142,47,X-linked agammaglobulinemia,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.18,France,Validated,19419768[PMID]
142,47,X-linked agammaglobulinemia,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.21,Italy,Validated,19419768[PMID]
142,47,X-linked agammaglobulinemia,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.08,United Kingdom,Validated,19419768[PMID]
142,47,X-linked agammaglobulinemia,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.06,Spain,Validated,19419768[PMID]
142,47,X-linked agammaglobulinemia,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.03,Germany,Validated,19419768[PMID]
142,47,X-linked agammaglobulinemia,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.09,Poland,Validated,19419768[PMID]
142,47,X-linked agammaglobulinemia,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.13,Croatia,Validated,19419768[PMID]
142,47,X-linked agammaglobulinemia,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.16,Hungary,Validated,19419768[PMID]
142,47,X-linked agammaglobulinemia,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.25,North Macedonia,Validated,19419768[PMID]
142,47,X-linked agammaglobulinemia,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Slovenia,Validated,19419768[PMID]
142,47,X-linked agammaglobulinemia,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.09,Serbia,Validated,19419768[PMID]
142,47,X-linked agammaglobulinemia,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.04,Ukraine,Validated,19419768[PMID]
142,47,X-linked agammaglobulinemia,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.06,Belarus,Validated,19419768[PMID]
142,47,X-linked agammaglobulinemia,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.03,Romania,Validated,19419768[PMID]
142,47,X-linked agammaglobulinemia,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.26,United States,Validated,16862044[PMID]
142,47,X-linked agammaglobulinemia,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.07,United States,Validated,16862044[PMID]
142,47,X-linked agammaglobulinemia,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.11,"Korea, Republic of",Validated,22787376[PMID]
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.7,Europe,Validated,ORPHANET
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.31,Sweden,Validated,18681890[PMID]_25274184[PMID]
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,9.1,Denmark,Validated,18681890[PMID]_[EXPERT]
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.43,Czech Republic,Validated,20490927[PMID]_[EXPERT]
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.71,Ireland,Validated,9439667[PMID]_[EXPERT]
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.07,"Taiwan, Province of China",Validated,19396827[PMID]_[EXPERT]
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.74,Australia,Validated,9918480[PMID]_[EXPERT]
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.16,Estonia,Validated,22480138[PMID]_[EXPERT]
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.1,Canada,Validated,10617747[PMID]_[EXPERT]
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2,Europe,Validated,European Medicines Agency 2018 [INST]
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.09,Portugal,Validated,14685153[PMID]_[EXPERT]
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.64,Germany,Validated,16435194[PMID]_[EXPERT]
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.21,Italy,Validated,11953730[PMID]_[EXPERT]
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.67,Netherlands,Validated,10480370[PMID]_[EXPERT]
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.5,Sweden,Validated,18681890[PMID]_[EXPERT]
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.13,Norway,Validated,18681890[PMID]_[EXPERT]
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.4,Norway,Validated,18681890[PMID]_[EXPERT]
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.27,Denmark,Validated,18681890[PMID]_[EXPERT]
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.68,Worldwide,Validated,ORPHANET
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.46,Poland,Validated,25472774[PMID]
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.84,Japan,Validated,28595941[PMID]
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.46,Switzerland,Validated,28595941[PMID]
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.74,"Korea, Republic of",Validated,25364648[PMID]
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.29,Tunisia,Validated,20209839[PMID]
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.26,United States,Validated,34051828[PMID]
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.37,Brazil,Validated,PMID: 31926052
131,580,Mucopolysaccharidosis type 2,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.07,United States,Validated,34051828[PMID]
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Europe,Validated,[EXPERT]
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.69,Germany,Validated,16435194[PMID]
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.33,Portugal,Validated,14685153[PMID]
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.19,Netherlands,Validated,10480370[PMID]
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.67,Sweden,Validated,18681890[PMID]_25274184[PMID]
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.7,Sweden,Validated,18681890[PMID]
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.85,Norway,Validated,18681890[PMID]
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,31.0,Norway,Validated,18681890[PMID]
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.54,Denmark,Validated,18681890[PMID]
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.4,Denmark,Validated,18681890[PMID]
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.8,Ireland,Validated,18463126[PMID]
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.07,United Kingdom,Validated,18796143[PMID]
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.63,Tunisia,Validated,20209839[PMID]
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.11,"Taiwan, Province of China",Validated,19396827[PMID]
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.58,Canada,Validated,10617747[PMID]
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.14,Australia,Validated,9918480[PMID]
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.72,Czech Republic,Validated,20490927[PMID]
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,European Medicines Agency 2018[INST]
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.82,Worldwide,Validated,ORPHANET
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.22,Poland,Validated,25472774[PMID]
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.23,Japan,Validated,28595941[PMID]
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.19,Switzerland,Validated,28595941[PMID]
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.62,Saudi Arabia,Validated,20622343[PMID]
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.21,"Korea, Republic of",Validated,25364648[PMID]
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.24,Brazil,Validated,PMID: 31926052
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.34,United States,Validated,DOI: https://doi.org/10.1016/j.ymgme.2016.11.285[OTHER]
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Israel,Validated,33239050[PMID]
132,579,Mucopolysaccharidosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.1,Specific population,Validated,33239050[PMID]
134,905,Wilson disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.25,Worldwide,Validated,31449670[PMID]
134,905,Wilson disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.0,Europe,Validated,European Medicines Agency 2015[INST]
134,905,Wilson disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.02,Worldwide,Validated,31449670[PMID]
134,905,Wilson disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.5,France,Validated,28648494[PMID]
134,905,Wilson disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.94,Italy,Validated,11953730[PMID]
134,905,Wilson disease,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,3.0,Japan,Validated,7338703[PMID]_17276780 [PMID]
134,905,Wilson disease,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,China,Validated,20301685[PMID]
134,905,Wilson disease,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,13.5,Specific population,Validated,11953730[PMID]
134,905,Wilson disease,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,37.04,Specific population,Validated,23486543[PMID]
134,905,Wilson disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.37,Ireland,Validated,8459248[PMID]
134,905,Wilson disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.9,Germany,Validated,542546[PMID]_17276780[PMID]
134,905,Wilson disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.016,Finland,Validated,32618023[PMID]
134,905,Wilson disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.45,Finland,Validated,32618023[PMID]
155,792,X-linked retinoschisis,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.0,Denmark,Not yet validated,17172462[PMID]_ORPHANET
155,792,X-linked retinoschisis,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.0,Netherlands,Not yet validated,17172462[PMID]_ORPHANET
155,792,X-linked retinoschisis,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.0,Worldwide,Validated,[EXPERT]
155,792,X-linked retinoschisis,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.6,France,Validated,1918822[PMID]
155,792,X-linked retinoschisis,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.5,Europe,Validated,17172462[PMID]_1918822[PMID]_ ORPHANET
17500,163525,Subacute cutaneous lupus erythematosus,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.63,United States,Validated,19289752[PMID]
17500,163525,Subacute cutaneous lupus erythematosus,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.4805,United States,Validated,32141953[PMID]_35359921[PMID]_ORPHANET
158,827,Stargardt disease,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,13.0,Europe,Validated,European Medicines Agency 2018[INST]
144,906,Wiskott-Aldrich syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,European Medicines Agency 2012[INST]
144,906,Wiskott-Aldrich syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.18,France,Validated,[EXPERT]
144,906,Wiskott-Aldrich syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.2,Switzerland,Validated,3065352[PMID]
144,906,Wiskott-Aldrich syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.55,Norway,Not yet validated,11202238[PMID]_ORPHANET
144,906,Wiskott-Aldrich syndrome,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.07,Australia,Validated,9314356[PMID]
144,906,Wiskott-Aldrich syndrome,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.03,"Korea, Republic of",Validated,22787376[PMID]
144,906,Wiskott-Aldrich syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.2,United States,Validated,7381651[PMID]
144,906,Wiskott-Aldrich syndrome,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.0278,China,Validated,34103049[PMID]
145,904,Williams syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,13.3,Norway,Validated,12088082[PMID]
145,904,Williams syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.2,Hong Kong,Validated,14967851[PMID]
145,904,Williams syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,13.3,Norway,Validated,12088082[PMID]_ORPHANET
145,904,Williams syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.2,Hong Kong,Validated,14967851[PMID]_ORPHANET
147,280,Wolf-Hirschhorn syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.0,Europe,Validated,11480768[PMID]_[EXPERT]
147,280,Wolf-Hirschhorn syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,11480768[PMID]_[EXPERT]
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.73,Worldwide,Validated,32803853[PMID]
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.62,Europe,Validated,32803853[PMID]
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.645,France,Validated,32803853[PMID]_ORPHANET
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.7,Italy,Validated,3071354[PMID]_[EXPERT]
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.195,Sweden,Validated,32803853[PMID]_[ORPHANET]
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.6466,Spain,Validated,32803853[PMID]
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.37,Denmark,Validated,32803853[PMID]
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.2,Latin America,Validated,32803853[PMID]
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.8,Australia,Validated,458831[PMID]_[EXPERT]
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.63,Switzerland,Validated,32803853[PMID]
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.7877,United Kingdom,Validated,32803853[PMID]
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.0,Ukraine,Validated,32803853[PMID]
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,79.05,Iraq,Validated,32803853[PMID]_ORPHANET
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,36.73,"Iran, Islamic Republic of",Validated,32803853[PMID]_ORPHANET
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,12.92,Kuwait,Validated,32803853[PMID]
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,25.87,Lebanon,Validated,32803853[PMID]
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,48.14,Saudi Arabia,Validated,32803853[PMID]
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,10.51,United Arab Emirates,Validated,32803853[PMID]
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,16.53,Cameroon,Validated,32803853[PMID]
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.0,North America,Validated,32803853[PMID]
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.42,Cuba,Validated,32803853[PMID]
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.75,Mexico,Validated,32803853[PMID]_ORPHANET
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.75,Argentina,Validated,32803853[PMID]
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,14.25,Venezuela,Validated,32803853[PMID]
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.76,Germany,Validated,32803853[PMID]
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.35,Malta,Validated,32803853[PMID]
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.01,Netherlands,Validated,32803853[PMID]
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.39,Norway,Validated,32803853[PMID]
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.47,Poland,Validated,32803853[PMID]
148,15,Achondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,18.11,Nigeria,Validated,32803853[PMID]_ORPHANET
148,15,Achondroplasia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,32803853[PMID]_ORPHANET
149,96,Ataxia with vitamin E deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.33,Europe,Validated,[EXPERT]
150,101,Dentatorubral pallidoluysian atrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.48,Japan,Validated,18418674[PMID]_[EXPERT]
150,101,Dentatorubral pallidoluysian atrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.71,United Kingdom,Not yet validated,17965145[PMID]
150,101,Dentatorubral pallidoluysian atrophy,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
151,783,Rubinstein-Taybi syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.9,Netherlands,Validated,2118773[PMID]
151,783,Rubinstein-Taybi syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Netherlands,Validated,2118773[PMID]
151,783,Rubinstein-Taybi syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.7,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
151,783,Rubinstein-Taybi syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET
17514,163649,Spondyloepiphyseal dysplasia-craniosynostosis-cleft palate-cataracts-intellectual disability syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,9557884[PMID]
17514,163649,Spondyloepiphyseal dysplasia-craniosynostosis-cleft palate-cataracts-intellectual disability syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9557884[PMID]
171,631,Non-acquired isolated growth hormone deficiency,Disease,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,22851490[PMID]
170,276,T-B+ severe combined immunodeficiency due to gamma chain deficiency,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
17515,163654,Spondyloepiphyseal dysplasia-brachydactyly-speech disorder syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,17515304[PMID]
17515,163654,Spondyloepiphyseal dysplasia-brachydactyly-speech disorder syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17515304[PMID]
169,481,Kennedy disease,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.09,Italy,Validated,11949733[PMID]_[EXPERT]
169,481,Kennedy disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.6,Italy,Validated,11949733[PMID]_[EXPERT]
169,481,Kennedy disease,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Italy,Validated,11949733[PMID]_[EXPERT]
169,481,Kennedy disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.6,Finland,Validated,9724012[PMID]
169,481,Kennedy disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.8,Europe,Validated,9724012[PMID]_11949733[PMID]_ORPHANET
168,664,Ornithine transcarbamylase deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,European Medicines Agency 2018[INST]
168,664,Ornithine transcarbamylase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.4,Italy,Validated,11953730[PMID]
168,664,Ornithine transcarbamylase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.29,Australia,Validated,15050980[PMID]
168,664,Ornithine transcarbamylase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.6,Finland,Validated,18616627[PMID]
168,664,Ornithine transcarbamylase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.88,Canada,Validated,12788994[PMID]_10617747[PMID]_ORPHANET_[EXPERT]
168,664,Ornithine transcarbamylase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.77,United States,Validated,23972786[PMID]
168,664,Ornithine transcarbamylase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.77,Worldwide,Validated,23972786[PMID]_[EXPERT]
17518,163668,"Spondyloepiphyseal dysplasia, MacDermot type",Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,3681905[PMID]
17518,163668,"Spondyloepiphyseal dysplasia, MacDermot type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3681905[PMID]
17516,163662,"Spondyloepiphyseal dysplasia, Reardon type",Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,7747755[PMID]
17516,163662,"Spondyloepiphyseal dysplasia, Reardon type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7747755[PMID]
173,394,Homocystinuria due to cystathionine beta-synthase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.3,Worldwide,Not yet validated,10328723[PMID]
173,394,Homocystinuria due to cystathionine beta-synthase deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.65,Europe,Validated,European Medicines Agency 2001[INST]
173,394,Homocystinuria due to cystathionine beta-synthase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.5,Ireland,Validated,9587032[PMID]
173,394,Homocystinuria due to cystathionine beta-synthase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.77,Germany,Validated,9587032[PMID]
173,394,Homocystinuria due to cystathionine beta-synthase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,15.6,Norway,Validated,15192637[PMID]
173,394,Homocystinuria due to cystathionine beta-synthase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.0,Denmark,Validated,10328723[PMID]
173,394,Homocystinuria due to cystathionine beta-synthase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.7,Australia,Validated,646432[PMID]
173,394,Homocystinuria due to cystathionine beta-synthase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,55.5,Qatar,Validated,19914636[PMID]
173,394,Homocystinuria due to cystathionine beta-synthase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.11,Japan,Validated,9587032[PMID]
17517,163665,"Spondyloepiphyseal dysplasia tarda, Kohn type",Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,3612708[PMID]
17517,163665,"Spondyloepiphyseal dysplasia tarda, Kohn type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3612708[PMID]
172,508,Leprechaunism,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
172,508,Leprechaunism,Malformation syndrome,Disorder,Prevalence at birth,Class only,<1 / 1 000 000,0.0,Europe,Validated,9128805[PMID]
162,436,Hypophosphatasia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_[EXPERT]_21488855[PMID]
162,436,Hypophosphatasia,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.0208,China,Validated,34103049[PMID]
17507,163596,Hb Bart's hydrops fetalis,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,>1 / 1000,275.0,South East Asia,Validated,19459517[PMID]_2351917[PMID]_ [EXPERT]
17507,163596,Hb Bart's hydrops fetalis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
17507,163596,Hb Bart's hydrops fetalis,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.6,United States,Validated,21167500[PMID]
161,429,Hypochondroplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.0303,Worldwide,Validated,20301650[PMID]_33051983[PMID]
161,429,Hypochondroplasia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.0303,Worldwide,Validated,20301650[PMID]_33051983[PMID]
160,437,Hypophosphatemic rickets,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
167,104,Leber hereditary optic neuropathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.6,Netherlands,Validated,16564802[PMID]
167,104,Leber hereditary optic neuropathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.3,Worldwide,Validated,[EXPERT]
167,104,Leber hereditary optic neuropathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.3,Europe,Validated,21928272[PMID]
167,104,Leber hereditary optic neuropathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.22,United Kingdom,Not yet validated,12518276[PMID]
167,104,Leber hereditary optic neuropathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Finland,Validated,17406640[PMID]
167,104,Leber hereditary optic neuropathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.85,Denmark,Validated,27007794[PMID]
167,104,Leber hereditary optic neuropathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.9743,Japan,Validated,35987635[PMID]_ORPHANET
164,2182,Hydrocephalus with stenosis of the aqueduct of Sylvius,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.7,Worldwide,Not yet validated,22344793[PMID]_20301657[PMID]
164,2182,Hydrocephalus with stenosis of the aqueduct of Sylvius,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,1.7,Worldwide,Not yet validated,22344793[PMID]_20301657[PMID]
17509,163634,Maffucci syndrome,Disease,Disorder,Cases/families,Case(s),,250.0,Worldwide,Validated,ORPHANET
17509,163634,Maffucci syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
185,636,Neurofibromatosis type 1,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,21.0,United Kingdom,Validated,20082463[PMID]_2511318[PMID]
185,636,Neurofibromatosis type 1,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,24.46,Finland,Validated,29215653[PMID]
185,636,Neurofibromatosis type 1,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,47.5,New Zealand,Validated,2518509[PMID]
185,636,Neurofibromatosis type 1,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,21.3,Europe,Validated,10991696[PMID]_20082463[PMID]_2511318[PMID]_6807042[PMID]_ORPHANET
185,636,Neurofibromatosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,36.65,United States,Validated,ISBN:039800370X[OTHER]_ORPHANET
185,636,Neurofibromatosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,36.9,United Kingdom,Validated,20082463[PMID]
185,636,Neurofibromatosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,33.3,Worldwide,Validated,20301288[PMID]
185,636,Neurofibromatosis type 1,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,50.0,Finland,Validated,25354145[PMID]
185,636,Neurofibromatosis type 1,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.7,Canada,Validated,1685193[PMID]
185,636,Neurofibromatosis type 1,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.0,Sweden,Validated,6807042[PMID]
17528,163703,Febrile infection-related epilepsy syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Germany,Validated,PMID: 22911482
17528,163703,Febrile infection-related epilepsy syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Germany,Validated,28898171[PMID]_ORPHANET
190,649,Norrie disease,Malformation syndrome,Disorder,Cases/families,Case(s),,400.0,Worldwide,Validated,16052165[PMID]
190,649,Norrie disease,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
17533,163727,Rolandic epilepsy-paroxysmal exercise-induced dystonia-writer's cramp syndrome,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,10072049[PMID]
17533,163727,Rolandic epilepsy-paroxysmal exercise-induced dystonia-writer's cramp syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10072049[PMID]
17522,163684,Leukoencephalopathy-dystonia-motor neuropathy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,16685654[PMID]
17522,163684,Leukoencephalopathy-dystonia-motor neuropathy syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,ORPHANET_16685654[PMID]
17521,163681,CNTNAP2-related developmental and epileptic encephalopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
17521,163681,CNTNAP2-related developmental and epileptic encephalopathy,Disease,Disorder,Cases/families,Case(s),,28.0,Worldwide,,
176,379,Chronic granulomatous disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.46,Worldwide,Validated,ORPHANET
176,379,Chronic granulomatous disease,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Worldwide,Validated,[EXPERT]
176,379,Chronic granulomatous disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,United States,Validated,10844935[PMID]
176,379,Chronic granulomatous disease,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,United States,Not yet validated,10844935[PMID]
176,379,Chronic granulomatous disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,ORPHANET
176,379,Chronic granulomatous disease,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,ORPHANET
176,379,Chronic granulomatous disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.75,United Kingdom,Validated,18410635[PMID]
176,379,Chronic granulomatous disease,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,United Kingdom,Validated,18410635[PMID]
176,379,Chronic granulomatous disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.57,France,Validated,20700078[PMID]
176,379,Chronic granulomatous disease,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,France,Validated,20700078[PMID]
176,379,Chronic granulomatous disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.22,Sweden,Validated,8645957[PMID]
176,379,Chronic granulomatous disease,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Sweden,Validated,8645957[PMID]
176,379,Chronic granulomatous disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.1,Italy,Validated,18037347[PMID]
176,379,Chronic granulomatous disease,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Italy,Validated,18037347[PMID]
176,379,Chronic granulomatous disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.7,Denmark,Validated,18708296[PMID]
176,379,Chronic granulomatous disease,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Denmark,Validated,18708296[PMID]
176,379,Chronic granulomatous disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.48,Netherlands,Validated,18708296[PMID]
176,379,Chronic granulomatous disease,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Netherlands,Validated,18708296[PMID]
176,379,Chronic granulomatous disease,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.08,Australia,Validated,9314356[PMID]
176,379,Chronic granulomatous disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.35,Japan,Validated,10530081[PMID]
176,379,Chronic granulomatous disease,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Japan,Validated,10530081[PMID]
176,379,Chronic granulomatous disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.34,"Korea, Republic of",Validated,22787376[PMID]
176,379,Chronic granulomatous disease,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,"Korea, Republic of",Validated,22787376[PMID]
176,379,Chronic granulomatous disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.99,Latin America,Validated,17191150[PMID]_ORPHANET
176,379,Chronic granulomatous disease,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Latin America,Validated,17191150[PMID]_ORPHANET
176,379,Chronic granulomatous disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.53,Israel,Validated,18708296[PMID]
176,379,Chronic granulomatous disease,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Israel,Validated,18708296[PMID]
177,16,Blue cone monochromatism,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Worldwide,Validated,ISBN:9780521004398[OTHER]_[EXPERT]
177,16,Blue cone monochromatism,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Worldwide,Validated,ISBN:9780521004398[OTHER]_[EXPERT]
182,644,NARP syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET
183,637,Full NF2-related schwannomatosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.7,Europe,Validated,European Medicines Agency 2012[INST]
183,637,Full NF2-related schwannomatosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.0,United Kingdom,Validated,20082463[PMID]
183,637,Full NF2-related schwannomatosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.78,United Kingdom,Validated,20082463[PMID]
183,637,Full NF2-related schwannomatosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.56,Finland,Validated,25354145[PMID]
17526,163696,Action myoclonus-renal failure syndrome,Disease,Disorder,Cases/families,Case(s),,38.0,Worldwide,Validated,26677510[PMID]
17526,163696,Action myoclonus-renal failure syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26677510[PMID]
180,181,X-linked hypohidrotic ectodermal dysplasia,Etiological subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.75,Europe,Validated,[EXPERT]_ORPHANET
180,181,X-linked hypohidrotic ectodermal dysplasia,Etiological subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,[EXPERT]_ORPHANET
180,181,X-linked hypohidrotic ectodermal dysplasia,Etiological subtype,Subtype of disorder,Point prevalence,Value and class,1-5 / 10 000,12.7,Denmark,Not yet validated,23416623[PMID]_ORPHANET
17525,163693,2p21 microdeletion syndrome,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,11524703[PMID]
17525,163693,2p21 microdeletion syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11524703[PMID]
17524,163690,Hypotonia-cystinuria syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
17524,163690,Hypotonia-cystinuria syndrome,Disease,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,23794250[PMID]
205,337,Fibrodysplasia ossificans progressiva,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.05,Worldwide,Validated,22133093[PMID]_[EXPERT]
205,337,Fibrodysplasia ossificans progressiva,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.061,United Kingdom,Validated,7069743[PMID]
205,337,Fibrodysplasia ossificans progressiva,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.087,Spain,Validated,22796417[PMID]
205,337,Fibrodysplasia ossificans progressiva,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.036,Spain,Validated,22796417[PMID]
205,337,Fibrodysplasia ossificans progressiva,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.078,Europe,Validated,ORPHANET_22796417[PMID]_28666455[PMID]_7069743[PMID]
205,337,Fibrodysplasia ossificans progressiva,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.136,France,Validated,28666455[PMID]
205,337,Fibrodysplasia ossificans progressiva,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.085,United States,Validated,34353327[PMID]
207,377,Gorlin syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Europe,Validated,European Medicines Agency 2018[INST]
207,377,Gorlin syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.3,United Kingdom,Validated,20082463[PMID]
207,377,Gorlin syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.2,United Kingdom,Validated,20082463[PMID]
207,377,Gorlin syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.39,Italy,Validated,10066029[PMID]
207,377,Gorlin syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.61,Australia,Validated,8042673[PMID]
207,377,Gorlin syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.007,"Korea, Republic of",Validated,15183409[PMID]
207,377,Gorlin syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.1,Worldwide,Validated,24403894[PMID]_[EXPERT]
206,648,Noonan syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,70.0,United States,Validated,3895929[PMID]_ORPHANET
206,648,Noonan syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Worldwide,Validated,European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability[EXPERT]
201,281,Monosomy 5p syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.0,Japan,Validated,2092586[PMID]
201,281,Monosomy 5p syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.22,Denmark,Validated,365706[PMID]
201,281,Monosomy 5p syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
203,752,"46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency",Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.68,Netherlands,Validated,10599740[PMID]
203,752,"46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency",Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.68,Netherlands,Validated,ORPHANET
202,214,Cystinuria,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,50.0,United Kingdom,Validated,19096983[PMID]
202,214,Cystinuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,8.0,Canada,Validated,19096983[PMID]
202,214,Cystinuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.5,Japan,Validated,19096983[PMID]
202,214,Cystinuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,40.0,Specific population,Validated,[EXPERT]
202,214,Cystinuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,14.0,Worldwide,Validated,22480232[PMID]_[EXPERT]
202,214,Cystinuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Sweden,Validated,[EXPERT]
202,214,Cystinuria,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,25.0,Australia,Validated,19096983[PMID]
202,214,Cystinuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.9,United States,Validated,19096983[PMID]
202,214,Cystinuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.0,Europe,Validated,European Medicines Agency 2018[INST]
197,510,Lesch-Nyhan syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.43,Italy,Validated,11953730[PMID]
197,510,Lesch-Nyhan syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.34,Europe,Validated,[EXPERT]_ORPHANET
197,510,Lesch-Nyhan syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.42,Spain,Validated,18067674[PMID]
197,510,Lesch-Nyhan syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Spain,Not yet validated,18067674[PMID]
197,510,Lesch-Nyhan syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.18,Canada,Validated,4558815[PMID]
197,510,Lesch-Nyhan syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Canada,Not yet validated,4558815[PMID]
197,510,Lesch-Nyhan syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Italy,Validated,11953730[PMID]
197,510,Lesch-Nyhan syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.18,United Kingdom,Not yet validated,21152085[PMID]_21126241[PMID]
197,510,Lesch-Nyhan syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,United Kingdom,Validated,21152085[PMID]_21126241[PMID]
197,510,Lesch-Nyhan syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
196,524,Li-Fraumeni syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.0,United Kingdom,Validated,23939697[PMID]
196,524,Li-Fraumeni syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.0,United States,Validated,19556618[PMID]
196,524,Li-Fraumeni syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_30335319[PMID]
193,699,Pearson syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,33837965[PMID]_36820126[PMID]_ORPHANET
193,699,Pearson syndrome,Disease,Disorder,Cases/families,Case(s),,194.0,Worldwide,Validated,33837965[PMID]_36820126[PMID]_ORPHANET
192,640,Hereditary neuropathy with liability to pressure palsies,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.5,Europe,Validated,[EXPERT]_24646194[PMID]
192,640,Hereditary neuropathy with liability to pressure palsies,Malformation syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,16.0,Finland,Validated,9447611[PMID]
194,60,Alpha-1-antitrypsin deficiency,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,47.5,Ireland,Validated,21752289[PMID]
194,60,Alpha-1-antitrypsin deficiency,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.0,Europe,Validated,European Medicines Agency 2016[INST]
194,60,Alpha-1-antitrypsin deficiency,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,25.0,Germany,Validated,18855308[PMID]
194,60,Alpha-1-antitrypsin deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,17.0,United States,Validated,10954251[PMID]_18565211[PMID]
194,60,Alpha-1-antitrypsin deficiency,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,33.0,Specific population,Validated,18565211[PMID]
194,60,Alpha-1-antitrypsin deficiency,Disease,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,63.5,Sweden,Validated,1083485[PMID]_18565211[PMID]
220,895,Waardenburg syndrome type 2,Clinical subtype,Subtype of disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,9158138[PMID]_19938076[PMID]
220,895,Waardenburg syndrome type 2,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,9158138[PMID]_19938076[PMID]
221,896,Waardenburg syndrome type 3,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_Dr Véronique PINGAULT[EXPERT]
218,857,Townes-Brocks syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.42,Spain,Validated,10083645[PMID]
218,857,Townes-Brocks syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
219,894,Waardenburg syndrome type 1,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
219,894,Waardenburg syndrome type 1,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_Dr Véronique PINGAULT[EXPERT]
212,682,Hyperkalemic periodic paralysis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,20301669[PMID]_[EXPERT]
212,682,Hyperkalemic periodic paralysis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.17,United Kingdom,Validated,23516313[PMID]
212,682,Hyperkalemic periodic paralysis,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.06,Netherlands,Validated,29606556[PMID]
215,800,Schwartz-Jampel syndrome,Disease,Disorder,Cases/families,Case(s),,129.0,Worldwide,Validated,26436077[PMID]
215,800,Schwartz-Jampel syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26436077[PMID]
209,628,Diastrophic dysplasia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.2,Europe,Validated,[EXPERT]
209,628,Diastrophic dysplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.3,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
209,628,Diastrophic dysplasia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.03,Finland,Validated,1948373[PMID]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,6-9 / 10 000,73.0,Worldwide,Not yet validated,ORPHANET
210,673,Malaria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.0,Europe,Validated,European Medicines Agency2015[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,12.0,France,Not yet validated,ORPHANET
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.2,Europe,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.62,Denmark,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.75,Iceland,Validated,European Centre for Disease prevention and Control 2016-2017[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.8,Austria,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.1,Belgium,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.16,Bulgaria,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Croatia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.52,Cyprus,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.32,Czech Republic,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.2,Estonia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.74,Finland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.68,Greece,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.14,Hungary,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.7,Ireland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.18,Latvia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.22,Lithuania,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.84,Luxembourg,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.54,Malta,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.84,Netherlands,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.08,Poland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.44,Portugal,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.16,Romania,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.06,Slovakia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.28,Slovenia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.5,Spain,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.88,Sweden,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.38,United Kingdom,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
210,673,Malaria,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.62,Norway,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
211,681,Hypokalemic periodic paralysis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,20301512[PMID]_[EXPERT]
211,681,Hypokalemic periodic paralysis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.13,United Kingdom,Validated,23516313[PMID]
211,681,Hypokalemic periodic paralysis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.53,Netherlands,Validated,29606556[PMID]
238,126,Blepharophimosis-ptosis-epicanthus inversus syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
237,107,BOR syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.5,Canada,Validated,7468659[PMID]_[EXPERT]
237,107,BOR syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.5,Worldwide,Validated,7468659[PMID]_ORPHANET
236,774,Hereditary hemorrhagic telangiectasia,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,16.0,Europe,Validated,30111344[PMID]_[EXPERT]_European Medicines Agency 2018[INST]
236,774,Hereditary hemorrhagic telangiectasia,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,43.5,France,Validated,12157905[PMID]
236,774,Hereditary hemorrhagic telangiectasia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.5,United Kingdom,Validated,1518020[PMID]
236,774,Hereditary hemorrhagic telangiectasia,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,15.6,Denmark,Validated,10095814[PMID]
236,774,Hereditary hemorrhagic telangiectasia,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,16.25,Japan,Validated,11793473[PMID]_ORPHANET
236,774,Hereditary hemorrhagic telangiectasia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.1,United States,Validated,7802026[PMID]
236,774,Hereditary hemorrhagic telangiectasia,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,19.4,Specific population,Validated,8242961[PMID]
235,794,Saethre-Chotzen syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.0,Europe,Validated,15923834[PMID]_8988166[PMID]_[EXPERT]
235,794,Saethre-Chotzen syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,15923834[PMID]_[EXPERT]
235,794,Saethre-Chotzen syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Australia,Validated,34626670[PMID]
234,710,Pfeiffer syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Europe,Validated,16740155[PMID]_[EXPERT]
234,710,Pfeiffer syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
234,710,Pfeiffer syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.3,Australia,Validated,34626670[PMID]
233,2869,Peutz-Jeghers syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.2,Worldwide,Not yet validated,20301443[PMID]
233,2869,Peutz-Jeghers syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.4,Europe,Not yet validated,ORPHANET
233,2869,Peutz-Jeghers syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.65,Uruguay,Validated,24260271[PMID]
230,893,WAGR syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.2,Worldwide,Validated,20301534[PMID]
230,893,WAGR syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
225,912,Zellweger syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
225,912,Zellweger syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.2,Specific population,Validated,22894767[PMID]_[EXPERT]
225,912,Zellweger syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.6,Israel,Validated,33239050[PMID]
225,912,Zellweger syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,8.2,Specific population,Validated,33239050[PMID]
254,50,Aicardi syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.07,Netherlands,Validated,18182643[PMID]
254,50,Aicardi syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.95,United States,Validated,18182643[PMID]
254,50,Aicardi syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,United States,Not yet validated,18182643[PMID]
254,50,Aicardi syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
255,53,Albers-Schönberg osteopetrosis,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Worldwide,Not yet validated,20301306[PMID]
255,53,Albers-Schönberg osteopetrosis,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.5,Denmark,Validated,3829443[PMID]
255,53,Albers-Schönberg osteopetrosis,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2,Brazil,Validated,14496532[PMID]
255,53,Albers-Schönberg osteopetrosis,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.0,Europe,Validated,[EXPERT]
252,14,Abetalipoproteinemia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30358967[PMID]
252,14,Abetalipoproteinemia,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,30358967[PMID]
253,52,Alagille syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.4,Australia,Validated,559475[PMID]_[EXPERT]
253,52,Alagille syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Australia,Validated,559475[PMID]_[EXPERT]
253,52,Alagille syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.8,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
253,52,Alagille syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.7,United States,Not yet validated,14684686[PMID]
253,52,Alagille syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
249,167,Chédiak-Higashi syndrome,Disease,Disorder,Cases/families,Case(s),,500.0,Worldwide,Validated,23541537[PMID]_10527680[PMID]_18043242[PMID]
249,167,Chédiak-Higashi syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
246,195,Cat-eye syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.35,Europe,Validated,17001329[PMID]_Dr Catherine TURLEAU[EXPERT]
246,195,Cat-eye syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET_Dr Catherine TURLEAU[EXPERT]
244,207,Crouzon syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.9,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
244,207,Crouzon syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,ORPHANET_EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
244,207,Crouzon syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.65,Canada,Validated,1633640[PMID]
244,207,Crouzon syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.6,Australia,Validated,34626670[PMID]
242,205,Crigler-Najjar syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,[EXPERT]
242,205,Crigler-Najjar syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,European Medicines Agency 2014[INST]
17459,160148,Cap polyposis,Disease,Disorder,Cases/families,Case(s),,67.0,Worldwide,Validated,24949613[PMID]
17459,160148,Cap polyposis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24949613[PMID]
243,201,Cowden syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.45,Netherlands,Validated,10234502[PMID]
243,201,Cowden syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,10234502[PMID]_35422633[PMID]_ORPHANET
240,192,Coffin-Lowry syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.5,Worldwide,Not yet validated,19888300[PMID]
240,192,Coffin-Lowry syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.5,Europe,Validated,ORPHANET
275,2442,X-linked lymphoproliferative disease,Clinical group,Group of disorders,Point prevalence,Value and class,<1 / 1 000 000,0.05,Europe,Validated,20301580[PMID]_[EXPERT]
275,2442,X-linked lymphoproliferative disease,Clinical group,Group of disorders,Point prevalence,Value and class,<1 / 1 000 000,0.0347,China,Validated,34103049[PMID]
17872,169802,Severe hemophilia A,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,2.8,Europe,Not yet validated,ORPHANET
279,562,McCune-Albright syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.55,Europe,Validated,18489744[PMID]_[EXPERT]
278,565,Menkes disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.33,Europe,Not yet validated,1999344[PMID]
278,565,Menkes disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.28,Japan,Validated,15902550[PMID]
278,565,Menkes disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.5,Australia,Validated,15902550[PMID]
278,565,Menkes disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
277,2443,Mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,9.0,Europe,Not yet validated,ORPHANET
283,474,Jeune syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.4,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
283,474,Jeune syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.89,Australia,Not yet validated,931421[PMID]_ORPHANET
283,474,Jeune syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
282,540,Familial hemophagocytic lymphohistiocytosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.0,Sweden,Validated,9561910[PMID]_[EXPERT]
282,540,Familial hemophagocytic lymphohistiocytosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
282,540,Familial hemophagocytic lymphohistiocytosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.104,China,Validated,34344437[PMID]
281,568,"Microphthalmia, Lenz type",Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
280,564,Meckel syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.3,France,Validated,22925539[PMID]
280,564,Meckel syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,France,Validated,22925539[PMID]
280,564,Meckel syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.0,Finland,Validated,6486168[PMID]_[EXPERT]
280,564,Meckel syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.0,Worldwide,Validated,[EXPERT]
280,564,Meckel syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,[EXPERT]
280,564,Meckel syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.6,Europe,Validated,EUROCAT European surveillance of congenital anomalies 1990-2011[REG]_25182137[PMID]
287,289,Ellis Van Creveld syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,>1 / 1000,500.0,Specific population,Validated,10700162[PMID]
287,289,Ellis Van Creveld syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.4,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
287,289,Ellis Van Creveld syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.1,Worldwide,Not yet validated,ISBN:9780313387135[OTHER]_ORPHANET
287,289,Ellis Van Creveld syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
284,258,Laminin subunit alpha 2-related congenital muscular dystrophy,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.3,Europe,Validated,[EXPERT]
284,258,Laminin subunit alpha 2-related congenital muscular dystrophy,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.6,United Kingdom,Validated,19767415[PMID]
258,1247,Schistosomiasis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,18445419[PMID]
258,1247,Schistosomiasis,Disease,Disorder,Point prevalence,Class only,>1 / 1000,0.0,Africa,Not yet validated,ORPHANET
259,112,Bartter syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,[EXPERT]
259,112,Bartter syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Sweden,Validated,3421146[PMID]
259,112,Bartter syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.7,Kuwait,Validated,10365582[PMID]
259,112,Bartter syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
257,1646,Chromosome Y microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.8,Worldwide,Validated,ORPHANET_20301513[PMID]
257,1646,Chromosome Y microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.0,Europe,Validated,[EXPERT]
17863,169464,Primary CD59 deficiency,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,23149847[PMID]_16631367[PMID]
17863,169464,Primary CD59 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
263,99,Autosomal dominant cerebellar ataxia,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,2.7,Worldwide,Validated,24603320[PMID]
263,99,Autosomal dominant cerebellar ataxia,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,3.0,Netherlands,Validated,11889231[PMID]
263,99,Autosomal dominant cerebellar ataxia,Category,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.9,Italy,Validated,7793232[PMID]
263,99,Autosomal dominant cerebellar ataxia,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,5.6,Portugal,Validated,23609960[PMID]
263,99,Autosomal dominant cerebellar ataxia,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,5.6,Europe,Validated,23609960[PMID]
263,99,Autosomal dominant cerebellar ataxia,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,12.6,Japan,Validated,19169038[PMID]
260,116,Beckwith-Wiedemann syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.5,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
260,116,Beckwith-Wiedemann syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.3,Spain,Validated,10199027[PMID]
260,116,Beckwith-Wiedemann syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.25,Japan,Validated,2092586[PMID]_7424972[PMID]_ORPHANET
260,116,Beckwith-Wiedemann syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.4,Jamaica,Validated,5434588[PMID]
260,116,Beckwith-Wiedemann syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,10.0,Italy,Validated,23918458[PMID]
260,116,Beckwith-Wiedemann syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET
261,87,Apert syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
261,87,Apert syndrome,Malformation syndrome,Disorder,Prevalence at birth,Class only,1-9 / 100 000,0.0,Worldwide,Validated,ORPHANET
261,87,Apert syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Worldwide,Not yet validated,ORPHANET
261,87,Apert syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.1,Spain,Validated,10666902[PMID]
261,87,Apert syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.1,Spain,Validated,10666902[PMID]
261,87,Apert syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.2,United States,Validated,9375719[PMID]
261,87,Apert syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.2,United States,Validated,9375719[PMID]
261,87,Apert syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.47,Canada,Validated,1303629[PMID]_1602157[PMID]
261,87,Apert syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.47,Canada,Validated,1303629[PMID]_1602157[PMID]
261,87,Apert syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.6,Australia,Validated,34626670[PMID]
264,97,Familial paroxysmal ataxia,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,United States,Not yet validated,20301674[PMID]
264,97,Familial paroxysmal ataxia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
265,313,Lamellar ichthyosis,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,9887377[PMID]_22000705[PMID]_ORPHANET
265,313,Lamellar ichthyosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.35,Spain,Validated,22000705[PMID]
265,313,Lamellar ichthyosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.1,Norway,Validated,9887377[PMID]
17871,169799,Mild hemophilia B,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.6,Europe,Not yet validated,ORPHANET
17870,169796,Moderate hemophilia B,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.6,Europe,Not yet validated,ORPHANET
17869,169793,Severe hemophilia B,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.8,Europe,Not yet validated,ORPHANET
305,1000,Ocular albinism with late-onset sensorineural deafness,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,6542750[PMID]_10330347[PMID]
305,1000,Ocular albinism with late-onset sensorineural deafness,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10330347[PMID]
304,999,Ermine phenotype,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,3055988[PMID]_19449401[PMID]
304,999,Ermine phenotype,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3055988[PMID]_19449401[PMID]
17906,171430,Severe congenital nemaline myopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
17907,171433,Intermediate nemaline myopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
17908,171436,Typical nemaline myopathy,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
17909,171439,Childhood-onset nemaline myopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
311,55,Oculocutaneous albinism,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,5.9,Worldwide,Validated,17980020[PMID]_[EXPERT]
311,55,Oculocutaneous albinism,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,3.9,Denmark,Validated,19060277[PMID]
311,55,Oculocutaneous albinism,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,45.0,South Africa,Validated,17620156[PMID]
17910,171442,Adult-onset nemaline myopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
17912,171607,X-linked spastic paraplegia type 34,Disease,Disorder,Cases/families,Case(s),,24.0,Worldwide,Validated,1084423[PMID]
17912,171607,X-linked spastic paraplegia type 34,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1084423[PMID]
313,2771,Bruck syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,25238597[PMID]
313,2771,Bruck syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25238597[PMID]
17913,171612,Autosomal dominant spastic paraplegia type 37,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,17605047[PMID]
17913,171612,Autosomal dominant spastic paraplegia type 37,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17605047[PMID]
17914,171617,Autosomal dominant spastic paraplegia type 38,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,18401025[PMID]
17914,171617,Autosomal dominant spastic paraplegia type 38,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18401025[PMID]
315,1349,Mitochondrial DNA-related cardiomyopathy and hearing loss,Malformation syndrome,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,8651277[PMID]
315,1349,Mitochondrial DNA-related cardiomyopathy and hearing loss,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8651277[PMID]
17915,171622,Autosomal recessive spastic paraplegia type 32,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,17515546[PMID]
17915,171622,Autosomal recessive spastic paraplegia type 32,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17515546[PMID]
17916,171629,Autosomal recessive spastic paraplegia type 35,Disease,Disorder,Cases/families,Case(s),,38.0,Worldwide,Validated,24359114[PMID]
17916,171629,Autosomal recessive spastic paraplegia type 35,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24359114[PMID]
293,861,Treacher-Collins syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.63,France,Validated,22925539[PMID]
293,861,Treacher-Collins syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,France,Validated,22925539[PMID]
293,861,Treacher-Collins syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.9,Japan,Validated,7424972[PMID]
293,861,Treacher-Collins syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Japan,Not yet validated,7424972[PMID]
293,861,Treacher-Collins syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.0,Europe,Validated,6024864[PMID]_14198411[PMID]_21131976[PMID]_[EXPERT]
293,861,Treacher-Collins syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,6024864[PMID]_14198411[PMID]_ [EXPERT]
294,308,Progressive myoclonic epilepsy type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.0,Finland,Validated,20301321[PMID]
294,308,Progressive myoclonic epilepsy type 1,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Finland,Validated,20301321[PMID]
297,1991,Cleft lip with or without cleft palate,Clinical group,Group of disorders,Prevalence at birth,Class only,6-9 / 10 000,0.0,Worldwide,Validated,20507242[PMID]
297,1991,Cleft lip with or without cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,>1 / 1000,190.5,Japan,Validated,22374000[PMID]
297,1991,Cleft lip with or without cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,77.5,United States,Validated,22374000[PMID]
299,199,Cornelia de Lange syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.24,Europe,Validated,18074387[PMID]
299,199,Cornelia de Lange syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.65,France,Validated,22925539[PMID]
299,199,Cornelia de Lange syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Denmark,Validated,961413[PMID]
301,2162,Holoprosencephaly,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,13.4,Europe,Validated,20104599[PMID]_[EXPERT]_EUROCAT European surveillance of congenital anomalies[REG]
301,2162,Holoprosencephaly,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.5,United States,Not yet validated,9409876[PMID]_ORPHANET
301,2162,Holoprosencephaly,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,21.6,Latin America,Validated,17987642[PMID]
301,2162,Holoprosencephaly,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,15.0,United Kingdom,Not yet validated,11349198[PMID]_17286306[PMID]_8818944[PMID]_ORPHANET
301,2162,Holoprosencephaly,Malformation syndrome,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,60.6,"Taiwan, Province of China",Validated,15844779[PMID]
301,2162,Holoprosencephaly,Malformation syndrome,Disorder,Prevalence at birth,Value and class,>1 / 1000,502.0,Japan,Validated,15329827[PMID]
301,2162,Holoprosencephaly,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
301,2162,Holoprosencephaly,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,10.9,Specific population,Validated,10703035[PMID]
302,930,Idiopathic achalasia,Disease,Disorder,Prevalence at birth,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,23871090[PMID]
302,930,Idiopathic achalasia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.0,Worldwide,Validated,11319059[PMID]
302,930,Idiopathic achalasia,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.82,Canada,Validated,20465592[PMID]
302,930,Idiopathic achalasia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.29,"Korea, Republic of",Validated,24753707[PMID]
302,930,Idiopathic achalasia,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,13.5,Ireland,Validated,3423207[PMID]
302,930,Idiopathic achalasia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.7,Iceland,Validated,17420933[PMID]
302,930,Idiopathic achalasia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.8,Singapore,Validated,10482430[PMID]
302,930,Idiopathic achalasia,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.59,Italy,Validated,21116729[PMID]
302,930,Idiopathic achalasia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.73,Iceland,Validated,17420933[PMID]
302,930,Idiopathic achalasia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.3,Singapore,Validated,10482430[PMID]
302,930,Idiopathic achalasia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.39,"Korea, Republic of",Validated,24753707[PMID]
302,930,Idiopathic achalasia,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.63,Canada,Validated,20465592[PMID]
302,930,Idiopathic achalasia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.77,Worldwide,Validated,11319059[PMID]
303,998,Albinism-deafness syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,14469778[PMID]
303,998,Albinism-deafness syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_14469778[PMID]
343,1727,22q11.2 duplication syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,216.0,Worldwide,Validated,36735193[PMID]
343,1727,22q11.2 duplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,36735193[PMID]_ORPHANET
17815,169079,Cernunnos-XLF deficiency,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,[EXPERT]
17815,169079,Cernunnos-XLF deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
340,1715,Trisomy 18p syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,25.0,Worldwide,Validated,26042156[PMID]
340,1715,Trisomy 18p syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26042156[PMID]
339,3380,Trisomy 18 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,16.7,Worldwide,Not yet validated,23088440[PMID]
339,3380,Trisomy 18 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.8,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2007[REG]
339,3380,Trisomy 18 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.4,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
339,3380,Trisomy 18 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,25.3,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
339,3380,Trisomy 18 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.1,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
339,3380,Trisomy 18 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.4,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
339,3380,Trisomy 18 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.2,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
339,3380,Trisomy 18 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,10.4,Europe,Validated,22713804[PMID]_EUROCAT European surveillance of congenital anomalies 2005-2009[REG]
339,3380,Trisomy 18 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2009[REG]
339,3380,Trisomy 18 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.8,France,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
339,3380,Trisomy 18 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,8.9,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
339,3380,Trisomy 18 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.8,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
339,3380,Trisomy 18 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,48.2,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
339,3380,Trisomy 18 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.4,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
339,3380,Trisomy 18 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.5,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
339,3380,Trisomy 18 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.9,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
339,3380,Trisomy 18 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,24.6,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
339,3380,Trisomy 18 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,13.0,United Kingdom,Validated,20384468 [PMID]_ORPHANET
339,3380,Trisomy 18 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.5,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
339,3380,Trisomy 18 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,14.6,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
339,3380,Trisomy 18 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,38.8,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
339,3380,Trisomy 18 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,18.0,Japan,Validated,2092586[PMID]
339,3380,Trisomy 18 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Japan,Validated,2092586[PMID]
339,3380,Trisomy 18 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,19.1,United States,Not yet validated,ORPHANET_18348276[PMID]_20878909[PMID]
339,3380,Trisomy 18 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,12.6,Specific population,Validated,10627940[PMID]
17810,168984,CLAPO syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,18798326[PMID]
17810,168984,CLAPO syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18798326[PMID]
17811,168999,Malignant melanoma of the mucosa,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.26,Europe,Validated,22119735[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
17811,168999,Malignant melanoma of the mucosa,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
17811,168999,Malignant melanoma of the mucosa,Disease,Disorder,Lifetime Prevalence,Value and class,1-9 / 100 000,1.5,Europe,Validated,22119735[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
17811,168999,Malignant melanoma of the mucosa,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.32,Belgium,Validated,Belgium Cancer registry[INST]
17811,168999,Malignant melanoma of the mucosa,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.23,United States,Validated,National Cancer Institute[INST]_24272143[PMID]
337,3378,Trisomy 13 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.7,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2009[REG]
337,3378,Trisomy 13 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.9,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
337,3378,Trisomy 13 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.8,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2007[REG]
337,3378,Trisomy 13 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.2,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
337,3378,Trisomy 13 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,24.1,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
337,3378,Trisomy 13 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.8,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
337,3378,Trisomy 13 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.2,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
337,3378,Trisomy 13 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.0,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
337,3378,Trisomy 13 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.3,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
337,3378,Trisomy 13 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,18.0,Japan,Validated,2092586[PMID]_7424972[PMID]
337,3378,Trisomy 13 syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,15.9,Japan,Not yet validated,2092586[PMID]_7424972[PMID]_ ORPHANET
337,3378,Trisomy 13 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,12.6,United States,Validated,20878909[PMID]_Center for Diseases Control and Prevention[INST]
337,3378,Trisomy 13 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.9,France,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
337,3378,Trisomy 13 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.8,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
337,3378,Trisomy 13 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.1,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
337,3378,Trisomy 13 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.4,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
337,3378,Trisomy 13 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.4,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
337,3378,Trisomy 13 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.2,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2008[REG]
337,3378,Trisomy 13 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.5,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
337,3378,Trisomy 13 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,13.2,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2007[REG]
337,3378,Trisomy 13 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
17820,169100,Immunodeficiency due to CD25 deficiency,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,17196245[PMID]_9096364[PMID]
17820,169100,Immunodeficiency due to CD25 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17196245[PMID]_9096364[PMID]
17821,169105,Good syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_20149753[PMID]
17821,169105,Good syndrome,Disease,Disorder,Cases/families,Case(s),,241.0,Worldwide,Validated,20149753[PMID]
17818,169090,Combined immunodeficiency due to CRAC channel dysfunction,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,[EXPERT]
17818,169090,Combined immunodeficiency due to CRAC channel dysfunction,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
346,236,Trisomy 9p syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,25526829[PMID]
346,236,Trisomy 9p syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25526829[PMID]
17819,169095,Severe combined immunodeficiency due to FOXN1 deficiency,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,28077132[PMID]
17819,169095,Severe combined immunodeficiency due to FOXN1 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28077132[PMID]
17817,169085,Susceptibility to respiratory infections associated with CD8alpha chain mutation,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
17798,168829,Primary peritoneal carcinoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
17797,168816,Peritoneal inclusion cyst,Disease,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,[EXPERT]
17797,168816,Peritoneal inclusion cyst,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
324,753,"46,XY difference of sex development due to 5-alpha-reductase 2 deficiency",Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
325,868,Triose phosphate-isomerase deficiency,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,10916682[PMID]_[EXPERT]
325,868,Triose phosphate-isomerase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
17796,168811,Malignant peritoneal mesothelioma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.2,France,Validated,[EXPERT]
17796,168811,Malignant peritoneal mesothelioma,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,European Medicines Agency 2016[INST]
17796,168811,Malignant peritoneal mesothelioma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.5,Italy,Validated,[EXPERT]
323,218,Darier disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.0,United Kingdom,Validated,1390140[PMID]_11841374[PMID]
323,218,Darier disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Denmark,Validated,13835928[PMID]
323,218,Darier disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.8,Slovenia,Validated,16001099[PMID]
323,218,Darier disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.4,Europe,Validated,1390140[PMID]_11841374[PMID]_16001099[PMID]
323,218,Darier disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.31,Singapore,Validated,15727640[PMID]
17793,168796,"Heart-hand syndrome, Slovenian type",Malformation syndrome,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,15996213[PMID]_27723096[PMID]
17793,168796,"Heart-hand syndrome, Slovenian type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15996213[PMID]_27723096[PMID]
321,1465,Coffin-Siris syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,190.0,Worldwide,Validated,22711679[PMID]_11170086[PMID]_23906836[PMID]_24092917[PMID]_23929686[PMID]
321,1465,Coffin-Siris syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
17792,168782,Childhood disintegrative disorder,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Europe,Not yet validated,ORPHANET
334,1642,Distal deletion 9p syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,89.0,Worldwide,Validated,23824832[PMID]_24330994[PMID]
334,1642,Distal deletion 9p syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23824832[PMID]_24330994[PMID]
17807,168966,Composite lymphoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
17806,168960,Refractory anemia with excess blasts in transformation,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.04,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
335,8,"47,XYY syndrome",Malformation syndrome,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Denmark,Not yet validated,20509956[PMID]
335,8,"47,XYY syndrome",Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,50.0,Europe,Not yet validated,22893477[PMID]
335,8,"47,XYY syndrome",Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,14.1,Denmark,Validated,20509956[PMID]
335,8,"47,XYY syndrome",Malformation syndrome,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,22893477[PMID]
17805,168956,Hypereosinophilic syndrome,Clinical group,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.027,United States,Validated,20639012[PMID]
17805,168956,Hypereosinophilic syndrome,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
17805,168956,Hypereosinophilic syndrome,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,3.3,United States,Validated,20639012[PMID]_[EXPERT]
17805,168956,Hypereosinophilic syndrome,Clinical group,Group of disorders,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
330,1600,Monosomy 18q syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.5,Worldwide,Not yet validated,21977138[PMID]_1614460[PMID]
330,1600,Monosomy 18q syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
328,1598,Monosomy 18p syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET_[EXPERT]
328,1598,Monosomy 18p syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.0,Europe,Validated,18284672[PMID]_[EXPERT]
373,2773,Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,7515752[PMID]
373,2773,Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7515752[PMID]
372,2772,Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,728577[PMID]
372,2772,Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_728577[PMID]
369,2609,Isolated complex I deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_15190193[PMID]_20818732[PMID]
370,626,Large/giant congenital melanocytic nevus,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.75,Europe,Validated,21139903[PMID]_[EXPERT]_ ORPHANET
381,773,Refsum disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,20301527[PMID]_[EXPERT]
381,773,Refsum disease,Disease,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,ISBN 13:9789350901885[OTHER]_[EXPERT]
378,11,Pentasomy X syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
17829,169154,T-B+ severe combined immunodeficiency due to IL-7Ralpha deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.15,Worldwide,Validated,14726805[PMID]
17829,169154,T-B+ severe combined immunodeficiency due to IL-7Ralpha deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
17829,169154,T-B+ severe combined immunodeficiency due to IL-7Ralpha deficiency,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.04,Chile,Validated,33861827[PMID]_ORPHANET
357,370,Glycogen storage disease due to phosphorylase kinase deficiency,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Europe,Validated,[EXPERT]
357,370,Glycogen storage disease due to phosphorylase kinase deficiency,Clinical group,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
357,370,Glycogen storage disease due to phosphorylase kinase deficiency,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 1 000 000,0.3,Israel,Validated,33239050[PMID]
357,370,Glycogen storage disease due to phosphorylase kinase deficiency,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Specific population,Validated,33239050[PMID]
17831,169160,T-B+ severe combined immunodeficiency due to CD3delta/CD3epsilon/CD3zeta,Disease,Disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
17831,169160,T-B+ severe combined immunodeficiency due to CD3delta/CD3epsilon/CD3zeta,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
358,385,Neurodegeneration with brain iron accumulation,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.2,Europe,Validated,[EXPERT]_European Medicines Agency 2018[INST]
17830,169157,T-B+ severe combined immunodeficiency due to CD45 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9068311[PMID]_10700239[PMID]_22689986[PMID]
17830,169157,T-B+ severe combined immunodeficiency due to CD45 deficiency,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,9068311[PMID]_10700239[PMID]_22689986[PMID]
353,1947,"Progressive epilepsy-intellectual disability syndrome, Finnish type",Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
355,352,Galactosemia,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,2.0,Europe,Validated,ORPHANET
355,352,Galactosemia,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.1,Europe,Validated,[EXPERT]_ORPHANET
355,352,Galactosemia,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.3,United States,Validated,22766612[PMID]
355,352,Galactosemia,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
364,596,X-linked centronuclear myopathy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,France,Validated,18817572[PMID]_[EXPERT]
364,596,X-linked centronuclear myopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
364,596,X-linked centronuclear myopathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2,Europe,Validated,European Medicines Agency 2015[INST]
367,610,Bethlem muscular dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.77,United Kingdom,Validated,19767415[PMID]
367,610,Bethlem muscular dystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
17833,169186,Autosomal recessive centronuclear myopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
360,464,Incontinentia pigmenti,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.62,United States,Validated,[EXPERT]_Texas Birth Defect Registry[REG]
360,464,Incontinentia pigmenti,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.2,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
360,464,Incontinentia pigmenti,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Worldwide,Not yet validated,ORPHANET
361,3307,Tetrasomy 18p syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
17834,169189,Autosomal dominant centronuclear myopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
410,44,Neonatal adrenoleukodystrophy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.2,Italy,Validated,11953730[PMID]
410,44,Neonatal adrenoleukodystrophy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
411,56,Alkaptonuria,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Worldwide,Validated,[EXPERT]
411,56,Alkaptonuria,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,European Medicines Agency 2003[INST]
411,56,Alkaptonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.15,France,Validated,21927854[PMID]
411,56,Alkaptonuria,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,France,Not yet validated,21927854[PMID]
411,56,Alkaptonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.25,United States,Not yet validated,20301627[PMID]
411,56,Alkaptonuria,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,United States,Not yet validated,20301627[PMID]
411,56,Alkaptonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.3,Slovakia,Validated,12051967[PMID]
411,56,Alkaptonuria,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Slovakia,Validated,12051967[PMID]
408,963,Acromegaly,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.47,Worldwide,Validated,17893253[PMID]_26792654[PMID]_ORPHANET_[EXPERT]
408,963,Acromegaly,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.6,Spain,Validated,15476442[PMID]
408,963,Acromegaly,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,9.7,Italy,Validated,20621957[PMID]
408,963,Acromegaly,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.6,United Kingdom,Validated,19650784[PMID]
408,963,Acromegaly,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.19,Belgium,Validated,17893253[PMID]
408,963,Acromegaly,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,12.0,Belgium,Validated,[EXPERT]_17893253[PMID]
408,963,Acromegaly,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.4,Ireland,Validated,2349750[PMID]
408,963,Acromegaly,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.3,Ireland,Validated,2349750[PMID]
408,963,Acromegaly,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.34,Finland,Validated,20534753[PMID]
408,963,Acromegaly,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.39,"Korea, Republic of",Validated,22909047[PMID]
408,963,Acromegaly,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.79,"Korea, Republic of",Validated,22909047[PMID]
408,963,Acromegaly,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.77,Iceland,Validated,25893613[PMID]
408,963,Acromegaly,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,13.4,Iceland,Validated,25893613[PMID]
408,963,Acromegaly,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.8,United States,Validated,26792654[PMID]
408,963,Acromegaly,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.1,United States,Validated,26792654[PMID]
408,963,Acromegaly,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.5,Denmark,Validated,27280374[PMID]
408,963,Acromegaly,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.31,Malta,Validated,23239049[PMID]
408,963,Acromegaly,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,12.5,Malta,Validated,23239049[PMID]
408,963,Acromegaly,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.35,Sweden,Validated,25084775[PMID]
408,963,Acromegaly,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.38,Denmark,Validated,27280374[PMID]
408,963,Acromegaly,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
415,1059,Blue rubber bleb nevus,Malformation syndrome,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,ORPHANET
415,1059,Blue rubber bleb nevus,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
412,1006,Alopecia antibody deficiency,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,978318[PMID]
412,1006,Alopecia antibody deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_978318[PMID]
413,1046,Lethal hemolytic anemia-genital anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,7726230[PMID]
413,1046,Lethal hemolytic anemia-genital anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7726230[PMID]
402,22,Succinic semialdehyde dehydrogenase deficiency,Disease,Disorder,Cases/families,Case(s),,450.0,Worldwide,Validated,20301374[PMID]
402,22,Succinic semialdehyde dehydrogenase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_20301374[PMID]
403,29,Mevalonic aciduria,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,16722536[PMID]
403,29,Mevalonic aciduria,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
407,245,Nager syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,ISBN:1437725562[OTHER]
407,245,Nager syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_ISBN:1437725562[OTHER]
407,245,Nager syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.3,Finland,Validated,17119427[PMID]
404,30,Hereditary orotic aciduria,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,25757096[PMID]
404,30,Hereditary orotic aciduria,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25757096[PMID]
405,36,Acrocallosal syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,38.0,Worldwide,Validated,22696705[PMID]
405,36,Acrocallosal syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22696705[PMID]
394,915,Aarskog-Scott syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
394,915,Aarskog-Scott syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
392,2614,Nail-patella syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.2,United Kingdom,Validated,10972657[PMID]
392,2614,Nail-patella syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Worldwide,Validated,10972657[PMID]_16825280[PMID]
392,2614,Nail-patella syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.2,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
392,2614,Nail-patella syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Australia,Validated,16825280[PMID]
399,33,Isovaleric acidemia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,[EXPERT]
399,33,Isovaleric acidemia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.55,Germany,Not yet validated,12777559[PMID]_21335445[PMID]
399,33,Isovaleric acidemia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.28,Australia,Validated,12788994[PMID]
399,33,Isovaleric acidemia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.63,Italy,Validated,18956250[PMID]
399,33,Isovaleric acidemia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.53,United States,Not yet validated,16601872[PMID]_16735252[PMID]_ ORPHANET
387,819,Smith-Magenis syndrome,Malformation syndrome,Disorder,Prevalence at birth,Class only,1-9 / 100 000,0.0,Worldwide,Not yet validated,17468296[PMID]
387,819,Smith-Magenis syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.0,Worldwide,Not yet validated,17468296[PMID]
387,819,Smith-Magenis syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.35,Europe,Validated,[EXPERT]_ORPHANET
387,819,Smith-Magenis syndrome,Malformation syndrome,Disorder,Prevalence at birth,Class only,1-9 / 100 000,0.0,United States,Not yet validated,1746552[PMID]_16354942[PMID]
387,819,Smith-Magenis syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.35,United States,Not yet validated,1746552[PMID]_16354942[PMID]_ ORPHANET
384,3085,Retinitis pigmentosa-intellectual disability-deafness-hypogonadism syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,8456839[PMID]_1251844[PMID]
384,3085,Retinitis pigmentosa-intellectual disability-deafness-hypogonadism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8456839[PMID]_1251844[PMID]
390,9,Tetrasomy X syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,23494840[PMID]
390,9,Tetrasomy X syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23494840[PMID]
17785,168615,Hereditary persistence of alpha-fetoprotein,Biological anomaly,Disorder,Cases/families,Family(ies),,19.0,Worldwide,Validated,21116028[PMID]
17785,168615,Hereditary persistence of alpha-fetoprotein,Biological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21116028[PMID]
17784,168612,Congenital deficiency in alpha-fetoprotein,Biological anomaly,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,18854864[PMID]
17784,168612,Congenital deficiency in alpha-fetoprotein,Biological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18854864[PMID]
442,1442,Ring chromosome 18 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,70.0,Worldwide,Validated,21333764[PMID]
442,1442,Ring chromosome 18 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
17787,168621,"Dysplasia of head of femur, Meyer type",Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
443,1452,Cleidocranial dysplasia,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Worldwide,Validated,[EXPERT]
443,1452,Cleidocranial dysplasia,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.4,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
443,1452,Cleidocranial dysplasia,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.2,United States,Validated,22461456[PMID]_[EXPERT]
17788,168624,"Familial scaphocephaly syndrome, McGillivray type",Malformation syndrome,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,16061565[PMID]
17788,168624,"Familial scaphocephaly syndrome, McGillivray type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16061565[PMID]
445,193,Cohen syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,[EXPERT]_20301655[PMID]
445,193,Cohen syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_20301655[PMID]
446,1488,Cooper-Jabs syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,3572627[PMID]
446,1488,Cooper-Jabs syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3572627[PMID]
447,200,Isolated corpus callosum agenesis,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,United States,Validated,ORPHANET
447,200,Isolated corpus callosum agenesis,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Hungary,Validated,ORPHANET
447,200,Isolated corpus callosum agenesis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.37,United States,Validated,18642362[PMID]
447,200,Isolated corpus callosum agenesis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.2,Hungary,Validated,ORPHANET_21555052[PMID]
432,1334,Chronic mucocutaneous candidiasis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
17777,168583,Hereditary North American Indian childhood cirrhosis,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,36.0,Worldwide,Validated,ORPHANET
17777,168583,Hereditary North American Indian childhood cirrhosis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
433,1369,Congenital cataract-hypertrophic cardiomyopathy-mitochondrial myopathy syndrome,Disease,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,22284826[PMID]
433,1369,Congenital cataract-hypertrophic cardiomyopathy-mitochondrial myopathy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
17776,168577,Hereditary cryohydrocytosis with reduced stomatin,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,22492876[PMID]
17776,168577,Hereditary cryohydrocytosis with reduced stomatin,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22492876[PMID]
17779,168593,Sudden infant death-dysgenesis of the testes syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,21.0,Worldwide,Validated,15273283[PMID]
17779,168593,Sudden infant death-dysgenesis of the testes syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15273283[PMID]
435,1406,Charlie M syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_940017[PMID]
435,1406,Charlie M syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,940017[PMID]
17778,168588,Hyperandrogenism due to cortisone reductase deficiency,Malformation syndrome,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,ORPHANET
17778,168588,Hyperandrogenism due to cortisone reductase deficiency,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
437,1414,Cholestasis-lymphedema syndrome,Disease,Disorder,Cases/families,Case(s),,47.0,Worldwide,Validated,25039919[PMID]
437,1414,Cholestasis-lymphedema syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25039919[PMID]
17780,168598,Methionine adenosyltransferase I/III deficiency,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8770875[PMID]
17780,168598,Methionine adenosyltransferase I/III deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8770875[PMID]
17782,168606,Seborrhea-like dermatitis with psoriasiform elements,Disease,Disorder,Cases/families,Case(s),,44.0,Worldwide,Validated,ORPHANET
17782,168606,Seborrhea-like dermatitis with psoriasiform elements,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
17768,168549,Axial spondylometaphyseal dysplasia,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,26974433[PMID]
17768,168549,Axial spondylometaphyseal dysplasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26974433[PMID]
17769,168552,Spondylometaphyseal dysplasia-bowed forearms-facial dysmorphism syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,12503112[PMID]
17769,168552,Spondylometaphyseal dysplasia-bowed forearms-facial dysmorphism syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12503112[PMID]
424,1154,Arthrogryposis-oculomotor limitation-electroretinal anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
17770,168555,"Spondylometaphyseal dysplasia, A4 type",Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,9637426[PMID]_15517830[PMID]
17770,168555,"Spondylometaphyseal dysplasia, A4 type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9637426[PMID]_15517830[PMID]
17771,168558,"46,XY difference of sex development-adrenal insufficiency due to CYP11A1 deficiency",Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,21880796[PMID]
17771,168558,"46,XY difference of sex development-adrenal insufficiency due to CYP11A1 deficiency",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21880796[PMID]
17772,168563,"46,XY gonadal dysgenesis-motor and sensory neuropathy syndrome",Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,22209139[PMID]
17772,168563,"46,XY gonadal dysgenesis-motor and sensory neuropathy syndrome",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22209139[PMID]
429,124,Diamond-Blackfan anemia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.67,Europe,Validated,20824457[PMID]_[EXPERT]
429,124,Diamond-Blackfan anemia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,United Kingdom,Validated,8826887[PMID]
429,124,Diamond-Blackfan anemia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.65,Italy,Validated,10192448[PMID]
429,124,Diamond-Blackfan anemia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.75,United States,Validated,18671700[PMID]
429,124,Diamond-Blackfan anemia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
429,124,Diamond-Blackfan anemia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.194,China,Validated,34103049[PMID]
17773,168566,Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,25037205[PMID]
17773,168566,Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25037205[PMID]
431,1310,Caffey disease,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
431,1310,Caffey disease,Malformation syndrome,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,[EXPERT]_22855962[PMID]
17774,168569,H syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,24172204[PMID]
17774,168569,H syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24172204[PMID]
17775,168572,Native American myopathy,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
430,125,Bloom syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.08,Specific population,Validated,10464606[PMID]_9758720[PMID]_10464671[PMID]
430,125,Bloom syndrome,Disease,Disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,20301572[PMID]
430,125,Bloom syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
417,90,Argininemia,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.04,Finland,Validated,18616627[PMID]
417,90,Argininemia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.27,United States,Validated,8794176[PMID]
417,90,Argininemia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,European Medicines Agency 2016[INST]
17761,168443,Spondyloepimetaphyseal dysplasia-hypotrichosis syndrome,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,2363424[PMID]
17761,168443,Spondyloepimetaphyseal dysplasia-hypotrichosis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2363424[PMID]
416,1065,Aniridia-cerebellar ataxia-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,22.0,Worldwide,Validated,27108797[PMID]
416,1065,Aniridia-cerebellar ataxia-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27108797[PMID]
17763,168451,Spondyloepimetaphyseal dysplasia-abnormal dentition syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,9018411[PMID]
17763,168451,Spondyloepimetaphyseal dysplasia-abnormal dentition syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9018411[PMID]
17764,168454,"Spondyloepimetaphyseal dysplasia, Geneviève type",Disease,Disorder,Cases/families,Family(ies),,6.0,Worldwide,Validated,27213289[PMID]
17764,168454,"Spondyloepimetaphyseal dysplasia, Geneviève type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27213289[PMID]
421,1146,Distal arthrogryposis type 1,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
420,1143,Neurogenic arthrogryposis multiplex congenita,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.3,Europe,Not yet validated,23050160[PMID]_22005589[PMID]
420,1143,Neurogenic arthrogryposis multiplex congenita,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
17767,168544,"Spondylometaphyseal dysplasia, Golden type",Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,Golden 1977[AUTHOR]
17767,168544,"Spondylometaphyseal dysplasia, Golden type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
422,1147,Sheldon-Hall syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
478,246,Postaxial acrofacial dysostosis,Malformation syndrome,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
478,246,Postaxial acrofacial dysostosis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
476,1770,XY type gonadal dysgenesis-associated anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,6158563[PMID]
476,1770,XY type gonadal dysgenesis-associated anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6158563[PMID]
477,1775,Dyskeratosis congenita,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,[EXPERT]
474,1764,Familial dysautonomia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
474,1764,Familial dysautonomia,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,18.5,Specific population,Validated,27317387[PMID]_3652488[PMID]_4322121[PMID]_ORPHANET
472,235,Dubowitz syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.2,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
472,235,Dubowitz syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
473,239,Dyggve-Melchior-Clausen disease,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,[EXPERT]
473,239,Dyggve-Melchior-Clausen disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
470,1672,Diencephalic syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
468,833,Encephalopathy due to sulfite oxidase deficiency,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,[EXPERT]
468,833,Encephalopathy due to sulfite oxidase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
17684,167714,Unclassified acute myeloid leukemia,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.49,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
17682,167635,Scleromyxedema,Disease,Disorder,Cases/families,Case(s),,250.0,Worldwide,Validated,25814746[PMID]
17682,167635,Scleromyxedema,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_25814746[PMID]
467,765,Pyruvate dehydrogenase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
467,765,Pyruvate dehydrogenase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,European Medicines Agency 2015[INST]
465,395,Homocystinuria due to methylene tetrahydrofolate reductase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
463,408,Isolated glycerol kinase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
462,148,Multiple carboxylase deficiency,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
461,147,Carbamoyl-phosphate synthetase 1 deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
461,147,Carbamoyl-phosphate synthetase 1 deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.19,Finland,Validated,18616627[PMID]
461,147,Carbamoyl-phosphate synthetase 1 deficiency,Disease,Disorder,Prevalence at birth,Class only,1-9 / 1 000 000,0.0,Worldwide,Validated,20142522[PMID]_[EXPERT]
461,147,Carbamoyl-phosphate synthetase 1 deficiency,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.077,United States,Validated,23972786[PMID]
461,147,Carbamoyl-phosphate synthetase 1 deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.125,Japan,Validated,2063931[PMID]
459,23,Argininosuccinic aciduria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.46,United States,Validated,23972786[PMID]
459,23,Argininosuccinic aciduria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.69,Finland,Validated,18616627[PMID]
459,23,Argininosuccinic aciduria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,European Medicines Agency 2019[INST]_[EXPERT]
459,23,Argininosuccinic aciduria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.05,Austria,Validated,20236848[PMID]
458,45,Adenosine monophosphate deaminase deficiency,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,[EXPERT]
458,45,Adenosine monophosphate deaminase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
457,226,Dihydropteridine reductase deficiency,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,14705166[PMID]
457,226,Dihydropteridine reductase deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
456,217,Isolated Dandy-Walker malformation,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Europe,Validated,[EXPERT]_ORPHANET
456,217,Isolated Dandy-Walker malformation,Morphological anomaly,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.1,Europe,Validated,[EXPERT]_ORPHANET
454,1556,Cutis marmorata telangiectatica congenita,Malformation syndrome,Disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,ORPHANET
454,1556,Cutis marmorata telangiectatica congenita,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
450,1538,Craniosynostosis-Dandy-Walker malformation-hydrocephalus syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,8266990[PMID]
450,1538,Craniosynostosis-Dandy-Walker malformation-hydrocephalus syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8266990[PMID]
448,1496,Corpus callosum agenesis-neuronopathy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Not yet validated,20301546[PMID]
448,1496,Corpus callosum agenesis-neuronopathy syndrome,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,47.0,Specific population,Validated,20301546[PMID]
508,417,Neonatal severe primary hyperparathyroidism,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
510,2233,Hypogonadism-mitral valve prolapse-intellectual disability syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,2502012[PMID]
510,2233,Hypogonadism-mitral valve prolapse-intellectual disability syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2502012[PMID]
511,2248,Hypoplastic left heart syndrome,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,18.0,Worldwide,Not yet validated,27409588[PMID]_30661430[PMID]_2339046[PMID]_ORPHANET
511,2248,Hypoplastic left heart syndrome,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,16.2,United States,Validated,2339046[PMID]
511,2248,Hypoplastic left heart syndrome,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,15.1,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
511,2248,Hypoplastic left heart syndrome,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,49.1,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
511,2248,Hypoplastic left heart syndrome,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,29.1,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
511,2248,Hypoplastic left heart syndrome,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,56.8,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
511,2248,Hypoplastic left heart syndrome,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,21.3,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
511,2248,Hypoplastic left heart syndrome,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.8,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
511,2248,Hypoplastic left heart syndrome,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,23.8,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
511,2248,Hypoplastic left heart syndrome,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,19.9,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
511,2248,Hypoplastic left heart syndrome,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,18.1,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
511,2248,Hypoplastic left heart syndrome,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.9,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
511,2248,Hypoplastic left heart syndrome,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,49.8,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
511,2248,Hypoplastic left heart syndrome,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.8,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
511,2248,Hypoplastic left heart syndrome,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,16.4,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
511,2248,Hypoplastic left heart syndrome,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.2,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
511,2248,Hypoplastic left heart syndrome,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.5,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
511,2248,Hypoplastic left heart syndrome,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,12.5,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
511,2248,Hypoplastic left heart syndrome,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,16.6,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
511,2248,Hypoplastic left heart syndrome,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,22.3,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
511,2248,Hypoplastic left heart syndrome,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.9,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
511,2248,Hypoplastic left heart syndrome,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
511,2248,Hypoplastic left heart syndrome,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,8.0,China,Validated,27409588[PMID]
511,2248,Hypoplastic left heart syndrome,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.6,Sweden,Validated,30661430[PMID]
504,446,Neonatal hemochromatosis,Disease,Disorder,Cases/families,Case(s),,35.0,Worldwide,Validated,21247995[PMID]_16237701[PMID]
504,446,Neonatal hemochromatosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
505,2135,Cutaneous mastocytosis-deafness-microtia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,19764024[PMID]
505,2135,Cutaneous mastocytosis-deafness-microtia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19764024[PMID]
506,2140,Congenital diaphragmatic hernia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,30.0,Worldwide,Validated,8982563[PMID]_[EXPERT]_ ORPHANET
506,2140,Congenital diaphragmatic hernia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,21.2,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
506,2140,Congenital diaphragmatic hernia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,39.3,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
506,2140,Congenital diaphragmatic hernia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,14.6,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
506,2140,Congenital diaphragmatic hernia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.4,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
506,2140,Congenital diaphragmatic hernia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,19.8,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
506,2140,Congenital diaphragmatic hernia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,23.6,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
506,2140,Congenital diaphragmatic hernia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.9,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
506,2140,Congenital diaphragmatic hernia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,23.2,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
506,2140,Congenital diaphragmatic hernia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,21.7,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
506,2140,Congenital diaphragmatic hernia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,22.6,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
506,2140,Congenital diaphragmatic hernia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,49.8,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
506,2140,Congenital diaphragmatic hernia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,29.2,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
506,2140,Congenital diaphragmatic hernia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,22.9,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
506,2140,Congenital diaphragmatic hernia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,8.2,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
506,2140,Congenital diaphragmatic hernia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,18.9,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
506,2140,Congenital diaphragmatic hernia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.4,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
506,2140,Congenital diaphragmatic hernia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,38.9,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
506,2140,Congenital diaphragmatic hernia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,19.7,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
506,2140,Congenital diaphragmatic hernia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,22.3,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
506,2140,Congenital diaphragmatic hernia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,33.0,United States,Validated,1290156[PMID]
506,2140,Congenital diaphragmatic hernia,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
507,2185,Congenital hydrocephalus,Malformation syndrome,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,59.0,United States,Validated,21763944[PMID]
507,2185,Congenital hydrocephalus,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
507,2185,Congenital hydrocephalus,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,46.5,Europe,Validated,19410489[PMID]
502,2116,Hartnup disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.2,Worldwide,Validated,ISBN:79130356[OTHER]_[EXPERT]
502,2116,Hartnup disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.3,Australia,Validated,ISBN:79130356[OTHER]
502,2116,Hartnup disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.85,United States,Validated,ISBN:79130356[OTHER]_17555458[PMID]
502,2116,Hartnup disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.9,Specific population,Validated,ISBN:79130356[OTHER]
502,2116,Hartnup disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.0,United Kingdom,Validated,909480[PMID]
503,2118,Hawkinsinuria,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
503,2118,Hawkinsinuria,Disease,Disorder,Cases/families,Family(ies),,5.0,Worldwide,Validated,11073718[PMID]
498,351,Galactosialidosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
498,351,Galactosialidosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.14,Sweden,Validated,25274184[PMID]
498,351,Galactosialidosis,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,23915561[PMID]
493,2020,Congenital fiber-type disproportion myopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
494,2053,Freeman-Sheldon syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
494,2053,Freeman-Sheldon syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,19309503[PMID]_[EXPERT]_23277889[PMID]
488,295,Fetal parvovirus syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
491,1933,"Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria",Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,2738799[PMID]
491,1933,"Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2738799[PMID]
485,1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.25,Europe,Validated,[EXPERT]_ORPHANET
485,1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.5,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
485,1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.8,France,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
485,1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,19.5,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2008[REG]
485,1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.1,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2007[REG]
485,1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,16.5,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2005[REG]
485,1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,18.2,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2005[REG]
485,1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.6,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
485,1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.1,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
485,1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.6,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
485,1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.1,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
485,1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,24.1,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
485,1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.7,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
485,1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
485,1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.6,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
485,1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,27.2,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2006[REG]
485,1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.5,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
485,1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.5,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
485,1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.7,"Taiwan, Province of China",Validated,20138303[PMID]
485,1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.0,United States,Not yet validated,21465650[PMID]_19818453[PMID]_18657826[PMID]
485,1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.6,Specific population,Validated,15535817[PMID]
485,1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.8,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
484,255,Dopa-responsive dystonia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.3,Europe,Validated,ORPHANET
484,255,Dopa-responsive dystonia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Worldwide,Validated,8420194[PMID]_19533203[PMID]
487,1915,Fetal alcohol syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.6,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
487,1915,Fetal alcohol syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.8,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2008[REG]
487,1915,Fetal alcohol syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.8,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
487,1915,Fetal alcohol syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,14.8,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
487,1915,Fetal alcohol syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.1,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
487,1915,Fetal alcohol syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,8.1,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
487,1915,Fetal alcohol syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.4,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2006[REG]
487,1915,Fetal alcohol syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.6,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
487,1915,Fetal alcohol syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,13.2,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2007[REG]
487,1915,Fetal alcohol syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.9,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
487,1915,Fetal alcohol syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,>1 / 1000,6800.0,South Africa,Validated,17127017[PMID]
487,1915,Fetal alcohol syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,13.6,France,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
487,1915,Fetal alcohol syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
487,1915,Fetal alcohol syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.2,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
487,1915,Fetal alcohol syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,80.8,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
487,1915,Fetal alcohol syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
486,1885,Isolated ectopia lentis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
486,1885,Isolated ectopia lentis,Malformation syndrome,Disorder,Cases/families,Case(s),,90.0,Worldwide,Validated,[EXPERT]
481,1851,Multicystic dysplastic kidney,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,23.26,Worldwide,Validated,19171687[PMID]
481,1851,Multicystic dysplastic kidney,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
551,660,Omphalocele,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.7,Europe,Validated,[EXPERT]_EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Validated,[EXPERT]_EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,19.6,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,14.6,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,10.9,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,19.8,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,13.6,France,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,France,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.6,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.6,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,25.3,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.0,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,48.2,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,22.9,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.2,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,12.1,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.9,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,12.3,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.6,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,16.2,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
551,660,Omphalocele,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,10.0,Czech Republic,Validated,23116348[PMID]
551,660,Omphalocele,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Czech Republic,Not yet validated,23116348[PMID]
551,660,Omphalocele,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.3,Japan,Validated,10646777[PMID]
551,660,Omphalocele,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Japan,Not yet validated,10646777[PMID]
551,660,Omphalocele,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,15.2,China,Validated,15498248[PMID]
551,660,Omphalocele,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,18.6,United States,Validated,Center for Diseases Control and Prevention 2010[INST]
551,660,Omphalocele,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,United States,Validated,Center for Diseases Control and Prevention 2010[INST]
548,635,Neuroblastoma,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,11.0,Europe,Validated,European Medicines Agency 2018[INST]
548,635,Neuroblastoma,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.8,Europe,Not yet validated,16919772[PMID]
548,635,Neuroblastoma,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.5,United States,Validated,21108439[PMID]
548,635,Neuroblastoma,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,14.0,Germany,Validated,11932471[PMID]
548,635,Neuroblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.26,Worldwide,Not yet validated,22796286[PMID]
549,2612,Linear nevus sebaceus syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
546,2635,Metatropic dysplasia,Disease,Disorder,Cases/families,Case(s),,81.0,Worldwide,Validated,ORPHANET_24223250[PMID]
546,2635,Metatropic dysplasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
546,2635,Metatropic dysplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.2,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
547,2655,Thanatophoric dysplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.5,Europe,Validated,[EXPERT]
547,2655,Thanatophoric dysplasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
547,2655,Thanatophoric dysplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.8,France,Validated,2785882[PMID]
547,2655,Thanatophoric dysplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.5,Italy,Validated,3071354[PMID]
547,2655,Thanatophoric dysplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.7,Sweden,Validated,8449630[PMID]
547,2655,Thanatophoric dysplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.8,Denmark,Validated,2783977[PMID]
547,2655,Thanatophoric dysplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,8.0,Ireland,Validated,22375084[PMID]
547,2655,Thanatophoric dysplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.7,Latin America,Validated,22407836[PMID]
547,2655,Thanatophoric dysplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.3,United States,Validated,22461456[PMID]
545,606,Proximal myotonic myopathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Germany,Validated,12921797[PMID]_12970845[PMID]
545,606,Proximal myotonic myopathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,[EXPERT]
545,606,Proximal myotonic myopathy,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,Finland,Validated,16684600[PMID]_22995693[PMID]
545,606,Proximal myotonic myopathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.17,United Kingdom,Validated,19767415[PMID]
558,705,Pendred syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.0,Europe,Validated,[EXPERT]
556,2801,Juvenile Paget disease,Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,ORPHANET
556,2801,Juvenile Paget disease,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
557,884,Tetrasomy 12p syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.0,Europe,Validated,[EXPERT]
557,884,Tetrasomy 12p syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
555,2785,Osteopetrosis with renal tubular acidosis,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,[EXPERT]
555,2785,Osteopetrosis with renal tubular acidosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
552,2744,Horizontal gaze palsy with progressive scoliosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
553,2746,Opsismodysplasia,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,23273569[PMID]
553,2746,Opsismodysplasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
567,2971,Peroxisomal acyl-CoA oxidase deficiency,Disease,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,ORPHANET
567,2971,Peroxisomal acyl-CoA oxidase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
566,2970,Prune belly syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.4,Italy,Validated,22506933[PMID]_ORPHANET
566,2970,Prune belly syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.38,United Kingdom,Not yet validated,8876090[PMID]_ORPHANET
566,2970,Prune belly syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.42,Canada,Validated,6454342[PMID]
566,2970,Prune belly syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.8,United States,Validated,20381841[PMID]
566,2970,Prune belly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
565,744,Proteus syndrome,Malformation syndrome,Disorder,Prevalence at birth,Class only,<1 / 1 000 000,0.0,Europe,Validated,21793738[PMID]_[EXPERT]
565,744,Proteus syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,21793738[PMID]_[EXPERT]_European Medicines Agency 2018[INST]
564,2903,Familial spontaneous pneumothorax,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,54.64,Finland,Validated,22643181[PMID]_21364698[PMID]
563,2901,Neuralgic amyotrophy,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.64,United States,Validated,2996415[PMID]_[EXPERT]
563,2901,Neuralgic amyotrophy,Disease,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Validated,[EXPERT]
563,2901,Neuralgic amyotrophy,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.0,United Kingdom,Validated,10733998[PMID]
563,2901,Neuralgic amyotrophy,Disease,Disorder,Lifetime Prevalence,Value and class,1-5 / 10 000,30.0,United Kingdom,Validated,10733998[PMID]
562,718,Isolated Pierre Robin sequence,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,United Kingdom,Not yet validated,6626822[PMID]
562,718,Isolated Pierre Robin sequence,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,8.0,France,Validated,22925539[PMID]
562,718,Isolated Pierre Robin sequence,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,France,Validated,22925539[PMID]
562,718,Isolated Pierre Robin sequence,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,12.4,Germany,Validated,24433508[PMID]
562,718,Isolated Pierre Robin sequence,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.5,Denmark,Validated,14697070[PMID]
562,718,Isolated Pierre Robin sequence,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Denmark,Not yet validated,14697070[PMID]
562,718,Isolated Pierre Robin sequence,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.5,Sweden,Validated,8897214[PMID]
562,718,Isolated Pierre Robin sequence,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Sweden,Not yet validated,8897214[PMID]
562,718,Isolated Pierre Robin sequence,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.9,United Kingdom,Validated,6626822[PMID]
562,718,Isolated Pierre Robin sequence,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.9,United States,Not yet validated,ORPHANET
562,718,Isolated Pierre Robin sequence,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,United States,Not yet validated,ORPHANET
562,718,Isolated Pierre Robin sequence,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.0,Europe,Validated,[EXPERT]
562,718,Isolated Pierre Robin sequence,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,[EXPERT]
562,718,Isolated Pierre Robin sequence,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.4,Netherlands,Validated,25994858[PMID]
562,718,Isolated Pierre Robin sequence,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,18.8,Australia,Validated,34626670[PMID]
575,290,Congenital rubella syndrome,Disease,Disorder,Prevalence at birth,Class only,1-9 / 1 000 000,0.0,Worldwide,Validated,[EXPERT]_World Health Organization 2005[INST]
575,290,Congenital rubella syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.29,France,Validated,22178098[PMID]
575,290,Congenital rubella syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.24,Germany,Validated,22178098[PMID]
575,290,Congenital rubella syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.8,Italy,Validated,22178098[PMID]
575,290,Congenital rubella syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.64,Netherlands,Validated,22178098[PMID]
575,290,Congenital rubella syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.27,Austria,Validated,22178098[PMID]
575,290,Congenital rubella syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.18,Romania,Validated,22178098[PMID]
575,290,Congenital rubella syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.22,Spain,Validated,22178098[PMID]
575,290,Congenital rubella syndrome,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.02,Turkey,Validated,22178098[PMID]
575,290,Congenital rubella syndrome,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.03,Europe,Not yet validated,22178098[PMID]
575,290,Congenital rubella syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.35,Europe,Not yet validated,22178098[PMID]
575,290,Congenital rubella syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
574,3071,Costello syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,20301680[PMID]
574,3071,Costello syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.08,Japan,Validated,22495831[PMID]
574,3071,Costello syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
571,763,Pycnodysostosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.13,Worldwide,Not yet validated,21569238[PMID]
571,763,Pycnodysostosis,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,[EXPERT]
570,2983,Difference of sex development-intellectual disability syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,2098045[PMID]_8031539[PMID]
570,2983,Difference of sex development-intellectual disability syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2098045[PMID]_8031539[PMID]
516,2301,Congenital short bowel syndrome,Morphological anomaly,Disorder,Cases/families,Case(s),,43.0,Worldwide,Validated,21042453[PMID]_22155368[PMID]_27352967[PMID]
516,2301,Congenital short bowel syndrome,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21042453[PMID]_22155368[PMID]
517,469,Hereditary fructose intolerance,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.0,Europe,Validated,[EXPERT]
517,469,Hereditary fructose intolerance,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.0,Switzerland,Validated,15880727[PMID]
517,469,Hereditary fructose intolerance,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Switzerland,Validated,15880727[PMID]
517,469,Hereditary fructose intolerance,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.0,United Kingdom,Not yet validated,12042775[PMID]_15880727[PMID]_8933337[PMID]
517,469,Hereditary fructose intolerance,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,United Kingdom,Not yet validated,12042775[PMID]_15880727[PMID]_8933337[PMID]
517,469,Hereditary fructose intolerance,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.8,Germany,Validated,15880727[PMID]
517,469,Hereditary fructose intolerance,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Germany,Validated,15880727[PMID]
517,469,Hereditary fructose intolerance,Disease,Disorder,Prevalence at birth,Class only,1-9 / 100 000,0.0,Poland,Not yet validated,16406649[PMID]
517,469,Hereditary fructose intolerance,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.2,Poland,Validated,16406649[PMID]
517,469,Hereditary fructose intolerance,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.5,Finland,Not yet validated,14565820[PMID]_ORPHANET
517,469,Hereditary fructose intolerance,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.753,United States,Validated,20033295[PMID]_36028839[PMID]
517,469,Hereditary fructose intolerance,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.38,Specific population,Validated,36028839[PMID]
517,469,Hereditary fructose intolerance,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1981,China,Validated,36028839[PMID]
518,2308,Jacobsen syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.5,United States,Validated,[EXPERT]_19267933[PMID]
518,2308,Jacobsen syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
519,2318,Joubert syndrome with oculorenal defect,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
519,2318,Joubert syndrome with oculorenal defect,Malformation syndrome,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,23845172[PMID]
512,2253,Foveal hypoplasia-presenile cataract syndrome,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,ORPHANET
512,2253,Foveal hypoplasia-presenile cataract syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
515,2300,Multiple intestinal atresia,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,29437734[PMID]_ORPHANET
515,2300,Multiple intestinal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.05,Worldwide,Validated,29437734[PMID]_ORPHANET
18125,180226,Embryonal carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
526,502,Trichorhinophalangeal syndrome type 2,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26269715[PMID]
526,502,Trichorhinophalangeal syndrome type 2,Malformation syndrome,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,26269715[PMID]
18126,180229,Polyembryoma,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
527,2370,Larsen-like osseous dysplasia-short stature syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,12784294[PMID]_1916762[PMID]
527,2370,Larsen-like osseous dysplasia-short stature syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_ 12784294[PMID]_1916762[PMID]
520,477,KID syndrome,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,ISBN:0723436657[OTHER]
520,477,KID syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_ISBN:0723436657[OTHER]
523,2346,Angioosteohypertrophic syndrome,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 1 000 000,0.8,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
523,2346,Angioosteohypertrophic syndrome,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
532,506,Leigh syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.8,Europe,Validated,[EXPERT]
532,506,Leigh syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.3,Australia,Validated,8602753[PMID]
532,506,Leigh syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
532,506,Leigh syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Europe,Validated,European Medicines Agency 2011[INST]
534,2414,Congenital pulmonary lymphangiectasia,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,ISBN:019974808X[OTHER]
534,2414,Congenital pulmonary lymphangiectasia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
18128,180234,Mixed germ cell tumor,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
531,2377,Laurence-Moon syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
530,2374,Isolated congenital laryngeal web,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,33194889[PMID]_ORPHANET
18131,180242,Malignant tumor of fallopian tubes,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,European Medicines Agency 2009[INST]
18131,180242,Malignant tumor of fallopian tubes,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.11,United Kingdom,Validated,16263546[PMID]
18131,180242,Malignant tumor of fallopian tubes,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.15,Denmark,Validated,2706135[PMID]
18131,180242,Malignant tumor of fallopian tubes,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.16,United States,Validated,18027113[PMID]
541,2466,MASA syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18141,180275,Paget disease of the nipple,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.51,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18141,180275,Paget disease of the nipple,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.065,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18141,180275,Paget disease of the nipple,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.096,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18141,180275,Paget disease of the nipple,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.179,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18141,180275,Paget disease of the nipple,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.433,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18141,180275,Paget disease of the nipple,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.235,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18141,180275,Paget disease of the nipple,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.192,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18141,180275,Paget disease of the nipple,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.287,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18141,180275,Paget disease of the nipple,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.434,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18141,180275,Paget disease of the nipple,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.29,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18141,180275,Paget disease of the nipple,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.682,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18141,180275,Paget disease of the nipple,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.487,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18141,180275,Paget disease of the nipple,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.421,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18141,180275,Paget disease of the nipple,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.254,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18141,180275,Paget disease of the nipple,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.215,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18141,180275,Paget disease of the nipple,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.345,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18141,180275,Paget disease of the nipple,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.709,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18141,180275,Paget disease of the nipple,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.209,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18141,180275,Paget disease of the nipple,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.21,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18141,180275,Paget disease of the nipple,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.457,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18141,180275,Paget disease of the nipple,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.415,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18141,180275,Paget disease of the nipple,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.394,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18141,180275,Paget disease of the nipple,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.335,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18141,180275,Paget disease of the nipple,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.637,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
540,560,Marshall syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,17236192[PMID]_19449424[PMID]
540,560,Marshall syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17236192[PMID]_19449424[PMID]
542,570,Moebius syndrome,Disease,Disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,ORPHANET
542,570,Moebius syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
542,570,Moebius syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.12,Netherlands,Validated,12913192[PMID]
542,570,Moebius syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.27,Italy,Validated,33827605[PMID]
542,570,Moebius syndrome,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.06,Italy,Validated,33827605[PMID]
537,1505,Short rib-polydactyly syndrome,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
538,2444,Congenital pulmonary airway malformation,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,8.2,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
538,2444,Congenital pulmonary airway malformation,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.9,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
538,2444,Congenital pulmonary airway malformation,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,17.7,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
538,2444,Congenital pulmonary airway malformation,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.9,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
538,2444,Congenital pulmonary airway malformation,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
538,2444,Congenital pulmonary airway malformation,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.2,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
538,2444,Congenital pulmonary airway malformation,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.4,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
538,2444,Congenital pulmonary airway malformation,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,17.1,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
538,2444,Congenital pulmonary airway malformation,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.9,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
538,2444,Congenital pulmonary airway malformation,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.7,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
538,2444,Congenital pulmonary airway malformation,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.8,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
538,2444,Congenital pulmonary airway malformation,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,12.3,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
538,2444,Congenital pulmonary airway malformation,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,18.1,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
538,2444,Congenital pulmonary airway malformation,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.2,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
538,2444,Congenital pulmonary airway malformation,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
610,612,Potassium-aggravated myotonia,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.0,France,Validated,11641035[PMID]_17616847[PMID]_[EXPERT]_Haute Autorité de Santé 2010[INST]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.99,France,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.4,Europe,Validated,34082800[PMID]_ORPHANET
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,11.5079,Europe,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.4,United Kingdom,Validated,34082800[PMID]_ORPHANET
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,United Kingdom,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,22.0,Ireland,Validated,9254847[PMID]_[EXPERT]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,22.0,Ireland,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Class only,1-9 / 1 000 000,0.0,Finland,Validated,8825928[PMID]_[EXPERT]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.8928,Finland,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.577,United States,Validated,34082800[PMID]_ORPHANET
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.0,United States,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.8,Latin America,Validated,34082800[PMID]_ORPHANET
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.5999,Latin America,Validated,32668217[PMID]_ORPHANET
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.5,Brazil,Validated,34082800[PMID]_ORPHANET
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.0,Brazil,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.266,Australia,Validated,34082800[PMID]_ORPHANET
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.89,Australia,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.9,Iceland,Validated,21659675[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,11.9,Iceland,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.16,Japan,Not yet validated,6468444[PMID]_20971365[PMID]_ ORPHANET
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.8,Japan,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.412,China,Validated,34082800[PMID]_ORPHANET
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.2798,China,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.68,Thailand,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.4399,Thailand,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.95,Turkey,Validated,34082800[PMID]_ORPHANET
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,14.99,Turkey,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.6,United Arab Emirates,Validated,34082800[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.89,United Arab Emirates,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.0,Jordan,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.6,Jordan,Validated,DOI:10.1007/978-3-642-05080-0_11[OTHER]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.4644,India,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.439,"Korea, Republic of",Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.862,Philippines,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.2,Singapore,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.6999,"Taiwan, Province of China",Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.5,Bahrain,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.0,"Iran, Islamic Republic of",Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.9998,Iraq,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,15.603,Israel,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.02,Saudi Arabia,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.0,Egypt,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,13.0005,Tunisia,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,17.349,Austria,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,13.0005,Belarus,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,Bosnia and Herzegovina,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.746,Bulgaria,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,12.0004,Croatia,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.6923,Cyprus,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,19.1534,Czech Republic,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.4437,Denmark,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,13.9997,Estonia,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,18.6567,Germany,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,9.5969,Greece,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,11.1111,Hungary,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,25.0,Italy,Validated,32668217[PMID]`
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,12.2399,Latvia,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.7526,Lithuania,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,13.5998,"Moldova, Republic of",Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.661,Netherlands,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.7282,Norway,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,12.3051,Poland,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.0,Portugal,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,Romania,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,12.9634,Russian Federation,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.13,Serbia,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,17.3822,Slovakia,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.9,Slovenia,Validated,34082800[PMID]_ORPHANET
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,9.8366,Spain,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.8858,Sweden,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,12.5,Switzerland,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,14.0016,Ukraine,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.6666,Canada,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.2798,New Caledonia,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.2798,New Zealand,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.3633,Argentina,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.1999,Chile,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0333,Costa rica,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.5999,Mexico,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.129,Peru,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Cuba,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.1366,Worldwide,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,13.34,India,Validated,32668217[PMID]_ORPHANET
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,22.7,Pakistan,Validated,32668217[PMID]
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.8,Saudi Arabia,Validated,34082800[PMID]
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,8.75,Austria,Validated,34082800[PMID]_ORPHANET
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,16.6,Estonia,Validated,34082800[PMID]
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.316,Germany,Validated,34082800[PMID]_ORPHANET
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.25,Greece,Validated,34082800[PMID]_ORPHANET
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,8.5,Hungary,Validated,34082800[PMID]
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.933,Italy,Validated,34082800[PMID]_ORPHANET
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,24.6,North Macedonia,Validated,34082800[PMID]_ORPHANET
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.85,Poland,Validated,34082800[PMID]_ORPHANET
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.0,Portugal,Validated,34082800[PMID]_ORPHANET
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,16.9,Slovakia,Validated,34082800[PMID]
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.6,Spain,Validated,34082800[PMID]
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.55,Chile,Validated,34082800[PMID]_ORPHANET
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.271,"Iran, Islamic Republic of",Validated,34082800[PMID]_ORPHANET
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.5,Canada,Validated,34082800[PMID]_ORPHANET
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.1,"Korea, Republic of",Validated,34082800[PMID]
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.433,"Taiwan, Province of China",Validated,34082800[PMID]_ORPHANET
611,716,Phenylketonuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.4,Worldwide,Validated,34082800[PMID]
612,287,Classical Ehlers-Danlos syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.0,Worldwide,Validated,20301422[PMID]_20847697[PMID]_[EXPERT]
631,1020,Early-onset autosomal dominant Alzheimer disease,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
630,63,Alport syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,[EXPERT]
630,63,Alport syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.9,Finland,Validated,8955456[PMID]
629,54,X-linked recessive ocular albinism,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.58,Europe,Validated,[EXPERT]_ORPHANET
629,54,X-linked recessive ocular albinism,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,[EXPERT]_ORPHANET
629,54,X-linked recessive ocular albinism,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.84,Denmark,Validated,9887374[PMID]_[EXPERT]
629,54,X-linked recessive ocular albinism,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Denmark,Validated,9887374[PMID]_[EXPERT]
629,54,X-linked recessive ocular albinism,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,United States,Validated,20301517[PMID]
629,54,X-linked recessive ocular albinism,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,United States,Not yet validated,20301517[PMID]
635,154,Familial isolated dilated cardiomyopathy,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.91,Europe,Validated,16839424[PMID]_[EXPERT]_ ORPHANET
635,154,Familial isolated dilated cardiomyopathy,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,17.5,Europe,Validated,16839424[PMID]_[EXPERT]_ ORPHANET
635,154,Familial isolated dilated cardiomyopathy,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,6.0,United States,Validated,2766509[PMID]
634,84,Fanconi anemia,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.3,Specific population,Validated,7492758[PMID]
634,84,Fanconi anemia,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.3,Europe,Validated,20824457[PMID]_European Medicines Agency 2018[INST]
634,84,Fanconi anemia,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.62,Europe,Validated,[EXPERT]
634,84,Fanconi anemia,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.2,Israel,Validated,20435624[PMID]
634,84,Fanconi anemia,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.5,Specific population,Validated,11344308[PMID]
634,84,Fanconi anemia,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.5,Specific population,Validated,15522956[PMID]
634,84,Fanconi anemia,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.111,China,Validated,34103049[PMID]
633,70,Proximal spinal muscular atrophy,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.6,Europe,Validated,European Medicines Agency[INST]
633,70,Proximal spinal muscular atrophy,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,20.0,Europe,Not yet validated,23107878[PMID]
633,70,Proximal spinal muscular atrophy,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
632,69,Amyloidosis,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
632,69,Amyloidosis,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.91,"Korea, Republic of",Validated,28877709[PMID]
638,191,Cockayne syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,[EXPERT]
638,191,Cockayne syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.2,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
638,191,Cockayne syndrome,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.09,Germany,Validated,18329345[PMID]
638,191,Cockayne syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.18,France,Validated,18329345[PMID]
638,191,Cockayne syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.2,Italy,Validated,18329345[PMID]
638,191,Cockayne syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.45,Netherlands,Validated,18329345[PMID]
638,191,Cockayne syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.38,United Kingdom,Validated,18329345[PMID]
638,191,Cockayne syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
637,166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,25.0,Europe,Not yet validated,21820100[PMID]_20301532[PMID]_ ORPHANET
637,166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,15.95,United Kingdom,Not yet validated,21984771[PMID]_8026104[PMID]_ ORPHANET
637,166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Category,Group of disorders,Point prevalence,Value and class,6-9 / 10 000,61.0,Norway,Not yet validated,20482598[PMID]_4430158[PMID]_ ORPHANET
637,166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,28.2,Spain,Validated,3472423[PMID]
637,166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,17.5,Italy,Validated,12207152[PMID]
637,166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,19.55,Sweden,Not yet validated,6576612[PMID]_8333247[PMID]_ ORPHANET
637,166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,6.1,Denmark,Validated,2096315[PMID]
637,166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,12.0,Iceland,Validated,19893324[PMID]
637,166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,10.8,Japan,Validated,12207153[PMID]
637,166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,16.0,Cyprus,Validated,20571287[PMID]
637,166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,9.7,Serbia,Validated,21546779[PMID]
578,834,Free sialic acid storage disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16584062[PMID]
578,834,Free sialic acid storage disease,Disease,Disorder,Cases/families,Case(s),,130.0,Worldwide,Validated,16584062[PMID]
580,799,Schizencephaly,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.48,United Kingdom,Validated,21647999[PMID]
580,799,Schizencephaly,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.54,United States,Validated,16059942[PMID]
580,799,Schizencephaly,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
580,799,Schizencephaly,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Japan,Validated,26545857[PMID]
582,3151,Multiple sclerosis-ichthyosis-factor VIII deficiency syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8336172[PMID]
582,3151,Multiple sclerosis-ichthyosis-factor VIII deficiency syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8336172[PMID]
18054,178566,Mycosis fungoides and variants,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.59,Europe,Validated,ORPHANET
18054,178566,Mycosis fungoides and variants,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
584,813,Silver-Russell syndrome,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,15.5,Europe,Validated,[EXPERT]_ORPHANET
584,813,Silver-Russell syndrome,Disease,Disorder,Prevalence at birth,Class only,1-9 / 100 000,0.0,United Kingdom,Not yet validated,16128241[PMID]
584,813,Silver-Russell syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,United Kingdom,Validated,16128241[PMID]
584,813,Silver-Russell syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.7,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
584,813,Silver-Russell syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
585,3169,Sirenomelia,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.98,Worldwide,Not yet validated,22002878[PMID]
585,3169,Sirenomelia,Malformation syndrome,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.01,Worldwide,Not yet validated,ORPHANET
585,3169,Sirenomelia,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.71,Europe,Not yet validated,ORPHANET
585,3169,Sirenomelia,Malformation syndrome,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.009,Europe,Not yet validated,ORPHANET
585,3169,Sirenomelia,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.04,France,Validated,22002878[PMID]
585,3169,Sirenomelia,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.62,Italy,Validated,22002878[PMID]
585,3169,Sirenomelia,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.64,Spain,Validated,22002878[PMID]
585,3169,Sirenomelia,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.54,Netherlands,Validated,22002878[PMID]
585,3169,Sirenomelia,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.7,Finland,Validated,22002878[PMID]
585,3169,Sirenomelia,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.31,Slovakia,Validated,22002878[PMID]
585,3169,Sirenomelia,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.33,Hungary,Validated,22002878[PMID]
585,3169,Sirenomelia,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.74,United States,Validated,22002878[PMID]
585,3169,Sirenomelia,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.6,Canada,Validated,22002878[PMID]
585,3169,Sirenomelia,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.83,China,Validated,22002878[PMID]
585,3169,Sirenomelia,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.79,Australia,Validated,22002878[PMID]
585,3169,Sirenomelia,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.36,Mexico,Validated,22002878[PMID]
585,3169,Sirenomelia,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.36,Latin America,Validated,22002878[PMID]
585,3169,Sirenomelia,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,12.0,Colombia,Validated,22030798[PMID]
585,3169,Sirenomelia,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.98,Brazil,Validated,35209917[PMID]
586,816,Sjögren-Larsson syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.6,Sweden,Validated,7273467[PMID]
586,816,Sjögren-Larsson syndrome,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,16.0,"Taiwan, Province of China",Validated,22899470[PMID]
586,816,Sjögren-Larsson syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
588,821,Sotos syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.1,Worldwide,Not yet validated,20301652[PMID]
588,821,Sotos syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Worldwide,Not yet validated,20301652[PMID]
588,821,Sotos syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
588,821,Sotos syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,ORPHANET_EUROCAT European surveillance of congenital anomalies 2005-2010[REG]
589,3173,Infantile spasms-broad thumbs syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,2335044[PMID]
589,3173,Infantile spasms-broad thumbs syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2335044[PMID]
590,3204,Stormorken-Sjaastad-Langslet syndrome,Disease,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,25044882[PMID]_25577287[PMID]
590,3204,Stormorken-Sjaastad-Langslet syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25044882[PMID]_25577287[PMID]
591,3205,Sturge-Weber syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.5,Europe,Validated,24275166[PMID]
591,3205,Sturge-Weber syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
595,3320,Thrombocytopenia-absent radius syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
595,3320,Thrombocytopenia-absent radius syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
597,3346,Tracheal agenesis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.0,Europe,Validated,ORPHANET
597,3346,Tracheal agenesis,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,ORPHANET
596,858,Congenital toxoplasmosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,33.0,Europe,Validated,[EXPERT]
596,858,Congenital toxoplasmosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,30.0,France,Validated,20587361[PMID]
596,858,Congenital toxoplasmosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Greece,Validated,23173875[PMID]
596,858,Congenital toxoplasmosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.2,United Kingdom,Validated,16547084[PMID]
596,858,Congenital toxoplasmosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.3,Sweden,Validated,11561964[PMID]
596,858,Congenital toxoplasmosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,30.0,Denmark,Validated,10359408[PMID]
596,858,Congenital toxoplasmosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,50.0,Switzerland,Validated,7597405[PMID]
596,858,Congenital toxoplasmosis,Disease,Disorder,Prevalence at birth,Value and class,>1 / 1000,130.0,Germany,Validated,23173875[PMID]
596,858,Congenital toxoplasmosis,Disease,Disorder,Prevalence at birth,Value and class,>1 / 1000,113.0,Poland,Validated,11326012[PMID]
596,858,Congenital toxoplasmosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,40.0,Brazil,Validated,22974376[PMID]
596,858,Congenital toxoplasmosis,Disease,Disorder,Prevalence at birth,Value and class,>1 / 1000,138.0,Italy,Validated,19430667[PMID]
596,858,Congenital toxoplasmosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,55.0,United States,Validated,Center for Diseases Control and Prevention[INST]_ORPHANET
596,858,Congenital toxoplasmosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
596,858,Congenital toxoplasmosis,Disease,Disorder,Prevalence at birth,Value and class,>1 / 1000,640.0,"Iran, Islamic Republic of",Validated,31096746[PMID]
603,887,VACTERL/VATER association,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.25,Europe,Validated,21846383[PMID]_[EXPERT]_ ORPHANET
603,887,VACTERL/VATER association,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
602,291,Congenital varicella syndrome,Disease,Disorder,Cases/families,Case(s),,130.0,Worldwide,Validated,26965725[PMID]
602,291,Congenital varicella syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_26965725[PMID]
605,909,Cerebrotendinous xanthomatosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Specific population,Validated,16157755[PMID]_[EXPERT]
605,909,Cerebrotendinous xanthomatosis,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.056,Spain,Validated,21645175[PMID]
605,909,Cerebrotendinous xanthomatosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.0,United States,Validated,16157755[PMID]
605,909,Cerebrotendinous xanthomatosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
604,3447,Weaver syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,48.0,Worldwide,Validated,24214728[PMID]
604,3447,Weaver syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24214728[PMID]
606,1422,Chondrodysplasia-difference of sex development syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,1342874[PMID]
606,1422,Chondrodysplasia-difference of sex development syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1342874[PMID]
18030,178478,Infant botulism,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.2,Europe,Validated,[EXPERT]
18030,178478,Infant botulism,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.3,Europe,Validated,[EXPERT]_Center for Diseases Control and Prevention[INST]_ ORPHANET
18030,178478,Infant botulism,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.1,United States,Validated,[EXPERT]
18030,178478,Infant botulism,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.2,Argentina,Validated,[EXPERT]
18030,178478,Infant botulism,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18031,178481,Intestinal botulism,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18029,178475,Wound botulism,Etiological subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,[EXPERT]_Center for Diseases Control and Prevention[INST]_ ORPHANET
18029,178475,Wound botulism,Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
18026,178461,X-linked myopathy with postural muscle atrophy,Disease,Disorder,Cases/families,Family(ies),,7.0,Worldwide,Validated,19687455[PMID]
18026,178461,X-linked myopathy with postural muscle atrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19687455[PMID]
18027,178464,Hereditary myopathy with early respiratory failure,Disease,Disorder,Cases/families,Family(ies),,10.0,Worldwide,Validated,10407851[PMID]_10053013[PMID]_2376753[PMID]
18027,178464,Hereditary myopathy with early respiratory failure,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10407851[PMID]_10053013[PMID]_2376753[PMID]
18024,178396,Hemorrhagic disease due to alpha-1-antitrypsin Pittsburgh mutation,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,19483159[PMID]
18024,178396,Hemorrhagic disease due to alpha-1-antitrypsin Pittsburgh mutation,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19483159[PMID]
18025,178400,Distal myopathy with anterior tibial onset,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,11198284[PMID]
18025,178400,Distal myopathy with anterior tibial onset,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11198284[PMID]
18022,178382,Congenital vertical talus,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18023,178389,Osteopetrosis-hypogammaglobulinemia syndrome,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,18606301[PMID]
18023,178389,Osteopetrosis-hypogammaglobulinemia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18606301[PMID]
678,62,Alpha-sarcoglycan-related limb-girdle muscular dystrophy R3,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.07,United Kingdom,Validated,19767415[PMID]
678,62,Alpha-sarcoglycan-related limb-girdle muscular dystrophy R3,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18020,178364,Syndromic microphthalmia type 5,Malformation syndrome,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,ORPHANET
18020,178364,Syndromic microphthalmia type 5,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
677,715,Glycogen storage disease due to muscle phosphorylase kinase deficiency,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,[EXPERT]
677,715,Glycogen storage disease due to muscle phosphorylase kinase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18021,178377,Osteosclerosis-developmental delay-craniosynostosis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,15940380[PMID]
18021,178377,Osteosclerosis-developmental delay-craniosynostosis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15940380[PMID]
676,348,"Fructose-1,6-bisphosphatase deficiency",Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.67,Italy,Validated,11953730[PMID]
676,348,"Fructose-1,6-bisphosphatase deficiency",Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18018,178345,Aromatase excess syndrome,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,24716396[PMID]
18018,178345,Aromatase excess syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24716396[PMID]
18019,178355,Smith-McCort dysplasia,Disease,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,23042644[PMID]_28127940[PMID]
18019,178355,Smith-McCort dysplasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28127940[PMID]
18016,178338,UV-sensitive syndrome,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,19329487[PMID]_7264357[PMID]_9777763[PMID]_22466610[PMID]
18016,178338,UV-sensitive syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19329487[PMID]_7264357[PMID]_9777763[PMID]_22466610[PMID]
673,3137,Alpha-N-acetylgalactosaminidase deficiency,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,ORPHANET
673,3137,Alpha-N-acetylgalactosaminidase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
703,117,Behçet disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.66,Spain,Validated,10743812[PMID]
703,117,Behçet disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.24,Italy,Validated,17266063[PMID]
703,117,Behçet disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.2,United States,Validated,19405011[PMID]
703,117,Behçet disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.58,"Iran, Islamic Republic of",Validated,21199472[PMID]
703,117,Behçet disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.1,France,Validated,19035493[PMID]
703,117,Behçet disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.8,Italy,Validated,17266063[PMID]
703,117,Behçet disease,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,11.1,United Kingdom,Validated,36068543[PMID]
703,117,Behçet disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.2,Sweden,Validated,7904097[PMID]
703,117,Behçet disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.5,Portugal,Validated,10519357[PMID]
703,117,Behçet disease,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,Japan,Validated,19035493[PMID]_[EXPERT]
703,117,Behçet disease,Disease,Disorder,Point prevalence,Value and class,>1 / 1000,225.0,Turkey,Validated,19035493[PMID]_[EXPERT]
703,117,Behçet disease,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,16.7,"Iran, Islamic Republic of",Validated,10519357[PMID]
703,117,Behçet disease,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,15.2,Israel,Validated,16897122[PMID]
703,117,Behçet disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.4,"Taiwan, Province of China",Not yet validated,22899470[PMID]
703,117,Behçet disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.8,"Taiwan, Province of China",Validated,22899470[PMID]
703,117,Behçet disease,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.0,Saudi Arabia,Validated,10519357[PMID]
703,117,Behçet disease,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
703,117,Behçet disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.51,"Korea, Republic of",Validated,32770715[PMID]
700,732,Polymyositis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.585,Europe,Validated,ORPHANET
700,732,Polymyositis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.1,Europe,Validated,[EXPERT]
700,732,Polymyositis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.75,Argentina,Validated,23965482[PMID]
700,732,Polymyositis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.2,Argentina,Validated,23965482[PMID]
700,732,Polymyositis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.41,Australia,Validated,23981756[PMID]
700,732,Polymyositis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.2,Australia,Validated,23981756[PMID]
700,732,Polymyositis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.39,Spain,Validated,18053482[PMID]
700,732,Polymyositis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.76,Sweden,Validated,9137324[PMID]
701,221,Dermatomyositis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Australia,Validated,23981756[PMID]
701,221,Dermatomyositis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.97,Australia,Validated,23981756[PMID]
701,221,Dermatomyositis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.32,Argentina,Validated,23965482[PMID]
701,221,Dermatomyositis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.2,Argentina,Validated,23965482[PMID]
701,221,Dermatomyositis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.49,Spain,Validated,18053482[PMID]
701,221,Dermatomyositis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.1,United States,Validated,34549549[PMID]
701,221,Dermatomyositis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,13.0,United States,Validated,34549549[PMID]
701,221,Dermatomyositis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.9172,Norway,Validated,24695011[PMID]_ORPHANET
701,221,Dermatomyositis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.32,Sweden,Validated,28160487[PMID]
701,221,Dermatomyositis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.8,Sweden,Validated,28160487[PMID]
701,221,Dermatomyositis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.5,Germany,Validated,36581896[PMID]
701,221,Dermatomyositis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,11.3,Germany,Validated,36581896[PMID]
701,221,Dermatomyositis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,0.9704,Worldwide,Validated,36581896[PMID]_ORPHANET
701,221,Dermatomyositis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.5312,Worldwide,Validated,36581896[PMID]_ORPHANET
698,598,Multiminicore myopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.125,Australia,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.0937,Australia,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.152,Austria,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.114,Austria,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.117,Belgium,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.087,Belgium,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.105,Canada,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.078,Canada,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Czech Republic,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.09,Czech Republic,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.104,Cyprus,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.078,Cyprus,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.147,Denmark,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.11,Denmark,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.032,Estonia,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.024,Estonia,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.141,Finland,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.105,Finland,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.16,France,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.12,France,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.133,Germany,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.099,Germany,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.062,Greece,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.0465,Greece,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.0107,Hungary,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.08,Hungary,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.142,Italy,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1065,Italy,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.123,Netherlands,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.092,Netherlands,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.102,Norway,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.0765,Norway,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.0086,Slovakia,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.0645,Slovakia,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.146,Slovenia,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1095,Slovenia,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.128,Spain,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.096,Spain,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.142,Sweden,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1065,Sweden,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.173,Switzerland,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.129,Switzerland,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.055,"Taiwan, Province of China",Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.041,"Taiwan, Province of China",Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.124,United Kingdom,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.093,United Kingdom,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.122,United States,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.0915,United States,Validated,31876504[PMID]
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.088,Worldwide,Validated,31876504[PMID]_ 32344417[PMID]_ORPHANET
697,204,Sporadic Creutzfeldt-Jakob disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.118,Worldwide,Validated,31876504[PMID]
18039,178517,Localized pagetoid reticulosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18038,178512,Folliculotropic mycosis fungoides,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18037,178509,Perry syndrome,Disease,Disorder,Cases/families,Case(s),,53.0,Worldwide,Validated,[EXPERT]
18037,178509,Perry syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18036,178506,"Brain calcification, Rajab type",Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,19161147[PMID]
18036,178506,"Brain calcification, Rajab type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19161147[PMID]
690,611,Inclusion body myositis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,European Medicines Agency 2012[INST]
690,611,Inclusion body myositis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,2.5,Sweden,Validated,35596584[PMID]
690,611,Inclusion body myositis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.49,Netherlands,Validated,11087787[PMID]
690,611,Inclusion body myositis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.2,Australia,Not yet validated,10842277[PMID]_18815046[PMID]_ ORPHANET
690,611,Inclusion body myositis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.1,United States,Validated,11552086[PMID]
690,611,Inclusion body myositis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Turkey,Validated,21842592[PMID]
690,611,Inclusion body myositis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.2,Sweden,Validated,35596584[PMID]
18032,178487,Adult intestinal botulism,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,[EXPERT]
18032,178487,Adult intestinal botulism,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
17996,177926,Bleeding disorder in hemophilia A carriers,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.21,Brazil,Validated,PMID: 31926052
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.87,Europe,Not yet validated,ORPHANET
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.57,Germany,Validated,16435194[PMID]
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.84,Portugal,Validated,14685153[PMID]
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.89,Netherlands,Validated,10480370[PMID]
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.42,Australia,Validated,9918480[PMID]
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.91,Czech Republic,Validated,20490927[PMID]
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.84,Sweden,Validated,18681890[PMID]_25274184[PMID]
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.63,Sweden,Validated,18681890[PMID]
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.27,Norway,Validated,18681890[PMID]
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.88,Norway,Validated,18681890[PMID]
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.43,Denmark,Validated,18681890[PMID]
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.92,Denmark,Validated,18681890[PMID]
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.36,Ireland,Validated,9439667[PMID]
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.29,Canada,Validated,10617747[PMID]
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.39,"Taiwan, Province of China",Validated,19396827[PMID]
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.7,Tunisia,Validated,20209839[PMID]
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Prevalence at birth,Class only,1-9 / 1 000 000,0.0,Worldwide,Not yet validated,ORPHANET
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.3,Europe,Validated,European Medicines Agency 2012[INST]
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.86,Poland,Validated,25472774[PMID]
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.26,Japan,Validated,28595941[PMID]
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.38,Switzerland,Validated,28595941[PMID]
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.8,Saudi Arabia,Validated,20622343[PMID]
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.25,"Korea, Republic of",Validated,25364648[PMID]
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.62,Estonia,Validated,22480138[PMID]
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.4,Israel,Validated,33239050[PMID]_ORPHANET
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.8,Specific population,Validated,33239050[PMID]_ORPHANET
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.071,United States,Validated,34051828[PMID]
653,581,Mucopolysaccharidosis type 3,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.26,United States,Validated,34051828[PMID]
17997,177929,Bleeding disorder in hemophilia B carriers,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
655,685,Hereditary spastic paraplegia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,4.8,Europe,Validated,ORPHANET_2043954[PMID]_19339254[PMID]_19039240[PMID]_23609960[PMID]_1512613[PMID]
655,685,Hereditary spastic paraplegia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,9.6,Spain,Validated,2043954[PMID]_24603320[PMID]
655,685,Hereditary spastic paraplegia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,4.1,Portugal,Validated,23609960[PMID]_24603320[PMID]
655,685,Hereditary spastic paraplegia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.3,Sweden,Not yet validated,ORPHANET
655,685,Hereditary spastic paraplegia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,4.2,Worldwide,Validated,ORPHANET_24603320[PMID]
655,685,Hereditary spastic paraplegia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,5.75,Tunisia,Validated,19438933[PMID]_24603320[PMID]
655,685,Hereditary spastic paraplegia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,7.4,Norway,Validated,19339254[PMID]_24603320[PMID]
655,685,Hereditary spastic paraplegia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,2.7,Italy,Validated,1512613[PMID]_3759416[PMID]_7793232[PMID]
655,685,Hereditary spastic paraplegia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,4.4,Estonia,Validated,19039240[PMID]_24603320[PMID]
655,685,Hereditary spastic paraplegia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,2.1,Libyan Arab Jamahiriya,Validated,4075075[PMID]_24603320[PMID]
654,666,Osteogenesis imperfecta,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,8.06,Worldwide,Validated,31769437[PMID]_25944380[PMID]_24715559[PMID]
654,666,Osteogenesis imperfecta,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.4,France,Validated,2785882[PMID]
654,666,Osteogenesis imperfecta,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.4,Latin America,Validated,3746832[PMID]
654,666,Osteogenesis imperfecta,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.5,Ireland,Validated,22375084[PMID]
654,666,Osteogenesis imperfecta,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.95,United States,Validated,22461456[PMID]_24715559[PMID]
654,666,Osteogenesis imperfecta,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.4,Sweden,Validated,25944380[PMID]
654,666,Osteogenesis imperfecta,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.375,China,Validated,34103049[PMID]
17999,178029,Arginine vasopressin deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.0,Europe,Validated,[EXPERT]
649,423,Malignant hyperthermia of anesthesia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
648,418,Congenital adrenal hyperplasia,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,13.35,Europe,Validated,[EXPERT]_ORPHANET
648,418,Congenital adrenal hyperplasia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,10.0,Europe,Validated,European Medicines Agency 2018[INST]
648,418,Congenital adrenal hyperplasia,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,6.7,Europe,Not yet validated,15964450[PMID]_15554889[PMID]
648,418,Congenital adrenal hyperplasia,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,8.6,France,Validated,10079883[PMID]
648,418,Congenital adrenal hyperplasia,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,6.65,Italy,Not yet validated,8784357[PMID]_15818055[PMID]_ ORPHANET
648,418,Congenital adrenal hyperplasia,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,12.8,Germany,Validated,20148377[PMID]
648,418,Congenital adrenal hyperplasia,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,10.2,Sweden,Validated,9521977[PMID]
648,418,Congenital adrenal hyperplasia,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,5.6,United Kingdom,Not yet validated,22241917[PMID]_3259306[PMID]
648,418,Congenital adrenal hyperplasia,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,7.65,Netherlands,Not yet validated,15554889[PMID]_11731654[PMID]_ ORPHANET
648,418,Congenital adrenal hyperplasia,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,4.0,Belgium,Validated,15554889[PMID]
648,418,Congenital adrenal hyperplasia,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,9.3,Switzerland,Validated,12213856[PMID]
648,418,Congenital adrenal hyperplasia,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,5.35,Japan,Not yet validated,23330248[PMID]_ORPHANET
648,418,Congenital adrenal hyperplasia,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,6.9,New Zealand,Validated,3259306[PMID]
648,418,Congenital adrenal hyperplasia,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,6.3,Cuba,Validated,23481450[PMID]
648,418,Congenital adrenal hyperplasia,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,6.7,"Taiwan, Province of China",Validated,12517042[PMID]
648,418,Congenital adrenal hyperplasia,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,38.8,India,Validated,15053381[PMID]
648,418,Congenital adrenal hyperplasia,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,4.8,United States,Not yet validated,21641615[PMID]_15964450[PMID]_22766612[PMID]
648,418,Congenital adrenal hyperplasia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.36,China,Validated,34103049[PMID]
648,418,Congenital adrenal hyperplasia,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,7.98,Czech Republic,Validated,31241292[PMID]
650,216,Neuronal ceroid lipofuscinosis,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
650,216,Neuronal ceroid lipofuscinosis,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.12,Italy,Validated,23374165[PMID]
650,216,Neuronal ceroid lipofuscinosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.98,Italy,Validated,23374165[PMID]
650,216,Neuronal ceroid lipofuscinosis,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 1 000 000,0.56,Italy,Validated,7668318[PMID]
650,216,Neuronal ceroid lipofuscinosis,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,4.0,Norway,Validated,17092455[PMID]
650,216,Neuronal ceroid lipofuscinosis,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,2.0,Europe,Validated,European Medicines Agency 2018[INST]
645,364,Glycogen storage disease due to glucose-6-phosphatase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
645,364,Glycogen storage disease due to glucose-6-phosphatase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Worldwide,Validated,21599942[PMID]_[EXPERT]
644,355,Gaucher disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.7,Europe,Validated,[EXPERT]
644,355,Gaucher disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,[EXPERT]
644,355,Gaucher disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.3,Worldwide,Not yet validated,23046562[PMID]
644,355,Gaucher disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.67,Spain,Validated,22429443[PMID]
644,355,Gaucher disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.7,Austria,Validated,22133539[PMID]
644,355,Gaucher disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.6,France,Validated,23046562[PMID]
644,355,Gaucher disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.0,France,Validated,23046562[PMID]
644,355,Gaucher disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.74,France,Validated,23046562[PMID]
644,355,Gaucher disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.7,Australia,Validated,9918480[PMID]
644,355,Gaucher disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.13,Czech Republic,Validated,20490927[PMID]
644,355,Gaucher disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.35,Portugal,Validated,14685153[PMID]
644,355,Gaucher disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.16,Netherlands,Validated,10480370[PMID]
644,355,Gaucher disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.5,Hungary,Validated,23430949[PMID]
644,355,Gaucher disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.45,Turkey,Validated,15275696[PMID]
644,355,Gaucher disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.11,Sweden,Validated,25274184[PMID]
644,355,Gaucher disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.224,China,Validated,34103049[PMID]
647,388,Hirschsprung disease,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,13.2,Europe,Validated,25066220[PMID]_Eurocat
647,388,Hirschsprung disease,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,21.0,United States,Validated,27702942[PMID]
647,388,Hirschsprung disease,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,13.2,Europe,Validated,25066220[PMID]_ORPHANET
647,388,Hirschsprung disease,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,15.0,Worldwide,Validated,31644668[PMID]_27702942[PMID]_ORPHANET
647,388,Hirschsprung disease,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,22.0,"Taiwan, Province of China",Validated,27118113[PMID]
647,388,Hirschsprung disease,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,15.0,Worldwide,Validated,31644668[PMID]_27702942[PMID]
17991,177107,Syndromic hypothyroidism,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
646,448,Hemophilia,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,6.25,Europe,Not yet validated,ORPHANET
646,448,Hemophilia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,7.7,Europe,Not yet validated,ORPHANET
646,448,Hemophilia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,6.46,China,Validated,34103049[PMID]
641,304,Epidermolysis bullosa simplex,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.656,Worldwide,Validated,20566927[PMID]_ 25201089[PMID]_ 33095945[PMID]
641,304,Epidermolysis bullosa simplex,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.58,Australia,Validated,20566927[PMID]
641,304,Epidermolysis bullosa simplex,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.19,Netherlands,Validated,33095945[PMID]
641,304,Epidermolysis bullosa simplex,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.197,Romania,Validated,25201089[PMID]
643,354,GM1 gangliosidosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.75,Europe,Validated,ORPHANET
643,354,GM1 gangliosidosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,27.0,Malta,Validated,9323577[PMID]_[EXPERT]
643,354,GM1 gangliosidosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.9,Brazil,Validated,10517258[PMID]_[EXPERT]
643,354,GM1 gangliosidosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
643,354,GM1 gangliosidosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.34,Sweden,Validated,25274184[PMID]
18013,178320,Acute lung injury,Particular clinical situation in a disease or syndrome,Disorder,Annual incidence,Value and class,1-5 / 10 000,25.0,Europe,Not yet validated,15659944[PMID]_15166842[PMID]
18013,178320,Acute lung injury,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Validated,European Medicines Agency 2012[INST]
18013,178320,Acute lung injury,Particular clinical situation in a disease or syndrome,Disorder,Annual incidence,Value and class,1-5 / 10 000,25.0,Australia,Not yet validated,15659944[PMID]_15166842[PMID]
18013,178320,Acute lung injury,Particular clinical situation in a disease or syndrome,Disorder,Annual incidence,Value and class,6-9 / 10 000,65.0,United States,Not yet validated,15659944[PMID]_20073554[PMID]_9468178[PMID]
18015,178333,Åland Islands eye disease,Disease,Disorder,Cases/families,Family(ies),,5.0,Worldwide,Validated,17525176[PMID]
18015,178333,Åland Islands eye disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
671,760,Purine nucleoside phosphorylase deficiency,Disease,Disorder,Cases/families,Case(s),,72.0,Worldwide,Validated,30885031[PMID]
671,760,Purine nucleoside phosphorylase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,ORPHANET_30885031[PMID]
664,270,Oculopharyngeal muscular dystrophy,Disease,Disorder,Point prevalence,Value and class,>1 / 1000,167.0,Specific population,Validated,9392014[PMID]
664,270,Oculopharyngeal muscular dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,France,Validated,9392013[PMID]_2204987[PMID]
664,270,Oculopharyngeal muscular dystrophy,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET
664,270,Oculopharyngeal muscular dystrophy,Disease,Disorder,Point prevalence,Value and class,>1 / 1000,100.0,Specific population,Validated,7795598[PMID]
18009,178303,8q22.1 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,22821852[PMID]
18009,178303,8q22.1 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
665,244,Primary ciliary dyskinesia,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,44.0,Pakistan,Validated,19720631[PMID]
665,244,Primary ciliary dyskinesia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.0,Europe,Validated,23871404[PMID]
18010,178307,Reticulate acropigmentation of Kitamura,Disease,Disorder,Cases/families,Case(s),,130.0,Worldwide,Validated,23666529[PMID]
18010,178307,Reticulate acropigmentation of Kitamura,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
667,589,Myasthenia gravis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.7,Europe,Validated,20130418[PMID]_[EXPERT]_ ORPHANET
667,589,Myasthenia gravis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.0,Europe,Validated,17986328[PMID]_[EXPERT]_European Medicines Agency 2018[INST]
667,589,Myasthenia gravis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.77,Worldwide,Validated,20565885[PMID]
667,589,Myasthenia gravis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.9,United States,Validated,8909435[PMID]
667,589,Myasthenia gravis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.0,Canada,Validated,14664466[PMID]
667,589,Myasthenia gravis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.1,Spain,Validated,12654975[PMID]
667,589,Myasthenia gravis,Disease,Disorder,Lifetime Prevalence,Value and class,1-5 / 10 000,40.0,United Kingdom,Validated,10733998[PMID]
667,589,Myasthenia gravis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.11,United Kingdom,Validated,9771771[PMID]
667,589,Myasthenia gravis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,15.0,United Kingdom,Validated,9771771[PMID]
667,589,Myasthenia gravis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.33,Serbia,Validated,23363926[PMID]
667,589,Myasthenia gravis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,17.0,United States,Validated,8909435[PMID]
667,589,Myasthenia gravis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,31.8,Serbia,Validated,23363926[PMID]
667,589,Myasthenia gravis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.94,Italy,Validated,21757957[PMID]_20623298[PMID]_ ORPHANET
667,589,Myasthenia gravis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,15.7,Austria,Validated,23129486[PMID]
667,589,Myasthenia gravis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.5,Australia,Validated,22469211[PMID]
667,589,Myasthenia gravis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,18.5,Italy,Validated,21757957[PMID]_22377708[PMID]_ ORPHANET
667,589,Myasthenia gravis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.1,"Taiwan, Province of China",Validated,20523074[PMID]
667,589,Myasthenia gravis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,11.7,Australia,Validated,22469211[PMID]
667,589,Myasthenia gravis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.74,Greece,Validated,11511710[PMID]
667,589,Myasthenia gravis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,14.0,"Taiwan, Province of China",Validated,20523074[PMID]
667,589,Myasthenia gravis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.65,Croatia,Validated,9705586[PMID]
667,589,Myasthenia gravis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.8,Estonia,Validated,14638881[PMID]
667,589,Myasthenia gravis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.1,Greece,Validated,11511710[PMID]
667,589,Myasthenia gravis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,9.9,Croatia,Validated,9705586[PMID]
667,589,Myasthenia gravis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.2,Egypt,Validated,20948236[PMID]
667,589,Myasthenia gravis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.53,Worldwide,Validated,20565885[PMID]
660,805,Tuberous sclerosis complex,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.58,"Taiwan, Province of China",Validated,34344419[PMID]
660,805,Tuberous sclerosis complex,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.62,Germany,Validated,30016967[PMID]
660,805,Tuberous sclerosis complex,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Worldwide,Validated,ORPHANET
660,805,Tuberous sclerosis complex,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.87,Hong Kong,Validated,32988393[PMID]
660,805,Tuberous sclerosis complex,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.38,Sweden,Validated,29078087[PMID]
660,805,Tuberous sclerosis complex,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.45,United Kingdom,Validated,16700943[PMID]_18456692[PMID]
662,886,Usher syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,4.53,Worldwide,Validated,15178965[PMID]_ORPHANET
662,886,Usher syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.0,Denmark,Validated,9212179[PMID]
662,886,Usher syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.2,Germany,Validated,12107518[PMID]
662,886,Usher syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.2,United Kingdom,Validated,9135408[PMID]
662,886,Usher syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.6,Norway,Validated,3594933[PMID]
662,886,Usher syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.2,Spain,Validated,15178965[PMID]
662,886,Usher syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.5,Finland,Validated,5516287[PMID]
662,886,Usher syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.4,United States,Validated,6885960[PMID]
662,886,Usher syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.2,Colombia,Validated,1756603[PMID]
662,886,Usher syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.0,Specific population,Validated,14569126[PMID]
663,3440,Waardenburg syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.37,Europe,Validated,[EXPERT]
663,3440,Waardenburg syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.74,United States,Not yet validated,9279758[PMID]_ORPHANET
663,3440,Waardenburg syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.4,Netherlands,Validated,9279758[PMID]
663,3440,Waardenburg syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Netherlands,Not yet validated,9279758[PMID]
663,3440,Waardenburg syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
656,702,Pelizaeus-Merzbacher disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.25,Europe,Validated,[EXPERT]
656,702,Pelizaeus-Merzbacher disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.35,United States,Not yet validated,20301361[PMID]_ORPHANET
656,702,Pelizaeus-Merzbacher disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.13,Germany,Validated,9286459[PMID]
657,738,Porphyria,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,5.25,Worldwide,Not yet validated,15652607[PMID]_ORPHANET
657,738,Porphyria,Clinical group,Group of disorders,Lifetime Prevalence,Value and class,1-9 / 1 000 000,0.7,Japan,Validated,15239394[PMID]
657,738,Porphyria,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.52,Denmark,Validated,27139922[PMID]
658,768,Familial long QT syndrome,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
659,791,Retinitis pigmentosa,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,30.0,Europe,Validated,European Medicines Agency 2018[INST]
659,791,Retinitis pigmentosa,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,26.7,Worldwide,Validated,[EXPERT]
659,791,Retinitis pigmentosa,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,25.4,Denmark,Validated,11921605[PMID]
659,791,Retinitis pigmentosa,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,22.5,Norway,Validated,3594933[PMID]
659,791,Retinitis pigmentosa,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,21.0,United States,Validated,6702974[PMID]
659,791,Retinitis pigmentosa,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.5,United Kingdom,Validated,6512829[PMID]
659,791,Retinitis pigmentosa,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,26.4,China,Validated,3500313[PMID]
659,791,Retinitis pigmentosa,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,16.7,Slovenia,Validated,1395082[PMID]
659,791,Retinitis pigmentosa,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,11.09,"Korea, Republic of",Validated,28130043[PMID]
747,375,Anti-glomerular basement membrane disease,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.08,Europe,Validated,[EXPERT]_ORPHANET
747,375,Anti-glomerular basement membrane disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.179,New Zealand,Validated,22032242[PMID]
747,375,Anti-glomerular basement membrane disease,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.06,China,Validated,15056270[PMID]
747,375,Anti-glomerular basement membrane disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
747,375,Anti-glomerular basement membrane disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2,Europe,Validated,European Medicines Agency 2018 [INST]
745,183,Eosinophilic granulomatosis with polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.56,Europe,Validated,ORPHANET_25805746[PMID]
745,183,Eosinophilic granulomatosis with polyangiitis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.09,Sweden,Validated,19797309[PMID]
745,183,Eosinophilic granulomatosis with polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.13,France,Validated,20039171[PMID]_25805746[PMID]
745,183,Eosinophilic granulomatosis with polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.4,Sweden,Validated,17553910[PMID]_25805746[PMID]
745,183,Eosinophilic granulomatosis with polyangiitis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.09,United Kingdom,Validated,21798892[PMID]_25805746[PMID]
745,183,Eosinophilic granulomatosis with polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.3,Norway,Validated,9805179[PMID]
745,183,Eosinophilic granulomatosis with polyangiitis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.09,Spain,Validated,11156552[PMID]
745,183,Eosinophilic granulomatosis with polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.23,Australia,Validated,18771432[PMID]_25805746[PMID]
745,183,Eosinophilic granulomatosis with polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.18,Europe,Validated,ORPHANET_19797309[PMID]_18565978[PMID]_11156552[PMID]
745,183,Eosinophilic granulomatosis with polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.5,Worldwide,Validated,18771432[PMID]_9805179[PMID]_17553910[PMID]_14872461[PMID]
745,183,Eosinophilic granulomatosis with polyangiitis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.05,Norway,Validated,11760724[PMID]_25805746[PMID]
745,183,Eosinophilic granulomatosis with polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.11,Germany,Validated,15696553[PMID]_25805746[PMID]
745,183,Eosinophilic granulomatosis with polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.13,Lithuania,Validated,15647446[PMID]_25805746[PMID]
745,183,Eosinophilic granulomatosis with polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.12,France,Validated,20039171[PMID]_25805746[PMID]
745,183,Eosinophilic granulomatosis with polyangiitis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.06,Turkey,Validated,25805746[PMID]
745,183,Eosinophilic granulomatosis with polyangiitis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.014,Peru,Validated,25805746[PMID]
745,183,Eosinophilic granulomatosis with polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.4,Germany,Validated,24425780[PMID]_25805746[PMID]
745,183,Eosinophilic granulomatosis with polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.78,Japan,Validated,24289197[PMID]_25805746[PMID]
745,183,Eosinophilic granulomatosis with polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.4,United States,Validated,28881446[PMID]
744,1164,Allergic bronchopulmonary aspergillosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
751,2406,Locked-in syndrome,Clinical syndrome,Disorder,Cases/families,Case(s),,33.0,Worldwide,Validated,ORPHANET
751,2406,Locked-in syndrome,Clinical syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
750,509,Leptospirosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Europe,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
750,509,Leptospirosis,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
750,509,Leptospirosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.92,France,Validated,23337900[PMID]
750,509,Leptospirosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Austria,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
750,509,Leptospirosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Belgium,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
750,509,Leptospirosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.18,Bulgaria,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
750,509,Leptospirosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.13,Croatia,Validated,European Centre for Disease prevention and Control 2013-2015[INST]
750,509,Leptospirosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.22,Czech Republic,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
750,509,Leptospirosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Denmark,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
750,509,Leptospirosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.24,Estonia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
750,509,Leptospirosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Finland,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
750,509,Leptospirosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Germany,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
750,509,Leptospirosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.22,Greece,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
750,509,Leptospirosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.16,Hungary,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
750,509,Leptospirosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.36,Ireland,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
750,509,Leptospirosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Italy,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
750,509,Leptospirosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.14,Latvia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
750,509,Leptospirosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.3,Lithuania,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
750,509,Leptospirosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.04,Luxembourg,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
750,509,Leptospirosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.42,Malta,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
750,509,Leptospirosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.36,Netherlands,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
750,509,Leptospirosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.38,Portugal,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
750,509,Leptospirosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.38,Romania,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
750,509,Leptospirosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Slovakia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
750,509,Leptospirosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.52,Slovenia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
750,509,Leptospirosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.04,Sweden,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
750,509,Leptospirosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,United Kingdom,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
749,761,Immunoglobulin A vasculitis,Disease,Disorder,Annual incidence,Value and class,6-9 / 10 000,55.9,"Korea, Republic of",Validated,36263029[PMID]
749,761,Immunoglobulin A vasculitis,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,30.0,France,Validated,36263029[PMID]
749,761,Immunoglobulin A vasculitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,6.79,Croatia,Validated,36263029[PMID]
749,761,Immunoglobulin A vasculitis,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,13.0,United Kingdom,Validated,36263029[PMID]
749,761,Immunoglobulin A vasculitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,6.1,Netherlands,Validated,36263029[PMID]
749,761,Immunoglobulin A vasculitis,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,17.55,Sweden,Validated,36263029[PMID]
749,761,Immunoglobulin A vasculitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,12.9,"Taiwan, Province of China",Validated,36263029[PMID]
749,761,Immunoglobulin A vasculitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,36263029[PMID]_ORPHANET
748,2131,Alternating hemiplegia of childhood,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.94,Denmark,Validated,24100174[PMID]
748,2131,Alternating hemiplegia of childhood,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
17954,171901,Primary cutaneous T-cell lymphoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.2,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]_21493798[PMID]
17954,171901,Primary cutaneous T-cell lymphoma,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,24.0,Europe,Validated,European Medicines Agency 2012[INST]
17954,171901,Primary cutaneous T-cell lymphoma,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.09,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
17954,171901,Primary cutaneous T-cell lymphoma,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.097,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
17954,171901,Primary cutaneous T-cell lymphoma,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.02,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
17954,171901,Primary cutaneous T-cell lymphoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.577,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
17954,171901,Primary cutaneous T-cell lymphoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.539,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
17954,171901,Primary cutaneous T-cell lymphoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.158,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
17954,171901,Primary cutaneous T-cell lymphoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.341,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
17954,171901,Primary cutaneous T-cell lymphoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.185,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
17954,171901,Primary cutaneous T-cell lymphoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.326,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
17954,171901,Primary cutaneous T-cell lymphoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.767,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
17954,171901,Primary cutaneous T-cell lymphoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.647,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
17954,171901,Primary cutaneous T-cell lymphoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.323,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
17954,171901,Primary cutaneous T-cell lymphoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.431,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
17954,171901,Primary cutaneous T-cell lymphoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.355,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
17954,171901,Primary cutaneous T-cell lymphoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.273,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
17954,171901,Primary cutaneous T-cell lymphoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.225,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
17954,171901,Primary cutaneous T-cell lymphoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.594,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
17954,171901,Primary cutaneous T-cell lymphoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.231,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
17954,171901,Primary cutaneous T-cell lymphoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.441,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
17954,171901,Primary cutaneous T-cell lymphoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.197,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
17954,171901,Primary cutaneous T-cell lymphoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.163,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
17954,171901,Primary cutaneous T-cell lymphoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.57,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
739,713,Glycogen storage disease due to phosphoglycerate kinase 1 deficiency,Disease,Disorder,Cases/families,Family(ies),,30.0,Worldwide,Validated,[EXPERT]
739,713,Glycogen storage disease due to phosphoglycerate kinase 1 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
17955,171915,B-cell non-Hodgkin lymphoma,Category,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,17.45,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
738,57,Glycogen storage disease due to aldolase A deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
743,249,Fibrous dysplasia of bone,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
742,2334,Autosomal dominant keratitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
17956,171918,T-cell non-Hodgkin lymphoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.99,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
17957,171929,Trisomy 10p syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,[EXPERT]
17957,171929,Trisomy 10p syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
762,187,Citrullinemia,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
763,46,Adenylosuccinate lyase deficiency,Disease,Disorder,Cases/families,Case(s),,56.0,Worldwide,Validated,18830228[PMID]
763,46,Adenylosuccinate lyase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,38.0,Europe,Validated,[EXPERT]
760,442,Congenital hypothyroidism,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Validated,[EXPERT]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,10.0,France,Validated,15807875[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,France,Not yet validated,15807875[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,57.0,United Kingdom,Not yet validated,10102157[PMID]_21048833[PMID]_16595645[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,United Kingdom,Not yet validated,10102157[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,45.5,Italy,Validated,23025761[PMID]_23426615[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,57.0,Greece,Validated,20591982[PMID]_23426615[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,55.5,Cyprus,Validated,15921174[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,15.5,Latvia,Validated,11400783[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Latvia,Not yet validated,11400783[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,49.1,China,Validated,23430943[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,China,Not yet validated,23430943[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,30.2,Germany,Validated,16318620[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Germany,Not yet validated,16318620[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,29.4,Denmark,Validated,9782755[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,25.0,Poland,Validated,12762638[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Poland,Not yet validated,12762638[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,35.0,Estonia,Validated,9575454[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Estonia,Not yet validated,9575454[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,54.8,Lebanon,Validated,17146215[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,>1 / 1000,150.0,"Iran, Islamic Republic of",Validated,23060475[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,73.35,Brazil,Not yet validated,23033178[PMID]_22911283[PMID]_ ORPHANET
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,43.0,Turkey,Validated,15857333[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Turkey,Not yet validated,15857333[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,35.4,Australia,Validated,12031004[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Australia,Not yet validated,12031004[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,63.7,United Arab Emirates,Validated,15751925[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,76.9,Bangladesh,Validated,15906726[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,62.5,Pakistan,Validated,19904471[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,50.2,"Taiwan, Province of China",Validated,23291568[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,43.0,Mexico,Validated,18782254[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Mexico,Not yet validated,18782254[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,25.3,Bosnia and Herzegovina,Validated,18668261[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Bosnia and Herzegovina,Not yet validated,18668261[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,33.7,Bahrain,Validated,20432804[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Bahrain,Not yet validated,20432804[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,36.0,New Zealand,Validated,22723332[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,New Zealand,Not yet validated,22723332[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,16.0,Thailand,Validated,11400774[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Thailand,Not yet validated,11400774[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Class only,1-5 / 10 000,0.0,United States,Not yet validated,17512233[PMID]_16509526[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,44.0,United States,Not yet validated,17512233[PMID]_16509526[PMID]_ ORPHANET
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,37.3,Specific population,Validated,21632812[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Annual incidence,Value and class,6-9 / 10 000,97.0873,Brazil,Validated,35209917[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,34.76,Czech Republic,Validated,31241292[PMID]
760,442,Congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,45.0,Ireland,Validated,30242075[PMID]
761,43,X-linked adrenoleukodystrophy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.8,Israel,Validated,33239050[PMID]
761,43,X-linked adrenoleukodystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.8,Norway,Validated,23419472[PMID]
761,43,X-linked adrenoleukodystrophy,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,2.0639,United States,Validated,31074578[PMID]
766,3166,Sialuria,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,11486897[PMID]
766,3166,Sialuria,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11486897[PMID]
765,2882,Sitosterolemia,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,18441155[PMID]
765,2882,Sitosterolemia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18441155[PMID]
754,810,Shigellosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.68,Europe,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.78,Austria,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,8.18,Bulgaria,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.33,Croatia,Validated,European Centre for Disease prevention and Control 2012-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.04,Cyprus,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.6,Czech Republic,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.08,Denmark,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.38,Estonia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.82,Finland,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.54,France,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.7,Germany,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.74,Greece,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.38,Hungary,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.12,Ireland,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.34,Latvia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.12,Lithuania,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.6,Luxembourg,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.34,Malta,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.4,Netherlands,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Poland,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.08,Portugal,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.18,Romania,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,6.1,Slovakia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.02,Slovenia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.44,Spain,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.68,Sweden,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.32,United Kingdom,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.3,Iceland,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
754,810,Shigellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.06,Norway,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
755,3165,Eosinophilic fasciitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
755,3165,Eosinophilic fasciitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.4,France,Validated,29526049[PMID]
752,2420,Primary pulmonary lymphoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
753,727,Microscopic polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.0,Europe,Validated,[EXPERT]
753,727,Microscopic polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.26,Germany,Validated,15696553[PMID]_25805746[PMID]
753,727,Microscopic polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.2843,Worldwide,Validated,25805746[PMID]_ORPHANET
753,727,Microscopic polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.16,Spain,Validated,11156552[PMID]
753,727,Microscopic polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,9.4,Sweden,Validated,17553910[PMID]
753,727,Microscopic polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.5,Australia,Validated,18771432[PMID]
753,727,Microscopic polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.5,France,Validated,14872461[PMID]
753,727,Microscopic polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.27,Norway,Validated,11760724[PMID]
753,727,Microscopic polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.7,New Zealand,Validated,16368729[PMID]
753,727,Microscopic polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.74,United Kingdom,Not yet validated,11156552[PMID]_22258386[PMID]_10693883[PMID]_ORPHANET
753,727,Microscopic polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.3,United Kingdom,Validated,22258386[PMID]_25805746[PMID]
753,727,Microscopic polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.8,Germany,Validated,24425780[PMID]_25805746[PMID]
753,727,Microscopic polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.91,Australia,Validated,18771432[PMID]_25805746[PMID]
753,727,Microscopic polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.38,Japan,Validated,17699321[PMID]_25805746[PMID]
753,727,Microscopic polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.4,Kuwait,Validated,9306338[PMID]_25805746[PMID]
753,727,Microscopic polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.82,Japan,Validated,21798892[PMID]_25805746[PMID]
753,727,Microscopic polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.71,Canada,Validated,23838025[PMID]_25805746[PMID]
753,727,Microscopic polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.02,Greece,Validated,19604432[PMID]_25805746[PMID]
753,727,Microscopic polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.3,Lithuania,Validated,15647446[PMID]_25805746[PMID]
753,727,Microscopic polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.01,Sweden,Validated,19797309[PMID]_25805746[PMID]
753,727,Microscopic polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.6,United States,Validated,28881446[PMID]
759,900,Granulomatosis with polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.85,Europe,Validated,16859601[PMID]
759,900,Granulomatosis with polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,9.0,Europe,Validated,16859601[PMID]
759,900,Granulomatosis with polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.0,United Kingdom,Validated,10693883[PMID]_11156552[PMID]_22258386[PMID]_19790134[PMID]
759,900,Granulomatosis with polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,16.0,Sweden,Validated,17553910[PMID]_25805746[PMID]
759,900,Granulomatosis with polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.86,Germany,Validated,15696553[PMID]_25805746[PMID]
759,900,Granulomatosis with polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.37,France,Validated,14872461[PMID]_25805746[PMID]
759,900,Granulomatosis with polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.19,Sweden,Validated,16960922[PMID]_25805746[PMID]
759,900,Granulomatosis with polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.49,Spain,Validated,11156552[PMID]
759,900,Granulomatosis with polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,9.51,Norway,Validated,11083271[PMID]_25805746[PMID]
759,900,Granulomatosis with polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.0,Norway,Validated,11760724[PMID]_11083271[PMID]_ ORPHANET
759,900,Granulomatosis with polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,9.5,Australia,Validated,18771432[PMID]_25805746[PMID]
759,900,Granulomatosis with polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,9.35,New Zealand,Validated,16368729[PMID]_25805746[PMID]
759,900,Granulomatosis with polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.93,Finland,Validated,18799060[PMID]
759,900,Granulomatosis with polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.6,United States,Validated,8546743[PMID]
759,900,Granulomatosis with polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.94,China,Validated,26989646[PMID]
759,900,Granulomatosis with polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.21,Lithuania,Validated,15647446[PMID]_25805746[PMID]
759,900,Granulomatosis with polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.66,Greece,Validated,19604432[PMID]_25805746[PMID]
759,900,Granulomatosis with polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.24,Italy,Validated,24932888[PMID]_25805746[PMID]
759,900,Granulomatosis with polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.46,Canada,Validated,23838025[PMID]_25805746[PMID]
759,900,Granulomatosis with polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.21,Japan,Validated,21798892[PMID]_25805746[PMID]
759,900,Granulomatosis with polyangiitis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.037,"Taiwan, Province of China",Validated,24560699[PMID]_25805746[PMID]
759,900,Granulomatosis with polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.23,Japan,Validated,17699321[PMID]_25805746[PMID]
759,900,Granulomatosis with polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.43,Italy,Validated,24932888[PMID]_25805746[PMID]
759,900,Granulomatosis with polyangiitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,Denmark,Validated,17582741[PMID]_25805746[PMID]
759,900,Granulomatosis with polyangiitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.3,United States,Validated,28881446[PMID]
757,863,Trichinellosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
757,863,Trichinellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.06,Europe,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
757,863,Trichinellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.48,Bulgaria,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
757,863,Trichinellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.067,Croatia,Validated,European Centre for Disease prevention and Control 2013-2015[INST]
757,863,Trichinellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.04,Estonia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
757,863,Trichinellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.04,Italy,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
757,863,Trichinellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.06,Latvia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
757,863,Trichinellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.6,Lithuania,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
757,863,Trichinellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.64,Romania,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
757,863,Trichinellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.08,Slovakia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
713,134,Beta-ketothiolase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
713,134,Beta-ketothiolase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.72,Australia,Validated,10626578[PMID]_[EXPERT]
713,134,Beta-ketothiolase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.43,United States,Validated,21669895[PMID]_[EXPERT]
713,134,Beta-ketothiolase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.98,China,Validated,31156707[PMID]_[EXPERT]
713,134,Beta-ketothiolase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.53,Viet Nam,Validated,28220263[PMID]_[EXPERT]
17929,171700,Diffuse panbronchiolitis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
17930,171703,Microcephaly-polymicrogyria-corpus callosum agenesis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,17353897[PMID]
17930,171703,Microcephaly-polymicrogyria-corpus callosum agenesis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17353897[PMID]
17931,171706,Short stature-delayed bone age due to thyroid hormone metabolism deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
17934,171719,Cutis laxa-Marfanoid syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1864606[PMID]
17934,171719,Cutis laxa-Marfanoid syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,1864606[PMID]
719,1163,Aspergillosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
704,3467,Hereditary xanthinuria,Disease,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,ORPHANET
704,3467,Hereditary xanthinuria,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,9.05,Europe,Validated,[EXPERT]_ORPHANET
704,3467,Hereditary xanthinuria,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
17923,171673,Limbal stem cell deficiency,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.0,Europe,Validated,European Medicines Agency 2018[INST]
708,511,Maple syrup urine disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.67,Worldwide,Validated,[EXPERT]
708,511,Maple syrup urine disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.78,United States,Validated,20307994[PMID]
708,511,Maple syrup urine disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.79,Italy,Validated,11953730[PMID]
708,511,Maple syrup urine disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.3,Tunisia,Validated,22481200[PMID]
708,511,Maple syrup urine disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.19,Japan,Validated,6468444[PMID]
708,511,Maple syrup urine disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.15,Portugal,Validated,20466570[PMID]
708,511,Maple syrup urine disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.6,Australia,Validated,12788994[PMID]
708,511,Maple syrup urine disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.86,"Taiwan, Province of China",Validated,2056791[PMID]
708,511,Maple syrup urine disease,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,European Medicines Agency 2018[INST]
708,511,Maple syrup urine disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.8,Israel,Validated,33239050[PMID]
708,511,Maple syrup urine disease,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,10.2,Specific population,Validated,33239050[PMID]
708,511,Maple syrup urine disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.396,China,Validated,34103049[PMID]
708,511,Maple syrup urine disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.34,Czech Republic,Validated,31241292[PMID]
17925,171680,Lissencephaly due to TUBA1A mutation,Malformation syndrome,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,ORPHANET
17925,171680,Lissencephaly due to TUBA1A mutation,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
711,32,Glutathione synthetase deficiency,Disease,Disorder,Cases/families,Case(s),,70.0,Worldwide,Validated,26984560[PMID]
711,32,Glutathione synthetase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26984560[PMID]
710,26,Methylmalonic acidemia with homocystinuria,Disease,Disorder,Cases/families,Case(s),,500.0,Worldwide,Validated,16714133[PMID]_[EXPERT]
710,26,Methylmalonic acidemia with homocystinuria,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
17945,171863,Autosomal dominant spastic paraplegia type 42,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,19061983[PMID]
17945,171863,Autosomal dominant spastic paraplegia type 42,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19061983[PMID]
17947,171871,Renal pseudohypoaldosteronism type 1,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.51,United Kingdom,Validated,PMID: 24616761
730,322,Exstrophy-epispadias complex,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
17946,171866,"Spondyloepimetaphyseal dysplasia, aggrecan type",Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,19110214[PMID]
17946,171866,"Spondyloepimetaphyseal dysplasia, aggrecan type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19110214[PMID]
731,2368,Gastroschisis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,16.9,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010-2016[REG]_[EXPERT]
731,2368,Gastroschisis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,29.4,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
731,2368,Gastroschisis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,14.6,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
731,2368,Gastroschisis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,22.7,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
731,2368,Gastroschisis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,21.3,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
731,2368,Gastroschisis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,17.7,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
731,2368,Gastroschisis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,41.6,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
731,2368,Gastroschisis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.2,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
731,2368,Gastroschisis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,18.1,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
731,2368,Gastroschisis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.9,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
731,2368,Gastroschisis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,25.8,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2006[REG]
731,2368,Gastroschisis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,17.5,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
731,2368,Gastroschisis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,36.0,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
731,2368,Gastroschisis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.6,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
731,2368,Gastroschisis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.0,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
731,2368,Gastroschisis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.6,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
731,2368,Gastroschisis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,12.3,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
731,2368,Gastroschisis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,36.3,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
731,2368,Gastroschisis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.5,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
731,2368,Gastroschisis,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Validated,ORPHANET_[EXPERT]
17949,171881,Cap myopathy,Disease,Disorder,Cases/families,Case(s),,21.0,Worldwide,Validated,25079567[PMID]
17949,171881,Cap myopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25079567[PMID]
732,2512,Autosomal recessive primary microcephaly,Etiological subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Specific population,Validated,21668957[PMID]
732,2512,Autosomal recessive primary microcephaly,Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
732,2512,Autosomal recessive primary microcephaly,Etiological subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 100 000,1.0,Pakistan,Validated,21668957[PMID]
17948,171876,Generalized pseudohypoaldosteronism type 1,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.6,United Kingdom,Validated,PMID: 24616761
734,795,Rare form of salmonellosis,Category,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
735,797,Sarcoidosis,Disease,Disorder,Point prevalence,Value and class,6-9 / 10 000,60.0,United States,Validated,2750915[PMID]_[EXPERT]
735,797,Sarcoidosis,Disease,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Worldwide,Validated,[EXPERT]_ORPHANET_DOI:10.1016/B978-0-323-54429-0.00001-X[OTHER]
735,797,Sarcoidosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,48.1,Ireland,Validated,[EXPERT]_DOI:10.1016/B978-0-323-54429-0.00001-X[OTHER]
735,797,Sarcoidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.3,Croatia,Validated,21906764[PMID]
735,797,Sarcoidosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.0,Europe,Validated,European Medicines Agency 2007[INST]_DOI:10.1016/B978-0-323-54429-0.00001-X[OTHER]
735,797,Sarcoidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.0,United Kingdom,Validated,16844727[PMID]
735,797,Sarcoidosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,30.2,France,Validated,28775045 [PMID]_[EXPERT]
735,797,Sarcoidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.5,Spain,Validated,21546016[PMID]
735,797,Sarcoidosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,28.2,Finland,Validated,7617979[PMID]
735,797,Sarcoidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.68,Denmark,Validated,18983653[PMID]
735,797,Sarcoidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,7.0,Switzerland,Validated,19897550[PMID]
735,797,Sarcoidosis,Disease,Disorder,Point prevalence,Class only,6-9 / 10 000,0.0,Switzerland,Validated,DOI:10.1016/B978-0-323-54429-0.00001-X[OTHER]_[EXPERT]
735,797,Sarcoidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.07,Greece,Validated,19345567[PMID]
735,797,Sarcoidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.89,Greece,Validated,19345567[PMID]
735,797,Sarcoidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.84,Iceland,Validated,17277405[PMID]
735,797,Sarcoidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.0,Czech Republic,Validated,7809493[PMID]
735,797,Sarcoidosis,Disease,Disorder,Point prevalence,Value and class,6-9 / 10 000,63.0,Czech Republic,Validated,7809493[PMID]
735,797,Sarcoidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.35,Australia,Validated,17535377[PMID]_ORPHANET_[EXPERT]
735,797,Sarcoidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.01,Japan,Validated,17959635[PMID]
735,797,Sarcoidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.7,Japan,Validated,7617979[PMID]
735,797,Sarcoidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.125,"Korea, Republic of",Validated,11436538[PMID]
735,797,Sarcoidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.56,Singapore,Validated,17539838[PMID]
735,797,Sarcoidosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,49.0,Italy,Validated,28475583[PMID]
735,797,Sarcoidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.9,France,Validated,28775045 [PMID]_[EXPERT]
735,797,Sarcoidosis,Disease,Disorder,Point prevalence,Value and class,>1 / 1000,160.0,Sweden,Validated,27471207[PMID]
735,797,Sarcoidosis,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,11.5,Sweden,Validated,27471207[PMID]
735,797,Sarcoidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.17,"Taiwan, Province of China",Validated,27786368 [PMID]
735,797,Sarcoidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2,Portugal,Validated,5884467[PMID]
735,797,Sarcoidosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,26.7,Norway,Validated,5884453[PMID]
735,797,Sarcoidosis,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,14.4,Norway,Validated,5884453[PMID]
735,797,Sarcoidosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.5,Canada,Validated,5884470[PMID]
735,797,Sarcoidosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,21.0,Guadeloupe,Validated,24962008[PMID]
735,797,Sarcoidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.3,Guadeloupe,Validated,24962008[PMID]
735,797,Sarcoidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.4,Uruguay,Validated,5884475[PMID]
720,92,Juvenile idiopathic arthritis,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,13.0,Czech Republic,Validated,17181917[PMID]
720,92,Juvenile idiopathic arthritis,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.5,Europe,Validated,[EXPERT]_ORPHANET
720,92,Juvenile idiopathic arthritis,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,4.7,France,Validated,Haute Autorité de Santé 2009[INST]_ORPHANET_16821272[PMID]
720,92,Juvenile idiopathic arthritis,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,8.9,United States,Not yet validated,23588938[PMID]_ORPHANET
720,92,Juvenile idiopathic arthritis,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,21.0,Czech Republic,Not yet validated,17181917[PMID]_ORPHANET
720,92,Juvenile idiopathic arthritis,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,20.5,Worldwide,Validated,24210707[PMID]
720,92,Juvenile idiopathic arthritis,Clinical group,Group of disorders,Point prevalence,Value and class,6-9 / 10 000,74.6,Specific population,Validated,31150159[PMID]
720,92,Juvenile idiopathic arthritis,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,7.8,Worldwide,Validated,24210707[PMID]
17936,171829,6q16 microdeletion syndrome,Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,24038875[PMID]
17936,171829,6q16 microdeletion syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
722,1201,Small bowel atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.0,Europe,Validated,229330959[PMID]
722,1201,Small bowel atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.0,Spain,Validated,2293309[PMID]_EUROCAT
722,1201,Small bowel atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.0,Ireland,Validated,2293309[PMID]_EUROCAT
722,1201,Small bowel atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,10.0,Portugal,Validated,2293309[PMID]_EUROCAT
722,1201,Small bowel atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,14.5,Italy,Validated,2293309[PMID]_EUROCAT
722,1201,Small bowel atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,22.0,Reunion,Validated,2293309[PMID]_EUROCAT
722,1201,Small bowel atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.0,Switzerland,Validated,2293309[PMID]_EUROCAT
722,1201,Small bowel atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,10.0,Austria,Validated,2293309[PMID]_EUROCAT
722,1201,Small bowel atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,14.0,Germany,Validated,2293309[PMID]_EUROCAT
722,1201,Small bowel atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,19.0,Denmark,Validated,2293309[PMID]_EUROCAT
722,1201,Small bowel atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,12.0,Malta,Validated,2293309[PMID]_EUROCAT
722,1201,Small bowel atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,18.0,France,Validated,2293309[PMID]_EUROCAT
722,1201,Small bowel atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,18.0,United Kingdom,Validated,2293309[PMID]_EUROCAT
722,1201,Small bowel atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,15.0,Belgium,Validated,2293309[PMID]_EUROCAT
722,1201,Small bowel atresia,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
17939,171844,Blindness-scoliosis-arachnodactyly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,18990988[PMID]
17939,171844,Blindness-scoliosis-arachnodactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18990988[PMID]
17938,171839,Craniosynostosis-hydrocephalus-Arnold-Chiari malformation type I-radioulnar synostosis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,19022412[PMID]
17938,171839,Craniosynostosis-hydrocephalus-Arnold-Chiari malformation type I-radioulnar synostosis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19022412[PMID]
723,1202,Larynx atresia,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
724,1199,Esophageal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,24.3,Europe,Validated,22247246[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
724,1199,Esophageal atresia,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Validated,22247246[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
724,1199,Esophageal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,19.5,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2008[REG]
724,1199,Esophageal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,17.5,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
724,1199,Esophageal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.4,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
724,1199,Esophageal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,42.5,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
724,1199,Esophageal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.8,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
724,1199,Esophageal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,23.8,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
724,1199,Esophageal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,26.6,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
724,1199,Esophageal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,10.8,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
724,1199,Esophageal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,18.4,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
724,1199,Esophageal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,24.9,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
724,1199,Esophageal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,17.1,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
724,1199,Esophageal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,34.4,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
724,1199,Esophageal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.7,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
724,1199,Esophageal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,18.9,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
724,1199,Esophageal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,15.7,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
724,1199,Esophageal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,25.1,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
724,1199,Esophageal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,22.4,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
724,1199,Esophageal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,22.3,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
724,1199,Esophageal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,21.0,United States,Validated,8013895[PMID]_15826889[PMID]
17941,171851,MEDNIK syndrome,Disease,Disorder,Cases/families,Family(ies),,5.0,Worldwide,Validated,23423674[PMID]
17941,171851,MEDNIK syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23423674[PMID]
17940,171848,Polyneuropathy-hearing loss-ataxia-retinitis pigmentosa-cataract syndrome,Disease,Disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,23490117[PMID]
17940,171848,Polyneuropathy-hearing loss-ataxia-retinitis pigmentosa-cataract syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
725,1304,Brucellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.09,Europe,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
725,1304,Brucellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.03,France,Validated,27717526[PMID]_European Centre for Disease prevention and Control 2013-2017[INST]
725,1304,Brucellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.04,Austria,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
725,1304,Brucellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.05,Germany,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
725,1304,Brucellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.13,Greece,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
725,1304,Brucellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.03,Ireland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
725,1304,Brucellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.22,Italy,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
725,1304,Brucellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Lithuania,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
725,1304,Brucellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.03,Luxembourg,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
725,1304,Brucellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.05,Malta,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
725,1304,Brucellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.05,Norway,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
725,1304,Brucellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.35,Portugal,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
725,1304,Brucellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Spain,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
725,1304,Brucellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.15,Sweden,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
725,1304,Brucellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,United Kingdom,Validated,European Centre for Disease prevention and Control 2013-2016[INST]
725,1304,Brucellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Romania,Validated,European Centre for Disease prevention and Control 2013-2016[INST]
725,1304,Brucellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Slovakia,Validated,European Centre for Disease prevention and Control 2013-2016[INST]
725,1304,Brucellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Slovenia,Validated,European Centre for Disease prevention and Control 2013-2016[INST]
725,1304,Brucellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Netherlands,Validated,European Centre for Disease prevention and Control 2013-2016[INST]
725,1304,Brucellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Poland,Validated,European Centre for Disease prevention and Control 2013-2016[INST]
725,1304,Brucellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.04,Belgium,Validated,European Centre for Disease prevention and Control 2013-2016[INST]
725,1304,Brucellosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.11,Bulgaria,Validated,European Centre for Disease prevention and Control 2013-2016[INST]
725,1304,Brucellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Croatia,Validated,European Centre for Disease prevention and Control 2013-2016[INST]
725,1304,Brucellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.004,Czech Republic,Validated,European Centre for Disease prevention and Control 2013-2016[INST]
725,1304,Brucellosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.008,Finland,Validated,European Centre for Disease prevention and Control 2013-2016[INST]
726,173,Cholera,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,World Health Organization 2011[INST]
726,173,Cholera,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,United States,Validated,World Health Organization 2011[INST]
726,173,Cholera,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
726,173,Cholera,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,United Kingdom,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
726,173,Cholera,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Germany,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
726,173,Cholera,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Austria,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
726,173,Cholera,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Belgium,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
726,173,Cholera,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Czech Republic,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
726,173,Cholera,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Denmark,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
726,173,Cholera,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,France,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
726,173,Cholera,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Norway,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
726,173,Cholera,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Spain,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
726,173,Cholera,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Sweden,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
820,3303,Tetralogy of Fallot,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,34.0,Worldwide,Validated,22078432[PMID]
820,3303,Tetralogy of Fallot,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,29.3,Europe,Validated,[EXPERT]_EUROCAT European surveillance of congenital anomalies 2010[REG]
820,3303,Tetralogy of Fallot,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,39.3,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
820,3303,Tetralogy of Fallot,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,40.8,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
820,3303,Tetralogy of Fallot,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.4,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
820,3303,Tetralogy of Fallot,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,39.7,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
820,3303,Tetralogy of Fallot,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,13.8,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
820,3303,Tetralogy of Fallot,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.9,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
820,3303,Tetralogy of Fallot,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,34.3,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
820,3303,Tetralogy of Fallot,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,14.5,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
820,3303,Tetralogy of Fallot,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,26.8,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
820,3303,Tetralogy of Fallot,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,48.2,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
820,3303,Tetralogy of Fallot,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,29.2,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
820,3303,Tetralogy of Fallot,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,31.1,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
820,3303,Tetralogy of Fallot,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,16.2,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
820,3303,Tetralogy of Fallot,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,23.7,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
820,3303,Tetralogy of Fallot,Malformation syndrome,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,63.0,"Taiwan, Province of China",Validated,20138303[PMID]
820,3303,Tetralogy of Fallot,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.9,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
820,3303,Tetralogy of Fallot,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,25.1,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
820,3303,Tetralogy of Fallot,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,32.0,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
820,3303,Tetralogy of Fallot,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,25.4,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
820,3303,Tetralogy of Fallot,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,47.0,United States,Validated,18657826[PMID]
820,3303,Tetralogy of Fallot,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,40.0,China,Validated,23350618[PMID]
820,3303,Tetralogy of Fallot,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
820,3303,Tetralogy of Fallot,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
18421,200418,Immunodeficiency with factor I anomaly,Disease,Disorder,Cases/families,Family(ies),,35.0,Worldwide,Validated,22710145[PMID]
18421,200418,Immunodeficiency with factor I anomaly,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
823,730,Autosomal dominant polycystic kidney disease,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,39.6,Europe,Validated,27325254[PMID]_European Medicines Agency 2018[INST]
822,486,Autosomal dominant severe congenital neutropenia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
817,1209,Tricuspid atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.5625,Europe,Validated,31270117[PMID]
817,1209,Tricuspid atresia,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
817,1209,Tricuspid atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.9,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2012[REG]
817,1209,Tricuspid atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.0,France,Validated,31270117[PMID]
817,1209,Tricuspid atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.0,Germany,Validated,31270117[PMID]
817,1209,Tricuspid atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,10.5,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
817,1209,Tricuspid atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.5,Italy,Validated,31270117[PMID]
817,1209,Tricuspid atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.0,Netherlands,Validated,31270117[PMID]
817,1209,Tricuspid atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.3,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
817,1209,Tricuspid atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.5,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
817,1209,Tricuspid atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.9,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
817,1209,Tricuspid atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.1,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
817,1209,Tricuspid atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,12.6,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
817,1209,Tricuspid atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.0,United Kingdom,Validated,31270117[PMID]
817,1209,Tricuspid atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.7,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
817,1209,Tricuspid atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.6,"Taiwan, Province of China",Validated,20138303[PMID]
817,1209,Tricuspid atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,8.0,Malta,Validated,31270117[PMID]
817,1209,Tricuspid atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.0,Czech Republic,Validated,31270117[PMID]
817,1209,Tricuspid atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.0,Slovakia,Validated,31270117[PMID]
816,98,Autosomal recessive spastic ataxia of Charlevoix-Saguenay,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_20301432[PMID]
816,98,Autosomal recessive spastic ataxia of Charlevoix-Saguenay,Disease,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,51.76,Specific population,Validated,8472930[PMID]
818,1478,Interatrial communication,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
829,330,Congenital factor XII deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
831,1959,Evans syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,[EXPERT]
830,284,Alveolar echinococcosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.16,Europe,Validated,23301116[PMID]_ORPHANET
830,284,Alveolar echinococcosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.26,Switzerland,Validated,17553227[PMID]
830,284,Alveolar echinococcosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.014,Poland,Validated,23301116[PMID]
830,284,Alveolar echinococcosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.8,Austria,Validated,23628138[PMID]
830,284,Alveolar echinococcosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.026,France,Validated,FrancEchino[REG]_Institut de Veille Sanitaire 2010[INST]
830,284,Alveolar echinococcosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
825,1177,Early-onset cerebellar ataxia with retained tendon reflexes,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.08,Italy,Validated,8330454[PMID]
825,1177,Early-onset cerebellar ataxia with retained tendon reflexes,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Italy,Validated,8330454[PMID]
825,1177,Early-onset cerebellar ataxia with retained tendon reflexes,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET
824,828,Stickler syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
824,828,Stickler syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET_EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
824,828,Stickler syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.65,France,Validated,22925539[PMID]
824,828,Stickler syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,France,Validated,22925539[PMID]
824,828,Stickler syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,12.2,Worldwide,Not yet validated,20301479[PMID]
827,1431,Paroxysmal dyskinesia,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
804,293,Congenital herpes simplex virus infection,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,6.6,Sweden,Not yet validated,ORPHANET
804,293,Congenital herpes simplex virus infection,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
804,293,Congenital herpes simplex virus infection,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.6,United Kingdom,Not yet validated,ORPHANET
18405,199340,"Muscular dystrophy, Selcen type",Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,22734908[PMID]
18405,199340,"Muscular dystrophy, Selcen type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18404,199337,Pancreatic insufficiency-anemia-hyperostosis syndrome,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,19268275[PMID]
18404,199337,Pancreatic insufficiency-anemia-hyperostosis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19268275[PMID]
805,234,Dubin-Johnson syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18407,199348,Thiamine-responsive encephalopathy,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,19387023[PMID]
18407,199348,Thiamine-responsive encephalopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19387023[PMID]
806,3287,Takayasu arteritis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.084,Europe,Validated,ORPHANET_27159262[PMID]
806,3287,Takayasu arteritis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.34,Europe,Validated,ORPHANET_27159262[PMID]
806,3287,Takayasu arteritis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.06,United Kingdom,Validated,ORPHANET_19542212[PMID]
806,3287,Takayasu arteritis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.0,Japan,Validated,9119531[PMID]
806,3287,Takayasu arteritis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Sweden,Validated,ORPHANET_6133485[PMID]_25774057[PMID]
806,3287,Takayasu arteritis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.98,Sweden,Validated,ORPHANET_6133485[PMID]_25774057[PMID]
806,3287,Takayasu arteritis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.47,United Kingdom,Validated,19542212[PMID]
806,3287,Takayasu arteritis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.04,Denmark,Validated,21385546[PMID]
806,3287,Takayasu arteritis,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Worldwide,Not yet validated,ORPHANET
806,3287,Takayasu arteritis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.07,Germany,Not yet validated,15696553[PMID]_ORPHANET
806,3287,Takayasu arteritis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.78,Kuwait,Validated,7563255[PMID]
806,3287,Takayasu arteritis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.15,Japan,Not yet validated,1360971[PMID]_ORPHANET
806,3287,Takayasu arteritis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.13,Lithuania,Validated,15647446[PMID]
806,3287,Takayasu arteritis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.22,Kuwait,Validated,7563255[PMID]
806,3287,Takayasu arteritis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.26,United States,Validated,2858047[PMID]
806,3287,Takayasu arteritis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.15,Norway,Validated,27159262[PMID]
806,3287,Takayasu arteritis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.56,Norway,Validated,27159262[PMID]
806,3287,Takayasu arteritis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.82,"Korea, Republic of",Validated,28283361[PMID]
806,3287,Takayasu arteritis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.24,"Korea, Republic of",Validated,28283361[PMID]
806,3287,Takayasu arteritis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.46,Poland,Validated,30260188[PMID]
806,3287,Takayasu arteritis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.092,Poland,Validated,30260188[PMID
18406,199343,EAST syndrome,Disease,Disorder,Cases/families,Case(s),,26.0,Worldwide,Validated,27500072[PMID]
18406,199343,EAST syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27500072[PMID]
807,2800,Extramammary Paget disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
18401,199326,"Isolated autosomal dominant hypomagnesemia, Glaudemans type",Disease,Disorder,Cases/families,Case(s),,21.0,Worldwide,Validated,19307729[PMID]
18401,199326,"Isolated autosomal dominant hypomagnesemia, Glaudemans type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
802,1928,Congenital lobar emphysema,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.0,Worldwide,Validated,24068262[PMID]
802,1928,Congenital lobar emphysema,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Worldwide,Validated,24068262[PMID]_ORPHANET_[EXPERT]
18403,199332,Endocrine-cerebro-osteodysplasia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,19185282[PMID]_27069622[PMID]
18403,199332,Endocrine-cerebro-osteodysplasia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19185282[PMID]_27069622[PMID]
18402,199329,"Congenital myopathy, Paradas type",Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,19084402[PMID]
18402,199329,"Congenital myopathy, Paradas type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19084402[PMID]
812,3463,Wolfram syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.13,United Kingdom,Validated,7490992[PMID]
812,3463,Wolfram syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.12,India,Validated,21726277[PMID]
812,3463,Wolfram syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.13,Worldwide,Validated,ORPHANET_7490992[PMID]_21726277[PMID]_25211237[PMID]
812,3463,Wolfram syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.83,Specific population,Validated,24497219[PMID]
812,3463,Wolfram syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.13,Japan,Validated,25211237[PMID]
812,3463,Wolfram syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.62,Europe,Validated,[EXPERT]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.4,Europe,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.5,France,Validated,21109475[PMID]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.82,Austria,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.38,Belgium,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.8,Croatia,Validated,European Centre for Disease prevention and Control 2014-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.42,Cyprus,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.24,Czech Republic,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.18,Denmark,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.84,Estonia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.32,Finland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.18,Germany,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.3,Greece,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.5,Hungary,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.83,Iceland,Validated,European Centre for Disease prevention and Control 2014-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.28,Ireland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.72,Italy,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.5,Latvia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.28,Lithuania,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.02,Luxembourg,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.88,Malta,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.48,Netherlands,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.96,Norway,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.06,Poland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.42,Portugal,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.26,Slovakia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.38,Slovenia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.16,Spain,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.52,Sweden,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.62,United Kingdom,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Romania,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
815,549,Legionnaires disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.4,New Zealand,Validated,31294928[PMID]
808,704,Pemphigus vulgaris,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.13,France,Validated,7829889[PMID]
808,704,Pemphigus vulgaris,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,18.0,Europe,Validated,European Medicines Agency[INST]
808,704,Pemphigus vulgaris,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.7,United Kingdom,Validated,18614511[PMID]
808,704,Pemphigus vulgaris,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.076,Finland,Validated,6187153[PMID]
808,704,Pemphigus vulgaris,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.47,Bulgaria,Validated,10692058[PMID]
808,704,Pemphigus vulgaris,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.42,United States,Validated,7416755[PMID]
808,704,Pemphigus vulgaris,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.25,Tunisia,Validated,7829889[PMID]
808,704,Pemphigus vulgaris,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,9.482,Germany,Validated,27456755[PMID]
18409,199354,Cerebral autosomal recessive arteriopathy-subcortical infarcts-leukoencephalopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18408,199351,Adult-onset dystonia-parkinsonism,Disease,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,18570303[PMID]_20938027[PMID]
18408,199351,Adult-onset dystonia-parkinsonism,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
809,356,Gerstmann-Straussler-Scheinker syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
809,356,Gerstmann-Straussler-Scheinker syndrome,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.0055,Worldwide,Validated,16903147[PMID]
810,466,Fatal familial insomnia,Disease,Disorder,Cases/families,Case(s),,27.0,Worldwide,Validated,ORPHANET
810,466,Fatal familial insomnia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18391,199293,Congenital microgastria,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28361011[PMID]
789,3452,Whipple disease,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,[EXPERT]
789,3452,Whipple disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
789,3452,Whipple disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.29,Italy,Validated,25804189[PMID]
789,3452,Whipple disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.98,United States,Validated,30488239[PMID]
18388,199282,Harlequin syndrome,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,28018464[PMID]
18388,199282,Harlequin syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28018464[PMID]
18389,199285,Hereditary hypercarotenemia and vitamin A deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
788,2331,Kawasaki disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
787,2102,GTP cyclohydrolase I deficiency,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,ORPHANET
787,2102,GTP cyclohydrolase I deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
784,3002,Immune thrombocytopenia,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,25.0,Europe,Validated,European Medicines Agency 2007[INST]
784,3002,Immune thrombocytopenia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,9.5,United States,Validated,19200301[PMID]
784,3002,Immune thrombocytopenia,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.9,United Kingdom,Validated,19245432[PMID]
784,3002,Immune thrombocytopenia,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,6.75,Europe,Not yet validated,ISBN:70703868[OTHER]_ORPHANET
784,3002,Immune thrombocytopenia,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.68,Denmark,Validated,10419881[PMID]
784,3002,Immune thrombocytopenia,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,45.0,Denmark,Validated,20066507[PMID]
784,3002,Immune thrombocytopenia,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.9,France,Validated,25305203[PMID]
18385,199267,Infantile digital fibromatosis,Disease,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,23157779[PMID]
18385,199267,Infantile digital fibromatosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
798,2040,Congenital respiratory-biliary fistula,Morphological anomaly,Disorder,Cases/families,Case(s),,35.0,Worldwide,Validated,21516501[PMID]_19586763[PMID]
798,2040,Congenital respiratory-biliary fistula,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18399,199318,15q13.3 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,246.0,Worldwide,Validated,25077648[PMID]_[EXPERT]
18399,199318,15q13.3 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
797,2357,Bronchogenic cyst,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
796,274,Bernard-Soulier syndrome,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,17109744[PMID]_24051937[PMID]
796,274,Bernard-Soulier syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17109744[PMID]
795,1195,Congenital atransferrinemia,Disease,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,19696475[PMID]_23888904[PMID]
795,1195,Congenital atransferrinemia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18394,199302,Isolated cleft lip,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Validated,Pr Marie-Paule VAZQUEZ_Dr Eva GALLIANI[EXPERT]
18395,199306,Cleft lip/palate,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Validated,Pr Marie-Paule VAZQUEZ_Dr Eva GALLIANI[EXPERT]
18395,199306,Cleft lip/palate,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,56.0,United States,Validated,25399767[PMID]
18395,199306,Cleft lip/palate,Morphological anomaly,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,98.0,France,Validated,1842671[PMID]
18395,199306,Cleft lip/palate,Morphological anomaly,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,80.0,Worldwide,Validated,22374000[PMID]
794,926,Acatalasemia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.2,Europe,Validated,[EXPERT]
793,3020,Ramsay Hunt syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.0,United States,Validated,23763077[PMID]_24799517[PMID]
793,3020,Ramsay Hunt syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
792,1531,Craniosynostosis,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,24.3,Europe,Not yet validated,EUROCAT European surveillance of congenital anomalies 2012[REG]
792,1531,Craniosynostosis,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,47.6,France,Validated,7762595[PMID]
792,1531,Craniosynostosis,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,49.4,Australia,Validated,34626670[PMID]
792,1531,Craniosynostosis,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,43.0,United States,Validated,18344207[PMID]
792,1531,Craniosynostosis,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
774,1675,Dihydropyrimidine dehydrogenase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18374,189427,Cushing syndrome due to bilateral macronodular adrenocortical disease,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.08,Europe,Validated,[EXPERT]
775,976,Adenine phosphoribosyltransferase deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.5,Specific population,Validated,[EXPERT]
775,976,Adenine phosphoribosyltransferase deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.7,Japan,Validated,[EXPERT]
775,976,Adenine phosphoribosyltransferase deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.7,Iceland,Validated,[EXPERT]
775,976,Adenine phosphoribosyltransferase deficiency,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
773,3129,Sarcosinemia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.28,United States,Validated,6207480[PMID]
773,3129,Sarcosinemia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.0,Worldwide,Validated,ORPHANET
773,3129,Sarcosinemia,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Worldwide,Validated,ORPHANET
773,3129,Sarcosinemia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.3,Specific population,Validated,ISBN:79092543[OTHER]
770,415,Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_25874378[PMID]
770,415,Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,European Medicines Agency 2013[INST]
770,415,Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome,Disease,Disorder,Cases/families,Case(s),,111.0,Worldwide,Validated,25874378[PMID]
770,415,Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome,Disease,Disorder,Prevalence at birth,Class only,<1 / 1 000 000,0.0,United States,Validated,23972786[PMID]
771,13,6-pyruvoyl-tetrahydropterin synthase deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,30853107[PMID]_32456656[PMID]_ORPHANET
771,13,6-pyruvoyl-tetrahydropterin synthase deficiency,Clinical subtype,Subtype of disorder,Prevalence at birth,Class only,<1 / 1 000 000,0.0,Europe,Validated,30853107[PMID]_32456656[PMID]
771,13,6-pyruvoyl-tetrahydropterin synthase deficiency,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.0854,Brazil,Validated,28801146[PMID]
771,13,6-pyruvoyl-tetrahydropterin synthase deficiency,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.3094,China,Validated,33980295[PMID]
771,13,6-pyruvoyl-tetrahydropterin synthase deficiency,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.5258,Hong Kong,Validated,24803483[PMID]_24992243[PMID]
782,2494,Ménétrier disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
783,171,Primary sclerosing cholangitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.77,Europe,Validated,21351115[PMID]_[EXPERT]
783,171,Primary sclerosing cholangitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.84,Europe,Validated,ORPHANET_9489916[PMID]_18433916[PMID]_23775876[PMID]_7890895[PMID]_20683956[PMID]
783,171,Primary sclerosing cholangitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.1,Worldwide,Validated,22245904[PMID]
783,171,Primary sclerosing cholangitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.65,Worldwide,Validated,22245904[PMID]
783,171,Primary sclerosing cholangitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.77,United States,Not yet validated,14598252[PMID]_21351115[PMID]
783,171,Primary sclerosing cholangitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.81,United States,Not yet validated,14598252[PMID]_ORPHANET
783,171,Primary sclerosing cholangitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.3,Norway,Validated,9489916[PMID]
783,171,Primary sclerosing cholangitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.5,Norway,Validated,9489916[PMID]
783,171,Primary sclerosing cholangitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.22,Sweden,Validated,22098097[PMID]
783,171,Primary sclerosing cholangitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,16.2,Sweden,Validated,20683956[PMID]
783,171,Primary sclerosing cholangitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.66,United Kingdom,Not yet validated,18433916[PMID]_15188211[PMID]_ ORPHANET
783,171,Primary sclerosing cholangitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.28,United Kingdom,Not yet validated,18433916[PMID]_15188211[PMID]_ ORPHANET
783,171,Primary sclerosing cholangitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.5,Netherlands,Validated,23775876[PMID]
783,171,Primary sclerosing cholangitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.0,Netherlands,Validated,23775876[PMID]
783,171,Primary sclerosing cholangitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.9,Canada,Validated,17313496[PMID]
783,171,Primary sclerosing cholangitis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.07,Spain,Validated,7890895[PMID]
783,171,Primary sclerosing cholangitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.22,Spain,Validated,7890895[PMID]
783,171,Primary sclerosing cholangitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.3,Singapore,Validated,12164967[PMID]_22245904[PMID]
18381,199247,Corticosteroid-binding globulin deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
18379,199241,Pulmonary capillary hemangiomatosis,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,24493495[PMID]
18379,199241,Pulmonary capillary hemangiomatosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_24493495[PMID]
779,2134,Atypical hemolytic uremic syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.2,United States,Validated,15168377[PMID]_21902819[PMID]
779,2134,Atypical hemolytic uremic syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,European Medicines Agency 2015[INST]
779,2134,Atypical hemolytic uremic syndrome,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.0278,China,Validated,34103049[PMID]
776,17,Fatal infantile lactic acidosis with methylmalonic aciduria,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
880,3006,Pyridoxine-dependent epilepsy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.2,Europe,Validated,[EXPERT]
880,3006,Pyridoxine-dependent epilepsy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.13,United Kingdom,Validated,10519720[PMID]
880,3006,Pyridoxine-dependent epilepsy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.25,Netherlands,Validated,16159904[PMID]
880,3006,Pyridoxine-dependent epilepsy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.0,Germany,Not yet validated,10356240[PMID]_ORPHANET
880,3006,Pyridoxine-dependent epilepsy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
883,780,Rhabdomyosarcoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.59,Europe,Validated,[EXPERT]
883,780,Rhabdomyosarcoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
882,3111,Rotor syndrome,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,ORPHANET
882,3111,Rotor syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
885,2382,Lennox-Gastaut syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,[EXPERT]
885,2382,Lennox-Gastaut syndrome,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,15.0,Europe,Validated,[EXPERT]_European Medicines Agency 2004[INST]
884,2806,Subacute sclerosing leukoencephalitis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
884,2806,Subacute sclerosing leukoencephalitis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,United States,Validated,[EXPERT]_22277189[PMID]
884,2806,Subacute sclerosing leukoencephalitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.0,India,Validated,[EXPERT]
887,2467,Systemic mastocytosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.3,Italy,Validated,8645532[PMID]
887,2467,Systemic mastocytosis,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Worldwide,Validated,[EXPERT]_ORPHANET
887,2467,Systemic mastocytosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.9,Denmark,Validated,24761987[PMID]
887,2467,Systemic mastocytosis,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,9.6,Denmark,Validated,24761987[PMID]
887,2467,Systemic mastocytosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.6,Europe,Validated,24761987[PMID]_8645532[PMID]
887,2467,Systemic mastocytosis,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,13.0,Netherlands,Validated,23219169[PMID]
887,2467,Systemic mastocytosis,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,11.3,Europe,Validated,23219169[PMID]_24761987[PMID]
889,1934,Early infantile epileptic encephalopathy,Clinical syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Japan,Validated,19828294[PMID]
889,1934,Early infantile epileptic encephalopathy,Clinical syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.0,United Kingdom,Validated,23252366[PMID]_[EXPERT]
889,1934,Early infantile epileptic encephalopathy,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
888,845,Tay-Sachs disease,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,27.8,Specific population,Validated,20301397[PMID]
888,845,Tay-Sachs disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.5,Specific population,Not yet validated,ORPHANET
888,845,Tay-Sachs disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.31,Europe,Validated,ORPHANET
888,845,Tay-Sachs disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.13,Portugal,Validated,14685153[PMID]
888,845,Tay-Sachs disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.3,Czech Republic,Validated,20490927[PMID]
888,845,Tay-Sachs disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Australia,Validated,9918480[PMID]
888,845,Tay-Sachs disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.28,Worldwide,Validated,ISBN:0870684507[OTHER]
888,845,Tay-Sachs disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.41,Netherlands,Validated,10480370[PMID]
888,845,Tay-Sachs disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.29,Canada,Validated,10617747[PMID]
888,845,Tay-Sachs disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.74,United Arab Emirates,Validated,23430803[PMID]
888,845,Tay-Sachs disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.23,Turkey,Validated,15275696[PMID]
888,845,Tay-Sachs disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.48,Sweden,Validated,25274184[PMID]
888,845,Tay-Sachs disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
888,845,Tay-Sachs disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
891,1942,Myoclonic-astatic epilepsy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
892,1943,Early-onset progressive encephalopathy with migrant continuous myoclonus,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,8737801[PMID]
892,1943,Early-onset progressive encephalopathy with migrant continuous myoclonus,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8737801[PMID]
894,3451,Infantile epileptic spasms syndrome,Clinical syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.0,Europe,Validated,European Medicines Agency 2017[INST]
894,3451,Infantile epileptic spasms syndrome,Clinical syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.5,Europe,Validated,ORPHANET_11701251[PMID]_8082625[PMID]_7555969[PMID]
894,3451,Infantile epileptic spasms syndrome,Clinical syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.7,Worldwide,Validated,[EXPERT]_ORPHANET
894,3451,Infantile epileptic spasms syndrome,Clinical syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.5,Finland,Validated,11701251[PMID]_8082625[PMID]
894,3451,Infantile epileptic spasms syndrome,Clinical syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.5,Iceland,Validated,11701251[PMID]_8082625[PMID]
894,3451,Infantile epileptic spasms syndrome,Clinical syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.5,Sweden,Validated,7555969[PMID]
894,3451,Infantile epileptic spasms syndrome,Clinical syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.9,United States,Validated,10368073[PMID]
894,3451,Infantile epileptic spasms syndrome,Clinical syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,31.0,Singapore,Validated,11701260[PMID]
894,3451,Infantile epileptic spasms syndrome,Clinical syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,25.0,"Korea, Republic of",Validated,11701256[PMID]
894,3451,Infantile epileptic spasms syndrome,Clinical syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.25,Japan,Not yet validated,11701258[PMID]_17633081[PMID]_ORPHANET
864,3299,Tetanus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.014,France,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
864,3299,Tetanus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.024,Europe,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
864,3299,Tetanus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.044,Malta,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
864,3299,Tetanus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Slovakia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
864,3299,Tetanus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.014,Bulgaria,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
864,3299,Tetanus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.028,Croatia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
864,3299,Tetanus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.004,Czech Republic,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
864,3299,Tetanus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.014,Denmark,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
864,3299,Tetanus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.032,Estonia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
864,3299,Tetanus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.036,Greece,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
864,3299,Tetanus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.024,Hungary,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
864,3299,Tetanus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.016,Ireland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
864,3299,Tetanus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.076,Italy,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
864,3299,Tetanus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.07,Lithuania,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
864,3299,Tetanus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.008,Netherlands,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
864,3299,Tetanus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.012,Norway,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
864,3299,Tetanus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.032,Poland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
864,3299,Tetanus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.008,Portugal,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
864,3299,Tetanus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.032,Romania,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
864,3299,Tetanus,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.118,Slovenia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
864,3299,Tetanus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.016,Spain,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
864,3299,Tetanus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Sweden,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
864,3299,Tetanus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,United Kingdom,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
864,3299,Tetanus,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
865,2302,Asbestos intoxication,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
866,770,Rabies,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,[EXPERT]
866,770,Rabies,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,United States,Not yet validated,22699971[PMID]
866,770,Rabies,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,European Centre for Disease prevention and Control 2017[INST]
867,3386,American trypanosomiasis,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,21944556[PMID]
867,3386,American trypanosomiasis,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,France,Not yet validated,21944556[PMID]
867,3386,American trypanosomiasis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Germany,Not yet validated,21944556[PMID]
867,3386,American trypanosomiasis,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Italy,Not yet validated,21944556[PMID]
867,3386,American trypanosomiasis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Netherlands,Not yet validated,21944556[PMID]
867,3386,American trypanosomiasis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Portugal,Not yet validated,21944556[PMID]
867,3386,American trypanosomiasis,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Spain,Not yet validated,21944556[PMID]
867,3386,American trypanosomiasis,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Switzerland,Not yet validated,21944556[PMID]
867,3386,American trypanosomiasis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,United Kingdom,Not yet validated,21944556[PMID]
867,3386,American trypanosomiasis,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Belgium,Not yet validated,21944556[PMID]
867,3386,American trypanosomiasis,Disease,Disorder,Point prevalence,Value and class,6-9 / 10 000,95.0,United States,Validated,19640226[PMID]_Center for Diseases Control and Prevention [INST]
870,267,Calpain-3-related limb-girdle muscular dystrophy R1,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,European Medicines Agency 2006[INST]
870,267,Calpain-3-related limb-girdle muscular dystrophy R1,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.6,United Kingdom,Validated,19767415[PMID]
870,267,Calpain-3-related limb-girdle muscular dystrophy R1,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.8,Reunion,Validated,8624690[PMID]
870,267,Calpain-3-related limb-girdle muscular dystrophy R1,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.65,Italy,Not yet validated,ORPHANET_15725583[PMID]_16141003[PMID]
871,1329,Complete atrioventricular septal defect,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
871,1329,Complete atrioventricular septal defect,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,20.0,Europe,Validated,16722604[PMID]_[EXPERT]
872,582,Mucopolysaccharidosis type 4,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.07,Sweden,Validated,28595941[PMID]
872,582,Mucopolysaccharidosis type 4,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.76,Norway,Validated,18681890[PMID]
872,582,Mucopolysaccharidosis type 4,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,24.2,Norway,Validated,18681890[PMID]
872,582,Mucopolysaccharidosis type 4,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.48,Denmark,Validated,18681890[PMID]
872,582,Mucopolysaccharidosis type 4,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,31.0,Denmark,Validated,18681890[PMID]
872,582,Mucopolysaccharidosis type 4,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.73,Czech Republic,Validated,20490927[PMID]
872,582,Mucopolysaccharidosis type 4,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.45,Tunisia,Validated,20209839[PMID]
872,582,Mucopolysaccharidosis type 4,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.33,"Taiwan, Province of China",Validated,19396827[PMID]
872,582,Mucopolysaccharidosis type 4,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.45,Europe,Validated,28595941[PMID]
872,582,Mucopolysaccharidosis type 4,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.36,Netherlands,Validated,10480370[PMID]
872,582,Mucopolysaccharidosis type 4,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.14,Poland,Validated,25472774[PMID]
872,582,Mucopolysaccharidosis type 4,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,27.6,Europe,Validated,18681890[PMID]_ORPHANET
872,582,Mucopolysaccharidosis type 4,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.15,Japan,Validated,28595941[PMID]
872,582,Mucopolysaccharidosis type 4,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.38,Switzerland,Validated,28595941[PMID]
872,582,Mucopolysaccharidosis type 4,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.62,Saudi Arabia,Validated,20622343[PMID]
872,582,Mucopolysaccharidosis type 4,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.13,"Korea, Republic of",Validated,25364648[PMID]
872,582,Mucopolysaccharidosis type 4,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.14,Brazil,Validated,31926052[PMID]
872,582,Mucopolysaccharidosis type 4,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.6,Portugal,Validated,14685153[PMID]
872,582,Mucopolysaccharidosis type 4,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.038,United States,Validated,34051828[PMID]
872,582,Mucopolysaccharidosis type 4,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.14,United States,Validated,34051828[PMID]
872,582,Mucopolysaccharidosis type 4,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.07,Worldwide,Validated,28595941[PMID]
873,2137,Autoimmune hepatitis,Disease,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET
873,2137,Autoimmune hepatitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.2,Worldwide,Not yet validated,ORPHANET_24326217[PMID]
873,2137,Autoimmune hepatitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,23.5,Worldwide,Not yet validated,ORPHANET_24326217[PMID]
873,2137,Autoimmune hepatitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.75,Europe,Validated,[EXPERT]
873,2137,Autoimmune hepatitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.9,Norway,Validated,9489916[PMID]
873,2137,Autoimmune hepatitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,16.9,Norway,Validated,9489916[PMID]
873,2137,Autoimmune hepatitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.85,Sweden,Validated,18609163[PMID]
873,2137,Autoimmune hepatitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,24.5,New Zealand,Validated,20880179[PMID]
873,2137,Autoimmune hepatitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.95,Spain,Validated,15056409[PMID]_20163033[PMID]_ORPHANET
873,2137,Autoimmune hepatitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,11.6,Spain,Validated,15056409[PMID]
873,2137,Autoimmune hepatitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.7,Sweden,Validated,18609163[PMID]
873,2137,Autoimmune hepatitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.67,Israel,Validated,23815477[PMID]
873,2137,Autoimmune hepatitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,11.0,Israel,Validated,23815477[PMID]
873,2137,Autoimmune hepatitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.68,Denmark,Validated,24326217[PMID]
873,2137,Autoimmune hepatitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,23.9,Denmark,Validated,24326217[PMID]
873,2137,Autoimmune hepatitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.0,Singapore,Validated,11851837[PMID]
873,2137,Autoimmune hepatitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,42.9,Specific population,Validated,12358264[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.57,Europe,Validated,[EXPERT]_ORPHANET
874,186,Primary biliary cholangitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,21.05,Worldwide,Validated,[EXPERT]_22245904[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.0,Worldwide,Validated,22245904[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,25.0,Europe,Validated,17873609[PMID]_22562114[PMID]_24387641[PMID]_17918011[PMID]_22961000[PMID]_10421645[PMID]_9279616[PMID]_20347176[PMID]_24502439[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.9,France,Validated,20347176[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.7,Spain,Validated,17873609[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,19.5,Spain,Validated,17873609[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.5,Iceland,Validated,22562114[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,38.3,Iceland,Validated,22562114[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.1,Netherlands,Validated,24387641[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,13.2,Netherlands,Validated,24387641[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.7,Denmark,Validated,17918011[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,12.0,Denmark,Validated,17918011[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.7,Finland,Validated,17918011[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,18.0,Finland,Validated,17918011[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,25.0,United Kingdom,Validated,22961000[PMID]_9279616[PMID]_10421645[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.5,United States,Validated,11113084[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,40.2,United States,Validated,11113084[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.0,Canada,Validated,19821525[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,22.7,Canada,Validated,19821525[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.1,Australia,Validated,15300579[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.5,Israel,Validated,16308995[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.9,China,Validated,20815889[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.0,Brunei Darussalam,Validated,21134832[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.6,Brunei Darussalam,Validated,21134832[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,36.5,Greece,Validated,24502439[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.1,Greece,Validated,24502439[PMID]
874,186,Primary biliary cholangitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.3,United Kingdom,Validated,10421645[PMID]_9279616[PMID]
876,397,Giant cell arteritis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.9,Germany,Validated,11136884[PMID]
876,397,Giant cell arteritis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.35,United States,Validated,6626279[PMID]
876,397,Giant cell arteritis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.8,Italy,Validated,2003856[PMID]
876,397,Giant cell arteritis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,7.7,Sweden,Validated,10587547[PMID]
876,397,Giant cell arteritis,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,11.2,United Kingdom,Validated,25132663[PMID]
876,397,Giant cell arteritis,Disease,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Validated,ORPHANET
876,397,Giant cell arteritis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,30.4,Italy,Validated,27214746[PMID]
876,397,Giant cell arteritis,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,16.8,Norway,Validated,31909871[PMID]
877,2932,Chronic inflammatory demyelinating polyneuropathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.7,Europe,Not yet validated,ORPHANET
877,2932,Chronic inflammatory demyelinating polyneuropathy,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.36,Italy,Validated,17494979[PMID]
877,2932,Chronic inflammatory demyelinating polyneuropathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.6,United Kingdom,Not yet validated,23679015[PMID]_10209187[PMID]_19260065[PMID]
877,2932,Chronic inflammatory demyelinating polyneuropathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.86,Italy,Validated,17494979[PMID]
877,2932,Chronic inflammatory demyelinating polyneuropathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.7,Norway,Validated,11284994[PMID]
877,2932,Chronic inflammatory demyelinating polyneuropathy,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,12.0,Egypt,Validated,23146298[PMID]
877,2932,Chronic inflammatory demyelinating polyneuropathy,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.48,Japan,Validated,18223015[PMID]
877,2932,Chronic inflammatory demyelinating polyneuropathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.61,Japan,Validated,18223015[PMID]
877,2932,Chronic inflammatory demyelinating polyneuropathy,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.15,Australia,Validated,10589544[PMID]
877,2932,Chronic inflammatory demyelinating polyneuropathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.9,Australia,Validated,10589544[PMID]
878,2398,Multiple symmetric lipomatosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
878,2398,Multiple symmetric lipomatosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Italy,Validated,[EXPERT]
879,1656,Dermatitis herpetiformis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,27.0,Europe,Validated,[EXPERT]
879,1656,Dermatitis herpetiformis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.9,Italy,Validated,[EXPERT]
879,1656,Dermatitis herpetiformis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.5,Ireland,Validated,5023901[PMID]_6641006[PMID]_[EXPERT]_ORPHANET
879,1656,Dermatitis herpetiformis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,17.6,Ireland,Validated,5023901[PMID]_6641006[PMID]_[EXPERT]_ORPHANET
879,1656,Dermatitis herpetiformis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.1,Sweden,Validated,6208718[PMID]
879,1656,Dermatitis herpetiformis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,21.0,Sweden,Not yet validated,6208718[PMID]
879,1656,Dermatitis herpetiformis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.98,United States,Validated,1456754[PMID]
879,1656,Dermatitis herpetiformis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,11.2,United States,Validated,1456754[PMID]
879,1656,Dermatitis herpetiformis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.5,Finland,Validated,21517799[PMID]
879,1656,Dermatitis herpetiformis,Disease,Disorder,Point prevalence,Value and class,6-9 / 10 000,75.3,Finland,Validated,21517799[PMID]
879,1656,Dermatitis herpetiformis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,11.5,United Kingdom,Validated,6693042[PMID]
849,3198,Stiff person spectrum disorder,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,21921002[PMID]_ORPHANET
849,3198,Stiff person spectrum disorder,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.15,United Kingdom,Validated,21921002[PMID]
849,3198,Stiff person spectrum disorder,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.09,"Tanzania, United Republic of",Validated,26316197[PMID]
848,2929,Juvenile polyposis syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.85,Europe,Validated,20301642[PMID]_[EXPERT]
848,2929,Juvenile polyposis syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
854,131,Budd-Chiari syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.5,Europe,Validated,[EXPERT]
854,131,Budd-Chiari syndrome,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.08,Sweden,Validated,18694401[PMID]
854,131,Budd-Chiari syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.14,Sweden,Validated,18694401[PMID]
854,131,Budd-Chiari syndrome,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.05,Denmark,Validated,2010159[PMID]
854,131,Budd-Chiari syndrome,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Japan,Validated,7751574[PMID]
854,131,Budd-Chiari syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.24,Japan,Validated,7751574[PMID]
854,131,Budd-Chiari syndrome,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.04,France,Validated,19433611[PMID]
854,131,Budd-Chiari syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.21,Italy,Validated,28180235[PMID]
854,131,Budd-Chiari syndrome,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.087,"Korea, Republic of",Validated,26558363[PMID]
854,131,Budd-Chiari syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.529,"Korea, Republic of",Validated,26558363[PMID]
854,131,Budd-Chiari syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Worldwide,Validated,30528513[PMID]
854,131,Budd-Chiari syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.1,Worldwide,Validated,30528513[PMID]
853,646,Niemann-Pick disease type C,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,20525256[PMID]_European Medicines Agency 2011[INST]
853,646,Niemann-Pick disease type C,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.77,France,Validated,20525256[PMID]_12974729[PMID]_[EXPERT]
853,646,Niemann-Pick disease type C,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.75,United Kingdom,Not yet validated,12974729[PMID]
853,646,Niemann-Pick disease type C,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.75,Germany,Not yet validated,12974729[PMID]
853,646,Niemann-Pick disease type C,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.35,Netherlands,Validated,10480370[PMID]
853,646,Niemann-Pick disease type C,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.2,Portugal,Validated,14685153[PMID]
853,646,Niemann-Pick disease type C,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.47,Australia,Validated,9918480[PMID]
853,646,Niemann-Pick disease type C,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.91,Czech Republic,Validated,20490927[PMID]
853,646,Niemann-Pick disease type C,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.48,Sweden,Validated,25274184[PMID]
852,654,Nephroblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.14,Europe,Validated,22357215[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
852,654,Nephroblastoma,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
852,654,Nephroblastoma,Disease,Disorder,Lifetime Prevalence,Value and class,1-9 / 100 000,3.65,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
852,654,Nephroblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.144,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
852,654,Nephroblastoma,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,10.0,Europe,Validated,[EXPERT]
852,654,Nephroblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.072,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
852,654,Nephroblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
852,654,Nephroblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.089,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
852,654,Nephroblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.043,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
852,654,Nephroblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.065,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
852,654,Nephroblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.066,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
852,654,Nephroblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.121,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
852,654,Nephroblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.195,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
852,654,Nephroblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.155,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
852,654,Nephroblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.139,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
852,654,Nephroblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.158,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
852,654,Nephroblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.17,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
852,654,Nephroblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.111,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
852,654,Nephroblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
852,654,Nephroblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.157,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
852,654,Nephroblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.131,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
852,654,Nephroblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.111,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
852,654,Nephroblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.162,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
852,654,Nephroblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.144,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
852,654,Nephroblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.113,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
852,654,Nephroblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.135,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
852,654,Nephroblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.176,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,8.9,Europe,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,9.76,Austria,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,10.08,Belgium,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.08,Bulgaria,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.88,Cyprus,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,10.7,Czech Republic,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,19.16,Denmark,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.66,Estonia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.1,Finland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,15.4,Germany,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.38,Greece,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.16,Hungary,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.34,Croatia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.3,Iceland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.58,Ireland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.2,Italy,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,8.48,Latvia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.22,Lithuania,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.14,Luxembourg,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.52,Malta,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,31.72,Netherlands,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,47.24,Norway,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,10.6,Poland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.1,Portugal,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.42,Romania,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,10.5,Slovakia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,9.5,Slovenia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,8.3,Spain,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,6.2,Sweden,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
859,1489,Whooping cough,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,8.5,United Kingdom,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
858,2764,Osteochondritis dissecans,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,35.0,Europe,Not yet validated,16958015[PMID]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.0,Greece,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.0,Iceland,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,6.0,Israel,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,15.0,Spain,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,24.0,Portugal,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,8.0,Belgium,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.0,Austria,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,6-9 / 10 000,90.0,Algeria,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,23.0,Poland,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,42.0,Latvia,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,59.0,Lithuania,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,49.0,Bosnia and Herzegovina,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,17.0,Croatia,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,>1 / 1000,101.0,Romania,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,6-9 / 10 000,97.0,Russian Federation,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,>1 / 1000,139.0,Worldwide,Validated,21420560[PMID]
863,3389,Tuberculosis,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,16.0,Europe,Validated,European Medicines Agency 2018[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.4,United States,Validated,Centers for Disease Control and Prevention 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,20.0,Japan,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,6.0,Australia,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.0,France,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,8.0,Finland,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,18.0,Hungary,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,>1 / 1000,181.0,India,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,7.0,Netherlands,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,14.0,United Kingdom,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,6.0,Norway,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,7.0,Sweden,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,6-9 / 10 000,75.0,China,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,47.0,Latin America,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,>1 / 1000,993.0,South Africa,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,7.1,Denmark,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,6.0,Czech Republic,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.0,Germany,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,10.7,Ireland,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.0,Italy,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,25.0,Estonia,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,24.0,Turkey,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,6-9 / 10 000,89.0,Ukraine,Validated,World Health Organization 2011[INST]
863,3389,Tuberculosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,9.0,Europe,Validated,World Health Organization 2011[INST]
862,1679,Diphtheria,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,European Centre for Disease prevention and Control 2011[INST]
861,1267,Botulism,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.022,Europe,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
861,1267,Botulism,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,[EXPERT]
861,1267,Botulism,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.255,France,Validated,Institut de Veille Sanitaire 2016[INST]
861,1267,Botulism,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.35,United States,Validated,Center for Diseases Control and Prevention 2006[INST]_ORPHANET
861,1267,Botulism,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.026,Austria,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
861,1267,Botulism,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Belgium,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
861,1267,Botulism,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.028,Bulgaria,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
861,1267,Botulism,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.04,Croatia,Validated,European Centre for Disease prevention and Control 2013-2015[INST]
861,1267,Botulism,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Czech Republic,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
861,1267,Botulism,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.024,Denmark,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
861,1267,Botulism,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.012,Finland,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
861,1267,Botulism,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Germany,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
861,1267,Botulism,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.052,Hungary,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
861,1267,Botulism,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.012,Ireland,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
861,1267,Botulism,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.052,Italy,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
861,1267,Botulism,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.086,Lithuania,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
861,1267,Botulism,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Netherlands,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
861,1267,Botulism,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.038,Poland,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
861,1267,Botulism,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.018,Portugal,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
861,1267,Botulism,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.104,Romania,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
861,1267,Botulism,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Slovenia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
861,1267,Botulism,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.004,Spain,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
861,1267,Botulism,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Sweden,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
861,1267,Botulism,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.008,United Kingdom,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
861,1267,Botulism,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.098,Norway,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
860,2897,Pityriasis rubra pilaris,Disease,Disorder,Cases/families,Case(s),,48.0,Worldwide,Validated,ORPHANET
860,2897,Pityriasis rubra pilaris,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
834,2103,Guillain-Barré syndrome,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.45,Worldwide,Validated,19088488[PMID]_[EXPERT]_ ORPHANET
834,2103,Guillain-Barré syndrome,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.72,United States,Validated,22846726[PMID]
834,2103,Guillain-Barré syndrome,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,3.5,Europe,Validated,[EXPERT]_European Medicines Agency 2007[INST]_ ORPHANET
834,2103,Guillain-Barré syndrome,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,25.0,Denmark,Validated,20066507[PMID]
834,2103,Guillain-Barré syndrome,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.4,Europe,Not yet validated,22694000[PMID]_ORPHANET
834,2103,Guillain-Barré syndrome,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,12.0,Egypt,Validated,23146298[PMID]
834,2103,Guillain-Barré syndrome,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.42,France,Validated,27991707[PMID]
18306,183669,Agammaglobulinemia,Category,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.13,Europe,Not yet validated,ORPHANET
18306,183669,Agammaglobulinemia,Category,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.287,France,Validated,22288591[PMID]
18306,183669,Agammaglobulinemia,Category,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.134,Spain,Validated,22288591[PMID]
18306,183669,Agammaglobulinemia,Category,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.192,Netherlands,Validated,22288591[PMID]
18306,183669,Agammaglobulinemia,Category,Group of disorders,Point prevalence,Value and class,<1 / 1 000 000,0.045,Turkey,Validated,22288591[PMID]
18306,183669,Agammaglobulinemia,Category,Group of disorders,Point prevalence,Value and class,<1 / 1 000 000,0.094,United Kingdom,Validated,22288591[PMID]
18306,183669,Agammaglobulinemia,Category,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.205,Italy,Validated,22288591[PMID]
18306,183669,Agammaglobulinemia,Category,Group of disorders,Point prevalence,Value and class,<1 / 1 000 000,0.077,Germany,Validated,22288591[PMID]
18306,183669,Agammaglobulinemia,Category,Group of disorders,Point prevalence,Value and class,<1 / 1 000 000,0.071,Poland,Validated,22288591[PMID]
833,2070,Eosinophilic gastroenteritis,Disease,Disorder,Cases/families,Case(s),,280.0,Worldwide,Validated,11345185[PMID]_23904840[PMID]
833,2070,Eosinophilic gastroenteritis,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
833,2070,Eosinophilic gastroenteritis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_11345185[PMID]_23904840[PMID]
18311,183707,Infantile LAD-like disease due to RAC2 deficiency,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,10758162[PMID]
18311,183707,Infantile LAD-like disease due to RAC2 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10758162[PMID]
839,2314,Autosomal dominant hyper-IgE syndrome due to STAT3 deficiency,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,[EXPERT]
839,2314,Autosomal dominant hyper-IgE syndrome due to STAT3 deficiency,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,[EXPERT]_ORPHANET
18309,183678,Hermansky-Pudlak syndrome due to AP-3 deficiency,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,29580292[PMID]
18309,183678,Hermansky-Pudlak syndrome due to AP-3 deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29580292[PMID]
836,449,Hepatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
836,449,Hepatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.009,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
836,449,Hepatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.019,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
836,449,Hepatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.008,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
836,449,Hepatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.042,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
836,449,Hepatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
836,449,Hepatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.046,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
836,449,Hepatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.031,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
836,449,Hepatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.021,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
836,449,Hepatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.043,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
836,449,Hepatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.017,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
836,449,Hepatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.022,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
836,449,Hepatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.004,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
836,449,Hepatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.031,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
836,449,Hepatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.033,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
836,449,Hepatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.023,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
836,449,Hepatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.008,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
836,449,Hepatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.032,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
836,449,Hepatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.025,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
836,449,Hepatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.009,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
836,449,Hepatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.011,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
836,449,Hepatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.032,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
836,449,Hepatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.028,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18308,183675,Recurrent infections associated with rare immunoglobulin isotypes deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
837,2177,Hydranencephaly,Malformation syndrome,Disorder,Prevalence at birth,Class only,1-9 / 100 000,0.0,Worldwide,Validated,10207424[PMID]
837,2177,Hydranencephaly,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
837,2177,Hydranencephaly,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.1,Japan,Validated,26545857[PMID]
837,2177,Hydranencephaly,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.8,United States,Validated,18383510[PMID]
842,533,Listeriosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.43,Europe,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.337,Worldwide,Validated,25241232[PMID]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.31,United States,Validated,17243053[PMID]_CDC Centers for disease Control and prevention 1996-2003[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.48,Austria,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.07,Belgium,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.09,Bulgaria,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.05,Croatia,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.05,Cyprus,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.36,Czech Republic,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.98,Denmark,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.4,Estonia,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.1,Finland,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.57,France,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.68,Germany,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.15,Greece,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.28,Hungary,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.29,Ireland,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.24,Italy,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.28,Latvia,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.25,Lithuania,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.4,Luxembourg,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.38,Malta,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.47,Netherlands,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.23,Poland,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.29,Portugal,Validated,European Centre for Disease prevention and Control 2015-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.05,Romania,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.31,Slovakia,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.67,Slovenia,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.9,Spain,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.92,Sweden,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.3,United Kingdom,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.56,Iceland,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
842,533,Listeriosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.46,Norway,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
18313,183713,OBSOLETE:Bacterial susceptibility due to TLR signaling pathway deficiency,Disease,Disorder,Cases/families,Case(s),,24.0,Worldwide,Validated,[EXPERT]
18313,183713,OBSOLETE:Bacterial susceptibility due to TLR signaling pathway deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
841,2380,Legg-Calvé-Perthes disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
846,683,Progressive supranuclear palsy,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,0.65,Worldwide,Validated,11487180[PMID]_9371909[PMID]_4792160[PMID]_3405368[PMID]_6333204[PMID]_3386818[PMID]_[EXPERT]
846,683,Progressive supranuclear palsy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.26,Worldwide,Validated,PMID: 27037234  ; 34220661; ORPHANET
846,683,Progressive supranuclear palsy,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,14.0,Europe,Validated,European Medicines Agency 2015[INST]
846,683,Progressive supranuclear palsy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.39,United States,Validated,3386818[PMID]
846,683,Progressive supranuclear palsy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.2,Italy,Validated,9613728[PMID]
846,683,Progressive supranuclear palsy,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,14.0,Guadeloupe,Validated,11912113[PMID]
846,683,Progressive supranuclear palsy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.75,United Kingdom,Validated,21088431[PMID]_10577638[PMID]_11408338[PMID]_ORPHANET
846,683,Progressive supranuclear palsy,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.3,Libyan Arab Jamahiriya,Validated,3405368[PMID]
846,683,Progressive supranuclear palsy,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.63,United States,Validated,6333204[PMID]_9371909[PMID]_3386818[PMID]
846,683,Progressive supranuclear palsy,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.4,Australia,Validated,4792160[PMID]
844,677,Pancreatoblastoma,Disease,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,16080945[PMID]
844,677,Pancreatoblastoma,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
844,677,Pancreatoblastoma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
844,677,Pancreatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.008,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
844,677,Pancreatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.013,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
844,677,Pancreatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
844,677,Pancreatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.001,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
844,677,Pancreatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.016,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
844,677,Pancreatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.004,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
844,677,Pancreatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.008,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
844,677,Pancreatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
844,677,Pancreatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.001,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
844,677,Pancreatoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.001,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18303,183660,Severe combined immunodeficiency,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.65,Europe,Validated,[EXPERT]_ORPHANET
18303,183660,Severe combined immunodeficiency,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.6,France,Validated,22288591[PMID]
18303,183660,Severe combined immunodeficiency,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.7,Greece,Validated,21732012[PMID]
18303,183660,Severe combined immunodeficiency,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.75,Australia,Not yet validated,18221464[PMID]_9314356[PMID]_ ORPHANET
18303,183660,Severe combined immunodeficiency,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.28,Chile,Validated,17191150[PMID]
18303,183660,Severe combined immunodeficiency,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,3.79,Costa rica,Validated,17191150[PMID]
18303,183660,Severe combined immunodeficiency,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18303,183660,Severe combined immunodeficiency,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.72,United States,Validated,25138334[PMID]
18303,183660,Severe combined immunodeficiency,Clinical group,Group of disorders,Prevalence at birth,Class only,1-9 / 100 000,0.0,Worldwide,Not yet validated,ORPHANET
959,897,Waardenburg-Shah syndrome,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,Dr Véronique PINGAULT[EXPERT]
959,897,Waardenburg-Shah syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
954,808,Seckel syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,20301772[PMID]
954,808,Seckel syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25284118[PMID]
954,808,Seckel syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.2,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
950,844,Lown-Ganong-Levine syndrome,Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,836114[PMID]
950,844,Lown-Ganong-Levine syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_836114[PMID]
946,3027,Caudal regression syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
946,3027,Caudal regression syndrome,Malformation syndrome,Disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
946,3027,Caudal regression syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.75,Australia,Validated,20734338[PMID]
937,676,Hereditary chronic pancreatitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.3,France,Validated,18755888[PMID]
937,676,Hereditary chronic pancreatitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.57,Denmark,Validated,20502448[PMID]
937,676,Hereditary chronic pancreatitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.43,Europe,Validated,18755888[PMID]_20502448[PMID]
936,643,Giant axonal neuropathy,Disease,Disorder,Cases/families,Family(ies),,50.0,Worldwide,Validated,20301315[PMID]
936,643,Giant axonal neuropathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_20301315[PMID]
938,634,Netherton syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,[EXPERT]
938,634,Netherton syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,[EXPERT]
933,140,Campomelic dysplasia,Malformation syndrome,Disorder,Point prevalence,Value and class,<1 / 1 000 000,3.0E-4,Worldwide,Validated,[https://www.ncbi.nlm.nih.gov/books/NBK1760/]_ORPHANET
933,140,Campomelic dysplasia,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.875,Worldwide,,[https://www.ncbi.nlm.nih.gov/books/NBK1760/]_ORPHANET
932,2828,Young-onset Parkinson disease,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,15.0,Europe,Validated,ORPHANET_23083512[PMID]
932,2828,Young-onset Parkinson disease,Disease,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Worldwide,Not yet validated,15172778[PMID]
935,642,Hereditary sensory and autonomic neuropathy type 4,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.14,Japan,Validated,23495212[PMID]
935,642,Hereditary sensory and autonomic neuropathy type 4,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
931,627,Nance-Horan syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,196.0,Worldwide,Validated,27616609[PMID]
931,627,Nance-Horan syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_27616609[PMID]
930,638,Neurofibromatosis-Noonan syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
926,326,Congenital factor V deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,ORPHANET_19598066[PMID]
927,526,Liddle syndrome,Disease,Disorder,Cases/families,Family(ies),,72.0,Worldwide,Validated,29534496[PMID]_[EXPERT]
927,526,Liddle syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
924,650,LCAT deficiency,Disease,Disorder,Cases/families,Case(s),,125.0,Worldwide,Validated,ORPHANET
924,650,LCAT deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
925,427,Familial hypoaldosteronism,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
923,215,Congenital stationary night blindness,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
920,342,Familial Mediterranean fever,Disease,Disorder,Point prevalence,Value and class,>1 / 1000,175.0,Turkey,Not yet validated,9858443[PMID]_15515780[PMID]_15643295[PMID]
920,342,Familial Mediterranean fever,Disease,Disorder,Point prevalence,Value and class,>1 / 1000,200.0,Armenia,Validated,18403822[PMID]
920,342,Familial Mediterranean fever,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.5,Sweden,Validated,23194659[PMID]
920,342,Familial Mediterranean fever,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.23,Japan,Not yet validated,23111802[PMID]_ORPHANET
920,342,Familial Mediterranean fever,Disease,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET
920,342,Familial Mediterranean fever,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,14.0,Specific population,Not yet validated,ORPHANET
921,180,Choroideremia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Europe,Validated,European Medicines Agency 2014[INST]
918,754,Androgen insensitivity syndrome,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.01,Netherlands,Validated,11549642[PMID]
918,754,Androgen insensitivity syndrome,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
918,754,Androgen insensitivity syndrome,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,4.1,Denmark,Validated,27603905[PMID]
918,754,Androgen insensitivity syndrome,Clinical group,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.04,Denmark,Validated,27603905[PMID]
919,253,Spondyloepiphyseal dysplasia and spondyloepimetaphyseal dysplasia,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
916,327,Congenital factor VII deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.33,Europe,Validated,[EXPERT]
18259,183518,Hereditary ataxia,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,22689585[PMID]
912,373,Simpson-Golabi-Behmel syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
912,373,Simpson-Golabi-Behmel syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,250.0,Worldwide,Validated,25238977[PMID]_[EXPERT]
913,403,Familial hyperaldosteronism type I,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,23610123[PMID]_ORPHANET
910,574,21q deletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,[EXPERT]
910,574,21q deletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
906,653,Multiple endocrine neoplasia type 2,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.9,Europe,Validated,ISBN:9283224167[OTHER]_[EXPERT]
906,653,Multiple endocrine neoplasia type 2,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.25,Germany,Validated,23211574[PMID]
905,146,Differentiated thyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.25,Worldwide,Validated,[EXPERT]_ORPHANET
905,146,Differentiated thyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
905,146,Differentiated thyroid carcinoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
903,1331,Familial prostate cancer,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,9.4,United States,Validated,[EXPERT]_National Cancer Institute 2006-2010[INST]_ ORPHANET
901,157,Carnitine palmitoyltransferase II deficiency,Disease,Disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,ORPHANET
901,157,Carnitine palmitoyltransferase II deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
901,157,Carnitine palmitoyltransferase II deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.2,United States,Validated,22766612[PMID]
901,157,Carnitine palmitoyltransferase II deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,European Medicines Agency 2015[INST]
900,847,X-linked alpha-thalassemia-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,20301622[PMID]_16722615[PMID]
900,847,X-linked alpha-thalassemia-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,20301622[PMID]_16722615[PMID]_ORPHANET
896,1446,Ring chromosome 22 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,ISBN:978-3-8055-9280-2[OTHER]
896,1446,Ring chromosome 22 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_ISBN:978-3-8055-9280-2[OTHER]
18232,183435,Inherited ichthyosis,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.33,France,Not yet validated,24393603[PMID]
1018,2268,ICF syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,66.0,Worldwide,Validated,23486536[PMID]
1018,2268,ICF syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1022,475,Joubert syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.47,Italy,Validated,31969461[PMID]
1022,475,Joubert syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.6666,Worldwide,Validated,35860112[PMID]
1022,475,Joubert syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,35860112[PMID]_ORPHANET
1022,475,Joubert syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.0,Spain,Validated,34308544[PMID]
1023,392,Holt-Oram syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.7,Europe,Validated,25344219[PMID]_EUROCAT European surveillance of congenital anomalies 1990-2011[REG]
1023,392,Holt-Oram syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.95,Hungary,Validated,1996196[PMID]_[EXPERT]
1023,392,Holt-Oram syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1009,113,Bazex-Dupré-Christol syndrome,Disease,Disorder,Cases/families,Case(s),,143.0,Worldwide,Validated,ORPHANET
1009,113,Bazex-Dupré-Christol syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1011,243,"46,XX gonadal dysgenesis",Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,8178824[PMID]_16877870[PMID]_ORPHANET
1011,243,"46,XX gonadal dysgenesis",Malformation syndrome,Disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,8178824[PMID]_16877870[PMID]_ORPHANET
18230,183422,Polymalformative genetic syndrome with increased risk of developing cancer,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,10.0,Europe,Validated,[EXPERT]
1001,136,Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.0,Europe,Validated,12146805[PMID]_15834040[PMID]_22422895[PMID]_[EXPERT]_ORPHANET
1001,136,Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,United Kingdom,Validated,22422895[PMID]_15834040[PMID]_ [EXPERT]
1001,136,Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.0,Finland,Validated,12146805[PMID]_[EXPERT]_ ORPHANET
18217,182114,Rare urogenital tumor,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.13,Europe,Not yet validated,22425262[PMID]
18217,182114,Rare urogenital tumor,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.21,United States,Validated,22425262[PMID]
1000,48,Congenital bilateral absence of vas deferens,Morphological anomaly,Disorder,Point prevalence,Value and class,1-5 / 10 000,50.0,Europe,Not yet validated,ORPHANET
18222,182130,Tumor of endocrine glands,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.75,Europe,Not yet validated,22361014[PMID]
18222,182130,Tumor of endocrine glands,Category,Group of disorders,Point prevalence,Value and class,6-9 / 10 000,64.0,Europe,Not yet validated,22361014[PMID]
1007,528,Congenital generalized lipodystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,European Medicines Agency 2012[INST]
1007,528,Congenital generalized lipodystrophy,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.01,United States,Validated,16722806[PMID]
1007,528,Congenital generalized lipodystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.86,Peru,Validated,32201678[PMID]
1007,528,Congenital generalized lipodystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Norway,Validated,https://www.ncbi.nlm.nih.gov/books/NBK1212/
1007,528,Congenital generalized lipodystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Lebanon,Validated,https://www.ncbi.nlm.nih.gov/books/NBK1212/
1007,528,Congenital generalized lipodystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2,Portugal,Validated,https://www.ncbi.nlm.nih.gov/books/NBK1212/
1007,528,Congenital generalized lipodystrophy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.0,Oman,Validated,15767751[PMID]
1007,528,Congenital generalized lipodystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.6812,Worldwide,Validated,ORPHANET
1007,528,Congenital generalized lipodystrophy,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.05,Turkey,Validated,27144933[PMID]
1007,528,Congenital generalized lipodystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.23,Brazil,Validated,35209917[PMID]
993,275,Severe combined immunodeficiency due to DCLRE1C deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
18210,182090,Pulmonary arterial hypertension,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,2.0,Europe,Validated,European Medicines Agency 2018[INST]_16456139[PMID]_17360728[PMID]
18210,182090,Pulmonary arterial hypertension,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.6,Spain,Validated,22362843[PMID]
18210,182090,Pulmonary arterial hypertension,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.37,Spain,Validated,22362843[PMID]
18210,182090,Pulmonary arterial hypertension,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.5,France,Validated,16456139[PMID]
18210,182090,Pulmonary arterial hypertension,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.24,France,Validated,16456139[PMID]
18210,182090,Pulmonary arterial hypertension,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.09,United States,Validated,21793646[PMID]
18210,182090,Pulmonary arterial hypertension,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.07,Czech Republic,Validated,24629043[PMID]
18210,182090,Pulmonary arterial hypertension,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,2.24,Czech Republic,Validated,24629043[PMID]
18210,182090,Pulmonary arterial hypertension,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.55,Switzerland,Validated,18587690[PMID]
18210,182090,Pulmonary arterial hypertension,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.35,Switzerland,Validated,18587690[PMID]
18210,182090,Pulmonary arterial hypertension,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.72,United Kingdom,Validated,21885399[PMID]_17360728[PMID]
18210,182090,Pulmonary arterial hypertension,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,5.2,United Kingdom,Validated,17360728[PMID]
18211,182095,Interstitial lung disease,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.1,Denmark,Validated,24636811[PMID]
18211,182095,Interstitial lung disease,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.4,Europe,Not yet validated,24636811[PMID]
18211,182095,Interstitial lung disease,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,7.6,Spain,Validated,15127977[PMID]
18211,182095,Interstitial lung disease,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.63,Greece,Validated,19345567[PMID]
18211,182095,Interstitial lung disease,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,17.3,Greece,Validated,19345567[PMID]
996,184,Cherubism,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
996,184,Cherubism,Malformation syndrome,Disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,[EXPERT]
999,1047,Sideroblastic anemia,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
998,71,Chylomicron retention disease,Disease,Disorder,Cases/families,Case(s),,55.0,Worldwide,Validated,ORPHANET
998,71,Chylomicron retention disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18203,182067,Glial tumor,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.26,United States,Validated,Central Brain Tumor registry of the United States 2004[REG]_24193082[PMID]
18203,182067,Glial tumor,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,26.0,Europe,Validated,European Medicines Agency 2018[INST]
18203,182067,Glial tumor,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.7,Greece,Validated,19494549[PMID]
18203,182067,Glial tumor,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,6.2,Croatia,Validated,15103760[PMID]
18203,182067,Glial tumor,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.35,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
990,1949,Self-limited neonatal epilepsy,Disease,Disorder,Cases/families,Family(ies),,100.0,Worldwide,Validated,[EXPERT]_20437616[PMID]_24375629[PMID]
990,1949,Self-limited neonatal epilepsy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
991,189,Hidrotic ectodermal dysplasia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Not yet validated,ORPHANET
988,1473,Uveal coloboma-cleft lip and palate-intellectual disability,Malformation syndrome,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,24462371[PMID]
988,1473,Uveal coloboma-cleft lip and palate-intellectual disability,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
982,1344,Atrial standstill,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18198,182050,MYH9-related disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.29,Italy,Validated,20301740[PMID]
18198,182050,MYH9-related disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.3,Europe,Validated,20301740[PMID]_[EXPERT]
971,3103,Roberts syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,20301332[PMID]
971,3103,Roberts syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_20301332[PMID]
968,709,Peters plus syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,20301637[PMID]
968,709,Peters plus syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20301637[PMID]
972,776,Lujan-Fryns syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
960,902,Werner syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,[EXPERT]
960,902,Werner syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,United States,Validated,10484259[PMID]
960,902,Werner syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Japan,Validated,10347997[PMID]_[EXPERT]
960,902,Werner syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Specific population,Validated,17478382[PMID]_[EXPERT]
967,888,Van der Woude syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.7,Finland,Validated,7459520[PMID]
967,888,Van der Woude syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.3,France,Validated,22925539[PMID]
967,888,Van der Woude syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,France,Validated,22925539[PMID]
967,888,Van der Woude syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.4,Australia,Validated,20415912[PMID]
967,888,Van der Woude syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.85,"Taiwan, Province of China",Validated,18177185[PMID]_ORPHANET
967,888,Van der Woude syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,"Taiwan, Province of China",Validated,18177185[PMID]_ORPHANET
967,888,Van der Woude syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.9,United States,Validated,9450872[PMID]
967,888,Van der Woude syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,United States,Validated,9450872[PMID]
967,888,Van der Woude syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET
967,888,Van der Woude syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.7,Australia,Validated,34626670[PMID]
965,871,Familial progressive cardiac conduction defect,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,[EXPERT]
965,871,Familial progressive cardiac conduction defect,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
1096,1597,Distal deletion 17q syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1092,1590,Distal deletion 13q syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,24433316[PMID]
1092,1590,Distal deletion 13q syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_24433316[PMID]
1090,1587,Monosomy 13q14 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
1090,1587,Monosomy 13q14 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
1115,1621,3q13 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,42.0,Worldwide,Validated,24650298[PMID]
1115,1621,3q13 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24650298[PMID]
1114,1620,Distal deletion 3p syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,34.0,Worldwide,Validated,ISBN-10:0781730635[OTHER]
1114,1620,Distal deletion 3p syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_ISBN-10:0781730635[OTHER]
1121,1627,Deletion 5q35 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,11562936[PMID]_[EXPERT]
1121,1627,Deletion 5q35 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1150,1699,Trisomy 12p syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,16502429[PMID]
1150,1699,Trisomy 12p syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.0,Worldwide,Not yet validated,8723118[PMID]
1150,1699,Trisomy 12p syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,8723118[PMID]_ORPHANET
1032,500,Noonan syndrome with multiple lentigines,Malformation syndrome,Disorder,Cases/families,Case(s),,296.0,Worldwide,Validated,21500339[PMID]
1032,500,Noonan syndrome with multiple lentigines,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_21500339[PMID]
1033,507,Leishmaniasis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,European Medicines Agency 2012[INST]
1033,507,Leishmaniasis,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,25.0,Worldwide,Validated,World Health Organization[INST]_ORPHANET
1036,548,Leprosy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
1036,548,Leprosy,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.7,Worldwide,Validated,[EXPERT]
1039,233,Duane retraction syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,Europe,Not yet validated,ISBN:3642022014[OTHER]
1025,657,Congenital isolated hyperinsulinism,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,2.24,Czech Republic,Validated,26431509[PMID]
1025,657,Congenital isolated hyperinsulinism,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,5.25,Japan,Validated,31742894[PMID]
1025,657,Congenital isolated hyperinsulinism,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,3.52,United Kingdom,Validated,32027664[PMID]
1025,657,Congenital isolated hyperinsulinism,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,2.0,Netherlands,Validated,14518075[PMID]
1025,657,Congenital isolated hyperinsulinism,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,40.0,Saudi Arabia,Validated,21967988[PMID]
1025,657,Congenital isolated hyperinsulinism,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,3.67,Worldwide,Validated,ORPHANET
1025,657,Congenital isolated hyperinsulinism,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
1025,657,Congenital isolated hyperinsulinism,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,23.2,China,Validated,34103049[PMID]
1030,2495,Meningioma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.15,Germany,Validated,25249493[PMID]
1030,2495,Meningioma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
1030,2495,Meningioma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,8.14,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
1031,569,Familial or sporadic hemiplegic migraine,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,Europe,Validated,[EXPERT]
1031,569,Familial or sporadic hemiplegic migraine,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,Denmark,Validated,12023326[PMID]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,53.6,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,19.6,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,40.8,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,56.8,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,>1 / 1000,127.6,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,>1 / 1000,0.0,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,25.5,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,47.5,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,67.5,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,6-9 / 10 000,0.0,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,54.2,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,39.6,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,74.7,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,6-9 / 10 000,0.0,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,11.7,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,65.4,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,6-9 / 10 000,0.0,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,36.5,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,14.2,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,30.7,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,25.1,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,60.2,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,6-9 / 10 000,0.0,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,57.2,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,>1 / 1000,101.2,Australia,Validated,23371924[PMID]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,>1 / 1000,0.0,Australia,Not yet validated,23371924[PMID]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,52.0,Chile,Validated,11372296[PMID]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Chile,Not yet validated,11372296[PMID]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,27.0,Sudan,Validated,15854114[PMID]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Sudan,Not yet validated,15854114[PMID]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,26.0,"Iran, Islamic Republic of",Validated,20648890[PMID]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,"Iran, Islamic Republic of",Not yet validated,20648890[PMID]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,27.0,Mexico,Validated,8442867[PMID]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Mexico,Not yet validated,8442867[PMID]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,4.0,Bolivia,Validated,14989684[PMID]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Bolivia,Not yet validated,14989684[PMID]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,68.0,Specific population,Validated,15516165[PMID]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,6-9 / 10 000,0.0,Specific population,Validated,15516165[PMID]
1052,2014,Cleft palate,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,40.0,"Taiwan, Province of China",Validated,23555592[PMID]
1052,2014,Cleft palate,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,"Taiwan, Province of China",Not yet validated,23555592[PMID]
1043,240,Léri-Weill dyschondrosteosis,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
1042,2311,Autosomal recessive spondylocostal dysostosis,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1045,358,Gitelman syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.5,Europe,Not yet validated,ORPHANET
1044,242,"46,XY complete gonadal dysgenesis",Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,18410658[PMID]_27603905[PMID]_ORPHANET
1044,242,"46,XY complete gonadal dysgenesis",Malformation syndrome,Disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,18410658[PMID]_27603905[PMID]_ORPHANET
1046,2052,Fraser syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.2,Europe,Validated,23532946[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1046,2052,Fraser syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1046,2052,Fraser syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.43,Spain,Validated,9662850[PMID]
1070,1354,Heart defects-limb shortening syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,2074559[PMID]
1070,1354,Heart defects-limb shortening syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2074559[PMID]
1071,1358,Carey-Fineman-Ziter syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,27232676[PMID]
1071,1358,Carey-Fineman-Ziter syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27232676[PMID]
1058,557,Non-syndromic anorectal malformation,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,20.0,Worldwide,Validated,17651510[PMID]_[EXPERT]
1058,557,Non-syndromic anorectal malformation,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,24.0,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2009[REG]
1058,557,Non-syndromic anorectal malformation,Clinical group,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,78.0,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2006[REG]
1058,557,Non-syndromic anorectal malformation,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,26.2,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1058,557,Non-syndromic anorectal malformation,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,11.4,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1058,557,Non-syndromic anorectal malformation,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,21.3,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1058,557,Non-syndromic anorectal malformation,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,23.6,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1058,557,Non-syndromic anorectal malformation,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,53.5,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1058,557,Non-syndromic anorectal malformation,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,43.2,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1058,557,Non-syndromic anorectal malformation,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,28.9,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1058,557,Non-syndromic anorectal malformation,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,11.3,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1058,557,Non-syndromic anorectal malformation,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,29.2,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1058,557,Non-syndromic anorectal malformation,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,29.5,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1058,557,Non-syndromic anorectal malformation,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,11.6,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1058,557,Non-syndromic anorectal malformation,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,4.7,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1058,557,Non-syndromic anorectal malformation,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,13.8,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1058,557,Non-syndromic anorectal malformation,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,49.0,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1058,557,Non-syndromic anorectal malformation,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,21.6,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1058,557,Non-syndromic anorectal malformation,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,28.6,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1058,557,Non-syndromic anorectal malformation,Clinical group,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,60.8,Saudi Arabia,Validated,23232683[PMID]
1058,557,Non-syndromic anorectal malformation,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET
1059,111,Barth syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.22,Europe,Validated,[EXPERT]
1059,111,Barth syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.29,United States,Validated,[EXPERT]
1059,111,Barth syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.15,France,Validated,23656970[PMID]
1059,111,Barth syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.71,United Kingdom,Validated,23398819[PMID]_[EXPERT]
1056,10,"48,XXYY syndrome",Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.9,Europe,Validated,[EXPERT]_568179[PMID]_14477077[PMID]_2090319[PMID]
1056,10,"48,XXYY syndrome",Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1062,1308,C syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.11,Europe,Validated,[EXPERT]_17162528[PMID]
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.2,China,Validated,8061578[PMID]
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Europe,Validated,European Medicines Agency 2015[INST]
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.36,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]_28687376[PMID]
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.337,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.317,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.766,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.423,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.437,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.24,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.177,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.35,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.383,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.207,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.618,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.254,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.228,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.264,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.426,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.62,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.491,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.394,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.779,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.462,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.288,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.211,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1063,150,Nasopharyngeal carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.256,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1061,133,Chronic beryllium disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1082,1552,Currarino syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Not yet validated,ORPHANET
1081,1450,Ring chromosome 8 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,15337475[PMID]_ISBN 10:3110116073[OTHER]
1081,1450,Ring chromosome 8 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_ISBN 10:3110116073[OTHER]_15337475[PMID]
1080,1448,Ring chromosome 6 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,25.0,Worldwide,Validated,23398904[PMID]
1080,1448,Ring chromosome 6 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23398904[PMID]
1085,1580,Distal deletion 10p syndrome,Clinical group,Group of disorders,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
1075,1437,Ring chromosome 1 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,35.0,Worldwide,Validated,17710876[PMID]
1075,1437,Ring chromosome 1 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17710876[PMID]
1073,172,Progressive familial intrahepatic cholestasis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1079,1447,Ring chromosome 4 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,27610251[PMID]
1079,1447,Ring chromosome 4 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27610251[PMID]
1078,1444,Ring chromosome 20 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,ORPHANET
1078,1444,Ring chromosome 20 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1077,1439,Ring chromosome 12 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,17880954[PMID]_20933620[PMID]
1077,1439,Ring chromosome 12 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17880954[PMID]_20933620[PMID]
1076,1438,Ring chromosome 10 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,23247912[PMID]
1076,1438,Ring chromosome 10 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1228,3306,Inverted duplicated chromosome 15 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.33,Worldwide,Validated,11579431[PMID]
1228,3306,Inverted duplicated chromosome 15 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
1231,3375,Trisomy X syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,42.5,Europe,Not yet validated,ORPHANET
1230,3310,Tetrasomy 9p syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,70.0,Worldwide,Validated,ORPHANET_25847481[PMID]_25944096[PMID]_25951732[PMID]_26216333[PMID]
1230,3310,Tetrasomy 9p syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25847481[PMID]
1225,3000,Familial peripheral male-limited precocious puberty,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,ORPHANET
1226,3176,Spina bifida-hypospadias syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.1,Spain,Validated,7977461[PMID]_37868647[PMID]_ORPHANET
1226,3176,Spina bifida-hypospadias syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.1,Spain,Validated,7977461[PMID]
1236,1708,Mosaic trisomy 16 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_16557642[PMID]
1236,1708,Mosaic trisomy 16 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,226.0,Worldwide,Validated,16557642[PMID]
1237,1711,Mosaic trisomy 17 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,31.0,Worldwide,Validated,27751421[PMID]
1237,1711,Mosaic trisomy 17 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27751421[PMID]
1232,3376,Triploidy syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,12.6,Europe,Validated,22234154[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1232,3376,Triploidy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1233,1692,Mosaic trisomy 1 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,8835327[PMID]
1233,1692,Mosaic trisomy 1 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8835327[PMID]
1234,1698,Mosaic trisomy 12 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28345774[PMID]
1235,1706,Mosaic trisomy 15 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25736076[PMID]
1244,916,Aase-Smith syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,ORPHANET
1244,916,Aase-Smith syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1247,920,Ablepharon macrostomia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,27196381[PMID]
1247,920,Ablepharon macrostomia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27196381[PMID]
1241,1445,Ring chromosome 21 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
1242,7,3C syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,25.0,Worldwide,Validated,18957854[PMID]
1242,7,3C syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18957854[PMID]
1255,931,Isolated acheiropodia,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1255,931,Isolated acheiropodia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.4,Brazil,Validated,1155460[PMID]
1255,931,Isolated acheiropodia,Morphological anomaly,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.03,Brazil,Validated,1155460[PMID]
1254,929,Achalasia-microcephaly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,3048841[PMID]_2591072[PMID]
1254,929,Achalasia-microcephaly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3048841[PMID]_2591072[PMID]
1253,869,Triple A syndrome,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,14723589[PMID]_[EXPERT]
1253,869,Triple A syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1251,2297,Insulin-resistance syndrome type A,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1249,922,Familial nasal acilia,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,4002006[PMID]_8813877[PMID]
1249,922,Familial nasal acilia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4002006[PMID]_8813877[PMID]
1248,921,Abruzzo-Erickson syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,839509[PMID]_[EXPERT]
1248,921,Abruzzo-Erickson syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1263,27,Vitamin B12-unresponsive methylmalonic acidemia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1260,939,3-hydroxyisobutyric aciduria,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,16466957[PMID]_19650361[PMID]
1260,939,3-hydroxyisobutyric aciduria,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16466957[PMID]_19650361[PMID]
1259,31,Oxoglutaric aciduria,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
1258,935,Short-limb skeletal dysplasia with severe combined immunodeficiency,Disease,Disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,1999827[PMID]
1258,935,Short-limb skeletal dysplasia with severe combined immunodeficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1999827[PMID]
1256,932,Achondrogenesis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.8,France,Validated,2785882[PMID]
1256,932,Achondrogenesis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
1268,37,Acrodermatitis enteropathica,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.2,Denmark,Validated,17190629[PMID]_8562288[PMID]
1268,37,Acrodermatitis enteropathica,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Denmark,Not yet validated,17190629[PMID]
1268,37,Acrodermatitis enteropathica,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,[EXPERT]
1269,950,Acrodysostosis,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1269,950,Acrodysostosis,Malformation syndrome,Disorder,Cases/families,Case(s),,80.0,Worldwide,Validated,[EXPERT]
1267,949,Acrocraniofacial dysostosis,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,3344780[PMID]
1267,949,Acrocraniofacial dysostosis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3344780[PMID]
1264,945,Acalvaria,Malformation syndrome,Disorder,Prevalence at birth,Class only,1-9 / 1 000 000,0.0,Europe,Validated,[EXPERT]
1264,945,Acalvaria,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1278,957,Acropectorovertebral dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
1278,957,Acropectorovertebral dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1279,958,Acro-renal-mandibular syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,25075450[PMID]
1279,958,Acro-renal-mandibular syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25075450[PMID]
1276,955,Hajdu-Cheney syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,25491639[PMID]
1276,955,Hajdu-Cheney syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25491639[PMID]
1272,952,"Acrofacial dysostosis, Weyers type",Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1160,1713,17p11.2 microduplication syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,170.0,Worldwide,Validated,ORPHANET
1160,1713,17p11.2 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
1174,1738,Trisomy 4p syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,85.0,Worldwide,Validated,12239731[PMID]
1174,1738,Trisomy 4p syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12239731[PMID]
1178,1742,Trisomy 5p syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,ORPHANET
1178,1742,Trisomy 5p syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1181,1745,Distal duplication 6p syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,ORPHANET
1181,1745,Distal duplication 6p syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1186,1752,Trisomy 8q syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,15581839[PMID]
1186,1752,Trisomy 8q syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1190,1762,Proximal Xq28 duplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET_EXPERT
1190,1762,Proximal Xq28 duplication syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.65,Australia,Validated,30756435[PMID]
1190,1762,Proximal Xq28 duplication syndrome,Malformation syndrome,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.07,Australia,Validated,30756435[PMID]
1195,1878,TRIM32-related limb-girdle muscular dystrophy R8,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1193,1876,Oculogastrointestinal muscular dystrophy,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,3366929[PMID]
1193,1876,Oculogastrointestinal muscular dystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1199,1948,Epilepsy-microcephaly-skeletal dysplasia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8867658[PMID]
1199,1948,Epilepsy-microcephaly-skeletal dysplasia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8867658[PMID]
1198,1946,Amelocerebrohypohidrotic syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1201,1951,Epilepsy-telangiectasia syndrome,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,627106[PMID]
1201,1951,Epilepsy-telangiectasia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_627106[PMID]
1206,381,Griscelli syndrome,Disease,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,30207398[PMID]
1206,381,Griscelli syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30207398[PMID]
1209,2604,Familial visceral myopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1215,156,Carnitine palmitoyl transferase 1A deficiency,Disease,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,20301700[PMID]
1215,156,Carnitine palmitoyl transferase 1A deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20301700[PMID]
1215,156,Carnitine palmitoyl transferase 1A deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.3,Israel,Validated,33239050[PMID]
1215,156,Carnitine palmitoyl transferase 1A deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Specific population,Validated,33239050[PMID]
1212,2597,Mitochondrial myopathy-lactic acidosis-deafness syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,4725145[PMID]
1212,2597,Mitochondrial myopathy-lactic acidosis-deafness syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4725145[PMID]
1213,2598,Mitochondrial myopathy and sideroblastic anemia,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,15971356[PMID]
1213,2598,Mitochondrial myopathy and sideroblastic anemia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1372,1078,Thumb stiffness-brachydactyly-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,6631421[PMID]_2363441[PMID]
1372,1078,Thumb stiffness-brachydactyly-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6631421[PMID]_2363441[PMID]
1371,1077,Dental ankylosis,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1368,1074,Ankyloblepharon filiforme adnatum-imperforate anus syndrome,Clinical subtype,Subtype of disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,8135297[PMID]
1368,1074,Ankyloblepharon filiforme adnatum-imperforate anus syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8135297[PMID]
1366,1072,Ankyloblepharon filiforme adnatum-cleft palate syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1365,1071,Ankyloblepharon-ectodermal defects-cleft lip/palate syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1364,1069,Aniridia-absent patella syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,1218204[PMID]
1364,1069,Aniridia-absent patella syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1218204[PMID]
1363,1068,Aniridia-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,4422267[PMID]
1363,1068,Aniridia-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4422267[PMID]
1362,1067,Aniridia-ptosis-intellectual disability-familial obesity syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,3091805[PMID]
1362,1067,Aniridia-ptosis-intellectual disability-familial obesity syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3091805[PMID]
1360,1064,Aniridia-renal agenesis-psychomotor retardation syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,4419812[PMID]
1360,1064,Aniridia-renal agenesis-psychomotor retardation syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4419812[PMID]
1359,1062,Hereditary neurocutaneous malformation,Disease,Disorder,Cases/families,Family(ies),,9.0,Worldwide,Validated,537017[PMID]_3342546[PMID]_7189031[PMID]_998575[PMID]_14186663[PMID]_8929507[PMID]
1359,1062,Hereditary neurocutaneous malformation,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3342546[PMID]
1352,1053,Vein of Galen aneurysmal malformation,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET_1997895[PMID]
1351,1052,Mosaic variegated aneuploidy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,41.0,Worldwide,Validated,16059936[PMID]_[EXPERT]
1351,1052,Mosaic variegated aneuploidy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1346,1040,Metaphyseal anadysplasia,Disease,Disorder,Cases/families,Case(s),,27.0,Worldwide,Validated,ORPHANET
1346,1040,Metaphyseal anadysplasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1347,1041,Hydrops fetalis,Malformation syndrome,Disorder,Prevalence at birth,Value and class,>1 / 1000,134.0,Ireland,Validated,16964808[PMID]
1347,1041,Hydrops fetalis,Malformation syndrome,Disorder,Prevalence at birth,Value and class,>1 / 1000,380.0,Turkey,Validated,24094760[PMID]
1347,1041,Hydrops fetalis,Malformation syndrome,Disorder,Prevalence at birth,Value and class,>1 / 1000,180.0,Thailand,Validated,19459517[PMID]
1347,1041,Hydrops fetalis,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1344,1037,Arthrogryposis multiplex congenita,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,5.7,Europe,Validated,22005589[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1344,1037,Arthrogryposis multiplex congenita,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,8.3,Australia,Validated,9928642[PMID]
1344,1037,Arthrogryposis multiplex congenita,Clinical group,Group of disorders,Prevalence at birth,Class only,1-5 / 10 000,0.0,Canada,Not yet validated,21157886[PMID]
1344,1037,Arthrogryposis multiplex congenita,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
1405,1126,Aprosencephaly cerebellar dysgenesis,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8826432[PMID]
1405,1126,Aprosencephaly cerebellar dysgenesis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8826432[PMID]
1404,1125,"Ocular motor apraxia, Cogan type",Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,ORPHANET
1404,1125,"Ocular motor apraxia, Cogan type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1401,1121,Radial deficiency-tibial hypoplasia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8723109[PMID]
1400,1120,Lung agenesis-heart defect-thumb anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25487726[PMID]_26513515[PMID]
1400,1120,Lung agenesis-heart defect-thumb anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,25487726[PMID]_26513515[PMID]
1402,1122,Ulnar hypoplasia-split foot syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_565745[PMID]
1402,1122,Ulnar hypoplasia-split foot syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,565745[PMID]
1397,1116,Aplasia cutis congenita-intestinal lymphangiectasia syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,3984978[PMID]
1397,1116,Aplasia cutis congenita-intestinal lymphangiectasia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3984978[PMID]
1399,1118,Fibular aplasia-ectrodactyly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,ORPHANET
1399,1118,Fibular aplasia-ectrodactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1398,1117,Aplasia cutis-myopia syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,3395567[PMID]_8741916[PMID]
1398,1117,Aplasia cutis-myopia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3395567[PMID]_8741916[PMID]
1392,1110,Aortic arch anomaly-facial dysmorphism-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,5696314[PMID]
1392,1110,Aortic arch anomaly-facial dysmorphism-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5696314[PMID]
1395,1113,Aphalangy-syndactyly-microcephaly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,19449409[PMID]
1395,1113,Aphalangy-syndactyly-microcephaly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19449409[PMID]
1394,1112,Aphalangy-hemivertebrae-urogenital-intestinal dysgenesis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,2282714[PMID]
1394,1112,Aphalangy-hemivertebrae-urogenital-intestinal dysgenesis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2282714[PMID]
1388,1106,Microphthalmia with limb anomalies,Malformation syndrome,Disorder,Cases/families,Family(ies),,35.0,Worldwide,Validated,21750680[PMID]_21194680[PMID]
1388,1106,Microphthalmia with limb anomalies,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1391,83,Antley-Bixler syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,[EXPERT]_ORPHANET
1387,1104,Anophthalmia plus syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,24341146[PMID]_25804017[PMID]
1387,1104,Anophthalmia plus syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24341146[PMID]_25804017[PMID]
1380,1094,Anonychia-microcephaly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,8985482[PMID]
1380,1094,Anonychia-microcephaly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8985482[PMID]
1306,991,PAGOD syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,8291549[PMID]
1306,991,PAGOD syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8291549[PMID]
1305,990,Agnathia-holoprosencephaly-situs inversus syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,20849990[PMID]_ORPHANET
1304,989,Hypoglossia-hypodactyly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,47.0,Worldwide,Validated,23431477[PMID]
1304,989,Hypoglossia-hypodactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23431477[PMID]
1310,994,Fetal akinesia deformation sequence,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.6,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1310,994,Fetal akinesia deformation sequence,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET_EUROCAT European surveillance of congenital anomalies 2010[REG]
1309,51,Aicardi-Goutières syndrome,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,Europe,Validated,European Medicines Agency 2015[INST]
1309,51,Aicardi-Goutières syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_20301648[PMID]
1299,981,Internal carotid absence,Morphological anomaly,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,[EXPERT]_22851490[PMID]
1299,981,Internal carotid absence,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1297,978,ADULT syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,Pr MANOUVRIER-HANU Sylvie[EXPERT]
1297,978,ADULT syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27469932[PMID]_22607287[PMID]_21078104[PMID]_16114047[PMID]_16724007[PMID]
1296,977,Adrenomyodystrophy,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,7153060[PMID]
1296,977,Adrenomyodystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7153060[PMID]
1300,983,Testicular regression syndrome,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
1290,970,Hereditary sensory and autonomic neuropathy type 2,Disease,Disorder,Cases/families,Case(s),,35.0,Worldwide,Validated,ORPHANET
1290,970,Hereditary sensory and autonomic neuropathy type 2,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1291,971,Acrorenal syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,ORPHANET
1291,971,Acrorenal syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1288,40,"Acromesomelic dysplasia, Maroteaux type",Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,ORPHANET
1288,40,"Acromesomelic dysplasia, Maroteaux type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1289,969,Acromicric dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,[EXPERT]
1289,969,Acromicric dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1294,974,Adams-Oliver syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_28160419[PMID]
1294,974,Adams-Oliver syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,398.0,Worldwide,Validated,28160419[PMID]
1293,973,"Isolated absence/hypoplasia of fingers excluding thumb, unilateral",Morphological anomaly,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,3725479[PMID]
1293,973,"Isolated absence/hypoplasia of fingers excluding thumb, unilateral",Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3725479[PMID]
1280,959,Acro-renal-ocular syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,20.0,Worldwide,Validated,ORPHANET
1280,959,Acro-renal-ocular syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1287,968,"Acromesomelic dysplasia, Hunter-Thompson type",Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,ORPHANET
1287,968,"Acromesomelic dysplasia, Hunter-Thompson type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
16888,139411,Carney triad,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
16888,139411,Carney triad,Disease,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,23652673[PMID]
16889,139414,Congenital panfollicular nevus,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,26822169[PMID]
16889,139414,Congenital panfollicular nevus,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26822169[PMID]
1336,1028,Amelo-onycho-hypohidrotic syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,122795[PMID]
1336,1028,Amelo-onycho-hypohidrotic syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_122795[PMID]
16890,139417,Acute transverse myelitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,8.6,United States,Validated,PMID: 31235660
16890,139417,Acute transverse myelitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.9,United States,Validated,PMID: 31235660
16890,139417,Acute transverse myelitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.72,Worldwide,Validated,PMID: 19812117 ; 19896453 ; 31235660
1339,1031,Enamel-renal syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,21212699[PMID]
1339,1031,Enamel-renal syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
16892,139423,Idiopathic acute transverse myelitis,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.25,Europe,Validated,[EXPERT]
16892,139423,Idiopathic acute transverse myelitis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
16893,139426,Perioral myoclonia with absences,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,ORPHANET
16893,139426,Perioral myoclonia with absences,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
16894,139431,Epilepsy with eyelid myoclonia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1342,1035,Beta-mercaptolactate cysteine disulfiduria,Biological anomaly,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,4973015[PMID]
1342,1035,Beta-mercaptolactate cysteine disulfiduria,Biological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4973015[PMID]
16895,139436,Multicentric reticulohistiocytosis,Disease,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,ORPHANET
16895,139436,Multicentric reticulohistiocytosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
1329,1021,Amaurosis-hypertrichosis syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,2769722[PMID]
1329,1021,Amaurosis-hypertrichosis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2769722[PMID]
1328,64,Alström syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,[EXPERT]_22043170[PMID]
1328,64,Alström syndrome,Disease,Disorder,Cases/families,Case(s),,950.0,Worldwide,Validated,[EXPERT]
1331,1023,"Congenital generalized hypertrichosis, Ambras type",Clinical subtype,Subtype of disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,ORPHANET
1331,1023,"Congenital generalized hypertrichosis, Ambras type",Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
16884,139396,X-linked cerebral adrenoleukodystrophy,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
16886,139402,Drug reaction with eosinophilia and systemic symptoms,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
16887,139406,Encephalopathy due to prosaposin deficiency,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,ORPHANET
16887,139406,Encephalopathy due to prosaposin deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1320,1008,Alopecia-epilepsy-pyorrhea-intellectual disability syndrome,Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,830443[PMID]
1320,1008,Alopecia-epilepsy-pyorrhea-intellectual disability syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_830443[PMID]
1321,701,Alopecia universalis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,25.0,Europe,Validated,European Medicines Agency 2006[INST]
1323,1010,Autosomal dominant palmoplantar keratoderma and congenital alopecia,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,[EXPERT]
1323,1010,Autosomal dominant palmoplantar keratoderma and congenital alopecia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1327,1014,Alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8721564[PMID]
1327,1014,Alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8721564[PMID]
1313,1001,2q37 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,115.0,Worldwide,Validated,36833393[PMID]
1313,1001,2q37 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,36833393[PMID]_ORPHANET
1315,59,Allan-Herndon-Dudley syndrome,Disease,Disorder,Cases/families,Case(s),,320.0,Worldwide,Validated,25905294[PMID]
1315,59,Allan-Herndon-Dudley syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_25905294[PMID]
1315,59,Allan-Herndon-Dudley syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,European Medecines Agency 2017[INST]
1316,1003,Scalp defects-postaxial polydactyly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,4029956[PMID]_468253[PMID]
1316,1003,Scalp defects-postaxial polydactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4029956[PMID]_468253[PMID]
1318,1005,Alopecia-contractures-dwarfism-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,6250998[PMID]_7158638[PMID]_10861681[PMID]
1318,1005,Alopecia-contractures-dwarfism-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6250998[PMID]_7158638[PMID]_10861681[PMID]
1494,1253,Ascher syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,8994475[PMID]
1494,1253,Ascher syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1493,1252,Blepharonasofacial malformation syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,10631920[PMID]
1493,1252,Blepharonasofacial malformation syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10631920[PMID]
1490,1248,Maxillonasal dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1502,127,Borjeson-Forssman-Lehmann syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,22190899[PMID]_15994862[PMID]_14756673[PMID]_[EXPERT]
1502,127,Borjeson-Forssman-Lehmann syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1503,1264,Tricho-retino-dento-digital syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,8279493[PMID]
1503,1264,Tricho-retino-dento-digital syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8279493[PMID]
1500,1262,Böök syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,26.0,Worldwide,Validated,[EXPERT]
1500,1262,Böök syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1501,1263,Boomerang dysplasia,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,15994868[PMID]_22354125[PMID]
1501,1263,Boomerang dysplasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15994868[PMID]_22354125[PMID]
1498,1259,Blepharoptosis-myopia-ectopia lentis syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,6978128[PMID]
1498,1259,Blepharoptosis-myopia-ectopia lentis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6978128[PMID]
1499,1261,Bonnemann-Meinecke-Reich syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,2654691[PMID]_1941968[PMID]
1499,1261,Bonnemann-Meinecke-Reich syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2654691[PMID]_1941968[PMID]
1478,1234,Bartsocas-Papas syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,24.0,Worldwide,Validated,ORPHANET
1478,1234,Bartsocas-Papas syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1478,1234,Bartsocas-Papas syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.15,Spain,Validated,1867261[PMID]
1476,1231,Barber-Say syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,27196381[PMID]
1476,1231,Barber-Say syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27196381[PMID]
1474,1229,Congenital intrauterine infection-like syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
1474,1229,Congenital intrauterine infection-like syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1473,109,Bannayan-Riley-Ruvalcaba syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1472,1228,Banki syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,DOI: 10.1055/s-0029-1227792[OTHER]
1472,1228,Banki syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_DOI: 10.1055/s-0029-1227792[OTHER]
1487,1241,Bencze syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,519901[PMID]
1487,1241,Bencze syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_519901[PMID]
1483,1237,Beemer-Ertbruggen syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,6507485[PMID]
1483,1237,Beemer-Ertbruggen syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6507485[PMID]
1482,114,Auriculoosteodysplasia,Malformation syndrome,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,6065451[PMID]
1482,114,Auriculoosteodysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6065451[PMID]
1481,115,Congenital contractural arachnodactyly,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1480,1236,Severe microbrachycephaly-intellectual disability-athetoid cerebral palsy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,1609828[PMID]
1480,1236,Severe microbrachycephaly-intellectual disability-athetoid cerebral palsy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1609828[PMID]
16693,137622,Intractable diarrhea-choanal atresia-eye anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,17786112[PMID]
16693,137622,Intractable diarrhea-choanal atresia-eye anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17786112[PMID]
1525,1292,Brachymorphism-onychodysplasia-dysphalangism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,5567413[PMID]_8445623[PMID]
1525,1292,Brachymorphism-onychodysplasia-dysphalangism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5567413[PMID]_8445623[PMID]
16695,137628,Cardiac anomalies-heterotaxy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,17938964[PMID]
16695,137628,Cardiac anomalies-heterotaxy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17938964[PMID]
1526,1293,Brachyolmia,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1526,1293,Brachyolmia,Clinical group,Group of disorders,Cases/families,Case(s),,100.0,Worldwide,Validated,[EXPERT]
16694,137625,Glycogen storage disease due to muscle and heart glycogen synthase deficiency,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,17928598[PMID]_19699667[PMID]
16694,137625,Glycogen storage disease due to muscle and heart glycogen synthase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17928598[PMID]_19699667[PMID]
1533,1299,Branchioskeletogenital syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,5141271[PMID]_9843000[PMID]_20949527[PMID]
1533,1299,Branchioskeletogenital syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5141271[PMID]_9843000[PMID]_20949527[PMID]
1534,1300,Autosomal dominant popliteal pterygium syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
1534,1300,Autosomal dominant popliteal pterygium syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,ORPHANET_[EXPERT]
16702,137667,Capillary malformation-arteriovenous malformation,Malformation syndrome,Disorder,Cases/families,Case(s),,261.0,Worldwide,Validated,24038909[PMID]
16702,137667,Capillary malformation-arteriovenous malformation,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
16697,137634,Overgrowth-macrocephaly-facial dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,6.0,Worldwide,Validated,17632510[PMID]
16697,137634,Overgrowth-macrocephaly-facial dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17632510[PMID]
1528,1295,Brachytelephalangy-dysmorphism-Kallmann syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,3728571[PMID]
1528,1295,Brachytelephalangy-dysmorphism-Kallmann syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3728571[PMID]
16696,137631,"Lung fibrosis-immunodeficiency-46,XX gonadal dysgenesis syndrome",Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,17937424[PMID]
16696,137631,"Lung fibrosis-immunodeficiency-46,XX gonadal dysgenesis syndrome",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17937424[PMID]
1529,1296,Lambert syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,2352262[PMID]
1529,1296,Lambert syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2352262[PMID]
1530,1297,Branchio-oculo-facial syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,21634087[PMID]
1530,1297,Branchio-oculo-facial syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21634087[PMID]
16698,137639,Hypomyelinating leukodystrophy-ataxia-hypodontia-hypomyelination syndrome,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,15851747[PMID]_17712733[PMID]
16698,137639,Hypomyelinating leukodystrophy-ataxia-hypodontia-hypomyelination syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15851747[PMID]_17712733[PMID]
16677,137577,Neonatal hypoxic and ischemic brain injury,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,European Medicines Agency 2015[INST]
16678,137583,Vulvar intraepithelial neoplasia,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.0,Europe,Validated,European Medicines Agency 2008[INST]
1511,1276,Brachydactyly-arterial hypertension syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,10.0,Worldwide,Validated,ORPHANET
1511,1276,Brachydactyly-arterial hypertension syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1510,1275,Brachydactyly-elbow wrist dysplasia syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,4.0,Worldwide,Validated,23587911[PMID]
1510,1275,Brachydactyly-elbow wrist dysplasia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23587911[PMID]
1506,1270,Bowen-Conradi syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,[EXPERT]
1506,1270,Bowen-Conradi syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1506,1270,Bowen-Conradi syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,>1 / 1000,281.0,Specific population,Validated,12838567[PMID]
16684,137605,Legius syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.2,Worldwide,Validated,[EXPERT]
16684,137605,Legius syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
16681,137596,Neurotrophic keratopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_24672223[PMID]
16681,137596,Neurotrophic keratopathy,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,4.2,Europe,Validated,European Medicines Agency 2015[INST]
1512,1278,Brachydactyly-preaxial hallux varus syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,5082920[PMID]
1512,1278,Brachydactyly-preaxial hallux varus syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5082920[PMID]
16682,137599,Herpes simplex virus stromal keratitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.2091,Worldwide,Validated,32732703[PMID]_34622738[PMID]_33607690[PMID]_3391390{PMID]
16682,137599,Herpes simplex virus stromal keratitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.4,France,Validated,22944008[PMID]
1426,1166,Congenital unilateral hypoplasia of depressor anguli oris,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1427,1168,Ataxia-oculomotor apraxia type 1,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1424,1160,Chylous ascites,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_22319743[PMID]
16721,137817,Arachnoiditis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1431,1174,Cerebellar ataxia-ectodermal dysplasia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
16726,137839,Lemierre syndrome,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,10.0,Europe,Not yet validated,20181152[PMID]
16726,137839,Lemierre syndrome,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,36.0,Denmark,Validated,22633566[PMID]
16726,137839,Lemierre syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
16725,137834,Frank-Ter Haar syndrome,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,22037860[PMID]_23140272[PMID]
16725,137834,Frank-Ter Haar syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22037860[PMID]_23140272[PMID]
16724,137831,X-linked intellectual disability-cerebellar hypoplasia syndrome,Disease,Disorder,Cases/families,Family(ies),,14.0,Worldwide,Validated,20528889[PMID]
16724,137831,X-linked intellectual disability-cerebellar hypoplasia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20528889[PMID]
1429,1170,Autosomal recessive cerebelloparenchymal disorder type 3,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1435,1178,Ataxia-tapetoretinal degeneration syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
1433,1175,X-linked progressive cerebellar ataxia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1438,1180,Ataxia-hypogonadism-choroidal dystrophy syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1436,1179,Benign paroxysmal tonic upgaze of childhood with ataxia,Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,8495825[PMID]
1436,1179,Benign paroxysmal tonic upgaze of childhood with ataxia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8495825[PMID]
1437,1173,Cerebellar ataxia-hypogonadism syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
16732,137867,Madras motor neuron disease,Disease,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,ORPHANET
16732,137867,Madras motor neuron disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
16706,137681,Hepatoencephalopathy due to combined oxidative phosphorylation defect type 1,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,21119709[PMID]
16706,137681,Hepatoencephalopathy due to combined oxidative phosphorylation defect type 1,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21119709[PMID]
1409,1133,AREDYLD syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,6638067[PMID]_1488989[PMID]
1409,1133,AREDYLD syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6638067[PMID]_1488989[PMID]
16704,137675,Histiocytoid cardiomyopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,25921236[PMID]_ORPHANET
16704,137675,Histiocytoid cardiomyopathy,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,25921236[PMID]
1408,1131,X-linked mandibulofacial dysostosis,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,4039890[PMID]_8465866[PMID]_12002155[PMID]
1408,1131,X-linked mandibulofacial dysostosis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4039890[PMID]_8465866[PMID]_12002155[PMID]
16705,137678,Spondyloepiphyseal dysplasia with metatarsal shortening,Disease,Disorder,Cases/families,Family(ies),,13.0,Worldwide,Validated,30363003[PMID]_19764028[PMID]_[EXPERT]
16705,137678,Spondyloepiphyseal dysplasia with metatarsal shortening,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30363003[PMID]
16710,137698,Cytomegalovirus disease in patients with impaired cell mediated immunity deemed at risk,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,25.5,Europe,Validated,European Medicines Agency 2012[INST]_ORPHANET
16711,137754,Aminoacylase 1 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29653693[PMID]
16711,137754,Aminoacylase 1 deficiency,Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,29653693[PMID]
1414,1145,Infantile-onset X-linked spinal muscular atrophy,Disease,Disorder,Cases/families,Family(ies),,14.0,Worldwide,Validated,20301739[PMID]
1414,1145,Infantile-onset X-linked spinal muscular atrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20301739[PMID]
1413,1144,Arthrogryposis-like hand anomaly-sensorineural deafness syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,5539065[PMID]
1413,1144,Arthrogryposis-like hand anomaly-sensorineural deafness syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5539065[PMID]
16708,137686,Asherman syndrome,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,44.0,Europe,Validated,European Medicines Agency 2017[INST]
16715,137776,Lethal congenital contracture syndrome type 2,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,12548738[PMID]
16715,137776,Lethal congenital contracture syndrome type 2,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12548738[PMID]
1417,1150,Arthrogryposis multiplex congenita-whistling face syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,ORPHANET
1417,1150,Arthrogryposis multiplex congenita-whistling face syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1416,1149,Kuskokwim syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23712425[PMID]
1416,1149,Kuskokwim syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,8.0,Worldwide,Validated,23712425[PMID]
16718,137807,Primary cutaneous amyloidosis,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,9.8,"Taiwan, Province of China",Validated,21070198[PMID]
16718,137807,Primary cutaneous amyloidosis,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1423,1159,Progressive pseudorheumatoid dysplasia,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
16716,137783,Lethal congenital contracture syndrome type 3,Malformation syndrome,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,17701898[PMID]_22610851[PMID]
16716,137783,Lethal congenital contracture syndrome type 3,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17701898[PMID]_22610851[PMID]
1460,1214,Progressive hemifacial atrophy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1460,1214,Progressive hemifacial atrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.143,United States,Validated,12963760[PMID]_[EXPERT]
1461,1215,Autosomal dominant optic atrophy plus syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,22197506[PMID]_22776096[PMID]_ORPHANET
16760,138044,Rare disease with Pierre Robin syndrome,Category,Group of disorders,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Not yet validated,24433508[PMID]
16760,138044,Rare disease with Pierre Robin syndrome,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
1466,1221,Cheilitis glandularis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1466,1221,Cheilitis glandularis,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,[EXPERT]
1469,1225,Baller-Gerold syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,29080750[PMID]
1469,1225,Baller-Gerold syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29080750[PMID]
1470,1226,Bamforth-Lazarus syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,[EXPERT]
1470,1226,Bamforth-Lazarus syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1471,1227,Bangstad syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,2662702[PMID]
1471,1227,Bangstad syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2662702[PMID]
1441,1184,Ataxia-photosensitivity-short stature syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,6620277[PMID]
1441,1184,Ataxia-photosensitivity-short stature syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6620277[PMID]
1440,1182,Spastic ataxia with congenital miosis,Disease,Disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,6821680[PMID]_17584505[PMID]
1440,1182,Spastic ataxia with congenital miosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17584505[PMID]
16737,137888,Auriculocondylar syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
16737,137888,Auriculocondylar syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,22560091[PMID]_23315542[PMID]
1443,1186,Infantile-onset spinocerebellar ataxia,Disease,Disorder,Cases/families,Case(s),,29.0,Worldwide,Validated,27551684[PMID]
1443,1186,Infantile-onset spinocerebellar ataxia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20301746[PMID]_27551684[PMID]
1442,1185,Spinocerebellar ataxia-dysmorphism syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,3980016[PMID]
1442,1185,Spinocerebellar ataxia-dysmorphism syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3980016[PMID]
16739,137898,Leukoencephalopathy with brain stem and spinal cord involvement-high lactate syndrome,Disease,Disorder,Cases/families,Case(s),,127.0,Worldwide,Validated,24566671[PMID]
16739,137898,Leukoencephalopathy with brain stem and spinal cord involvement-high lactate syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1445,1188,Ataxia-deafness-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,4728186[PMID]_3470627[PMID]_8411058[PMID]
1445,1188,Ataxia-deafness-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4728186[PMID]_3470627[PMID]_8411058[PMID]
1444,1187,Lethal ataxia with deafness and optic atrophy,Disease,Disorder,Cases/families,Family(ies),,4.0,Worldwide,Validated,27256512[PMID]
1444,1187,Lethal ataxia with deafness and optic atrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27256512[PMID]
1447,1190,Atelosteogenesis type I,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
16742,137908,Hypotonia with lactic acidemia and hyperammonemia,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,17873122[PMID]_21189481[PMID]
16742,137908,Hypotonia with lactic acidemia and hyperammonemia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17873122[PMID]_21189481[PMID]
16744,137914,Choanal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,8.6,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2012[REG]
16744,137914,Choanal atresia,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET
16744,137914,Choanal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.8,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
16744,137914,Choanal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,14.6,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
16744,137914,Choanal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,21.3,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
16744,137914,Choanal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,15.7,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
16744,137914,Choanal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.9,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
16744,137914,Choanal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,10.0,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
16744,137914,Choanal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.2,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
16744,137914,Choanal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.7,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
16744,137914,Choanal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.7,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
16744,137914,Choanal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.9,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
16744,137914,Choanal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.2,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
16744,137914,Choanal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.3,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
16744,137914,Choanal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,12.6,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
16744,137914,Choanal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,8.9,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
16744,137914,Choanal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.2,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1449,1193,Atkin-Flaitz syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,4025397[PMID]
1449,1193,Atkin-Flaitz syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4025397[PMID]
16745,137917,"Choanal atresia, unilateral",Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET_EUROCAT European surveillance of congenital anomalies[REG]
16745,137917,"Choanal atresia, unilateral",Clinical subtype,Subtype of disorder,Prevalence at birth,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET_EUROCAT European surveillance of congenital anomalies[REG]
1451,1200,Burn-McKeown syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,20.0,Worldwide,Validated,25434003[PMID]
1451,1200,Burn-McKeown syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25434003[PMID]
16746,137920,"Choanal atresia, bilateral",Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
1450,1198,Colonic atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.0,Worldwide,Validated,31891361[PMID]
1450,1198,Colonic atresia,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
1450,1198,Colonic atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.5,United Kingdom,Validated,2342005[PMID]
1450,1198,Colonic atresia,Morphological anomaly,Disorder,Prevalence at birth,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET_2342005[PMID]_16080929[PMID]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.0,Europe,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Point prevalence,Value and class,1-9 / 100 000,9.0,Europe,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.0,Belgium,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Belgium,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.0,Spain,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Spain,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.0,Ireland,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Ireland,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.0,Italy,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Italy,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.0,United Kingdom,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,United Kingdom,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.0,Malta,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Malta,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.0,Denmark,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Denmark,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.0,France,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,France,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.0,Reunion,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Reunion,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.0,Portugal,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Portugal,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.0,Germany,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Germany,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.0,Austria,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Austria,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.0,Switzerland,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1452,1203,Duodenal atresia,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Switzerland,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1455,1208,Pulmonary atresia-intact ventricular septum syndrome,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.5,United Kingdom,Validated,9714114[PMID]
1455,1208,Pulmonary atresia-intact ventricular septum syndrome,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.2,Sweden,Validated,11515692[PMID]
1455,1208,Pulmonary atresia-intact ventricular septum syndrome,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,United Kingdom,Validated,9714114[PMID]_ORPHANET
1455,1208,Pulmonary atresia-intact ventricular septum syndrome,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Sweden,Validated,11515692[PMID]_ORPHANET
1642,1449,Ring chromosome 7 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,23509645[PMID]
1642,1449,Ring chromosome 7 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23509645[PMID]
1643,1453,Cleidorhizomelic syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,3239579[PMID]
1643,1453,Cleidorhizomelic syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3239579[PMID]
1640,1440,Ring chromosome 14 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,80.0,Worldwide,Validated,28399932[PMID]
1640,1440,Ring chromosome 14 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28399932[PMID]
1641,1443,Ring chromosome 19 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,15270770[PMID]
1641,1443,Ring chromosome 19 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15270770[PMID]
17070,141258,Tessier number 4 facial cleft,Morphological anomaly,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,3398011[PMID]_21703590[PMID]
17070,141258,Tessier number 4 facial cleft,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3398011[PMID]_21703590[PMID]
1647,1458,CODAS syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,25574826[PMID]_20503327[PMID]
1647,1458,CODAS syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
17069,141253,Oblique facial cleft,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 1 000 000,0.31,United States,Not yet validated,21703590[PMID]_ORPHANET
17069,141253,Oblique facial cleft,Clinical group,Group of disorders,Point prevalence,Class only,1-9 / 1 000 000,0.0,United States,Not yet validated,21703590[PMID]_ORPHANET
17069,141253,Oblique facial cleft,Clinical group,Group of disorders,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
1644,1454,Joubert syndrome with hepatic defect,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,ORPHANET
1644,1454,Joubert syndrome with hepatic defect,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1645,190,Coats disease,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.09,United Kingdom,Validated,20865031[PMID]_[EXPERT]
1645,190,Coats disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1632,1426,Greenberg dysplasia,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,14684697[PMID]
1632,1426,Greenberg dysplasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
17056,141184,Rapidly involuting congenital hemangioma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1633,1427,Autosomal recessive otospondylomegaepiphyseal dysplasia,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
1633,1427,Autosomal recessive otospondylomegaepiphyseal dysplasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1638,1435,Xq21 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,7258279[PMID]_2624260[PMID]_17935254[PMID]
1638,1435,Xq21 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7258279[PMID]_2624260[PMID]_17935254[PMID]
1639,1436,X-linked skeletal dysplasia-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,837562[PMID]
1639,1436,X-linked skeletal dysplasia-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_837562[PMID]
1637,1433,Choroidal atrophy-alopecia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,10994447[PMID]
1637,1433,Choroidal atrophy-alopecia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10994447[PMID]
1659,1484,Contractures-ectodermal dysplasia-cleft lip/palate syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,7504881[PMID]
1659,1484,Contractures-ectodermal dysplasia-cleft lip/palate syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7504881[PMID]
17080,141333,Biemond syndrome type 2,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9098485[PMID]
1663,1490,Corneal dystrophy-perceptive deafness syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,24.0,Worldwide,Validated,18922146[PMID]
1663,1490,Corneal dystrophy-perceptive deafness syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18922146[PMID]
1662,1487,Cooks syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,22329539[PMID]
1662,1487,Cooks syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22329539[PMID]
1660,1486,Lethal congenital contracture syndrome type 1,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Finland,Validated,32670090[PMID]_ORPHANET
1660,1486,Lethal congenital contracture syndrome type 1,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.96,Finland,Validated,16892327[PMID]
1649,1466,COFS syndrome,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,ORPHANET
1649,1466,COFS syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1654,1471,Coloboma of macula-brachydactyly type B syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,3385739[PMID]_12919145[PMID]
1654,1471,Coloboma of macula-brachydactyly type B syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3385739[PMID]_12919145[PMID]
17077,141291,Cleft lip and alveolus,Morphological anomaly,Disorder,Point prevalence,Class only,6-9 / 10 000,0.0,Europe,Not yet validated,ORPHANET
17033,141091,Polyrrhinia,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
17032,141083,Nasolacrimal duct cyst,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,25.7,United States,Validated,21035068[PMID]
17032,141083,Nasolacrimal duct cyst,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
1610,1410,Uncombable hair syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
17035,141099,Proboscis lateralis,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
17034,141096,Supernumerary nostril,Malformation syndrome,Disorder,Cases/families,Case(s),,32.0,Worldwide,Validated,23348320[PMID]
17034,141096,Supernumerary nostril,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,23348320[PMID]
1612,1412,Tarsal-carpal coalition syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,10.0,Worldwide,Validated,[EXPERT]
1612,1412,Tarsal-carpal coalition syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1614,1416,Familial calcium pyrophosphate deposition,Disease,Disorder,Cases/families,Family(ies),,100.0,Worldwide,Validated,[EXPERT]
1614,1416,Familial calcium pyrophosphate deposition,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
1600,1394,Cerebrofaciothoracic dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,24194475[PMID]
1600,1394,Cerebrofaciothoracic dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24194475[PMID]
1604,1397,Hydrocephaly-cerebellar agenesis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_657584[PMID]
1604,1397,Hydrocephaly-cerebellar agenesis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,657584[PMID]
1605,1398,Isolated cerebellar agenesis,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1606,1399,Richards-Rundle syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
17031,141077,Epignathus,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.0017,Worldwide,Validated,21701667[PMID]_ORPHANET
17031,141077,Epignathus,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.68,Worldwide,Validated,ORPHANET_21701667[PMID]
1607,1401,CHAND syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28940926[PMID]
17048,141152,Isolated congenital hypoglossia/aglossia,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1624,174,"Metaphyseal chondrodysplasia, Schmid type",Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
17051,141163,Glossopalatine ankylosis,Malformation syndrome,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
17051,141163,Glossopalatine ankylosis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1631,1425,Desbuquois syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,16642505[PMID]_[EXPERT]
1631,1425,Desbuquois syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
17055,141179,Non-involuting congenital hemangioma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
17043,141127,Congenital tracheal stenosis,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Canada,Validated,16410137[PMID]_30159250[PMID]_32851317[PMID]_ORPHANET
17043,141127,Congenital tracheal stenosis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.6,Canada,Validated,17712567[PMID]
17044,141132,Oculo-auriculo-vertebral spectrum,Malformation syndrome,Disorder,Prevalence at birth,Class only,1-9 / 100 000,0.0,Worldwide,Validated,ORPHANET
17044,141132,Oculo-auriculo-vertebral spectrum,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Worldwide,Validated,ORPHANET
17044,141132,Oculo-auriculo-vertebral spectrum,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.0,Japan,Validated,2092586[PMID}
17044,141132,Oculo-auriculo-vertebral spectrum,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.65,France,Validated,22925539[PMID]
17044,141132,Oculo-auriculo-vertebral spectrum,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.7,Australia,Validated,34626670[PMID]
17046,141145,Hemifacial hyperplasia,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.16,United States,Validated,ISBN-10:0867153903[OTHER]_28163490[PMID]_ORPHANET
17046,141145,Hemifacial hyperplasia,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.16,United States,Validated,ISBN-10:0867153903[OTHER]_28163490[PMID]
17047,141148,Hemifacial myohyperplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,20583183[PMID]
17047,141148,Hemifacial myohyperplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20583183[PMID]
17135,156728,"Spondyloepimetaphyseal dysplasia, matrilin-3 type",Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,15121775[PMID]
17135,156728,"Spondyloepimetaphyseal dysplasia, matrilin-3 type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15121775[PMID]
1582,1375,Cataract-hypertrichosis-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
1580,163,Hereditary hyperferritinemia-cataract syndrome,Disease,Disorder,Cases/families,Case(s),,120.0,Worldwide,Validated,34789084[PMID]_36287435[PMID]
1580,163,Hereditary hyperferritinemia-cataract syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,34789084[PMID]_36287435[PMID]_ORPHANET
1579,1373,Cataract-aberrant oral frenula-growth delay syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,1951441[PMID]
1579,1373,Cataract-aberrant oral frenula-growth delay syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1951441[PMID]
1575,1368,Cataract-ataxia-deafness syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,1661780[PMID]
1575,1368,Cataract-ataxia-deafness syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1661780[PMID]
1573,1366,Autosomal recessive palmoplantar keratoderma and congenital alopecia,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,ORPHANET
1573,1366,Autosomal recessive palmoplantar keratoderma and congenital alopecia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1569,1361,Carnosinase deficiency,Biological anomaly,Disorder,Cases/families,Case(s),,24.0,Worldwide,Validated,ISBN:0-7817-3063-5[OTHER]
1569,1361,Carnosinase deficiency,Biological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
1569,1361,Carnosinase deficiency,Biological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.2,Worldwide,Validated,16722645[PMID]
1599,1393,Cerebrocostomandibular syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,75.0,Worldwide,Validated,20507350[PMID]
1599,1393,Cerebrocostomandibular syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
17151,157826,Congenital epulis,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
1596,1390,Night blindness-skeletal anomalies-dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,314984 [PMID]
1596,1390,Night blindness-skeletal anomalies-dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_314984 [PMID]
17149,157820,Cold-induced sweating syndrome,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,ORPHANET
17149,157820,Cold-induced sweating syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1595,1389,Cortical blindness-intellectual disability-polydactyly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,4064363[PMID]
1595,1389,Cortical blindness-intellectual disability-polydactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4064363[PMID]
17146,157798,Serrated polyposis syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.0,Worldwide,Not yet validated,22851664[PMID]_21636642[PMID]
17146,157798,Serrated polyposis syndrome,Disease,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET
1594,1388,Catel-Manzke syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,33.0,Worldwide,Validated,ORPHANET
1594,1388,Catel-Manzke syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
17147,157801,Mesoaxial synostotic syndactyly with phalangeal reduction,Morphological anomaly,Disorder,Cases/families,Family(ies),,6.0,Worldwide,Validated,25466284[PMID]
17147,157801,Mesoaxial synostotic syndactyly with phalangeal reduction,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1593,1387,Cataract-intellectual disability-hypogonadism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,23420520[PMID]
1593,1387,Cataract-intellectual disability-hypogonadism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
17144,157791,Epithelioid hemangioendothelioma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET_25992243[PMID]
1588,1381,Cataract-intellectual disability-anal atresia-urinary defects syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,541035[PMID]
1588,1381,Cataract-intellectual disability-anal atresia-urinary defects syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_541035[PMID]
1587,1380,Cataract-nephropathy-encephalopathy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,14065995[PMID]
1587,1380,Cataract-nephropathy-encephalopathy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_14065995[PMID]
1584,1377,Cataract-microcornea syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,8.0,Worldwide,Validated,ORPHANET
1584,1377,Cataract-microcornea syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_25406294[PMID]
17137,157215,Hereditary hypophosphatemic rickets with hypercalciuria,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
1548,1325,Camptodactyly-taurinuria syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,16178082[PMID]
1548,1325,Camptodactyly-taurinuria syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16178082[PMID]
1549,1326,"Camptodactyly syndrome, Guadalajara type 2",Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,4040823[PMID]
1549,1326,"Camptodactyly syndrome, Guadalajara type 2",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4040823[PMID]
1550,1327,"Camptodactyly syndrome, Guadalajara type 1",Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,7192193[PMID]_7681735[PMID]_8116673[PMID]_12002144[PMID]
1550,1327,"Camptodactyly syndrome, Guadalajara type 1",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7192193[PMID]_7681735[PMID]_8116673[PMID]_12002144[PMID]
1551,1328,Camurati-Engelmann disease,Malformation syndrome,Disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,20301335[PMID]
1551,1328,Camurati-Engelmann disease,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
1546,1323,Camptodactyly-joint contractures-facial skeletal defects syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,16688750[PMID]
1546,1323,Camptodactyly-joint contractures-facial skeletal defects syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16688750[PMID]
17099,156152,Anti-neutrophil cytoplasmic antibody-associated vasculitis,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,14.9,Germany,Not yet validated,24425780[PMID]
17099,156152,Anti-neutrophil cytoplasmic antibody-associated vasculitis,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET
17099,156152,Anti-neutrophil cytoplasmic antibody-associated vasculitis,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.3,United States,Validated,28881446[PMID]
17099,156152,Anti-neutrophil cytoplasmic antibody-associated vasculitis,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,42.1,United States,Validated,28881446[PMID]
1540,1314,Symmetrical thalamic calcifications,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,28063749[PMID]
1540,1314,Symmetrical thalamic calcifications,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28063749[PMID]
1542,1318,"Campomelia, Cumming type",Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,15754354[PMID]
1542,1318,"Campomelia, Cumming type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15754354[PMID]
1543,1319,Camptobrachydactyly,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,5031984[PMID]
1543,1319,Camptobrachydactyly,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5031984[PMID]
1536,1305,Feingold syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,123.0,Worldwide,Validated,ORPHANET
1536,1305,Feingold syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1537,1307,Distal limb deficiencies-micrognathia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,19584065[PMID]
1537,1307,Distal limb deficiencies-micrognathia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19584065[PMID]
1539,1313,Infantile choroidocerebral calcification syndrome,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,315525[PMID]_8232964[PMID]
1539,1313,Infantile choroidocerebral calcification syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_315525[PMID]_8232964[PMID]
1565,1350,Heart-hand syndrome type 2,Malformation syndrome,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,1976459[PMID]
1565,1350,Heart-hand syndrome type 2,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1567,1355,Congenital heart defect-round face-developmental delay syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,3225826[PMID]
1567,1355,Congenital heart defect-round face-developmental delay syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3225826[PMID]
1566,1352,Atrioventricular defect-blepharophimosis-radial and anal defect syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8031543[PMID]
1566,1352,Atrioventricular defect-blepharophimosis-radial and anal defect syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8031543[PMID]
1563,1345,Cardiomyopathy-cataract-hip spine disease syndrome,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,3965265[PMID]
1563,1345,Cardiomyopathy-cataract-hip spine disease syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3965265[PMID]
1557,1338,Heart defect-tongue hamartoma-polysyndactyly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,25427950[PMID]_1516223[PMID]_8733055[PMID]
1557,1338,Heart defect-tongue hamartoma-polysyndactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25427950[PMID]_1516223[PMID]_8733055[PMID]
1559,1340,Cardiofaciocutaneous syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.12,Japan,Validated,22495831[PMID]
1559,1340,Cardiofaciocutaneous syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,22495831[PMID]_[EXPERT]
1559,1340,Cardiofaciocutaneous syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
1553,2856,Persistent Müllerian duct syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1555,1336,Hyperkeratosis-hyperpigmentation syndrome,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,151611[PMID]_8448904[PMID]
1555,1336,Hyperkeratosis-hyperpigmentation syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_151611[PMID]_8448904[PMID]
1554,1335,Pentalogy of Cantrell,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.55,Europe,Validated,ORPHANET
1554,1335,Pentalogy of Cantrell,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
1554,1335,Pentalogy of Cantrell,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.67,Worldwide,Validated,25092102[PMID]_[EXPERT]
1762,1682,Arterial dissection-lentiginosis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,7838191[PMID]
1762,1682,Arterial dissection-lentiginosis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7838191[PMID]
1773,1757,Fibular dimelia-diplopodia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,ORPHANET
1773,1757,Fibular dimelia-diplopodia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1772,1756,Caudal duplication,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1777,1766,Dysequilibrium syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22973972[PMID]_21885617[PMID]_19461874[PMID]_22892528[PMID]
1777,1766,Dysequilibrium syndrome,Disease,Disorder,Cases/families,Case(s),,51.0,Worldwide,Validated,Dr Kym Boycott[EXPERT]_22973972[PMID]_21885617[PMID]_19461874[PMID]_22892528[PMID]
1782,1777,Temtamy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,56.0,Worldwide,Validated,24798461[PMID]
1782,1777,Temtamy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24798461[PMID]
1783,1780,Thakker-Donnai syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,1956065[PMID]
1783,1780,Thakker-Donnai syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1956065[PMID]
1780,1772,"45,X/46,XY mixed gonadal dysgenesis",Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1786,1784,Acrofrontofacionasal dysostosis,Malformation syndrome,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,22052670[PMID]_18553510[PMID]_2830788[PMID]_2986457[PMID]
1786,1784,Acrofrontofacionasal dysostosis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22052670[PMID]_18553510[PMID]_2830788[PMID]_2986457[PMID]
1784,1782,Dysosteosclerosis,Malformation syndrome,Disorder,Cases/families,Case(s),,23.0,Worldwide,Validated,20499338[PMID]
1784,1782,Dysosteosclerosis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,20499338[PMID]_ORPHANET
1790,1790,Hypomandibular faciocranial dysostosis,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,8135280[PMID]
1790,1790,Hypomandibular faciocranial dysostosis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8135280[PMID]
1788,1786,"Acrofacial dysostosis, Catania type",Malformation syndrome,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,8826434[PMID]
1788,1786,"Acrofacial dysostosis, Catania type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8826434[PMID]
1789,1788,"Acrofacial dysostosis, Rodríguez type",Malformation syndrome,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,18000904[PMID]
1789,1788,"Acrofacial dysostosis, Rodríguez type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18000904[PMID]
1729,859,Transcobalamin deficiency,Disease,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,21312325[PMID]
1729,859,Transcobalamin deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
16896,139441,Hypomyelination with atrophy of basal ganglia and cerebellum,Disease,Disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,ORPHANET
16896,139441,Hypomyelination with atrophy of basal ganglia and cerebellum,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1728,3196,Steroid dehydrogenase deficiency-dental anomalies syndrome,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,8832133[PMID]
1728,3196,Steroid dehydrogenase deficiency-dental anomalies syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8832133[PMID]
16897,139444,Leukoencephalopathy with bilateral anterior temporal lobe cysts,Disease,Disorder,Cases/families,Case(s),,29.0,Worldwide,Validated,ORPHANET
16897,139444,Leukoencephalopathy with bilateral anterior temporal lobe cysts,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
16898,139447,Progressive cavitating leukoencephalopathy,Disease,Disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,ORPHANET
16898,139447,Progressive cavitating leukoencephalopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1731,1573,Hypotrichosis with juvenile macular degeneration,Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,[EXPERT]
1731,1573,Hypotrichosis with juvenile macular degeneration,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1730,726,Alpers-Huttenlocher syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.7,Europe,Validated,19766516_Pr Robert NAVIAUX[EXPERT]
1730,726,Alpers-Huttenlocher syndrome,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.07,Europe,Not yet validated,ORPHANET
16899,139450,Microtia-eye coloboma-imperforation of the nasolacrimal duct syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,18179897[PMID]
16899,139450,Microtia-eye coloboma-imperforation of the nasolacrimal duct syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18179897[PMID]
16900,139455,Autosomal recessive bestrophinopathy,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,21825197[PMID]_24337562[PMID]
16900,139455,Autosomal recessive bestrophinopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1732,1574,Retinal degeneration-nanophthalmos-glaucoma syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,3827713[PMID]
1732,1574,Retinal degeneration-nanophthalmos-glaucoma syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3827713[PMID]
16903,139466,SERKAL syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,18179883[PMID]
16903,139466,SERKAL syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18179883[PMID]
1737,1596,Distal deletion 15q syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,22065603[PMID]
1737,1596,Distal deletion 15q syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22065603[PMID]
16904,139471,Microphthalmia with brain and digit anomalies,Malformation syndrome,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,18252212[PMID]
16904,139471,Microphthalmia with brain and digit anomalies,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18252212[PMID]
16905,139474,17q11.2 microduplication syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,18183042[PMID]
16905,139474,17q11.2 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18183042[PMID]
1739,1617,Developmental delay-language impairment-dopa responsive dystonia-parkinsonism syndrome due to 2q24 microdeletion,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,23.0,Worldwide,Validated,[EXPERT]
1739,1617,Developmental delay-language impairment-dopa responsive dystonia-parkinsonism syndrome due to 2q24 microdeletion,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1738,1606,1p36 deletion syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,15.0,United States,Validated,9326330[PMID]
1738,1606,1p36 deletion syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,15.0,United States,Validated,9326330[PMID]_ORPHANET
16907,139480,Autosomal recessive spastic paraplegia type 39,Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,24355708[PMID]
16907,139480,Autosomal recessive spastic paraplegia type 39,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24355708[PMID]
1741,1647,Oculocerebrocutaneous syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,38.0,Worldwide,Validated,ORPHANET
1741,1647,Oculocerebrocutaneous syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
16908,139485,Autosomal recessive ataxia due to ubiquinone deficiency,Disease,Disorder,Cases/families,Case(s),,31.0,Worldwide,Validated,24164873[PMID]
16908,139485,Autosomal recessive ataxia due to ubiquinone deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1743,1653,Dentin dysplasia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
16913,139515,Charcot-Marie-Tooth disease type 4J,Disease,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,21705420[PMID]_23489662[PMID]_24878229[PMID]
16913,139515,Charcot-Marie-Tooth disease type 4J,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21705420[PMID]_23489662[PMID]_24878229[PMID]
16912,139512,Neuropathy with hearing impairment,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,11309368[PMID]
16912,139512,Neuropathy with hearing impairment,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11309368[PMID]
1745,1657,"Dermatoosteolysis, Kirghizian type",Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,6224420[PMID]
1745,1657,"Dermatoosteolysis, Kirghizian type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6224420[PMID]
16915,139525,Distal hereditary motor neuropathy type 2,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3789668[PMID]_7125978[PMID]_3789668[PMID]_1517763[PMID]
16915,139525,Distal hereditary motor neuropathy type 2,Disease,Disorder,Cases/families,Family(ies),,4.0,Worldwide,Validated,3789668[PMID]_7125978[PMID]_3789668[PMID]_1517763[PMID]
1746,1658,Absence of fingerprints-congenital milia syndrome,Disease,Disorder,Cases/families,Family(ies),,10.0,Worldwide,Validated,26932190[PMID]
1746,1658,Absence of fingerprints-congenital milia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26932190[PMID]
1747,1659,Dermatoleukodystrophy,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,655904[PMID]
1747,1659,Dermatoleukodystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_655904[PMID]
16917,139547,Distal spinal muscular atrophy type 3,Disease,Disorder,Cases/families,Case(s),,28.0,Worldwide,Validated,512678[PMID]_12112104[PMID]_15054395[PMID]
16917,139547,Distal spinal muscular atrophy type 3,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_512678[PMID]_12112104[PMID]_15054395[PMID]
1749,1660,Dermoodontodysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,6616948[PMID]
1749,1660,Dermoodontodysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6616948[PMID]
16919,139557,X-linked distal spinal muscular atrophy type 3,Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,14985388[PMID]_19153371[PMID]_20170900[PMID]
16919,139557,X-linked distal spinal muscular atrophy type 3,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_14985388[PMID]_19153371[PMID]_20170900[PMID]
1750,1661,X-linked corneal dermoid,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,11594343[PMID]
1750,1661,X-linked corneal dermoid,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11594343[PMID]
1751,1662,Restrictive dermopathy,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
1751,1662,Restrictive dermopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
16918,139552,"Distal hereditary motor neuropathy, Jerash type",Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,11117544[PMID]_26078401[PMID]
16918,139552,"Distal hereditary motor neuropathy, Jerash type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11117544[PMID]_26078401[PMID]
16921,139573,Hereditary sensory and autonomic neuropathy with deafness and global delay,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,12160974[PMID]
16921,139573,Hereditary sensory and autonomic neuropathy with deafness and global delay,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12160974[PMID]
16920,139564,Hereditary sensory and autonomic neuropathy type 1B,Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,12870133[PMID]
16920,139564,Hereditary sensory and autonomic neuropathy type 1B,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12870133[PMID]
16923,139583,X-linked hereditary sensory and autonomic neuropathy with deafness,Disease,Disorder,Cases/families,Family(ies),,5.0,Worldwide,Validated,25986071[PMID]
16923,139583,X-linked hereditary sensory and autonomic neuropathy with deafness,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25986071
1754,1667,Wolcott-Rallison syndrome,Disease,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,21050479[PMID]
1754,1667,Wolcott-Rallison syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
16922,139578,Mutilating hereditary sensory neuropathy with spastic paraplegia,Disease,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,218673[PMID]_7922454[PMID]_16333315[PMID]
16922,139578,Mutilating hereditary sensory neuropathy with spastic paraplegia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16333315[PMID]
1757,1671,Split cord malformation type I,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_22371545[PMID]
16998,140917,Stapes ankylosis with broad thumbs and toes,Malformation syndrome,Disorder,Cases/families,Family(ies),,6.0,Worldwide,Validated,ORPHANET
16998,140917,Stapes ankylosis with broad thumbs and toes,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1703,1548,Cryptorchidism-arachnodactyly-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,4394203[PMID]
1703,1548,Cryptorchidism-arachnodactyly-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4394203[PMID]
1702,1547,Cryptomicrotia-brachydactyly-excess fingertip arch syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,3400730[PMID]
1702,1547,Cryptomicrotia-brachydactyly-excess fingertip arch syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3400730[PMID]
16999,140922,Titin-related limb-girdle muscular dystrophy R10,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,1745277[PMID]_1487757[PMID]
16999,140922,Titin-related limb-girdle muscular dystrophy R10,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1745277[PMID]_1487757[PMID]
1701,1545,Crisponi syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
1701,1545,Crisponi syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1699,1540,Jackson-Weiss syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1699,1540,Jackson-Weiss syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,200.0,Worldwide,Not yet validated,ORPHANET
16992,140874,Joubert syndrome and related disorders,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.1,Worldwide,Validated,18054307[PMID]_17377524[PMID]_20301500[PMID]_20615230[PMID]_[EXPERT]
16992,140874,Joubert syndrome and related disorders,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.0,United States,Validated,20615230[PMID]
16992,140874,Joubert syndrome and related disorders,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Netherlands,Validated,18054307[PMID]
16992,140874,Joubert syndrome and related disorders,Category,Group of disorders,Point prevalence,Value and class,>1 / 1000,666.67,North America,Validated,22152675[PMID]
16992,140874,Joubert syndrome and related disorders,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
16993,140896,Severe acute respiratory syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
16993,140896,Severe acute respiratory syndrome,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,European Centre for Disease prevention and Control 2011[INST]
1696,1532,Gómez-López-Hernández syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,36.0,Worldwide,Validated,28357184[PMID]
1696,1532,Gómez-López-Hernández syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28357184[PMID]
17006,140952,Syndactyly-telecanthus-anogenital and renal malformations syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,PMID: 18297069 ; EXPERT
17006,140952,Syndactyly-telecanthus-anogenital and renal malformations syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18297069[PMID]
17007,140957,Autosomal dominant macrothrombocytopenia,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,18065693[PMID]_18849486[PMID]_24069336[PMID]
17007,140957,Autosomal dominant macrothrombocytopenia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
17004,140944,CLOVES syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,31334068[PMID]
17004,140944,CLOVES syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_31334068[PMID]
17005,140949,Low-flow priapism,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,European Medicines Agency 2010[INST]
1707,1555,Cutis gyrata-acanthosis nigricans-craniosynostosis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,19610084[PMID]
1707,1555,Cutis gyrata-acanthosis nigricans-craniosynostosis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19610084[PMID]
17002,140936,Lelis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,1628512[PMID]_12457412[PMID]_18627052[PMID]
17002,140936,Lelis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1628512[PMID]_12457412[PMID]_18627052[PMID]
17003,140941,Short stature due to primary acid-labile subunit deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
1705,1553,Curry-Jones syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,18798318[PMID]
1705,1553,Curry-Jones syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
17000,140927,Self-limited neonatal-infantile epilepsy,Disease,Disorder,Cases/families,Family(ies),,10.0,Worldwide,Validated,15048894[PMID]
17000,140927,Self-limited neonatal-infantile epilepsy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15048894[PMID]
17001,140933,Linear atrophoderma of Moulin,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
17001,140933,Linear atrophoderma of Moulin,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
17015,140989,Primary angiitis of the central nervous system,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.24,United States,Validated,21601163[PMID]_21180634[PMID]_22575778[PMID]
17015,140989,Primary angiitis of the central nervous system,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1718,1566,Dandy-Walker malformation-postaxial polydactyly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,23324646[PMID]
1718,1566,Dandy-Walker malformation-postaxial polydactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23324646[PMID]
17013,140976,RHYNS syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,9375913[PMID]
17013,140976,RHYNS syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9375913[PMID]
1716,1563,Dahlberg-Borer-Newcomer syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,6638075[PMID]
1716,1563,Dahlberg-Borer-Newcomer syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6638075[PMID
17012,140969,Saldino-Mainzer syndrome,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,22503633[PMID]_23418020[PMID]_28724397[PMID]
17012,140969,Saldino-Mainzer syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22503633[PMID]_23418020[PMID]_28724397[PMID]
17011,140966,"Palmoplantar keratoderma, Nagashima type",Disease,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,27666198[PMID]
17011,140966,"Palmoplantar keratoderma, Nagashima type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27666198[PMID]
17010,140963,Bilateral microtia-deafness-cleft palate syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,23775976[PMID]_27503514[PMID]
17010,140963,Bilateral microtia-deafness-cleft palate syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23775976[PMID]_27503514[PMID]
1726,382,Guanidinoacetate methyltransferase deficiency,Disease,Disorder,Cases/families,Case(s),,80.0,Worldwide,Validated,20301745[PMID]
1726,382,Guanidinoacetate methyltransferase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1727,742,Prolidase deficiency,Disease,Disorder,Cases/families,Case(s),,90.0,Worldwide,Validated,26110198[PMID]
1727,742,Prolidase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,Dr Heng Wang[EXPERT]_ORPHANET
1727,742,Prolidase deficiency,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.08,Canada,Validated,ISBN:978-2-550-55181-2[OTHER]
1725,1979,Lipodystrophy due to peptidic growth factors deficiency,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,2477323[PMID]
1725,1979,Lipodystrophy due to peptidic growth factors deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2477323[PMID]
1722,1571,Knobloch syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,119.0,Worldwide,Validated,35693012[PMID]_36684549[PMID]_ORPHANET
1722,1571,Knobloch syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,35693012[PMID]_36684549[PMID]_ORPHANET
17018,141007,Orofaciodigital syndrome type 9,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,[EXPERT]
17018,141007,Orofaciodigital syndrome type 9,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1723,1551,Familial benign copper deficiency,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,2978614[PMID]
1723,1551,Familial benign copper deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2978614[PMID]
1720,1568,X-linked intellectual disability-Dandy-Walker malformation-basal ganglia disease-seizures syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,23756445[PMID]_23756445[PMID]
1720,1568,X-linked intellectual disability-Dandy-Walker malformation-basal ganglia disease-seizures syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
17017,141000,Orofaciodigital syndrome type 11,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
1668,1497,X-linked complicated corpus callosum dysgenesis,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,ORPHANET
1668,1497,X-linked complicated corpus callosum dysgenesis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1665,1493,Vici syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,26917586[PMID]
1665,1493,Vici syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26917586[PMID]
16962,140286,Secondary hypoparathyroidism due to impaired parathormon secretion,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,24.75,Europe,Validated,29087618[PMID]_23661265[PMID]_29516129[PMID]_30375660[PMID]
16962,140286,Secondary hypoparathyroidism due to impaired parathormon secretion,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
16962,140286,Secondary hypoparathyroidism due to impaired parathormon secretion,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.8,Denmark,Validated,23661265[PMID]
16962,140286,Secondary hypoparathyroidism due to impaired parathormon secretion,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.7,Spain,Validated,32155210[PMID]
1667,1495,Intellectual disability-hypoplastic corpus callosum-preauricular tag syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,3400727[PMID]
1667,1495,Intellectual disability-hypoplastic corpus callosum-preauricular tag syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3400727[PMID]
1676,1509,Coxopodopatellar syndrome,Disease,Disorder,Cases/families,Case(s),,47.0,Worldwide,Validated,11303519[PMID]
1676,1509,Coxopodopatellar syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11303519[PMID]
1679,1512,Crane-Heise syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,21094705[PMID]
1679,1512,Crane-Heise syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21094705[PMID]
1673,1506,Thin ribs-tubular bones-dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,2400886[PMID]
1673,1506,Thin ribs-tubular bones-dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2400886[PMID]
1675,1508,Coxoauricular syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,7282772[PMID]
1675,1508,Coxoauricular syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7282772[PMID]
1674,1507,Autosomal recessive Robinow syndrome,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,[EXPERT]
1674,1507,Autosomal recessive Robinow syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1684,1517,Cantú syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,28690487[PMID]
1684,1517,Cantú syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28690487[PMID]
1686,1519,SPECC1L-related hypertelorism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,25.0,Worldwide,Validated,26111080[PMID]
1686,1519,SPECC1L-related hypertelorism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26111080[PMID]
1687,1520,Craniofrontonasal dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1680,1513,Craniodiaphyseal dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,21221996[PMID]
1680,1513,Craniodiaphyseal dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1681,1514,Craniodigital-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,17715284[PMID]
1681,1514,Craniodigital-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17715284[PMID]
16976,140481,Autosomal dominant slowed nerve conduction velocity,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,9678704[PMID]
16976,140481,Autosomal dominant slowed nerve conduction velocity,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9678704[PMID]
1682,1515,Cranioectodermal dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,24027799[PMID]
1682,1515,Cranioectodermal dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24027799[PMID]
1683,1516,Non-syndromic bilambdoid and sagittal craniosynostosis,Malformation syndrome,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,15723305[PMID]
1683,1516,Non-syndromic bilambdoid and sagittal craniosynostosis,Malformation syndrome,Disorder,Prevalence at birth,Class only,<1 / 1 000 000,0.0,Worldwide,Not yet validated,ORPHANET
1683,1516,Non-syndromic bilambdoid and sagittal craniosynostosis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1683,1516,Non-syndromic bilambdoid and sagittal craniosynostosis,Malformation syndrome,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.05,Spain,Validated,15551327[PMID]_[EXPERT]
1693,1527,"Craniosynostosis, Philadelphia type",Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,8882401[PMID]
1693,1527,"Craniosynostosis, Philadelphia type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8882401[PMID]
1694,1528,Craniotelencephalic dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,6859106[PMID]
1694,1528,Craniotelencephalic dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6859106[PMID]
1695,1529,Craniofacial-deafness-hand syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,14556253[PMID]
1695,1529,Craniofacial-deafness-hand syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_14556253[PMID]
1688,1521,Craniofrontonasal dysplasia-Poland anomaly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,2225532[PMID]
1688,1521,Craniofrontonasal dysplasia-Poland anomaly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2225532[PMID]
1689,1522,Craniometaphyseal dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,160.0,Worldwide,Validated,ISBN:781730635[OTHER]
1689,1522,Craniometaphyseal dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_ISBN:0781730635[OTHER]
1691,1525,Cranio-osteoarthropathy,Malformation syndrome,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
1691,1525,Cranio-osteoarthropathy,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1913,1969,Facial dysmorphism-anorexia-cachexia-eye and skin anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,6438152[PMID]
1913,1969,Facial dysmorphism-anorexia-cachexia-eye and skin anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6438152[PMID]
1912,1968,Flat face-microstomia-ear anomaly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,2929657[PMID]
1912,1968,Flat face-microstomia-ear anomaly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2929657[PMID]
1914,1970,Facial dysmorphism-macrocephaly-myopia-Dandy-Walker malformation syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,2591071[PMID]
1914,1970,Facial dysmorphism-macrocephaly-myopia-Dandy-Walker malformation syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2591071[PMID]
1917,1973,Faciocardiorenal syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,880742[PMID]_1887846[PMID]
1917,1973,Faciocardiorenal syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_880742[PMID]_1887846[PMID]
1916,1972,Lethal faciocardiomelic dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,1218241[PMID]
1916,1972,Lethal faciocardiomelic dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1218241[PMID]
1918,1974,Autosomal recessive faciodigitogenital syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,26.0,Worldwide,Validated,3398008[PMID]_1770541[PMID]_20607856[PMID]
1918,1974,Autosomal recessive faciodigitogenital syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3398008[PMID]_1770541[PMID]_20607856[PMID]
1907,1962,Exostoses-anetodermia-brachydactyly type E syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,6334993[PMID]
1907,1962,Exostoses-anetodermia-brachydactyly type E syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6334993[PMID]
1908,1964,Extrasystoles-short stature-hyperpigmentation-microcephaly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,1218236[PMID]
1908,1964,Extrasystoles-short stature-hyperpigmentation-microcephaly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1218236[PMID]
1896,1822,Dysplasia epiphysealis hemimelica,Malformation syndrome,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Worldwide,Not yet validated,13295331[PMID]_29252895[PMID]
1896,1822,Dysplasia epiphysealis hemimelica,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
1897,1824,Lowry-Wood syndrome,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,12605445[PMID]_19288552[PMID]
1897,1824,Lowry-Wood syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12605445[PMID]_19288552[PMID]
1899,1952,Epiphyseal stippling-osteoclastic hyperplasia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,12709756[PMID]
1899,1952,Epiphyseal stippling-osteoclastic hyperplasia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12709756[PMID]
1901,1954,Congenital lethal erythroderma,Disease,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,1535034[PMID]
1901,1954,Congenital lethal erythroderma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1535034[PMID]
1902,1955,Spinocerebellar ataxia type 34,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_31105016[PMID]_31750392[PMID]_[EXPERT]
1902,1955,Spinocerebellar ataxia type 34,Disease,Disorder,Cases/families,Case(s),,45.0,Worldwide,Validated,31105016[PMID]_31750392[PMID]_[EXPERT]
1888,1926,Diabetic embryopathy,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1889,2209,Maternal phenylketonuria,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
1889,2209,Maternal phenylketonuria,Malformation syndrome,Disorder,Annual incidence,Value and class,1-5 / 10 000,10.0,Europe,Validated,[EXPERT]
1890,1927,Emery-Nelson syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,5501704[PMID]
1890,1927,Emery-Nelson syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5501704[PMID]
1891,1937,Eng-Strom syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3812565[PMID]
1891,1937,Eng-Strom syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,3812565[PMID]
1882,1920,Toluene embryopathy,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1881,1919,Phenobarbital embryopathy,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1880,1917,Fetal methylmercury syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,34881051[PMID]_https://www3.kumagaku.ac.jp/srs/pdf/no14_no01_200901_005.pdf_ORPHANET
1885,1923,Methimazole embryofetopathy,Malformation syndrome,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,ORPHANET
1885,1923,Methimazole embryofetopathy,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1875,1912,Fetal hydantoin syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1874,1918,Fetal minoxidil syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1873,1911,Cocaine embryofetopathy,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1872,1910,Fetal iodine syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1879,1916,Diethylstilbestrol syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1878,294,Fetal cytomegalovirus syndrome,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,40.0,Europe,Not yet validated,ORPHANET
1877,1914,Vitamin K antagonist embryofetopathy,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1876,1913,Fetal trimethadione syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1864,1896,EEC syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.11,Europe,Validated,ISBN:978-0-387-21753-6[OTHER]
1864,1896,EEC syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET_ISBN:978-0-387-21753-6[OTHER]
1865,1897,EEM syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,7.0,Worldwide,Validated,15805154[PMID]
1865,1897,EEM syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1870,1908,Aminopterin/methotrexate embryofetopathy,Malformation syndrome,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,ORPHANET
1870,1908,Aminopterin/methotrexate embryofetopathy,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1871,1909,Indomethacin embryofetopathy,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1868,1906,Fetal valproate spectrum disorder,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_Dr Asher Ornoy[PMID]
1868,1906,Fetal valproate spectrum disorder,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.02,Europe,Validated,29753923[PMID]_EUROCAT European surveillance of congenital anomalies 2005-2014[REG]
1868,1906,Fetal valproate spectrum disorder,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.7,Reunion,Validated,29753923[PMID]_EUROCAT European surveillance of congenital anomalies 2005-2014[REG]
1868,1906,Fetal valproate spectrum disorder,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Belgium,Validated,29753923[PMID]_EUROCAT European surveillance of congenital anomalies 2005-2014[REG]
1868,1906,Fetal valproate spectrum disorder,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.7,Netherlands,Validated,29753923[PMID]_EUROCAT European surveillance of congenital anomalies 2005-2014[REG]
1868,1906,Fetal valproate spectrum disorder,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.3,Switzerland,Validated,29753923[PMID]_EUROCAT European surveillance of congenital anomalies 2005-2014[REG]
1868,1906,Fetal valproate spectrum disorder,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.2,Germany,Validated,29753923[PMID]_EUROCAT European surveillance of congenital anomalies 2005-2014[REG]
1868,1906,Fetal valproate spectrum disorder,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.3,Ireland,Validated,29753923[PMID]_EUROCAT European surveillance of congenital anomalies 2005-2014[REG]
1863,1895,Edinburgh malformation syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,2057251[PMID]
1863,1895,Edinburgh malformation syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2057251[PMID]
1860,1891,Intellectual disability-spasticity-ectrodactyly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,8368260[PMID]
1860,1891,Intellectual disability-spasticity-ectrodactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8368260[PMID]
1861,1892,Ectrodactyly-polydactyly syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,7151304[PMID]
1861,1892,Ectrodactyly-polydactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7151304[PMID]
1853,1816,Leukomelanoderma-infantilism-intellectual disability-hypodontia-hypotrichosis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,13867923[PMID]
1853,1816,Leukomelanoderma-infantilism-intellectual disability-hypodontia-hypotrichosis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_13867923[PMID]
1855,1807,Focal facial dermal dysplasia type III,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
1855,1807,Focal facial dermal dysplasia type III,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,21931173[PMID]
1854,1818,"Ectodermal dysplasia, trichoodontoonychial type",Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,3740884[PMID]
1854,1818,"Ectodermal dysplasia, trichoodontoonychial type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3740884[PMID]
1851,1883,Ectodermal dysplasia-sensorineural deafness syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5422345[PMID]
1851,1883,Ectodermal dysplasia-sensorineural deafness syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,5422345[PMID]
1850,1882,Hypohidrotic ectodermal dysplasia-hypothyroidism-ciliary dyskinesia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,7463217[PMID]_3944674[PMID]
1850,1882,Hypohidrotic ectodermal dysplasia-hypothyroidism-ciliary dyskinesia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7463217[PMID]_3944674[PMID]
1845,1875,Congenital muscular dystrophy-infantile cataract-hypogonadism syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_13385309[PMID]
1845,1875,Congenital muscular dystrophy-infantile cataract-hypogonadism syndrome,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,13385309[PMID]
1844,1873,Jalili syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.3,"Palestinian Territory, occupied",Validated,20706282[PMID]
1844,1873,Jalili syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,49.0,Worldwide,Validated,23362848[PMID]_20706282[PMID]_21728811[PMID]_[EXPERT]
1844,1873,Jalili syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1847,1879,Melorheostosis with osteopoikilosis,Malformation syndrome,Disorder,Cases/families,Family(ies),,5.0,Worldwide,Validated,[EXPERT]
1847,1879,Melorheostosis with osteopoikilosis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1840,1867,"Hereditary bullous dystrophy, macular type",Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,7943046[PMID]
1840,1867,"Hereditary bullous dystrophy, macular type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7943046[PMID]
1843,1872,Cone rod dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.5,Europe,Not yet validated,ORPHANET
1842,1871,Progressive cone dystrophy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1837,1860,Thanatophoric dysplasia type 1,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1838,1861,Thoracic dysplasia-hydrocephalus syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,3295244[PMID]
1838,1861,Thoracic dysplasia-hydrocephalus syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3295244[PMID]
1839,1865,"Dyssegmental dysplasia, Silverman-Handmaker type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20542149[PMID]
1835,1858,Skeletal dysplasia-epilepsy-short stature syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,9916849[PMID]_1488978[PMID]_8882779[PMID]
1835,1858,Skeletal dysplasia-epilepsy-short stature syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9916849[PMID]_1488978[PMID]_8882779[PMID]
1831,254,Spondylometaphyseal dysplasia,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Europe,Validated,ORPHANET
1831,254,Spondylometaphyseal dysplasia,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1826,1852,X-linked retinal dysplasia,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,7333018[PMID]
1826,1852,X-linked retinal dysplasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,7333018[PMID]_ORPHANET
1821,1842,"Bone dysplasia, lethal Holmgren type",Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,3396596[PMID]
1821,1842,"Bone dysplasia, lethal Holmgren type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3396596[PMID]
1818,1839,Hereditary mucoepithelial dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1816,1837,"Metaphyseal chondrodysplasia, Rosenberg type",Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,3732330[PMID]
1816,1837,"Metaphyseal chondrodysplasia, Rosenberg type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3732330[PMID]
1815,1836,"Mesomelic dysplasia, Kantaputra type",Malformation syndrome,Disorder,Cases/families,Family(ies),,5.0,Worldwide,Validated,15211647[PMID]_15264287[PMID]_1481840[PMID]_20577005[PMID]_21654727[PMID]
1815,1836,"Mesomelic dysplasia, Kantaputra type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15211647[PMID]_15264287[PMID]_1481840[PMID]_20577005[PMID]_21654727[PMID]
1814,1834,Axial mesodermal dysplasia spectrum,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_7243441[PMID]_26949683[PMID]
1812,1830,Schimke immuno-osseous dysplasia,Disease,Disorder,Cases/families,Case(s),,133.0,Worldwide,Validated,37051678[PMID]_ORPHANET
1812,1830,Schimke immuno-osseous dysplasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,37051678[PMID]_ORPHANET
1811,1825,Epiphyseal dysplasia-hearing loss-dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,1642273[PMID]
1811,1825,Epiphyseal dysplasia-hearing loss-dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1642273[PMID]
1809,251,Multiple epiphyseal dysplasia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,5.0,Europe,Validated,[EXPERT]
1804,1811,Odontomicronychial dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,8728698[PMID]
1804,1811,Odontomicronychial dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8728698[PMID]
1805,1812,Ectodermal dysplasia-intellectual disability-central nervous system malformation syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1802,1808,"Hidrotic ectodermal dysplasia, Christianson-Fourie type",Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,8826433[PMID]
1802,1808,"Hidrotic ectodermal dysplasia, Christianson-Fourie type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8826433[PMID]
1803,1809,"Hidrotic ectodermal dysplasia, Halal type",Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,2063897[PMID]
1803,1809,"Hidrotic ectodermal dysplasia, Halal type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1801,1806,Ectodermal dysplasia-blindness syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,1583659[PMID]
1801,1806,Ectodermal dysplasia-blindness syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1583659[PMID]
1798,1802,Ghosal hematodiaphyseal dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
1799,1803,Thoracomelic dysplasia,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,3184141[PMID]
1799,1803,Thoracomelic dysplasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3184141[PMID]
1794,1798,Craniofacial dysostosis-diaphyseal hyperplasia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
1795,1799,Familial developmental dysphasia,Clinical syndrome,Disorder,Cases/families,Family(ies),,6.0,Worldwide,Validated,8031532[PMID]
1795,1799,Familial developmental dysphasia,Clinical syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8031532[PMID]
1793,1794,Oculomaxillofacial dysostosis,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,7856656[PMID]
1793,1794,Oculomaxillofacial dysostosis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7856656[PMID]
2035,2130,Non-syndromic hemimelia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,4.15,Europe,Not yet validated,ORPHANET
2036,2136,Hennekam syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,29560340[PMID]
2036,2136,Hennekam syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,29560340[PMID]_ORPHANET
2037,2138,"46,XX ovotesticular difference of sex development",Malformation syndrome,Disorder,Cases/families,Case(s),,500.0,Worldwide,Validated,[EXPERT]_23926413[PMID]
2037,2138,"46,XX ovotesticular difference of sex development",Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.5,Worldwide,Validated,[EXPERT]
2037,2138,"46,XX ovotesticular difference of sex development",Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET_[EXPERT]
2038,2139,Hernández-Aguirre Negrete syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
2040,2141,Diaphragmatic defect-limb deficiency-skull defect syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,8779324[PMID]_19318925[PMID]_23448910[PMID]
2040,2141,Diaphragmatic defect-limb deficiency-skull defect syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8779324[PMID]_19318925[PMID]_23448910[PMID]
2043,2143,Donnai-Barrow syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,[EXPERT]
2043,2143,Donnai-Barrow syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2044,2145,"Craniosynostosis, Herrmann-Opitz type",Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,3300335[PMID]_5783388[PMID]
2044,2145,"Craniosynostosis, Herrmann-Opitz type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3300335[PMID]_5783388[PMID]
2046,2149,Nodular neuronal heterotopia,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2047,2148,Lissencephaly type 1 due to doublecortin gene mutation,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
17184,158048,Hemophagocytic syndrome associated with an infection,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
17185,158057,Acquired hemophagocytic lymphohistiocytosis associated with malignant disease,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2019,2108,Hallermann-Streiff syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,10388418[PMID]
2019,2108,Hallermann-Streiff syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_10388418[PMID]
2019,2108,Hallermann-Streiff syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.6,Japan,Validated,2092586[PMID]
17186,158061,Macrophage activation syndrome,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2018,2107,Hall-Riggs syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,11185076[PMID]
2018,2107,Hall-Riggs syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11185076[PMID]
2021,2110,Hallux varus-preaxial polysyndactyly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,6255798[PMID]
2021,2110,Hallux varus-preaxial polysyndactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6255798[PMID]
2020,2109,Hallermann-Streiff-like syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8585575[PMID]
2020,2109,Hallermann-Streiff-like syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8585575[PMID]
2022,2111,Cystic hamartoma of lung and kidney,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,3605206[PMID]
2022,2111,Cystic hamartoma of lung and kidney,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3605206[PMID]
17192,158266,Huntington disease-like syndrome,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.85,Brazil,Validated,35209917[PMID]
2025,2115,Harrod syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,8669446[PMID]
2025,2115,Harrod syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8669446[PMID]
2024,2114,"Hip dysplasia, Beukes type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
2027,2994,Short stature-craniofacial anomalies-genital hypoplasia syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,10733241[PMID]
2027,2994,Short stature-craniofacial anomalies-genital hypoplasia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10733241[PMID]
2026,2117,Hartsfield syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,35.0,Worldwide,Validated,23812909[PMID]_EXPERT
2026,2117,Hartsfield syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,23812909[PMID]_ORPHANET
2028,2119,HEC syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,7747788[PMID]
2028,2119,HEC syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7747788[PMID]
2030,2123,Multifocal infantile hemangioma with extracutenous involvement,Malformation syndrome,Disorder,Cases/families,Case(s),,70.0,Worldwide,Validated,ORPHANET
2030,2123,Multifocal infantile hemangioma with extracutenous involvement,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
17171,157997,Benign cephalic histiocytosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
2002,2090,GMS syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,1308345[PMID]
2002,2090,GMS syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1308345[PMID]
17170,157991,Generalized eruptive histiocytosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
2003,2091,Multinodular goiter-cystic kidney-polydactyly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,4020555[PMID]
2003,2091,Multinodular goiter-cystic kidney-polydactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4020555[PMID]
2007,376,Gordon syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2004,2092,Focal dermal hypoplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,ORPHANET
2004,2092,Focal dermal hypoplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
17172,158000,Juvenile xanthogranuloma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,Germany,Validated,22969141[PMID]
17172,158000,Juvenile xanthogranuloma,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.0225,Germany,Validated,22969141[PMID]_ORPHANET
2010,2098,"Acromesomelic dysplasia, Grebe type",Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
17179,158025,Hereditary progressive mucinous histiocytosis,Disease,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,28556021[PMID]
17179,158025,Hereditary progressive mucinous histiocytosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28556021[PMID]
2011,380,Greig cephalopolysyndactyly syndrome,Malformation syndrome,Disorder,Prevalence at birth,Class only,1-9 / 1 000 000,0.0,Europe,Validated,ORPHANET_ 25297527[PMID]_[EXPERT]
2011,380,Greig cephalopolysyndactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
2008,2095,Gorlin-Chaudhry-Moss syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,23686885[PMID]
2008,2095,Gorlin-Chaudhry-Moss syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
17176,158014,Rosaï-Dorfman disease,Disease,Disorder,Cases/families,Case(s),,1000.0,Worldwide,Validated,21816647[PMID]
17176,158014,Rosaï-Dorfman disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
2009,2097,Grant syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,3742858[PMID]
2009,2097,Grant syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3742858[PMID]
2014,2101,Grubben-de Cock-Borghgraef syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,1378778[PMID]
2014,2101,Grubben-de Cock-Borghgraef syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1378778[PMID]
2015,2104,Dysmorphism-pectus carinatum-joint laxity syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,7438507[PMID]
2015,2104,Dysmorphism-pectus carinatum-joint laxity syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7438507[PMID]
17181,158032,Hemophagocytic syndrome,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
17181,158032,Hemophagocytic syndrome,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,0.198,United Kingdom,Validated,34875131[PMID]
17180,158029,Sea-blue histiocytosis,Disease,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,ORPHANET
17180,158029,Sea-blue histiocytosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1987,2069,Gastrocutaneous syndrome,Disease,Disorder,Cases/families,Case(s),,24.0,Worldwide,Validated,7065007[PMID]
1987,2069,Gastrocutaneous syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7065007[PMID]
17155,157846,Neuroferritinopathy,Disease,Disorder,Cases/families,Case(s),,90.0,Worldwide,Validated,27022507[PMID]
17155,157846,Neuroferritinopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27022507[PMID]
17152,157832,Craniorhiny,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,1896543[PMID]_1897582[PMID]
17152,157832,Craniorhiny,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1896543[PMID]_1897582[PMID]
1985,2067,GAPO syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,30575274[PMID]_29304326[PMID]_30255493[PMID]_31448094[PMID]
1985,2067,GAPO syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
17153,157835,Paroxysmal hemicrania,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,[EXPERT]_29720814[PMID]
1984,2065,Galloway-Mowat syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,159.0,Worldwide,Validated,33791874[PMID]_ORPHANET
1984,2065,Galloway-Mowat syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,33791874[PMID]_ORPHANET
1991,2075,Genitopalatocardiac syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,19283856[PMID]
1991,2075,Genitopalatocardiac syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19283856[PMID]
1990,2074,Gemignani syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,3958822[PMID]
1990,2074,Gemignani syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3958822[PMID]
17156,157850,Pantothenate kinase-associated neurodegeneration,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.15,Europe,Validated,22027213[PMID]_[EXPERT]_ ORPHANET
1989,2072,Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,ORPHANET
1989,2072,Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
17162,157954,ANE syndrome,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,18439547[PMID]
17162,157954,ANE syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18439547[PMID]
17163,157962,"Oculoauricular syndrome, Schorderet type",Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,18423520[PMID]_25574057[PMID]
17163,157962,"Oculoauricular syndrome, Schorderet type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18423520[PMID]_25574057[PMID]
17160,157946,Huntington disease-like 3,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
1993,2078,Geroderma osteodysplastica,Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,18304158[PMID]
1993,2078,Geroderma osteodysplastica,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1992,2077,German syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,3812590[PMID]
1992,2077,German syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3812590[PMID]
17166,157973,Congenital muscular dystrophy due to LMNA mutation,Disease,Disorder,Cases/families,Case(s),,23.0,Worldwide,Validated,28125586[PMID]
17166,157973,Congenital muscular dystrophy due to LMNA mutation,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28125586[PMID]
1999,2085,Glaucoma-sleep apnea syndrome,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,7164003[PMID]
1999,2085,Glaucoma-sleep apnea syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7164003[PMID]
1998,2084,Glaucoma-ectopia lentis-microspherophakia-stiff joints-short stature syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,1519650[PMID]
1998,2084,Glaucoma-ectopia lentis-microspherophakia-stiff joints-short stature syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1519650[PMID]
17164,157965,SLC39A13-related spondylodysplastic Ehlers-Danlos syndrome,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,18513683[PMID]_18985159[PMID]
17164,157965,SLC39A13-related spondylodysplastic Ehlers-Danlos syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18513683[PMID]_18985159[PMID]
1997,2083,Prominent glabella-microcephaly-hypogenitalism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,2705483[PMID]
1997,2083,Prominent glabella-microcephaly-hypogenitalism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2705483[PMID]
1974,1791,Frontofacionasal dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,26495166[PMID]
1974,1791,Frontofacionasal dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26495166[PMID]
1975,1826,Frontometaphyseal dysplasia,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,ORPHANET
1975,1826,Frontometaphyseal dysplasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1968,2047,Flynn-Aird syndrome,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,5878601[PMID]
1968,2047,Flynn-Aird syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5878601[PMID]
1969,2048,Foix-Chavany-Marie syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,ORPHANET
1969,2048,Foix-Chavany-Marie syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1971,2050,Cole-Carpenter syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,25683117[PMID]
1971,2050,Cole-Carpenter syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25683117[PMID]
1982,2063,Splenogonadal fusion-limb defects-micrognathia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,10494091[PMID]_12884431[PMID]
1982,2063,Splenogonadal fusion-limb defects-micrognathia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10494091[PMID]_12884431[PMID]
1983,2064,Posterior fusion of lumbosacral vertebrae-blepharoptosis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,5443339[PMID]
1983,2064,Posterior fusion of lumbosacral vertebrae-blepharoptosis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5443339[PMID]
1976,250,Frontonasal dysplasia,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
1976,250,Frontonasal dysplasia,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 1 000 000,0.7,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
1978,2057,Blepharophimosis-ptosis-esotropia-syndactyly-short stature syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,1311991[PMID]
1978,2057,Blepharophimosis-ptosis-esotropia-syndactyly-short stature syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1311991[PMID]
1979,2059,Fryns syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.0,France,Validated,2650934[PMID]
1979,2059,Fryns syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1979,2059,Fryns syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.0,Europe,Validated,2650934[PMID]
1957,2026,Gingival fibromatosis-hypertrichosis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1956,2025,Gingival fibromatosis-facial dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,1493643[PMID]
1956,2025,Gingival fibromatosis-facial dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1493643[PMID]
1959,2028,Juvenile hyaline fibromatosis,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,70.0,Worldwide,Validated,DOI: 10.1016/j.jdds.2014.06.003[OTHER]
1959,2028,Juvenile hyaline fibromatosis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_DOI: 10.1016/j.jdds.2014.06.003[OTHER]
1958,2027,Gingival fibromatosis-progressive deafness syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,4061496[PMID]
1958,2027,Gingival fibromatosis-progressive deafness syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4061496[PMID]
1953,2021,Fibrochondrogenesis,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,24127948[PMID]
1953,2021,Fibrochondrogenesis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24127948[PMID]
1952,2019,Femur-fibula-ulna complex,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.5,Europe,Validated,[EXPERT]
1952,2019,Femur-fibula-ulna complex,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,[EXPERT]
1955,2024,Hereditary gingival fibromatosis,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,26818898[PMID]
1954,2022,Endocardial fibroelastosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1965,2824,Paraplegia-intellectual disability-hyperkeratosis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,23613454[PMID]
1965,2824,Paraplegia-intellectual disability-hyperkeratosis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1967,2045,FLOTCH syndrome,Disease,Disorder,Cases/families,Family(ies),,6.0,Worldwide,Validated,24816854[PMID]
1967,2045,FLOTCH syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24816854[PMID]
1966,2044,Floating-Harbor syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_30425916[PMID]
1961,2031,Hepatic fibrosis-renal cysts-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,3085498[PMID]_4430157[PMID]
1961,2031,Hepatic fibrosis-renal cysts-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3085498[PMID]_4430157[PMID]
1962,2036,Scalp-ear-nipple syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
1962,2036,Scalp-ear-nipple syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1942,2006,Median cleft lip/mandible,Morphological anomaly,Disorder,Cases/families,Case(s),,70.0,Worldwide,Validated,ORPHANET
1942,2006,Median cleft lip/mandible,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1943,2007,Alar cartilages hypoplasia-coloboma-telecanthus syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,1273139[PMID]
1943,2007,Alar cartilages hypoplasia-coloboma-telecanthus syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1273139[PMID]
1940,2003,Cleft lip/palate-deafness-sacral lipoma syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,2002486[PMID]
1940,2003,Cleft lip/palate-deafness-sacral lipoma syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2002486[PMID]
17237,158687,Lethal acantholytic erosive disorder,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,20613772[PMID]_20302578[PMID]
17237,158687,Lethal acantholytic erosive disorder,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20613772[PMID]_20302578[PMID]
17236,158684,Epidermolysis bullosa simplex with pyloric atresia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1941,2004,Laryngotracheoesophageal cleft,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.5,Europe,Validated,[EXPERT]
1941,2004,Laryngotracheoesophageal cleft,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1938,2001,Cleft lip/palate-intestinal malrotation-cardiopathy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,8779326[PMID]_9415467[PMID]
1938,2001,Cleft lip/palate-intestinal malrotation-cardiopathy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8779326[PMID]_9415467[PMID]
17235,158681,Epidermolysis bullosa simplex with circinate migratory erythema,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
17234,158676,"Localized dystrophic epidermolysis bullosa, nails only",Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
17234,158676,"Localized dystrophic epidermolysis bullosa, nails only",Clinical subtype,Subtype of disorder,Cases/families,Family(ies),,10.0,Worldwide,Validated,ORPHANET
17233,158673,"Localized dystrophic epidermolysis bullosa, acral form",Clinical subtype,Subtype of disorder,Cases/families,Family(ies),,10.0,Worldwide,Validated,ORPHANET
17233,158673,"Localized dystrophic epidermolysis bullosa, acral form",Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
17232,158668,Ectodermal dysplasia-skin fragility syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
1950,2016,Cleft palate-lateral synechia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,19368978[PMID]_24163560[PMID]
1950,2016,Cleft palate-lateral synechia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1951,2017,Sternal cleft,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.0,Europe,Validated,[EXPERT]
1951,2017,Sternal cleft,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,[EXPERT]
1949,2013,Cleft palate-large ears-small head syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,10449654[PMID]
1949,2013,Cleft palate-large ears-small head syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10449654[PMID]
1946,2010,Cleft palate-stapes fixation-oligodontia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,5173249[PMID]
1946,2010,Cleft palate-stapes fixation-oligodontia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5173249[PMID]
17241,158775,Smoldering systemic mastocytosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
1945,2008,Acrocardiofacial syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,20920258[PMID]_1746602[PMID]_15937946[PMID]
1945,2008,Acrocardiofacial syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20920258[PMID]
1926,1986,Gollop-Wolfgang complex,Malformation syndrome,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,ORPHANET_[EXPERT]
1926,1986,Gollop-Wolfgang complex,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
1923,1980,Bilateral striopallidodentate calcinosis,Disease,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,9065541[PMID]
1923,1980,Bilateral striopallidodentate calcinosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
1934,1997,Blepharo-cheilo-odontic syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,55.0,Worldwide,Validated,EXPERT_24719364[PMID]_28181393[PMID]
1934,1997,Blepharo-cheilo-odontic syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,EXPERT_ORPHANET
1932,1995,Cleft lip-retinopathy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8905195[PMID]
1932,1995,Cleft lip-retinopathy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
1931,1993,Pai syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,67.0,Worldwide,Validated,30195458[PMID]
1931,1993,Pai syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30195458[PMID]
1928,1988,Femoral-facial syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,62.0,Worldwide,Validated,25210574[PMID]
1928,1988,Femoral-facial syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25210574[PMID]
2200,2348,"Familial partial lipodystrophy, Dunnigan type",Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19545,247775,Mayer-Rokitansky-Küster-Hauser syndrome type 1,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Worldwide,Not yet validated,ORPHANET
2201,2351,Kousseff syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,22380655[PMID]
2201,2351,Kousseff syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22380655[PMID]
19544,247768,Müllerian aplasia and hyperandrogenism,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2202,2353,Schilbach-Rott syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,19921646[PMID]
2202,2353,Schilbach-Rott syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19921646[PMID]
19546,247790,FTH1-related iron overload,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,11389486[PMID]
19546,247790,FTH1-related iron overload,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11389486[PMID]
19548,247794,Juvenile cataract-microcornea-renal glucosuria syndrome,Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,18304496[PMID]
19548,247794,Juvenile cataract-microcornea-renal glucosuria syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18304496[PMID]
19551,247815,Autosomal recessive ataxia due to PEX10 deficiency,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,27230853[PMID]
19551,247815,Autosomal recessive ataxia due to PEX10 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27230853[PMID]
2207,2363,Lacrimoauriculodentodigital syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,23010692[PMID]_Pr MANOUVRIER-HANU Sylvie[EXPERT]
2207,2363,Lacrimoauriculodentodigital syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23010692[PMID]
19537,247691,Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2192,2340,Keratosis follicularis spinulosa decalvans,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
19536,247685,Odontohypophosphatasia,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2194,2342,Haim-Munk syndrome,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,ORPHANET
2194,2342,Haim-Munk syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19539,247709,Multiple endocrine neoplasia type 2B,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
2198,485,Kniest dysplasia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19542,247762,Lipoblastoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2199,2347,Lethal Kniest-like dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,6358440[PMID]
2199,2347,Lethal Kniest-like dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6358440[PMID]
19528,247585,Citrullinemia type II,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2185,2333,Kenny-Caffey syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,65.0,Worldwide,Validated,22522175[PMID]
2185,2333,Kenny-Caffey syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19529,247598,Neonatal intrahepatic cholestasis due to citrin deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2184,2332,KBG syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,164.0,Worldwide,Validated,21782149[PMID]_29565525[PMID]
2184,2332,KBG syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
19530,247604,Juvenile primary lateral sclerosis,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,ORPHANET
19530,247604,Juvenile primary lateral sclerosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
19531,247623,Perinatal lethal hypophosphatasia,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19532,247638,Prenatal benign hypophosphatasia,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2188,2337,"Diffuse palmoplantar keratoderma, Bothnian type",Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.5,Europe,Not yet validated,ORPHANET
19533,247651,Infantile hypophosphatasia,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19534,247667,Childhood-onset hypophosphatasia,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2191,2339,Keratosis follicularis-dwarfism-cerebral atrophy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,4834251[PMID]
2191,2339,Keratosis follicularis-dwarfism-cerebral atrophy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4834251[PMID]
19535,247676,Adult hypophosphatasia,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2190,494,Keratoderma hereditarium mutilans,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,19282408[PMID]
2190,494,Keratoderma hereditarium mutilans,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19282408[PMID]
2177,2322,Kabuki syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.16,New Zealand,Validated,15108197[PMID]
2177,2322,Kabuki syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.16,Australia,Validated,15108197[PMID]
2177,2322,Kabuki syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.1,Europe,Validated,[EXPERT]_21882399[PMID]
2177,2322,Kabuki syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.1,Japan,Validated,3067577[PMID]
19521,247378,Autosomal recessive secondary polycythemia not associated with VHL gene,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2176,2321,Jung syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,7537583[PMID]
2176,2321,Jung syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7537583[PMID]
2179,2324,Osteopenia-intellectual disability-sparse hair syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,1415349[PMID]
2179,2324,Osteopenia-intellectual disability-sparse hair syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1415349[PMID]
19522,247511,Autosomal dominant secondary polycythemia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2178,2323,Sanjad-Sakati syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19523,247522,Primary ciliary dyskinesia-retinitis pigmentosa syndrome,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,ORPHANET
19523,247522,Primary ciliary dyskinesia-retinitis pigmentosa syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19524,247525,Citrullinemia type I,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.4,Europe,Validated,European Medicines Agency 2012[INST]
19524,247525,Citrullinemia type I,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.28,Austria,Validated,20938748[PMID]
19524,247525,Citrullinemia type I,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.5,"Korea, Republic of",Validated,15906713[PMID]
19524,247525,Citrullinemia type I,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.84,"Taiwan, Province of China",Validated,20567911[PMID]
19524,247525,Citrullinemia type I,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.13,United States,Not yet validated,ISBN:79130356[OTHER]_15906712[PMID]_ ORPHANET
2180,2325,Epidermolysis bullosa simplex with anodontia/hypodontia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2180,2325,Epidermolysis bullosa simplex with anodontia/hypodontia,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,2420118[PMID]_7911628[PMID]_25251718[PMID]
2183,2329,Karsch-Neugebauer syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,9450888[PMID]_23066244[PMID]
2183,2329,Karsch-Neugebauer syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9450888[PMID]_23066244[PMID]
19527,247582,Citrin deficiency,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2182,2328,Kapur-Toriello syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,1776630[PMID]_10319207[PMID]_18831061[PMID]_20358618[PMID]_26049588[PMID]
2182,2328,Kapur-Toriello syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1776630[PMID]_10319207[PMID]_18831061[PMID]_20358618[PMID]_26049588[PMID]
2234,2408,Lowe-Kohn-Cohen syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,6627722[PMID]
2234,2408,Lowe-Kohn-Cohen syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6627722[PMID]
2235,2409,Lowry-MacLean syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,9415481[PMID]
2235,2409,Lowry-MacLean syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9415481[PMID]
2232,2405,Thickened earlobes-conductive deafness syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,5657116[PMID]_5428055[PMID]
2232,2405,Thickened earlobes-conductive deafness syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5657116[PMID]_5428055[PMID]
2233,2407,Laryngo-onycho-cutaneous syndrome,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,[EXPERT]
2233,2407,Laryngo-onycho-cutaneous syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2239,2412,Dislocation of the hip-dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,8574416[PMID]
2239,2412,Dislocation of the hip-dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8574416[PMID]
2236,2575,Cystic fibrosis-gastritis-megaloblastic anemia syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,2029916[PMID]
2236,2575,Cystic fibrosis-gastritis-megaloblastic anemia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2029916[PMID]
2237,2410,Hypergonadotropic hypogonadism-cataract syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,6418006[PMID]
2237,2410,Hypergonadotropic hypogonadism-cataract syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6418006[PMID]
2226,2399,Nasopalpebral lipoma-coloboma syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,27139419[PMID]_ORPHANET
2226,2399,Nasopalpebral lipoma-coloboma syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2227,2400,Peripheral motor neuropathy-dysautonomia syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,7282784[PMID]
2227,2400,Peripheral motor neuropathy-dysautonomia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7282784[PMID]
2225,2396,Encephalocraniocutaneous lipomatosis,Disease,Disorder,Cases/families,Case(s),,77.0,Worldwide,Validated,24881613[PMID]
2225,2396,Encephalocraniocutaneous lipomatosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2219,2388,Choreoacanthocytosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19562,248111,Juvenile Huntington disease,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.04,Europe,Validated,[EXPERT]
19562,248111,Juvenile Huntington disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.6,Europe,Validated,[EXPERT]
2217,2386,Leukoencephalopathy-palmoplantar keratoderma syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,7854535[PMID]
2217,2386,Leukoencephalopathy-palmoplantar keratoderma syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7854535[PMID]
19561,248095,Primary hypertrophic osteoarthropathy,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2216,2379,Early-onset parkinsonism-intellectual disability syndrome,Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,4025396[PMID]_25434005[PMID]
2216,2379,Early-onset parkinsonism-intellectual disability syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4025396[PMID]_25434005[PMID]
2222,2391,Congenitally short costocoracoid ligament,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,2596500[PMID]
2222,2391,Congenitally short costocoracoid ligament,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2596500[PMID]
2221,2390,Lichtenstein syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,Lichtenstein 1972[AUTHOR]
2221,2390,Lichtenstein syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19554,247834,Occult macular dystrophy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2211,2371,Lethal Larsen-like syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,19014058[PMID]
2211,2371,Lethal Larsen-like syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19014058[PMID]
2210,2369,Limb body wall complex,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.0,Australia,Validated,12420845[PMID]
2210,2369,Limb body wall complex,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
2210,2369,Limb body wall complex,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.5,Japan,Validated,8092190[PMID]
19552,247820,Ectodermal dysplasia-pili torti-cutaneous syndactyly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,25529316[PMID]
19552,247820,Ectodermal dysplasia-pili torti-cutaneous syndactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25529316[PMID]
19553,247827,Ectodermal dysplasia-hyperhidrosis-cutaneous syndactyly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,19221800[PMID]
19553,247827,Ectodermal dysplasia-hyperhidrosis-cutaneous syndactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19221800[PMID]
2215,2378,Laurin-Sandrow syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,18792985[PMID]
2215,2378,Laurin-Sandrow syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18792985[PMID]
19559,247868,NLRP12-associated hereditary periodic fever syndrome,Disease,Disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,24131530[PMID]
19559,247868,NLRP12-associated hereditary periodic fever syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24131530[PMID]
2213,2375,Laryngeal abductor paralysis-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,ORPHANET
2213,2375,Laryngeal abductor paralysis-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2271,2457,Mandibuloacral dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,24123119[PMID]
2271,2457,Mandibuloacral dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24123119[PMID]
2266,2451,Mucocutaneous venous malformations,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
2260,2439,Patterson-Stevenson-Fontaine syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,9098499[PMID]
2260,2439,Patterson-Stevenson-Fontaine syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9098499[PMID]
19477,244305,Dominant hypophosphatemia with nephrolithiasis or osteoporosis,Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,12324554[PMID]_18784102[PMID]_26787776[PMID]_29924459[PMID]
19477,244305,Dominant hypophosphatemia with nephrolithiasis or osteoporosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29924459[PMID]
19476,244283,Biliary atresia with splenic malformation syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2261,2440,Isolated split hand-split foot malformation,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.4,Europe,Validated,8766141[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
2261,2440,Isolated split hand-split foot malformation,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,16.4,China,Validated,20506663[PMID]
2261,2440,Isolated split hand-split foot malformation,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.1,Canada,Validated,20506663[PMID]
2261,2440,Isolated split hand-split foot malformation,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.0,Hungary,Validated,ISBN:9630566311[OTHER]
2261,2440,Isolated split hand-split foot malformation,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.0,United States,Validated,11581472[PMID]
2261,2440,Isolated split hand-split foot malformation,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
19478,244310,RFT1-CDG,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,23111317[PMID]
19478,244310,RFT1-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23111317[PMID]
19473,244242,HELLP syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
2257,296,Ollier disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,16995932[PMID]
2258,2437,Czeizel-Losonci syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,3308683[PMID]
2258,2437,Czeizel-Losonci syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3308683[PMID]
19474,244275,De novo thrombotic microangiopathy after kidney transplantation,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19468,243343,Dimethylglycine dehydrogenase deficiency,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,10102904[PMID]
19468,243343,Dimethylglycine dehydrogenase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10102904[PMID]
2255,2435,Hypo- and hypermelanotic cutaneous macules-retarded growth-intellectual disability syndrome,Disease,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,666331[PMID]
2255,2435,Hypo- and hypermelanotic cutaneous macules-retarded growth-intellectual disability syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_666331[PMID]
2249,2429,Macrocephaly-spastic paraplegia-dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2251,2432,Macrosomia-microphthalmia-cleft palate syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,2791331[PMID]
2251,2432,Macrosomia-microphthalmia-cleft palate syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2791331[PMID]
2302,2489,Upper limb defect-eye and ear abnormalities syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,1518028[PMID]
2302,2489,Upper limb defect-eye and ear abnormalities syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1518028[PMID]
19519,247353,Generalized pustular psoriasis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.18,France,Validated,17229609[PMID]
19519,247353,Generalized pustular psoriasis,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
19518,247262,Hyperphosphatasia-intellectual disability syndrome,Disease,Disorder,Cases/families,Case(s),,24.0,Worldwide,Validated,ORPHANET
19518,247262,Hyperphosphatasia-intellectual disability syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2300,2487,Lower limb malformation-hypospadias syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,592351[PMID]
2300,2487,Lower limb malformation-hypospadias syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_592351[PMID]
19517,247257,Inhalational anthrax,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,European Medicines Agency 2018[INST]
19516,247245,Superficial siderosis,Disease,Disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,20083040[PMID]
19516,247245,Superficial siderosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
2298,2485,Melorheostosis,Malformation syndrome,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.09,Europe,Validated,9040882[PMID]
19513,247234,Sporadic adult-onset ataxia of unknown etiology,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.6,Europe,Not yet validated,20083040[PMID]
19513,247234,Sporadic adult-onset ataxia of unknown etiology,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.9,Italy,Validated,7793232[PMID]
19513,247234,Sporadic adult-onset ataxia of unknown etiology,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.4,United Kingdom,Validated,15258214[PMID]
2296,2483,Melkersson-Rosenthal syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19512,247203,Collecting duct carcinoma,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
2297,2484,Melnick-Needles syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,70.0,Worldwide,Validated,ORPHANET
2297,2484,Melnick-Needles syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19511,247198,Progressive cerebello-cerebral atrophy,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,12920088[PMID]_25044680[PMID]
19511,247198,Progressive cerebello-cerebral atrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12920088[PMID]_25044680[PMID]
2294,2481,Neurocutaneous melanocytosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.25,Europe,Validated,[EXPERT]
2295,2482,Melhem-Fahl syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,3969298[PMID]
2295,2482,Melhem-Fahl syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3969298[PMID]
19510,247165,Infantile mercury poisoning,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2288,2475,White forelock with malformations,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7398117[PMID]
2288,2475,White forelock with malformations,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,7398117[PMID]
2289,2476,Dysraphism-cleft lip/palate-limb reduction defects syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,7981865[PMID]
2289,2476,Dysraphism-cleft lip/palate-limb reduction defects syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7981865[PMID]
2286,2473,McKusick-Kaufman syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_20301675[PMID]
2286,2473,McKusick-Kaufman syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,90.0,Worldwide,Validated,20301675[PMID]
2286,2473,McKusick-Kaufman syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,10.0,Specific population,Validated,20301675[PMID]
2284,2471,McDonough syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,6147215[PMID]_1189520[PMID]
2284,2471,McDonough syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6147215[PMID]_1189520[PMID]
2283,2470,Matthew-Wood syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,43.0,Worldwide,Validated,26373900[PMID]
2283,2470,Matthew-Wood syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26373900[PMID]
2279,561,Marshall-Smith syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,74.0,Worldwide,Validated,34925682[PMID]_ORPHANET
2279,561,Marshall-Smith syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2278,2464,"Marfanoid syndrome, De Silva type",Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,13880014[PMID]_8976669[PMID]
2278,2464,"Marfanoid syndrome, De Silva type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_13880014[PMID]_8976669[PMID]
2277,559,Marinesco-Sjögren syndrome,Disease,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,ORPHANET
2277,559,Marinesco-Sjögren syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2276,2463,Marfanoid habitus-autosomal recessive intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,6705253[PMID]
2276,2463,Marfanoid habitus-autosomal recessive intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6705253[PMID]
2275,2462,Shprintzen-Goldberg syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,20301454[PMID]
2275,2462,Shprintzen-Goldberg syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20301454[PMID]
2273,2461,Marden-Walker syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,ORPHANET
2273,2461,Marden-Walker syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2273,2461,Marden-Walker syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.5,Belgium,Validated,[EXPERT]
19664,251630,Anaplastic oligodendroglioma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.09,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
19664,251630,Anaplastic oligodendroglioma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.11,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
2065,2172,Microcephaly-glomerulonephritis-marfanoid habitus syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,1345513[PMID]
2065,2172,Microcephaly-glomerulonephritis-marfanoid habitus syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1345513[PMID]
19666,251636,Ependymoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.16,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
19666,251636,Ependymoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
19667,251639,Subependymoma,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
2069,2176,Infantile systemic hyalinosis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25754064[PMID]
19668,251643,Myxopapillary ependymoma,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
19668,251643,Myxopapillary ependymoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
19669,251646,Anaplastic ependymoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.04,United States,Validated,23660944[PMID]
19670,251651,Oligoastrocytic tumor,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.11,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
19670,251651,Oligoastrocytic tumor,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.19,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
2071,2181,Hydrocephaly-tall stature-joint laxity syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,2918526[PMID]
2071,2181,Hydrocephaly-tall stature-joint laxity syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2918526[PMID]
2070,2180,Hydrocephalus-costovertebral dysplasia-Sprengel anomaly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,8585573[PMID]_6893487[PMID]
2070,2180,Hydrocephalus-costovertebral dysplasia-Sprengel anomaly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8585573[PMID]_6893487[PMID]
2072,2186,Hydrocephalus-blue sclerae-nephropathy syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,728573[PMID]
2072,2186,Hydrocephalus-blue sclerae-nephropathy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_728573[PMID]
19674,251671,Angiocentric glioma,Disease,Disorder,Cases/families,Case(s),,52.0,Worldwide,Validated,24348765[PMID]
19674,251671,Angiocentric glioma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,24348765[PMID]
2075,2189,Hydrolethalus,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.0,Finland,Validated,11152149[PMID]
2075,2189,Hydrolethalus,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Finland,Not yet validated,11152149[PMID]
2075,2189,Hydrolethalus,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
19676,251679,Astroblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
2079,312,Autosomal dominant epidermolytic ichthyosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.4317,Japan,Validated,23182068[PMID]
2079,312,Autosomal dominant epidermolytic ichthyosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
2079,312,Autosomal dominant epidermolytic ichthyosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.29,Denmark,Validated,22930352[PMID]
2079,312,Autosomal dominant epidermolytic ichthyosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.65,United States,Not yet validated,8053700[PMID]_7692917[PMID]_ ORPHANET
2079,312,Autosomal dominant epidermolytic ichthyosis,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
2078,2196,Primary hypomagnesemia with hypercalciuria and nephrocalcinosis with severe ocular involvement,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,72.0,Worldwide,Validated,[EXPERT]
2078,2196,Primary hypomagnesemia with hypercalciuria and nephrocalcinosis with severe ocular involvement,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
19679,251852,Embryonal tumor of neuroepithelial tissue,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.22,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
19649,251576,Gliosarcoma,Histopathological subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.03,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
2050,2150,Hirschsprung disease-type D brachydactyly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,6823428[PMID]
2050,2150,Hirschsprung disease-type D brachydactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6823428[PMID]
19651,251582,Gliomatosis cerebri,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
19650,251579,Giant cell glioblastoma,Histopathological subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
2051,2152,Mowat-Wilson syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,35646055[PMID]_ORPHANET
2051,2152,Mowat-Wilson syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.7,Europe,Validated,21343952[PMID]_20301585[PMID]_ ISBN:470191414[OTHER]
2052,2153,Hirschsprung disease-nail hypoplasia-dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,3236354[PMID]
2052,2153,Hirschsprung disease-nail hypoplasia-dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19652,251589,Anaplastic astrocytoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.4,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
19655,251598,Protoplasmic astrocytoma,Histopathological subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
2054,2155,Hirschsprung disease-deafness-polydactyly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,3351909[PMID]
2054,2155,Hirschsprung disease-deafness-polydactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3351909[PMID]
19654,251595,Diffuse astrocytoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.48,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
2057,2158,Histidinuria-renal tubular defect syndrome,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,1481808[PMID]
2057,2158,Histidinuria-renal tubular defect syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1481808[PMID]
19659,251612,Pilocytic astrocytoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.36,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
2058,2163,Holoprosencephaly-craniosynostosis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,20104614[PMID]
2058,2163,Holoprosencephaly-craniosynostosis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20104614[PMID]
19658,251607,Pleomorphic xanthoastrocytoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
2060,2165,Holoprosencephaly-caudal dysgenesis syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.9,Spain,Validated,7802035[PMID]
2060,2165,Holoprosencephaly-caudal dysgenesis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Spain,Validated,ORPHANET
2061,2166,Holoprosencephaly-postaxial polydactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19663,251627,Oligodendroglioma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.25,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
2062,2167,Holzgreve syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,6741992[PMID]_3309184[PMID]_3232694[PMID]
2062,2167,Holzgreve syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6741992[PMID]_3309184[PMID]_3232694[PMID]
2063,2169,Methylcobalamin deficiency type cblE,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,27.0,Worldwide,Validated,ORPHANET
2063,2169,Methylcobalamin deficiency type cblE,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2098,2222,Hypertrichosis lanuginosa congenita,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,ORPHANET
2098,2222,Hypertrichosis lanuginosa congenita,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2097,2220,Hypertrichosis cubiti,Malformation syndrome,Disorder,Cases/families,Case(s),,28.0,Worldwide,Validated,16355816[PMID]
2097,2220,Hypertrichosis cubiti,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2103,1051,Ramos-Arroyo syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,21910235[PMID]
2103,1051,Ramos-Arroyo syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2102,2228,Hypodontia-dysplasia of nails syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2100,2224,Hypertryptophanemia,Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,[EXPERT]
2100,2224,Hypertryptophanemia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2107,2232,Primary hypergonadotropic hypogonadism-partial alopecia syndrome,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,19213036[PMID]
2107,2232,Primary hypergonadotropic hypogonadism-partial alopecia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19213036[PMID]
2105,2230,Hypogonadotropic hypogonadism-frontoparietal alopecia syndrome,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,466617[PMID]
2105,2230,Hypogonadotropic hypogonadism-frontoparietal alopecia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_466617[PMID]
2104,2229,Dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,20.0,Worldwide,Validated,ORPHANET
2104,2229,Dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2111,2238,Familial isolated hypoparathyroidism,Disease,Disorder,Cases/families,Family(ies),,10.0,Worldwide,Validated,ORPHANET
2111,2238,Familial isolated hypoparathyroidism,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2110,2237,Hypoparathyroidism-sensorineural deafness-renal disease syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_29663634[PMID]
2110,2237,Hypoparathyroidism-sensorineural deafness-renal disease syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,180.0,Worldwide,Validated,29663634[PMID]
2109,2235,Hypogonadotropic hypogonadism-retinitis pigmentosa syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,6795223[PMID]
2109,2235,Hypogonadotropic hypogonadism-retinitis pigmentosa syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6795223[PMID]
2108,2234,Male hypergonadotropic hypogonadism-intellectual disability-skeletal anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,13030490[PMID]
2108,2234,Male hypergonadotropic hypogonadism-intellectual disability-skeletal anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_13030490[PMID]
19682,251863,Desmoplastic/nodular medulloblastoma,Histopathological subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
2080,2198,Palmoplantar keratoderma-esophageal carcinoma syndrome,Disease,Disorder,Cases/families,Family(ies),,10.0,Worldwide,Validated,ORPHANET
2080,2198,Palmoplantar keratoderma-esophageal carcinoma syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2087,2206,Ankylosing vertebral hyperostosis with tylosis,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,5346342[PMID]
2087,2206,Ankylosing vertebral hyperostosis with tylosis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5346342[PMID]
2084,2201,Palmoplantar keratoderma-spastic paralysis syndrome,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,6227331[PMID]
2084,2201,Palmoplantar keratoderma-spastic paralysis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6227331[PMID]
2085,2202,Palmoplantar keratoderma-deafness syndrome,Disease,Disorder,Cases/families,Family(ies),,10.0,Worldwide,Validated,ORPHANET
2085,2202,Palmoplantar keratoderma-deafness syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19684,251870,Central nervous system embryonal tumor,Clinical group,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.07,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
19690,251899,Choroid plexus carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Europe,Validated,2033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
19690,251899,Choroid plexus carcinoma,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,2033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
19690,251899,Choroid plexus carcinoma,Disease,Disorder,Lifetime Prevalence,Value and class,1-9 / 1 000 000,0.35,Europe,Validated,2033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
2091,2213,Hypertelorism-microtia-facial clefting syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,11152141[PMID]
2091,2213,Hypertelorism-microtia-facial clefting syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11152141[PMID]
19689,251896,Choroid plexus tumor,Clinical group,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.05,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
2089,2211,Hypertelorism-hypospadias-polysyndactyly syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,18553510[PMID]
2089,2211,Hypertelorism-hypospadias-polysyndactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18553510[PMID]
2095,2218,Cervical hypertrichosis-peripheral neuropathy syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,1666396[PMID]_8281287[PMID]
2095,2218,Cervical hypertrichosis-peripheral neuropathy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1666396[PMID]_8281287[PMID]
19693,251909,Pineoblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
2092,2215,Multiple pterygium-malignant hyperthermia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,3346884[PMID]
2092,2215,Multiple pterygium-malignant hyperthermia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3346884[PMID]
19604,251019,2q32q33 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,25.0,Worldwide,Validated,[EXPERT]
19604,251019,2q32q33 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2133,2266,"Hypotrichosis-intellectual disability, Lopes type",Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8652088[PMID]
2133,2266,"Hypotrichosis-intellectual disability, Lopes type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8652088[PMID]
19605,251028,SATB2-associated syndrome due to a chromosomal rearrangement,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,21343628[PMID]
19605,251028,SATB2-associated syndrome due to a chromosomal rearrangement,Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
2135,2269,Ichthyosis-alopecia-eclabion-ectropion-intellectual disability syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,3829441[PMID]
2135,2269,Ichthyosis-alopecia-eclabion-ectropion-intellectual disability syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3829441[PMID]
19607,251038,3q29 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19600,250999,1q41q42 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2129,2261,"Hypospadias-intellectual disability, Goldblatt type syndrome",Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,3673966[PMID]
2129,2261,"Hypospadias-intellectual disability, Goldblatt type syndrome",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3673966[PMID]
19601,251004,Paternal uniparental disomy of chromosome 1 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19602,251009,Maternal uniparental disomy of chromosome 1 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2130,672,Pallister-Hall syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,20301638[PMID]
2130,672,Pallister-Hall syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20301638[PMID]
19603,251014,2q31.1 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2141,455,Superficial epidermolytic ichthyosis,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,ORPHANET
2141,455,Superficial epidermolytic ichthyosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19612,251061,7q31 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,27075776[PMID]
19612,251061,7q31 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27075776[PMID]
19613,251066,8p11.2 deletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,15948194[PMID]
19613,251066,8p11.2 deletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15948194[PMID]
2140,2272,Ichthyosis-oral and digital anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,2732996[PMID]
2140,2272,Ichthyosis-oral and digital anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2732996[PMID]
19614,251071,8p23.1 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2143,2274,Ichthyosis-hepatosplenomegaly-cerebellar degeneration syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,444432[PMID]
2143,2274,Ichthyosis-hepatosplenomegaly-cerebellar degeneration syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_444432[PMID]
19615,251076,8p23.1 duplication syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.72,Worldwide,Validated,23345203[PMID]
2142,2273,Ichthyosis follicularis-alopecia-photophobia syndrome,Disease,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,21600032[PMID]
2142,2273,Ichthyosis follicularis-alopecia-photophobia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19608,251043,Ring chromosome 5 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2137,165,Neutral lipid storage disease,Clinical group,Group of disorders,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2137,165,Neutral lipid storage disease,Clinical group,Group of disorders,Cases/families,Case(s),,50.0,Worldwide,Validated,ORPHANET
2136,139,CHILD syndrome,Disease,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,20929975[PMID]
2136,139,CHILD syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19609,251046,6p22 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,23294540[PMID]
19609,251046,6p22 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2139,457,Harlequin ichthyosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_24920541[PMID]
2139,457,Harlequin ichthyosis,Disease,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,24920541[PMID]
2138,2271,Congenital ichthyosis-microcephalus-tetraplegia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7619196[PMID]
2138,2271,Congenital ichthyosis-microcephalus-tetraplegia syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,7619196[PMID]
19611,251056,6q25.2q25.3 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,19034313[PMID]
19611,251056,6q25.2q25.3 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19034313[PMID]
2117,2246,Cerebellar hypoplasia-tapetoretinal degeneration syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,1622524[PMID]
2117,2246,Cerebellar hypoplasia-tapetoretinal degeneration syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1622524[PMID]
2119,2249,Ulna hypoplasia-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,7625433[PMID]
2119,2249,Ulna hypoplasia-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7625433[PMID]
2112,2239,Familial isolated hypoparathyroidism due to agenesis of parathyroid gland,Clinical subtype,Subtype of disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,14431322[PMID]_8981958[PMID]
2112,2239,Familial isolated hypoparathyroidism due to agenesis of parathyroid gland,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_14431322[PMID]_8981958[PMID]
2113,2241,Megacystis-microcolon-intestinal hypoperistalsis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,230.0,Worldwide,Validated,[EXPERT]
2113,2241,Megacystis-microcolon-intestinal hypoperistalsis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
19597,250984,Autosomal recessive Stickler syndrome,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,16909383[PMID]_ 21421862[PMID]_21671392[PMID]
19597,250984,Autosomal recessive Stickler syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16909383[PMID]_ 21421862[PMID]_21671392[PMID]
2124,2256,Fibulo-ulnar hypoplasia-renal anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,2773984[PMID]
2124,2256,Fibulo-ulnar hypoplasia-renal anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2773984[PMID]
19596,250977,AICA-ribosiduria,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,15114530[PMID]_32557644[PMID]
19596,250977,AICA-ribosiduria,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15114530[PMID]_32557644[PMID]
19599,250994,1q21.1 microduplication syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,46.0,Worldwide,Validated,ORPHANET
19599,250994,1q21.1 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19598,250989,1q21.1 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2120,2250,Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,6802865[PMID]
2120,2250,Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6802865[PMID]
19593,250923,Isolated aniridia,Morphological anomaly,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.31,Europe,Validated,[EXPERT]_ORPHANET
19593,250923,Isolated aniridia,Morphological anomaly,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.38,Norway,Validated,18494745[PMID]
19593,250923,Isolated aniridia,Morphological anomaly,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.38,Sweden,Validated,18494745[PMID]
19593,250923,Isolated aniridia,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
2121,2251,Thumb deformity-alopecia-pigmentation anomaly syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,3344769[PMID]
2121,2251,Thumb deformity-alopecia-pigmentation anomaly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3344769[PMID]
2122,2252,Radial hypoplasia-triphalangeal thumbs-hypospadias-maxillary diastema syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,7137222[PMID]
2122,2252,Radial hypoplasia-triphalangeal thumbs-hypospadias-maxillary diastema syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7137222[PMID]
19595,250972,Polymicrogyria with optic nerve hypoplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,19896110[PMID]
19595,250972,Polymicrogyria with optic nerve hypoplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19896110[PMID]
2123,2255,Pancreatic hypoplasia-diabetes-congenital heart disease syndrome,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,ORPHANET
2123,2255,Pancreatic hypoplasia-diabetes-congenital heart disease syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19638,251380,Hereditary persistence of fetal hemoglobin-sickle cell disease syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,10.6,United States,Validated,22766612[PMID]
19638,251380,Hereditary persistence of fetal hemoglobin-sickle cell disease syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
2167,2306,Isotretinoin-like syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,15602090[PMID]
2167,2306,Isotretinoin-like syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15602090[PMID]
19639,251383,CK syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,24.0,Worldwide,Validated,21290788[PMID]
19639,251383,CK syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21290788[PMID]
2166,2305,Isotretinoin syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19636,251370,Sickle cell-hemoglobin D disease syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19637,251375,Sickle cell-hemoglobin E disease syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19634,251359,Sickle cell-beta-thalassemia disease syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19635,251365,Sickle cell-hemoglobin C disease syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2162,2295,Familial articular hypermobility syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2175,2319,Juberg-Hayward syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,22811276[PMID]
2175,2319,Juberg-Hayward syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22811276[PMID]
19644,251523,Hyperzincemia and hypercalprotectinemia,Disease,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,12480428[PMID]_DOI: 10.1007/978-3-319-96929-9_4[OTHER]
19644,251523,Hyperzincemia and hypercalprotectinemia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_DOI: 10.1007/978-3-319-96929-9_4[OTHER]
2173,2316,Johnson neuroectodermal syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2172,2315,Johanson-Blizzard syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.4,Europe,Validated,16311597[PMID]
2172,2315,Johanson-Blizzard syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
19642,251510,"46,XY partial gonadal dysgenesis",Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19643,251515,Distal arthrogryposis type 10,Malformation syndrome,Disorder,Cases/families,Case(s),,53.0,Worldwide,Validated,17103435[PMID]
19643,251515,Distal arthrogryposis type 10,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2170,2310,Absence deformity of leg-cataract syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,5694533[PMID]
2170,2310,Absence deformity of leg-cataract syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5694533[PMID]
2169,2309,Pachyonychia congenita,Disease,Disorder,Cases/families,Case(s),,1000.0,Worldwide,Validated,[EXPERT]
2169,2309,Pachyonychia congenita,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
19640,251393,Localized junctional epidermolysis bullosa,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,[EXPERT]
19640,251393,Localized junctional epidermolysis bullosa,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2168,2307,IVIC syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,4.0,Worldwide,Validated,17256792[PMID]
2168,2307,IVIC syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19623,251295,Pigmented paravenous retinochoroidal atrophy,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,24926324[PMID]
19623,251295,Pigmented paravenous retinochoroidal atrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24926324[PMID]
19622,251290,Parietal foramina with clavicular hypoplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,14571277[PMID]
19622,251290,Parietal foramina with clavicular hypoplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_14571277[PMID]
2151,2282,Dysmorphism-short stature-deafness-difference of sex development syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,3757305[PMID]
2151,2282,Dysmorphism-short stature-deafness-difference of sex development syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3757305[PMID]
19621,251287,Benign concentric annular macular dystrophy,Disease,Disorder,Cases/families,Case(s),,27.0,Worldwide,Validated,ORPHANET
19621,251287,Benign concentric annular macular dystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19620,251282,Autosomal dominant spastic ataxia type 1,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22958904[PMID]
19620,251282,Autosomal dominant spastic ataxia type 1,Disease,Disorder,Cases/families,Case(s),,53.0,Worldwide,Validated,22958904[PMID]
19619,251279,Microphthalmia-retinitis pigmentosa-foveoschisis-optic disc drusen syndrome,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,19753314[PMID]
19619,251279,Microphthalmia-retinitis pigmentosa-foveoschisis-optic disc drusen syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19753314[PMID]
19618,251274,Familial hyperaldosteronism type III,Disease,Disorder,Cases/families,Family(ies),,7.0,Worldwide,Validated,24037882[PMID]
19618,251274,Familial hyperaldosteronism type III,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2147,2278,Ichthyosis-intellectual disability-dwarfism-renal impairment syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,1149323[PMID]
2147,2278,Ichthyosis-intellectual disability-dwarfism-renal impairment syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_ 1149323[PMID]
19616,251262,Familial osteochondritis dissecans,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19631,251347,Ataxia-telangiectasia-like disorder,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2156,2289,Neuronal intranuclear inclusion disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2157,2290,Microvillus inclusion disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,16800870[PMID]
2157,2290,Microvillus inclusion disease,Disease,Disorder,Cases/families,Case(s),,137.0,Worldwide,Validated,24014347[PMID]
2157,2290,Microvillus inclusion disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24014347[PMID]
2152,2285,Primary basilar invagination,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19625,251307,Idiopathic recurrent pericarditis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19624,251304,Infantile onset panniculitis with uveitis and systemic granulomatosis,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,18035159[PMID]
19624,251304,Infantile onset panniculitis with uveitis and systemic granulomatosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18035159[PMID]
2442,2674,Cyprus facial-neuromusculoskeletal syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,1481843[PMID]
2442,2674,Cyprus facial-neuromusculoskeletal syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1481843[PMID]
2441,2673,Neurofaciodigitorenal syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,7081297[PMID]_9354842[PMID]
2441,2673,Neurofaciodigitorenal syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7081297[PMID]
2440,2672,Neuhauser-Eichner-Opitz syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,6859111[PMID]
2440,2672,Neuhauser-Eichner-Opitz syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6859111[PMID]
2446,2678,Familial isolated café-au-lait macules,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2435,2668,Nephropathy-deafness-hyperparathyroidism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,2732989[PMID]
2435,2668,Nephropathy-deafness-hyperparathyroidism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2732989[PMID]
2434,2663,Nathalie syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,1204231[PMID]
2434,2663,Nathalie syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1204231[PMID]
2433,2662,Keipert syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,21567928[PMID]
2433,2662,Keipert syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21567928[PMID]
2439,2671,Neu-Laxova syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,91.0,Worldwide,Validated,25152457[PMID]_24371398[PMID]
2439,2671,Neu-Laxova syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25152457[PMID]_24371398[PMID]
2438,1475,Renal coloboma syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,180.0,Worldwide,Validated,22213154[PMID]
2438,1475,Renal coloboma syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
2437,2670,Pierson syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,98.0,Worldwide,Validated,29051055[PMID]
2437,2670,Pierson syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,29051055[PMID]_ORPHANET
2436,2669,Nephrosis-deafness-urinary tract-digital malformations syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,13872585[PMID]
2436,2669,Nephrosis-deafness-urinary tract-digital malformations syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_13872585[PMID]
19803,254930,Combined oxidative phosphorylation defect type 7,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,24284555[PMID]
19803,254930,Combined oxidative phosphorylation defect type 7,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24284555[PMID]
19802,254925,Combined oxidative phosphorylation defect type 4,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,17160893[PMID]
19802,254925,Combined oxidative phosphorylation defect type 4,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17160893[PMID]
2459,2697,Arthrogryposis-renal dysfunction-cholestasis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,ORPHANET
2459,2697,Arthrogryposis-renal dysfunction-cholestasis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19801,254920,Combined oxidative phosphorylation defect type 2,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,15505824[PMID]
19801,254920,Combined oxidative phosphorylation defect type 2,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15505824[PMID]
2457,2695,Bifid nose,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
19807,255182,Pyruvate dehydrogenase E3-binding protein deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2462,2701,Noonan syndrome-like disorder with loose anagen hair,Malformation syndrome,Disorder,Cases/families,Case(s),,70.0,Worldwide,Validated,ORPHANET
2462,2701,Noonan syndrome-like disorder with loose anagen hair,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19806,255138,Pyruvate dehydrogenase E1-beta deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19805,255132,Adult-onset autosomal recessive sideroblastic anemia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17485548[PMID]_25342667[PMID]
19805,255132,Adult-onset autosomal recessive sideroblastic anemia,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,17485548[PMID]_25342667[PMID]
2460,2698,Knuckle pads-leukonychia-sensorineural deafness-palmoplantar hyperkeratosis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22421650[PMID]
2461,2699,Median nodule of the upper lip,Malformation syndrome,Disorder,Cases/families,Family(ies),,4.0,Worldwide,Validated,8030663[PMID]_1068420[PMID]
2461,2699,Median nodule of the upper lip,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,8030663[PMID]_1068420[PMID]_ORPHANET
19793,254875,"Mitochondrial DNA depletion syndrome, myopathic form",Disease,Disorder,Cases/families,Case(s),,45.0,Worldwide,Validated,23230576[PMID]
19793,254875,"Mitochondrial DNA depletion syndrome, myopathic form",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23230576[PMID]
2452,2690,Neutropenia-monocytopenia-deafness syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,6604450[PMID]
2452,2690,Neutropenia-monocytopenia-deafness syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6604450[PMID]
19797,254898,Deafness-encephaloneuropathy-obesity-valvulopathy syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,17332895[PMID]
19797,254898,Deafness-encephaloneuropathy-obesity-valvulopathy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17332895[PMID]
2473,2712,Oculofaciocardiodental syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2475,2714,Oculo-palato-cerebral syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,3995792[PMID]_11241490[PMID]_15368502[PMID]
2475,2714,Oculo-palato-cerebral syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3995792[PMID]_11241490[PMID]_15368502[PMID]
2474,2713,Oculoosteocutaneous syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,4974459[PMID]
2474,2713,Oculoosteocutaneous syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4974459[PMID]
2476,2715,Severe oculo-renal-cerebellar syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,7091183[PMID]
2476,2715,Severe oculo-renal-cerebellar syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7091183[PMID]
2479,2718,Oculotrichodysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,3398012[PMID]
2479,2718,Oculotrichodysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3398012[PMID]
2478,2717,Oculotrichoanal syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,20301721[PMID]
2478,2717,Oculotrichoanal syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20301721[PMID]
2465,2704,Urofacial syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,ORPHANET
2465,2704,Urofacial syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
2464,2703,Port-wine nevi-mega cisterna magna-hydrocephalus syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,501430[PMID]
2464,2703,Port-wine nevi-mega cisterna magna-hydrocephalus syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_501430[PMID]
19809,255210,Mitochondrial DNA-associated Leigh syndrome,Disease,Disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
19809,255210,Mitochondrial DNA-associated Leigh syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
19812,255229,Navajo neurohepatopathy,Disease,Disorder,Cases/families,Case(s),,49.0,Worldwide,Validated,23714749[PMID]
19812,255229,Navajo neurohepatopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,23714749[PMID]
2468,2707,"Oculocerebrofacial syndrome, Kaufman type",Malformation syndrome,Disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,27763745[PMID]
2468,2707,"Oculocerebrofacial syndrome, Kaufman type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27763745[PMID]
19813,255235,"Mitochondrial DNA depletion syndrome, encephalomyopathic form with renal tubulopathy",Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,17486094[PMID]_19138848[PMID]
19813,255235,"Mitochondrial DNA depletion syndrome, encephalomyopathic form with renal tubulopathy",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17486094[PMID]_19138848[PMID]
2471,2710,Oculodentodigital dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,243.0,Worldwide,Validated,12021949[PMID]
2471,2710,Oculodentodigital dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
2470,2709,"Oculodental syndrome, Rutherfurd type",Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,25714557[PMID]
2470,2709,"Oculodental syndrome, Rutherfurd type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25714557[PMID]
2489,2728,"Blepharophimosis-intellectual disability syndrome, Ohdo type",Malformation syndrome,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
2489,2728,"Blepharophimosis-intellectual disability syndrome, Ohdo type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2490,2730,Postaxial tetramelic oligodactyly,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,8100684[PMID]
2490,2730,Postaxial tetramelic oligodactyly,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8100684[PMID]
2492,2732,Olivopontocerebellar atrophy-deafness syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2493,2733,Omodysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2493,2733,Omodysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
2480,2719,"Oculocerebral hypopigmentation syndrome, Cross type",Malformation syndrome,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,9112000[PMID]
2480,2719,"Oculocerebral hypopigmentation syndrome, Cross type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9112000[PMID]
2481,2720,"Oculocerebral hypopigmentation syndrome, Preus type",Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,6663291[PMID]
2481,2720,"Oculocerebral hypopigmentation syndrome, Preus type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6663291[PMID]
2482,2721,Odonto-onycho-dermal dysplasia,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,26964878[PMID]
2482,2721,Odonto-onycho-dermal dysplasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26964878[PMID]
2483,2722,Odonto-onycho dysplasia-alopecia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,2982262[PMID]
2483,2722,Odonto-onycho dysplasia-alopecia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2982262[PMID]
2484,2723,Odontotrichomelic syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,5432287[PMID]
2484,2723,Odontotrichomelic syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5432287[PMID]
2485,2724,Odontomatosis-aortae esophagus stenosis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,4424740[PMID]_5229432[PMID]
2485,2724,Odontomatosis-aortae esophagus stenosis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4424740[PMID]_5229432[PMID]
2511,2755,Orofaciodigital syndrome type 8,Malformation syndrome,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,[EXPERT]
2511,2755,Orofaciodigital syndrome type 8,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,[EXPERT]_ORPHANET
2510,2754,Orofaciodigital syndrome type 6,Malformation syndrome,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,20512146[PMID]
2510,2754,Orofaciodigital syndrome type 6,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20512146[PMID]
19727,252164,Benign schwannoma,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.0,Europe,Validated,European Medicines Agency[INST]
2509,2753,Orofaciodigital syndrome type 4,Malformation syndrome,Disorder,Cases/families,Case(s),,29.0,Worldwide,Validated,ORPHANET
2509,2753,Orofaciodigital syndrome type 4,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2507,2751,Orofaciodigital syndrome type 2,Malformation syndrome,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,Pr Marie-Paule VAZQUEZ [EXPERT]
2507,2751,Orofaciodigital syndrome type 2,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2506,2750,Orofaciodigital syndrome type 1,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.65,France,Validated,22925539[PMID]
2506,2750,Orofaciodigital syndrome type 1,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.2,Europe,Validated,20301367[PMID]
2506,2750,Orofaciodigital syndrome type 1,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19720,252057,Tumor of cranial and spinal nerves,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.89,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
2503,2743,Ophthalmoplegia-intellectual disability-lingua scrotalis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,1167409[PMID]
2503,2743,Ophthalmoplegia-intellectual disability-lingua scrotalis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1167409[PMID]
2501,2741,Ophthalmomandibulomelic dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,14161103[PMID]
2501,2741,Ophthalmomandibulomelic dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_14161103[PMID]
19715,252028,Primary melanocytic tumor of central nervous system,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.01,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
2497,661,Congenital central hypoventilation syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,France,Validated,15653965[PMID]
2497,661,Congenital central hypoventilation syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2496,2736,Lethal omphalocele-cleft palate syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,6873946[PMID]_26867152[PMID]
2496,2736,Lethal omphalocele-cleft palate syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6873946[PMID]_26867152[PMID]
19743,254367,Rare lichen planus,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2526,2776,Autosomal recessive distal osteolysis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2527,2777,Osteomesopyknosis,Malformation syndrome,Disorder,Cases/families,Case(s),,35.0,Worldwide,Validated,26185059[PMID]
2527,2777,Osteomesopyknosis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26185059[PMID]
19742,254361,Plectin-related limb-girdle muscular dystrophy R17,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,21109228[PMID]
19742,254361,Plectin-related limb-girdle muscular dystrophy R17,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21109228[PMID]
2524,2774,Multicentric carpo-tarsal osteolysis with or without nephropathy,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19740,254351,Distal 7q11.23 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,41.0,Worldwide,Validated,23637006[PMID]
19740,254351,Distal 7q11.23 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2522,2769,"Familial osteodysplasia, Anderson type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5067603[PMID]
2522,2769,"Familial osteodysplasia, Anderson type",Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,5067603[PMID]
19739,254346,19p13.12 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,22419660[PMID]
19739,254346,19p13.12 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22419660[PMID]
2523,2770,Nasu-Hakola disease,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
2523,2770,Nasu-Hakola disease,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.15,Finland,Validated,9463329[PMID]
19738,254343,Autosomal recessive spastic ataxia-optic atrophy-dysarthria syndrome,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,20970105[PMID]
19738,254343,Autosomal recessive spastic ataxia-optic atrophy-dysarthria syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20970105[PMID]
2520,2767,Carpotarsal osteochondromatosis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
19736,254334,Autosomal recessive intermediate Charcot-Marie-Tooth disease type B,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,20920668[PMID]
19736,254334,Autosomal recessive intermediate Charcot-Marie-Tooth disease type B,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20920668[PMID]
2521,2768,Blount disease,Malformation syndrome,Disorder,Point prevalence,Class only,Not yet documented,0.0,Worldwide,Not yet validated,ORPHANET
19733,252212,Malignant triton tumor,Histopathological subtype,Subtype of disorder,Cases/families,Case(s),,170.0,Worldwide,Validated,24474920[PMID]
19733,252212,Malignant triton tumor,Histopathological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_24474920[PMID]
2517,2763,Osteocraniostenosis,Malformation syndrome,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,12210352[PMID]
2517,2763,Osteocraniostenosis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2514,2759,Imperforate oropharynx-costovertebral anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,2929659[PMID]
2514,2759,Imperforate oropharynx-costovertebral anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2929659[PMID]
2515,2760,OSLAM syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,201363[PMID]
2515,2760,OSLAM syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_201363[PMID]
19728,252175,Vestibular schwannoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 100 000,2.0,Denmark,Validated,20871439[PMID]_24655069[PMID]
19728,252175,Vestibular schwannoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 100 000,1.2,United States,Validated,National Cancer Institute[INST]_23432451[PMID]
19728,252175,Vestibular schwannoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.8,Specific population,Validated,21897393[PMID]
19728,252175,Vestibular schwannoma,Clinical subtype,Subtype of disorder,Annual incidence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,
19756,254516,Temple syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,53.0,Worldwide,Validated,26377239[PMID]
19756,254516,Temple syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26377239[PMID]
2541,2793,Otoonychoperoneal syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,15216555[PMID]
2541,2793,Otoonychoperoneal syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15216555[PMID]
19757,254519,Kagami-Ogata syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,84.0,Worldwide,Validated,28640239[PMID]
19757,254519,Kagami-Ogata syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28640239[PMID]
19758,254525,Temple syndrome due to paternal 14q32.2 microdeletion,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,26377239[PMID]
19758,254525,Temple syndrome due to paternal 14q32.2 microdeletion,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26377239[PMID]
2543,2798,Pachygyria-intellectual disability-epilepsy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,17343267[PMID]_8129645[PMID]
2543,2798,Pachygyria-intellectual disability-epilepsy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17343267[PMID]_8129645[PMID]
2542,2796,Pachydermoperiostosis,Malformation syndrome,Disorder,Cases/families,Case(s),,204.0,Worldwide,Validated,16283874[PMID]
2542,2796,Pachydermoperiostosis,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
19759,254528,Kagami-Ogata syndrome due to maternal 14q32.2 microdeletion,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,28640239[PMID]_24891339[PMID]
19759,254528,Kagami-Ogata syndrome due to maternal 14q32.2 microdeletion,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28640239[PMID]_24891339[PMID]
19752,254478,Lichen planus pemphigoides,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,23237497[PMID]
19752,254478,Lichen planus pemphigoides,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2537,2789,Lateral meningocele syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,23696373[PMID]_24311540[PMID]
2537,2789,Lateral meningocele syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2536,2788,Osteoporosis-pseudoglioma syndrome,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.05,Europe,Not yet validated,ORPHANET
19753,254492,Frontal fibrosing alopecia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2539,2791,Otodental syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,10.0,Worldwide,Validated,16722606[PMID]
2539,2791,Otodental syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19754,254504,Inhalational botulism,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,[EXPERT]
19754,254504,Inhalational botulism,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2538,2790,"Endosteal hyperostosis, Worth type",Malformation syndrome,Disorder,Cases/families,Family(ies),,6.0,Worldwide,Validated,8030669[PMID]_18031587 [PMID]
2538,2790,"Endosteal hyperostosis, Worth type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8030669[PMID]_18031587 [PMID]
19755,254509,Iatrogenic botulism,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,180.0,Worldwide,Validated,[EXPERT]
19755,254509,Iatrogenic botulism,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19748,254411,Annular atrophic lichen planus,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,[EXPERT]
19748,254411,Annular atrophic lichen planus,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19749,254424,Annular lichen planus,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2532,2783,Autosomal dominant osteopetrosis type 1,Malformation syndrome,Disorder,Cases/families,Case(s),,33.0,Worldwide,Validated,ORPHANET
2532,2783,Autosomal dominant osteopetrosis type 1,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19750,254449,Atrophic lichen planus,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2534,2786,Osteoporosis-oculocutaneous hypopigmentation syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8721572[PMID]
2534,2786,Osteoporosis-oculocutaneous hypopigmentation syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,8721572[PMID]
19751,254463,Lichen planus pigmentosus,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2529,2780,Osteopathia striata-cranial sclerosis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,15266607[PMID]
2529,2780,Osteopathia striata-cranial sclerosis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2528,2779,Osteopathia striata-pigmentary dermopathy-white forelock syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,7405956[PMID]
2528,2779,Osteopathia striata-pigmentary dermopathy-white forelock syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7405956[PMID]
19746,254379,Linear lichen planus,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19747,254395,Actinic lichen planus,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2530,667,Autosomal recessive malignant osteopetrosis,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.75,Europe,Not yet validated,ORPHANET
2530,667,Autosomal recessive malignant osteopetrosis,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
2556,2815,Spastic paraparesis-deafness syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,3741213[PMID]
2556,2815,Spastic paraparesis-deafness syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3741213[PMID]
2559,2818,Spastic paraplegia-glaucoma-intellectual disability syndrome,Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,7298353[PMID_3802560[PMID]
2559,2818,Spastic paraplegia-glaucoma-intellectual disability syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7298353[PMID_3802560[PMID]
2552,2808,Laryngeal abductor paralysis,Malformation syndrome,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,2277390[PMID]_7149532[PMID]_4058983[PMID]
2552,2808,Laryngeal abductor paralysis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2277390[PMID]_7149532[PMID]_4058983[PMID]
2554,2812,Parana hard skin syndrome,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,4129896[PMID]
2554,2812,Parana hard skin syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4129896[PMID]
2548,2805,Partial pancreatic agenesis,Morphological anomaly,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,8988180[PMID]
2548,2805,Partial pancreatic agenesis,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19765,254698,Epithelioid trophoblastic tumor,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
19765,254698,Epithelioid trophoblastic tumor,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
19765,254698,Epithelioid trophoblastic tumor,Disease,Disorder,Lifetime Prevalence,Class only,,0.0,Worldwide,Validated,ORPHANET
19764,254693,Partial hydatidiform mole,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2549,675,Annular pancreas,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.8,Europe,Validated,[EXPERT]_EUROCAT European surveillance of congenital anomalies 2010[REG]
2549,675,Annular pancreas,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,29.4,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
2549,675,Annular pancreas,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.9,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2549,675,Annular pancreas,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,21.3,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2549,675,Annular pancreas,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.9,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2549,675,Annular pancreas,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.9,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2549,675,Annular pancreas,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
2549,675,Annular pancreas,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.6,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2549,675,Annular pancreas,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.7,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2549,675,Annular pancreas,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,24.9,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2549,675,Annular pancreas,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,17.1,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2549,675,Annular pancreas,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.7,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2549,675,Annular pancreas,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.1,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2549,675,Annular pancreas,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.8,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2549,675,Annular pancreas,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.2,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2549,675,Annular pancreas,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2551,678,Papillon-Lefèvre syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.25,Worldwide,Validated,14244097[PMID]
19766,254704,Genetic hyperferritinemia without iron overload,Biological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19761,254534,Kagami-Ogata syndrome due to maternal 14q32.2 hypermethylation,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,26377239[PMID]
19761,254534,Kagami-Ogata syndrome due to maternal 14q32.2 hypermethylation,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26377239[PMID]
2545,2802,X-linked sideroblastic anemia and spinocerebellar ataxia,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,22398176[PMID]
2545,2802,X-linked sideroblastic anemia and spinocerebellar ataxia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,22398176[PMID]_ORPHANET
19760,254531,Temple syndrome due to paternal 14q32.2 hypomethylation,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,28640239[PMID]_24891339[PMID]
19760,254531,Temple syndrome due to paternal 14q32.2 hypomethylation,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28640239[PMID]_24891339[PMID]
19763,254688,Complete hydatidiform mole,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2547,2804,W syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,10594887[PMID]
2547,2804,W syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2304,2491,Müllerian duct anomalies-limb anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,3706400[PMID]
2304,2491,Müllerian duct anomalies-limb anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3706400[PMID]
2305,2492,FATCO syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,DOI:10.15520.v3i12.33[OTHER]
2305,2492,FATCO syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_DOI:10.15520.v3i12.33[OTHER]
2311,2499,Metachondromatosis,Malformation syndrome,Disorder,Cases/families,Case(s),,25.0,Worldwide,Validated,ORPHANET
2311,2499,Metachondromatosis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2308,2496,Mesomelia-synostoses syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,PMID: 30450550 & ORPHANET
2308,2496,Mesomelia-synostoses syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19725128[PMID]
2309,2497,"Upper limb mesomelic dysplasia, type Fryns",Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,3342548[PMID]_16283892[PMID]
2309,2497,"Upper limb mesomelic dysplasia, type Fryns",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3342548[PMID]_16283892[PMID]
2314,2502,Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,5173335[PMID]
2314,2502,Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5173335[PMID]
2313,2501,"Metaphyseal chondrodysplasia, Spahr type",Disease,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,24648384[PMID]_2225533[PMID]_19615667[PMID]_24781753[PMID]_18553549[PMID]
2313,2501,"Metaphyseal chondrodysplasia, Spahr type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24648384[PMID]
2316,2504,Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,23290074[PMID]
2316,2504,Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2323,2511,Microbrachycephaly-ptosis-cleft lip syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,1605250[PMID]
2323,2511,Microbrachycephaly-ptosis-cleft lip syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1605250[PMID]
2322,2510,Micro syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,203.0,Worldwide,Validated,23420520[PMID]_24239381[PMID]
2322,2510,Micro syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
2320,2508,Corpus callosum agenesis-abnormal genitalia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2327,2516,Microcephaly-cardiac defect-lung malsegmentation syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,8723562[PMID]
2327,2516,Microcephaly-cardiac defect-lung malsegmentation syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8723562[PMID]
2326,2515,Microcephaly-cardiomyopathy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,1956062[PMID]_10544231[PMID]
2326,2515,Microcephaly-cardiomyopathy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1956062[PMID]_10544231[PMID]
2324,2513,Microcephaly-albinism-digital anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,6660641[PMID]
2324,2513,Microcephaly-albinism-digital anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6660641[PMID]
2331,2521,Microcephaly-cleft palate-abnormal retinal pigmentation syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,6859112[PMID]
2331,2521,Microcephaly-cleft palate-abnormal retinal pigmentation syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6859112[PMID]
2334,2524,Pontocerebellar hypoplasia type 2,Malformation syndrome,Disorder,Cases/families,Family(ies),,81.0,Worldwide,Validated,[EXPERT]
2334,2524,Pontocerebellar hypoplasia type 2,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
2333,2523,Microcephaly-brain defect-spasticity-hypernatremia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,3784440[PMID]
2333,2523,Microcephaly-brain defect-spasticity-hypernatremia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3784440[PMID]
2332,2522,Microcephaly-cervical spine fusion anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,5033742[PMID]
2332,2522,Microcephaly-cervical spine fusion anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5033742[PMID]
2336,2526,Microcephaly-lymphedema-chorioretinopathy syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,50.0,Worldwide,Validated,[EXPERT]
2336,2526,Microcephaly-lymphedema-chorioretinopathy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19076985[PMID]
2338,2528,"Microcephaly-microcornea syndrome, Seemanova type",Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8958326[PMID]
2338,2528,"Microcephaly-microcornea syndrome, Seemanova type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8958326[PMID]
2342,2533,Microcephaly-deafness-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,3608216[PMID]
2342,2533,Microcephaly-deafness-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3608216[PMID]
2344,2536,Microcornea-glaucoma-absent frontal sinuses syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,5781804[PMID]_7636671[PMID]
2344,2536,Microcornea-glaucoma-absent frontal sinuses syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5781804[PMID]_7636671[PMID
2355,2551,Microspherophakia-metaphyseal dysplasia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
2357,2554,Ear-patella-short stature syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,67.0,Worldwide,Validated,26381604[PMID]
2357,2554,Ear-patella-short stature syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26381604[PMID]
2359,2556,Microphthalmia with linear skin defects syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,55.0,Worldwide,Validated,23122588[PMID]
2359,2556,Microphthalmia with linear skin defects syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2361,2558,Mikati-Najjar-Sahli syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,2998187[PMID]
2361,2558,Mikati-Najjar-Sahli syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2998187[PMID]
2360,2557,Mietens syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,16760739[PMID]
2360,2557,Mietens syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16760739[PMID]
2363,2561,Pyramidal molars-abnormal upper lip syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,4349385[PMID]
2363,2561,Pyramidal molars-abnormal upper lip syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4349385[PMID]
2362,2560,Moebius syndrome-axonal neuropathy-hypogonadotropic hypogonadism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,17401577[PMID]
2362,2560,Moebius syndrome-axonal neuropathy-hypogonadotropic hypogonadism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17401577[PMID]
2365,2564,Tetramelic monodactyly,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1308366[PMID]
2364,2563,MOMO syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,23034868[PMID]_22821547[PMID]
2364,2563,MOMO syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2366,2565,Mononen-Karnes-Senac syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,1632443[PMID]
2366,2565,Mononen-Karnes-Senac syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1632443[PMID]
2374,2574,Moynahan syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,26.0,Worldwide,Validated,2319580[PMID]
2374,2574,Moynahan syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2319580[PMID]
2375,575,Muckle-Wells syndrome,Disease,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,ORPHANET
2375,575,Muckle-Wells syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
2372,2572,Spastic ataxia-corneal dystrophy syndrome,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,3465874[PMID]
2372,2572,Spastic ataxia-corneal dystrophy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3465874[PMID]
2373,2573,Moyamoya disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.74,Japan,Not yet validated,9409395[PMID]_18048855[PMID]
2373,2573,Moyamoya disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.2,Japan,Not yet validated,9409395[PMID]_18048855[PMID]_23041378[PMID]
2373,2573,Moyamoya disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.43,China,Validated,20004511[PMID]
2373,2573,Moyamoya disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.92,China,Validated,20004511[PMID]
2373,2573,Moyamoya disease,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.048,"Taiwan, Province of China",Validated,9409399[PMID]
2373,2573,Moyamoya disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.44,"Taiwan, Province of China",Validated,9409399[PMID]
2373,2573,Moyamoya disease,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.086,United States,Validated,16186547[PMID]
2373,2573,Moyamoya disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.33,France,Validated,[EXPERT]
2373,2573,Moyamoya disease,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.035,Europe,Not yet validated,ISBN:9783211243381[OTHER]
2373,2573,Moyamoya disease,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
2370,2570,Lethal intrauterine growth restriction-cortical malformation-congenital contractures syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,3321025[PMID]_3211858[PMID]
2370,2570,Lethal intrauterine growth restriction-cortical malformation-congenital contractures syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3321025[PMID]_3211858[PMID]
2371,2571,X-linked immunoneurologic disorder,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,7783167[PMID]
2371,2571,X-linked immunoneurologic disorder,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7783167[PMID]
19855,261183,15q11.2 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,25689425[PMID]
19855,261183,15q11.2 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_25689425[PMID]
19853,261144,FOXG1 syndrome due to 14q12 microdeletion,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,19303466[PMID]_18627055[PMID]
19853,261144,FOXG1 syndrome due to 14q12 microdeletion,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19851,261120,14q11.2 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,17545556[PMID]
19851,261120,14q11.2 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2378,2578,Mayer-Rokitansky-Küster-Hauser syndrome type 2,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Europe,Not yet validated,19821675[PMID]
2378,2578,Mayer-Rokitansky-Küster-Hauser syndrome type 2,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
2379,2579,Muscular atrophy-ataxia-retinitis pigmentosa-diabetes mellitus syndrome,Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,5748751[PMID]_6302225[PMID]
2379,2579,Muscular atrophy-ataxia-retinitis pigmentosa-diabetes mellitus syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5748751[PMID]_6302225[PMID]
19849,261102,Distal 7q11.23 microduplication syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,DOI:10.1159/000448698[OTHER]
19849,261102,Distal 7q11.23 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_DOI:10.1159/000448698[OTHER]
2376,2576,Mulibrey nanism,Malformation syndrome,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,29731032[PMID]
2376,2576,Mulibrey nanism,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_29731032[PMID]
2376,2576,Mulibrey nanism,Malformation syndrome,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.7,Finland,Validated,12627297[PMID]
19862,261236,16p13.11 microdeletion syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.0,Worldwide,Not yet validated,24105370[PMID]
19862,261236,16p13.11 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,ORPHANET_23637818[PMID]
19863,261243,16p13.11 microduplication syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,162.0,Worldwide,Validated,27378146[PMID]
19863,261243,16p13.11 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_27378146[PMID]
2390,2608,N syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,4216437[PMID]
2390,2608,N syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4216437[PMID]
19860,261222,Distal 16p11.2 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2389,1359,Carney complex,Disease,Disorder,Cases/families,Case(s),,750.0,Worldwide,Validated,34167977[PMID]_35165607[PMID]
2389,1359,Carney complex,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,34167977[PMID]_35165607[PMID]_ORPHANET
19861,261229,14q11.2 microduplication syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,20736978[PMID]
19861,261229,14q11.2 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2387,2590,Spinal muscular atrophy-progressive myoclonic epilepsy syndrome,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,ORPHANET
2387,2590,Spinal muscular atrophy-progressive myoclonic epilepsy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19858,261204,16p11.2p12.2 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24259393[PMID]
19858,261204,16p11.2p12.2 microduplication syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,24259393[PMID]
19859,261211,16p11.2p12.2 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,24259393[PMID]
19859,261211,16p11.2p12.2 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24259393[PMID]
2386,2589,Myoclonus-cerebellar ataxia-deafness syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,5698045[PMID]_6537856[PMID]
2386,2589,Myoclonus-cerebellar ataxia-deafness syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5698045[PMID]_6537856[PMID]
19856,261190,Cleft palate-congenital heart defect-intellectual disability syndrome due to 15q14 microdeletion,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,24678003[PMID]
19856,261190,Cleft palate-congenital heart defect-intellectual disability syndrome due to 15q14 microdeletion,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24678003[PMID]
2385,2588,Myhre syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28406602[PMID]
19857,261197,Proximal 16p11.2 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.0,Europe,Validated,19306953[PMID]_[EXPERT]
19857,261197,Proximal 16p11.2 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.0,United States,Validated,21731881[PMID]
19870,261295,20p12.3 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,18812404[PMID]
19870,261295,20p12.3 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18812404[PMID]
19871,261304,Paternal 20q13.2q13.3 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,15915160[PMID]
19871,261304,Paternal 20q13.2q13.3 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15915160[PMID]
19868,261279,17q23.1q23.2 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,20206336[PMID]
19868,261279,17q23.1q23.2 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20206336[PMID]
19869,261290,Trisomy 17p syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2396,2617,"Microcephalic primordial dwarfism, Montreal type",Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,5458566[PMID]
2396,2617,"Microcephalic primordial dwarfism, Montreal type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5458566[PMID]
19866,261265,17q12 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27409573[PMID]
19866,261265,17q12 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.16,Denmark,Validated,27409573[PMID]
19866,261265,17q12 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,103.0,Worldwide,Validated,27409573[PMID]
19867,261272,17q12 microduplication syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,118.0,Worldwide,Validated,27409573[PMID]
19867,261272,17q12 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27409573[PMID]
19867,261272,17q12 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.46,Denmark,Validated,27409573[PMID]
2393,2616,3M syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,ORPHANET_22624670[PMID]
2393,2616,3M syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
19864,261250,16q24.3 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,27.0,Worldwide,Validated,28422132[PMID]
19864,261250,16q24.3 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28422132[PMID]
2392,2613,Nail-patella-like renal disease,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,6507504[PMID]
2392,2613,Nail-patella-like renal disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6507504[PMID]
19865,261257,Distal 17p13.3 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,20599530[PMID]
19865,261257,Distal 17p13.3 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20599530[PMID]
19877,261344,Trisomy 1q syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,28437579[PMID]
19877,261344,Trisomy 1q syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28437579[PMID]
19876,261337,Distal 22q11.2 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19879,261476,Xp21 deletion syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25917374[PMID]
19879,261476,Xp21 deletion syndrome,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,25917374[PMID]
19878,261349,2p15p16.1 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,24810580[PMID]
19878,261349,2p15p16.1 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24810580[PMID]
19873,261318,Trisomy 20p syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
19872,261311,20q13.33 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2401,2623,Geleophysic dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,27.0,Worldwide,Validated,15088061[PMID]
2401,2623,Geleophysic dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19875,261330,Distal 22q11.2 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19874,261323,21q22.11q22.12 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,20578134[PMID]_7515754[PMID]
19874,261323,21q22.11q22.12 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20578134[PMID]_7515754[PMID]
19885,261524,Paternal uniparental disomy of chromosome X syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19884,261519,Maternal uniparental disomy of chromosome X syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19887,261534,"49,XXXYY syndrome",Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,3697588[PMID]_14015109[PMID]
19887,261534,"49,XXXYY syndrome",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19886,261529,Ring chromosome Y syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2408,2631,Mesomelic dwarfism-cleft palate-camptodactyly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8267013[PMID]
2408,2631,Mesomelic dwarfism-cleft palate-camptodactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8267013[PMID]
19881,261494,Kleefstra syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,114.0,Worldwide,Validated,22670141[PMID]_[EXPERT]
19881,261494,Kleefstra syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19880,261483,Xq27.3q28 duplication syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,19844254[PMID]
19880,261483,Xq27.3q28 duplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2409,2632,Langer mesomelic dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,23863349[PMID]_[EXPERT]
2409,2632,Langer mesomelic dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
19882,261501,Atypical Norrie disease due to Xp11.3 microdeletion,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2411,2634,"Mesomelic dwarfism, Reinhardt-Pfeiffer type",Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2420,2645,Osteoglosphonic dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,3409933[PMID]
2420,2645,Osteoglosphonic dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3409933[PMID]
19894,261600,Alagille syndrome due to 20p12 microdeletion,Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2417,2643,"Microcephalic primordial dwarfism, Toriello type",Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,3799711[PMID]
2417,2643,"Microcephalic primordial dwarfism, Toriello type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3799711[PMID]
2418,2636,Microcephalic osteodysplastic primordial dwarfism types I and III,Malformation syndrome,Disorder,Cases/families,Case(s),,53.0,Worldwide,Validated,ORPHANET
2418,2636,Microcephalic osteodysplastic primordial dwarfism types I and III,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2429,2658,Lenz-Majewski hyperostotic dwarfism,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,10756342[PMID]_24241535[PMID]
2429,2658,Lenz-Majewski hyperostotic dwarfism,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19897,261638,Okihiro syndrome due to 20q13 microdeletion,Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19899,261652,Kleefstra syndrome due to a point mutation,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,23.0,Worldwide,Validated,22670141[PMID]_[EXPERT]
19899,261652,Kleefstra syndrome due to a point mutation,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20095,264200,14q22q23 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,24311462[PMID]
20095,264200,14q22q23 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24311462[PMID]
2747,3057,Monoamine oxidase A deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2745,3055,X-linked intellectual disability-hypogonadism-ichthyosis-obesity-short stature syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,7175926[PMID]
2745,3055,X-linked intellectual disability-hypogonadism-ichthyosis-obesity-short stature syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7175926[PMID]
2741,3052,X-linked intellectual disability-seizures-psoriasis syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,3177453[PMID]
2741,3052,X-linked intellectual disability-seizures-psoriasis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3177453[PMID]
2739,3047,"Blepharophimosis-intellectual disability syndrome, SBBYS type",Malformation syndrome,Disorder,Cases/families,Case(s),,122.0,Worldwide,Validated,[EXPERT]
2739,3047,"Blepharophimosis-intellectual disability syndrome, SBBYS type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2737,3044,Intellectual disability-dysmorphism-hypogonadism-diabetes mellitus syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,2107046[PMID]
2737,3044,Intellectual disability-dysmorphism-hypogonadism-diabetes mellitus syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2107046[PMID]
2735,3042,Intellectual disability-cataracts-calcified pinnae-myopathy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,27061120[PMID]_28462983[PMID]
2735,3042,Intellectual disability-cataracts-calcified pinnae-myopathy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28462983[PMID]
2734,3041,Intellectual disability-balding-patella luxation-acromicria syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,2002488[PMID]_8487281[PMID]
2734,3041,Intellectual disability-balding-patella luxation-acromicria syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2002488[PMID]_8487281[PMID]
2732,3038,Delayed speech-facial asymmetry-strabismus-ear lobe creases syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,16055361[PMID]
2732,3038,Delayed speech-facial asymmetry-strabismus-ear lobe creases syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16055361[PMID]
20074,263665,NK-cell enteropathy,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,20966166[PMID]
20074,263665,NK-cell enteropathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2729,3035,Growth delay-hydrocephaly-lung hypoplasia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,2764038[PMID]
2729,3035,Growth delay-hydrocephaly-lung hypoplasia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2764038[PMID]
20073,263662,Familial multiple meningioma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2728,3034,Delayed membranous cranial ossification,Malformation syndrome,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,10861662[PMID]_1481847[PMID]
2728,3034,Delayed membranous cranial ossification,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10861662[PMID]_1481847[PMID]
20070,263548,Peeling skin syndrome type A,Clinical subtype,Subtype of disorder,Cases/families,Family(ies),,40.0,Worldwide,Validated,ORPHANET
20070,263548,Peeling skin syndrome type A,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2726,3033,Renal tubular dysgenesis,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
2726,3033,Renal tubular dysgenesis,Malformation syndrome,Disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,16790508[PMID]_19344005[PMID]_ 33163725[PMID]
20071,263553,Peeling skin syndrome type B,Clinical subtype,Subtype of disorder,Cases/families,Family(ies),,30.0,Worldwide,Validated,ORPHANET
20071,263553,Peeling skin syndrome type B,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2725,3032,NPHP3-related Meckel-like syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,ORPHANET
2725,3032,NPHP3-related Meckel-like syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20068,263534,Acral peeling skin syndrome,Disease,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,22622422[PMID]
20068,263534,Acral peeling skin syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20069,263543,Generalized peeling skin syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
20066,263516,Progressive myoclonic epilepsy type 3,Disease,Disorder,Cases/families,Family(ies),,9.0,Worldwide,Validated,22693283[PMID]_22748208[PMID]
20066,263516,Progressive myoclonic epilepsy type 3,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22693283[PMID]_22748208[PMID]
20067,263524,Acute necrotizing encephalopathy of childhood,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20064,263501,COG4-CDG,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,22516080[PMID]
20064,263501,COG4-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2720,3026,Radial ray hypoplasia-choanal atresia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3425633[PMID]
2720,3026,Radial ray hypoplasia-choanal atresia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,3425633[PMID]
20065,263508,COG1-CDG,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,16537452[PMID]_19008299[PMID]
20065,263508,COG1-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16537452[PMID]_19008299[PMID]
20061,263482,"Spondyloepimetaphyseal dysplasia, Maroteaux type",Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,ORPHANET
20061,263482,"Spondyloepimetaphyseal dysplasia, Maroteaux type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2716,3021,RAPADILINO syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,18716613[PMID]
2716,3021,RAPADILINO syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18716613[PMID]
20060,263479,Fuchs heterochromic iridocyclitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.2,Finland,Validated,9088407[PMID]
20060,263479,Fuchs heterochromic iridocyclitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Finland,Validated,9088407[PMID]
20060,263479,Fuchs heterochromic iridocyclitis,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
20063,263494,DPM3-CDG,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,19576565[PMID]
20063,263494,DPM3-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19576565[PMID]
2718,3023,External auditory canal atresia-vertical talus-hypertelorism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,22152683[PMID]_495079[PMID]_12116258[PMID]
2718,3023,External auditory canal atresia-vertical talus-hypertelorism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22152683[PMID]_495079[PMID]_12116258[PMID]
20062,263487,COG5-CDG,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,22516080[PMID]_23228021[PMID]
20062,263487,COG5-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20057,263458,Hyperinsulinism due to INSR deficiency,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,15161766[PMID]
20057,263458,Hyperinsulinism due to INSR deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15161766[PMID]
20056,263455,Congenital hyperinsulinism due to HNF4A deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2713,1832,Osteosclerotic bone dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,25974638[PMID]
2713,1832,Osteosclerotic bone dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25974638[PMID]
2714,3018,Retinal ischemic syndrome-digestive tract small vessel hyalinosis-diffuse cerebral calcifications syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,3485063[PMID]
2714,3018,Retinal ischemic syndrome-digestive tract small vessel hyalinosis-diffuse cerebral calcifications syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3485063[PMID]
2715,3019,Ramon syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,11746043[PMID]
2715,3019,Ramon syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11746043[PMID]_6829604[PMID]
20058,263463,CHST3-related skeletal dysplasia,Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,24458487[PMID]
20058,263463,CHST3-related skeletal dysplasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24458487[PMID]
20053,263432,Nevus of Ito,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.17,Europe,Not yet validated,ORPHANET
20053,263432,Nevus of Ito,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20052,263425,Nevus of Ota,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2710,3015,Radio-renal syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,7363497[PMID]_6829604[PMID]
2710,3015,Radio-renal syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7363497[PMID]_
20055,263440,Neuroacanthocytosis,Clinical group,Group of disorders,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Not yet validated,22027213[PMID]
20054,263435,Congenital smooth muscle hamartoma,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,38.5,Israel,Validated,2356798[PMID]
20054,263435,Congenital smooth muscle hamartoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2711,3016,Absent radius-anogenital anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8456854[PMID]
2711,3016,Absent radius-anogenital anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8456854[PMID]
20049,263410,Infantile spasms-psychomotor retardation-progressive brain atrophy-basal ganglia disease syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,21176162[PMID]
20049,263410,Infantile spasms-psychomotor retardation-progressive brain atrophy-basal ganglia disease syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2705,3010,Qazi-Markouizos syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,8064821[PMID]
2705,3010,Qazi-Markouizos syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8064821[PMID]
2706,3011,Spastic tetraplegia-retinitis pigmentosa-intellectual disability syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,1271602[PMID]
2706,3011,Spastic tetraplegia-retinitis pigmentosa-intellectual disability syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1271602[PMID]
2707,769,Rabson-Mendenhall syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20050,263413,Angiosarcoma,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2011[REG]
20050,263413,Angiosarcoma,Disease,Disorder,Lifetime Prevalence,Value and class,<1 / 1 000 000,0.02,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
20050,263413,Angiosarcoma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
2701,3003,Pyknoachondrogenesis,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,7460382[PMID]_3791681[PMID]
2701,3003,Pyknoachondrogenesis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7460382[PMID]_3791681[PMID]
20044,263335,Moderately-differentiated thymic neuroendocrine carcinoma,Histopathological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20045,263339,Poorly differentiated thymic neuroendocrine carcinoma,Histopathological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2703,3005,Pyle disease,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
2703,3005,Pyle disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20046,263347,MRCS syndrome,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,16458719[PMID]_12543751[PMID]
20046,263347,MRCS syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16458719[PMID]_12543751[PMID]
20047,263352,Postcardiotomy right ventricular failure,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,European Medicines Agency 2010[INST]
2702,3004,Mirror polydactyly-vertebral segmentation-limbs defects syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.3,Spain,Validated,9409874[PMID]
2702,3004,Mirror polydactyly-vertebral segmentation-limbs defects syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.3,Europe,Validated,[EXPERT]
20040,263310,Thymoma type A,Histopathological subtype,Subtype of disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2011[REG]
20040,263310,Thymoma type A,Histopathological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2697,2997,Ptosis-vocal cord paralysis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,6633110[PMID]
2697,2997,Ptosis-vocal cord paralysis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6633110[PMID]
20041,263317,Thymoma type B,Histopathological subtype,Subtype of disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2011[REG]
20041,263317,Thymoma type B,Histopathological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20042,263324,Thymoma type AB,Histopathological subtype,Subtype of disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2011[REG]
20042,263324,Thymoma type AB,Histopathological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2699,2999,Ptosis-strabismus-ectopic pupils syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,949861[PMID]
2699,2999,Ptosis-strabismus-ectopic pupils syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_949861[PMID]
20043,263331,Well-differentiated thymic neuroendocrine carcinoma,Histopathological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2692,2990,Autosomal recessive multiple pterygium syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30868735[PMID]
2692,2990,Autosomal recessive multiple pterygium syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,64.0,Worldwide,Validated,30868735[PMID]
20039,263297,Glycogen storage disease with severe cardiomyopathy due to glycogenin deficiency,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,20357282[PMID]
20039,263297,Glycogen storage disease with severe cardiomyopathy due to glycogenin deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20357282[PMID]
2689,2987,Antecubital pterygium syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,3409540[PMID]
2689,2987,Antecubital pterygium syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3409540[PMID]
2688,2985,Pseudoprogeria syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,4418946[PMID]
2688,2985,Pseudoprogeria syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4418946[PMID]
2690,2988,Pterygium colli-intellectual disability-digital anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,7977463[PMID]
2690,2988,Pterygium colli-intellectual disability-digital anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7977463[PMID]
2808,3138,Ulnar-mammary syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,128.0,Worldwide,Validated,24679913[PMID]_30654152[PMID]_ 30550377[PMID]_ 28145909[PMID]
2808,3138,Ulnar-mammary syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
2814,3145,Arginine vasopressin resistance-intracranial calcification-short stature-facial dysmorphism syndrome,Disease,Disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,24053747[PMID]
2814,3145,Arginine vasopressin resistance-intracranial calcification-short stature-facial dysmorphism syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,24053747[PMID]
2812,3143,Autoimmune polyendocrinopathy type 2,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2813,3144,Schneckenbecken dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25997753[PMID]
2803,3132,Say-Barber-Miller syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,3746838[PMID]_8728697[PMID]_19108857[PMID]
2803,3132,Say-Barber-Miller syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3746838[PMID]_8728697[PMID]
2801,3130,Satoyoshi syndrome,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,19839037[PMID]
2801,3130,Satoyoshi syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19839037[PMID]
2807,798,Schinzel-Giedion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18398855[PMID]
2807,798,Schinzel-Giedion syndrome,Malformation syndrome,Disorder,Prevalence at birth,Class only,1-9 / 100 000,0.0,Europe,Validated,[EXPERT]
2807,798,Schinzel-Giedion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,46.0,Worldwide,Validated,18398855[PMID]_[EXPERT]
20021,262941,Partial duplication of the long arm of chromosome 14 syndrome,Category,Group of disorders,Cases/families,Case(s),,50.0,Worldwide,Validated,27286879[PMID]
20021,262941,Partial duplication of the long arm of chromosome 14 syndrome,Category,Group of disorders,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27286879[PMID]
2805,3134,SCARF syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,2596519[PMID]
2805,3134,SCARF syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2596519[PMID]
2795,3121,Ruvalcaba syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2785,2909,Rothmund-Thomson syndrome,Disease,Disorder,Cases/families,Case(s),,400.0,Worldwide,Validated,29642415[PMID]
2785,2909,Rothmund-Thomson syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_29642415[PMID]
2784,3110,Rombo syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
2776,3101,Richieri Costa-da Silva syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,6716408[PMID]
2776,3101,Richieri Costa-da Silva syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6716408[PMID]
2777,3102,Richieri Costa-Pereira syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,33.0,Worldwide,Validated,23794199[PMID]
2777,3102,Richieri Costa-Pereira syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2778,3104,Robin sequence-oligodactyly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,3777025[PMID]_3425604[PMID]
2778,3104,Robin sequence-oligodactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3777025[PMID]_3425604[PMID]
2781,3107,Autosomal dominant Robinow syndrome,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,[EXPERT]
2781,3107,Autosomal dominant Robinow syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2783,3109,Mayer-Rokitansky-Küster-Hauser syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.0,Worldwide,Validated,[EXPERT]_22740494[PMID]_17359527[PMID]
2783,3109,Mayer-Rokitansky-Küster-Hauser syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Worldwide,Validated,[EXPERT]
2769,3086,Autosomal dominant vitreoretinochoroidopathy,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,15452077[PMID]
2769,3086,Autosomal dominant vitreoretinochoroidopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
2771,3088,Revesz syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,1404302[PMID]_18252230[PMID]_21477109[PMID]
2771,3088,Revesz syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET_1404302[PMID]_18252230[PMID]_21477109[PMID]
2773,3097,Meacham syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,17853480[PMID]
2773,3097,Meacham syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17853480[PMID]
2774,3098,"Rhizomelic syndrome, Urbach type",Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,3948431[PMID]
2774,3098,"Rhizomelic syndrome, Urbach type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3591839[PMID]
2765,3078,"Severe X-linked intellectual disability, Gustavson type",Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,8456840[PMID]
2765,3078,"Severe X-linked intellectual disability, Gustavson type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8456840[PMID]
2764,3077,X-linked intellectual disability-psychosis-macroorchidism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,8651288[PMID]
2764,3077,X-linked intellectual disability-psychosis-macroorchidism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8651288[PMID]
2767,3080,"Intellectual disability, Wolff type",Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8151642[PMID]
2767,3080,"Intellectual disability, Wolff type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8151642[PMID]
2766,3079,"Intellectual disability, Buenos-Aires type",Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,5025484[PMID]_10190479[PMID]
2766,3079,"Intellectual disability, Buenos-Aires type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5025484[PMID]_10190479[PMID]
2752,3063,"X-linked intellectual disability, Snyder type",Disease,Disorder,Cases/families,Case(s),,21.0,Worldwide,Validated,23897707[PMID]_23696453[PMID]
2752,3063,"X-linked intellectual disability, Snyder type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23897707[PMID]_23696453[PMID]
2757,3068,Intellectual disability-myopathy-short stature-endocrine defect syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,3970066[PMID]
2757,3068,Intellectual disability-myopathy-short stature-endocrine defect syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3970066[PMID]
20214,268843,"Malformation of the neurenteric canal, spinal cord and column",Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2614,2886,TARP syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,6.0,Worldwide,Validated,24259342[PMID]
2614,2886,TARP syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,"ORPHANET_24259342,[PMID]"
20215,268861,Primary tethered cord syndrome,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2613,2885,Piebald trait-neurologic defects syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,5097904[PMID]
2613,2885,Piebald trait-neurologic defects syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5097904[PMID]
2612,2884,Piebaldism,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2611,2881,Cutaneous photosensitivity-lethal colitis syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,2002480[PMID]
2611,2881,Cutaneous photosensitivity-lethal colitis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2002480[PMID]
2610,2879,"Phocomelia, Schinzel type",Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20208,268826,Parietal encephalocele,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20209,268829,Basal encephalocele,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20223,268920,Isolated megalencephaly,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20220,268882,Arnold-Chiari malformation type I,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2620,2892,Pilodental dysplasia-refractive errors syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,4018802[PMID]
2620,2892,Pilodental dysplasia-refractive errors syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4018802[PMID]
2619,2891,Pili torti-developmental delay-neurological abnormalities syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,1379303[PMID]
2619,2891,Pili torti-developmental delay-neurological abnormalities syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1379303[PMID]
2618,2889,Pili torti,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2617,2890,Pili torti-onychodysplasia syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,1879585[PMID]
2617,2890,Pili torti-onychodysplasia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1879585[PMID]
20216,268865,Neurenteric cyst,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2616,2888,Pierre Robin syndrome-faciodigital anomaly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,1897570[PMID]
2616,2888,Pierre Robin syndrome-faciodigital anomaly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1897570[PMID]
20217,268868,Isolated amyelia,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2598,2865,Short stature-webbed neck-heart disease syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,8905197[PMID]
2598,2865,Short stature-webbed neck-heart disease syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8905197[PMID]
2599,2866,Short stature-deafness-neutrophil dysfunction-dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,654917[PMID]
2599,2866,Short stature-deafness-neutrophil dysfunction-dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_654917[PMID]
2596,2863,Short stature-wormian bones-dextrocardia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,15211658[PMID]
2596,2863,Short stature-wormian bones-dextrocardia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15211658[PMID]
20193,268744,Spinal dysraphism with a posterior meningocele,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,33.0,Saudi Arabia,Validated,17587020[PMID]
20193,268744,Spinal dysraphism with a posterior meningocele,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20207,268823,Occipital encephalocele,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2607,2876,PHAVER syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8279476[PMID]
2607,2876,PHAVER syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8279476[PMID]
20206,268820,Cranial meningocele,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20205,268817,Cephalocele,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2605,2874,Phakomatosis pigmentokeratotica,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2605,2874,Phakomatosis pigmentokeratotica,Malformation syndrome,Disorder,Cases/families,Case(s),,34.0,Worldwide,Validated,24877171[PMID]
20204,268813,Myelocystocele,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20203,268810,Isolated posterior meningocele,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2602,2871,Pfeiffer-Palm-Teller syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,144791[PMID]
2602,2871,Pfeiffer-Palm-Teller syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_144791[PMID]
2603,2872,"Cardiocranial syndrome, Pfeiffer type",Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,16531733[PMID]_9415478[PMID]
2603,2872,"Cardiocranial syndrome, Pfeiffer type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16531733[PMID]_9415478[PMID]
2600,2867,"Short stature, Brussels type",Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8867654[PMID]
2600,2867,"Short stature, Brussels type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8867654[PMID]
2601,2868,Short stature-valvular heart disease-characteristic facies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,2302822[PMID]
2601,2868,Short stature-valvular heart disease-characteristic facies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2302822[PMID]
2581,2846,Congenital pericardium anomaly,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2580,2842,Penoscrotal transposition,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2583,2848,Camptodactyly-arthropathy-coxa-vara-pericarditis syndrome,Disease,Disorder,Cases/families,Family(ies),,30.0,Worldwide,Validated,15702367[PMID]
2583,2848,Camptodactyly-arthropathy-coxa-vara-pericarditis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2582,2847,Pericardial and diaphragmatic defect,Malformation syndrome,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,ORPHANET
2582,2847,Pericardial and diaphragmatic defect,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20183,268357,Neural tube closure defect,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2577,2838,Renal caliceal diverticuli-deafness syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,6785452[PMID]
2577,2838,Renal caliceal diverticuli-deafness syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6785452[PMID]
20176,268322,Hereditary thrombocytopenia with normal platelets,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2579,2840,Pelvic dysplasia-arthrogryposis of lower limbs syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,9489787[PMID]
2579,2840,Pelvic dysplasia-arthrogryposis of lower limbs syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9489787[PMID]
2578,2839,Pelvis-shoulder dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,ORPHANET
2578,2839,Pelvis-shoulder dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2589,2855,Perrault syndrome,Disease,Disorder,Cases/families,Case(s),,124.0,Worldwide,Validated,Haute Autorité de Santé[OTHER]
2589,2855,Perrault syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2588,2854,Fuhrmann syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,16826533[PMID]_12868468[PMID]
2588,2854,Fuhrmann syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12868468[PMID]_16826533[PMID]
2590,708,Peters anomaly,Morphological anomaly,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,21448066[PMID]
2590,708,Peters anomaly,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20184,268363,Open iniencephaly,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20185,268366,Closed iniencephaly,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2584,2850,Alopecia-intellectual disability syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28054173[PMID]
2584,2850,Alopecia-intellectual disability syndrome,Disease,Disorder,Cases/families,Family(ies),,15.0,Worldwide,Validated,18616779[PMID]_28054173[PMID]
20186,268369,Open spinal dysraphism,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,51.5,Germany,Validated,2785614[PMID]
20186,268369,Open spinal dysraphism,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20186,268369,Open spinal dysraphism,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,50.0,France,Not yet validated,ORPHANET
20186,268369,Open spinal dysraphism,Clinical group,Group of disorders,Prevalence at birth,Value and class,>1 / 1000,400.0,Ireland,Not yet validated,ORPHANET
20186,268369,Open spinal dysraphism,Clinical group,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,62.0,Latin America,Validated,3907353[PMID]
20186,268369,Open spinal dysraphism,Clinical group,Group of disorders,Point prevalence,Value and class,>1 / 1000,400.0,United Kingdom,Not yet validated,ORPHANET
20165,268114,RAS-associated autoimmune leukoproliferative disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20165,268114,RAS-associated autoimmune leukoproliferative disease,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,[EXPERT]
2564,2825,PARC syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,2242783[PMID]
2564,2825,PARC syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2242783[PMID]
2565,2826,Spastic paraplegia-precocious puberty syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,6639408[PMID]
2565,2826,Spastic paraplegia-precocious puberty syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6639408[PMID]
20167,268139,Intraocular medulloepithelioma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20166,268129,Spheroid body myopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2560,2819,Spastic paraplegia-facial-cutaneous lesions syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,7117711[PMID]
2560,2819,Spastic paraplegia-facial-cutaneous lesions syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7117711[PMID]
2561,2820,Spastic paraplegia-nephritis-deafness syndrome,Clinical syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,3351903[PMID]
2561,2820,Spastic paraplegia-nephritis-deafness syndrome,Clinical syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3351903[PMID]
2562,2821,Spastic paraplegia-neuropathy-poikiloderma syndrome,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,1623621[PMID]
2562,2821,Spastic paraplegia-neuropathy-poikiloderma syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1623621[PMID]
2563,2822,Autosomal recessive spastic paraplegia type 11,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.26,Portugal,Validated,23609960[PMID]
2572,2835,Pectus excavatum-macrocephaly-dysplastic nails syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,Zori 1992[AUTHOR]
2572,2835,Pectus excavatum-macrocephaly-dysplastic nails syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20173,268261,DYRK1A-related intellectual disability syndrome due to 21q22.13q22.2 microdeletion,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,26922654[PMID]
20173,268261,DYRK1A-related intellectual disability syndrome due to 21q22.13q22.2 microdeletion,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26922654[PMID]
2573,2836,PEHO syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20172,268249,Mycophenolate mofetil embryopathy,Malformation syndrome,Disorder,Cases/families,Case(s),,25.0,Worldwide,Validated,[EXPERT]
20172,268249,Mycophenolate mofetil embryopathy,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20175,268316,Complication in hemodialysis,Particular clinical situation in a disease or syndrome,Disorder,Annual incidence,Value and class,1-5 / 10 000,13.0,Europe,Validated,European Medicines Agency 2011[INST]
20175,268316,Complication in hemodialysis,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET
20169,268162,Intermediate maple syrup urine disease,Clinical subtype,Subtype of disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
20169,268162,Intermediate maple syrup urine disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
2569,2832,Short tarsus-absence of lower eyelashes syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,7889642[PMID]
2569,2832,Short tarsus-absence of lower eyelashes syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7889642[PMID]
20168,268145,Classic maple syrup urine disease,Clinical subtype,Subtype of disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
20168,268145,Classic maple syrup urine disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
20171,268184,Thiamine-responsive maple syrup urine disease,Clinical subtype,Subtype of disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
20171,268184,Thiamine-responsive maple syrup urine disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
2570,2833,Stiff skin syndrome,Disease,Disorder,Cases/families,Case(s),,54.0,Worldwide,Validated,27846975[PMID]_26944597[PMID]
2570,2833,Stiff skin syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27846975[PMID]_26944597[PMID]
2571,2834,Wrinkly skin syndrome,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
2571,2834,Wrinkly skin syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20170,268173,Intermittent maple syrup urine disease,Clinical subtype,Subtype of disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
20170,268173,Intermittent maple syrup urine disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
2675,2969,Proteus-like syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2673,2962,De Barsy syndrome,Disease,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,ORPHANET
2673,2962,De Barsy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2678,2972,Non-eruption of teeth-maxillary hypoplasia-genu valgum syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,975598[PMID]
2678,2972,Non-eruption of teeth-maxillary hypoplasia-genu valgum syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2676,750,Pseudoachondroplasia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.3,Worldwide,Not yet validated,20301660[PMID]
2682,2976,"Pseudoleprechaunism syndrome, Patterson type",Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,7277424 [PMID]
2682,2976,"Pseudoleprechaunism syndrome, Patterson type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7277424 [PMID][PMID]
2681,2975,"46,XX difference of sex development-skeletal anomalies syndrome",Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,5042791[PMID]
2681,2975,"46,XX difference of sex development-skeletal anomalies syndrome",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5042791[PMID]
2686,2980,Acrootoocular syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
2684,2978,Chronic intestinal pseudoobstruction,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2659,2946,Brachydactyly-long thumb syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,7246605[PMID]
2659,2946,Brachydactyly-long thumb syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7246605[PMID]
2656,1848,"Renal agenesis, bilateral",Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.7,Europe,Validated,16053904[PMID]_EUROCAT European surveillance of congenital anomalies 2009-2010[REG]
2656,1848,"Renal agenesis, bilateral",Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.5,France,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
2656,1848,"Renal agenesis, bilateral",Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.8,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2656,1848,"Renal agenesis, bilateral",Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.4,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2656,1848,"Renal agenesis, bilateral",Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.7,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2656,1848,"Renal agenesis, bilateral",Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-5 / 10 000,10.8,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2656,1848,"Renal agenesis, bilateral",Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.2,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2656,1848,"Renal agenesis, bilateral",Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.2,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2656,1848,"Renal agenesis, bilateral",Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.6,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
2656,1848,"Renal agenesis, bilateral",Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.2,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2656,1848,"Renal agenesis, bilateral",Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-5 / 10 000,19.0,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2656,1848,"Renal agenesis, bilateral",Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.7,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2656,1848,"Renal agenesis, bilateral",Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.0,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2656,1848,"Renal agenesis, bilateral",Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-5 / 10 000,13.6,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2656,1848,"Renal agenesis, bilateral",Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-5 / 10 000,24.1,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
2656,1848,"Renal agenesis, bilateral",Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.2,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2656,1848,"Renal agenesis, bilateral",Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.2,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2656,1848,"Renal agenesis, bilateral",Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
2663,2951,Absent thumb-short stature-immunodeficiency syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,728551[PMID]
2663,2951,Absent thumb-short stature-immunodeficiency syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_728551[PMID]
2660,2947,Triphalangeal thumbs-brachyectrodactyly syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,4.0,Worldwide,Validated,7438506[PMID]_3568429[PMID]_8946115[PMID]
2660,2947,Triphalangeal thumbs-brachyectrodactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7438506[PMID]_3568429[PMID]_8946115[PMID]
20132,264978,Drug or radiation exposure-related interstitial lung disease,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2667,2956,Acrodysplasia scoliosis,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,6335370[PMID]
2667,2956,Acrodysplasia scoliosis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6335370[PMID]
2664,2952,"Adducted thumbs-arthrogryposis syndrome, Christian type",Malformation syndrome,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,6662143[PMID]
2664,2952,"Adducted thumbs-arthrogryposis syndrome, Christian type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6662143[PMID]
2670,740,Hutchinson-Gilford progeria syndrome,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.025,Worldwide,Validated,[EXPERT]
2670,740,Hutchinson-Gilford progeria syndrome,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.005,Worldwide,Validated,[EXPERT]
2671,2959,Progeria-short stature-pigmented nevi syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,29718885[PMID]
2671,2959,Progeria-short stature-pigmented nevi syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29718885[PMID]
2668,2957,Guttmacher syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8484413[PMID]
2668,2957,Guttmacher syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,8484413[PMID]
2669,2958,X-linked intellectual disability-dysmorphism-cerebral atrophy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,3121220[PMID]
2669,2958,X-linked intellectual disability-dysmorphism-cerebral atrophy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3121220[PMID]
2641,2924,Isolated polycystic liver disease,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,[EXPERT]
2643,2926,Digital extensor muscle aplasia-polyneuropathy,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,3459358[PMID]
2643,2926,Digital extensor muscle aplasia-polyneuropathy,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3459358[PMID]
2645,2928,Polyneuropathy-intellectual disability-acromicria-premature menopause syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,5117105[PMID]
2645,2928,Polyneuropathy-intellectual disability-acromicria-premature menopause syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5117105[PMID]
2646,2930,Cronkhite-Canada syndrome,Disease,Disorder,Cases/families,Case(s),,500.0,Worldwide,Validated,25004941[PMID]
2646,2930,Cronkhite-Canada syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_25004941[PMID]
2649,2935,Crossed polysyndactyly,Malformation syndrome,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,8042663[PMID]_20127219 [PMID]
2649,2935,Crossed polysyndactyly,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8042663[PMID]_20127219 [PMID]
2648,2934,Polysyndactyly-cardiac malformation syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,12749069[PMID]_19400539[PMID]
2648,2934,Polysyndactyly-cardiac malformation syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12749069[PMID]_19400539[PMID]
2655,2941,Porencephaly-cerebellar hypoplasia-internal malformations syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8737647[PMID]
2655,2941,Porencephaly-cerebellar hypoplasia-internal malformations syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8737647[PMID]
2654,2940,Porencephaly,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
2654,2940,Porencephaly,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.5,United States,Validated,18383510[PMID]
2654,2940,Porencephaly,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.2,Japan,Validated,26545857[PMID]
2624,2896,Pitt-Hopkins syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,ORPHANET_[EXPERT]_30677142[PMID]
2624,2896,Pitt-Hopkins syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
2626,2900,Leri pleonosteosis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
2627,2905,POEMS syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
2627,2905,POEMS syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.33,Japan,Validated,22338030[PMID]
2629,2907,Hereditary acrokeratotic poikiloderma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4253719[PMID]_7015974[PMID]
2629,2907,Hereditary acrokeratotic poikiloderma,Disease,Disorder,Cases/families,Case(s),,41.0,Worldwide,Validated,4253719[PMID]_7015974[PMID]
2630,2911,Poland syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.1,Canada,Validated,205132[PMID]
2630,2911,Poland syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Canada,Not yet validated,205132[PMID]
2630,2911,Poland syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.5,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
2630,2911,Poland syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET_EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
20103,264580,Glycogen storage disease due to liver phosphorylase kinase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Europe,Validated,[EXPERT]
20103,264580,Glycogen storage disease due to liver phosphorylase kinase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
2634,2916,Postaxial polydactyly-dental and vertebral anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,187745[PMID]
2634,2916,Postaxial polydactyly-dental and vertebral anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_187745[PMID]
2635,2917,Polydactyly-myopia syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,3802559[PMID]
2635,2917,Polydactyly-myopia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3802559[PMID]
2637,2919,Orofaciodigital syndrome type 5,Malformation syndrome,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,7150858[PMID]_23972372[PMID]
2637,2919,Orofaciodigital syndrome type 5,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7150858[PMID]_23972372[PMID]
20108,264675,Hereditary pulmonary alveolar proteinosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20622029[PMID]
2638,2920,Oliver syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,16278897[PMID]
2638,2920,Oliver syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16278897[PMID]
20111,264691,Isolated pulmonary capillaritis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2639,2921,Preaxial polydactyly-colobomata-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3441111[PMID]
2639,2921,Preaxial polydactyly-colobomata-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,3441111[PMID]
20110,264688,Congenital chylothorax,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20110,264688,Congenital chylothorax,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.17,Germany,Validated,25480460[PMID]
2989,3374,Unilateral ocular duplication,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17558850[PMID]
20332,275803,Pulmonary arterial hypertension associated with congenital heart disease,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.17,France,Validated,16456139[PMID]
20332,275803,Pulmonary arterial hypertension associated with congenital heart disease,Clinical group,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.026,France,Validated,16456139[PMID]
20332,275803,Pulmonary arterial hypertension associated with congenital heart disease,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.95,United Kingdom,Validated,21885399[PMID]_17360728[PMID]
20332,275803,Pulmonary arterial hypertension associated with congenital heart disease,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.2,United Kingdom,Validated,21885399[PMID]_17360728[PMID]
20332,275803,Pulmonary arterial hypertension associated with congenital heart disease,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.3,Spain,Validated,22362843[PMID]
20332,275803,Pulmonary arterial hypertension associated with congenital heart disease,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.46,Czech Republic,Validated,24629043[PMID]
20332,275803,Pulmonary arterial hypertension associated with congenital heart disease,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.22,Czech Republic,Validated,24629043[PMID]
20332,275803,Pulmonary arterial hypertension associated with congenital heart disease,Clinical group,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Netherlands,Validated,24794056[PMID]
20332,275803,Pulmonary arterial hypertension associated with congenital heart disease,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.57,Europe,Validated,22362843[PMID]_16456139[PMID]_24629043[PMID]_21885399[PMID]_17360728[PMID]
20333,275808,Pulmonary arterial hypertension associated with HIV infection,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
20334,275813,Pulmonary arterial hypertension associated with portal hypertension,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
2990,3377,Trismus-pseudocamptodactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20335,275823,Pulmonary arterial hypertension associated with schistosomiasis,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
2985,3368,Trigonocephaly-bifid nose-acral anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,2063891[PMID]
2985,3368,Trigonocephaly-bifid nose-acral anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2063891[PMID]
20328,275777,Heritable pulmonary arterial hypertension,Etiological subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.08,Europe,Validated,16456139[PMID]_ORPHANET
20328,275777,Heritable pulmonary arterial hypertension,Etiological subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.08,France,Validated,16456139[PMID]_ORPHANET
20328,275777,Heritable pulmonary arterial hypertension,Etiological subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.8,Czech Republic,Validated,24629043[PMID]_ORPHANET
20329,275786,Drug- or toxin-induced pulmonary arterial hypertension,Clinical group,Group of disorders,Point prevalence,Class only,1-9 / 1 000 000,0.0,France,Validated,16456139[PMID]_ORPHANET
20330,275791,Pulmonary arterial hypertension associated with another disease,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
2986,3369,Trigonocephaly-short stature-developmental delay syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,6168197[PMID]
2986,3369,Trigonocephaly-short stature-developmental delay syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6168197[PMID]
20331,275798,Pulmonary arterial hypertension associated with connective tissue disease,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.23,France,Validated,16456139[PMID]
20331,275798,Pulmonary arterial hypertension associated with connective tissue disease,Clinical group,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.036,France,Validated,16456139[PMID]
20331,275798,Pulmonary arterial hypertension associated with connective tissue disease,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.25,Spain,Validated,22362843[PMID]
20331,275798,Pulmonary arterial hypertension associated with connective tissue disease,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.25,United Kingdom,Validated,21885399[PMID]_17360728[PMID]
20331,275798,Pulmonary arterial hypertension associated with connective tissue disease,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.25,United Kingdom,Validated,21885399[PMID]_17360728[PMID]
20331,275798,Pulmonary arterial hypertension associated with connective tissue disease,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.25,Czech Republic,Validated,24629043[PMID]
20331,275798,Pulmonary arterial hypertension associated with connective tissue disease,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Czech Republic,Validated,24629043[PMID]
20331,275798,Pulmonary arterial hypertension associated with connective tissue disease,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.25,Europe,Validated,24629043[PMID]_22362843[PMID]_16456139[PMID]_21885399[PMID]_17360728[PMID]
2981,3363,Trichomegaly-retina pigmentary degeneration-dwarfism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,25480986[PMID]
2981,3363,Trichomegaly-retina pigmentary degeneration-dwarfism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25480986[PMID]
20326,275761,Lysosomal acid lipase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.27,Czech Republic,Validated,20490927[PMID]
20326,275761,Lysosomal acid lipase deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Europe,Validated,European Medicines Agency 2015[INST]
2983,3366,Non-syndromic metopic craniosynostosis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.7,Europe,Not yet validated,21931569[PMID]_19326483[PMID]
2983,3366,Non-syndromic metopic craniosynostosis,Morphological anomaly,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.2979,Europe,Validated,ORPHANET
2982,3365,Trigonocephaly-broad thumbs syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,1271432[PMID]
2982,3365,Trigonocephaly-broad thumbs syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1271432[PMID]
20327,275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20327,275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.59,France,Validated,16456139[PMID]
20327,275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,France,Validated,16456139[PMID]
20327,275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.56,Spain,Validated,22362843[PMID]
20327,275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Spain,Validated,22362843[PMID]
20327,275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,1.4,Czech Republic,Validated,24629043[PMID]
20327,275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.62,Czech Republic,Validated,24629043[PMID]
20327,275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.86,Switzerland,Validated,18587690[PMID]
20327,275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Switzerland,Validated,18587690[PMID]
20327,275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.25,United Kingdom,Validated,21885399[PMID]_17360728[PMID]
20327,275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,1.7,United Kingdom,Validated,21885399[PMID]_17360728[PMID]
20327,275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.11,United States,Validated,20558556[PMID]
20327,275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.17,Belgium,Validated,8692238[PMID]
20327,275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.14,Israel,Validated,11399707[PMID]
20327,275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.8,Israel,Validated,11399707[PMID]
20327,275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,1.1,Europe,Validated,16456139[PMID]_22362843[PMID]_18587690[PMID]_21885399[PMID]_17360728[PMID]_24629043[PMID]
2979,3361,Trichodysplasia-xeroderma syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,3608221[PMID]
2979,3361,Trichodysplasia-xeroderma syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3608221[PMID]
3004,3408,Upington disease,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,5316541[PMID]
3004,3408,Upington disease,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5316541[PMID]
3005,3409,Urban-Rogers-Meyer syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,758422[PMID]_3239569[PMID]
3005,3409,Urban-Rogers-Meyer syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_758422[PMID]_3239569[PMID]
20348,276145,Malignant epithelial tumor of salivary glands,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.73,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
20348,276145,Malignant epithelial tumor of salivary glands,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.85,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
20348,276145,Malignant epithelial tumor of salivary glands,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.986,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
20348,276145,Malignant epithelial tumor of salivary glands,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.809,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
20348,276145,Malignant epithelial tumor of salivary glands,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.737,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
20348,276145,Malignant epithelial tumor of salivary glands,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.98,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
20348,276145,Malignant epithelial tumor of salivary glands,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.817,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
20348,276145,Malignant epithelial tumor of salivary glands,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.864,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
20348,276145,Malignant epithelial tumor of salivary glands,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.937,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
20348,276145,Malignant epithelial tumor of salivary glands,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.899,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
20348,276145,Malignant epithelial tumor of salivary glands,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.99,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
20348,276145,Malignant epithelial tumor of salivary glands,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.657,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
20348,276145,Malignant epithelial tumor of salivary glands,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.919,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
20348,276145,Malignant epithelial tumor of salivary glands,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.906,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
20348,276145,Malignant epithelial tumor of salivary glands,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.786,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
20348,276145,Malignant epithelial tumor of salivary glands,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.906,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
20348,276145,Malignant epithelial tumor of salivary glands,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.121,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
20348,276145,Malignant epithelial tumor of salivary glands,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.026,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
20348,276145,Malignant epithelial tumor of salivary glands,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.261,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
20348,276145,Malignant epithelial tumor of salivary glands,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.113,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
20348,276145,Malignant epithelial tumor of salivary glands,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.127,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
20348,276145,Malignant epithelial tumor of salivary glands,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.093,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
20348,276145,Malignant epithelial tumor of salivary glands,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.227,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
20348,276145,Malignant epithelial tumor of salivary glands,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.213,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
20351,276161,Multiple endocrine neoplasia,Clinical group,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.05,Ireland,Validated,2575263[PMID]
20351,276161,Multiple endocrine neoplasia,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET_[EXPERT]
3007,3412,VACTERL with hydrocephalus,Malformation syndrome,Disorder,Cases/families,Family(ies),,10.0,Worldwide,Validated,ORPHANET
3007,3412,VACTERL with hydrocephalus,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20350,276152,Multiple endocrine neoplasia type 4,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3001,3403,Uhl anomaly,Morphological anomaly,Disorder,Cases/families,Case(s),,84.0,Worldwide,Validated,ORPHANET
3001,3403,Uhl anomaly,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Worldwide,Not yet validated,ORPHANET
3001,3403,Uhl anomaly,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3002,3404,Ulbright-Hodes syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,6711618[PMID]_2240030[PMID]
3002,3404,Ulbright-Hodes syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6711618[PMID]_2240030[PMID]
20346,276066,Bile acid CoA ligase deficiency and defective amidation,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20341,275872,Frontotemporal dementia with motor neuron disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2996,3383,Humerus trochlea aplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,Mead 1963[AUTHOR]
2996,3383,Humerus trochlea aplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2997,3384,Common arterial trunk,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.3,Worldwide,Validated,[EXPERT]
2997,3384,Common arterial trunk,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.8,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2997,3384,Common arterial trunk,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.8,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2997,3384,Common arterial trunk,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.8,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2997,3384,Common arterial trunk,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.8,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2997,3384,Common arterial trunk,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.5,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2997,3384,Common arterial trunk,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.6,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2997,3384,Common arterial trunk,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.8,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2997,3384,Common arterial trunk,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.8,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2997,3384,Common arterial trunk,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.3,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2997,3384,Common arterial trunk,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.2,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2997,3384,Common arterial trunk,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.9,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2997,3384,Common arterial trunk,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,12.6,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2997,3384,Common arterial trunk,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.7,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2997,3384,Common arterial trunk,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.4,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2997,3384,Common arterial trunk,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20340,275864,Behavioral variant of frontotemporal dementia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.0,Netherlands,Validated,22950490[PMID]
20343,275944,Hemolytic disease of the newborn with Kell alloimmunization,Disease,Disorder,Annual incidence,Value and class,>1 / 1000,116.0,United Kingdom,Validated,2081378[PMID]
20343,275944,Hemolytic disease of the newborn with Kell alloimmunization,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2998,3387,Isolated anterior cervical hypertrichosis,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,ORPHANET
2998,3387,Isolated anterior cervical hypertrichosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2999,3388,Neural tube defect,Category,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,55.0,United States,Validated,Center for Diseases Control and Prevention 2004[INST]_26108864[PMID]
2999,3388,Neural tube defect,Category,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,91.05,Europe,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG]
2999,3388,Neural tube defect,Category,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,88.75,Belgium,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG]
2999,3388,Neural tube defect,Category,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,76.8,Austria,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2009[REG]
2999,3388,Neural tube defect,Category,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,74.7,Czech Republic,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 2000-2009[REG]
2999,3388,Neural tube defect,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,47.9,Croatia,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2010[REG]
2999,3388,Neural tube defect,Category,Group of disorders,Prevalence at birth,Value and class,>1 / 1000,109.6,Denmark,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG]
2999,3388,Neural tube defect,Category,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,86.7,Finland,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1993-2010[REG]
2999,3388,Neural tube defect,Category,Group of disorders,Prevalence at birth,Value and class,>1 / 1000,120.2,France,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG]
2999,3388,Neural tube defect,Category,Group of disorders,Prevalence at birth,Value and class,>1 / 1000,138.25,Germany,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG]
2999,3388,Neural tube defect,Category,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,67.2,Hungary,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1998-2010[REG]
2999,3388,Neural tube defect,Category,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,87.4,Ireland,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG]
2999,3388,Neural tube defect,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,54.65,Italy,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG]
2999,3388,Neural tube defect,Category,Group of disorders,Prevalence at birth,Value and class,>1 / 1000,109.5,Malta,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2010[REG]
2999,3388,Neural tube defect,Category,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,84.2,Netherlands,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG]
2999,3388,Neural tube defect,Category,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,92.7,Norway,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1999-2011[REG]
2999,3388,Neural tube defect,Category,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,92.5,Poland,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1999-2010[REG]
2999,3388,Neural tube defect,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,47.3,Portugal,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2010[REG]
2999,3388,Neural tube defect,Category,Group of disorders,Prevalence at birth,Value and class,6-9 / 10 000,98.5,Spain,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2010[REG]
2999,3388,Neural tube defect,Category,Group of disorders,Prevalence at birth,Value and class,>1 / 1000,101.7,Switzerland,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG]
2999,3388,Neural tube defect,Category,Group of disorders,Prevalence at birth,Value and class,>1 / 1000,115.5,United Kingdom,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG]
2999,3388,Neural tube defect,Category,Group of disorders,Prevalence at birth,Value and class,>1 / 1000,1387.0,China,Validated,16575897[PMID]
2999,3388,Neural tube defect,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,31.0,Brazil,Validated,23990401[PMID]
2992,1723,Mosaic trisomy 2 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,23276565[PMID]
2992,1723,Mosaic trisomy 2 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23276565[PMID]
20336,275828,Pulmonary arterial hypertension associated with chronic hemolytic anemia,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
2993,1724,Mosaic trisomy 20 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_23548241[PMID]
2994,1747,Mosaic trisomy 7 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,31.0,Worldwide,Validated,28099615[PMID]_21056320[PMID]
2994,1747,Mosaic trisomy 7 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28099615[PMID]_21056320[PMID]
2954,3329,Tibial aplasia-ectrodactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,[EXPERT]
2953,3328,Absent tibia-polydactyly-arachnoid cyst syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,8592337[PMID]
2953,3328,Absent tibia-polydactyly-arachnoid cyst syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8592337[PMID]
2952,3327,Thyrocerebrorenal syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,728567[PMID]
2952,3327,Thyrocerebrorenal syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_728567[PMID]
2951,3326,Thymic-renal-anal-lung dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,2260572[PMID]
2951,3326,Thymic-renal-anal-lung dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2260572[PMID]
2949,3322,Hoyeraal-Hreidarsson syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2949,3322,Hoyeraal-Hreidarsson syndrome,Disease,Disorder,Cases/families,Case(s),,33.0,Worldwide,Validated,23453664[PMID]_23453664[PMID]_23329068[PMID]
2947,3317,Thoracolaryngopelvic dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,ORPHANET
2947,3317,Thoracolaryngopelvic dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2946,3316,Thomas syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,8456859[PMID]_8882777[PMID]
2946,3316,Thomas syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8456859[PMID]_8882777[PMID]
2945,3314,"Thiemann disease, familial form",Disease,Disorder,Cases/families,Case(s),,33.0,Worldwide,Validated,31248428[PMID]
2945,3314,"Thiemann disease, familial form",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_31248428[PMID]
2974,3355,Trichoodontoonychial dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,6859125[PMID]
2974,3355,Trichoodontoonychial dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6859125[PMID]
20319,275555,Preeclampsia,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,45.0,Europe,Validated,European Medicines Agency 2011[INST]
20318,275543,L1 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2972,3353,Trichodermodysplasia-dental alterations syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,3720011[PMID]
2972,3353,Trichodermodysplasia-dental alterations syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3720011[PMID]
20316,275523,Dianzani autoimmune lymphoproliferative disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20316,275523,Dianzani autoimmune lymphoproliferative disease,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,[EXPERT]
2970,3351,Trichodental syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,5.0,Worldwide,Validated,8574424[PMID]
2970,3351,Trichodental syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8574424[PMID]
20315,275517,Autoimmune lymphoproliferative syndrome-recurrent viral infections due to CASP8 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12353035[PMID]
20315,275517,Autoimmune lymphoproliferative syndrome-recurrent viral infections due to CASP8 deficiency,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,12353035[PMID]_Dr Koneti RAO[EXPERT]
2971,3352,Tricho-dento-osseous syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
2971,3352,Tricho-dento-osseous syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2969,3350,Tremor-nystagmus-duodenal ulcer syndrome,Disease,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,1248168[PMID]
2969,3350,Tremor-nystagmus-duodenal ulcer syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1248168[PMID]
2966,3344,Weismann-Netter syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,19839038[PMID]
2966,3344,Weismann-Netter syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_19839038[PMID]
2967,3347,Mounier-Kühn syndrome,Clinical syndrome,Disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,[EXPERT]_25130790[PMID]
2967,3347,Mounier-Kühn syndrome,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_25130790[PMID]
2964,3341,Torticollis-keloids-cryptorchidism-renal dysplasia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,12725596[PMID]_4387470[PMID]
2964,3341,Torticollis-keloids-cryptorchidism-renal dysplasia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12725596[PMID]_4387470[PMID]
2965,3342,Arterial tortuosity syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,102.0,Worldwide,Validated,29323665[PMID]
2965,3342,Arterial tortuosity syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29323665[PMID]
2962,3339,Oculoectodermal syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,25251940[PMID]
2962,3339,Oculoectodermal syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25251940[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2222,Worldwide,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1474,Argentina,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.147,Australia,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1511,Austria,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1484,Bangladesh,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1504,Belgium,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5694,Bulgaria,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1476,Canada,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1481,China,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.25,Cyprus,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1509,Czech Republic,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1403,Denmark,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.149,Ecuador,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1454,Finland,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.7514,France,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1486,Germany,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1481,Greece,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.153,Hungary,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1481,India,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1578,Ireland,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1428,Israel,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.9046,Italy,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1473,Poland,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,19.9126,Portugal,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1464,Romania,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1485,Russian Federation,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1428,Slovenia,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1487,Spain,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1476,Sri Lanka,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.5816,Sweden,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Lifetime Prevalence,Value and class,1-9 / 1 000 000,0.1445,Switzerland,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1489,"Taiwan, Province of China",Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.0317,Turkey,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.149,United Kingdom,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.0968,Japan,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1482,"Korea, Republic of",Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1666,Luxembourg,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1485,Malaysia,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.148,Mexico,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2662,Netherlands,Validated,29211930[PMID]
20307,271861,Hereditary ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,0.1521,New Zealand,Validated,29211930[PMID]
2961,3338,Toriello-Carey syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,59.0,Worldwide,Validated,27510950[PMID]
2961,3338,Toriello-Carey syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27510950[PMID]
3049,3469,XK aprosencephaly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,ORPHANET
3049,3469,XK aprosencephaly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3051,3472,Yunis-Varon syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,25.0,Worldwide,Validated,23623387[PMID]
3051,3472,Yunis-Varon syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3050,3471,Young syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3053,3319,Congenital amegakaryocytic thrombocytopenia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
3053,3319,Congenital amegakaryocytic thrombocytopenia,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,21337678[PMID]_22102270[PMID]
3053,3319,Congenital amegakaryocytic thrombocytopenia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.15,United Kingdom,Validated,[EXPERT]
3052,3473,Zimmermann-Laband syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,52.0,Worldwide,Validated,23994350[PMID]
3052,3473,Zimmermann-Laband syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,23994350[PMID]_ORPHANET
3041,3459,Wilson-Turner syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,28.0,Worldwide,Validated,1746601[PMID]_22889856[PMID]
3041,3459,Wilson-Turner syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1746601[PMID]_22889856[PMID]
3045,3464,Woodhouse-Sakati syndrome,Disease,Disorder,Cases/families,Family(ies),,25.0,Worldwide,Validated,18175354[PMID]
3045,3464,Woodhouse-Sakati syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18175354[PMID]
3047,3466,WT limb-blood syndrome,Disease,Disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,890097[PMID]
3047,3466,WT limb-blood syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_890097[PMID]
3046,3465,Worster-Drought syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.7,Europe,Validated,ORPHANET
3064,2749,Oromandibular-limb hypogenesis syndrome,Clinical group,Group of disorders,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
3066,2995,Baraitser-Winter cerebrofrontofacial syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,27625340[PMID]
3066,2995,Baraitser-Winter cerebrofrontofacial syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27625340[PMID]
3069,3200,Arthrogryposis-ectodermal dysplasia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,1590979[PMID]
3069,3200,Arthrogryposis-ectodermal dysplasia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1590979[PMID]
3071,1570,Symbrachydactyly of hands and feet,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,9555583[PMID]
3071,1570,Symbrachydactyly of hands and feet,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9555583[PMID]
3057,3243,Sweet syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_17655751[PMID]
3060,1827,Acromelic frontonasal dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,15264282[PMID]_25105228[PMID]_26706854[PMID]
3060,1827,Acromelic frontonasal dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15264282[PMID]_25105228[PMID]_26706854[PMID]
3063,2076,X-linked intellectual disability-epilepsy syndrome,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20234,268980,Isolated focal cortical dysplasia type Ib,Histopathological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20235,268987,Isolated focal cortical dysplasia type Ic,Histopathological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3017,3424,Velo-facial-skeletal syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,7573161[PMID]
3017,3424,Velo-facial-skeletal syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7573161[PMID]
20233,268973,Isolated focal cortical dysplasia type Ia,Histopathological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20238,269008,Isolated focal cortical dysplasia type IIb,Histopathological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3023,3433,Microcephaly-brachydactyly-kyphoscoliosis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,1884519[PMID]
3023,3433,Microcephaly-brachydactyly-kyphoscoliosis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1884519[PMID]
20236,268994,Isolated focal cortical dysplasia type II,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3020,3429,Verloove Vanhorick-Brubakk syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,7324930[PMID]
3020,3429,Verloove Vanhorick-Brubakk syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7324930[PMID]
20237,269001,Isolated focal cortical dysplasia type IIa,Histopathological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3011,2460,Van den Ende-Gupta syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,29.0,Worldwide,Validated,24478002[PMID]
3011,2460,Van den Ende-Gupta syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24478002[PMID]
20226,268940,Bilateral polymicrogyria,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20227,268943,Unilateral polymicrogyria,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3010,3416,Hyperostosis corticalis generalisata,Malformation syndrome,Disorder,Cases/families,Case(s),,35.0,Worldwide,Validated,26968112[PMID]
3010,3416,Hyperostosis corticalis generalisata,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26968112[PMID]
20224,268926,Midline cerebral malformation,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20225,268936,Isolated arhinencephaly,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20231,268961,Isolated focal cortical dysplasia type I,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20228,268947,Unilateral focal polymicrogyria,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3012,3417,Van den Bosch syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,DOI:10.1159/000303582[OTHER]
3012,3417,Van den Bosch syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_DOI:10.1159/000303582[OTHER]
20229,268950,Cerebral cortical dysplasia,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20251,269229,Pontine tegmental cap dysplasia,Morphological anomaly,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,21651769[PMID]_21705787[PMID]
20251,269229,Pontine tegmental cap dysplasia,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3035,3453,Autoimmune polyendocrinopathy type 1,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.0,Finland,Validated,[EXPERT]
3035,3453,Autoimmune polyendocrinopathy type 1,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,France,Validated,[EXPERT]
3035,3453,Autoimmune polyendocrinopathy type 1,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
20250,269224,Global cerebellar malformation,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3032,3448,Weaver-Williams syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,890101[PMID]
3032,3448,Weaver-Williams syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_890101[PMID]
20249,269221,Isolated bilateral hemispheric cerebellar hypoplasia,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3033,3449,Weill-Marchesani syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Worldwide,Not yet validated,20301293[PMID]
20248,269218,Isolated unilateral hemispheric cerebellar hypoplasia,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3038,3456,Wildervanck syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20534924[PMID]
20253,269510,Congenital non-communicating hydrocephalus,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3036,3454,Wieacker-Wolff syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,5.0,Worldwide,Validated,ORPHANET_23623388[PMID]
3036,3454,Wieacker-Wolff syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3037,3455,Wiedemann-Rautenstrauch syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,37.0,Worldwide,Validated,EXPERT
3037,3455,Wiedemann-Rautenstrauch syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28447407[PMID]
20252,269505,Congenital communicating hydrocephalus,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20243,269203,Isolated cerebellar vermis agenesis,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_10488899[PMID]_7724272[PMID]
20241,269197,Glioependymal/ependymal cyst,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3024,3434,MMEP syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20247,269215,Isolated Dandy-Walker malformation without hydrocephalus,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20246,269212,Isolated Dandy-Walker malformation with hydrocephalus,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20245,269209,Isolated partial cerebellar vermis agenesis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20244,269206,Isolated total cerebellar vermis agenesis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2852,1856,Spondyloperipheral dysplasia-short ulna syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23545312[PMID]
2852,1856,Spondyloperipheral dysplasia-short ulna syndrome,Disease,Disorder,Cases/families,Family(ies),,10.0,Worldwide,Validated,23545312[PMID]
20452,280302,Autoimmune pancreatitis type 1,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20455,280333,Alpha-dystroglycan-related limb-girdle muscular dystrophy R16,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,14678799[PMID]_21388311[PMID]
20455,280333,Alpha-dystroglycan-related limb-girdle muscular dystrophy R16,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21388311[PMID]
20454,280325,Distal deletion 12p syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,21144913[PMID]
20454,280325,Distal deletion 12p syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20449,280293,Pelizaeus-Merzbacher-like disease due to AIMP1 mutation,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20448,280288,Pelizaeus-Merzbacher-like disease due to HSPD1 mutation,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2860,3194,Corneodermatoosseous syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,6234802[PMID]
2860,3194,Corneodermatoosseous syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6234802[PMID]
20460,280365,Autosomal semi-dominant severe lipodystrophic laminopathy,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,21346069[PMID]
20460,280365,Autosomal semi-dominant severe lipodystrophic laminopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20463,280379,Erythropoietic uroporphyria associated with myeloid malignancy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
2862,3197,Hereditary hyperekplexia,Disease,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,ORPHANET
2862,3197,Hereditary hyperekplexia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2863,3199,Stimmler syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,5477682[PMID]
2863,3199,Stimmler syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5477682[PMID]
2856,3184,Steatocystoma multiplex-natal teeth syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
2857,3186,Holoprosencephaly-radial heart renal anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,20583155[PMID]
2857,3186,Holoprosencephaly-radial heart renal anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20583155[PMID]
2858,3191,Subaortic stenosis-short stature syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,573203[PMID]
2858,3191,Subaortic stenosis-short stature syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_573203[PMID]
2859,3193,Supravalvular aortic stenosis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.0,Europe,Validated,[EXPERT]
2859,3193,Supravalvular aortic stenosis,Morphological anomaly,Disorder,Point prevalence,Value and class,1-5 / 10 000,13.3,Europe,Validated,[EXPERT]
20458,280356,PLIN1-related familial partial lipodystrophy,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,21345103[PMID]
20458,280356,PLIN1-related familial partial lipodystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2869,3214,"Deaf blind hypopigmentation syndrome, Yemenite type",Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,2280978[PMID]
2869,3214,"Deaf blind hypopigmentation syndrome, Yemenite type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20469,280403,Familial omphalocele syndrome with facial dysmorphism,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,21333766[PMID]
20469,280403,Familial omphalocele syndrome with facial dysmorphism,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20470,280406,Familial steroid-resistant nephrotic syndrome with sensorineural deafness,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,21540551[PMID]
20470,280406,Familial steroid-resistant nephrotic syndrome with sensorineural deafness,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2864,3201,Ventricular extrasystoles with syncopal episodes-perodactyly-Robin sequence syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
20465,280384,Recessive intellectual disability-motor dysfunction-multiple joint contractures syndrome,Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,21330303[PMID]
20465,280384,Recessive intellectual disability-motor dysfunction-multiple joint contractures syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20467,280397,Familial Alzheimer-like prion disease,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,21416485[PMID]
20467,280397,Familial Alzheimer-like prion disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21416485[PMID]
20476,280576,Nestor-Guillermo progeria syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,21932319[PMID]_21549337[PMID]
20476,280576,Nestor-Guillermo progeria syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2877,3220,Deafness-enamel hypoplasia-nail defects syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,15.0,Worldwide,Validated,26387595[PMID]_27633571[PMID]_27302843[PMID]
2877,3220,Deafness-enamel hypoplasia-nail defects syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26387595[PMID]_27633571[PMID]_27302843[PMID]
2876,3219,Fountain syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,8897038[PMID]
2876,3219,Fountain syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8897038[PMID]
2879,3222,Phosphoribosylpyrophosphate synthetase superactivity,Disease,Disorder,Cases/families,Family(ies),,30.0,Worldwide,Validated,23190330[PMID]
2879,3222,Phosphoribosylpyrophosphate synthetase superactivity,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20478,280586,"Chondrodysplasia with joint dislocations, gPAPP type",Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,21549340[PMID]
20478,280586,"Chondrodysplasia with joint dislocations, gPAPP type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2873,3217,Deafness-small bowel diverticulosis-neuropathy syndrome,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,4028504[PMID]
2873,3217,Deafness-small bowel diverticulosis-neuropathy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4028504[PMID]
20472,280553,Fatal infantile hypertonic myofibrillar myopathy,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,21337604[PMID]_22734908[PMID]
20472,280553,Fatal infantile hypertonic myofibrillar myopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21337604[PMID]_22734908[PMID]
20473,280558,Warsaw breakage syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,20137776[PMID]_21490908[PMID]_23033317[PMID]
20473,280558,Warsaw breakage syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2872,3216,Conductive deafness-malformed external ear syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,5771216[PMID]_624552[PMID]
2872,3216,Conductive deafness-malformed external ear syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5771216[PMID]_624552[PMID]
2875,3218,Deafness-epiphyseal dysplasia-short stature syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8867655[PMID]
2875,3218,Deafness-epiphyseal dysplasia-short stature syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8867655[PMID]
2823,647,Nijmegen breakage syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Worldwide,Not yet validated,20301355[PMID]
2823,647,Nijmegen breakage syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
2823,647,Nijmegen breakage syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.7,Russian Federation,Validated,33488600[PMID]
2823,647,Nijmegen breakage syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,3.1,Poland,Validated,33488600[PMID]
2823,647,Nijmegen breakage syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,3.1,Czech Republic,Validated,33488600[PMID]
2823,647,Nijmegen breakage syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,2.6,Slovakia,Validated,33488600[PMID]
2823,647,Nijmegen breakage syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,2.3,Belarus,Validated,33488600[PMID]
2823,647,Nijmegen breakage syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,1.3,Ukraine,Validated,33488600[PMID]
20422,280062,Calciphylaxis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
20421,279947,Postorgasmic illness syndrome,Clinical syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20421,279947,Postorgasmic illness syndrome,Clinical syndrome,Disorder,Cases/families,Case(s),,45.0,Worldwide,Validated,21241453[PMID]
20420,279943,Hereditary neutrophilia,Disease,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,19620628[PMID]
20420,279943,Hereditary neutrophilia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19620628[PMID]
20419,279934,"Mitochondrial DNA depletion syndrome, hepatocerebral form due to DGUOK deficiency",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
20419,279934,"Mitochondrial DNA depletion syndrome, hepatocerebral form due to DGUOK deficiency",Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,29137425[PMID]_[EXPERT]
2819,3152,Sclerosteosis,Malformation syndrome,Disorder,Cases/families,Case(s),,80.0,Worldwide,Validated,20301406[PMID]
2819,3152,Sclerosteosis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20301406[PMID]
20431,280142,Severe combined immunodeficiency due to LCK deficiency,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,9664084[PMID]_22985903[PMID]
20431,280142,Severe combined immunodeficiency due to LCK deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2830,3164,"Omphalocele syndrome, Shprintzen-Goldberg type",Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,16411191[PMID]
2830,3164,"Omphalocele syndrome, Shprintzen-Goldberg type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16411191[PMID]
2831,3168,Sillence syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,671485[PMID]
2831,3168,Sillence syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20430,280133,Complement component 3 deficiency,Disease,Disorder,Cases/families,Case(s),,27.0,Worldwide,Validated,21664996[PMID]
20430,280133,Complement component 3 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21664996[PMID]
2829,3163,SHORT syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,32.0,Worldwide,Validated,26497935[PMID]
2829,3163,SHORT syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26497935[PMID]
2826,1479,Atrial septal defect-atrioventricular conduction defects syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,9561886[PMID]
2826,1479,Atrial septal defect-atrioventricular conduction defects syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2824,3156,Senior-Loken syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Worldwide,Validated,33109693[PMID]
20425,280071,ALG11-CDG,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,28122681[PMID]
20425,280071,ALG11-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28122681[PMID]
2825,3157,Septo-optic dysplasia spectrum,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,10.0,Europe,Validated,[EXPERT]
2825,3157,Septo-optic dysplasia spectrum,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
2839,3180,Spondylocamptodactyly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,8591666[PMID]
2839,3180,Spondylocamptodactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8591666[PMID]
20438,280210,"Pelizaeus-Merzbacher disease, connatal form",Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.03,Europe,Validated,[EXPERT]
20439,280219,"Pelizaeus-Merzbacher disease, classic form",Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.17,Europe,Validated,[EXPERT]
20436,280200,Microform holoprosencephaly,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
2836,3177,Spinocerebellar degeneration-corneal dystrophy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,3872072[PMID]
2836,3177,Spinocerebellar degeneration-corneal dystrophy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3872072[PMID]
20437,280205,Laryngotracheoesophageal cleft type 0,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2835,3175,X-linked spasticity-intellectual disability-epilepsy syndrome,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,12177367[PMID]
2835,3175,X-linked spasticity-intellectual disability-epilepsy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12177367[PMID]
20435,280195,Septopreoptic holoprosencephaly,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2833,3172,Eyebrow duplication-syndactyly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,3359678[PMID]_2736796[PMID]
2833,3172,Eyebrow duplication-syndactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3359678[PMID]_2736796[PMID]
20433,280183,Methylmalonic aciduria due to transcobalamin receptor defect,Biological anomaly,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,20524213[PMID]
20433,280183,Methylmalonic aciduria due to transcobalamin receptor defect,Biological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20447,280282,Pelizaeus-Merzbacher-like disease due to GJC2 mutation,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20445,280270,Pelizaeus-Merzbacher-like disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20442,280234,Null syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2842,1855,Spondyloenchondrodysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,36.0,Worldwide,Validated,16470600[PMID]
2842,1855,Spondyloenchondrodysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16470600[PMID]
20440,280224,"Pelizaeus-Merzbacher disease, transitional form",Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.03,Europe,Validated,[EXPERT]
2841,1797,Autosomal dominant spondylocostal dysostosis,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20441,280229,Pelizaeus-Merzbacher disease in female carriers,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20385,276580,Autosomal dominant hyperinsulinism due to Kir6.2 deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2913,3258,Cenani-Lenz syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,[EXPERT]
2913,3258,Cenani-Lenz syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20384,276575,Autosomal dominant hyperinsulinism due to SUR1 deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2914,3262,Dobrow syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,6580396[PMID]_15365455[PMID]
2914,3262,Dobrow syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6580396[PMID]_15365455[PMID]
20387,276598,Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20389,276608,Non-insulinoma pancreatogenous hypoglycemia syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2916,3265,Isolated humero-radial synostosis,Morphological anomaly,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,ORPHANET
2916,3265,Isolated humero-radial synostosis,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20388,276603,Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2917,3266,Isolated humero-radio-ulnar synostosis,Morphological anomaly,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
2917,3266,Isolated humero-radio-ulnar synostosis,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20390,276621,Sporadic pheochromocytoma/secreting paraganglioma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
2919,3268,Radioulnar synostosis-microcephaly-scoliosis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,20635354[PMID]
2919,3268,Radioulnar synostosis-microcephaly-scoliosis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20635354[PMID]
20393,276630,Symptomatic form of Coffin-Lowry syndrome in female carriers,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2920,3270,Radioulnar synostosis-developmental delay-hypotonia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,1384331[PMID]_18618994[PMID]
2920,3270,Radioulnar synostosis-developmental delay-hypotonia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1384331[PMID]_18618994[PMID]
2923,3275,Spondylocarpotarsal synostosis,Malformation syndrome,Disorder,Cases/families,Case(s),,35.0,Worldwide,Validated,29566257[PMID]
2923,3275,Spondylocarpotarsal synostosis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29566257[PMID]
2927,425,Apolipoprotein A-I deficiency,Disease,Disorder,Cases/families,Family(ies),,30.0,Worldwide,Validated,17991756[PMID]
2927,425,Apolipoprotein A-I deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2927,425,Apolipoprotein A-I deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,European Medicines Agency 2014[INST]
2931,3291,Teebi-Shaltout syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,23918592[PMID]
2931,3291,Teebi-Shaltout syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23918592[PMID]
2933,3293,Telecanthus-hypertelorism-strabismus-pes cavus syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,3970067[PMID]
2933,3293,Telecanthus-hypertelorism-strabismus-pes cavus syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3970067[PMID]
2932,3292,Tel Hashomer camptodactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
20407,279882,Spasmus nutans,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
2934,3294,Extensor tendons of finger anomalies,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,7363507[PMID]
2934,3294,Extensor tendons of finger anomalies,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7363507[PMID]
20408,279888,Acute endophthalmitis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20409,279891,Chronic endophthalmitis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20410,279894,Toxic maculopathy due to antimalarial drugs,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2939,3301,Tetraamelia-multiple malformations syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20301453[PMID]
2939,3301,Tetraamelia-multiple malformations syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,5.0,Worldwide,Validated,20301453[PMID]
20411,279897,Primary oculocerebral lymphoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20412,279904,Primary intraocular lymphoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2940,3304,Fallot complex-intellectual disability-growth delay syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,8010348[PMID]_15578610[PMID]
2940,3304,Fallot complex-intellectual disability-growth delay syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8010348[PMID]_15578610[PMID]
2943,3312,Thalidomide embryopathy,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.77,Worldwide,Not yet validated,ORPHANET
20414,279914,Intermediate uveitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20355,276198,Spinocerebellar ataxia type 36,Disease,Disorder,Cases/families,Family(ies),,100.0,Worldwide,Validated,25101480[PMID]
20355,276198,Spinocerebellar ataxia type 36,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_25101480[PMID]
20354,276193,Spinocerebellar ataxia type 35,Disease,Disorder,Cases/families,Case(s),,28.0,Worldwide,Validated,30229425[PMID]
20354,276193,Spinocerebellar ataxia type 35,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
20353,276183,Spinocerebellar ataxia type 32,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,Jiang_Zhu_Gomez 2010[AUTHOR]
20353,276183,Spinocerebellar ataxia type 32,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2881,3224,Deafness-genital anomalies-metacarpal and metatarsal synostosis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,15887301[PMID]
2881,3224,Deafness-genital anomalies-metacarpal and metatarsal synostosis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15887301[PMID]
20352,276174,Idiopathic recurrent stupor,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20359,276238,Machado-Joseph disease type 1,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20358,276234,Non-syndromic male infertility due to sperm motility disorder,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2890,3230,Deafness-oligodontia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_646726[PMID]_485932[PMID]_9720683[PMID]
2890,3230,Deafness-oligodontia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,646726[PMID]_485932[PMID]_9720683[PMID]
2891,3231,Deafness-onychodystrophy syndrome,Clinical group,Group of disorders,Cases/families,Case(s),,50.0,Worldwide,Validated,ORPHANET
2891,3231,Deafness-onychodystrophy syndrome,Clinical group,Group of disorders,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20361,276244,Machado-Joseph disease type 3,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,23994570[PMID]
20360,276241,Machado-Joseph disease type 2,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2894,3235,Progressive deafness with stapes fixation,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2895,3236,Conductive deafness-ptosis-skeletal anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,728561[PMID]
2895,3236,Conductive deafness-ptosis-skeletal anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_728561[PMID]
2892,3232,Deafness-ear malformation-facial palsy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,6851230[PMID]
2892,3232,Deafness-ear malformation-facial palsy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6851230[PMID]
2893,3233,Cochleosaccular degeneration-cataract syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,7121157[PMID]_1623624[PMID]
2893,3233,Cochleosaccular degeneration-cataract syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7121157[PMID]_1623624[PMID]
2899,3241,Deafness-craniofacial syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,3690878[PMID]
2899,3241,Deafness-craniofacial syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3690878[PMID]
20370,276280,Hemihyperplasia-multiple lipomatosis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,9781913[PMID]_20058713[PMID]_19438675[PMID]_20105568[PMID]
20370,276280,Hemihyperplasia-multiple lipomatosis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20371,276399,Familial multinodular goiter,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2898,3239,Deafness-vitiligo-achalasia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,5100941[PMID]
2898,3239,Deafness-vitiligo-achalasia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5100941[PMID]
2897,3238,Cardiospondylocarpofacial syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,5901343[PMID]_20186786[PMID]
2897,3238,Cardiospondylocarpofacial syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5901343[PMID]_20186786[PMID]
2896,3237,Multiple synostoses syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,30.0,Worldwide,Validated,ORPHANET
2896,3237,Multiple synostoses syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2903,3246,Symphalangism with multiple anomalies of hands and feet,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,6272576[PMID]
2903,3246,Symphalangism with multiple anomalies of hands and feet,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6272576[PMID]
20375,276413,10q22.3q23.3 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2900,3242,Renpenning syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,64.0,Worldwide,Validated,20950397[PMID]_16493439[PMID]_17033686[PMID]_11950858[PMID]_[EXPERT]
2900,3242,Renpenning syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20373,276405,Hyperbiliverdinemia,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,19580635[PMID]_21278388[PMID]
20373,276405,Hyperbiliverdinemia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2907,3250,Proximal symphalangism,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2905,3248,Isolated distal symphalangism,Morphological anomaly,Disorder,Cases/families,Family(ies),,8.0,Worldwide,Validated,3436086[PMID]_2061594[PMID]
2905,3248,Isolated distal symphalangism,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3436086[PMID]_2061594[PMID]
20376,276422,10q22.3q23.3 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20377,276429,Hypnic headache,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
2910,3255,Filippi syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,29.0,Worldwide,Validated,26813917[PMID]
2910,3255,Filippi syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26813917[PMID]
20383,276556,Hyperinsulinism due to UCP2 deficiency,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,19065272[PMID]
20383,276556,Hyperinsulinism due to UCP2 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20380,276432,Ogden syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,21700266[PMID]
20380,276432,Ogden syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
2908,3253,Cleft lip/palate-ectodermal dysplasia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
2908,3253,Cleft lip/palate-ectodermal dysplasia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,[EXPERT]
20381,276435,Lower motor neuron syndrome with late-adult onset,Disease,Disorder,Cases/families,Case(s),,55.0,Worldwide,Validated,25428574[PMID]
20381,276435,Lower motor neuron syndrome with late-adult onset,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25428574[PMID]
3280,911,Combined immunodeficiency due to ZAP70 deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3282,3325,Heparin-induced thrombocytopenia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3294,746,Mitochondrial trifunctional protein deficiency,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,ORPHANET_22000755[PMID]
3294,746,Mitochondrial trifunctional protein deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_22000755[PMID
3294,746,Mitochondrial trifunctional protein deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,European Medicines Agency 2015[INST]
3295,943,Malonic aciduria,Disease,Disorder,Cases/families,Case(s),,34.0,Worldwide,Validated,23177061[PMID]
3295,943,Malonic aciduria,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3290,621,Hereditary methemoglobinemia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3271,2089,Glycogen storage disease due to hepatic glycogen synthase deficiency,Disease,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,12072888[PMID]
3271,2089,Glycogen storage disease due to hepatic glycogen synthase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3264,412,Dysbetalipoproteinemia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.8,Europe,Not yet validated,ORPHANET
3264,412,Dysbetalipoproteinemia,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,Worldwide,Validated,21354122[PMID]_24314366[PMID]
3267,743,Severe hereditary thrombophilia due to congenital protein S deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,Pr Jenny GOUDEMAND [EXPERT]
3267,743,Severe hereditary thrombophilia due to congenital protein S deficiency,Disease,Disorder,Prevalence at birth,Class only,Unknown,0.0,Europe,Validated,Pr Jenny GOUDEMAND [EXPERT]
3266,424,Familial hyperthyroidism due to mutations in TSH receptor,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3266,424,Familial hyperthyroidism due to mutations in TSH receptor,Disease,Disorder,Cases/families,Family(ies),,28.0,Worldwide,Validated,[EXPERT]
3277,325,Congenital factor II deficiency,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.05,Europe,Validated,10595621[PMID]
3276,343,Hyperimmunoglobulinemia D with periodic fever,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,ORPHANET
3276,343,Hyperimmunoglobulinemia D with periodic fever,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
3279,572,Immunodeficiency by defective expression of MHC class II,Disease,Disorder,Cases/families,Case(s),,179.0,Worldwide,Validated,27510876[PMID]
3279,572,Immunodeficiency by defective expression of MHC class II,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_27510876[PMID]
3275,1930,Herpes simplex virus encephalitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.3,Worldwide,Validated,16675036[PMID]
3275,1930,Herpes simplex virus encephalitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.3,United Kingdom,Validated,20657024[PMID]
3275,1930,Herpes simplex virus encephalitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.3,United States,Validated,16675036[PMID]
3275,1930,Herpes simplex virus encephalitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
3316,158,Systemic primary carnitine deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.2,Europe,Validated,22989098[PMID]
3316,158,Systemic primary carnitine deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.2,United States,Validated,22989098[PMID]
3316,158,Systemic primary carnitine deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.5,Japan,Validated,10545605[PMID]
3316,158,Systemic primary carnitine deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.83,Australia,Validated,12788994[PMID]
3316,158,Systemic primary carnitine deficiency,Disease,Disorder,Point prevalence,Value and class,6-9 / 10 000,77.0,Faroe Islands,Validated,17417720[PMID]
3316,158,Systemic primary carnitine deficiency,Disease,Disorder,Annual incidence,Value and class,>1 / 1000,138.9,Faroe Islands,Validated,17417720[PMID]
3316,158,Systemic primary carnitine deficiency,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.0069,China,Validated,34103049[PMID]
3313,2056,Essential fructosuria,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18495,206436,Infantile Krabbe disease,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.254,United States,Validated,26795590[PMID]
18495,206436,Infantile Krabbe disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_29391017[PMID]
3327,820,Sneddon syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.4,Europe,Validated,[EXPERT]
3327,820,Sneddon syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18494,206428,Hypoxanthine-guanine phosphoribosyltransferase deficiency,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3321,1945,Self-limited epilepsy with centrotemporal spikes,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3321,1945,Self-limited epilepsy with centrotemporal spikes,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,20.0,Sweden,Validated,16638642[PMID]
3298,832,Succinyl-CoA:3-oxoacid CoA transferase deficiency,Disease,Disorder,Cases/families,Case(s),,32.0,Worldwide,Validated,[EXPERT]
3298,832,Succinyl-CoA:3-oxoacid CoA transferase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
3297,6,3-methylcrotonyl-CoA carboxylase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.65,Europe,Validated,[EXPERT]
3297,6,3-methylcrotonyl-CoA carboxylase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.9,United States,Validated,12872837[PMID]
3297,6,3-methylcrotonyl-CoA carboxylase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.3,Germany,Validated,11170888[PMID]
3297,6,3-methylcrotonyl-CoA carboxylase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.36,"Taiwan, Province of China",Validated,20567911[PMID]
3297,6,3-methylcrotonyl-CoA carboxylase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3297,6,3-methylcrotonyl-CoA carboxylase deficiency,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
3296,20,3-hydroxy-3-methylglutaric aciduria,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,19177531[PMID]_[EXPERT]
3296,20,3-hydroxy-3-methylglutaric aciduria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.8,Portugal,Validated,[EXPERT]
3296,20,3-hydroxy-3-methylglutaric aciduria,Disease,Disorder,Prevalence at birth,Class only,<1 / 1 000 000,0.0,United States,Validated,22766612[PMID]
3296,20,3-hydroxy-3-methylglutaric aciduria,Disease,Disorder,Prevalence at birth,Class only,<1 / 1 000 000,0.0,China,Validated,19036343[PMID]_29039164[PMID]
3304,712,Hemolytic anemia due to glucophosphate isomerase deficiency,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,ORPHANET
3304,712,Hemolytic anemia due to glucophosphate isomerase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3219,2831,"Rhizomelic dysplasia, Patterson-Lowry type",Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,15103724[PMID]
3219,2831,"Rhizomelic dysplasia, Patterson-Lowry type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15103724[PMID]
3221,1129,Arachnodactyly-abnormal ossification-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,8533819[PMID]
3221,1129,Arachnodactyly-abnormal ossification-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8533819[PMID]
18519,206546,Symptomatic form of muscular dystrophy of Duchenne and Becker in female carriers,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3222,1383,Cataract-deafness-hypogonadism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,8574417[PMID]
3222,1383,Cataract-deafness-hypogonadism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8574417[PMID]
18518,206538,Malignant non-dysgerminomatous germ cell tumor of ovary,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
18521,206554,Fukutin-related limb-girdle muscular dystrophy R13,Disease,Disorder,Cases/families,Family(ies),,5.0,Worldwide,Validated,17878207[PMID]_19342235[PMID]_19179078[PMID]
18521,206554,Fukutin-related limb-girdle muscular dystrophy R13,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17878207[PMID]_19342235[PMID]_19179078[PMID]
3225,1524,Craniomicromelic syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
18520,206549,Anoctamin-5-related limb-girdle muscular dystrophy R12,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_23670307[PMID]
3226,1123,Caudal appendage-deafness syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,7894739[PMID]
3226,1123,Caudal appendage-deafness syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7894739[PMID]
18523,206564,POMGNT1-related limb-girdle muscular dystrophy R15,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,18195152[PMID]_22419172[PMID]
18523,206564,POMGNT1-related limb-girdle muscular dystrophy R15,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18195152[PMID]_22419172[PMID]
18522,206559,POMT2-related limb-girdle muscular dystrophy R14,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17923109[PMID]
18522,206559,POMT2-related limb-girdle muscular dystrophy R14,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,17923109[PMID]
18525,206572,Overlap myositis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
18524,206569,Immune-mediated necrotizing myopathy,Disease,Disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,[EXPERT]
18524,206569,Immune-mediated necrotizing myopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
18527,206580,Autosomal recessive lower motor neuron disease with childhood onset,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,16728649[PMID]
18527,206580,Autosomal recessive lower motor neuron disease with childhood onset,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16728649[PMID]
3200,3439,Von Voss-Cherstvoy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,DOI:10.2147/IMCRJ.S108746[OTHER]
3200,3439,Von Voss-Cherstvoy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_DOI:10.2147/IMCRJ.S108746[OTHER]
3202,1217,Spinal atrophy-ophthalmoplegia-pyramidal syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8068160[PMID]
3202,1217,Spinal atrophy-ophthalmoplegia-pyramidal syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8068160[PMID]
3207,2680,Hypomyelination neuropathy-arthrogryposis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,24319099[PMID]
3207,2680,Hypomyelination neuropathy-arthrogryposis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24319099[PMID]
3206,1681,Diprosopus,Morphological anomaly,Disorder,Cases/families,Case(s),,33.0,Worldwide,Validated,27704687[PMID]
3206,1681,Diprosopus,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27704687[PMID]
3206,1681,Diprosopus,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.2,Argentina,Validated,27704687[PMID]
3214,1655,Müllerian derivatives-lymphangiectasia-polydactyly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,8256813[PMID]_11746031[PMID]_11746030[PMID]
3214,1655,Müllerian derivatives-lymphangiectasia-polydactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8256813[PMID]_11746031[PMID]_11746030[PMID]
3250,633,Laron syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.3,Europe,Validated,European Medicines Agency 2003[INST]
3250,633,Laron syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.86,China,Validated,34103049[PMID]
3249,478,Kallmann syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,3.75,Europe,Validated,[EXPERT]
3249,478,Kallmann syndrome,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 100 000,5.0,France,Validated,4147392[PMID]
3249,478,Kallmann syndrome,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 100 000,2.1,Finland,Validated,21682876[PMID]
3249,478,Kallmann syndrome,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.6,Specific population,Validated,3791676[PMID]
3252,822,Hereditary spherocytosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,50.0,Germany,Validated,1554800[PMID]
3252,822,Hereditary spherocytosis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,20.0,United States,Validated,14476391[PMID]
3252,822,Hereditary spherocytosis,Disease,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Validated,[EXPERT]_1554800[PMID]
3253,910,Xeroderma pigmentosum,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,United States,Validated,[EXPERT]
3253,910,Xeroderma pigmentosum,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.5,Japan,Validated,16905156[PMID]
3253,910,Xeroderma pigmentosum,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.23,Europe,Not yet validated,18329345[PMID]
3253,910,Xeroderma pigmentosum,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.19,United Kingdom,Validated,18329345[PMID]
3253,910,Xeroderma pigmentosum,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.41,Netherlands,Validated,18329345[PMID]
3253,910,Xeroderma pigmentosum,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.16,Italy,Validated,18329345[PMID]
3253,910,Xeroderma pigmentosum,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.34,France,Validated,18329345[PMID]
3253,910,Xeroderma pigmentosum,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.18,Germany,Validated,18329345[PMID]
3253,910,Xeroderma pigmentosum,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.75,Libyan Arab Jamahiriya,Not yet validated,10440281[PMID]
3256,777,X-linked non-syndromic intellectual disability,Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3257,766,Hemolytic anemia due to red cell pyruvate kinase deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.1,Specific population,Validated,10828047[PMID]
3257,766,Hemolytic anemia due to red cell pyruvate kinase deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.0,Europe,Validated,European Medicines Agency 2014[INST]
3257,766,Hemolytic anemia due to red cell pyruvate kinase deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.96,Specific population,Validated,1511997[PMID]
3260,28,Vitamin B12-responsive methylmalonic acidemia,Disease,Disorder,Cases/families,Case(s),,192.0,Worldwide,Validated,[EXPERT]
3260,28,Vitamin B12-responsive methylmalonic acidemia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
18557,206973,Congenital myotonia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.0,Worldwide,Validated,1822774[PMID]_20301529[PMID]
18530,206594,Subacute inflammatory demyelinating polyneuropathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18531,206599,Isolated asymptomatic elevation of creatine phosphokinase,Biological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3233,3206,Stüve-Wiedemann syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19207241[PMID]
3233,3206,Stüve-Wiedemann syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,56.0,Worldwide,Validated,19207241[PMID]
3233,3206,Stüve-Wiedemann syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,20.0,United Arab Emirates,Validated,21337444[PMID]
18528,206583,Adult polyglucosan body disease,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,[EXPERT]
18528,206583,Adult polyglucosan body disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3243,65,Leber congenital amaurosis,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,European Medicines Agency 2015[INST]
3243,65,Leber congenital amaurosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.5,Worldwide,Not yet validated,20301475[PMID]
3243,65,Leber congenital amaurosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.23,United States,Validated,17964524[PMID]
3243,65,Leber congenital amaurosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.5,Worldwide,Validated,ORPHANET_[EXPERT]_20301475[PMID]
3247,321,Multiple osteochondromas,Disease,Disorder,Point prevalence,Value and class,>1 / 1000,100.0,Specific population,Validated,13754517[PMID]
3247,321,Multiple osteochondromas,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.9,United Kingdom,Validated,6417335[PMID]
3247,321,Multiple osteochondromas,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.35,Netherlands,Validated,1856833[PMID]
3247,321,Multiple osteochondromas,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.0,Europe,Validated,European Medicines Agency 2018[INST]
3247,321,Multiple osteochondromas,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,United States,Validated,8027127[PMID]
3245,144,Lynch syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
18540,206647,Myotonic dystrophy,Clinical group,Group of disorders,Point prevalence,Value and class,>1 / 1000,189.0,Specific population,Validated,2330114[PMID]
18540,206647,Myotonic dystrophy,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,6.7,Worldwide,Validated,ORPHANET_25532075[PMID]
18540,206647,Myotonic dystrophy,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,8.78,Europe,Validated,ORPHANET_25532075[PMID]
18540,206647,Myotonic dystrophy,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,2.1,Italy,Validated,25532075[PMID]
18540,206647,Myotonic dystrophy,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,5.5,Japan,Validated,25532075[PMID]
18540,206647,Myotonic dystrophy,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,8.4,Ireland,Validated,8845721[PMID]
18540,206647,Myotonic dystrophy,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,13.3,Croatia,Validated,9088385[PMID]_25532075[PMID]
18540,206647,Myotonic dystrophy,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,11.6,New Zealand,Validated,16964297[PMID]_25532075[PMID]
18540,206647,Myotonic dystrophy,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,20.0,Finland,Validated,21364698[PMID]
18540,206647,Myotonic dystrophy,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.22,Norway,Validated,3263224[PMID]
18540,206647,Myotonic dystrophy,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,10.9,Spain,Validated,1369611[PMID]_25532075[PMID]
18540,206647,Myotonic dystrophy,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,2.0,United States,Validated,6333203[PMID]_25532075[PMID]
3244,110,Bardet-Biedl syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.4,Specific population,Validated,2591073[PMID]
3244,110,Bardet-Biedl syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
3244,110,Bardet-Biedl syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.64,Tunisia,Validated,22109794[PMID]
3244,110,Bardet-Biedl syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,United States,Validated,20949666[PMID]
3167,2326,Kallmann syndrome-heart disease syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,8322819[PMID]
3167,2326,Kallmann syndrome-heart disease syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8322819[PMID]
3161,1130,Arachnodactyly-intellectual disability-dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,8357568[PMID]_7794564[PMID]
3161,1130,Arachnodactyly-intellectual disability-dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8357568[PMID]_7794564[PMID]
3157,3207,White matter hypoplasia-corpus callosum agenesis-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,8327066[PMID]
3157,3207,White matter hypoplasia-corpus callosum agenesis-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8327066[PMID]
3152,2058,Fryns-Smeets-Thiry syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8172258[PMID]
3152,2058,Fryns-Smeets-Thiry syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8172258[PMID]
3155,2538,Microgastria-limb reduction defect syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,12072798[PMID]
3155,2538,Microgastria-limb reduction defect syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3154,1192,Atherosclerosis-deafness-diabetes-epilepsy-nephropathy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8172238[PMID]
3154,1192,Atherosclerosis-deafness-diabetes-epilepsy-nephropathy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8172238[PMID]
3148,2062,Progressive non-infectious anterior vertebral fusion,Malformation syndrome,Disorder,Cases/families,Case(s),,67.0,Worldwide,Validated,25485486[PMID]_28235247[PMID]
3148,2062,Progressive non-infectious anterior vertebral fusion,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,25485486[PMID]_28235247[PMID]_ORPHANET
3149,2015,Cleft palate-short stature-vertebral anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8110419[PMID]
3149,2015,Cleft palate-short stature-vertebral anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8110419[PMID]
3150,2427,Macrocephaly-short stature-paraplegia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8471221[PMID]
3150,2427,Macrocephaly-short stature-paraplegia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8471221[PMID]
3144,2898,X-linked intellectual disability-plagiocephaly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,1433236[PMID]
3144,2898,X-linked intellectual disability-plagiocephaly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1433236[PMID]
3143,2349,Muscular pseudohypertrophy-hypothyroidism syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3136,1423,Lethal recessive chondrodysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,3396596[PMID]
3136,1423,Lethal recessive chondrodysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3137,2183,Hydrocephalus-obesity-hypogonadism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,4039476[PMID]
3137,2183,Hydrocephalus-obesity-hypogonadism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4039476[PMID]
3198,1114,Aplasia cutis congenita,Malformation syndrome,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Worldwide,Validated,12596124[PMID]_[EXPERT]
3198,1114,Aplasia cutis congenita,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,10.0,Worldwide,Validated,5910871[PMID]_12596124[PMID]_[EXPERT]
3198,1114,Aplasia cutis congenita,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.69,Denmark,Validated,25430571[PMID]
18621,209004,Axonal polyneuropathy associated with IgG/IgM/IgA monoclonal gammopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
18621,209004,Axonal polyneuropathy associated with IgG/IgM/IgA monoclonal gammopathy,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
3191,1101,Anophthalmia-megalocornea-cardiopathy-skeletal anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,1415344[PMID]
3191,1101,Anophthalmia-megalocornea-cardiopathy-skeletal anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1415344[PMID]
3189,2184,Hydrocephaly-low insertion umbilicus syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8305966[PMID]
3189,2184,Hydrocephaly-low insertion umbilicus syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8305966[PMID]
18613,208650,NLRP3-associated autoinflammatory disease,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.28,France,Validated,21109514[PMID]
3187,1272,Aymé-Gripp syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,19396831[PMID]_19251507[PMID]_25865493[PMID]_28482824[PMID]
3187,1272,Aymé-Gripp syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28482824[PMID]
18608,208513,Spinocerebellar ataxia type 29,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,ORPHANET_[EXPERT]
18608,208513,Spinocerebellar ataxia type 29,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
3182,1485,"Arthrogryposis-hyperkeratosis syndrome, lethal form",Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8213913[PMID]
3182,1485,"Arthrogryposis-hyperkeratosis syndrome, lethal form",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8213913[PMID]
3183,3051,Nicolaides-Baraitser syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,61.0,Worldwide,Validated,25169878[PMID]
3183,3051,Nicolaides-Baraitser syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25169878[PMID]
3181,1134,Isolated arrhinia,Malformation syndrome,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,ORPHANET
3181,1134,Isolated arrhinia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3174,1768,Familial caudal dysgenesis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2225526[PMID]
3174,1768,Familial caudal dysgenesis,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,2225526[PMID]
3175,2204,"Dysplastic cortical hyperostosis, Kozlowski-Tsuruta type",Clinical subtype,Subtype of disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,12401992[PMID]
3175,2204,"Dysplastic cortical hyperostosis, Kozlowski-Tsuruta type",Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12401992[PMID]
3173,2963,"Progeroid syndrome, Petty type",Malformation syndrome,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,2309786[PMID]
3173,2963,"Progeroid syndrome, Petty type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2309786[PMID]
3171,2619,"Brachydactylous dwarfism, Mseleni type",Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3169,1541,"Craniosynostosis, Boston type",Malformation syndrome,Disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,23949913[PMID]_23918290[PMID]_8357019[PMID]
3169,1541,"Craniosynostosis, Boston type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23949913[PMID]_23918290[PMID]_8357019[PMID]
3096,1415,Hardikar syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,22243360[PMID]
3096,1415,Hardikar syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22243360[PMID]
18654,209335,Autosomal dominant adult-onset proximal spinal muscular atrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Europe,Not yet validated,ORPHANET
18655,209341,DYNC1H1-related autosomal dominant childhood-onset proximal spinal muscular atrophy,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20697106[PMID]_22459677[PMID]_22847149[PMID]
18655,209341,DYNC1H1-related autosomal dominant childhood-onset proximal spinal muscular atrophy,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,37.0,Worldwide,Validated,20697106[PMID]_22459677[PMID]_22847149[PMID]
3091,3167,Siegler-Brewer-Carey syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,1442888[PMID]
3091,3167,Siegler-Brewer-Carey syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1442888[PMID]
3080,1277,Brachydactyly-mesomelia-intellectual disability-heart defects syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8484398[PMID]_8074158[PMID]
3080,1277,Brachydactyly-mesomelia-intellectual disability-heart defects syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8484398[PMID]_8074158[PMID]
3081,2547,Microphthalmia-microtia-fetal akinesia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8484406[PMID]
3081,2547,Microphthalmia-microtia-fetal akinesia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8484406[PMID]
3086,1778,Facial dysmorphism-shawl scrotum-joint laxity syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,1776627[PMID]
3086,1778,Facial dysmorphism-shawl scrotum-joint laxity syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1776627[PMID]
3087,3074,Intellectual disability-short stature-hypertelorism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,1877628[PMID]
3087,3074,Intellectual disability-short stature-hypertelorism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1877628[PMID]
18682,210110,Intermediate osteopetrosis,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3130,3405,Umbilical cord ulceration-intestinal atresia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,66.0,Worldwide,Validated,[EXPERT]_20881370[PMID]_29516584[PMID]
3130,3405,Umbilical cord ulceration-intestinal atresia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
18683,210115,Sterile multifocal osteomyelitis with periostitis and pustulosis,Disease,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,24131530[PMID]
18683,210115,Sterile multifocal osteomyelitis with periostitis and pustulosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24131530[PMID]
3129,1884,Ectopia lentis-chorioretinal dystrophy-myopia syndrome,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,8334934[PMID]_10420198[PMID]_12049599[PMID]
3129,1884,Ectopia lentis-chorioretinal dystrophy-myopia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8334934[PMID]_10420198[PMID]_12049599[PMID]
18680,209981,IRIDA syndrome,Disease,Disorder,Cases/families,Case(s),,75.0,Worldwide,Validated,28491880[PMID]
18680,209981,IRIDA syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28491880[PMID]
18681,209989,Non-papillary transitional cell carcinoma of the bladder,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,37.0,Europe,Validated,European Medicines Agency 2009[INST]
3128,1459,Celiac disease-epilepsy-cerebral calcification syndrome,Disease,Disorder,Cases/families,Case(s),,170.0,Worldwide,Validated,ORPHANET
3128,1459,Celiac disease-epilepsy-cerebral calcification syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18686,210133,Leukonychia totalis-acanthosis-nigricans-like lesions-abnormal hair syndrome,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,19401242[PMID]
18686,210133,Leukonychia totalis-acanthosis-nigricans-like lesions-abnormal hair syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19401242[PMID]
18687,210136,Pulmonary fibrosis-hepatic hyperplasia-bone marrow hypoplasia syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,19401489[PMID]
18687,210136,Pulmonary fibrosis-hepatic hyperplasia-bone marrow hypoplasia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19401489[PMID]
3134,2582,Myalgia-eosinophilia syndrome associated with tryptophan,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_21702023[PMID]
18684,210122,Congenital alveolar capillary dysplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.2,Canada,Validated,10735455[PMID]_9369882[PMID]
18684,210122,Congenital alveolar capillary dysplasia,Disease,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,10735455[PMID]
18684,210122,Congenital alveolar capillary dysplasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18685,210128,Urocanic aciduria,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,19304569[PMID]
18685,210128,Urocanic aciduria,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19304569[PMID]
3132,2254,Pontocerebellar hypoplasia type 1,Malformation syndrome,Disorder,Cases/families,Family(ies),,40.0,Worldwide,Validated,[EXPERT]
3132,2254,Pontocerebellar hypoplasia type 1,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18674,209959,Phacoanaphylactic uveitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18675,209964,Solitary rectal ulcer syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.0,Europe,Not yet validated,18188027[PMID]
18675,209964,Solitary rectal ulcer syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18672,209951,Autosomal spastic paraplegia type 18,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,16636240[PMID]_23109145[PMID]_21796390[PMID]
18672,209951,Autosomal spastic paraplegia type 18,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16636240[PMID]_23109145[PMID]_21796390[PMID]
18673,209956,Idiopathic uveal effusion syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18678,209973,Benign nocturnal alternating hemiplegia of childhood,Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,23820111[PMID]
18678,209973,Benign nocturnal alternating hemiplegia of childhood,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23820111[PMID]
18676,209967,Episodic ataxia type 6,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,ORPHANET_19139306[PMID]_16116111[PMID]_23107647[PMID]
18676,209967,Episodic ataxia type 6,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18677,209970,Episodic ataxia type 7,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,ORPHANET_17502476[PMID]
18677,209970,Episodic ataxia type 7,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3114,2795,Fowler urethral sphincter dysfunction syndrome,Disease,Disorder,Cases/families,Case(s),,33.0,Worldwide,Validated,3147005[PMID]
3114,2795,Fowler urethral sphincter dysfunction syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3147005[PMID]
18667,209908,Isolated childhood apraxia of speech,Disease,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,ORPHANET
18667,209908,Isolated childhood apraxia of speech,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18666,209905,Brain-lung-thyroid syndrome,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,28286255[PMID]
18666,209905,Brain-lung-thyroid syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28286255[PMID]
18665,209902,Hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency,Disease,Disorder,Cases/families,Case(s),,24.0,Worldwide,Validated,ORPHANET
18665,209902,Hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3118,2666,Adult familial nephronophthisis-spastic quadriparesia syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,2354560[PMID]
3118,2666,Adult familial nephronophthisis-spastic quadriparesia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2354560[PMID]
18671,209943,IRVAN syndrome,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
18671,209943,IRVAN syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18670,209932,Cone dystrophy with supernormal rod response,Disease,Disorder,Cases/families,Case(s),,45.0,Worldwide,Validated,ORPHANET
18670,209932,Cone dystrophy with supernormal rod response,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18669,209919,Idiopathic copper-associated cirrhosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18668,209916,Extraskeletal myxoid chondrosarcoma,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2,Europe,Not yet validated,ORPHANET
3106,2519,Microcephaly-seizures-intellectual disability-heart disease syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,2585466[PMID]
3106,2519,Microcephaly-seizures-intellectual disability-heart disease syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2585466[PMID]
18656,209370,Severe neonatal-onset encephalopathy with microcephaly,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
18656,209370,Severe neonatal-onset encephalopathy with microcephaly,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18662,209867,Autosomal dominant rhegmatogenous retinal detachment,Disease,Disorder,Cases/families,Case(s),,38.0,Worldwide,Validated,ORPHANET
18662,209867,Autosomal dominant rhegmatogenous retinal detachment,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18695,210571,Dystonia 16,Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,18420150[PMID]_22842711[PMID]_25142429[PMID]
18695,210571,Dystonia 16,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18420150[PMID]_22842711[PMID]_25142429[PMID]
3525,3286,Catecholaminergic polymorphic ventricular tachycardia,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,Europe,Validated,23916535[PMID]
18692,210272,Mal de débarquement,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
18693,210548,Macrocephaly-intellectual disability-autism syndrome,Disease,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,ORPHANET
18693,210548,Macrocephaly-intellectual disability-autism syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18690,210159,Adult hepatocellular carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.22,Europe,Validated,PMID: 22033323
3523,3283,His bundle tachycardia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18691,210163,"Congenital lethal myopathy, Compton-North type",Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,19026398[PMID]
18691,210163,"Congenital lethal myopathy, Compton-North type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19026398[PMID]
3521,3240,Early-onset progressive leukoencephalopathy-central nervous system calcification-deafness-visual impairment syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,9112970[PMID]
3521,3240,Early-onset progressive leukoencephalopathy-central nervous system calcification-deafness-visual impairment syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9112970[PMID]
18688,210141,Inherited congenital spastic tetraplegia,Disease,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,16301218[PMID]_23836506[PMID]_9084927[PMID]
18688,210141,Inherited congenital spastic tetraplegia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16301218[PMID]_23836506[PMID]_9084927[PMID]
18689,210144,"Lethal polymalformative syndrome, Boissel type",Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,26378117[PMID]_19559399[PMID]
18689,210144,"Lethal polymalformative syndrome, Boissel type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26378117[PMID]_19559399[PMID]
3535,1546,Cryptococcosis,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,11.0,Europe,Validated,[EXPERT]
3535,1546,Cryptococcosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
3534,67,Amoebiasis due to Entamoeba histolytica,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18698,210584,Spindle cell hemangioma,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,[WHO Classification of Tumours]
18698,210584,Spindle cell hemangioma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[WHO Classification of Tumours]
3530,2023,Undifferentiated pleomorphic sarcoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.9,Europe,Validated,[EXPERT]
3530,2023,Undifferentiated pleomorphic sarcoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.9,United States,Validated,National Cancer institute[INST]_17013893[PMID]
3530,2023,Undifferentiated pleomorphic sarcoma,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
3529,416,Primary hyperoxaluria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2,Germany,Validated,15961947[PMID]
3529,416,Primary hyperoxaluria,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15961947[PMID]
3529,416,Primary hyperoxaluria,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,19225556[PMID]
3528,599,Distal myopathy,Category,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.33,United Kingdom,Validated,19767415[PMID]_[EXPERT]
3542,3392,Tularemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.2,Europe,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3542,3392,Tularemia,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,United Kingdom,Validated,26738841[PMID]
3542,3392,Tularemia,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Netherlands,Validated,26738841[PMID]
3542,3392,Tularemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.0,Sweden,Validated,26738841[PMID]
3542,3392,Tularemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.27,Czech Republic,Validated,26738841[PMID]
3542,3392,Tularemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,9.1,Finland,Validated,26738841[PMID]
3542,3392,Tularemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Austria,Validated,26738841[PMID]
3542,3392,Tularemia,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,Belgium,Validated,26738841[PMID]
3542,3392,Tularemia,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.05,Denmark,Validated,26738841[PMID]
3542,3392,Tularemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.3,Croatia,Validated,26738841[PMID]
3542,3392,Tularemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.6,Bulgaria,Validated,26738841[PMID]
3542,3392,Tularemia,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.075,Estonia,Validated,26738841[PMID]
3542,3392,Tularemia,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.08,France,Validated,26738841[PMID]
3542,3392,Tularemia,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Germany,Validated,26738841[PMID]
3542,3392,Tularemia,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.035,Italy,Validated,26738841[PMID]
3542,3392,Tularemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.145,Latvia,Validated,26738841[PMID]
3542,3392,Tularemia,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.07,Lithuania,Validated,26738841[PMID]
3542,3392,Tularemia,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Poland,Validated,26738841[PMID]
3542,3392,Tularemia,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Romania,Validated,26738841[PMID]
3542,3392,Tularemia,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Slovenia,Validated,26738841[PMID]
3542,3392,Tularemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.25,Switzerland,Validated,26738841[PMID]
3542,3392,Tularemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.75,Spain,Validated,26738841[PMID]
3542,3392,Tularemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.83,Norway,Validated,26738841[PMID]
3542,3392,Tularemia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Europe,Validated,European Medicines Agency 2015[INST]
3542,3392,Tularemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.5,Hungary,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3542,3392,Tularemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Slovakia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3543,1063,Tufted angioma,Disease,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,25365496[PMID]
3543,1063,Tufted angioma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_25365496[PMID]
3540,2737,Onchocerciasis,Disease,Disorder,Point prevalence,Class only,>1 / 1000,0.0,Specific population,Not yet validated,ORPHANET
3540,2737,Onchocerciasis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
18709,211067,Episodic ataxia type 5,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,ORPHANET_16100538[PMID]
18709,211067,Episodic ataxia type 5,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3541,3343,Toxocariasis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.3,United States,Not yet validated,emedicine[OTHER]
3541,3343,Toxocariasis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18708,211062,Hereditary episodic ataxia,Category,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Worldwide,Not yet validated,ORPHANET
3538,2034,Filariasis,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
3538,2034,Filariasis,Category,Group of disorders,Point prevalence,Class only,>1 / 1000,0.0,Specific population,Validated,World Health Organization 2016[INST]
3539,2583,Mycetoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3536,1685,Distomatosis,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18704,211017,Spinocerebellar ataxia type 30,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,18996908[PMID]
18704,211017,Spinocerebellar ataxia type 30,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18996908[PMID]
3537,1902,Ehrlichiosis,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,ORPHANET
3537,1902,Ehrlichiosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.25,United States,Validated,Center for Diseases Control and Prevention[INST]
3537,1902,Ehrlichiosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
3551,656,Hereditary steroid-resistant nephrotic syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3549,655,Nephronophthisis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.25,Finland,Validated,10196704[PMID]
3549,655,Nephronophthisis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,[EXPERT]
3547,2415,Rare lymphatic malformation,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,12.5,Europe,Validated,ORPHANET
3544,2122,Kaposiform hemangioendothelioma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3545,2591,Infantile myofibromatosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.67,Europe,Validated,ISBN:443043469[OTHER]_23686518[PMID]
3545,2591,Infantile myofibromatosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
3557,35,Propionic acidemia,Disease,Disorder,Prevalence at birth,Value and class,>1 / 1000,100.0,Canada,Validated,10820128[PMID]_23509210[PMID]
3557,35,Propionic acidemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.5,Worldwide,Validated,22593918[PMID]_14586648[PMID]
3557,35,Propionic acidemia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2,Europe,Validated,23509210[PMID]
3557,35,Propionic acidemia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.6,Italy,Validated,11953730[PMID]
3557,35,Propionic acidemia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.0,Germany,Validated,23509210[PMID]
3557,35,Propionic acidemia,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,33.0,Saudi Arabia,Validated,23509210[PMID]
3557,35,Propionic acidemia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.7,Japan,Validated,12189489[PMID]_23509210[PMID]
3557,35,Propionic acidemia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.23,"Korea, Republic of",Validated,24101962[PMID]
3557,35,Propionic acidemia,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.0278,China,Validated,34103049[PMID]
3556,407,Glycine encephalopathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.17,Europe,Validated,European Medicines Agency 2002[INST]
3556,407,Glycine encephalopathy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.8,Finland,Validated,20301531[PMID]
3556,407,Glycine encephalopathy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.59,Canada,Validated,10617747[PMID]
3556,407,Glycine encephalopathy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Saudi Arabia,Validated,20622343[PMID]
3556,407,Glycine encephalopathy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.0,Portugal,Validated,22532538[PMID]
3556,407,Glycine encephalopathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.13,Portugal,Validated,22532538[PMID]
3556,407,Glycine encephalopathy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.8,Israel,Validated,33239050[PMID]
3556,407,Glycine encephalopathy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,8.0,Specific population,Validated,33239050[PMID]
3559,2968,Leukocyte adhesion deficiency,Disease,Disorder,Cases/families,Case(s),,350.0,Worldwide,Validated,ORPHANET
3559,2968,Leukocyte adhesion deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Latin America,Not yet validated,22965369[PMID]
3559,2968,Leukocyte adhesion deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
3558,663,Mitochondrial DNA-related progressive external ophthalmoplegia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3553,137,Congenital disorder of glycosylation,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.5,Europe,Validated,ORPHANET
3553,137,Congenital disorder of glycosylation,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3552,220,Denys-Drash syndrome,Disease,Disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,[EXPERT]
3552,220,Denys-Drash syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
3555,5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Europe,Not yet validated,ORPHANET
3555,5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.4,Australia,Validated,20373143[PMID]
3555,5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.4,United States,Validated,20373143[PMID]
3555,5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Germany,Validated,15896654[PMID]
3555,5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.0,Sweden,Validated,7564259[PMID]
3555,5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.84,Poland,Validated,20814823[PMID]
3555,5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.09,Estonia,Validated,23430857[PMID]
3555,5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3555,5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.0,Europe,Validated,European Medicines Agency 2015[INST]
3555,5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Israel,Validated,33239050[PMID]
3555,5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.3,Specific population,Validated,33239050[PMID]
3555,5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.24,Czech Republic,Validated,31241292[PMID]
3565,85,Congenital dyserythropoietic anemia,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 1 000 000,0.16,Europe,Not yet validated,20824457[PMID]
3565,85,Congenital dyserythropoietic anemia,Clinical group,Group of disorders,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,20824457[PMID]
3565,85,Congenital dyserythropoietic anemia,Clinical group,Group of disorders,Cases/families,Case(s),,740.0,Worldwide,Validated,20665989[PMID]
3565,85,Congenital dyserythropoietic anemia,Clinical group,Group of disorders,Point prevalence,Class only,1-9 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3564,25,Glutaryl-CoA dehydrogenase deficiency,Disease,Disorder,Point prevalence,Value and class,>1 / 1000,333.0,Specific population,Validated,[EXPERT]
3564,25,Glutaryl-CoA dehydrogenase deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Specific population,Validated,[EXPERT]
3564,25,Glutaryl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Worldwide,Validated,15505392[PMID]
3564,25,Glutaryl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.85,Spain,Validated,22000754[PMID]
3564,25,Glutaryl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.48,Japan,Validated,12127323[PMID]
3564,25,Glutaryl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.76,United States,Validated,6601872[PMID]
3564,25,Glutaryl-CoA dehydrogenase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3564,25,Glutaryl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.0,Israel,Validated,33239050[PMID]
3564,25,Glutaryl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.3,Specific population,Validated,33239050[PMID]
3564,25,Glutaryl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.56,Czech Republic,Validated,31241292[PMID]
3567,177,Rhizomelic chondrodysplasia punctata,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.7,Europe,Validated,34229749[PMID]
3567,177,Rhizomelic chondrodysplasia punctata,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,United States,Validated,34229749[PMID]
3567,177,Rhizomelic chondrodysplasia punctata,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,34229749[PMID]_ORPHANET
3566,1246,Brachydactyly-nystagmus-cerebellar ataxia syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,PDF:1934114230001a[OTHER]
3566,1246,Brachydactyly-nystagmus-cerebellar ataxia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_PDF:1934114230001a[OTHER]
3560,618,Familial melanoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.5,Europe,Validated,[EXPERT]
3560,618,Familial melanoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3563,359,Pediatric-onset glaucoma of genetic origin,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18741,213500,Ovarian cancer,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,49.0,Europe,Validated,European Medicines Agency 2018[INST]
3574,818,Smith-Lemli-Opitz syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.7,Europe,Validated,[EXPERT]_10807690[PMID]
3574,818,Smith-Lemli-Opitz syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.7,United Kingdom,Validated,9678700[PMID]
3574,818,Smith-Lemli-Opitz syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.85,Slovakia,Validated,10678669[PMID]
3574,818,Smith-Lemli-Opitz syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.6,Canada,Not yet validated,7395908[PMID]_11471166[PMID]_15480380[PMID]
3574,818,Smith-Lemli-Opitz syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.65,United States,Not yet validated,9024554[PMID]
3574,818,Smith-Lemli-Opitz syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3574,818,Smith-Lemli-Opitz syndrome,Malformation syndrome,Disorder,Prevalence at birth,Class only,1-5 / 10 000,0.0,Czech Republic,Validated,10439210[PMID]_23059950[PMID]
3574,818,Smith-Lemli-Opitz syndrome,Malformation syndrome,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.4314,"Korea, Republic of",Validated,33836803[PMID]
18743,213512,Malignant mixed Müllerian tumor of the ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18742,213504,Adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.97,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18742,213504,Adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.635,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18742,213504,Adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,6.773,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18742,213504,Adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,6.162,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18742,213504,Adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,6.103,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18742,213504,Adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,7.229,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18742,213504,Adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,6.881,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18742,213504,Adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.973,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18742,213504,Adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,6.593,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18742,213504,Adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.09,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18742,213504,Adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.079,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18742,213504,Adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.518,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18742,213504,Adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,8.353,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18742,213504,Adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,7.79,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18742,213504,Adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.653,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18742,213504,Adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,7.116,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18742,213504,Adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.698,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18742,213504,Adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.834,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18742,213504,Adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.519,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18742,213504,Adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,6.575,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18742,213504,Adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.263,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18742,213504,Adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,6.379,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18742,213504,Adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.306,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18742,213504,Adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,6.09,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3568,175,Cartilage-hair hypoplasia,Disease,Disorder,Point prevalence,Value and class,>1 / 1000,150.0,Specific population,Validated,22420014[PMID]
3568,175,Cartilage-hair hypoplasia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.34,Finland,Validated,1404295[PMID]
3568,175,Cartilage-hair hypoplasia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3569,209,Cutis laxa,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,[EXPERT]
3569,209,Cutis laxa,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3570,42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,12.0,Europe,Validated,Haute Autorité de Santé 2011[INST]
3570,42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,16.1,Germany,Not yet validated,11388605[PMID]_15832312[PMID]
3570,42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.25,United Kingdom,Not yet validated,22166308[PMID]_9797590[PMID]
3570,42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,8.5,Portugal,Validated,23842438[PMID]
3570,42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.8,Spain,Not yet validated,23842438[PMID]
3570,42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.49,Netherlands,Validated,22630369[PMID]
3570,42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.3,Canada,Validated,23543005[PMID]
3570,42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.26,Australia,Validated,19620191[PMID]
3570,42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.96,Japan,Validated,12127323[PMID]
3570,42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.38,"Taiwan, Province of China",Validated,23700290[PMID]
3570,42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.1,Denmark,Validated,22542437[PMID]
3570,42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.3,Greece,Validated,22683754[PMID]
3570,42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.85,United States,Not yet validated,12142359[PMID]_16617240[PMID]_ ORPHANET
3570,42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.85,Worldwide,Validated,ORPHANET_16763904[PMID]
3570,42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.02,Austria,Validated,20938748[PMID]
3570,42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.35,Italy,Validated,24294134[PMID]
3570,42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Israel,Validated,33239050[PMID]
3570,42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Specific population,Validated,33239050[PMID]
3570,42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.5,Czech Republic,Validated,31241292[PMID]
18748,213557,Salivary gland type cancer of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.05,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18748,213557,Salivary gland type cancer of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.038,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18748,213557,Salivary gland type cancer of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.095,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18748,213557,Salivary gland type cancer of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.024,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18748,213557,Salivary gland type cancer of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.014,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18748,213557,Salivary gland type cancer of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.068,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18748,213557,Salivary gland type cancer of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.024,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18748,213557,Salivary gland type cancer of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.077,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18748,213557,Salivary gland type cancer of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.037,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18748,213557,Salivary gland type cancer of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.075,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18748,213557,Salivary gland type cancer of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.043,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18748,213557,Salivary gland type cancer of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.017,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18748,213557,Salivary gland type cancer of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.031,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18748,213557,Salivary gland type cancer of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.06,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18748,213557,Salivary gland type cancer of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.013,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18748,213557,Salivary gland type cancer of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.039,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18748,213557,Salivary gland type cancer of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.019,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18748,213557,Salivary gland type cancer of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.044,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18748,213557,Salivary gland type cancer of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.054,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18748,213557,Salivary gland type cancer of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.09,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18748,213557,Salivary gland type cancer of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.064,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18748,213557,Salivary gland type cancer of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.053,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18748,213557,Salivary gland type cancer of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.323,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3577,2066,Gamma-aminobutyric acid transaminase deficiency,Disease,Disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,25738457[PMID]
3577,2066,Gamma-aminobutyric acid transaminase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25738457[PMID]
18747,213531,Metaplastic carcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.06,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18747,213531,Metaplastic carcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.081,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18747,213531,Metaplastic carcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.027,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18747,213531,Metaplastic carcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.059,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18747,213531,Metaplastic carcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.074,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18747,213531,Metaplastic carcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.065,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18747,213531,Metaplastic carcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.043,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18747,213531,Metaplastic carcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.096,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18747,213531,Metaplastic carcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.084,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18747,213531,Metaplastic carcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.06,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18747,213531,Metaplastic carcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.031,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18747,213531,Metaplastic carcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.045,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18747,213531,Metaplastic carcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.082,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18747,213531,Metaplastic carcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.074,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18747,213531,Metaplastic carcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.07,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18747,213531,Metaplastic carcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.226,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18747,213531,Metaplastic carcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.11,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18747,213531,Metaplastic carcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.136,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18747,213531,Metaplastic carcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.108,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18747,213531,Metaplastic carcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.104,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18747,213531,Metaplastic carcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.163,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18747,213531,Metaplastic carcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.128,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18747,213531,Metaplastic carcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.135,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18747,213531,Metaplastic carcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.238,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18746,213528,Rare adenocarcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.55,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18746,213528,Rare adenocarcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.898,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18746,213528,Rare adenocarcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.325,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18746,213528,Rare adenocarcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.221,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18746,213528,Rare adenocarcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.397,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18746,213528,Rare adenocarcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.175,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18746,213528,Rare adenocarcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.717,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18746,213528,Rare adenocarcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.371,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18746,213528,Rare adenocarcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.615,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18746,213528,Rare adenocarcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.812,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18746,213528,Rare adenocarcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.428,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18746,213528,Rare adenocarcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.305,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18746,213528,Rare adenocarcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.103,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18746,213528,Rare adenocarcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.191,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18746,213528,Rare adenocarcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.199,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18746,213528,Rare adenocarcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.017,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18746,213528,Rare adenocarcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.812,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18746,213528,Rare adenocarcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.697,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18746,213528,Rare adenocarcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.171,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18746,213528,Rare adenocarcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.315,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18746,213528,Rare adenocarcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.142,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18746,213528,Rare adenocarcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.187,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18746,213528,Rare adenocarcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.264,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18746,213528,Rare adenocarcinoma of the breast,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.638,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3459,3188,Congenital pulmonary veins atresia or stenosis,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3463,860,Congenitally uncorrected transposition of the great arteries,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,24.25,Europe,Validated,[EXPERT]
3463,860,Congenitally uncorrected transposition of the great arteries,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3462,185,Scimitar syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.0,Europe,Validated,[EXPERT]
3462,185,Scimitar syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3460,3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,27.2,France,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3460,3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,19.6,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
3460,3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,29.1,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3460,3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,14.6,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3460,3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,59.5,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3460,3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,63.6,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3460,3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,63.1,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3460,3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.6,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3460,3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,26.1,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3460,3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,48.2,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
3460,3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.3,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3460,3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,35.3,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3460,3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.4,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3460,3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,23.7,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3460,3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,25.7,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3460,3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,98.4,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3460,3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,42.5,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3460,3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,19.4,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3460,3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Disorder,Prevalence at birth,Class only,1-5 / 10 000,0.0,Europe,Validated,ORPHANET
3460,3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
3466,1464,Univentricular heart,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.5,Worldwide,Validated,23705101[PMID]
3466,1464,Univentricular heart,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
3465,3400,Aorto-ventricular tunnel,Morphological anomaly,Disorder,Cases/families,Case(s),,130.0,Worldwide,Validated,ORPHANET
3465,3400,Aorto-ventricular tunnel,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18761,213716,Squamous cell carcinoma of the corpus uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18761,213716,Squamous cell carcinoma of the corpus uteri,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.039,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18761,213716,Squamous cell carcinoma of the corpus uteri,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.014,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18761,213716,Squamous cell carcinoma of the corpus uteri,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.012,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18761,213716,Squamous cell carcinoma of the corpus uteri,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.044,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18761,213716,Squamous cell carcinoma of the corpus uteri,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.083,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18761,213716,Squamous cell carcinoma of the corpus uteri,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.031,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18761,213716,Squamous cell carcinoma of the corpus uteri,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.011,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18761,213716,Squamous cell carcinoma of the corpus uteri,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.045,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18761,213716,Squamous cell carcinoma of the corpus uteri,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.034,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18761,213716,Squamous cell carcinoma of the corpus uteri,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.019,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18761,213716,Squamous cell carcinoma of the corpus uteri,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.039,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18761,213716,Squamous cell carcinoma of the corpus uteri,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.056,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18761,213716,Squamous cell carcinoma of the corpus uteri,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.018,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18761,213716,Squamous cell carcinoma of the corpus uteri,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.041,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18761,213716,Squamous cell carcinoma of the corpus uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.117,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18761,213716,Squamous cell carcinoma of the corpus uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18761,213716,Squamous cell carcinoma of the corpus uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.177,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18761,213716,Squamous cell carcinoma of the corpus uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.139,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18761,213716,Squamous cell carcinoma of the corpus uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.113,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18761,213716,Squamous cell carcinoma of the corpus uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.173,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18761,213716,Squamous cell carcinoma of the corpus uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.228,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18761,213716,Squamous cell carcinoma of the corpus uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.106,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18767,213746,Transitional cell carcinoma of the corpus uteri,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3469,1572,Common variable immunodeficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.0,Specific population,Validated,[EXPERT]
3469,1572,Common variable immunodeficiency,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.3,Netherlands,Validated,22288591[PMID]
3469,1572,Common variable immunodeficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.98,France,Validated,22288591[PMID]
3469,1572,Common variable immunodeficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.66,Spain,Validated,22288591[PMID]
3469,1572,Common variable immunodeficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.87,Netherlands,Validated,22288591[PMID]
3469,1572,Common variable immunodeficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.6,United Kingdom,Validated,22288591[PMID]
3469,1572,Common variable immunodeficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.72,Italy,Validated,22288591[PMID]
3469,1572,Common variable immunodeficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.52,Germany,Validated,22288591[PMID]
3469,1572,Common variable immunodeficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Turkey,Validated,22288591[PMID]
3469,1572,Common variable immunodeficiency,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.073,Poland,Validated,22288591[PMID]
3469,1572,Common variable immunodeficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.77,Australia,Validated,9314356[PMID]
3469,1572,Common variable immunodeficiency,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
3468,3261,Autoimmune lymphoproliferative syndrome,Disease,Disorder,Cases/families,Case(s),,500.0,Worldwide,Validated,20538792[PMID]
3468,3261,Autoimmune lymphoproliferative syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_20538792[PMID]
3474,2849,Perlman syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
3474,2849,Perlman syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18771,213772,Adenocarcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.01,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18771,213772,Adenocarcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.762,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18771,213772,Adenocarcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.966,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18771,213772,Adenocarcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.968,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18771,213772,Adenocarcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.85,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18771,213772,Adenocarcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.899,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18771,213772,Adenocarcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.987,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18771,213772,Adenocarcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.789,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18771,213772,Adenocarcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.734,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18771,213772,Adenocarcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.774,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18771,213772,Adenocarcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.471,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18771,213772,Adenocarcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.766,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18771,213772,Adenocarcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.868,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18771,213772,Adenocarcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.738,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18771,213772,Adenocarcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.765,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18771,213772,Adenocarcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.918,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18771,213772,Adenocarcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.108,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18771,213772,Adenocarcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.108,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18771,213772,Adenocarcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.065,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18771,213772,Adenocarcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.118,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18771,213772,Adenocarcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.177,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18771,213772,Adenocarcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.007,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18771,213772,Adenocarcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.048,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18771,213772,Adenocarcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.12,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18770,213767,Squamous cell carcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.28,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18770,213767,Squamous cell carcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,11.822,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18770,213767,Squamous cell carcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,10.336,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18770,213767,Squamous cell carcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,11.192,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18770,213767,Squamous cell carcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.104,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18770,213767,Squamous cell carcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.67,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18770,213767,Squamous cell carcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.539,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18770,213767,Squamous cell carcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,8.277,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18770,213767,Squamous cell carcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.885,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18770,213767,Squamous cell carcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.871,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18770,213767,Squamous cell carcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.707,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18770,213767,Squamous cell carcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.204,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18770,213767,Squamous cell carcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.307,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18770,213767,Squamous cell carcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,7.362,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18770,213767,Squamous cell carcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.759,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18770,213767,Squamous cell carcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.756,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18770,213767,Squamous cell carcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,7.941,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18770,213767,Squamous cell carcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.478,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18770,213767,Squamous cell carcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,8.555,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18770,213767,Squamous cell carcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,7.507,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18770,213767,Squamous cell carcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.867,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18770,213767,Squamous cell carcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.657,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18770,213767,Squamous cell carcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.063,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18770,213767,Squamous cell carcinoma of the cervix uteri,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.312,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18775,213792,Adenosarcoma of the cervix uteri,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19685064[PMID]
18774,213787,Carcinosarcoma of the cervix uteri,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26023676[PMID]
18779,213812,Primitive neuroectodermal tumor of the cervix uteri,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21962148[PMID]
3482,747,Autoimmune pulmonary alveolar proteinosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.165,Japan,Validated,30895185[PMID]
3482,747,Autoimmune pulmonary alveolar proteinosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,2.66,Japan,Validated,30895185[PMID]
3482,747,Autoimmune pulmonary alveolar proteinosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,2.66,Worldwide,Validated,30895185[PMID]_30064481[PMID]
3482,747,Autoimmune pulmonary alveolar proteinosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.687,United States,Validated,30064481[PMID]
18778,213807,Leiomyosarcoma of the cervix uteri,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23519508[PMID]
3480,2953,Musculocontractural Ehlers-Danlos syndrome,Disease,Disorder,Cases/families,Case(s),,34.0,Worldwide,Validated,26373698[PMID]
3480,2953,Musculocontractural Ehlers-Danlos syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26373698[PMID]
3484,3082,Intellectual disability-polydactyly-uncombable hair syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,9028447[PMID]
3484,3082,Intellectual disability-polydactyly-uncombable hair syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9028447[PMID]
3485,782,Axenfeld-Rieger syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,[EXPERT]
3489,3269,Isolated radio-ulnar synostosis,Morphological anomaly,Disorder,Cases/families,Case(s),,350.0,Worldwide,Validated,22802806[PMID]
3489,3269,Isolated radio-ulnar synostosis,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_22802806[PMID]
3488,3259,Syndactyly-polydactyly-ear lobe syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,182299[PMID]
3488,3259,Syndactyly-polydactyly-ear lobe syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_182299[PMID]
3491,3309,Tetrasomy 5p syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25424187[PMID]
18787,216675,Transposition of the great arteries,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,31.7,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
18787,216675,Transposition of the great arteries,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,50.0,United States,Validated,17051527[PMID]_Center for Diseases Control and Prevention[INST]
18787,216675,Transposition of the great arteries,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,23.3,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
18787,216675,Transposition of the great arteries,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,59.5,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
18787,216675,Transposition of the great arteries,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,33.4,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
18787,216675,Transposition of the great arteries,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,47.5,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
18787,216675,Transposition of the great arteries,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,28.8,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
18787,216675,Transposition of the great arteries,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,18.1,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
18787,216675,Transposition of the great arteries,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,22.6,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
18787,216675,Transposition of the great arteries,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,40.9,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
18787,216675,Transposition of the great arteries,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,31.1,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
18787,216675,Transposition of the great arteries,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,14.0,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
18787,216675,Transposition of the great arteries,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,4.7,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
18787,216675,Transposition of the great arteries,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,15.7,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
18787,216675,Transposition of the great arteries,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,37.7,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
18787,216675,Transposition of the great arteries,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,33.9,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
18787,216675,Transposition of the great arteries,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,22.3,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
18787,216675,Transposition of the great arteries,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET
18788,216694,Congenitally corrected transposition of the great arteries,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.0,Worldwide,Validated,[EXPERT]
18788,216694,Congenitally corrected transposition of the great arteries,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
18789,216718,Isolated congenitally uncorrected transposition of the great arteries,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18790,216729,Congenitally uncorrected transposition of the great arteries with cardiac malformation,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3495,3411,Double uterus-hemivagina-renal agenesis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,ORPHANET
3495,3411,Double uterus-hemivagina-renal agenesis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3494,882,Tyrosinemia type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.9,Worldwide,Validated,20301688[PMID]
3494,882,Tyrosinemia type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.5,Norway,Not yet validated,20301688[PMID]_22554029[PMID]
3494,882,Tyrosinemia type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.1,Finland,Validated,33046095[PMID]
3494,882,Tyrosinemia type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.7,Tunisia,Validated,22481200[PMID]
3494,882,Tyrosinemia type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.25,Specific population,Validated,20301688[PMID]
3494,882,Tyrosinemia type 1,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,54.0,Specific population,Validated,2378355[PMID]
3494,882,Tyrosinemia type 1,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
18791,216796,Osteogenesis imperfecta type 1,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18791,216796,Osteogenesis imperfecta type 1,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.16,Sweden,Validated,25944380[PMID]
3497,903,Von Willebrand disease,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,Worldwide,Validated,10959685[PMID]_19874468[PMID]
18792,216804,Osteogenesis imperfecta type 2,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
18793,216812,Osteogenesis imperfecta type 3,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18793,216812,Osteogenesis imperfecta type 3,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.89,Sweden,Validated,25944380[PMID]
18794,216820,Osteogenesis imperfecta type 4,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18794,216820,Osteogenesis imperfecta type 4,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.35,Sweden,Validated,25944380[PMID]
18795,216828,Osteogenesis imperfecta type 5,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,47.0,Worldwide,Validated,ORPHANET
18795,216828,Osteogenesis imperfecta type 5,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3498,3474,CHIME syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,22444671[PMID]
3498,3474,CHIME syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22444671[PMID]
3505,1441,Ring chromosome 17 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,24393457[PMID]_25635406[PMID]
3505,1441,Ring chromosome 17 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24393457[PMID]_25635406[PMID]
18803,216978,"Niemann-Pick disease type C, late infantile neurologic onset",Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3506,361,Familial glucocorticoid deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.4953,Ireland,Validated,18430777[PMID]
3506,361,Familial glucocorticoid deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
18802,216975,"Niemann-Pick disease type C, severe early infantile neurologic onset",Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3508,1787,"Acrofacial dysostosis, Palagonia type",Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,9098488[PMID]
3508,1787,"Acrofacial dysostosis, Palagonia type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9098488[PMID]
18804,216981,"Niemann-Pick disease type C, juvenile neurologic onset",Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18807,217008,Bockenheimer syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,ISBN-13: 978-0323073677[OTHER]
18807,217008,Bockenheimer syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_ISBN-13: 978-0323073677[OTHER]
18809,217017,Zechi-Ceide syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,17907157[PMID]
18809,217017,Zechi-Ceide syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17907157[PMID]
18808,217012,Spinocerebellar ataxia type 31,Disease,Disorder,Cases/families,Family(ies),,30.0,Worldwide,Validated,22353852[PMID]_24344778[PMID]
18808,217012,Spinocerebellar ataxia type 31,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
3513,2088,Fanconi-Bickel syndrome,Disease,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,11949937[PMID]
3513,2088,Fanconi-Bickel syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
3513,2088,Fanconi-Bickel syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.3,Israel,Validated,33239050[PMID]
3513,2088,Fanconi-Bickel syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Specific population,Validated,33239050[PMID]
18811,217026,"Microcephaly-facio-cardio-skeletal syndrome, Hadziselimovic type",Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,11152145[PMID]_19373080[PMID]
18811,217026,"Microcephaly-facio-cardio-skeletal syndrome, Hadziselimovic type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11152145[PMID]_19373080[PMID]
18829,217266,BNAR syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,9.0,Worldwide,Validated,24115501[PMID]
18829,217266,BNAR syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3404,179,Birdshot chorioretinopathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.35,Worldwide,Validated,27175923[PMID]
3404,179,Birdshot chorioretinopathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.14,United States,Validated,16263368[PMID]
18828,217260,Progressive multifocal leukoencephalopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18828,217260,Progressive multifocal leukoencephalopathy,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.068,Sweden,Validated,29321229[PMID]
18828,217260,Progressive multifocal leukoencephalopathy,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.11,France,Validated,35779271[PMID]
3402,292,Congenital enterovirus infection,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18827,217253,NMDA receptor encephalitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3403,767,Polyarteritis nodosa,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.16,Europe,Validated,9805179[PMID]_14872461[PMID]_17553910[PMID]_ORPHANET
3403,767,Polyarteritis nodosa,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.1,Sweden,Validated,17553910[PMID]
3403,767,Polyarteritis nodosa,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.9,United Kingdom,Not yet validated,10693883[PMID]_11156552[PMID]
3403,767,Polyarteritis nodosa,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.07,France,Validated,14872461[PMID]
3403,767,Polyarteritis nodosa,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.11,Australia,Validated,18771432[PMID]
3403,767,Polyarteritis nodosa,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.62,Spain,Validated,11156552[PMID]
3403,767,Polyarteritis nodosa,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.3,Norway,Validated,9805179[PMID]
3403,767,Polyarteritis nodosa,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.05,Norway,Not yet validated,ORPHANET
3403,767,Polyarteritis nodosa,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.04,Germany,Validated,15696553[PMID]
3400,2584,Classic mycosis fungoides,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,[EXPERT]
3400,2584,Classic mycosis fungoides,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
18825,217093,"Mucopolysaccharidosis type 2, attenuated form",Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3401,3162,Sézary syndrome,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,United States,Validated,17638728[PMID]_National Cancer Institute[INST]_ORPHANET
3401,3162,Sézary syndrome,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.012,Norway,Validated,18808419[PMID]_ ORPHANET_[EXPERT]
3401,3162,Sézary syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18824,217085,"Mucopolysaccharidosis type 2, severe form",Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.4,Europe,Validated,[EXPERT]_ORPHANET
18824,217085,"Mucopolysaccharidosis type 2, severe form",Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18823,217080,Pulmonary fungal infections in patients deemed at risk,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,22.0,Europe,Validated,European Medicines Agency[INST]
18822,217074,Rare carcinoma of pancreas,Category,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,11.79,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2011[REG]
18822,217074,Rare carcinoma of pancreas,Category,Group of disorders,Lifetime Prevalence,Value and class,1-9 / 100 000,8.3,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
18822,217074,Rare carcinoma of pancreas,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,15.5,Europe,Validated,European Medicines Agency 2013[INST]_ORPHANET
18822,217074,Rare carcinoma of pancreas,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.9,Worldwide,Validated,World Health Organization 2008[INST]
18822,217074,Rare carcinoma of pancreas,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,3.5,Worldwide,Validated,World Health Organization 2008[INST]
3399,2330,Kasabach-Merritt phenomenon,Particular clinical situation in a disease or syndrome,Disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,ISBN-10: 0071354557[OTHER]
3399,2330,Kasabach-Merritt phenomenon,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_ISBN-10: 0071354557[OTHER]
18821,217071,Renal cell carcinoma,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,42.0,Europe,Validated,European Medicines Agency 2010[INST]
18821,217071,Renal cell carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,8.35,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
18820,217067,Pouchitis,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,22.0,Europe,Validated,European Medicines Agency[INST]
3394,2700,Noma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18819,217064,5-fluorouracil poisoning,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Europe,Validated,European Medicines Agency[INST]
3395,1451,CINCA syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_[EXPERT]_21109514[PMID]
18818,217059,Isolated nail clubbing,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET_24036948[PMID]
18817,217055,Autosomal recessive intermediate Charcot-Marie-Tooth disease type A,Disease,Disorder,Cases/families,Family(ies),,8.0,Worldwide,Validated,ORPHANET
18817,217055,Autosomal recessive intermediate Charcot-Marie-Tooth disease type A,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3392,556,Malakoplakia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18846,217335,RIN2 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,27277385[PMID]
18846,217335,RIN2 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27277385[PMID]
3423,2745,Opitz GBBB syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,EXPERT
18847,217340,17q21.31 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,ORPHANET
3422,3260,Idiopathic hypereosinophilic syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET_22740191[PMID]
18845,217330,REN-related autosomal dominant tubulointerstitial kidney disease,Clinical subtype,Subtype of disorder,Cases/families,Family(ies),,35.0,Worldwide,Validated,ORPHANET
18845,217330,REN-related autosomal dominant tubulointerstitial kidney disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3418,2086,Optic pathway glioma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Worldwide,Not yet validated,22796286[PMID]
3418,2086,Optic pathway glioma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
3417,2566,Chronic Epstein-Barr virus infection syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_21348109[PMID]
3416,3385,African trypanosomiasis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,23260189[PMID]
3415,1560,Cysticercosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
3414,566,Congenital microcoria,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3412,341,Viral hemorrhagic fever,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3411,340,Hemorrhagic fever-renal syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.74,Europe,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
3411,340,Hemorrhagic fever-renal syndrome,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,37.0,Europe,Validated,European Medicines Agency 2004[INST]
3411,340,Hemorrhagic fever-renal syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.92,Austria,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
3411,340,Hemorrhagic fever-renal syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.78,Belgium,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
3411,340,Hemorrhagic fever-renal syndrome,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.06,Bulgaria,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
3411,340,Hemorrhagic fever-renal syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.2,Croatia,Validated,European Centre for Disease prevention and Control 2012-2015[INST]
3411,340,Hemorrhagic fever-renal syndrome,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.08,Czech Republic,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
3411,340,Hemorrhagic fever-renal syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.36,Estonia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
3411,340,Hemorrhagic fever-renal syndrome,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,29.16,Finland,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
3411,340,Hemorrhagic fever-renal syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.18,France,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
3411,340,Hemorrhagic fever-renal syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.16,Germany,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
3411,340,Hemorrhagic fever-renal syndrome,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.08,Hungary,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
3411,340,Hemorrhagic fever-renal syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.3,Latvia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
3411,340,Hemorrhagic fever-renal syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.44,Luxembourg,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
3411,340,Hemorrhagic fever-renal syndrome,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Poland,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
3411,340,Hemorrhagic fever-renal syndrome,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Romania,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
3411,340,Hemorrhagic fever-renal syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.24,Slovakia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
3411,340,Hemorrhagic fever-renal syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.32,Slovenia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
3411,340,Hemorrhagic fever-renal syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.52,Sweden,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
3411,340,Hemorrhagic fever-renal syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.5,Norway,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
3410,2552,Microsporidiosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
3409,1171,Cerebellar ataxia-areflexia-pes cavus-optic atrophy-sensorineural hearing loss syndrome,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,24468074[PMID]
3409,1171,Cerebellar ataxia-areflexia-pes cavus-optic atrophy-sensorineural hearing loss syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24468074[PMID]
18861,217560,Neuroendocrine cell hyperplasia of infancy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18860,217557,Pulmonary interstitial glycogenosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3437,1686,Cardiac diverticulum,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18862,217563,Neonatal acute respiratory distress syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
18862,217563,Neonatal acute respiratory distress syndrome,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.067,Worldwide,Validated,14977415[PMID]
18856,217407,Hereditary hypotrichosis with recurrent skin vesicles,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,19765682[PMID]
18856,217407,Hereditary hypotrichosis with recurrent skin vesicles,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19765682[PMID]
3434,1456,Middle aortic syndrome,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.17,Europe,Not yet validated,ORPHANET
3434,1456,Middle aortic syndrome,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
3435,1457,Aorta coarctation,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,35.6,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3435,1457,Aorta coarctation,Morphological anomaly,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,78.5,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
3435,1457,Aorta coarctation,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,43.7,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3435,1457,Aorta coarctation,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,22.7,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3435,1457,Aorta coarctation,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,21.3,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3435,1457,Aorta coarctation,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,27.5,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3435,1457,Aorta coarctation,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,59.4,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3435,1457,Aorta coarctation,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,31.0,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3435,1457,Aorta coarctation,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,32.5,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3435,1457,Aorta coarctation,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,39.6,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3435,1457,Aorta coarctation,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,24.9,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3435,1457,Aorta coarctation,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.7,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3435,1457,Aorta coarctation,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,21.3,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3435,1457,Aorta coarctation,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,8.0,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3435,1457,Aorta coarctation,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.5,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3435,1457,Aorta coarctation,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,16.9,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3435,1457,Aorta coarctation,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,25.1,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3435,1457,Aorta coarctation,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,40.1,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3435,1457,Aorta coarctation,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,38.1,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3435,1457,Aorta coarctation,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18853,217390,Combined immunodeficiency due to DOCK8 deficiency,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,19776401[PMID]
18853,217390,Combined immunodeficiency due to DOCK8 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19776401[PMID]
3428,1132,Aortic arch defects,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18852,217385,17p13.3 microduplication syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,23813913[PMID]
18852,217385,17p13.3 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18855,217399,Congenital insensitivity to pain-hyperhidrosis-absence of cutaneous sensory innervation,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,19836135[PMID]
18855,217399,Congenital insensitivity to pain-hyperhidrosis-absence of cutaneous sensory innervation,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19836135[PMID]
18854,217396,Progressive polyneuropathy with bilateral striatal necrosis,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,19798730[PMID]
18854,217396,Progressive polyneuropathy with bilateral striatal necrosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19798730[PMID]
3424,982,Pulmonary valve agenesis,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18849,217371,Acute infantile liver failure due to synthesis defect of mtDNA-encoded proteins,Disease,Disorder,Cases/families,Case(s),,32.0,Worldwide,Validated,33365252[PMID]_ 33485800[PMID]
18849,217371,Acute infantile liver failure due to synthesis defect of mtDNA-encoded proteins,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18848,217346,19q13.11 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,24243649[PMID]
18848,217346,19q13.11 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3425,980,Absence of the pulmonary artery,Morphological anomaly,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,[EXPERT]
3425,980,Absence of the pulmonary artery,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18851,217382,Neurodegenerative syndrome due to cerebral folate transport deficiency,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,19732866[PMID]
18851,217382,Neurodegenerative syndrome due to cerebral folate transport deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19732866[PMID]
3426,1054,Aneurysm of sinus of Valsalva,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18850,217377,Microduplication Xp11.22p11.23 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,19716111[PMID]
18850,217377,Microduplication Xp11.22p11.23 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19716111[PMID]
18879,217622,Sensorineural deafness with dilated cardiomyopathy,Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,10769282[PMID]
18879,217622,Sensorineural deafness with dilated cardiomyopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10769282[PMID]
3454,3092,Fixed subaortic stenosis,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3448,2299,Aortic arch interruption,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.3,Europe,Not yet validated,24457106[PMID]
3448,2299,Aortic arch interruption,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
3451,3427,Double outlet left ventricle,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Worldwide,Validated,21106011[PMID]_22644696[PMID]
3451,3427,Double outlet left ventricle,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
3450,3426,Double outlet right ventricle,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,10.0,Germany,Validated,22644696[PMID]
3450,3426,Double outlet right ventricle,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET
3445,439,Isolated right ventricular hypoplasia,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3444,422,Idiopathic/heritable pulmonary arterial hypertension,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.11,United States,Validated,20558556[PMID]
3444,422,Idiopathic/heritable pulmonary arterial hypertension,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.65,France,Validated,16456139[PMID]
3444,422,Idiopathic/heritable pulmonary arterial hypertension,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,France,Validated,16456139[PMID]
3444,422,Idiopathic/heritable pulmonary arterial hypertension,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.4,Czech Republic,Validated,24629043[PMID]
3444,422,Idiopathic/heritable pulmonary arterial hypertension,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.62,Czech Republic,Validated,24629043[PMID]
3444,422,Idiopathic/heritable pulmonary arterial hypertension,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,16456139[PMID]_24629043[PMID]
3444,422,Idiopathic/heritable pulmonary arterial hypertension,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.25,China,Validated,34103049[PMID]
3441,2038,Pulmonary arteriovenous malformation,Morphological anomaly,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.5,Worldwide,Not yet validated,24008954[PMID]
3441,2038,Pulmonary arteriovenous malformation,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
3443,2041,Coronary arterial fistula,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET_24940026[PMID]
3338,282,Frontotemporal dementia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,3.0,Europe,Not yet validated,20971753[PMID]
3338,282,Frontotemporal dementia,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.05,Italy,Validated,30979859[PMID]
3336,331,Congenital factor XIII deficiency,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.04,Europe,Not yet validated,ORPHANET
3336,331,Congenital factor XIII deficiency,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.05,Europe,Validated,European Medicines Agency[INST]
3343,159,Carnitine-acylcarnitine translocase deficiency,Disease,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,24088670[PMID]
3343,159,Carnitine-acylcarnitine translocase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3340,542,Primary cutaneous lymphoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.75,Europe,Not yet validated,15692063[PMID]_16192622[PMID]_ ORPHANET
3340,542,Primary cutaneous lymphoma,Category,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
3341,707,Plague,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3341,707,Plague,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.2,Europe,Validated,European Centre for Disease prevention and Control 2011[INST]
3331,335,Congenital fibrinogen deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.15,Europe,Not yet validated,National haemophilia foundation[OTHER]
3335,79,Congenital alpha2-antiplasmin deficiency,Disease,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,23396430[PMID]
3335,79,Congenital alpha2-antiplasmin deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23396430[PMID]
18885,217656,Inherited isolated arrhythmogenic cardiomyopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3332,1070,Anisakiasis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.6,Japan,Validated,ORPHANET_17428725[PMID]
3332,1070,Anisakiasis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.32,Worldwide,Validated,23092000[PMID]
3332,1070,Anisakiasis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,24630706[PMID]
3333,1467,Cogan syndrome,Disease,Disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,18037121[PMID]
3333,1467,Cogan syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_18037121[PMID]
3355,2157,Histidinemia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.7,Sweden,Validated,8463510[PMID]
3355,2157,Histidinemia,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET
3355,2157,Histidinemia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,8.3,United States,Validated,[EXPERT]
3355,2157,Histidinemia,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.9,Japan,Validated,6468444[PMID]
3354,3124,Saccharopinuria,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18907,220407,Limited systemic sclerosis,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,23661427[PMID]
18907,220407,Limited systemic sclerosis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
18904,220386,Semilobar holoprosencephaly,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
3353,2203,Hyperlysinemia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18905,220393,Diffuse cutaneous systemic sclerosis,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,3.8,"Taiwan, Province of China",Not yet validated,22899470[PMID]
18905,220393,Diffuse cutaneous systemic sclerosis,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 100 000,1.5,"Taiwan, Province of China",Validated,22899470[PMID]
3359,332,Congenital intrinsic factor deficiency,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,[EXPERT]
3359,332,Congenital intrinsic factor deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18910,220448,Macrothrombocytopenia with mitral valve insufficiency,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,9482416[PMID]
18910,220448,Macrothrombocytopenia with mitral valve insufficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9482416[PMID]
18908,220436,Quebec platelet disorder,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.45,Specific population,Validated,21495923[PMID]_22102275[PMID]
18908,220436,Quebec platelet disorder,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.15,Canada,Validated,18988861[PMID]_21495923[PMID]_22102275[PMID]
3356,2195,Dicarboxylic aminoaciduria,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Specific population,Validated,17570073[PMID]_21123949[PMID]_ORPHANET
3356,2195,Dicarboxylic aminoaciduria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.76,Specific population,Validated,17570073[PMID]_21123949[PMID]
3351,2170,Methylcobalamin deficiency type cblG,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,33.0,Worldwide,Validated,ORPHANET
3351,2170,Methylcobalamin deficiency type cblG,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18903,220295,Xeroderma pigmentosum-Cockayne syndrome complex,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,[EXPERT]
18903,220295,Xeroderma pigmentosum-Cockayne syndrome complex,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3349,414,Gyrate atrophy of choroid and retina,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Finland,Not yet validated,ORPHANET
3349,414,Gyrate atrophy of choroid and retina,Disease,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,ORPHANET
3349,414,Gyrate atrophy of choroid and retina,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
3369,622,Homocystinuria without methylmalonic aciduria,Disease,Disorder,Cases/families,Case(s),,73.0,Worldwide,Validated,[EXPERT]
3369,622,Homocystinuria without methylmalonic aciduria,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3370,927,Hyperammonemia due to N-acetylglutamate synthase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,ORPHANET
3370,927,Hyperammonemia due to N-acetylglutamate synthase deficiency,Disease,Disorder,Cases/families,Case(s),,99.0,Worldwide,Validated,33036647[PMID]_33231058[PMID]
3374,2880,Phosphoenolpyruvate carboxykinase deficiency,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,ORPHANET
3374,2880,Phosphoenolpyruvate carboxykinase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3360,941,D-glyceric aciduria,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18913,220465,Laron syndrome with immunodeficiency,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,[EXPERT]
18913,220465,Laron syndrome with immunodeficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18915,220489,Rare hereditary hemochromatosis,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3362,19,2-hydroxyglutaric aciduria,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3363,2843,Pentosuria,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
18917,220497,Joubert syndrome with renal defect,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3365,212,Cystathioninuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.1,Canada,Validated,519848[PMID]
3365,212,Cystathioninuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.1,Canada,Validated,519848[PMID]
3365,212,Cystathioninuria,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
18916,220493,Joubert syndrome with ocular defect,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3366,470,Lysinuric protein intolerance,Disease,Disorder,Prevalence at birth,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
3366,470,Lysinuric protein intolerance,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.7,Italy,Validated,[EXPERT]
3366,470,Lysinuric protein intolerance,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.7,Finland,Validated,15050971[PMID]
3366,470,Lysinuric protein intolerance,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.75,Japan,Validated,10980538[PMID]
3366,470,Lysinuric protein intolerance,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18936,221074,Marchiafava-Bignami disease,Disease,Disorder,Cases/families,Case(s),,250.0,Worldwide,Validated,11328337[PMID]
18936,221074,Marchiafava-Bignami disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_11328337[PMID]
3384,145,Hereditary breast and/or ovarian cancer syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,28632866[PMID]
3387,2965,Prolactinoma,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,44.4,United Kingdom,Validated,19650784[PMID]
3387,2965,Prolactinoma,Disease,Disorder,Point prevalence,Value and class,6-9 / 10 000,62.0,Belgium,Validated,16968795[PMID]
3387,2965,Prolactinoma,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,45.7,Switzerland,Validated,19968031[PMID]
3387,2965,Prolactinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.05,Malta,Validated,23239049[PMID]
3387,2965,Prolactinoma,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,50.7,Europe,Validated,16968795[PMID]_ 19650784[PMID]_ 19968031[PMID]_ORPHANET
18939,221091,Trigeminal neuralgia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
18939,221091,Trigeminal neuralgia,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.3,United States,Validated,15062534[PMID]
18939,221091,Trigeminal neuralgia,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,8.0,United Kingdom,Validated,10733998[PMID]
3386,538,Lymphangioleiomyomatosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.0135,Worldwide,Validated,21764810[PMID]
3386,538,Lymphangioleiomyomatosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.15,Worldwide,Validated,21764810[PMID]_ ORPHANET_[EXPERT]
3386,538,Lymphangioleiomyomatosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.015,United States,Validated,21764810[PMID]
3386,538,Lymphangioleiomyomatosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.17,United States,Validated,21764810[PMID]
3386,538,Lymphangioleiomyomatosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,France,Validated,10499073[PMID]
3386,538,Lymphangioleiomyomatosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.19,Germany,Validated,21764810[PMID]
3386,538,Lymphangioleiomyomatosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.21,Canada,Validated,21764810[PMID]
3386,538,Lymphangioleiomyomatosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.25,United Kingdom,Validated,21764810[PMID]
3386,538,Lymphangioleiomyomatosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.32,Switzerland,Validated,21764810[PMID]
3386,538,Lymphangioleiomyomatosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.39,New Zealand,Validated,21764810[PMID]
3386,538,Lymphangioleiomyomatosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.26,Australia,Validated,21764810[PMID]
3386,538,Lymphangioleiomyomatosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.25,Europe,Validated,21764810[PMID]
3386,538,Lymphangioleiomyomatosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.25,Netherlands,Validated,DOI:10.1517/21678707.2015.1022529[OTHER]
18940,221098,Glossopharyngeal neuralgia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
18940,221098,Glossopharyngeal neuralgia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.7,United States,Validated,1798430[PMID]
3388,2942,Postpoliomyelitis syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
3391,1578,Pterin-4 alpha-carbinolamine dehydratase deficiency,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,21.0,Worldwide,Validated,ORPHANET
3391,1578,Pterin-4 alpha-carbinolamine dehydratase deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
3377,3208,Isolated succinate-CoQ reductase deficiency,Disease,Disorder,Cases/families,Case(s),,37.0,Worldwide,Validated,23322652[PMID]
3377,3208,Isolated succinate-CoQ reductase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,23322652[PMID]
18929,221008,Rothmund-Thomson syndrome type 1,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,ORPHANET
18929,221008,Rothmund-Thomson syndrome type 1,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3376,24,Fumaric aciduria,Disease,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,22069215[PMID]
3376,24,Fumaric aciduria,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22069215[PMID]
18930,221016,Rothmund-Thomson syndrome type 2,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,ORPHANET
18930,221016,Rothmund-Thomson syndrome type 2,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18931,221039,"Hereditary sclerosing poikiloderma, Weary type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10233244[PMID]
18931,221039,"Hereditary sclerosing poikiloderma, Weary type",Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,10233244[PMID]
3381,851,Paris-Trousseau thrombocytopenia,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,ORPHANET
3381,851,Paris-Trousseau thrombocytopenia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18932,221043,Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome,Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,26471370[PMID]
18932,221043,Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26471370[PMID]
18933,221046,Poikiloderma with neutropenia,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,18925663[PMID]_20004881[PMID]
18933,221046,Poikiloderma with neutropenia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3383,745,Severe hereditary thrombophilia due to congenital protein C deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.16,Worldwide,Validated,16689776[PMID]
3383,745,Severe hereditary thrombophilia due to congenital protein C deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
18934,221054,Acrocephalopolydactyly,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,22413886[PMID]
18934,221054,Acrocephalopolydactyly,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22413886[PMID]
18935,221061,Familial cerebral cavernous malformation,Malformation syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,15.0,Worldwide,Validated,[EXPERT]
3382,849,Glanzmann thrombasthenia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
18978,225154,Familial infantile bilateral striatal necrosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,ORPHANET
18976,225123,TFR2-related hemochromatosis,Disease,Disorder,Cases/families,Case(s),,33.0,Worldwide,Validated,ORPHANET
18976,225123,TFR2-related hemochromatosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
18977,225147,Sporadic infantile bilateral striatal necrosis,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,ORPHANET
18974,223727,Bone sarcoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.8,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
18974,223727,Bone sarcoma,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,9.29,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
18945,221120,Pseudoaminopterin syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,22811276[PMID]
18945,221120,Pseudoaminopterin syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22811276[PMID]
18946,221126,Fowler vasculopathy,Malformation syndrome,Disorder,Cases/families,Case(s),,44.0,Worldwide,Validated,25677735[PMID]
18946,221126,Fowler vasculopathy,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25677735[PMID]
18947,221139,Combined immunodeficiency with facio-oculo-skeletal anomalies,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,19863561[PMID]
18947,221139,Combined immunodeficiency with facio-oculo-skeletal anomalies,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19863561[PMID]
18948,221142,Confetti-like macular atrophy,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,19878392[PMID]
18948,221142,Confetti-like macular atrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19878392[PMID]
18949,221145,"Cutis laxa with severe pulmonary, gastrointestinal and urinary anomalies",Malformation syndrome,Disorder,Cases/families,Case(s),,21.0,Worldwide,Validated,26866239[PMID]
18949,221145,"Cutis laxa with severe pulmonary, gastrointestinal and urinary anomalies",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26866239[PMID]
19062,228003,Severe combined immunodeficiency due to CORO1A deficiency,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,29942301[PMID]
19062,228003,Severe combined immunodeficiency due to CORO1A deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29942301[PMID]
3764,3398,Thymic epithelial neoplasm,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.17,Europe,Validated,[EXPERT]_RARECARE surveillance of rare cancers in Europe 2011[REG]
3764,3398,Thymic epithelial neoplasm,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.3,United States,Validated,22406029[PMID]
3764,3398,Thymic epithelial neoplasm,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
19061,228000,Idiopathic CD4 lymphocytopenia,Biological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3765,547,Non-Hodgkin lymphoma,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,22835603[PMID]
3765,547,Non-Hodgkin lymphoma,Category,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,11.6,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3762,842,Testicular seminomatous germ cell tumor,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.71,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
3762,842,Testicular seminomatous germ cell tumor,Disease,Disorder,Lifetime Prevalence,Value and class,1-5 / 10 000,46.01,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
3762,842,Testicular seminomatous germ cell tumor,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19058,227976,"Autosomal recessive optic atrophy, OPA7 type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22815638[PMID]_20405026[PMID]_19327736[PMID]
19058,227976,"Autosomal recessive optic atrophy, OPA7 type",Disease,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,22815638[PMID]_20405026[PMID]_19327736[PMID]
3760,876,Yolk sac tumor,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
3760,876,Yolk sac tumor,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
19057,227972,Toxic oil syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_12192735[PMID]
19057,227972,Toxic oil syndrome,Disease,Disorder,Cases/families,Case(s),,20000.0,Worldwide,Validated,12192735[PMID]
19056,227796,Fundus albipunctatus,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
19071,228123,Coccidioidomycosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19070,228119,Fusariosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19069,228116,Hughes-Stovin syndrome,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,21489283[PMID]_15696563[PMID]_ [EXPERT]
19069,228116,Hughes-Stovin syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19068,228113,Anal fistula,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,18.3,Europe,Validated,DOI:10.12998/wjcc.v7.i14.1795[OTHER]
19068,228113,Anal fistula,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,18.0,United Kingdom,Validated,DOI:10.12998/wjcc.v7.i14.1795[OTHER]
3771,3399,Germ cell tumor,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3768,389,Langerhans cell histiocytosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.5,Europe,Validated,[EXPERT]
19064,228012,Progressive sensorineural hearing loss-hypertrophic cardiomyopathy syndrome,Disease,Disorder,Cases/families,Family(ies),,4.0,Worldwide,Validated,18212818[PMID]
19064,228012,Progressive sensorineural hearing loss-hypertrophic cardiomyopathy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18212818[PMID]
3751,616,Medulloblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.11,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3751,616,Medulloblastoma,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,European Medicines Agency 2010[INST]
3751,616,Medulloblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.74,United States,Validated,Central Brain Tumor registry of the United States 2004-2007[REG]
3750,301,Ependymal tumor,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.2,Europe,Validated,22227039[PMID]_22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
3750,301,Ependymal tumor,Clinical group,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
3750,301,Ependymal tumor,Clinical group,Group of disorders,Lifetime Prevalence,Value and class,1-9 / 100 000,3.85,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
3750,301,Ependymal tumor,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.2,United Kingdom,Validated,22227039[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
3750,301,Ependymal tumor,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.43,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
3749,541,Primary cutaneous CD30+ T-cell lymphoproliferative disease,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.18,Europe,Validated,Institut de Veille Sanitaire 1990[INST]
3749,541,Primary cutaneous CD30+ T-cell lymphoproliferative disease,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3747,543,Burkitt lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.17,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2003[REG]
3747,543,Burkitt lymphoma,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,12.5,Africa,Validated,National Institutes of Health[INST]
3747,543,Burkitt lymphoma,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.4,United States,Validated,National Cancer Institute 2001-2009[INST]
3747,543,Burkitt lymphoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3759,319,Skeletal Ewing sarcoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.13,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
3759,319,Skeletal Ewing sarcoma,Disease,Disorder,Lifetime Prevalence,Value and class,1-9 / 100 000,2.33,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
3759,319,Skeletal Ewing sarcoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3758,668,Osteosarcoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.23,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
3758,668,Osteosarcoma,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
3758,668,Osteosarcoma,Disease,Disorder,Lifetime Prevalence,Value and class,1-9 / 100 000,3.17,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
3758,668,Osteosarcoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.4,United States,Validated,19197972[PMID]
19053,227510,"Multiple system atrophy, cerebellar type",Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
3754,94,Astrocytoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.8,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3754,94,Astrocytoma,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,2.5,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]_ ORPHANET
3754,94,Astrocytoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.909,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3754,94,Astrocytoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.777,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3754,94,Astrocytoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.768,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3754,94,Astrocytoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.184,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3754,94,Astrocytoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.251,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3754,94,Astrocytoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.443,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3754,94,Astrocytoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.263,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3754,94,Astrocytoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.829,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3754,94,Astrocytoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.538,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3754,94,Astrocytoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.147,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3754,94,Astrocytoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.786,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3754,94,Astrocytoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.632,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3754,94,Astrocytoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.801,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3754,94,Astrocytoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.392,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3754,94,Astrocytoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.78,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3754,94,Astrocytoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.543,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3754,94,Astrocytoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.931,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3754,94,Astrocytoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.707,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3754,94,Astrocytoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.523,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3754,94,Astrocytoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.087,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3754,94,Astrocytoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.574,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3754,94,Astrocytoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.544,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3754,94,Astrocytoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.591,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3752,360,Glioblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.0,Worldwide,Validated,[EXPERT]
3752,360,Glioblastoma,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Worldwide,Validated,[EXPERT]
3752,360,Glioblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.52,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2003[REG]
3752,360,Glioblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.2,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
3752,360,Glioblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.2,Croatia,Validated,15103760[PMID]
3752,360,Glioblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.7,Greece,Validated,19494549[PMID]
3752,360,Glioblastoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.0,Specific population,Validated,14648713[PMID]
19029,226292,Permanent congenital hypothyroidism,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,33.3,Europe,Validated,[EXPERT]
19029,226292,Permanent congenital hypothyroidism,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3732,513,Acute lymphoblastic leukemia,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.75,Europe,Not yet validated,ORPHANET
3732,513,Acute lymphoblastic leukemia,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.3,France,Validated,Institut National du Cancer 2013[INST]
3732,513,Acute lymphoblastic leukemia,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.6,United States,Validated,National Cancer institute[INST]_23523389[PMID]
3732,513,Acute lymphoblastic leukemia,Clinical group,Group of disorders,Lifetime Prevalence,Value and class,1-5 / 10 000,22.0,United States,Validated,National Cancer institute 2009[INST]
3732,513,Acute lymphoblastic leukemia,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,11.0,Europe,Validated,European Medicines Agency 2005[INST]
3733,1957,Esthesioneuroblastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3733,1957,Esthesioneuroblastoma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,ORPHANET
19031,226298,Central congenital hypothyroidism,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3734,2030,Fibrosarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3734,2030,Fibrosarcoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3735,2126,Solitary fibrous tumor,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,24625420[PMID]
19030,226295,Primary congenital hypothyroidism,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,37.5,Europe,Validated,[EXPERT]
19030,226295,Primary congenital hypothyroidism,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,58.62,United States,Validated,22766612[PMID]
19030,226295,Primary congenital hypothyroidism,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,33.0,Finland,Validated,35661828[PMID]
3728,758,Pseudoxanthoma elasticum,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.5,Europe,Validated,22209248[PMID]
3729,419,Hyperprolinemia type 1,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3731,1501,Adrenocortical carcinoma,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.75,Europe,Validated,European Medicines Agency[INST]
3731,1501,Adrenocortical carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.03,Europe,Not yet validated,22796286[PMID]
3731,1501,Adrenocortical carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.082,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3731,1501,Adrenocortical carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.173,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3731,1501,Adrenocortical carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.18,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3731,1501,Adrenocortical carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.249,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3731,1501,Adrenocortical carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.547,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3731,1501,Adrenocortical carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.271,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3731,1501,Adrenocortical carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.314,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3731,1501,Adrenocortical carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.225,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3731,1501,Adrenocortical carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.173,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3731,1501,Adrenocortical carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.17,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3731,1501,Adrenocortical carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.133,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3731,1501,Adrenocortical carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.288,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3731,1501,Adrenocortical carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.514,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3731,1501,Adrenocortical carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.464,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3731,1501,Adrenocortical carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.188,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3731,1501,Adrenocortical carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.226,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3731,1501,Adrenocortical carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.433,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3731,1501,Adrenocortical carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.234,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3731,1501,Adrenocortical carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.244,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3731,1501,Adrenocortical carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.215,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3731,1501,Adrenocortical carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.141,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3731,1501,Adrenocortical carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.167,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3731,1501,Adrenocortical carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.183,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
19033,226307,Hypothyroidism due to deficient transcription factors involved in pituitary development or function,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3737,3148,Malignant peripheral nerve sheath tumor,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.0,Worldwide,Validated,24470531[PMID]
3737,3148,Malignant peripheral nerve sheath tumor,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_24470531[PMID]
3738,3273,Synovial sarcoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.463,Europe,Validated,RARECARE surveillance of rare cancers in Europe [REG]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.95,France,Validated,Institut National du Cancer 2013[INST]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2010[REG]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Lifetime Prevalence,Value and class,1-5 / 10 000,22.9,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2010[REG]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.8,United States,Validated,National Cancer Institute 2008[INST]_emedicine[OTHER]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.25,China,Not yet validated,emedicine[OTHER]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.25,Japan,Not yet validated,emedicine[OTHER]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.012,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.443,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.083,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.923,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.418,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.392,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.232,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.333,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.599,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.355,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.361,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.868,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.372,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.701,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.267,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.2,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.435,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.261,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.265,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.617,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.091,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.27,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3739,391,Classic Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.504,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3717,2260,Oligomeganephronia,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
3716,503,Larsen syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.65,France,Validated,22925539[PMID]
3716,503,Larsen syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,France,Validated,22925539[PMID]
3716,503,Larsen syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.4,Europe,Validated,[EXPERT]_EUROCAT European surveillance of congenital anomalies 2010[REG]
3716,503,Larsen syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,[EXPERT]_EUROCAT European surveillance of congenital anomalies 2010[REG]
3719,1652,Dent disease,Disease,Disorder,Cases/families,Family(ies),,250.0,Worldwide,Validated,20946626[PMID]
3719,1652,Dent disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
3713,2542,Isolated microphthalmia-anophthalmia-coloboma,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,2.18,France,Validated,8921488[PMID]
3713,2542,Isolated microphthalmia-anophthalmia-coloboma,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,3.33,Sweden,Validated,8921488[PMID]
3713,2542,Isolated microphthalmia-anophthalmia-coloboma,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,3.7,United States,Validated,8921488[PMID]
3713,2542,Isolated microphthalmia-anophthalmia-coloboma,Clinical group,Group of disorders,Prevalence at birth,Class only,1-9 / 100 000,0.0,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]_[EXPERT]
3713,2542,Isolated microphthalmia-anophthalmia-coloboma,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Europe,Validated,[EXPERT]
3712,3280,Syringomyelia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,8.4,Europe,Validated,[EXPERT]
3712,3280,Syringomyelia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,8.4,United Kingdom,Validated,4224973[PMID]
3712,3280,Syringomyelia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,9.0,Spain,Validated,2054207[PMID]
3712,3280,Syringomyelia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.94,Japan,Validated,21943925[PMID]
3712,3280,Syringomyelia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,8.2,New Zealand,Validated,16549414[PMID]
3715,2478,Megalencephalic leukoencephalopathy with subcortical cysts,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,21977097[PMID]_12189496[PMID]
3715,2478,Megalencephalic leukoencephalopathy with subcortical cysts,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3727,3337,Primary Fanconi renotubular syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
3726,223,Arginine vasopressin resistance,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.15,Europe,Validated,[EXPERT]
3726,223,Arginine vasopressin resistance,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.44,Specific population,Validated,10820168[PMID]
3723,757,Pseudohypoaldosteronism type 2,Disease,Disorder,Cases/families,Case(s),,180.0,Worldwide,Validated,22073419[PMID]
3723,757,Pseudohypoaldosteronism type 2,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_22073419[PMID]
19131,228423,GATA2 deficiency spectrum,Disease,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,20040766[PMID]_21242295[PMID]
19131,228423,GATA2 deficiency spectrum,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3705,521,Chronic myeloid leukemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.25,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
3705,521,Chronic myeloid leukemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.25,France,Validated,Institut National du Cancer 2013[INST]
3705,521,Chronic myeloid leukemia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.0,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
3705,521,Chronic myeloid leukemia,Disease,Disorder,Lifetime Prevalence,Value and class,1-9 / 100 000,5.63,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
3705,521,Chronic myeloid leukemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.7,United States,Validated,SEER Surveillance Epidemiology and End Results Program 2008-2012[REG]
19128,228415,5q35 microduplication syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,24819041[PMID]
19128,228415,5q35 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24819041[PMID]
3704,132,Hereditary butyrylcholinesterase deficiency,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET
3711,1172,Autosomal recessive cerebellar ataxia,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,3.3,Portugal,Validated,23609960[PMID]
3711,1172,Autosomal recessive cerebellar ataxia,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,3.3,Worldwide,Validated,24603320[PMID]
3711,1172,Autosomal recessive cerebellar ataxia,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,5.3,France,Validated,19440741[PMID]
3711,1172,Autosomal recessive cerebellar ataxia,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,2.3,Norway,Validated,19339254[PMID]
3711,1172,Autosomal recessive cerebellar ataxia,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,3.6,Europe,Validated,19440741[PMID]_19339254[PMID]_23609960[PMID]
19134,229717,Isolated agammaglobulinemia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.3,Worldwide,Validated,ORPHANET
19132,228426,Syndromic multisystem autoimmune disease due to Itch deficiency,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,20170897[PMID]
19132,228426,Syndromic multisystem autoimmune disease due to Itch deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20170897[PMID]
3709,2345,Isolated Klippel-Feil syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Europe,Validated,[EXPERT]
3709,2345,Isolated Klippel-Feil syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.6,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3708,1333,Familial pancreatic carcinoma,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
19123,228396,Ptosis-upper ocular movement limitation-absence of lacrimal punctum syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,19941420[PMID]
19123,228396,Ptosis-upper ocular movement limitation-absence of lacrimal punctum syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19941420[PMID]
19120,228387,Spondylo-megaepiphyseal-metaphyseal dysplasia,Disease,Disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,22791571[PMID]
19120,228387,Spondylo-megaepiphyseal-metaphyseal dysplasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22791571[PMID]
19121,228390,Frontonasal dysplasia-alopecia-genital anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,24668755[PMID]
19121,228390,Frontonasal dysplasia-alopecia-genital anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19127,228410,Cardiac anomalies-short stature-joint hypermobility-facial dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,19932204[PMID]
19127,228410,Cardiac anomalies-short stature-joint hypermobility-facial dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19932204[PMID]
19124,228399,8q12 microduplication syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,22902603[PMID]
19124,228399,8q12 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3700,2781,Osteopetrosis and related disorders,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.0,Europe,Not yet validated,16307387[PMID]
3700,2781,Osteopetrosis and related disorders,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19125,228402,2q23.1 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,22407754[PMID]
19125,228402,2q23.1 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19119,228384,5q14.3 microdeletion syndrome,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,23824879[PMID]
19119,228384,5q14.3 microdeletion syndrome,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23824879[PMID]
19118,228379,Virus-associated trichodysplasia spinulosa,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,ORPHANET
19118,228379,Virus-associated trichodysplasia spinulosa,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19117,228374,Charcot-Marie-Tooth disease type 2B5,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,20039262[PMID]
19117,228374,Charcot-Marie-Tooth disease type 2B5,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20039262[PMID]
19116,228371,Foodborne botulism,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,21495856[PMID]_[EXPERT]
19116,228371,Foodborne botulism,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
19116,228371,Foodborne botulism,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,United States,Validated,21495856[PMID]
19116,228371,Foodborne botulism,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.18,Romania,Validated,21495856[PMID]
19096,228290,White fibrous papulosis of the neck,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19097,228293,Pseudoxanthoma elasticum-like papillary dermal elastolysis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19098,228299,Mid-dermal elastolysis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19099,228302,"Carnitine palmitoyl transferase II deficiency, myopathic form",Clinical subtype,Subtype of disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,20301431[PMID]
19099,228302,"Carnitine palmitoyl transferase II deficiency, myopathic form",Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_20301431[PMID]
19100,228305,"Carnitine palmitoyl transferase II deficiency, severe infantile form",Clinical subtype,Subtype of disorder,Cases/families,Family(ies),,30.0,Worldwide,Validated,20301431[PMID]
19100,228305,"Carnitine palmitoyl transferase II deficiency, severe infantile form",Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20301431[PMID]
19101,228308,"Carnitine palmitoyl transferase II deficiency, neonatal form",Clinical subtype,Subtype of disorder,Cases/families,Family(ies),,20.0,Worldwide,Validated,20301431[PMID]
19101,228308,"Carnitine palmitoyl transferase II deficiency, neonatal form",Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20301431[PMID]
19102,228312,"Autoimmune hemolytic anemia, cold type",Clinical group,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
19088,228240,Elastoderma,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,25072684[PMID]
19088,228240,Elastoderma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25072684[PMID]
3664,135,CACH syndrome,Disease,Disorder,Cases/families,Case(s),,148.0,Worldwide,Validated,ORPHANET
3664,135,CACH syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
19090,228247,Acquired pseudoxanthoma elasticum,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,ORPHANET
19090,228247,Acquired pseudoxanthoma elasticum,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19091,228254,Elastoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19092,228264,Papular elastorrhexis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
19093,228272,Primary anetoderma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19094,228277,Familial anetoderma,Disease,Disorder,Cases/families,Family(ies),,12.0,Worldwide,Validated,21719400[PMID]
19094,228277,Familial anetoderma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21719400[PMID]
19095,228285,Acquired cutis laxa,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19081,228190,Patent ductus arteriosus-bicuspid aortic valve-hand anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,10533032[PMID]
19081,228190,Patent ductus arteriosus-bicuspid aortic valve-hand anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3656,3203,Overhydrated hereditary stomatocytosis,Disease,Disorder,Cases/families,Family(ies),,20.0,Worldwide,Validated,ORPHANET
3656,3203,Overhydrated hereditary stomatocytosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3657,3202,Dehydrated hereditary stomatocytosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9718354[PMID]_11001917[PMID]_23479567[PMID]
3657,3202,Dehydrated hereditary stomatocytosis,Disease,Disorder,Cases/families,Family(ies),,20.0,Worldwide,Validated,9718354[PMID]_11001917[PMID]_23479567[PMID]_Pr Loïc GARÇON_Dr Véronique PICARD[EXPERT]
19087,228236,Linear focal elastosis,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
19087,228236,Linear focal elastosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19086,228227,Late-onset focal dermal elastosis,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,15670180[PMID]
19086,228227,Late-onset focal dermal elastosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15670180[PMID]
19072,228140,"Idiopathic ventricular fibrillation, non Brugada type",Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3650,1018,X-linked Alport syndrome-diffuse leiomyomatosis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
19075,228165,Baló concentric sclerosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3651,306,Self-limited infantile epilepsy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19074,228157,Marburg acute multiple sclerosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3652,328,Congenital factor X deficiency,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,European Medicines Agency 2008[INST]
19077,228174,Autosomal dominant Charcot-Marie-Tooth disease type 2N,Disease,Disorder,Cases/families,Case(s),,28.0,Worldwide,Validated,ORPHANET
19077,228174,Autosomal dominant Charcot-Marie-Tooth disease type 2N,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19076,228169,Autosomal dominant striatal neurodegeneration,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,15210883[PMID]_26769607[PMID]_26475694[PMID]
19076,228169,Autosomal dominant striatal neurodegeneration,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15210883[PMID]_26769607[PMID]_26475694[PMID]
3653,2132,Hemoglobin C disease,Disease,Disorder,Point prevalence,Value and class,>1 / 1000,166.66,United States,Validated,23591685[PMID]
3653,2132,Hemoglobin C disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.65,Belgium,Validated,19103861[PMID]
3654,2133,Hemoglobin E disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19078,228179,Autosomal dominant Charcot-Marie-Tooth disease type 2M,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,ORPHANET
19078,228179,Autosomal dominant Charcot-Marie-Tooth disease type 2M,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3655,288,Hereditary elliptocytosis,Disease,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Worldwide,Validated,[EXPERT]
19198,231531,Hermansky-Pudlak syndrome due to BLOC-1 deficiency,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,PMID: 12923531; 23364359 ; 22461475 ; 16385460
19198,231531,Hermansky-Pudlak syndrome due to BLOC-1 deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19196,231512,Hermansky-Pudlak syndrome due to BLOC-2 deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3644,1320,Idiopathic camptocormia,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3643,256,Early-onset generalized limb-onset dystonia,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,20.0,Specific population,Validated,7719342[PMID]
3643,256,Early-onset generalized limb-onset dystonia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.2,United States,Validated,3264051[PMID]
3643,256,Early-onset generalized limb-onset dystonia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.4,Europe,Validated,17129379[PMID]_23596437[PMID]
3643,256,Early-onset generalized limb-onset dystonia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.4,United States,Validated,3264051[PMID]
3643,256,Early-onset generalized limb-onset dystonia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,8.3,France,Validated,17290457[PMID]
19195,231500,Hermansky-Pudlak syndrome due to BLOC-3 deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3641,441,Pure autonomic failure,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,European Medicines Agency 2007[INST]
3640,1576,Infantile bilateral striatal necrosis,Clinical group,Group of disorders,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,ORPHANET
19190,231445,Paraparetic variant of Guillain-Barré syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
19190,231445,Paraparetic variant of Guillain-Barré syndrome,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
3637,2073,Narcolepsy type 1,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,30.0,Europe,Validated,24849861[PMID]_[EXPERT]
3637,2073,Narcolepsy type 1,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.74,United States,Validated,11902429[PMID]
3637,2073,Narcolepsy type 1,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,22.0,Norway,Validated,19456307[PMID]_24849861[PMID]
3637,2073,Narcolepsy type 1,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,26.0,Finland,Validated,8210228[PMID]_24849861[PMID]
3637,2073,Narcolepsy type 1,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,34.0,China,Validated,11164060[PMID]_24849861[PMID]
3637,2073,Narcolepsy type 1,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,28.9,United States,Not yet validated,11902429[PMID]_19013100[PMID]_24849861[PMID]_ORPHANET
3637,2073,Narcolepsy type 1,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,40.0,United Kingdom,Validated,8894197[PMID]_24849861[PMID]
19184,231401,Alpha-thalassemia-myelodysplastic syndrome,Disease,Disorder,Cases/families,Case(s),,80.0,Worldwide,Validated,[EXPERT]
19184,231401,Alpha-thalassemia-myelodysplastic syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3632,1866,"Focal, segmental or multifocal dystonia",Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.0,Europe,Not yet validated,ORPHANET
3632,1866,"Focal, segmental or multifocal dystonia",Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,11.7,Europe,Not yet validated,11127535[PMID]
3632,1866,"Focal, segmental or multifocal dystonia",Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,11.2,Serbia,Validated,14639690[PMID]
3632,1866,"Focal, segmental or multifocal dystonia",Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,31.2,Iceland,Validated,16211610[PMID]
3632,1866,"Focal, segmental or multifocal dystonia",Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,29.5,United States,Validated,3264051[PMID]
3632,1866,"Focal, segmental or multifocal dystonia",Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,13.7,Japan,Validated,16755586[PMID]
3632,1866,"Focal, segmental or multifocal dystonia",Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,10.0,Egypt,Validated,7969703[PMID]
3632,1866,"Focal, segmental or multifocal dystonia",Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,14.3,Thailand,Validated,21999890[PMID]
19182,231393,Beta-thalassemia-X-linked thrombocytopenia syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3631,809,Mixed connective tissue disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.17,Norway,Validated,21398332[PMID]
3631,809,Mixed connective tissue disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.0,Norway,Validated,21398332[PMID]
3631,809,Mixed connective tissue disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.7,Japan,Validated,[EXPERT]
3631,809,Mixed connective tissue disease,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
3631,809,Mixed connective tissue disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.9,United States,Validated,26946215[PMID]
3631,809,Mixed connective tissue disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.8,Finland,Validated,8810933[PMID]_26946215[PMID]
3626,1309,Medullary sponge kidney,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
19177,231249,Hemoglobin E-beta-thalassemia syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19176,231242,Hemoglobin C-beta-thalassemia syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3625,2197,Idiopathic hypercalciuria,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
3625,2197,Idiopathic hypercalciuria,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
19175,231237,Delta-beta-thalassemia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19173,231226,Dominant beta-thalassemia,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3621,18,Distal renal tubular acidosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_22872862[PMID]
19172,231222,Beta-thalassemia intermedia,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3618,160,Castleman disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3618,160,Castleman disease,Disease,Disorder,Annual incidence,Class only,1-9 / 100 000,0.0,United States,Validated,ORPHANET_25120049[PMID]
19171,231214,Beta-thalassemia major,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19171,231214,Beta-thalassemia major,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.7,United States,Validated,22766612[PMID]
19171,231214,Beta-thalassemia major,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,>1 / 1000,160.0,Bahrain,Validated,24044606[PMID]
19171,231214,Beta-thalassemia major,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-5 / 10 000,40.0,Oman,Validated,11360093[PMID]_12934793[PMID]
3619,2841,Hailey-Hailey disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
19169,231183,Usher syndrome type 3,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Denmark,Validated,9212179[PMID]
19169,231183,Usher syndrome type 3,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
19169,231183,Usher syndrome type 3,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,1.2,Specific population,Validated,14569126[PMID]
3616,347,Frasier syndrome,Disease,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,[EXPERT]_25623218[PMID]
3616,347,Frasier syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_[EXPERT]_25623218[PMID]
19168,231178,Usher syndrome type 2,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,2.2,Denmark,Validated,9212179[PMID]
19168,231178,Usher syndrome type 2,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
3613,1670,Chronic diarrhea with villous atrophy,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8283377[PMID]
3613,1670,Chronic diarrhea with villous atrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8283377[PMID]
19165,231154,Combined immunodeficiency due to partial RAG1 deficiency,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,16276422[PMID]
19165,231154,Combined immunodeficiency due to partial RAG1 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16276422[PMID]
19166,231160,Familial cerebral saccular aneurysm,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
19166,231160,Familial cerebral saccular aneurysm,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
19167,231169,Usher syndrome type 1,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,1.5,Denmark,Validated,9212179[PMID]
19167,231169,Usher syndrome type 1,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
19163,231147,Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
19152,231080,High-grade dysplasia in patients with Barrett esophagus,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,36.0,Europe,Validated,European Medicines Agency 2002[INST]
19153,231108,Rhabdoid tumor predisposition syndrome,Disease,Disorder,Cases/families,Family(ies),,5.0,Worldwide,Validated,ORPHANET
19153,231108,Rhabdoid tumor predisposition syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
3600,405,Familial hypocalciuric hypercalcemia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
19154,231111,Drug-induced lupus erythematosus,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3596,1223,Balantidiasis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19148,231040,Familial generalized lentiginosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3599,3318,Essential thrombocythemia,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,24.0,United States,Validated,18181200[PMID]
3599,3318,Essential thrombocythemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.55,Sweden,Validated,16673273[PMID]
3599,3318,Essential thrombocythemia,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,30.0,Sweden,Validated,16673273[PMID]
3599,3318,Essential thrombocythemia,Disease,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET
3599,3318,Essential thrombocythemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.48,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
19145,230857,Ehlers-Danlos/osteogenesis imperfecta syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET_23692737[PMID]
19144,230851,Cardiac-valvular Ehlers-Danlos syndrome,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,16816023[PMID]_1507720[PMID]_2952379[PMID]
19144,230851,Cardiac-valvular Ehlers-Danlos syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19147,231031,Erythema palmare hereditarium,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
3595,913,Zollinger-Ellison syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.15,Europe,Validated,[EXPERT]
3595,913,Zollinger-Ellison syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,[EXPERT]
3595,913,Zollinger-Ellison syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.15,Denmark,Validated,ISBN:0849359937[OTHER]
3595,913,Zollinger-Ellison syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.3,Switzerland,Not yet validated,ISBN:0849359937[OTHER]
3595,913,Zollinger-Ellison syndrome,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.05,Ireland,Validated,2575263[PMID]
3595,913,Zollinger-Ellison syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.125,Worldwide,Validated,22261919[PMID]
19146,231013,Congenital trigeminal anesthesia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19141,230800,Toxin-mediated infectious botulism,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
3590,82,Hereditary thrombophilia due to congenital antithrombin deficiency,Disease,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Worldwide,Validated,ORPHANET
19142,230839,Classical-like Ehlers-Danlos syndrome type 1,Disease,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,27582382[PMID]
19142,230839,Classical-like Ehlers-Danlos syndrome type 1,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27582382[PMID]
3586,519,Acute myeloid leukemia,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.5,Worldwide,Validated,17019734[PMID]
3586,519,Acute myeloid leukemia,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,10.0,Europe,Validated,European Medicines Agency 2018[INST]
3586,519,Acute myeloid leukemia,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.39,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
3586,519,Acute myeloid leukemia,Clinical group,Group of disorders,Lifetime Prevalence,Value and class,1-5 / 10 000,10.98,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
3586,519,Acute myeloid leukemia,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.4,France,Validated,Institut National du Cancer 2013[INST]
3586,519,Acute myeloid leukemia,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.8,Denmark,Validated,24039451[PMID]
3586,519,Acute myeloid leukemia,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.7,United States,Validated,National Cancer institute 2010[INST]
19251,235936,Familial hyperaldosteronism,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
19263,238446,15q11q13 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19263,238446,15q11q13 microduplication syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
19262,238329,Severe X-linked mitochondrial encephalomyopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20362274[PMID]
19262,238329,Severe X-linked mitochondrial encephalomyopathy,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,20362274[PMID]
19202,231573,Congenital erosive and vesicular dermatosis,Disease,Disorder,Cases/families,Case(s),,31.0,Worldwide,Validated,28247410[PMID]
19202,231573,Congenital erosive and vesicular dermatosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28247410[PMID]
19203,231580,Primary unilateral adrenal hyperplasia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19200,231556,Late-onset localized junctional epidermolysis bullosa-intellectual disability syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,1642260[PMID]
19200,231556,Late-onset localized junctional epidermolysis bullosa-intellectual disability syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1642260[PMID]
19201,231568,Autosomal dominant generalized dystrophic epidermolysis bullosa,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19207,231637,Rare surgically correctable form of primary aldosteronism,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19205,231625,Adrenocortical carcinoma with pure aldosterone hypersecretion,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
4043,1900,Kyphoscoliotic Ehlers-Danlos syndrome due to lysyl hydroxylase 1 deficiency,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Worldwide,Not yet validated,21699693[PMID]_15666309[PMID]
4043,1900,Kyphoscoliotic Ehlers-Danlos syndrome due to lysyl hydroxylase 1 deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
4042,286,Vascular Ehlers-Danlos syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Worldwide,Validated,35779834[PMID]
4041,285,Hypermobile Ehlers-Danlos syndrome,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,12.5,Europe,Not yet validated,ORPHANET
19214,231736,Microcornea-posterior megalolenticonus-persistent fetal vasculature-coloboma syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,20417569[PMID]
19214,231736,Microcornea-posterior megalolenticonus-persistent fetal vasculature-coloboma syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20417569[PMID]
19215,231742,Epibulbar lipodermoid-preauricular appendage-polythelia syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,20450310[PMID]
19215,231742,Epibulbar lipodermoid-preauricular appendage-polythelia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20450310[PMID]
4046,257,Epidermolysis bullosa simplex with muscular dystrophy,Disease,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,[EXPERT]
4046,257,Epidermolysis bullosa simplex with muscular dystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
4045,1901,Dermatosparaxis Ehlers-Danlos syndrome,Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,26765342[PMID]
4045,1901,Dermatosparaxis Ehlers-Danlos syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26765342[PMID]
19213,231720,Non-acquired combined pituitary hormone deficiency-sensorineural hearing loss-spine abnormalities syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,ORPHANET_19762173[PMID]
19213,231720,Non-acquired combined pituitary hormone deficiency-sensorineural hearing loss-spine abnormalities syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
4044,1899,Arthrochalasia Ehlers-Danlos syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
4048,839,"Congenital nephrotic syndrome, Finnish type",Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
4048,839,"Congenital nephrotic syndrome, Finnish type",Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,12.2,Finland,Validated,4127143[PMID]
4054,531,Miller-Dieker syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Europe,Validated,[EXPERT]
4054,531,Miller-Dieker syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
4052,3394,Soft tissue sarcoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.6,France,Validated,21826194[PMID]
4052,3394,Soft tissue sarcoma,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,30.0,Europe,Validated,European Medicines Agency 2015[INST]
4052,3394,Soft tissue sarcoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.74,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
4058,1084,Isolated lissencephaly type 1 without known genetic defects,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
4059,1083,Microlissencephaly,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
4057,452,X-linked lissencephaly with abnormal genitalia,Malformation syndrome,Disorder,Cases/families,Family(ies),,30.0,Worldwide,Validated,17480217[PMID]
4057,452,X-linked lissencephaly with abnormal genitalia,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_17480217[PMID]
19300,238750,4q21 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19300,238750,4q21 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,20522426[PMID]_22903878[PMID]_21834054[PMID]
19302,238763,Glaucoma secondary to spherophakia/ectopia lentis and megalocornea,Malformation syndrome,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,22025892[PMID]
19302,238763,Glaucoma secondary to spherophakia/ectopia lentis and megalocornea,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22025892[PMID]
19298,238722,Familial congenital mirror movements,Disease,Disorder,Cases/families,Case(s),,75.0,Worldwide,Validated,19127048[PMID]_19720981[PMID]_21242494[PMID]_27830107[PMID]_25098561[PMID]
19298,238722,Familial congenital mirror movements,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19127048[PMID]_19720981[PMID]_21242494[PMID]_27830107[PMID]_25098561[PMID]
19299,238744,Mammary-digital-nail syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,20145678[PMID]
19299,238744,Mammary-digital-nail syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20145678[PMID]
19305,238769,1q44 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,21800092[PMID]
19305,238769,1q44 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19271,238517,Hypotonia-cystinuria type 1 syndrome,Clinical group,Group of disorders,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
19269,238505,Combined immunodeficiency due to CD27 deficiency,Disease,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,29942301[PMID]
19269,238505,Combined immunodeficiency due to CD27 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29942301[PMID]
19266,238468,Hypohidrotic ectodermal dysplasia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.7,Europe,Validated,[EXPERT]
19267,238475,Familial hypercholanemia,Disease,Disorder,Cases/families,Case(s),,23.0,Worldwide,Validated,ORPHANET
19267,238475,Familial hypercholanemia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19264,238455,Infantile dystonia-parkinsonism,Disease,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,24613933[PMID]_19478460[PMID]_22279524[PMID]
19264,238455,Infantile dystonia-parkinsonism,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24613933[PMID]_19478460[PMID]_22279524[PMID]
19265,238459,SLC35A1-CDG,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,11157507[PMID]_23873973[PMID]_28856833[PMID]
19265,238459,SLC35A1-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11157507[PMID]_23873973[PMID]_28856833[PMID]
19278,238578,Familial clubfoot due to 17q23.1q23.2 microduplication,Etiological subtype,Subtype of disorder,Cases/families,Family(ies),,4.0,Worldwide,Validated,20598276[PMID]_22678995[PMID]
19278,238578,Familial clubfoot due to 17q23.1q23.2 microduplication,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20598276[PMID]_22678995[PMID]
19279,238583,Hyperphenylalaninemia due to tetrahydrobiopterin deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.22,Japan,Validated,6468444[PMID]
19279,238583,Hyperphenylalaninemia due to tetrahydrobiopterin deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2,Worldwide,Validated,[EXPERT]
19279,238583,Hyperphenylalaninemia due to tetrahydrobiopterin deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.21,Brazil,Validated,35209917[PMID]
19276,238557,Chuvash erythrocytosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19277,238569,Immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections syndrome,Disease,Disorder,Cases/families,Case(s),,80.0,Worldwide,Validated,24089328[PMID]
19277,238569,Immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19275,238547,Acquired secondary polycythemia,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19272,238523,Atypical hypotonia-cystinuria syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,18234729[PMID]
19272,238523,Atypical hypotonia-cystinuria syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18234729[PMID]
19273,238536,Congenital secondary polycythemia,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19286,238624,Idiopathic intracranial hypertension,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,14.0,Europe,Validated,European Medicines Agency 2016[INST]
19285,238621,Ileal pouch anal anastomosis related faecal incontinence,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.0,Europe,Validated,European Medicines Agency 2009[INST]
19281,238606,Primary orthostatic tremor,Disease,Disorder,Cases/families,Case(s),,390.0,Worldwide,Validated,[EXPERT]
19281,238606,Primary orthostatic tremor,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
19280,238593,IgG4-related mesenteritis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19293,238670,Isolated thyrotropin-releasing hormone deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19292,238666,Isolated congenital hypogonadotropic hypogonadism,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
19292,238666,Isolated congenital hypogonadotropic hypogonadism,Disease,Disorder,Prevalence at birth,Class only,1-9 / 100 000,0.0,Worldwide,Validated,21682876[PMID]_ORPHANET
19291,238654,"Congenital primary megaureter, nonrefluxing and unobstructed form",Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19290,238650,"Congenital primary megaureter, refluxing form",Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19289,238646,"Congenital primary megaureter, obstructed form",Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19288,238642,"Primary megaureter, adult-onset form",Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
19331,240071,Classic progressive supranuclear palsy syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
19335,240112,Progressive supranuclear palsy-progressive non-fluent aphasia syndrome,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,[EXPERT]
19335,240112,Progressive supranuclear palsy-progressive non-fluent aphasia syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
19334,240103,Progressive supranuclear palsy-corticobasal syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.6,Europe,Validated,[EXPERT]
19333,240094,Progressive supranuclear palsy-pure akinesia with gait freezing syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,[EXPERT]
19332,240085,Progressive supranuclear palsy-predominant parkinsonism syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
19345,240760,Nijmegen breakage syndrome-like disorder,Malformation syndrome,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,1887849[PMID]_19409520[PMID]
19345,240760,Nijmegen breakage syndrome-like disorder,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1887849[PMID]_19409520[PMID]
22001,331226,Susceptibility to infection due to TYK2 deficiency,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,26304966[PMID]
22001,331226,Susceptibility to infection due to TYK2 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26304966[PMID]
22003,331235,Selective IgM deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_23760686[PMID]
21992,331176,Severe congenital neutropenia due to G6PC3 deficiency,Disease,Disorder,Cases/families,Case(s),,57.0,Worldwide,Validated,23758768[PMID]
21992,331176,Severe congenital neutropenia due to G6PC3 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21994,331187,Immunodeficiency due to MASP-2 deficiency,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,12904520[PMID]
21994,331187,Immunodeficiency due to MASP-2 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12904520[PMID]
21995,331190,Immunodeficiency due to ficolin3 deficiency,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,19535802[PMID]
21995,331190,Immunodeficiency due to ficolin3 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19535802[PMID]
21997,331206,Severe combined immunodeficiency due to complete RAG1/2 deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,European Medicines Agency 2014[INST]
21968,330064,Chronic actinic dermatitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,16.7,United Kingdom,Validated,15813653[PMID]
21968,330064,Chronic actinic dermatitis,Disease,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET
21955,330001,Wild type ATTR amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,1.72,Worldwide,Validated,32633805[PMID]
21952,329977,Classic neuroendocrine tumor of appendix,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.25,Worldwide,Not yet validated,20524865[PMID]
21952,329977,Classic neuroendocrine tumor of appendix,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21953,329984,Goblet cell carcinoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.025,Worldwide,Not yet validated,20524865[PMID]
21953,329984,Goblet cell carcinoma,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21958,330012,High altitude pulmonary edema,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,European Medicines Agency 2013[INST]
21959,330015,Lead poisoning,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.3,Europe,Validated,European Medicines Agency 2013[INST]
21959,330015,Lead poisoning,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.68,France,Validated,Institut de Veille Sanitaire 2010[INST]_ORPHANET
21962,330032,Hemoglobin Lepore-beta-thalassemia syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21963,330041,Hemoglobin M disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21960,330021,Mercury poisoning,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,European Medicines Agency 2012[INST]
21961,330029,Hypotrichosis-deafness syndrome,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,16280295[PMID]
21961,330029,Hypotrichosis-deafness syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21966,330058,Hydroa vacciniforme,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.34,United Kingdom,Validated,10642674[PMID]
21966,330058,Hydroa vacciniforme,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
21967,330061,Actinic prurigo,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21964,330050,DNM1L-related encephalopathy due to mitochondrial and peroxisomal fission defect,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,17460227[PMID]_26825290[PMID]_26992161[PMID]_26604000[PMID]_27145208[PMID]_30109270[PMID]_27328748[PMID]
21964,330050,DNM1L-related encephalopathy due to mitochondrial and peroxisomal fission defect,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17460227[PMID]_26825290[PMID]_26992161[PMID]_26604000[PMID]_27145208[PMID]_30109270[PMID]_27328748[PMID]
21965,330054,Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,19409522[PMID]
21965,330054,Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21941,329813,Mosaic genome-wide paternal uniparental disomy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,23804593[PMID]
21941,329813,Mosaic genome-wide paternal uniparental disomy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23804593[PMID]
21940,329802,5p13 microduplication syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,20052029[PMID]_21211577[PMID]_23085304[PMID]
21940,329802,5p13 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21943,329883,Non-hypoproteinemic hypertrophic gastropathy,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,22711003[PMID]
21943,329883,Non-hypoproteinemic hypertrophic gastropathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21942,329874,Idiopathic giant cell myocarditis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21937,329475,Spastic paraplegia-Paget disease of bone syndrome,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,22991237[PMID]
21937,329475,Spastic paraplegia-Paget disease of bone syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21939,329481,Lipoprotein glomerulopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24149835[PMID]
21939,329481,Lipoprotein glomerulopathy,Disease,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,24149835[PMID]
21938,329478,Adult-onset distal myopathy due to VCP mutation,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,21684747[PMID]
21938,329478,Adult-onset distal myopathy due to VCP mutation,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21949,329942,Transient neonatal multiple acyl-CoA dehydrogenase deficiency,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,17689999[PMID]_21089064[PMID]_21089064[PMID]
21949,329942,Transient neonatal multiple acyl-CoA dehydrogenase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21951,329971,Generalized juvenile polyposis/juvenile polyposis coli,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21950,329967,Intermittent hydrarthrosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
21947,329918,C3 glomerulopathy,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.15,Europe,Validated,27056062[PMID]
21946,329903,Immunoglobulin-mediated membranoproliferative glomerulonephritis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,,ORPHANET
21924,329308,Fatty acid hydroxylase-associated neurodegeneration,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21735565[PMID]
21925,329314,Adult-onset multiple mitochondrial DNA deletion syndrome due to DGUOK deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21926,329319,Thrombocythemia with distal limb defects,Disease,Disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,19553636[PMID]
21926,329319,Thrombocythemia with distal limb defects,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21927,329324,Inverse Klippel-Trénaunay syndrome,Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,17341861[PMID]_23000147[PMID]
21927,329324,Inverse Klippel-Trénaunay syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21922,329284,Beta-propeller protein-associated neurodegeneration,Disease,Disorder,Cases/families,Case(s),,68.0,Worldwide,Validated,29445477[PMID]
21922,329284,Beta-propeller protein-associated neurodegeneration,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29445477[PMID]
21933,329457,Distal arthrogryposis type 5D,Disease,Disorder,Cases/families,Case(s),,33.0,Worldwide,Validated,25099528[PMID]_24782201[PMID]
21933,329457,Distal arthrogryposis type 5D,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25099528[PMID]_24782201[PMID]
21934,329466,"Autosomal dominant focal dystonia, DYT25 type",Disease,Disorder,Cases/families,Case(s),,28.0,Worldwide,Validated,23222958[PMID]
21934,329466,"Autosomal dominant focal dystonia, DYT25 type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23222958[PMID]
21935,329469,Acute megakaryoblastic leukemia in children without Down syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21928,329329,Autosomal recessive frontotemporal pachygyria,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,23022981[PMID]
21928,329329,Autosomal recessive frontotemporal pachygyria,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21929,329332,Microcephaly-cerebellar hypoplasia-cardiac conduction defect syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,22002884[PMID]
21929,329332,Microcephaly-cerebellar hypoplasia-cardiac conduction defect syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21930,329336,Adult-onset chronic progressive external ophthalmoplegia with mitochondrial myopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21911,329228,Microcephalic primordial dwarfism due to ZNF335 deficiency,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,23178126[PMID]_27540107[PMID]_29652087[PMID]
21911,329228,Microcephalic primordial dwarfism due to ZNF335 deficiency,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29652087[PMID]
21910,329224,Schuurs-Hoeijmakers syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,23159249[PMID]
21910,329224,Schuurs-Hoeijmakers syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21909,329217,Cerebral sinovenous thrombosis,Disease,Disorder,Annual incidence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,15858188[PMID]_ORPHANET
21909,329217,Cerebral sinovenous thrombosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21908,329211,Autosomal dominant neovascular inflammatory vitreoretinopathy,Disease,Disorder,Cases/families,Case(s),,99.0,Worldwide,Validated,23055945[PMID]
21908,329211,Autosomal dominant neovascular inflammatory vitreoretinopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21906,329195,Developmental delay with autism spectrum disorder and gait instability,Disease,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,23065719[PMID]_23243086[PMID]
21906,329195,Developmental delay with autism spectrum disorder and gait instability,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21905,329191,Tall stature-long halluces-multiple extra-epiphyses syndrome,Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,22870295[PMID]_23243086[PMID]_24259409[PMID]
21905,329191,Tall stature-long halluces-multiple extra-epiphyses syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21904,329178,Congenital muscular dystrophy with intellectual disability and severe epilepsy,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,23109149[PMID]
21904,329178,Congenital muscular dystrophy with intellectual disability and severe epilepsy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21919,329258,Autosomal dominant Charcot-Marie-Tooth disease type 2Q,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,23141294[PMID]
21919,329258,Autosomal dominant Charcot-Marie-Tooth disease type 2Q,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21916,329249,Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,23160192[PMID]
21916,329249,Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23160192[PMID]
21914,329242,Congenital chronic diarrhea with protein-losing enteropathy,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,23114594[PMID]
21914,329242,Congenital chronic diarrhea with protein-losing enteropathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21913,329235,X-linked central congenital hypothyroidism with late-onset testicular enlargement,Disease,Disorder,Cases/families,Case(s),,27.0,Worldwide,Validated,23143598[PMID]
21913,329235,X-linked central congenital hypothyroidism with late-onset testicular enlargement,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21903,329173,Autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,30936877[PMID]_23104095[PMID]_26008899[PMID]
21903,329173,Autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30936877[PMID]
4511,329,Congenital factor XI deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Europe,Not yet validated,ORPHANET
4510,1243,Best vitelliform macular dystrophy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.5,Denmark,Validated,22633354[PMID]
4510,1243,Best vitelliform macular dystrophy,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.0,Sweden,Validated,4448697[PMID]
4510,1243,Best vitelliform macular dystrophy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
4510,1243,Best vitelliform macular dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.5,Denmark,Validated,22633354[PMID]
4510,1243,Best vitelliform macular dystrophy,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET_22633354[PMID]_4448697[PMID]
21817,324964,Chronic nonbacterial osteomyelitis/Chronic recurrent multifocal osteomyelitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.3,Worldwide,Validated,12183714[PMID]
21817,324964,Chronic nonbacterial osteomyelitis/Chronic recurrent multifocal osteomyelitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.5,Worldwide,Validated,12183714[PMID]
21818,324972,MAGIC syndrome,Disease,Disorder,Cases/families,Case(s),,21.0,Worldwide,Validated,27293269[PMID]
21818,324972,MAGIC syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27293269[PMID]
21819,324977,Proteasome-associated autoinflammatory syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24131530[PMID]
21819,324977,Proteasome-associated autoinflammatory syndrome,Disease,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,24131530[PMID]
21801,324718,ABetaA21G amyloidosis,Clinical subtype,Subtype of disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,[EXPERT]
21801,324718,ABetaA21G amyloidosis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21800,324713,"ABeta amyloidosis, Italian type",Clinical subtype,Subtype of disorder,Cases/families,Family(ies),,7.0,Worldwide,Validated,20697050[PMID]_10821838[PMID]
21800,324713,"ABeta amyloidosis, Italian type",Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20697050[PMID]_10821838[PMID]
21803,324737,SRD5A3-CDG,Disease,Disorder,Cases/families,Family(ies),,7.0,Worldwide,Validated,18271001[PMID]_20637498[PMID]
21803,324737,SRD5A3-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18271001[PMID]_20637498[PMID]
21802,324723,"ABeta amyloidosis, Arctic type",Clinical subtype,Subtype of disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,11528419[PMID]
21802,324723,"ABeta amyloidosis, Arctic type",Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11528419[PMID]
21797,324648,Invasive non-typhoidal salmonellosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21796,324636,Autoerythrocyte sensitization syndrome,Disease,Disorder,Cases/families,Case(s),,170.0,Worldwide,Validated,19192020[PMID]
21796,324636,Autoerythrocyte sensitization syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
21799,324708,"ABeta amyloidosis, Iowa type",Clinical subtype,Subtype of disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,11409420[PMID]_12654973[PMID]
21799,324708,"ABeta amyloidosis, Iowa type",Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11409420[PMID]_12654973[PMID]
21798,324703,ABetaL34V amyloidosis,Clinical subtype,Subtype of disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,16178030[PMID]_19225789[PMID]
21798,324703,ABetaL34V amyloidosis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16178030[PMID]_19225789[PMID]
21793,324611,Autosomal dominant Charcot-Marie-Tooth disease type 2 due to KIF5A mutation,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21795,324632,Hendra virus infection,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,22752412[PMID]
21795,324632,Hendra virus infection,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21794,324625,Chikungunya,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,France,Validated,Institut de Veille Sanitaire 2009[INST]
21794,324625,Chikungunya,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21794,324625,Chikungunya,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Europe,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
21794,324625,Chikungunya,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.32,Belgium,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
21794,324625,Chikungunya,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.06,Finland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
21794,324625,Chikungunya,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.13,Germany,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
21794,324625,Chikungunya,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.3,Italy,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
21794,324625,Chikungunya,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Latvia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
21794,324625,Chikungunya,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.35,Spain,Validated,European Centre for Disease prevention and Control 2014-2017[INST]
21794,324625,Chikungunya,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.16,Sweden,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
21794,324625,Chikungunya,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.24,United Kingdom,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
21794,324625,Chikungunya,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.4,Malta,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
21794,324625,Chikungunya,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Slovenia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
21794,324625,Chikungunya,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Greece,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
21794,324625,Chikungunya,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Hungary,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
21794,324625,Chikungunya,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Ireland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
21794,324625,Chikungunya,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Portugal,Validated,European Centre for Disease prevention and Control 2015-2017[INST]
21790,324588,Familial dyskinesia and facial myokymia,Disease,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,11310626[PMID]_22782511[PMID]
21790,324588,Familial dyskinesia and facial myokymia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21791,324601,X-linked cleft palate and ankyloglossia,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21788,324581,Benign Samaritan congenital myopathy,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,22752422[PMID]
21788,324581,Benign Samaritan congenital myopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21789,324585,Autosomal dominant intermediate Charcot-Marie-Tooth disease with neuropathic pain,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,22704856[PMID]
21789,324585,Autosomal dominant intermediate Charcot-Marie-Tooth disease with neuropathic pain,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21786,324569,Pontocerebellar hypoplasia type 8,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,23023333[PMID]
21786,324569,Pontocerebellar hypoplasia type 8,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21787,324575,Hyperinsulinism due to HNF1A deficiency,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,22802087[PMID]
21787,324575,Hyperinsulinism due to HNF1A deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21784,324540,Aphonia-deafness-retinal dystrophy-bifid halluces-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,22991300[PMID]
21784,324540,Aphonia-deafness-retinal dystrophy-bifid halluces-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21785,324561,Hypopigmentation-punctate palmoplantar keratoderma syndrome,Disease,Disorder,Cases/families,Family(ies),,6.0,Worldwide,Validated,24075184[PMID]
21785,324561,Hypopigmentation-punctate palmoplantar keratoderma syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21782,324530,Autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,23000145[PMID]
21782,324530,Autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23000145[PMID]
21783,324535,Combined oxidative phosphorylation defect type 11,Disease,Disorder,Cases/families,Case(s),,32.0,Worldwide,Validated,27412952[PMID]
21783,324535,Combined oxidative phosphorylation defect type 11,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27412952[PMID]
21781,324525,Hypertrophic cardiomyopathy with kidney anomalies due to mitochondrial DNA mutation,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,22781753[PMID]
21781,324525,Hypertrophic cardiomyopathy with kidney anomalies due to mitochondrial DNA mutation,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21778,324442,Autosomal recessive axonal neuropathy with neuromyotonia,Disease,Disorder,Cases/families,Family(ies),,33.0,Worldwide,Validated,22961002[PMID]
21778,324442,Autosomal recessive axonal neuropathy with neuromyotonia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21776,324416,Muscular hypertrophy-hepatomegaly-polyhydramnios syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,22683912[PMID]
21776,324416,Muscular hypertrophy-hepatomegaly-polyhydramnios syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21777,324422,ALG13-CDG,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,22492991[PMID]
21777,324422,ALG13-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22492991[PMID]
21774,324410,X-linked intellectual disability-cardiomegaly-congestive heart failure syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,22814392[PMID]
21774,324410,X-linked intellectual disability-cardiomegaly-congestive heart failure syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21769,324381,Hereditary inclusion body myopathy type 4,Disease,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,22723986[PMID]
21769,324381,Hereditary inclusion body myopathy type 4,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21767,324364,Mixed sclerosing bone dystrophy with extra-skeletal manifestations,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,22821701[PMID]
21767,324364,Mixed sclerosing bone dystrophy with extra-skeletal manifestations,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22821701[PMID]
21766,324353,Congenital achiasma,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21765,324321,Sinoatrial node dysfunction and deafness,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,21131953[PMID]
21765,324321,Sinoatrial node dysfunction and deafness,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21764,324313,9p13 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,22887577[PMID]
21764,324313,9p13 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21763,324307,Severe lateral tibial bowing-short stature-mild winged scapula-mild facial dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,22927185[PMID]
21763,324307,Severe lateral tibial bowing-short stature-mild winged scapula-mild facial dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21762,324299,Multiple paragangliomas associated with polycythemia,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,22931260[PMID]
21762,324299,Multiple paragangliomas associated with polycythemia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21761,324294,T-cell immunodeficiency with epidermodysplasia verruciformis,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,22850876[PMID]
21761,324294,T-cell immunodeficiency with epidermodysplasia verruciformis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21760,324290,Early-onset Lafora body disease,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,22961547[PMID]
21760,324290,Early-onset Lafora body disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22961547[PMID]
21758,324262,Autosomal recessive congenital cerebellar ataxia due to MGLUR1 deficiency,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,22901947[PMID]
21758,324262,Autosomal recessive congenital cerebellar ataxia due to MGLUR1 deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21713,320360,MT-ATP6-related mitochondrial spastic paraplegia,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,20656066[PMID]
21713,320360,MT-ATP6-related mitochondrial spastic paraplegia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20656066[PMID]
21712,320355,Autosomal dominant spastic paraplegia type 41,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,18364116[PMID]
21712,320355,Autosomal dominant spastic paraplegia type 41,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18364116[PMID]
21715,320370,Autosomal recessive spastic paraplegia type 43,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,20039086[PMID]
21715,320370,Autosomal recessive spastic paraplegia type 43,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20039086[PMID]
21714,320365,Autosomal dominant spastic paraplegia type 36,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,19357379[PMID]
21714,320365,Autosomal dominant spastic paraplegia type 36,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19357379[PMID]
21717,320380,Autosomal recessive spastic paraplegia type 54,Disease,Disorder,Cases/families,Family(ies),,6.0,Worldwide,Validated,23486545[PMID]_24482476[PMID]
21717,320380,Autosomal recessive spastic paraplegia type 54,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23486545[PMID]_24482476[PMID]
21716,320375,Autosomal recessive spastic paraplegia type 55,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24080142[PMID]_24424123[PMID]
21716,320375,Autosomal recessive spastic paraplegia type 55,Disease,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,24080142[PMID]_24424123[PMID]
21719,320391,Autosomal recessive spastic paraplegia type 46,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,20593214[PMID]
21719,320391,Autosomal recessive spastic paraplegia type 46,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20593214[PMID]
21718,320385,Hereditary sensory and autonomic neuropathy due to TECPR2 mutation,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,23176824[PMID]
21718,320385,Hereditary sensory and autonomic neuropathy due to TECPR2 mutation,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23176824[PMID]
21721,320401,Autosomal recessive spastic paraplegia type 44,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,19056803[PMID]
21721,320401,Autosomal recessive spastic paraplegia type 44,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19056803[PMID]
21720,320396,Autosomal recessive spastic paraplegia type 45,Disease,Disorder,Cases/families,Family(ies),,7.0,Worldwide,Validated,28884889[PMID]
21720,320396,Autosomal recessive spastic paraplegia type 45,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28884889[PMID]
21723,320411,Autosomal recessive spastic paraplegia type 56,Disease,Disorder,Cases/families,Family(ies),,5.0,Worldwide,Validated,23176821[PMID]
21723,320411,Autosomal recessive spastic paraplegia type 56,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23176821[PMID]
21722,320406,Spastic paraplegia-optic atrophy-neuropathy syndrome,Disease,Disorder,Cases/families,Case(s),,75.0,Worldwide,Validated,26385635[PMID]
21722,320406,Spastic paraplegia-optic atrophy-neuropathy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26385635[PMID]
21670,319543,Autosomal dominant mendelian susceptibility to mycobacterial diseases due to a partial deficiency,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21671,319547,Mendelian susceptibility to mycobacterial diseases due to complete IFNgammaR2 deficiency,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,25453225[PMID]
21671,319547,Mendelian susceptibility to mycobacterial diseases due to complete IFNgammaR2 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25453225[PMID]
21668,319535,Autosomal recessive mendelian susceptibility to mycobacterial diseases due to a complete deficiency,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21669,319539,Autosomal recessive mendelian susceptibility to mycobacterial diseases due to a partial deficiency,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21666,319519,Combined oxidative phosphorylation defect type 14,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,22833457[PMID]_22499341[PMID]
21666,319519,Combined oxidative phosphorylation defect type 14,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22833457[PMID]_22499341[PMID]
21667,319524,Combined oxidative phosphorylation defect type 15,Disease,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,24461907[PMID]
21667,319524,Combined oxidative phosphorylation defect type 15,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24461907[PMID]
21664,319509,Combined oxidative phosphorylation defect type 9,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,21786366[PMID]
21664,319509,Combined oxidative phosphorylation defect type 9,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21786366[PMID]
21665,319514,Combined oxidative phosphorylation defect type 13,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,23084291[PMID]
21665,319514,Combined oxidative phosphorylation defect type 13,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23084291[PMID]
21678,319589,Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,[EXPERT]_23963039[PMID]
21678,319589,Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21679,319595,Mendelian susceptibility to mycobacterial diseases due to partial STAT1 deficiency,Disease,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,25453225[PMID]
21679,319595,Mendelian susceptibility to mycobacterial diseases due to partial STAT1 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25453225[PMID]
21676,319574,Autosomal recessive mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,25453225[PMID]
21676,319574,Autosomal recessive mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25453225[PMID]
21677,319581,Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR1 deficiency,Disease,Disorder,Cases/families,Case(s),,68.0,Worldwide,Validated,25453225[PMID]
21677,319581,Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR1 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25453225[PMID]
21674,319563,Mendelian susceptibility to mycobacterial diseases due to complete ISG15 deficiency,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,25453225[PMID]
21674,319563,Mendelian susceptibility to mycobacterial diseases due to complete ISG15 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25453225[PMID]
21675,319569,Autosomal recessive mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR1 deficiency,Disease,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,25453225[PMID]
21675,319569,Autosomal recessive mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR1 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25453225[PMID]
21672,319552,Mendelian susceptibility to mycobacterial diseases due to complete IL12RB1 deficiency,Disease,Disorder,Cases/families,Case(s),,180.0,Worldwide,Validated,25453225[PMID]
21672,319552,Mendelian susceptibility to mycobacterial diseases due to complete IL12RB1 deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_25453225[PMID]
21673,319558,Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency,Disease,Disorder,Cases/families,Case(s),,49.0,Worldwide,Validated,[EXPERT]
21673,319558,Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21687,319651,Constitutional megaloblastic anemia with severe neurologic disease,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,21310276[PMID]_21310277[PMID]
21687,319651,Constitutional megaloblastic anemia with severe neurologic disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21310276[PMID]_21310277[PMID]
21686,319646,PGM1-CDG,Disease,Disorder,Cases/families,Case(s),,46.0,Worldwide,Validated,27206562[PMID]_24499211[PMID]
21686,319646,PGM1-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27206562[PMID]_24499211[PMID]
21685,319640,Retinal macular dystrophy type 2,Disease,Disorder,Cases/families,Family(ies),,5.0,Worldwide,Validated,20393116[PMID]
21685,319640,Retinal macular dystrophy type 2,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20393116[PMID]
21684,319635,Amyloidosis cutis dyschromia,Disease,Disorder,Cases/families,Case(s),,27.0,Worldwide,Validated,24746296[PMID]
21684,319635,Amyloidosis cutis dyschromia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24746296[PMID]
21683,319623,X-linked mendelian susceptibility to mycobacterial diseases due to CYBB deficiency,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,21278736[PMID]
21683,319623,X-linked mendelian susceptibility to mycobacterial diseases due to CYBB deficiency,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21278736[PMID]
21682,319612,X-linked mendelian susceptibility to mycobacterial diseases due to IKBKG deficiency,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,25453225[PMID]
21682,319612,X-linked mendelian susceptibility to mycobacterial diseases due to IKBKG deficiency,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25453225[PMID]
21681,319605,X-linked mendelian susceptibility to mycobacterial diseases,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,21278736[PMID]_16818673[PMID]
21681,319605,X-linked mendelian susceptibility to mycobacterial diseases,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21278736[PMID]_16818673[PMID]
21680,319600,Mendelian susceptibility to mycobacterial diseases due to partial IRF8 deficiency,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,25453225[PMID]
21680,319600,Mendelian susceptibility to mycobacterial diseases due to partial IRF8 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25453225[PMID]
21692,319678,Encephalopathy-hypertrophic cardiomyopathy-renal tubular disease syndrome,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,11562630[PMID]
21692,319678,Encephalopathy-hypertrophic cardiomyopathy-renal tubular disease syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11562630[PMID]
21691,319675,"Microcephalic primordial dwarfism, Dauber type",Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,22933543[PMID]
21691,319675,"Microcephalic primordial dwarfism, Dauber type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22933543[PMID]
21690,319671,Alazami syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,22865833[PMID]
21690,319671,Alazami syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22865833[PMID]
21639,319276,Clear cell renal carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.99,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21635,319251,Rift valley fever,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,European Centre for Disease prevention and Control 2011[INST]
21645,319319,Renal medullary carcinoma,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21641,319298,Papillary renal cell carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.14,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21642,319303,Chromophobe renal cell carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21649,319332,Autosomal recessive myogenic arthrogryposis multiplex congenita,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,19542096[PMID]
21649,319332,Autosomal recessive myogenic arthrogryposis multiplex congenita,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19542096[PMID]
21650,319340,Carney complex-trismus-pseudocamptodactyly syndrome,Disease,Disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,15282353[PMID]
21650,319340,Carney complex-trismus-pseudocamptodactyly syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15282353[PMID]
21663,319504,Combined oxidative phosphorylation defect type 8,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,21549344[PMID]_25058219[PMID]
21663,319504,Combined oxidative phosphorylation defect type 8,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21549344[PMID]_25058219[PMID]
21624,319195,Chondroectodermal dysplasia with night blindness,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,22579605[PMID]
21624,319195,Chondroectodermal dysplasia with night blindness,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22579605[PMID]
21625,319199,Autosomal recessive spastic paraplegia type 53,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,22717650[PMID]
21625,319199,Autosomal recessive spastic paraplegia type 53,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22717650[PMID]
21628,319218,Ebola hemorrhagic fever,Disease,Disorder,Cases/families,Case(s),,28220.0,Worldwide,Validated,World health Organisation 2015[INST]_26607790[PMID]
21628,319218,Ebola hemorrhagic fever,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,European Centre for Disease prevention and Control 2011[INST]
21628,319218,Ebola hemorrhagic fever,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,European Medicines Agency 2018[INST]
21618,319160,Congenital myopathy with internal nuclei and atypical cores,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,22818856[PMID]
21618,319160,Congenital myopathy with internal nuclei and atypical cores,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22818856[PMID]
21619,319171,Distal 17p13.1 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,24501763[PMID]
21619,319171,Distal 17p13.1 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24501763[PMID]
21622,319189,Familial cortical myoclonus,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,2292685[PMID]
21622,319189,Familial cortical myoclonus,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2292685[PMID]
21621,319182,Wiedemann-Steiner syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,84.0,Worldwide,Validated,ftp://ftp.sanger.ac.uk/pub/resources/theses/wj1/
21621,319182,Wiedemann-Steiner syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27777327[PMID]
21581,317428,Combined immunodeficiency due to ORAI1 deficiency,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,20004786[PMID]
21581,317428,Combined immunodeficiency due to ORAI1 deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20004786[PMID]
21580,317425,Severe combined immunodeficiency due to DNA-PKcs deficiency,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,19075392[PMID]_23722905[PMID]
21580,317425,Severe combined immunodeficiency due to DNA-PKcs deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19075392[PMID]_23722905[PMID]
21582,317430,Combined immunodeficiency due to STIM1 deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
21584,317473,Pancytopenia due to IKZF1 mutations,Disease,Disorder,Cases/families,Case(s),,39.0,Worldwide,Validated,21548011[PMID]_26981933[PMID]_27939403[PMID]
21584,317473,Pancytopenia due to IKZF1 mutations,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21548011[PMID]_26981933[PMID]_27939403[PMID]
21585,317476,XMEN,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,24550228[PMID]
21585,317476,XMEN,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24550228[PMID]
21549,315311,"Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, simple virilizing form",Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,2.5,Europe,Validated,[EXPERT]
21548,315306,"Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, salt wasting form",Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.5,Europe,Validated,[EXPERT]
21548,315306,"Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, salt wasting form",Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,7.5,Europe,Validated,[EXPERT]
21547,314993,Cataract-congenital heart disease-neural tube defect syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,11836368[PMID]
21547,314993,Cataract-congenital heart disease-neural tube defect syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11836368[PMID]
21546,314978,X-linked non progressive cerebellar ataxia,Disease,Disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,18241076[PMID]_22912398[PMID]
21546,314978,X-linked non progressive cerebellar ataxia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21545,314970,Lymphocytic hypereosinophilic syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21544,314962,Secondary hypereosinophilic syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21543,314950,Primary hypereosinophilic syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21538,314918,Mild Canavan disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,ORPHANET
21537,314911,Severe Canavan disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21517,314701,Primary systemic amyloidosis,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-5 / 10 000,30.0,Europe,Validated,European Medicines Agency 2003[INST]
21513,314679,Cerebrofacioarticular syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,22473091[PMID]_24056717[PMID]
21513,314679,Cerebrofacioarticular syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21512,314667,TMEM165-CDG,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,22683087[PMID]_26238249[PMID]
21512,314667,TMEM165-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22683087[PMID]_26238249[PMID]
21515,314689,Combined immunodeficiency due to STK4 deficiency,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,22294732[PMID]_22174160[PMID]
21515,314689,Combined immunodeficiency due to STK4 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21514,314684,Primary bone lymphoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21509,314652,Variant ABeta2M amyloidosis,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,22693999[PMID]
21509,314652,Variant ABeta2M amyloidosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22693999[PMID]
21508,314647,Non-progressive cerebellar ataxia with intellectual disability,Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,22693284[PMID]
21508,314647,Non-progressive cerebellar ataxia with intellectual disability,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21511,314662,Segmental progressive overgrowth syndrome with fibroadipose hyperplasia,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,22729222[PMID]
21511,314662,Segmental progressive overgrowth syndrome with fibroadipose hyperplasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21510,314655,Severe neonatal hypotonia-seizures-encephalopathy syndrome due to 5q31.3 microdeletion,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,23950017[PMID]
21510,314655,Severe neonatal hypotonia-seizures-encephalopathy syndrome due to 5q31.3 microdeletion,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23950017[PMID]
21504,314621,Duplication of the pituitary gland,Morphological anomaly,Disorder,Cases/families,Case(s),,38.0,Worldwide,Validated,22439114[PMID]
21504,314621,Duplication of the pituitary gland,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21507,314637,Mitochondrial hypertrophic cardiomyopathy with lactic acidosis due to MTO1 deficiency,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,23929671[PMID]
21507,314637,Mitochondrial hypertrophic cardiomyopathy with lactic acidosis due to MTO1 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21506,314632,CLN12 disease,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,22388936[PMID]
21506,314632,CLN12 disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21532,314802,Short stature due to partial GHR deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21533,314811,Short stature due to GHSR deficiency,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,16511605[PMID]
21533,314811,Short stature due to GHSR deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16511605[PMID]
21535,314889,Autosomal dominant proximal renal tubular acidosis,Clinical subtype,Subtype of disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,10972690[PMID]
21535,314889,Autosomal dominant proximal renal tubular acidosis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10972690[PMID]
21528,314777,Familial isolated pituitary adenoma,Disease,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,22720333[PMID]
21528,314777,Familial isolated pituitary adenoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
21531,314795,SHOX-related short stature,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21520,314718,Lethal arteriopathy syndrome due to fibulin-4 deficiency,Disease,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,22943132[PMID]
21520,314718,Lethal arteriopathy syndrome due to fibulin-4 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21521,314721,Atypical dentin dysplasia due to SMOC2 deficiency,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,15243476[PMID]_22152679[PMID]
21521,314721,Atypical dentin dysplasia due to SMOC2 deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22486,370127,Medich giant platelet syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,22931192[PMID]_15370096[PMID]
22486,370127,Medich giant platelet syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22482,370103,"Primary dystonia, DYT17 type",Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,18688663[PMID]
22482,370103,"Primary dystonia, DYT17 type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18688663[PMID]
22481,370097,Oculocutaneous albinism type 6,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,23364476[PMID]
22481,370097,Oculocutaneous albinism type 6,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22480,370091,Oculocutaneous albinism type 5,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,23050561[PMID]
22480,370091,Oculocutaneous albinism type 5,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22491,370348,Peripheral primitive neuroectodermal tumor,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
22490,370334,Extraskeletal Ewing sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.077,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22490,370334,Extraskeletal Ewing sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.056,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22490,370334,Extraskeletal Ewing sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22490,370334,Extraskeletal Ewing sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.023,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22490,370334,Extraskeletal Ewing sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.052,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22490,370334,Extraskeletal Ewing sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.083,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22490,370334,Extraskeletal Ewing sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.071,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22490,370334,Extraskeletal Ewing sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.055,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22490,370334,Extraskeletal Ewing sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.068,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22490,370334,Extraskeletal Ewing sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.043,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22490,370334,Extraskeletal Ewing sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.05,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22490,370334,Extraskeletal Ewing sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.076,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22490,370334,Extraskeletal Ewing sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.018,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22490,370334,Extraskeletal Ewing sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.092,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22490,370334,Extraskeletal Ewing sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.081,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22490,370334,Extraskeletal Ewing sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.087,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22490,370334,Extraskeletal Ewing sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.056,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22490,370334,Extraskeletal Ewing sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.089,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22490,370334,Extraskeletal Ewing sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.058,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22490,370334,Extraskeletal Ewing sarcoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.112,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22490,370334,Extraskeletal Ewing sarcoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.126,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22490,370334,Extraskeletal Ewing sarcoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.106,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22488,370131,White platelet syndrome,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,15203719[PMID]
22488,370131,White platelet syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22471,370046,Didymosis aplasticosebacea,Disease,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,11385232[PMID]
22471,370046,Didymosis aplasticosebacea,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22468,370034,Familial syringomyelia,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,7482254[PMID]_18050067[PMID]
22469,370039,Angora hair nevus,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,23858341[PMID]
22469,370039,Angora hair nevus,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22466,370022,Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,24013853[PMID]
22466,370022,Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22467,370026,Acute myeloid leukemia with t(8;16)(p11;p13) translocation,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,23974201[PMID]
22464,370015,"Spondyloepimetaphyseal dysplasia, Isidor-Toutain type",Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,23956136[PMID]
22464,370015,"Spondyloepimetaphyseal dysplasia, Isidor-Toutain type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22479,370088,Acute infantile liver failure-multisystemic involvement syndrome,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,22607940[PMID]
22479,370088,Acute infantile liver failure-multisystemic involvement syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22476,370076,Fetal carbamazepine syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
22472,370052,SCALP syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,22122611[PMID]
22472,370052,SCALP syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22122611[PMID]
22513,371007,Congenital muscular dystrophy with hyperlaxity,Disease,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,16760198[PMID]
22513,371007,Congenital muscular dystrophy with hyperlaxity,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16760198[PMID]
22512,370997,Muscle-eye-brain disease with bilateral multicystic leucodystrophy,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,24052401[PMID]
22512,370997,Muscle-eye-brain disease with bilateral multicystic leucodystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24052401[PMID]
22500,370921,STT3A-CDG,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,23842455[PMID]
22500,370921,STT3A-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23842455[PMID
22501,370924,STT3B-CDG,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,23842455[PMID]
22501,370924,STT3B-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23842455[PMID]
22502,370927,SSR4-CDG,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,26264460[PMID]
22502,370927,SSR4-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26264460[PMID]
22503,370930,XYLT1-CDG,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,23982343[PMID]
22503,370930,XYLT1-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22510,370968,Congenital muscular dystrophy with intellectual disability,Disease,Disorder,Point prevalence,Class only,Not yet documented,0.0,Worldwide,Validated,ORPHANET
22510,370968,Congenital muscular dystrophy with intellectual disability,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
22511,370980,Congenital muscular dystrophy without intellectual disability,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
22511,370980,Congenital muscular dystrophy without intellectual disability,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
22507,370943,Autism spectrum disorder-epilepsy-arthrogryposis syndrome,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,24031089[PMID]
22507,370943,Autism spectrum disorder-epilepsy-arthrogryposis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24031089[PMID]
22449,369929,Primary hyperaldosteronism-seizures-neurological abnormalities syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,23913001[PMID]
22449,369929,Primary hyperaldosteronism-seizures-neurological abnormalities syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22448,369920,Pontocerebellar hypoplasia type 9,Malformation syndrome,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,28815207[PMID]
22448,369920,Pontocerebellar hypoplasia type 9,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28815207[PMID]
22451,369942,CADDS,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,11992258[PMID]_22994209[PMID]
22451,369942,CADDS,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22450,369939,Severe motor and intellectual disabilities-sensorineural deafness-dystonia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,24011989[PMID]
22450,369939,Severe motor and intellectual disabilities-sensorineural deafness-dystonia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22453,369955,"Methylmalonic acidemia with homocystinuria, type cblJ",Clinical subtype,Subtype of disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,24011988[PMID]_22922874[PMID]
22453,369955,"Methylmalonic acidemia with homocystinuria, type cblJ",Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22452,369950,Intellectual disability-seizures-macrocephaly-obesity syndrome,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,23980137[PMID]
22452,369950,Intellectual disability-seizures-macrocephaly-obesity syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22455,369970,Microcornea-myopic chorioretinal atrophy-telecanthus syndrome,Disease,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,23818446[PMID]
22455,369970,Microcornea-myopic chorioretinal atrophy-telecanthus syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22454,369962,"Methylmalonic acidemia with homocystinuria, type cblX",Clinical subtype,Subtype of disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,24011988[PMID]_22922874[PMID]
22454,369962,"Methylmalonic acidemia with homocystinuria, type cblX",Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22456,369979,Finger hyperphalangy-toe anomalies-severe pectus excavatum syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,23824731[PMID]
22456,369979,Finger hyperphalangy-toe anomalies-severe pectus excavatum syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22459,369992,Severe dermatitis-multiple allergies-metabolic wasting syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,23974871[PMID]
22459,369992,Severe dermatitis-multiple allergies-metabolic wasting syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22461,370002,Focal palmoplantar keratoderma with joint keratoses,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,16484817[PMID]
22460,369999,Diffuse palmoplantar keratoderma with painful fissures,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,15897387[PMID]
22463,370010,Intellectual disability-facial dysmorphism-hand anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,23949889[PMID]
22463,370010,Intellectual disability-facial dysmorphism-hand anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22433,369837,Intellectual disability-seizures-hypophosphatasia-ophthalmic-skeletal anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,23636107[PMID]
22433,369837,Intellectual disability-seizures-hypophosphatasia-ophthalmic-skeletal anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22434,369840,TRAPPC11-related limb-girdle muscular dystrophy R18,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,23830518[PMID]
22434,369840,TRAPPC11-related limb-girdle muscular dystrophy R18,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22435,369847,Intellectual disability-hyperkinetic movement-truncal ataxia syndrome,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,23830518[PMID]
22435,369847,Intellectual disability-hyperkinetic movement-truncal ataxia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22437,369852,Congenital neutropenia-myelofibrosis-nephromegaly syndrome,Disease,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,26358756[PMID]_28453180[PMID]
22437,369852,Congenital neutropenia-myelofibrosis-nephromegaly syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26358756[PMID]_28453180[PMID]]
22438,369861,Congenital sideroblastic anemia-B-cell immunodeficiency-periodic fever-developmental delay syndrome,Disease,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,25193871[PMID]
22438,369861,Congenital sideroblastic anemia-B-cell immunodeficiency-periodic fever-developmental delay syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25193871[PMID]
22439,369867,Autosomal recessive intermediate Charcot-Marie-Tooth disease type C,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,23844677[PMID]
22439,369867,Autosomal recessive intermediate Charcot-Marie-Tooth disease type C,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
22440,369873,Obesity due to SIM1 deficiency,Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,23778136[PMID]_23778139[PMID]
22441,369881,2p21 microdeletion syndrome without cystinuria,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,23794250[PMID]
22441,369881,2p21 microdeletion syndrome without cystinuria,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22442,369886,Homozygous 2p21 microdeletion syndrome,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,23794250[PMID]
22443,369891,Developmental delay-facial dysmorphism syndrome due to MED13L deficiency,Malformation syndrome,Disorder,Cases/families,Case(s),,70.0,Worldwide,Validated,28645799[PMID]
22443,369891,Developmental delay-facial dysmorphism syndrome due to MED13L deficiency,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28645799[PMID]
22445,369897,"Mitochondrial DNA depletion syndrome, encephalomyopathic form with variable craniofacial anomalies",Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,23993193[PMID]_23993194[PMID]
22445,369897,"Mitochondrial DNA depletion syndrome, encephalomyopathic form with variable craniofacial anomalies",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22447,369913,Combined oxidative phosphorylation defect type 17,Disease,Disorder,Cases/families,Family(ies),,20.0,Worldwide,Validated,23849775[PMID]_27769300[PMID]_28441660[PMID]
22447,369913,Combined oxidative phosphorylation defect type 17,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27769300[PMID]_28441660[PMID]
22365,364055,Severe early-childhood-onset retinal dystrophy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,Pr Birgit LORENZ_Dr Markus PREISING[EXPERT]
22360,364028,X-linked intellectual disability due to GRIA3 mutations,Disease,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,24721225[PMID]
22360,364028,X-linked intellectual disability due to GRIA3 mutations,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24721225[PMID]
22361,364033,Systemic Epstein-Barr virus-positive T-cell lymphoproliferative disease of childhood,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
5016,772,Infantile Refsum disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
5015,1194,TMEM70-related mitochondrial encephalo-cardio-myopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
22358,363999,Non-immune hydrops fetalis,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-5 / 10 000,42.0,Worldwide,Not yet validated,ORPHANET
22358,363999,Non-immune hydrops fetalis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
22358,363999,Non-immune hydrops fetalis,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,>1 / 1000,300.0,Thailand,Validated,9280003[PMID]
5014,1048,Isolated anencephaly/exencephaly,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,35.0,Europe,Validated,[EXPERT]
5014,1048,Isolated anencephaly/exencephaly,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,[EXPERT]
5014,1048,Isolated anencephaly/exencephaly,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,20.6,United States,Validated,20878909[PMID]_Center for Diseases Control and Prevention 2004-2006[INST]
5014,1048,Isolated anencephaly/exencephaly,Morphological anomaly,Disorder,Prevalence at birth,Value and class,>1 / 1000,210.0,India,Validated,23873811[PMID]
5014,1048,Isolated anencephaly/exencephaly,Morphological anomaly,Disorder,Prevalence at birth,Value and class,>1 / 1000,120.0,"Iran, Islamic Republic of",Validated,20039767[PMID]
5014,1048,Isolated anencephaly/exencephaly,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,26.0,Thailand,Validated,16858850[PMID]
5014,1048,Isolated anencephaly/exencephaly,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,58.0,Singapore,Validated,17245510[PMID]
22359,364013,Immune hydrops fetalis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
22359,364013,Immune hydrops fetalis,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-5 / 10 000,33.3,United Kingdom,Validated,19334091[PMID]_[EXPERT]
5013,823,Spina bifida and other spinal dysraphisms,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,18.6,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2007-2011[REG]
5013,823,Spina bifida and other spinal dysraphisms,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2007-2011[REG]
5013,823,Spina bifida and other spinal dysraphisms,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,50.0,France,Validated,[EXPERT]
5013,823,Spina bifida and other spinal dysraphisms,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,24.8,United States,Validated,22140002[PMID]_Center for Diseases Control and Prevention 19129744[INST]_ ORPHANET
5013,823,Spina bifida and other spinal dysraphisms,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,9.8,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
5013,823,Spina bifida and other spinal dysraphisms,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,17.5,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
5013,823,Spina bifida and other spinal dysraphisms,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,11.4,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
5013,823,Spina bifida and other spinal dysraphisms,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,21.3,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
5013,823,Spina bifida and other spinal dysraphisms,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,19.6,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
5013,823,Spina bifida and other spinal dysraphisms,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,17.8,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
5013,823,Spina bifida and other spinal dysraphisms,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,14.4,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
5013,823,Spina bifida and other spinal dysraphisms,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,50.6,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
5013,823,Spina bifida and other spinal dysraphisms,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,12.7,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
5013,823,Spina bifida and other spinal dysraphisms,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,24.9,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
5013,823,Spina bifida and other spinal dysraphisms,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,17.5,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
5013,823,Spina bifida and other spinal dysraphisms,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,14.7,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
5013,823,Spina bifida and other spinal dysraphisms,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,24.4,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
5013,823,Spina bifida and other spinal dysraphisms,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,18.9,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
5013,823,Spina bifida and other spinal dysraphisms,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,5.0,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
5013,823,Spina bifida and other spinal dysraphisms,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,12.6,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
5013,823,Spina bifida and other spinal dysraphisms,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,13.1,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
5013,823,Spina bifida and other spinal dysraphisms,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,41.3,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
22357,363992,Ichthyosis-short stature-brachydactyly-microspherophakia syndrome,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,23754960[PMID]_24940034[PMID]
22357,363992,Ichthyosis-short stature-brachydactyly-microspherophakia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24940034[PMID]
22354,363976,Giant cell tumor of bone,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1404,Worldwide,Validated,[WHO Classification of Tumours]
22354,363976,Giant cell tumor of bone,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[WHO Classification of Tumours]
22355,363981,Charcot-Marie-Tooth disease type 4B3,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,23749797[PMID]
22355,363981,Charcot-Marie-Tooth disease type 4B3,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22352,363969,Autosomal recessive cerebral atrophy,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,23957953[PMID]
22352,363969,Autosomal recessive cerebral atrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22351,363965,Koolen-De Vries syndrome due to a point mutation,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,22544363[PMID]_22544367[PMID]
22351,363965,Koolen-De Vries syndrome due to a point mutation,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22350,363958,17q21.31 microdeletion syndrome,Etiological subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,1.82,Europe,Validated,26306646[PMID]_[EXPERT]
22348,363746,Balint syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,22999103[PMID]
22347,363741,Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Not yet validated,9098485[PMID]
22346,363727,X-linked dyserythropoietic anemia with abnormal platelets and neutropenia,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,16783379[PMID]
22346,363727,X-linked dyserythropoietic anemia with abnormal platelets and neutropenia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
22345,363722,Alexander disease type II,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,23700170[PMID]
22344,363717,Alexander disease type I,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,23700170[PMID]
22343,363710,Spinocerebellar ataxia type 37,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,23700170[PMID]
22343,363710,Spinocerebellar ataxia type 37,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22342,363705,Craniofaciofrontodigital syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,7151302[PMID]
22342,363705,Craniofaciofrontodigital syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7151302[PMID]
22340,363694,Hyperuricemia-pulmonary hypertension-renal failure-alkalosis syndrome,Disease,Disorder,Cases/families,Family(ies),,4.0,Worldwide,Validated,21255763[PMID]
22340,363694,Hyperuricemia-pulmonary hypertension-renal failure-alkalosis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22339,363686,Severe intellectual disability-poor language-strabismus-grimacing face-long fingers syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,23644463[PMID]
22339,363686,Severe intellectual disability-poor language-strabismus-grimacing face-long fingers syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22338,363680,2p13.2 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,23837398[PMID]
22338,363680,2p13.2 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22337,363677,Childhood-onset autosomal recessive myopathy with external ophthalmoplegia,Disease,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,15548556[PMID]_23388406[PMID]
22337,363677,Childhood-onset autosomal recessive myopathy with external ophthalmoplegia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22382,364577,Intellectual disability-brachydactyly-Pierre Robin syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,15057987[PMID]
22382,364577,Intellectual disability-brachydactyly-Pierre Robin syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15057987[PMID]
22369,364198,Bipartite talus,Morphological anomaly,Disorder,Cases/families,Case(s),,23.0,Worldwide,Validated,24095243[PMID]
22369,364198,Bipartite talus,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24095243[PMID]
22298,363417,Temtamy preaxial brachydactyly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,21129727[PMID]_2129728[PMID]_19952732[PMID]_15365460[PMID]_9823490[PMID]
22298,363417,Temtamy preaxial brachydactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22296,363409,Fetal akinesia-cerebral and retinal hemorrhage syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,23092955[PMID]
22296,363409,Fetal akinesia-cerebral and retinal hemorrhage syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22297,363412,Hypomyelination with brain stem and spinal cord involvement and leg spasticity,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,25527264[PMID]
22297,363412,Hypomyelination with brain stem and spinal cord involvement and leg spasticity,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25527264[PMID]
22302,363429,Autosomal recessive cerebellar ataxia-pyramidal signs-nystagmus-oculomotor apraxia syndrome,Disease,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,22901947[PMID]_24078737[PMID]_23611888[PMID]
22302,363429,Autosomal recessive cerebellar ataxia-pyramidal signs-nystagmus-oculomotor apraxia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22901947[PMID]_24078737[PMID]_23611888[PMID]
22303,363432,Autosomal recessive congenital cerebellar ataxia due to GRID2 deficiency,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,23611888[PMID]_24078737[PMID]
22303,363432,Autosomal recessive congenital cerebellar ataxia due to GRID2 deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22301,363424,Multiple mitochondrial dysfunctions syndrome type 3,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,23462291[PMID]
22301,363424,Multiple mitochondrial dysfunctions syndrome type 3,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22292,363396,High myopia-sensorineural deafness syndrome,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,23543054[PMID]
22292,363396,High myopia-sensorineural deafness syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22293,363400,Severe neurodegenerative syndrome with lipodystrophy,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,27632409[PMID]
22293,363400,Severe neurodegenerative syndrome with lipodystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27632409[PMID]
22278,363203,Ring chromosome syndrome,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,2.0,Worldwide,Validated,1175321[PMID]
22328,363618,LMNA-related cardiocutaneous progeria syndrome,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,23666920[PMID]
22328,363618,LMNA-related cardiocutaneous progeria syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23666920[PMID]
22329,363623,GMPPB-related limb-girdle muscular dystrophy R19,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,23768512[PMID]
22329,363623,GMPPB-related limb-girdle muscular dystrophy R19,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22331,363649,Mandibular hypoplasia-deafness-progeroid features-lipodystrophy syndrome,Disease,Disorder,Cases/families,Case(s),,21.0,Worldwide,Validated,28521875[PMID]
22331,363649,Mandibular hypoplasia-deafness-progeroid features-lipodystrophy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28521875[PMID]
22332,363654,X-linked parkinsonism-spasticity syndrome,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,20629132[PMID]_23595882[PMID]
22332,363654,X-linked parkinsonism-spasticity syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22333,363659,20q11.2 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,23704076[PMID]
22334,363665,Acroosteolysis-keloid-like lesions-premature aging syndrome,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,26279204[PMID]
22334,363665,Acroosteolysis-keloid-like lesions-premature aging syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26279204[PMID]
22320,363540,Leukoencephalopathy with mild cerebellar ataxia and white matter edema,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,23707145[PMID]
22320,363540,Leukoencephalopathy with mild cerebellar ataxia and white matter edema,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22322,363549,Acute encephalopathy with biphasic seizures and late reduced diffusion,Disease,Disorder,Cases/families,Case(s),,283.0,Worldwide,Validated,21924570[PMID]_23772250[PMID]
22322,363549,Acute encephalopathy with biphasic seizures and late reduced diffusion,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
22323,363558,New-onset refractory status epilepticus,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_28396650[PMID]
22324,363567,Acute encephalopathy with inflammation-mediated status epilepticus,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
22325,363579,Extragonadal germ cell tumor,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.13,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22327,363611,CTCF-related neurodevelopmental disorder,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,28619046[PMID]
22327,363611,CTCF-related neurodevelopmental disorder,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28619046[PMID]
22312,363494,Non-seminomatous germ cell tumor of testis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.21,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
22312,363494,Non-seminomatous germ cell tumor of testis,Disease,Disorder,Lifetime Prevalence,Value and class,1-5 / 10 000,33.53,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
22317,363523,Hypohidrosis-enamel hypoplasia-palmoplantar keratoderma-intellectual disability syndrome,Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,23606727[PMID]
22317,363523,Hypohidrosis-enamel hypoplasia-palmoplantar keratoderma-intellectual disability syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22319,363534,"Mitochondrial DNA depletion syndrome, hepatocerebrorenal form",Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,23375728[PMID]
22319,363534,"Mitochondrial DNA depletion syndrome, hepatocerebrorenal form",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22318,363528,Intellectual disability-strabismus syndrome,Disease,Disorder,Cases/families,Case(s),,34.0,Worldwide,Validated,23620220[PMID]
22318,363528,Intellectual disability-strabismus syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22305,363444,THOC6-related developmental delay-microcephaly-facial dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,23621916[PMID]
22305,363444,THOC6-related developmental delay-microcephaly-facial dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22307,363454,BICD2-related autosomal dominant childhood-onset proximal spinal muscular atrophy,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,26594138[PMID]_26998597[PMID]_27784775[PMID]
22307,363454,BICD2-related autosomal dominant childhood-onset proximal spinal muscular atrophy,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26594138[PMID]_27784775[PMID]
22306,363447,Autosomal dominant childhood-onset proximal spinal muscular atrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20697106[PMID]_22459677[PMID]_22847149[PMID]_26594138[PMID]_26998597[PMID]_27784775[PMID]
22306,363447,Autosomal dominant childhood-onset proximal spinal muscular atrophy,Disease,Disorder,Cases/families,Case(s),,97.0,Worldwide,Validated,20697106[PMID]_22459677[PMID]_22847149[PMID]_26594138[PMID]_26998597[PMID]_27784775[PMID]
22309,363478,Paratesticular adenocarcinoma,Disease,Disorder,Lifetime Prevalence,Value and class,<1 / 1 000 000,0.01,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
22309,363478,Paratesticular adenocarcinoma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
22309,363478,Paratesticular adenocarcinoma,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22309,363478,Paratesticular adenocarcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22309,363478,Paratesticular adenocarcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.004,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22309,363478,Paratesticular adenocarcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22309,363478,Paratesticular adenocarcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.001,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22309,363478,Paratesticular adenocarcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.001,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22309,363478,Paratesticular adenocarcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22309,363478,Paratesticular adenocarcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.001,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22309,363478,Paratesticular adenocarcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22309,363478,Paratesticular adenocarcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22309,363478,Paratesticular adenocarcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.001,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22309,363478,Paratesticular adenocarcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22308,363472,Tumor of testis and paratestis,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.15,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
22308,363472,Tumor of testis and paratestis,Category,Group of disorders,Lifetime Prevalence,Value and class,6-9 / 10 000,87.77,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
22308,363472,Tumor of testis and paratestis,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
22311,363489,Sex cord-stromal tumor of testis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
22311,363489,Sex cord-stromal tumor of testis,Disease,Disorder,Lifetime Prevalence,Value and class,1-9 / 1 000 000,0.44,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
22311,363489,Sex cord-stromal tumor of testis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.049,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22311,363489,Sex cord-stromal tumor of testis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.048,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22311,363489,Sex cord-stromal tumor of testis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22311,363489,Sex cord-stromal tumor of testis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.034,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22311,363489,Sex cord-stromal tumor of testis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.016,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22311,363489,Sex cord-stromal tumor of testis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.018,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22311,363489,Sex cord-stromal tumor of testis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.012,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22311,363489,Sex cord-stromal tumor of testis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22311,363489,Sex cord-stromal tumor of testis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.018,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22311,363489,Sex cord-stromal tumor of testis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.027,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22311,363489,Sex cord-stromal tumor of testis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.016,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22311,363489,Sex cord-stromal tumor of testis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.008,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22311,363489,Sex cord-stromal tumor of testis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.022,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22311,363489,Sex cord-stromal tumor of testis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.013,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22311,363489,Sex cord-stromal tumor of testis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22311,363489,Sex cord-stromal tumor of testis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.037,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22311,363489,Sex cord-stromal tumor of testis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22311,363489,Sex cord-stromal tumor of testis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.021,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22311,363489,Sex cord-stromal tumor of testis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.023,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22311,363489,Sex cord-stromal tumor of testis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.012,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22311,363489,Sex cord-stromal tumor of testis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.023,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22310,363483,Testicular teratoma,Disease,Disorder,Lifetime Prevalence,Value and class,<1 / 1 000 000,0.04,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
22310,363483,Testicular teratoma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
22212,357175,Short ulna-dysmorphism-hypotonia-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,20950399[PMID]
22212,357175,Short ulna-dysmorphism-hypotonia-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22220,357329,Combined immunodeficiency due to IL21R deficiency,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,23440042[PMID]_25769540[PMID]_25398835[PMID]
22220,357329,Combined immunodeficiency due to IL21R deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23440042[PMID]_25769540[PMID]_25398835[PMID]
22222,357332,Syndactyly-camptodactyly and clinodactyly of fifth fingers-bifid toes syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,26.0,Worldwide,Validated,20683984[PMID]
22222,357332,Syndactyly-camptodactyly and clinodactyly of fifth fingers-bifid toes syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22219,357237,Combined immunodeficiency due to CARD11 deficiency,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,25087226[PMID]
22219,357237,Combined immunodeficiency due to CARD11 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25087226[PMID]
22226,357502,Idiopathic nephrotic syndrome,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
22190,356978,"D,L-2-hydroxyglutaric aciduria",Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,23561848[PMID]
22190,356978,"D,L-2-hydroxyglutaric aciduria",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22188,356947,3q26q27 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,23357683[PMID]_24055528[PMID]
22188,356947,3q26q27 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22189,356961,SLC35A2-CDG,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,25778940[PMID]
22189,356961,SLC35A2-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22195,357008,Hemolytic uremic syndrome with DGKE deficiency,Disease,Disorder,Cases/families,Case(s),,47.0,Worldwide,Validated,23542698[PMID]_28526779 [PMID]_ 28242109[PMID]
22195,357008,Hemolytic uremic syndrome with DGKE deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28526779 [PMID]
22194,357001,19p13.13 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,23495138[PMID]
22194,357001,19p13.13 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22193,356996,ANK3-related intellectual disability-sleep disturbance syndrome,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,23390136[PMID]_28687526[PMID]
22193,356996,ANK3-related intellectual disability-sleep disturbance syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23390136[PMID]_28687526[PMID]
22199,357043,Amyotrophic lateral sclerosis type 4,Disease,Disorder,Cases/families,Case(s),,70.0,Worldwide,Validated,9497266[PMID]_12023320[PMID]
22199,357043,Amyotrophic lateral sclerosis type 4,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9497266[PMID]_12023320[PMID]
22198,357034,Non-hereditary retinoblastoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.038,Europe,Not yet validated,ORPHANET
22198,357034,Non-hereditary retinoblastoma,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
22197,357027,Hereditary retinoblastoma,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
22207,357158,Mandibulofacial dysostosis-macroblepharon-macrostomia syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,9018413[PMID]_23448909[PMID]
22207,357158,Mandibulofacial dysostosis-macroblepharon-macrostomia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9018413[PMID]_23448909[PMID
22206,357154,Oral submucous fibrosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
22093,352654,Early-onset progressive neurodegeneration-blindness-ataxia-spasticity syndrome,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,23359680[PMID]_28007905[PMID]
22093,352654,Early-onset progressive neurodegeneration-blindness-ataxia-spasticity syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28007905[PMID]
22095,352662,Corneal intraepithelial dyskeratosis-palmoplantar hyperkeratosis-laryngeal dyskeratosis syndrome,Disease,Disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,23349227[PMID]_27662089[PMID]
22095,352662,Corneal intraepithelial dyskeratosis-palmoplantar hyperkeratosis-laryngeal dyskeratosis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET__27662089[PMID]
22094,352657,Hereditary benign intraepithelial dyskeratosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
22089,352641,Autosomal recessive cerebellar ataxia with late-onset spasticity,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,23332917[PMID]
22089,352641,Autosomal recessive cerebellar ataxia with late-onset spasticity,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22088,352636,Phalangeal microgeodic syndrome,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,ORPHANET
22088,352636,Phalangeal microgeodic syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22091,352649,Brain dopamine-serotonin vesicular transport disease,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,23363473[PMID]
22091,352649,Brain dopamine-serotonin vesicular transport disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22084,352596,Progressive myoclonic epilepsy with dystonia,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,21087195[PMID]
22084,352596,Progressive myoclonic epilepsy with dystonia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22087,352629,16q24.1 microdeletion syndrome,Disease,Disorder,Cases/families,Case(s),,42.0,Worldwide,Validated,27071622[PMID]
22087,352629,16q24.1 microdeletion syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27071622[PMID]
22081,352577,Bainbridge-Ropers syndrome,Disease,Disorder,Cases/families,Case(s),,77.0,Worldwide,Validated,PMID: 28955728 & EXPERT
22081,352577,Bainbridge-Ropers syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET & PMID: 28955728
22083,352587,Focal epilepsy-intellectual disability-cerebro-cerebellar malformation,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,23517570[PMID]
22083,352587,Focal epilepsy-intellectual disability-cerebro-cerebellar malformation,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22082,352582,Familial infantile myoclonic epilepsy,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,20727515[PMID]
22082,352582,Familial infantile myoclonic epilepsy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22109,352731,Oculocutaneous albinism type 1,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.5,Worldwide,Not yet validated,ORPHANET
22110,352734,Minimal pigment oculocutaneous albinism type 1,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,[EXPERT]
22110,352734,Minimal pigment oculocutaneous albinism type 1,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22111,352737,Temperature-sensitive oculocutaneous albinism type 1,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,[EXPERT]
22111,352737,Temperature-sensitive oculocutaneous albinism type 1,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22105,352712,Facial dysmorphism-immunodeficiency-livedo-short stature syndrome,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,23230001[PMID]
22105,352712,Facial dysmorphism-immunodeficiency-livedo-short stature syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22106,352718,Progressive retinal dystrophy due to retinol transport defect,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,9888420[PMID]_23189188[PMID]_27892788[PMID]
22106,352718,Progressive retinal dystrophy due to retinol transport defect,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23189188[PMID]_27892788[PMID]
22107,352723,Attenuated Chédiak-Higashi syndrome,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,ORPHANET
22107,352723,Attenuated Chédiak-Higashi syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
22096,352665,Neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-skeletal anomalies syndrome due to 9q21.3 microdeletion,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,24501764[PMID]_25348648[PMID]
22096,352665,Neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-skeletal anomalies syndrome due to 9q21.3 microdeletion,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24501764[PMID]_25348648[PMID]
22097,352670,Autosomal dominant intermediate Charcot-Marie-Tooth disease type F,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,23434117[PMID]
22097,352670,Autosomal dominant intermediate Charcot-Marie-Tooth disease type F,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22098,352675,X-linked Charcot-Marie-Tooth disease type 6,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,23297365[PMID]
22098,352675,X-linked Charcot-Marie-Tooth disease type 6,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23297365[PMID]
22099,352682,Cobblestone lissencephaly without muscular or ocular involvement,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,23472759[PMID]_25925986[PMID]
22099,352682,Cobblestone lissencephaly without muscular or ocular involvement,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23472759[PMID]_25925986[PMID]
22126,353253,Burning mouth syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_10478959[PMID]
22126,353253,Burning mouth syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET_10478959[PMID]
22120,353220,Familial primary localized cutaneous amyloidosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
22117,352763,Scleredema,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
22113,352745,Oculocutaneous albinism type 7,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,23395477[PMID]
22113,352745,Oculocutaneous albinism type 7,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22139,353334,Congenital retinal arteriovenous communication,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
22136,353320,"Pyruvate carboxylase deficiency, benign type",Clinical subtype,Subtype of disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,20301764[PMID]
22136,353320,"Pyruvate carboxylase deficiency, benign type",Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20301764[PMID]
22137,353327,Congenital myasthenic syndromes with glycosylation defect,Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
22134,353308,"Pyruvate carboxylase deficiency, infantile type",Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
22135,353314,"Pyruvate carboxylase deficiency, severe neonatal type",Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
22133,353298,Roifman syndrome,Disease,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,PMID: 16901296; 21977988 & EXPERT
22133,353298,Roifman syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22129,353284,Rubinstein-Taybi syndrome due to EP300 haploinsufficiency,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,34.0,Worldwide,Validated,27465822[PMID]
22129,353284,Rubinstein-Taybi syndrome due to EP300 haploinsufficiency,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27465822[PMID]
22058,352403,Spectrin-associated autosomal recessive cerebellar ataxia,Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,23236289[PMID]_23838597[PMID]
22058,352403,Spectrin-associated autosomal recessive cerebellar ataxia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22057,352333,Congenital ichthyosis-intellectual disability-spastic quadriplegia syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,22100072[PMID]
22057,352333,Congenital ichthyosis-intellectual disability-spastic quadriplegia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22056,352328,MEGDEL syndrome,Disease,Disorder,Cases/families,Case(s),,67.0,Worldwide,Validated,29205472[PMID]
22056,352328,MEGDEL syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29205472[PMID]
22063,352447,Progressive external ophthalmoplegia-myopathy-emaciation syndrome,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,23313956[PMID]
22063,352447,Progressive external ophthalmoplegia-myopathy-emaciation syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22075,352530,Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,22549410[PMID]
22075,352530,Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22078,352563,Infantile hypertrophic cardiomyopathy due to MRPL44 deficiency,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,23315540[PMID]
22078,352563,Infantile hypertrophic cardiomyopathy due to MRPL44 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22076,352540,Oncogenic osteomalacia,Disease,Disorder,Cases/families,Case(s),,400.0,Worldwide,Validated,23220596[PMID]
22076,352540,Oncogenic osteomalacia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
22066,352479,ISPD-related limb-girdle muscular dystrophy R20,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,23288328[PMID]
22066,352479,ISPD-related limb-girdle muscular dystrophy R20,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22065,352470,DNA2-related mitochondrial DNA deletion syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,23352259[PMID]
22065,352470,DNA2-related mitochondrial DNA deletion syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22069,352490,Autism spectrum disorder due to AUTS2 deficiency,Disease,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,23332918[PMID]_27075013[PMID]
22069,352490,Autism spectrum disorder due to AUTS2 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23332918[PMID]_27075013[PMID]
20909,294422,Chronic intestinal failure,Clinical syndrome,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,86.0,Italy,Validated,18589446[PMID]
20909,294422,Chronic intestinal failure,Clinical syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,42.4691,Italy,Validated,36215864[PMID]_ORPHANET
20900,293987,Rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome,Disease,Disorder,Cases/families,Case(s),,96.0,Worldwide,Validated,[EXPERT]_30584530[PMID]
20900,293987,Rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
20901,294016,Microcephaly-capillary malformation syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,23542699[PMID]
20901,294016,Microcephaly-capillary malformation syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20902,294023,Neonatal inflammatory skin and bowel disease,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,22010916[PMID]_24691054[PMID]
20902,294023,Neonatal inflammatory skin and bowel disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22010916[PMID]_24691054[PMID]
20903,294026,Syndactyly-nystagmus syndrome due to 2q31.1 microduplication,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,21654727[PMID]
20903,294026,Syndactyly-nystagmus syndrome due to 2q31.1 microduplication,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21654727[PMID]
20896,293964,Hypoinsulinemic hypoglycemia and body hemihypertrophy,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,14764948[PMID]_21979934[PMID]
20896,293964,Hypoinsulinemic hypoglycemia and body hemihypertrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20897,293967,Hypogonadotropic hypogonadism-severe microcephaly-sensorineural hearing loss-dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,22002932[PMID]
20897,293967,Hypogonadotropic hypogonadism-severe microcephaly-sensorineural hearing loss-dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20898,293978,Deficiency in anterior pituitary function-variable immunodeficiency syndrome,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,22013103[PMID]
20898,293978,Deficiency in anterior pituitary function-variable immunodeficiency syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20895,293958,Hypertelorism-preauricular sinus-punctual pits-deafness syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,21480481[PMID]
20895,293958,Hypertelorism-preauricular sinus-punctual pits-deafness syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20894,293955,Childhood encephalopathy due to thiamine pyrophosphokinase deficiency,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,22152682[PMID]
20894,293955,Childhood encephalopathy due to thiamine pyrophosphokinase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20893,293948,1p21.3 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,22003227[PMID]_21114665[PMID]
20893,293948,1p21.3 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20892,293939,Distal Xq28 microduplication syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,21984752[PMID]
20892,293939,Distal Xq28 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20891,293936,EDICT syndrome,Disease,Disorder,Cases/families,Family(ies),,4.0,Worldwide,Validated,22131394[PMID]_24138095[PMID]
20891,293936,EDICT syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22131394[PMID]_24138095[PMID]
20889,293925,Lethal occipital encephalocele-skeletal dysplasia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,27410456[PMID]
20889,293925,Lethal occipital encephalocele-skeletal dysplasia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27410456
20883,293864,Hypoplastic pancreas-intestinal atresia-hypoplastic gallbladder syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,21965172[PMID]
20883,293864,Hypoplastic pancreas-intestinal atresia-hypoplastic gallbladder syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20879,293843,3MC syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,32.0,Worldwide,Validated,21258343[PMID]
20879,293843,3MC syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21258343[PMID]
20874,293822,MITF-related melanoma and renal cell carcinoma predisposition syndrome,Disease,Disorder,Cases/families,Family(ies),,30.0,Worldwide,Validated,ORPHANET
20874,293822,MITF-related melanoma and renal cell carcinoma predisposition syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20875,293825,Congenital dyserythropoietic anemia type IV,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,23522491[PMID]
20875,293825,Congenital dyserythropoietic anemia type IV,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23522491[PMID]
20872,293812,Fixed drug eruption,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_26548517[PMID]
20871,293807,Ketamine-induced biliary dilatation,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,22124288[PMID]
20871,293807,Ketamine-induced biliary dilatation,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_22124288[PMID]
20869,293725,"Blepharophimosis-intellectual disability syndrome, Verloes type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
20866,293642,Blepharophimosis-intellectual disability syndrome,Clinical group,Group of disorders,Cases/families,Case(s),,58.0,Worldwide,Validated,22077973[PMID]_21567902[PMID]_18798845[PMID]_16700052[PMID]_15176598[PMID]_15127758[PMID]_12868473[PMID]_10955481[PMID]_10631927[PMID]_9605288[PMID]_9546834[PMID]
20866,293642,Blepharophimosis-intellectual disability syndrome,Clinical group,Group of disorders,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20867,293707,"Blepharophimosis-intellectual disability syndrome, MKB type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
20937,294975,Isolated absence of upper arm and forearm with hand present,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.62,Worldwide,Validated,22002800[PMID]
20937,294975,Isolated absence of upper arm and forearm with hand present,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_22002800[PMID]
20931,294963,Popliteal pterygium syndrome,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 1 000 000,0.3,Europe,Validated,2352260[PMID]
20935,294971,Isolated tetra-amelia,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Not yet validated,ORPHANET
20768,289863,Atypical glycine encephalopathy,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,[EXPERT]
20768,289863,Atypical glycine encephalopathy,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20771,289877,Transient hyperammonemia of the newborn,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20777,289916,Vitamin B12-unresponsive methylmalonic acidemia type mut0,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20756,289661,Epstein-Barr virus-positive diffuse large B-cell lymphoma,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,[WHO Classification of Tumours]
20756,289661,Epstein-Barr virus-positive diffuse large B-cell lymphoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[WHO Classification of Tumours]
20766,289857,Neonatal glycine encephalopathy,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20767,289860,Infantile glycine encephalopathy,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20741,289560,Mitochondrial membrane protein-associated neurodegeneration,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Worldwide,Validated,[EXPERT]_24575447[PMID]
20740,289553,Dysmorphism-conductive hearing loss-heart defect syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20739,289548,Inherited isolated adrenal insufficiency due to partial CYP11A1 deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20737,289539,BAP1-related tumor predisposition syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20749,289601,Hereditary arterial and articular multiple calcification syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21288095[PMID]
20749,289601,Hereditary arterial and articular multiple calcification syndrome,Disease,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,21288095[PMID]
20748,289596,Juvenile nasopharyngeal angiofibroma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
20748,289596,Juvenile nasopharyngeal angiofibroma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.6666,Worldwide,Validated,28199045[PMID]
20746,289586,Exfoliative ichthyosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20854,293355,Methylmalonic acidemia without homocystinuria,Clinical group,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,[EXPERT]
20854,293355,Methylmalonic acidemia without homocystinuria,Clinical group,Group of disorders,Point prevalence,Value and class,<1 / 1 000 000,0.0555,China,Validated,34103049[PMID]
20855,293375,Grayson-Wilbrandt corneal dystrophy,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,8230838[PMID]_[EXPERT]
20855,293375,Grayson-Wilbrandt corneal dystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8230838[PMID]
20856,293381,Epithelial recurrent erosion dystrophy,Disease,Disorder,Cases/families,Case(s),,186.0,Worldwide,Validated,18700883[PMID]_6887751[PMID]_12035594[PMID]_18700883[PMID]_187789[PMID]_19710953[PMID]_20597871[PMID]
20856,293381,Epithelial recurrent erosion dystrophy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
20857,293462,Pre-Descemet corneal dystrophy,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,ORPHANET
20857,293462,Pre-Descemet corneal dystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20862,293603,Congenital hereditary endothelial dystrophy type II,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
20863,293621,X-linked endothelial corneal dystrophy,Disease,Disorder,Cases/families,Case(s),,35.0,Worldwide,Validated,16490493[PMID]
20863,293621,X-linked endothelial corneal dystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
5536,811,Shwachman-Diamond syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.59,Italy,Validated,22887728[PMID]
5536,811,Shwachman-Diamond syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,United Kingdom,Validated,ISBN:407002049[OTHER]
5536,811,Shwachman-Diamond syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.67,Puerto rico,Validated,8637967[PMID]
5536,811,Shwachman-Diamond syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.3,Canada,Validated,11254457[PMID]
5536,811,Shwachman-Diamond syndrome,Disease,Disorder,Prevalence at birth,Class only,1-9 / 1 000 000,0.0,Europe,Validated,ORPHANET
5536,811,Shwachman-Diamond syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Worldwide,Validated,[EXPERT]
5536,811,Shwachman-Diamond syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.28,Worldwide,Validated,22491737[PMID]
20839,293168,Infantile-onset ascending hereditary spastic paralysis,Disease,Disorder,Cases/families,Family(ies),,17.0,Worldwide,Validated,12145748[PMID]_12919135[PMID]_12601111[PMID]_12509863[PMID]_18394004[PMID]_16718699[PMID]_18810511[PMID]_18523452[PMID]
20839,293168,Infantile-onset ascending hereditary spastic paralysis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20838,293165,Skin fragility-woolly hair-palmoplantar keratoderma syndrome,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,20738328[PMID]
20838,293165,Skin fragility-woolly hair-palmoplantar keratoderma syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
5543,428,Autosomal dominant hypocalcemia,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.161,Denmark,Validated,25753591[PMID]
5543,428,Autosomal dominant hypocalcemia,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
5543,428,Autosomal dominant hypocalcemia,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,3.9,United States,Validated,32386559[PMID]
20841,293181,Epilepsy of infancy with migrating focal seizures,Disease,Disorder,Cases/families,Case(s),,114.0,Worldwide,Validated,19469847[PMID]_23086397[PMID]_23599387[PMID]
20841,293181,Epilepsy of infancy with migrating focal seizures,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_235999387[PMID]
20841,293181,Epilepsy of infancy with migrating focal seizures,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.11,United Kingdom,Validated,23599387[PMID]
20841,293181,Epilepsy of infancy with migrating focal seizures,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.4,United Kingdom,Validated,235999387[PMID]
5544,2298,Insulin-resistance syndrome type B,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
5545,2207,Familial primary hyperparathyroidism,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20840,293173,Acute generalized exanthematous pustulosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.3,Worldwide,Not yet validated,11168761[PMID]_ORPHANET
20840,293173,Acute generalized exanthematous pustulosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.035,Israel,Validated,18669133[PMID]
20840,293173,Acute generalized exanthematous pustulosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20843,293199,Pleomorphic rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2011[REG]
20843,293199,Pleomorphic rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
5546,393,"46,XX testicular difference of sex development",Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.5,Worldwide,Validated,16200839[PMID]_6945286[PMID]_[EXPERT]
20844,293202,Epithelioid sarcoma,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2011[REG]
20844,293202,Epithelioid sarcoma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
20844,293202,Epithelioid sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.04,United States,Validated,1922430[PMID]
20847,293284,Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20846,293208,Celiac artery compression syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
5522,2459,Mansonelliasis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
5522,2459,Mansonelliasis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
5521,2404,Loiasis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,22784545[PMID]
5521,2404,Loiasis,Disease,Disorder,Point prevalence,Class only,>1 / 1000,0.0,Specific population,Not yet validated,ORPHANET
5520,2394,Pyruvate dehydrogenase E3 deficiency,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,[EXPERT]
5520,2394,Pyruvate dehydrogenase E3 deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
5527,2356,Arachnoid cyst,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
5525,829,Adult-onset Still disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.16,France,Validated,7668903[PMID]
5525,829,Adult-onset Still disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.13,Japan,Validated,9465547[PMID]
5525,829,Adult-onset Still disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.9,Japan,Validated,25382730[PMID]
5525,829,Adult-onset Still disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.4,Norway,Validated,16467042[PMID]
5525,829,Adult-onset Still disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.9,Norway,Validated,16467042[PMID]
5525,829,Adult-onset Still disease,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET_16467042[PMID]
5525,829,Adult-onset Still disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.62,Turkey,Validated,26320744[PMID]
5525,829,Adult-onset Still disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.77,Turkey,Validated,26320744[PMID]
5529,1929,Rasmussen subacute encephalitis,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,ORPHANET
5529,1929,Rasmussen subacute encephalitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
5528,1183,Opsoclonus-myoclonus syndrome,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Europe,Validated,[EXPERT]_19423368[PMID]
5528,1183,Opsoclonus-myoclonus syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
5528,1183,Opsoclonus-myoclonus syndrome,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.018,United Kingdom,Validated,19423368[PMID]
5535,2688,Adult idiopathic neutropenia,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
5535,2688,Adult idiopathic neutropenia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
5534,2686,Cyclic neutropenia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Europe,Not yet validated,ORPHANET
5533,890,Hepatic veno-occlusive disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
5532,176,Non-rhizomelic chondrodysplasia punctata,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
5518,231,Dracunculiasis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
5518,231,Dracunculiasis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
5519,2035,Lymphatic filariasis,Disease,Disorder,Point prevalence,Class only,>1 / 1000,0.0,Specific population,Validated,World Health Organization[INST]
5519,2035,Lymphatic filariasis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
20612,284448,CLIPPERS,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,24028073[PMID]
20612,284448,CLIPPERS,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20613,284454,Acute zonal occult outer retinopathy,Disease,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,21056448[PMID]
20613,284454,Acute zonal occult outer retinopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
20614,284460,Acute annular outer retinopathy,Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,16181293[PMID]
20614,284460,Acute annular outer retinopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20609,284417,"Phosphoserine aminotransferase deficiency, infantile/juvenile form",Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
20610,284426,Glycogen storage disease due to lactate dehydrogenase M-subunit deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20611,284435,Glycogen storage disease due to lactate dehydrogenase H-subunit deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20631,284984,Aneurysm-osteoarthritis syndrome,Disease,Disorder,Cases/families,Case(s),,45.0,Worldwide,Validated,22167769[PMID]
20631,284984,Aneurysm-osteoarthritis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20630,284979,Neonatal Marfan syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20715,289365,Familial vesicoureteral reflux,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20712,289347,Infective dermatitis associated with HTLV-1,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20713,289356,Primary non-gestational choriocarcinoma of ovary,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
20718,289377,Early-onset myopathy with fatal cardiomyopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20719,289380,Myosclerosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20707,289290,Hypermethioninemia encephalopathy due to adenosine kinase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20705,289266,Early-onset epileptic encephalopathy and intellectual disability due to GRIN2A mutation,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20711,289326,Tropical spastic paraparesis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20709,289307,Developmental delay due to methylmalonate semialdehyde dehydrogenase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
20731,289504,Combined malonic and methylmalonic acidemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.3,United States,Validated,21841779[PMID]
20731,289504,Combined malonic and methylmalonic acidemia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20730,289499,Congenital cataract microcornea with corneal opacity,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20728,289494,4H leukodystrophy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
20728,289494,4H leukodystrophy,Disease,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,[EXPERT]_22855961[PMID]_25339210[PMID]
20734,289522,Microtriplication 11q24.1 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,21617255[PMID]
20734,289522,Microtriplication 11q24.1 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21617255[PMID]
20733,289513,12q15q21.1 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,28159701[PMID]
20733,289513,12q15q21.1 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28159701[PMID]
20723,289465,Isolated congenital adermatoglyphia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20721,289390,Primary Sjögren syndrome,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,11.343,France,Validated,23983119[PMID]_25387476[PMID]
20721,289390,Primary Sjögren syndrome,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,48.99,Europe,Validated,25387476[PMID]
20721,289390,Primary Sjögren syndrome,Disease,Disorder,Point prevalence,Value and class,6-9 / 10 000,86.398,Greece,Validated,16332955[PMID]_25387476[PMID]
20721,289390,Primary Sjögren syndrome,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,49.745,Norway,Validated,21231797[PMID]_25387476[PMID]
20721,289390,Primary Sjögren syndrome,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,45.47,Denmark,Validated,17582741[PMID]_25387476[PMID]
20721,289390,Primary Sjögren syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.95,United States,Validated,11393497[PMID]
20721,289390,Primary Sjögren syndrome,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,37.15,"Taiwan, Province of China",Validated,22899470[PMID]_23916348[PMID]_24938285[PMID]
20721,289390,Primary Sjögren syndrome,Disease,Disorder,Point prevalence,Value and class,>1 / 1000,207.83,Turkey,Validated,18422594[PMID]_24938285[PMID]
20721,289390,Primary Sjögren syndrome,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,30.91,Italy,Validated,22396771[PMID]_24938285[PMID]
20721,289390,Primary Sjögren syndrome,Disease,Disorder,Point prevalence,Value and class,>1 / 1000,165.98,Brazil,Validated,23588513[PMID]_24938285[PMID]
20721,289390,Primary Sjögren syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,9.5,"Taiwan, Province of China",Validated,21239759[PMID]_23916348[PMID]_22899470[PMID]_24938285[PMID]
20721,289390,Primary Sjögren syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.3,Greece,Validated,16332955[PMID]_24938285[PMID]
20721,289390,Primary Sjögren syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.9,Slovenia,Validated,15194588[PMID]_24938285[PMID]
20721,289390,Primary Sjögren syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,6.92,Worldwide,Validated,24938285[PMID]
20720,289385,Malignancy diagnosed during pregnancy,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20726,289483,Intellectual disability-alacrima-achalasia syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20725,289478,PASH syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28696038[PMID]
20725,289478,PASH syndrome,Disease,Disorder,Cases/families,Case(s),,36.0,Worldwide,Validated,28696038[PMID]
20703,289176,Autosomal recessive hypophosphatemic rickets,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20702,289157,Hypocalcemic vitamin D-dependent rickets,Disease,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET
20518,280921,Idiopathic panuveitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0194,Europe,Validated,ORPHANET
20518,280921,Idiopathic panuveitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.5051,Europe,Validated,ORPHANET
20518,280921,Idiopathic panuveitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,16.0,United States,Validated,27608193[PMID]
20518,280921,Idiopathic panuveitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.6,United States,Validated,34802369[PMID]
20515,280898,Panuveitis,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20514,280892,Posterior uveitis,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20513,280886,Anterior uveitis,Category,Group of disorders,Point prevalence,Value and class,>1 / 1000,185.0,Denmark,Validated,20066507[PMID]
20513,280886,Anterior uveitis,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20527,281103,Keratinopathic ichthyosis,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.11,France,Validated,24393603[PMID]
20526,281097,Autosomal recessive congenital ichthyosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.5,United States,Not yet validated,20301593[PMID]_ORPHANET
20526,281097,Autosomal recessive congenital ichthyosis,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,8006437[PMID]_European Medicines Agency 2012[INST]
20526,281097,Autosomal recessive congenital ichthyosis,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.77,Spain,Not yet validated,22000705[PMID]_21668430[PMID]
20526,281097,Autosomal recessive congenital ichthyosis,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.1,Norway,Validated,9887377[PMID]
20525,281090,Syndromic recessive X-linked ichthyosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.3,Europe,Validated,[EXPERT]
20524,281085,Inherited ichthyosis syndromic form,Category,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.19,France,Not yet validated,24393603[PMID]
20523,281082,Inherited non-syndromic ichthyosis,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.13,France,Not yet validated,24393603[PMID]
20532,281190,Congenital reticular ichthyosiform erythroderma,Disease,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,26381864[PMID]
20532,281190,Congenital reticular ichthyosiform erythroderma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26381864[PMID]
20533,281201,Keratosis linearis-ichthyosis congenita-sclerosing keratoderma syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20530,281139,Annular epidermolytic ichthyosis,Disease,Disorder,Cases/families,Family(ies),,7.0,Worldwide,Validated,17596149[PMID]_14594577[PMID]
20530,281139,Annular epidermolytic ichthyosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20528,281122,Self-improving collodion baby,Disease,Disorder,Cases/families,Case(s),,25.0,Worldwide,Validated,[EXPERT]
20528,281122,Self-improving collodion baby,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20529,281127,Acral self-healing collodion baby,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,19500103[PMID]_[EXPERT]
20529,281127,Acral self-healing collodion baby,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20484,280628,Familial progressive hyper- and hypopigmentation,Disease,Disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,21368769[PMID]
20484,280628,Familial progressive hyper- and hypopigmentation,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20486,280633,Multiple congenital anomalies-hypotonia-seizures syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,26394714[PMID]_26364997[PMID]
20486,280633,Multiple congenital anomalies-hypotonia-seizures syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26394714[PMID]_26364997[PMID]
20481,280615,Hemoglobinopathy Toms River,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,21561349[PMID]
20481,280615,Hemoglobinopathy Toms River,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20480,280598,Hereditary sensorimotor neuropathy with hyperelastic skin,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,21576112[PMID]
20480,280598,Hereditary sensorimotor neuropathy with hyperelastic skin,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20482,280620,Progressive myoclonic epilepsy type 6,Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,21549339[PMID]_23449775[PMID]
20482,280620,Progressive myoclonic epilepsy type 6,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21549339[PMID]_23449775[PMID]
20495,280671,Megaconial congenital muscular dystrophy,Disease,Disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,23945283[PMID]
20495,280671,Megaconial congenital muscular dystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20488,280640,Occipital pachygyria and polymicrogyria,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,21572413[PMID]
20488,280640,Occipital pachygyria and polymicrogyria,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20491,280654,Autosomal recessive nail dysplasia,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,21665003[PMID]
20491,280654,Autosomal recessive nail dysplasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20500,280779,Cutaneous collagenous vasculopathy,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,21916964[PMID]_21571177[PMID]_20525488[PMID]_20451292[PMID]_20000878[PMID]_18537865[PMID]_10660131[PMID]_[EXPERT]
20500,280779,Cutaneous collagenous vasculopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20501,280785,Bullous diffuse cutaneous mastocytosis,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,ORPHANET
20501,280785,Bullous diffuse cutaneous mastocytosis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20502,280794,Pseudoxanthomatous diffuse cutaneous mastocytosis,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,ORPHANET
20502,280794,Pseudoxanthomatous diffuse cutaneous mastocytosis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20497,280679,Moyamoya angiopathy-short stature-facial dysmorphism-hypergonadotropic hypogonadism syndrome,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,21596366[PMID]
20497,280679,Moyamoya angiopathy-short stature-facial dysmorphism-hypergonadotropic hypogonadism syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20498,280763,Severe intellectual disability and progressive spastic paraplegia,Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,21620353[PMID]
20498,280763,Severe intellectual disability and progressive spastic paraplegia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20499,280774,Generalized essential telangiectasia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20578,284149,Craniosynostosis-dental anomalies,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
20576,284139,"Larsen-like syndrome, B3GAT3 type",Malformation syndrome,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,25893793[PMID]
20576,284139,"Larsen-like syndrome, B3GAT3 type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25893793[PMID]
20583,284180,Xp22.13p22.2 duplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
20582,284169,Facial dysmorphism-developmental delay-behavioral abnormalities syndrome due to 10p11.21p12.31 microdeletion,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29663678[PMID]
20582,284169,Facial dysmorphism-developmental delay-behavioral abnormalities syndrome due to 10p11.21p12.31 microdeletion,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,29663678[PMID]
20581,284160,8q21.11 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,21802062[PMID]_[EXPERT]
20581,284160,8q21.11 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20587,284247,Familial retinal arterial macroaneurysm,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
20585,284232,Autosomal dominant Charcot-Marie-Tooth disease type 2O,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
20584,284227,TEMPI syndrome,Clinical syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,[EXPERT]
20584,284227,TEMPI syndrome,Clinical syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20590,284271,Autosomal recessive cerebellar ataxia-psychomotor delay syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
20589,284264,IgG4-related disease,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20595,284324,Childhood-onset autosomal recessive slowly progressive spinocerebellar ataxia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
20592,284282,Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to WWOX deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
20593,284289,Adult-onset autosomal recessive cerebellar ataxia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25182700[PMID]
20593,284289,Adult-onset autosomal recessive cerebellar ataxia,Disease,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,25182700[PMID]
20598,284343,DICER1 tumor-predisposition syndrome,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.007,Worldwide,Not yet validated,22796286[PMID]
20596,284332,Infantile-onset autosomal recessive nonprogressive cerebellar ataxia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
20597,284339,Pontocerebellar hypoplasia type 7,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,21594990[PMID]_[EXPERT]
20597,284339,Pontocerebellar hypoplasia type 7,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
20603,284388,Reversible cerebral vasoconstriction syndrome,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
20604,284395,Well-differentiated fetal adenocarcinoma of the lung,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
20605,284400,Small cell carcinoma of the bladder,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.14,United States,Validated,21567387[PMID]
20605,284400,Small cell carcinoma of the bladder,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
20605,284400,Small cell carcinoma of the bladder,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,[EXPERT]
20556,282166,Inherited Creutzfeldt-Jakob disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
21405,309854,Cirrhosis-dystonia-polycythemia-hypermanganesemia syndrome,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,22934317[PMID]
21405,309854,Cirrhosis-dystonia-polycythemia-hypermanganesemia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22934317[PMID]
21471,314029,High bone mass osteogenesis imperfecta,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,21344539[PMID]
21471,314029,High bone mass osteogenesis imperfecta,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21470,314022,Gastric adenocarcinoma and proximal polyposis of the stomach,Disease,Disorder,Cases/families,Case(s),,28.0,Worldwide,Validated,21813476[PMID]
21470,314022,Gastric adenocarcinoma and proximal polyposis of the stomach,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21468,314017,Idiopathic linear interstitial keratitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21467,314002,Contractures-webbed neck-micrognathia-hypoplastic nipples syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,22383252[PMID]
21467,314002,Contractures-webbed neck-micrognathia-hypoplastic nipples syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21466,313947,2q23.1 microduplication syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,22085900[PMID]
21466,313947,2q23.1 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21465,313936,PENS syndrome,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,22414678[PMID]_21315481[PMID]
21465,313936,PENS syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21464,313920,Epstein-Barr virus-associated gastric carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.2,Worldwide,Not yet validated,22392024[PMID]_ORPHANET
21464,313920,Epstein-Barr virus-associated gastric carcinoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21462,313906,Congenital pancreatic cyst,Morphological anomaly,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,19231513[PMID]_2202976[PMID]
21462,313906,Congenital pancreatic cyst,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21461,313892,Developmental and speech delay due to SOX5 deficiency,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,26111154[PMID]_29477873[PMID]
21461,313892,Developmental and speech delay due to SOX5 deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29477873[PMID]
21460,313884,12p12.1 microdeletion syndrome,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,22290657[PMID]_29477873[PMID]
21460,313884,12p12.1 microdeletion syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29477873[PMID]
21459,313855,FGFR2-related bent bone dysplasia,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,27240702[PMID]
21459,313855,FGFR2-related bent bone dysplasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27240702[PMID]
21458,313850,Infantile cerebellar-retinal degeneration,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,22405087[PMID]_25351951[PMID]
21458,313850,Infantile cerebellar-retinal degeneration,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22405087[PMID]_25351951[PMID]
21457,313846,Familial cutaneous telangiectasia and oropharyngeal cancer predisposition syndrome,Disease,Disorder,Cases/families,Case(s),,24.0,Worldwide,Validated,22341969[PMID]
21457,313846,Familial cutaneous telangiectasia and oropharyngeal cancer predisposition syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21456,313838,Coats plus syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
21452,313800,Retinal dystrophy-optic nerve edema-splenomegaly-anhidrosis-migraine headache syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,22307799[PMID]
21452,313800,Retinal dystrophy-optic nerve edema-splenomegaly-anhidrosis-migraine headache syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21453,313808,Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia,Disease,Disorder,Cases/families,Case(s),,27.0,Worldwide,Validated,22197934[PMID]_10668715[PMID]
21453,313808,Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21450,313781,20p13 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,22274139[PMID]_23165892[PMID]
21450,313781,20p13 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21451,313795,Jawad syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,21998596[PMID]_8434622[PMID]
21451,313795,Jawad syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21998596[PMID]_8434622[PMID]
21449,313772,Early-onset spastic ataxia-myoclonic epilepsy-neuropathy syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,22022284[PMID]
21449,313772,Early-onset spastic ataxia-myoclonic epilepsy-neuropathy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22022284[PMID]
21501,314603,Autosomal recessive spastic ataxia with leukoencephalopathy,Disease,Disorder,Cases/families,Case(s),,54.0,Worldwide,Validated,22448145[PMID]
21501,314603,Autosomal recessive spastic ataxia with leukoencephalopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22448145[PMID]
21500,314597,Chudley-McCullough syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,25.0,Worldwide,Validated,ORPHANET
21500,314597,Chudley-McCullough syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21502,314613,Growing teratoma syndrome,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21497,314575,Intellectual disability-hypotonia-brachycephaly-pyloric stenosis-cryptorchidism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,22611637[PMID]
21497,314575,Intellectual disability-hypotonia-brachycephaly-pyloric stenosis-cryptorchidism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21496,314572,Autosomal recessive leukoencephalopathy-ischemic stroke-retinitis pigmentosa syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,22436252[PMID]
21496,314572,Autosomal recessive leukoencephalopathy-ischemic stroke-retinitis pigmentosa syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21499,314588,Distal triplication 15q syndrome,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,23.0,Worldwide,Validated,24793337[PMID]
21499,314588,Distal triplication 15q syndrome,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24793337[PMID]
21498,314585,15q overgrowth syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,19133692[PMID]
21498,314585,15q overgrowth syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21492,314485,Young adult-onset distal hereditary motor neuropathy,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,22522442[PMID]
21492,314485,Young adult-onset distal hereditary motor neuropathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21495,314566,Primary progressive apraxia of speech,Disease,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,22382356[PMID]_23078273[PMID]
21495,314566,Primary progressive apraxia of speech,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21494,314555,Facial dysmorphism-ocular anomalies-osteopenia-intellectual disability-dental anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,22581230[PMID]
21494,314555,Facial dysmorphism-ocular anomalies-osteopenia-intellectual disability-dental anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21489,314466,Atypical Meigs syndrome,Clinical syndrome,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,7112481[PMID]_9336761[PMID]_12632574[PMID]_12087934[PMID]_15739106[PMID]
21489,314466,Atypical Meigs syndrome,Clinical syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21488,314459,Pseudo-Meigs syndrome,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21491,314478,Ovarian fibrothecoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21490,314473,Ovarian fibroma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21484,314422,Ameloblastic carcinoma,Disease,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,22493395[PMID]_19674470[PMID]_23251064[PMID]_23099227[PMID]
21484,314422,Ameloblastic carcinoma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21486,314432,Spigelian hernia-cryptorchidism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,20680633[PMID]
21486,314432,Spigelian hernia-cryptorchidism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21487,314451,Meigs syndrome,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21480,314394,Short stature-onychodysplasia-facial dysmorphism-hypotrichosis syndrome,Disease,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,22440536[PMID]_22840364[PMID]_22840363[PMID]
21480,314394,Short stature-onychodysplasia-facial dysmorphism-hypotrichosis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21481,314399,Autosomal dominant aplasia and myelodysplasia,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,22541560[PMID]
21481,314399,Autosomal dominant aplasia and myelodysplasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22541560[PMID]
21482,314404,Autosomal dominant cerebellar ataxia-deafness-narcolepsy syndrome,Disease,Disorder,Cases/families,Case(s),,80.0,Worldwide,Validated,EXPERT
21482,314404,Autosomal dominant cerebellar ataxia-deafness-narcolepsy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22328086[PMID]_23904686[PMID]
21483,314419,Ameloblastoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21476,314373,Chronic infantile diarrhea due to guanylate cyclase 2C overactivity,Disease,Disorder,Cases/families,Case(s),,32.0,Worldwide,Validated,22436048[PMID]
21476,314373,Chronic infantile diarrhea due to guanylate cyclase 2C overactivity,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21477,314376,Intestinal obstruction in the newborn due to guanylate cyclase 2C deficiency,Disease,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,22521417[PMID]_25370039[PMID]
21477,314376,Intestinal obstruction in the newborn due to guanylate cyclase 2C deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22521417[PMID]_25370039[PMID]
21478,314381,Hereditary sensory and autonomic neuropathy type 6,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,22522446[PMID]
21478,314381,Hereditary sensory and autonomic neuropathy type 6,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21479,314389,Xq12-q13.3 duplication syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,22213401[PMID]
21479,314389,Xq12-q13.3 duplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21472,314034,7p22.1 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26297194[PMID]
21472,314034,7p22.1 microduplication syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,26297194[PMID]
21474,314041,Marfanoid habitus-inguinal hernia-advanced bone age syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,22489068[PMID]
21474,314041,Marfanoid habitus-inguinal hernia-advanced bone age syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21475,314051,Leukoencephalopathy-thalamus and brainstem anomalies-high lactate syndrome,Disease,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,22492562[PMID]_23008233[PMID]_25854774[PMID]
21475,314051,Leukoencephalopathy-thalamus and brainstem anomalies-high lactate syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22492562[PMID]_23008233[PMID]_25854774[PMID]
21249,306674,Kufor-Rakeb syndrome,Disease,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,20853184[PMID]_21094623[PMID]_DOI: 10.1002/mdc3.12175[OTHER]
21249,306674,Kufor-Rakeb syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20853184[PMID]_21094623[PMID]
21248,306669,Hemiparkinsonism-hemiatrophy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23986429[PMID]
21248,306669,Hemiparkinsonism-hemiatrophy syndrome,Disease,Disorder,Cases/families,Case(s),,68.0,Worldwide,Validated,23986429[PMID]
21262,306741,Hemidystonia-hemiatrophy syndrome,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,[EXPERT]_ORPHANET
21262,306741,Hemidystonia-hemiatrophy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,[EXPERT]_ORPHANET
21261,306734,"Primary dystonia, DYT21 type",Disease,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,21301909[PMID]
21261,306734,"Primary dystonia, DYT21 type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21301909[PMID]
21260,306731,Sydenham chorea,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21301,308166,Erythrokeratoderma variabilis progressiva,Clinical group,Group of disorders,Point prevalence,Value and class,<1 / 1 000 000,0.046,France,Validated,24393603[PMID]_[EXPERT]
21306,308386,Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,ORPHANET_European Medicines Agency 2010[INST]
21310,308410,Autism-epilepsy syndrome due to branched chain ketoacid dehydrogenase kinase deficiency,Disease,Disorder,Cases/families,Family(ies),,5.0,Worldwide,Validated,24449431[PMID]
21310,308410,Autism-epilepsy syndrome due to branched chain ketoacid dehydrogenase kinase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,24449431[PMID]
21311,308425,Methylmalonic acidemia due to methylmalonyl-CoA epimerase deficiency,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,27699154[PMID]
21311,308425,Methylmalonic acidemia due to methylmalonyl-CoA epimerase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27699154[PMID]
21283,307766,Curly hair-acral keratoderma-caries syndrome,Disease,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,11453928[PMID]
21283,307766,Curly hair-acral keratoderma-caries syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11453928[PMID]
21289,307936,Hypotrichosis-osteolysis-periodontitis-palmoplantar keratoderma syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12207605[PMID]
21289,307936,Hypotrichosis-osteolysis-periodontitis-palmoplantar keratoderma syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,12207605[PMID]
21342,309111,Combined pancreatic lipase-colipase deficiency,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,2265786[PMID]
21342,309111,Combined pancreatic lipase-colipase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2265786[PMID]
21340,309031,Pancreatic triacylglycerol lipase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
21340,309031,Pancreatic triacylglycerol lipase deficiency,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
21341,309108,Pancreatic colipase deficiency,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,7068048[PMID]
21341,309108,Pancreatic colipase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7068048[PMID]
21338,309025,Mevalonate kinase deficiency,Disease,Disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,27142780[PMID]
21338,309025,Mevalonate kinase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_27142780[PMID]
21336,309015,Familial lipoprotein lipase deficiency,Etiological subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,United States,Validated,20301485[PMID]
21336,309015,Familial lipoprotein lipase deficiency,Etiological subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
21337,309020,Familial apolipoprotein C-II deficiency,Etiological subtype,Subtype of disorder,Cases/families,Family(ies),,10.0,Worldwide,Validated,25732519[PMID]
21337,309020,Familial apolipoprotein C-II deficiency,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25732519[PMID]
6023,178,Chordoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.06,United States,Validated,22300861[PMID]_ ORPHANET_[EXPERT]
6020,2637,Microcephalic osteodysplastic primordial dwarfism type II,Malformation syndrome,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,23498563[PMID]
6020,2637,Microcephalic osteodysplastic primordial dwarfism type II,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
6021,592,Macrophagic myofasciitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21321,308552,"Glycogen storage disease due to acid maltase deficiency, infantile onset",Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.0,"Taiwan, Province of China",Validated,18519449[PMID]_24243590[PMID]
21321,308552,"Glycogen storage disease due to acid maltase deficiency, infantile onset",Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.72,Netherlands,Validated,10482961[PMID]
21321,308552,"Glycogen storage disease due to acid maltase deficiency, infantile onset",Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
21364,309271,"Metachromatic leukodystrophy, adult form",Clinical subtype,Subtype of disorder,Prevalence at birth,Class only,1-9 / 1 000 000,0.0,Worldwide,Not yet validated,ORPHANET
21364,309271,"Metachromatic leukodystrophy, adult form",Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21360,309246,"GM2 gangliosidosis, AB variant",Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,26082327[PMID]
21360,309246,"GM2 gangliosidosis, AB variant",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26082327[PMID]
21362,309256,"Metachromatic leukodystrophy, late infantile form",Clinical subtype,Subtype of disorder,Prevalence at birth,Class only,1-9 / 1 000 000,0.0,Worldwide,Not yet validated,ORPHANET_24001781[PMID]
21362,309256,"Metachromatic leukodystrophy, late infantile form",Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21363,309263,"Metachromatic leukodystrophy, juvenile form",Clinical subtype,Subtype of disorder,Prevalence at birth,Class only,1-9 / 1 000 000,0.0,Worldwide,Not yet validated,ORPHANET
21363,309263,"Metachromatic leukodystrophy, juvenile form",Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21372,309324,"Free sialic acid storage disease, infantile form",Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21372,309324,"Free sialic acid storage disease, infantile form",Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.14,Sweden,Validated,25274184[PMID]
21374,309334,Salla disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,16584062[PMID]_ORPHANET
21374,309334,Salla disease,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.59,Sweden,Validated,25274184[PMID]
21368,309294,Sialidosis,Clinical group,Group of disorders,Prevalence at birth,Value and class,<1 / 1 000 000,0.05,Netherlands,Validated,10480370[PMID]
21368,309294,Sialidosis,Clinical group,Group of disorders,Prevalence at birth,Value and class,<1 / 1 000 000,0.02,Australia,Validated,9918480[PMID]
21368,309294,Sialidosis,Clinical group,Group of disorders,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,ORPHANET
21368,309294,Sialidosis,Clinical group,Group of disorders,Prevalence at birth,Value and class,<1 / 1 000 000,0.05,Europe,Validated,10480370[PMID]
21368,309294,Sialidosis,Clinical group,Group of disorders,Prevalence at birth,Value and class,<1 / 1 000 000,0.07,Czech Republic,Validated,20490927[PMID]
21368,309294,Sialidosis,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 1 000 000,0.1,Sweden,Validated,25274184[PMID]
21369,309297,Mucopolysaccharidosis type 4A,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-5 / 10 000,15.0,Europe,Validated,European Medicines Agency 2009[INST]
21369,309297,Mucopolysaccharidosis type 4A,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.15,Canada,Validated,25404155[PMID]
21369,309297,Mucopolysaccharidosis type 4A,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.38,Germany,Validated,16435194[PMID]_25404155[PMID]
21369,309297,Mucopolysaccharidosis type 4A,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.12,Germany,Validated,25404155[PMID]
21369,309297,Mucopolysaccharidosis type 4A,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.4,United Arab Emirates,Validated,23430803[PMID]_25404155[PMID]
21369,309297,Mucopolysaccharidosis type 4A,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.46,United Arab Emirates,Validated,25404155[PMID]
21369,309297,Mucopolysaccharidosis type 4A,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.497,Australia,Validated,9918480[PMID]_25404155[PMID]
21369,309297,Mucopolysaccharidosis type 4A,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.153,Australia,Validated,25404155[PMID]
21369,309297,Mucopolysaccharidosis type 4A,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.48,Canada,Validated,10617747[PMID]_25404155[PMID]
21369,309297,Mucopolysaccharidosis type 4A,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.29,Sweden,Validated,25274184[PMID]
21369,309297,Mucopolysaccharidosis type 4A,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.029,United States,Validated,34051828[PMID]
21369,309297,Mucopolysaccharidosis type 4A,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.11,United States,Validated,34051828[PMID]
21369,309297,Mucopolysaccharidosis type 4A,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.0848,Brazil,Validated,35209917[PMID]
21370,309310,Mucopolysaccharidosis type 4B,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.001,United States,Validated,34051828[PMID]
21370,309310,Mucopolysaccharidosis type 4B,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.004,United States,Validated,34051828[PMID]
21351,309147,Hyper-beta-alaninemia,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,17926374[PMID]_7936305[PMID]_ORPHANET
21351,309147,Hyper-beta-alaninemia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17926374[PMID]_7936305[PMID]
21352,309152,GM2 gangliosidosis,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 1 000 000,0.87,Sweden,Validated,25274184[PMID]
21352,309152,GM2 gangliosidosis,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,5.0,Europe,Validated,European Medecines Agency 2017[INST]
21128,300547,Autosomal recessive infantile hypercalcemia,Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,ORPHANET
21128,300547,Autosomal recessive infantile hypercalcemia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21129,300552,Follicular cholangitis and pancreatitis,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,22211284[PMID]
21129,300552,Follicular cholangitis and pancreatitis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21130,300557,Carcinoma of the ampulla of Vater,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.59,France,Validated,10656214[PMID]
21130,300557,Carcinoma of the ampulla of Vater,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
21130,300557,Carcinoma of the ampulla of Vater,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.57,United Kingdom,Validated,3664230[PMID]
21131,300564,Combined pulmonary fibrosis-emphysema syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21132,300570,Cortical dysgenesis with pontocerebellar hypoplasia due to TUBB3 mutation,Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,20829227[PMID]
21132,300570,Cortical dysgenesis with pontocerebellar hypoplasia due to TUBB3 mutation,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21133,300573,Polymicrogyria due to TUBB2B mutation,Malformation syndrome,Disorder,Cases/families,Case(s),,36.0,Worldwide,Validated,19465910[PMID]_17036343[PMID]
21133,300573,Polymicrogyria due to TUBB2B mutation,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21134,300576,Oligodontia-cancer predisposition syndrome,Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,15042511[PMID]_21416598[PMID]
21134,300576,Oligodontia-cancer predisposition syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21120,300496,Multiple congenital anomalies-hypotonia-seizures syndrome type 2,Malformation syndrome,Disorder,Cases/families,Case(s),,24.0,Worldwide,Validated,16783569[PMID]_22305531[PMID]_24357517[PMID]_24259288[PMID]_24259184[PMID]_24706016[PMID]_26545172[PMID]
21120,300496,Multiple congenital anomalies-hypotonia-seizures syndrome type 2,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26545172[PMID]
21121,300501,Painful orbital and systemic neurofibromas-marfanoid habitus syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,22258529[PMID]
21121,300501,Painful orbital and systemic neurofibromas-marfanoid habitus syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21122,300504,Onychocytic matricoma,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,22197859[PMID]
21122,300504,Onychocytic matricoma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21123,300512,Onychomatricoma,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,21965578[PMID]
21123,300512,Onychomatricoma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21125,300525,Pseudohypoaldosteronism type 2D,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,24.0,Worldwide,Validated,22266938[PMID]
21125,300525,Pseudohypoaldosteronism type 2D,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21126,300530,Pseudohypoaldosteronism type 2E,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,22266938[PMID]
21126,300530,Pseudohypoaldosteronism type 2E,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21127,300536,DDOST-CDG,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,22305527[PMID]
21127,300536,DDOST-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22305527[PMID]
21147,300865,Primary cutaneous anaplastic large cell lymphoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
21146,300857,T-cell/histiocyte rich large B cell lymphoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.023,United States,Validated,29845599[PMID]
21149,300878,Hairy cell leukemia variant,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.22,United States,Validated,[EXPERT]_ORPHANET
21149,300878,Hairy cell leukemia variant,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21151,300895,ALK-positive anaplastic large cell lymphoma,Histopathological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
21137,300605,Juvenile amyotrophic lateral sclerosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,ORPHANET
21139,300755,Laminopathy with striated muscle involvement,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21138,300751,Familial dilated cardiomyopathy with conduction defect due to LMNA mutation,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21141,300763,Laminopathy with lipodystrophy,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21140,300758,Laminopathy with peripheral neuropathy,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21143,300842,Indolent B-cell non-Hodgkin lymphoma,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21142,300766,Laminopathy with premature aging,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21152,300903,ALK-negative anaplastic large cell lymphoma,Histopathological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21153,300912,Marginal zone lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.8,France,Validated,Institut National du Cancer 2013[INST]
21153,300912,Marginal zone lymphoma,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,7.0,Europe,Validated,European Medicines Agency 2015[INST]
21153,300912,Marginal zone lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.3,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21212,306431,Adult-onset immunodeficiency with anti-interferon-gamma autoantibodies,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21230,306550,FADD-related immunodeficiency,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,21109225[PMID]
21230,306550,FADD-related immunodeficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21109225[PMID]
21231,306553,Myospherulosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21228,306542,Frontonasal dysplasia-severe microphthalmia-severe facial clefting syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,20451171[PMID]
21228,306542,Frontonasal dysplasia-severe microphthalmia-severe facial clefting syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21229,306547,Porencephaly-microcephaly-bilateral congenital cataract syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,21109224[PMID]
21229,306547,Porencephaly-microcephaly-bilateral congenital cataract syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21226,306530,Congenital hereditary facial paralysis-variable hearing loss syndrome,Morphological anomaly,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,3775291[PMID]_22770981[PMID]
21226,306530,Congenital hereditary facial paralysis-variable hearing loss syndrome,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3775291[PMID]_22770981[PMID]
21225,306527,Isolated hereditary congenital facial paralysis,Morphological anomaly,Disorder,Cases/families,Family(ies),,8.0,Worldwide,Validated,ORPHANET
21225,306527,Isolated hereditary congenital facial paralysis,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21222,306516,Primary hypomagnesemia with hypercalciuria and nephrocalcinosis,Disease,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,23334384[PMID]
21222,306516,Primary hypomagnesemia with hypercalciuria and nephrocalcinosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
21221,306511,Autosomal recessive spastic paraplegia type 48,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,20613862[PMID]
21221,306511,Autosomal recessive spastic paraplegia type 48,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21218,306498,PTEN hamartoma tumor syndrome,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21219,306504,Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,22512483[PMID]
21219,306504,Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22512483[PMID]
21243,306644,Complication after organ transplantation,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,9.0,Europe,Validated,European Medicines Agency 2013[INST]
21236,306577,Hereditary sodium channelopathy-related small fibers neuropathy,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,21698661[PMID]
21236,306577,Hereditary sodium channelopathy-related small fibers neuropathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21232,306558,Primary microcephaly-epilepsy-permanent neonatal diabetes syndrome,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,28711742[PMID]
21232,306558,Primary microcephaly-epilepsy-permanent neonatal diabetes syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28711742[PMID]
21080,298644,Disorder of thiamine metabolism and transport,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21100,300179,Kyphoscoliotic Ehlers-Danlos syndrome due to FKBP22 deficiency,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,27149304[PMID]
21100,300179,Kyphoscoliotic Ehlers-Danlos syndrome due to FKBP22 deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27149304[PMID]
21110,300319,Charcot-Marie-Tooth disease type 2P,Disease,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,22781092[PMID]
21110,300319,Charcot-Marie-Tooth disease type 2P,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21111,300324,Persistent polyclonal B-cell lymphocytosis,Disease,Disorder,Cases/families,Case(s),,154.0,Worldwide,Validated,18668130[PMID]_21396665[PMID]_2785931[PMID]_7934138[PMID]_11552996[PMID]
21111,300324,Persistent polyclonal B-cell lymphocytosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
21109,300313,Congenital cataract-hearing loss-severe developmental delay syndrome,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,15902551[PMID]_22243965[PMID]
21109,300313,Congenital cataract-hearing loss-severe developmental delay syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15902551[PMID]_22243965[PMID]
21106,300298,Severe congenital hypochromic anemia with ringed sideroblasts,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,22031863[PMID]
21106,300298,Severe congenital hypochromic anemia with ringed sideroblasts,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21107,300305,11p15.4 microduplication syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,22052655[PMID]
21107,300305,11p15.4 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21104,300284,Connective tissue disorder due to lysyl hydroxylase-3 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18834968[PMID]
21104,300284,Connective tissue disorder due to lysyl hydroxylase-3 deficiency,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,18834968[PMID]
21105,300293,Transient infantile hypertriglyceridemia and hepatosteatosis,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,22226083[PMID]_24549054[PMID]
21105,300293,Transient infantile hypertriglyceridemia and hepatosteatosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22226083[PMID]_24549054[PMID]
21118,300385,Pituitary carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.04,Europe,Validated,22361014[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
21118,300385,Pituitary carcinoma,Disease,Disorder,Lifetime Prevalence,Value and class,1-9 / 1 000 000,0.87,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
21118,300385,Pituitary carcinoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
21118,300385,Pituitary carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.026,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21118,300385,Pituitary carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.041,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21118,300385,Pituitary carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.014,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21118,300385,Pituitary carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.037,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21118,300385,Pituitary carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.009,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21118,300385,Pituitary carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.019,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21118,300385,Pituitary carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.033,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21118,300385,Pituitary carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.099,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21118,300385,Pituitary carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.052,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21118,300385,Pituitary carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.016,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21118,300385,Pituitary carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.025,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21118,300385,Pituitary carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.063,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21118,300385,Pituitary carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.025,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21118,300385,Pituitary carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.008,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21118,300385,Pituitary carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.021,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21118,300385,Pituitary carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21118,300385,Pituitary carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.021,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21118,300385,Pituitary carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21118,300385,Pituitary carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.015,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21118,300385,Pituitary carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.036,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21118,300385,Pituitary carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.135,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21118,300385,Pituitary carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.213,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21118,300385,Pituitary carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.171,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
21119,300493,Sagliker syndrome,Particular clinical situation in a disease or syndrome,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,22200434[PMID]
21119,300493,Sagliker syndrome,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21116,300373,X-linked acrogigantism,Disease,Disorder,Cases/families,Case(s),,33.0,Worldwide,Validated,29389097[PMID]
21116,300373,X-linked acrogigantism,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
21117,300382,Progeroid and marfanoid aspect-lipodystrophy syndrome,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,24613577[PMID]_24665001[PMID]
21117,300382,Progeroid and marfanoid aspect-lipodystrophy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21114,300345,Autosomal systemic lupus erythematosus,Disease,Disorder,Cases/families,Family(ies),,7.0,Worldwide,Validated,22019780[PMID]
21114,300345,Autosomal systemic lupus erythematosus,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21115,300359,PLCG2-associated antibody deficiency and immune dysregulation,Disease,Disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,22236196[PMID]
21115,300359,PLCG2-associated antibody deficiency and immune dysregulation,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
21112,300333,Nephrotic syndrome-epidermolysis bullosa-sensorineural deafness syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,15265795[PMID]
21112,300333,Nephrotic syndrome-epidermolysis bullosa-sensorineural deafness syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15265795[PMID]
24040,464724,Fever-associated acute infantile liver failure syndrome,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,26073778[PMID]
24040,464724,Fever-associated acute infantile liver failure syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26073778[PMID]
24042,464738,Basel-Vanagaite-Smirin-Yosef syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,PMID: 25792360
24042,464738,Basel-Vanagaite-Smirin-Yosef syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25792360[PMID]
24049,464760,Familial cavitary optic disc anomaly,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25581579[PMID]
24049,464760,Familial cavitary optic disc anomaly,Morphological anomaly,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,25581579[PMID]
24048,464756,Familial gastric type 1 neuroendocrine tumor,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,25678551[PMID]
24048,464756,Familial gastric type 1 neuroendocrine tumor,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25678551[PMID]
24056,465508,Symptomatic form of HFE-related hemochromatosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
24010,464282,Spastic paraplegia-severe developmental delay-epilepsy syndrome,Disease,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,26424145[PMID]_26437029[PMID]
24010,464282,Spastic paraplegia-severe developmental delay-epilepsy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26424145[PMID]_26437029[PMID]
24011,464288,Short stature-brachydactyly-obesity-global developmental delay syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,26437029[PMID]
24011,464288,Short stature-brachydactyly-obesity-global developmental delay syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26437029[PMID]
24015,464306,DYRK1A-related intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,54.0,Worldwide,Validated,26922654[PMID]
24015,464306,DYRK1A-related intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26922654[PMID]
24019,464329,Kaposiform lymphangiomatosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_27053281[PMID]
24018,464321,Multifocal lymphangioendotheliomatosis-thrombocytopenia syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_26148948[PMID]
24017,464318,Verrucous hemangioma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_25263605[PMID]
24016,464311,Intellectual disability syndrome due to a DYRK1A point mutation,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,35.0,Worldwide,Validated,26922654[PMID]
24016,464311,Intellectual disability syndrome due to a DYRK1A point mutation,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26922654[PMID]
24023,464366,NEK9-related lethal skeletal dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,26908619[PMID]
24023,464366,NEK9-related lethal skeletal dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26908619[PMID]
24022,464359,Benign metanephric tumor,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_26870216[PMID]_27227914[PMID]
24021,464343,Catastrophic antiphospholipid syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_27375916[PMID]
24020,464336,BENTA disease,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,25930198[PMID]
24020,464336,BENTA disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25930198[PMID]
24027,464453,Acquired methemoglobinemia,Disease,Disorder,Cases/families,Case(s),,242.0,Worldwide,Validated,15342970[PMID]_19224791[PMID]
24027,464453,Acquired methemoglobinemia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_15342970[PMID]_19224791[PMID]
24026,464443,COG6-CGD,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,26260076[PMID]_23430903[PMID]
24026,464443,COG6-CGD,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26260076[PMID]_23430903[PMID]
24025,464440,"Primary dystonia, DYT27 type",Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,26260724[PMID]_26004199[PMID]
24025,464440,"Primary dystonia, DYT27 type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26260724[PMID]_26004199[PMID]
24024,464370,Neonatal alloimmune neutropenia,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,16.6,Poland,Validated,11696231[PMID]
24024,464370,Neonatal alloimmune neutropenia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
24028,464458,Paracetamol poisoning,Particular clinical situation in a disease or syndrome,Disorder,Annual incidence,Value and class,1-5 / 10 000,16.0,Iceland,Validated,22827594[PMID]_15543083[PMID]
24028,464458,Paracetamol poisoning,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
6519,639,Polyneuropathy associated with IgM monoclonal gammopathy with anti-MAG,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
6520,662,Lymphedema with yellow nails,Disease,Disorder,Cases/families,Case(s),,400.0,Worldwide,Validated,28241848[PMID]
6520,662,Lymphedema with yellow nails,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_28241848[PMID]
6522,537,Toxic epidermal necrolysis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
6523,793,SAPHO syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
23675,456298,1p35.2 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,25900906[PMID]
23675,456298,1p35.2 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25900906[PMID]
23678,456328,X-linked myotubular myopathy-abnormal genitalia syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,10449925[PMID]
23678,456328,X-linked myotubular myopathy-abnormal genitalia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10449925[PMID]
23676,456312,Infantile multisystem neurologic-endocrine-pancreatic disease,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,25574476[PMID]
23676,456312,Infantile multisystem neurologic-endocrine-pancreatic disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25574476[PMID]
23677,456318,Hereditary sensory neuropathy-deafness-dementia syndrome,Disease,Disorder,Cases/families,Family(ies),,6.0,Worldwide,Validated,23365052[PMID]
23677,456318,Hereditary sensory neuropathy-deafness-dementia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23365052[PMID]
23664,454831,Acute radiation syndrome,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,European Medicines Agency 2018[INST]
23665,454836,Avian influenza,Disease,Disorder,Cases/families,Case(s),,826.0,Worldwide,Validated,World Health Organization 2015[INST]
23665,454836,Avian influenza,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
23665,454836,Avian influenza,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,ORPHANET_World Health Organization 2015[INST]
23668,454887,Corticobasal syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
23658,454723,Endometrioid carcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.51,"Korea, Republic of",Validated,26463436[PMID]
23658,454723,Endometrioid carcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.81,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23657,454718,Holmes-Adie syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.7,United States,Validated,613531[PMID]
23657,454718,Holmes-Adie syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
23656,454714,Plasma cell leukemia,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.04,Europe,Validated,20664057[PMID]
23663,454821,OBSOLETE: Pleomorphic salivary gland adenoma,Histopathological subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 100 000,2.725,Worldwide,Validated,World Health Organization 2005[INST]
23661,454750,Isolated tracheoesophageal fistula,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.2,Australia,Validated,25976171[PMID]
23661,454750,Isolated tracheoesophageal fistula,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.2,Worldwide,Validated,22945024[PMID]
23661,454750,Isolated tracheoesophageal fistula,Morphological anomaly,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.2,Worldwide,Validated,22945024[PMID]_ORPHANET
23661,454750,Isolated tracheoesophageal fistula,Morphological anomaly,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.2,Australia,Validated,25976171[PMID]_ORPHANET
23660,454745,Kuru,Disease,Disorder,Cases/families,Case(s),,2700.0,Worldwide,Validated,PMID: 16798390
23660,454745,Kuru,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET & PMID: 16798390
23649,453533,Polyendocrine-polyneuropathy syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,25248098[PMID]
23649,453533,Polyendocrine-polyneuropathy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25248098[PMID]
23648,453521,Autosomal recessive cerebellar ataxia due to CWF19L1 deficiency,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,15981765[PMID]
23648,453521,Autosomal recessive cerebellar ataxia due to CWF19L1 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15981765[PMID]
23655,454710,Anti-p200 pemphigoid,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,24767733[PMID]
23655,454710,Anti-p200 pemphigoid,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24767733[PMID]
23653,454700,Acquired Creutzfeldt-Jakob disease,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
23641,451602,Primary cutaneous plasmacytosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
23642,451607,Cutaneous pseudolymphoma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27057027[PMID]
23642,451607,Cutaneous pseudolymphoma,Disease,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,27057027[PMID]
23643,451612,Familial congenital nasolacrimal duct obstruction,Morphological anomaly,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,24372406[PMID]
23643,451612,Familial congenital nasolacrimal duct obstruction,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24372406[PMID]
23645,453499,Neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-skeletal anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,25.0,Worldwide,Validated,29904177[PMID]_30998304[PMID]
23645,453499,Neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-skeletal anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30998304[PMID]
23646,453504,Neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-skeletal anomalies syndrome due to a point mutation,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,29904177[PMID]
23646,453504,Neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-skeletal anomalies syndrome due to a point mutation,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29904177[PMID]
23647,453510,Congenital insensitivity to pain with severe intellectual disability,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,26068709[PMID]
23647,453510,Congenital insensitivity to pain with severe intellectual disability,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26068709[PMID]
23635,450322,Polyclonal hyperviscosity syndrome,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
23625,449566,Eosinophilic angiocentric fibrosis,Disease,Disorder,Cases/families,Case(s),,52.0,Worldwide,Validated,26674883[PMID]
23625,449566,Eosinophilic angiocentric fibrosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26674883[PMID]
23624,449563,IgG4-related ophthalmic disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_24513111[PMID]
23616,449291,Symptomatic form of fragile X syndrome in female carriers,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_19642710[PMID]
23619,449400,IgG4-related aortitis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_21124083[PMID]
23618,449395,IgG4-related kidney disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_26666884[PMID]
23623,449432,IgG4-related submandibular gland disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_24844187[PMID]
23622,449427,IgG4-related pachymeningitis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_24733677[PMID]
23614,449280,Scedosporiosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Australia,Validated,19549223[PMID]
23614,449280,Scedosporiosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,European Medicines Agency 2014[INST]
23615,449285,Snakebite envenomation,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,European Medicines Agency 2015[INST]
23612,449266,Pleural empyema,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,13.0,Europe,Validated,European Medicines Agency 2014[INST]
23565,448264,Isolated focal non-epidermolytic palmoplantar keratoderma,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,25285920[PMID]
23565,448264,Isolated focal non-epidermolytic palmoplantar keratoderma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25285920[PMID]
23564,448251,Progressive autosomal recessive ataxia-deafness syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3739762[PMID]_25205112[PMID]_3465984[PMID]_2603781[PMID]
23564,448251,Progressive autosomal recessive ataxia-deafness syndrome,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,3739762[PMID]_25205112[PMID]_3465984[PMID]_2603781[PMID]
23567,448270,Ectopia cordis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.67,Worldwide,Validated,20965559[PMID]
23567,448270,Ectopia cordis,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
23566,448267,Regressive spondylometaphyseal dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,25348816[PMID]_23824842[PMID]
23566,448267,Regressive spondylometaphyseal dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25348816[PMID]_23824842[PMID]
23561,448010,CAD-CDG,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,25678555[PMID]
23561,448010,CAD-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25678555[PMID]
23560,447997,Spastic tetraplegia-thin corpus callosum-progressive postnatal microcephaly syndrome,Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,25930971[PMID]_26041762[PMID]_26138499[PMID]
23560,447997,Spastic tetraplegia-thin corpus callosum-progressive postnatal microcephaly syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25930971[PMID]_26041762[PMID]_26138499[PMID]
23563,448242,Autosomal recessive brachyolmia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
23563,448242,Autosomal recessive brachyolmia,Malformation syndrome,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,Dr Gen NISHIMURA[EXPERT]
23562,448237,Zika virus disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
23562,448237,Zika virus disease,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,58.8,Brazil,Validated,World Health Organization 2016[INST]
23557,447977,Progressive scapulohumeroperoneal distal myopathy,Disease,Disorder,Cases/families,Case(s),,33.0,Worldwide,Validated,25938801[PMID]
23557,447977,Progressive scapulohumeroperoneal distal myopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25938801[PMID]
23556,447974,Klippel-Feil anomaly-myopathy-facial dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,25748484[PMID]
23556,447974,Klippel-Feil anomaly-myopathy-facial dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25748484[PMID]
23558,447980,19p13.3 microduplication syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,25858326[PMID]
23558,447980,19p13.3 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25858326[PMID]
23553,447954,Combined oxidative phosphorylation defect type 25,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,25754315[PMID]
23553,447954,Combined oxidative phosphorylation defect type 25,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25754315[PMID]
23555,447964,Autosomal dominant Charcot-Marie-Tooth disease type 2V,Disease,Disorder,Cases/families,Case(s),,21.0,Worldwide,Validated,25818867[PMID]
23555,447964,Autosomal dominant Charcot-Marie-Tooth disease type 2V,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25818867[PMID]
23554,447961,Pigmentation defects-palmoplantar keratoderma-skin carcinoma syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,25315659[PMID]
23554,447961,Pigmentation defects-palmoplantar keratoderma-skin carcinoma syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25315659[PMID]
23767,459033,Ataxia-oculomotor apraxia type 4,Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,25728773[PMID]_27066586[PMID]
23767,459033,Ataxia-oculomotor apraxia type 4,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25728773[PMID]_27066586[PMID]
23769,459051,"Spondyloepiphyseal dysplasia, Stanescu type",Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,6430256[PMID]_26183434[PMID]_9592900[PMID]
23769,459051,"Spondyloepiphyseal dysplasia, Stanescu type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6430256[PMID]_26183434[PMID]_9592900[PMID]
23771,459061,Craniofacial dysplasia-short stature-ectodermal anomalies-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,26220823[PMID]
23771,459061,Craniofacial dysplasia-short stature-ectodermal anomalies-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26220823[PMID]
23770,459056,Autosomal recessive spastic paraplegia type 75,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,24482476[PMID]_26179919[PMID]
23770,459056,Autosomal recessive spastic paraplegia type 75,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24482476[PMID]_26179919[PMID]
23773,459074,Corpus callosum agenesis-macrocephaly-hypertelorism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,25944787[PMID]
23773,459074,Corpus callosum agenesis-macrocephaly-hypertelorism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25944787[PMID]
23772,459070,X-linked intellectual disability-cerebellar hypoplasia-spondylo-epiphyseal dysplasia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,26290468[PMID]
23772,459070,X-linked intellectual disability-cerebellar hypoplasia-spondylo-epiphyseal dysplasia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26290468[PMID]
23749,458718,Idiopathic spontaneous coronary artery dissection,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
23750,458758,Composite hemangioendothelioma,Disease,Disorder,Cases/families,Case(s),,39.0,Worldwide,Validated,25666464[PMID]
23750,458758,Composite hemangioendothelioma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25666464[PMID]
23751,458763,Retiform hemangioendothelioma,Disease,Disorder,Cases/families,Case(s),,32.0,Worldwide,Validated,25812740[PMID]
23751,458763,Retiform hemangioendothelioma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25812740[PMID]
23752,458768,Papillary intralymphatic angioendothelioma,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,21238627[PMID]
23752,458768,Papillary intralymphatic angioendothelioma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21238627[PMID]
23756,458798,Spinocerebellar ataxia type 41,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,25477146[PMID]
23756,458798,Spinocerebellar ataxia type 41,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25477146[PMID]
23757,458803,Spinocerebellar ataxia type 42,Disease,Disorder,Cases/families,Case(s),,25.0,Worldwide,Validated,26456284[PMID]_26715324[PMID]
23757,458803,Spinocerebellar ataxia type 42,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26456284[PMID]_26715324[PMID]
23733,457485,Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,27753196[PMID]_DOI:10.4137/JGE.S12583[OTHER]_25851998[PMID]_26542245[PMID]
23733,457485,Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27753196[PMID]_DOI:10.4137/JGE.S12583[OTHER]_25851998[PMID]_26542245[PMID]
23718,457265,Progressive myoclonic epilepsy type 9,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,25954030[PMID]
23718,457265,Progressive myoclonic epilepsy type 9,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25954030[PMID]
23719,457279,Intellectual disability-macrocephaly-hypotonia-behavioral abnormalities syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,26168268[PMID]
23719,457279,Intellectual disability-macrocephaly-hypotonia-behavioral abnormalities syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26168268[PMID]
23717,457260,X-linked intellectual disability-hypotonia-movement disorder syndrome,Disease,Disorder,Cases/families,Case(s),,38.0,Worldwide,Validated,26235985[PMID]
23717,457260,X-linked intellectual disability-hypotonia-movement disorder syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26235985[PMID]
23714,457240,X-linked intellectual disability-short stature-overweight syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,26166480[PMID]
23714,457240,X-linked intellectual disability-short stature-overweight syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26166480[PMID]
23726,457395,Progressive spondyloepimetaphyseal dysplasia-short stature-short fourth metatarsals-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,26365341[PMID]
23726,457395,Progressive spondyloepimetaphyseal dysplasia-short stature-short fourth metatarsals-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26365341[PMID]
23727,457406,Multiple mitochondrial dysfunctions syndrome type 4,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,25539947[PMID]
23727,457406,Multiple mitochondrial dysfunctions syndrome type 4,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25539947[PMID]
23724,457375,ITPA-related lethal infantile neurological disorder with cataract and cardiac involvement,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,26224535[PMID]
23724,457375,ITPA-related lethal infantile neurological disorder with cataract and cardiac involvement,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26224535[PMID]
23725,457378,Complex lethal osteochondrodysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,26365339[PMID]
23725,457378,Complex lethal osteochondrodysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26365339[PMID]
23722,457359,Megalencephaly-severe kyphoscoliosis-overgrowth syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,26138117[PMID]
23722,457359,Megalencephaly-severe kyphoscoliosis-overgrowth syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26138117[PMID]
23723,457365,Intellectual disability-muscle weakness-short stature-facial dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,26192890[PMID]
23723,457365,Intellectual disability-muscle weakness-short stature-facial dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26192890[PMID]
23720,457284,Microcephaly-corpus callosum hypoplasia-intellectual disability-facial dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,25533962[PMID]_26168268[PMID]
23720,457284,Microcephaly-corpus callosum hypoplasia-intellectual disability-facial dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25533962[PMID]_26168268[PMID]
23721,457351,Microcephaly-intellectual disability-sensorineural hearing loss-epilepsy-abnormal muscle tone syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,26299366[PMID]
23721,457351,Microcephaly-intellectual disability-sensorineural hearing loss-epilepsy-abnormal muscle tone syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26299366[PMID]
23703,457185,Neonatal encephalomyopathy-cardiomyopathy-respiratory distress syndrome,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,26185144[PMID]
23703,457185,Neonatal encephalomyopathy-cardiomyopathy-respiratory distress syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26185144[PMID]
23697,457083,Isolated splenogonadal fusion,Morphological anomaly,Disorder,Cases/families,Case(s),,145.0,Worldwide,Validated,15349548[PMID]
23697,457083,Isolated splenogonadal fusion,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_15349548[PMID]
23696,457077,TAFRO syndrome,Disease,Disorder,Cases/families,Case(s),,28.0,Worldwide,Validated,27084250[PMID]
23696,457077,TAFRO syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27084250[PMID]
23699,457095,Actinomycosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_18078685[PMID]
23709,457223,Syndromic sensorineural deafness due to combined oxidative phosphorylation defect,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,25556185[PMID]
23709,457223,Syndromic sensorineural deafness due to combined oxidative phosphorylation defect,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25556185[PMID]
23708,457212,Progressive essential tremor-speech impairment-facial dysmorphism-intellectual disability-abnormal behavior syndrome,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,25704603[PMID]
23708,457212,Progressive essential tremor-speech impairment-facial dysmorphism-intellectual disability-abnormal behavior syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25704603[PMID]
23705,457193,KAT6-related intellectual disability-craniofacial anomalies-cardiac defects syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,76.0,Worldwide,Validated,EXPERT
23705,457193,KAT6-related intellectual disability-craniofacial anomalies-cardiac defects syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25728775[PMID]_25728777[PMID]_27133397[PMID]
23707,457205,Infantile-onset axonal motor and sensory neuropathy-optic atrophy-neurodegenerative syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,25504045[PMID]
23707,457205,Infantile-onset axonal motor and sensory neuropathy-optic atrophy-neurodegenerative syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25504045[PMID]
23680,456369,Polyglucosan body myopathy type 2,Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,25272951[PMID]_26203156[PMID]_26255073[PMID]_26652229[PMID]
23680,456369,Polyglucosan body myopathy type 2,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25272951[PMID]_26203156[PMID]_26255073[PMID]_26652229[PMID]
23691,457050,Autosomal dominant mitochondrial myopathy with exercise intolerance,Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,9324076[PMID]
23691,457050,Autosomal dominant mitochondrial myopathy with exercise intolerance,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9324076[PMID]
7023,317,Erythrokeratodermia variabilis,Disease,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,ORPHANET
7023,317,Erythrokeratodermia variabilis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
7024,629,Short stature due to growth hormone qualitative anomaly,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,263308[PMID]_3965948[PMID]
7024,629,Short stature due to growth hormone qualitative anomaly,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_263308[PMID]_3965948[PMID]
7026,248,Autosomal recessive hypohidrotic ectodermal dysplasia,Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
7027,1810,Autosomal dominant hypohidrotic ectodermal dysplasia,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,9375732[PMID]
7027,1810,Autosomal dominant hypohidrotic ectodermal dysplasia,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
7028,3437,Vogt-Koyanagi-Harada disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
7028,3437,Vogt-Koyanagi-Harada disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.75,United States,Validated,27008848[PMID]
7029,2032,Idiopathic pulmonary fibrosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,16.125,Worldwide,Validated,34233665[PMID]_ORPHANET
7029,2032,Idiopathic pulmonary fibrosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.55,Worldwide,Validated,34233665[PMID]_ORPHANET
7029,2032,Idiopathic pulmonary fibrosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,29.8,Canada,Validated,34233665[PMID]
7029,2032,Idiopathic pulmonary fibrosis,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,15.35,Canada,Validated,34233665[PMID]
7029,2032,Idiopathic pulmonary fibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.6,Finland,Validated,34233665[PMID]
7029,2032,Idiopathic pulmonary fibrosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.3,Finland,Validated,34233665[PMID]
7029,2032,Idiopathic pulmonary fibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.2,France,Validated,34233665[PMID]
7029,2032,Idiopathic pulmonary fibrosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.8,France,Validated,34233665[PMID]
7029,2032,Idiopathic pulmonary fibrosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,21.2,Italy,Validated,34233665[PMID]
7029,2032,Idiopathic pulmonary fibrosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.6,Italy,Validated,34233665[PMID]
7029,2032,Idiopathic pulmonary fibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.9,Japan,Validated,34233665[PMID]
7029,2032,Idiopathic pulmonary fibrosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,37.0,"Korea, Republic of",Validated,34233665[PMID]
7029,2032,Idiopathic pulmonary fibrosis,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,13.0,"Korea, Republic of",Validated,34233665[PMID]
7029,2032,Idiopathic pulmonary fibrosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,11.6,United Kingdom,Validated,34233665[PMID]
7029,2032,Idiopathic pulmonary fibrosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.2,United Kingdom,Validated,34233665[PMID]
7029,2032,Idiopathic pulmonary fibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.7,United States,Validated,34233665[PMID]
7029,2032,Idiopathic pulmonary fibrosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.6,United States,Validated,34233665[PMID]
7030,1303,Bronchiolitis obliterans,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
7032,3348,Tracheobronchopathia osteochondroplastica,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
7032,3348,Tracheobronchopathia osteochondroplastica,Disease,Disorder,Cases/families,Case(s),,400.0,Worldwide,Validated,24865333[PMID]
7033,2902,Idiopathic chronic eosinophilic pneumonia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
7033,2902,Idiopathic chronic eosinophilic pneumonia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.23,Iceland,Validated,17277407[PMID]
7034,1302,Cryptogenic organizing pneumonia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
7034,1302,Cryptogenic organizing pneumonia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.81,Spain,Validated,15127977[PMID]
7034,1302,Cryptogenic organizing pneumonia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.92,Greece,Validated,19345567[PMID]
7034,1302,Cryptogenic organizing pneumonia,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.1,Iceland,Validated,18204109[PMID]
7035,198,Occipital horn syndrome,Disease,Disorder,Cases/families,Case(s),,35.0,Worldwide,Validated,[EXPERT]
7035,198,Occipital horn syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
7036,891,Familial exudative vitreoretinopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
24156,466677,Scorpion envenomation,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_27912864[PMID]
24158,466688,Severe intellectual disability-corpus callosum agenesis-facial dysmorphism-cerebellar ataxia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,25388005[PMID]
24158,466688,Severe intellectual disability-corpus callosum agenesis-facial dysmorphism-cerebellar ataxia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25388005[PMID]
24159,466695,Supratip dysplasia,Morphological anomaly,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,26947355[PMID]
24159,466695,Supratip dysplasia,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26947355[PMID]
24154,466670,Cyanide poisoning,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_7662055[PMID]
24151,466650,Exercise-induced malignant hyperthermia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_22538307[PMID]_23476141[PMID]
24185,466962,SMARCA4-deficient sarcoma of thorax,Disease,Disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,26343384[PMID]
24185,466962,SMARCA4-deficient sarcoma of thorax,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26343384[PMID]
24183,466950,Facial dysmorphism-developmental delay-behavioral abnormalities syndrome due to WAC point mutation,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,27119754[PMID]
24183,466950,Facial dysmorphism-developmental delay-behavioral abnormalities syndrome due to WAC point mutation,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27119754[PMID]
24181,466943,WAC-related facial dysmorphism-developmental delay-behavioral abnormalities syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,27119754[PMID]
24181,466943,WAC-related facial dysmorphism-developmental delay-behavioral abnormalities syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27119754[PMID]
24178,466926,Seizures-scoliosis-macrocephaly syndrome,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,30997052[PMID]
24178,466926,Seizures-scoliosis-macrocephaly syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30997052[PMID]
24179,466934,VPS11-related autosomal recessive hypomyelinating leukodystrophy,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,26307567[PMID]_27119754[PMID]
24179,466934,VPS11-related autosomal recessive hypomyelinating leukodystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26307567[PMID]_27119754[PMID]
24176,466921,Childhood-onset progressive contractures-limb-girdle weakness-muscle dystrophy syndrome,Disease,Disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,26581302[PMID]
24176,466921,Childhood-onset progressive contractures-limb-girdle weakness-muscle dystrophy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26581302[PMID]
24172,466806,Autosomal dominant thrombocytopenia with platelet secretion defect,Disease,Disorder,Cases/families,Family(ies),,4.0,Worldwide,Validated,26280575[PMID]_26769223[PMID]
24172,466806,Autosomal dominant thrombocytopenia with platelet secretion defect,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26280575[PMID]_26769223[PMID]
24170,466794,Acute infantile liver failure-cerebellar ataxia-peripheral sensory motor neuropathy syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,26581903[PMID]
24170,466794,Acute infantile liver failure-cerebellar ataxia-peripheral sensory motor neuropathy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26581903[PMID]
24169,466791,Macrocephaly-intellectual disability-left ventricular non compaction syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,26571461[PMID]_27329731[PMID]_27550220[PMID]
24169,466791,Macrocephaly-intellectual disability-left ventricular non compaction syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26571461[PMID]_27329731[PMID]_27550220[PMID]
24168,466784,Neonatal severe cardiopulmonary failure due to mitochondrial methylation defect,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,26522469[PMID]
24168,466784,Neonatal severe cardiopulmonary failure due to mitochondrial methylation defect,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26522469[PMID]
24167,466775,Autosomal recessive Charcot-Marie-Tooth disease type 2X,Disease,Disorder,Cases/families,Case(s),,29.0,Worldwide,Validated,26556829[PMID]
24167,466775,Autosomal recessive Charcot-Marie-Tooth disease type 2X,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26556829[PMID]
24166,466768,Autosomal dominant Charcot-Marie-Tooth disease type 2Z,Disease,Disorder,Cases/families,Case(s),,21.0,Worldwide,Validated,26497905[PMID]_26659848[PMID]_26912637[PMID]_27105897[PMID]_27329773[PMID]
24166,466768,Autosomal dominant Charcot-Marie-Tooth disease type 2Z,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26497905[PMID]_26659848[PMID]_26912637[PMID]_27105897[PMID]_27329773[PMID]
24162,466722,Autosomal recessive spastic paraplegia type 77,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,26553276[PMID]_29126765[PMID]_25851414[PMID]
24162,466722,Autosomal recessive spastic paraplegia type 77,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29126765[PMID]
24161,466718,Martinique crinkled retinal pigment epitheliopathy,Disease,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,23370609[PMID]_26744326[PMID]
24161,466718,Martinique crinkled retinal pigment epitheliopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23370609[PMID]_26744326[PMID]
24160,466703,TMEM199-CDG,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,19067230[PMID]_26833330[PMID]_29321044[PMID]
24160,466703,TMEM199-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19067230[PMID]_26833330[PMID]_29321044[PMID]
24074,465824,Fetal encasement syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,20961246[PMID]
24074,465824,Fetal encasement syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20961246[PMID]
24102,466026,Class I glucose-6-phosphate dehydrogenase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20200584[PMID]
24220,468620,Intellectual disability-epilepsy-extrapyramidal syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,26048982[PMID]
24220,468620,Intellectual disability-epilepsy-extrapyramidal syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26048982[PMID]
24223,468631,Microcephalic cortical malformations-short stature due to RTTN deficiency,Malformation syndrome,Disorder,Cases/families,Case(s),,28.0,Worldwide,Validated,PMID: 30879067
24223,468631,Microcephalic cortical malformations-short stature due to RTTN deficiency,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,PMID: 30879067
24201,467166,Tubulinopathy-associated dysgyria,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,26130693[PMID]
24201,467166,Tubulinopathy-associated dysgyria,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26130693[PMID]
24203,467176,Severe hypotonia-psychomotor developmental delay-strabismus-cardiac septal defect syndrome,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,26358778[PMID]
24203,467176,Severe hypotonia-psychomotor developmental delay-strabismus-cardiac septal defect syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26358778[PMID]
24224,468635,Cryptogenic multifocal ulcerous stenosing enteritis,Disease,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,24369459[PMID]_25708899[PMID]
24224,468635,Cryptogenic multifocal ulcerous stenosing enteritis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24369459[PMID]_25708899[PMID]
24225,468641,Chronic enteropathy associated with SLCO2A1 gene,Disease,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,26539716[PMID]_17709045[PMID]
24225,468641,Chronic enteropathy associated with SLCO2A1 gene,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24035666[PMID]_23268370[PMID]_25708899[PMID]_26539716[PMID]_17709045[PMID]
24230,468661,Autosomal recessive spastic paraplegia type 74,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,25609768[PMID]
24230,468661,Autosomal recessive spastic paraplegia type 74,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25609768[PMID]
24231,468666,Isolated generalized anhidrosis with normal sweat glands,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,25329695[PMID]_2401610[PMID]
24231,468666,Isolated generalized anhidrosis with normal sweat glands,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25329695[PMID]_2401610[PMID]
24234,468678,White-Sutton syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26739615[PMID]_27148570[PMID]
24235,468684,CCDC115-CDG,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,26833332[PMID]_26833330[PMID]
24235,468684,CCDC115-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26833332[PMID]_26833330[PMID]
24233,468672,Colobomatous macrophthalmia-microcornea syndrome,Disease,Disorder,Cases/families,Case(s),,21.0,Worldwide,Validated,12900897[PMID]
24233,468672,Colobomatous macrophthalmia-microcornea syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12900897[PMID]
24238,468726,Severe primary trimethylaminuria,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_25335494[PMID]
24236,468699,SLC39A8-CDG,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,26637978[PMID]_26637979[PMID]
24236,468699,SLC39A8-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26637978[PMID]_26637979[PMID]
24237,468717,Rhizomelic chondrodysplasia punctata type 5,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,26220973[PMID]
24237,468717,Rhizomelic chondrodysplasia punctata type 5,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26220973[PMID]
22829,401785,Autosomal recessive spastic paraplegia type 62,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,24482476[PMID]
22829,401785,Autosomal recessive spastic paraplegia type 62,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24482476[PMID]
22828,401780,Autosomal recessive spastic paraplegia type 61,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,24482476[PMID]
22828,401780,Autosomal recessive spastic paraplegia type 61,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24482476[PMID]
22831,401800,Autosomal recessive spastic paraplegia type 60,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,24482476[PMID]
22831,401800,Autosomal recessive spastic paraplegia type 60,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24482476[PMID]
22830,401795,Autosomal recessive spastic paraplegia type 59,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,24482476[PMID]
22830,401795,Autosomal recessive spastic paraplegia type 59,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24482476[PMID]
22825,401768,Proximal myopathy with extrapyramidal signs,Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,24336167[PMID]
22825,401768,Proximal myopathy with extrapyramidal signs,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24336167[PMID]
22824,401764,Pancytopenia-developmental delay syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,24507776[PMID]_27185855[PMID]
22824,401764,Pancytopenia-developmental delay syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24507776[PMID]_27185855[PMID]
22827,401777,Optic atrophy-intellectual disability syndrome,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,24462372[PMID]
22827,401777,Optic atrophy-intellectual disability syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24462372[PMID]
22837,401830,Autosomal recessive spastic paraplegia type 69,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,24482476[PMID]
22837,401830,Autosomal recessive spastic paraplegia type 69,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24482476[PMID]
22838,401835,Autosomal recessive spastic paraplegia type 70,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,24482476[PMID]
22838,401835,Autosomal recessive spastic paraplegia type 70,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24482476[PMID]
22839,401840,Autosomal recessive spastic paraplegia type 71,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,24482476[PMID]
22839,401840,Autosomal recessive spastic paraplegia type 71,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24482476[PMID]
22832,401805,Autosomal recessive spastic paraplegia type 63,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,24482476[PMID]
22832,401805,Autosomal recessive spastic paraplegia type 63,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24482476[PMID]
22833,401810,Autosomal recessive spastic paraplegia type 64,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,24482476[PMID]
22833,401810,Autosomal recessive spastic paraplegia type 64,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24482476[PMID]
22834,401815,Autosomal recessive spastic paraplegia type 66,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,24482476[PMID]
22834,401815,Autosomal recessive spastic paraplegia type 66,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24482476[PMID]
22835,401820,Autosomal recessive spastic paraplegia type 67,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,24482476[PMID]
22835,401820,Autosomal recessive spastic paraplegia type 67,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24482476[PMID]
22844,401866,Childhood-onset spasticity with hyperglycinemia,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,24777537[PMID]_17485548[PMID]_24334290[PMID]
22844,401866,Childhood-onset spasticity with hyperglycinemia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17485548[PMID]_24334290[PMID]
22845,401869,Multiple mitochondrial dysfunctions syndrome type 1,Disease,Disorder,Cases/families,Case(s),,21.0,Worldwide,Validated,24777537[PMID]_22077971[PMID]
22845,401869,Multiple mitochondrial dysfunctions syndrome type 1,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24777537[PMID]_22077971[PMID]
22846,401874,Multiple mitochondrial dysfunctions syndrome type 2,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,24777537[PMID]_21944046[PMID]_24334290[PMID]_22562699[PMID]
22846,401874,Multiple mitochondrial dysfunctions syndrome type 2,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24777537[PMID]_21944046[PMID]_24334290[PMID]_22562699[PMID]
22840,401849,Autosomal spastic paraplegia type 72,Disease,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,24388663[PMID]
22840,401849,Autosomal spastic paraplegia type 72,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24388663[PMID]
22842,401859,Lipoic acid synthetase deficiency,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,24777537[PMID]_22152680[PMID]_24334290[PMID]
22842,401859,Lipoic acid synthetase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24777537[PMID]_22152680[PMID]_24334290[PMID]
22843,401862,Lipoyl transferase 1 deficiency,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,27247813[PMID]
22843,401862,Lipoyl transferase 1 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27247813[PMID]
22889,402823,Hepatitis delta,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,40.0,Europe,Validated,European Medicines Agency 2014[INST]
22851,401920,Fibrolamellar hepatocellular carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,United States,Validated,SEER Surveillance Epidemiology and end results [REG]_14999699[PMID]
22851,401920,Fibrolamellar hepatocellular carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.009,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22851,401920,Fibrolamellar hepatocellular carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.019,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22851,401920,Fibrolamellar hepatocellular carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.029,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22851,401920,Fibrolamellar hepatocellular carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.029,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22851,401920,Fibrolamellar hepatocellular carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.018,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22851,401920,Fibrolamellar hepatocellular carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22851,401920,Fibrolamellar hepatocellular carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.031,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22851,401920,Fibrolamellar hepatocellular carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.019,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22851,401920,Fibrolamellar hepatocellular carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.043,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22851,401920,Fibrolamellar hepatocellular carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.022,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22851,401920,Fibrolamellar hepatocellular carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.13,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22851,401920,Fibrolamellar hepatocellular carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.022,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22851,401920,Fibrolamellar hepatocellular carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22851,401920,Fibrolamellar hepatocellular carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22851,401920,Fibrolamellar hepatocellular carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22851,401920,Fibrolamellar hepatocellular carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.008,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22851,401920,Fibrolamellar hepatocellular carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.009,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22851,401920,Fibrolamellar hepatocellular carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.017,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22851,401920,Fibrolamellar hepatocellular carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.022,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22851,401920,Fibrolamellar hepatocellular carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.016,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22851,401920,Fibrolamellar hepatocellular carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.025,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22850,401911,AXIN2-related attenuated familial adenomatous polyposis,Clinical subtype,Subtype of disorder,Cases/families,Family(ies),,4.0,Worldwide,Validated,23838596[PMID]
22850,401911,AXIN2-related attenuated familial adenomatous polyposis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23838596[PMID]
22848,401901,Huntington disease-like syndrome due to C9ORF72 expansions,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,24363131[PMID]
22848,401901,Huntington disease-like syndrome due to C9ORF72 expansions,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24363131[PMID]
22855,401942,Familial median cleft of the upper and lower lips,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,23860042[PMID]
22855,401942,Familial median cleft of the upper and lower lips,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23860042[PMID]
22854,401935,14q24.1q24.3 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,24357125[PMID]
22854,401935,14q24.1q24.3 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24357125[PMID]
22852,401923,9q31.1q31.3 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,24376033[PMID]
22852,401923,9q31.1q31.3 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24376033[PMID]
22859,401959,Partial corpus callosum agenesis-cerebellar vermis hypoplasia with posterior fossa cysts syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,24045845[PMID]
22859,401959,Partial corpus callosum agenesis-cerebellar vermis hypoplasia with posterior fossa cysts syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24045845[PMID]
22858,401953,Episodic ataxia with slurred speech,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,23982692[PMID]
22858,401953,Episodic ataxia with slurred speech,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23982692[PMID]
22857,401948,Hyperammonemic encephalopathy due to carbonic anhydrase VA deficiency,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,25834911[PMID]
22857,401948,Hyperammonemic encephalopathy due to carbonic anhydrase VA deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25834911[PMID]
22856,401945,Moyamoya disease with early-onset achalasia,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,24581742[PMID]
22856,401945,Moyamoya disease with early-onset achalasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24581742[PMID]
22863,401986,1p31p32 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,24462883[PMID]
22863,401986,1p31p32 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24462883[PMID]
22862,401979,"Autosomal recessive spondylometaphyseal dysplasia, Mégarbané type",Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,18925669[PMID]_2445848[PMID]
22862,401979,"Autosomal recessive spondylometaphyseal dysplasia, Mégarbané type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18925669[PMID]_2445848[PMID]
22861,401973,MEND syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,24.0,Worldwide,Validated,22229330[PMID]_24459067[PMID]_24700572[PMID]_27276700[PMID]
22861,401973,MEND syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22229330[PMID]_24459067[PMID]_24700572[PMID]_27276700[PMID]
22860,401964,Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons,Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,24500646[PMID]_15111691[PMID]_14557576[PMID]
22860,401964,Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24500646[PMID]_15111691[PMID]_14557576[PMID]
22866,402003,Autosomal dominant focal non-epidermolytic palmoplantar keratoderma with plantar blistering,Disease,Disorder,Cases/families,Case(s),,21.0,Worldwide,Validated,21801157[PMID]_19609311[PMID]
22866,402003,Autosomal dominant focal non-epidermolytic palmoplantar keratoderma with plantar blistering,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21801157[PMID]_19609311[PMID]
22865,401996,Karyomegalic interstitial nephritis,Disease,Disorder,Cases/families,Family(ies),,12.0,Worldwide,Validated,22772369[PMID]
22865,401996,Karyomegalic interstitial nephritis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22772369[PMID]
22875,402035,Eosinophilic colitis,Disease,Disorder,Cases/families,Case(s),,196.0,Worldwide,Validated,22012125[PMID]
22875,402035,Eosinophilic colitis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22012125[PMID]
22878,402082,Progressive myoclonic epilepsy type 5,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,21276947[PMID]
22878,402082,Progressive myoclonic epilepsy type 5,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21276947[PMID]
22879,402364,Infantile cerebral and cerebellar atrophy with postnatal progressive microcephaly,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,20950787[PMID]
22879,402364,Infantile cerebral and cerebellar atrophy with postnatal progressive microcephaly,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20950787[PMID]
22876,402041,Autosomal recessive distal renal tubular acidosis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
7521,806,Scott syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,8608230[PMID]_15790791[PMID]_19814742[PMID]
7521,806,Scott syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22927,404473,Severe intellectual disability-progressive spastic diplegia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,24668549[PMID]_23033978[PMID]_24614104[PMID]
22927,404473,Severe intellectual disability-progressive spastic diplegia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24668549[PMID]_23033978[PMID]_24614104[PMID]
22924,404463,Multisystemic smooth muscle dysfunction syndrome,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,20734336[PMID]
22924,404463,Multisystemic smooth muscle dysfunction syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20734336[PMID]
22925,404466,Female infertility due to zona pellucida defect,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,24670168[PMID]
22925,404466,Female infertility due to zona pellucida defect,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24670168[PMID]
22922,404451,FBLN1-related developmental delay-central nervous system anomaly-syndactyly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,24084572[PMID]
22922,404451,FBLN1-related developmental delay-central nervous system anomaly-syndactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24084572[PMID]
22923,404454,Alacrimia-choreoathetosis-liver dysfunction syndrome,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,24651605[PMID]_22581936[PMID]
22923,404454,Alacrimia-choreoathetosis-liver dysfunction syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24651605[PMID]_22581936[PMID]
22920,404443,Tatton-Brown-Rahman syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,24614070[PMID]_27991732[PMID]_28941052[PMID]
22920,404443,Tatton-Brown-Rahman syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24614070[PMID]_27991732[PMID]_28941052[PMID]
22921,404448,ADNP syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Worldwide,Validated,24531329[PMID]_[EXPERT]
22918,404437,Diffuse cerebral and cerebellar atrophy-intractable seizures-progressive microcephaly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,24656866[PMID]
22918,404437,Diffuse cerebral and cerebellar atrophy-intractable seizures-progressive microcephaly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24656866[PMID]
22919,404440,Intellectual disability-facial dysmorphism syndrome due to SETD5 haploinsufficiency,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,24680889[PMID]
22919,404440,Intellectual disability-facial dysmorphism syndrome due to SETD5 haploinsufficiency,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24680889[PMID]
22939,404560,Familial atypical multiple mole melanoma syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
22938,404553,Adenosine deaminase 2 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28516235[PMID]
22938,404553,Adenosine deaminase 2 deficiency,Disease,Disorder,Cases/families,Case(s),,48.0,Worldwide,Validated,28516235[PMID]
22937,404546,DITRA,Disease,Disorder,Cases/families,Case(s),,70.0,Worldwide,Validated,25848350[PMID]
22937,404546,DITRA,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25848350[PMID]
22935,404521,Spinal muscular atrophy with respiratory distress type 2,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,24647030[PMID]
22935,404521,Spinal muscular atrophy with respiratory distress type 2,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24647030[PMID]
22932,404507,Chondromyxoid fibroma,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,24658000[PMID]
22932,404507,Chondromyxoid fibroma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24658000[PMID]
22931,404499,Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to RUBCN deficiency,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,23728897[PMID]
22931,404499,Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to RUBCN deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23728897[PMID]
22930,404493,Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to TUD deficiency,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,24658003[PMID]
22930,404493,Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to TUD deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24658003[PMID]
22928,404476,Global developmental delay-lung cysts-overgrowth-Wilms tumor syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,24676357[PMID]
22928,404476,Global developmental delay-lung cysts-overgrowth-Wilms tumor syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24676357[PMID]
23016,411527,Central retinal vein occlusion,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,28.0,Europe,Validated,European Medecines Agency 2014[INST]
23018,411536,Mild phosphoribosylpyrophosphate synthetase superactivity,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Not yet validated,ORPHANET
23019,411543,Severe phosphoribosylpyrophosphate synthetase superactivity,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,20301734[PMID]_ORPHANET
23019,411543,Severe phosphoribosylpyrophosphate synthetase superactivity,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,33.0,Worldwide,Validated,20301734[PMID]
23021,411593,Insulin autoimmune syndrome,Disease,Disorder,Cases/families,Case(s),,404.0,Worldwide,Validated,24111525[PMID]
23021,411593,Insulin autoimmune syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_24111525[PMID]
23022,411602,Hereditary late-onset Parkinson disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
23023,411629,Infantile nephropathic cystinosis,Clinical subtype,Subtype of disorder,Prevalence at birth,Class only,1-9 / 1 000 000,0.0,Europe,Validated,[EXPERT]_12110740[PMID]
23023,411629,Infantile nephropathic cystinosis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
23012,411493,Pontocerebellar hypoplasia type 10,Malformation syndrome,Disorder,Cases/families,Case(s),,23.0,Worldwide,Validated,24766809[PMID]_24766810[PMID]
23012,411493,Pontocerebellar hypoplasia type 10,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24766809[PMID]_24766810[PMID]
23033,411777,Generalized eruptive keratoacanthoma,Disease,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,25070745[PMID]
23033,411777,Generalized eruptive keratoacanthoma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25070745[PMID]
23032,411712,Maternal riboflavin deficiency,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,21089064[PMID]_29122468[PMID]
23032,411712,Maternal riboflavin deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21089064[PMID]_29122468[PMID]
23034,411788,Familial isolated trichomegaly,Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,24989505[PMID]
23034,411788,Familial isolated trichomegaly,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_ 24989505[PMID]
23037,411986,Early-onset epileptic encephalopathy-cortical blindness-intellectual disability-facial dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,24814191[PMID]
23037,411986,Early-onset epileptic encephalopathy-cortical blindness-intellectual disability-facial dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24814191[PMID]
23039,412035,13q12.3 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,24664804[PMID]
23039,412035,13q12.3 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24664804[PMID]
23038,412022,Facial dysmorphism-lens dislocation-anterior segment abnormalities-spontaneous filtering blebs syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,4.0,Worldwide,Validated,24768550[PMID]
23038,412022,Facial dysmorphism-lens dislocation-anterior segment abnormalities-spontaneous filtering blebs syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24768550[PMID]
23025,411641,Ocular cystinosis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
23024,411634,Juvenile nephropathic cystinosis,Clinical subtype,Subtype of disorder,Prevalence at birth,Class only,<1 / 1 000 000,0.0,Europe,Validated,[EXPERT]
23024,411634,Juvenile nephropathic cystinosis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
23029,411696,Proton-pump inhibitor-responsive esophageal eosinophilia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,23567357[PMID]_25132757[PMID]
23031,411709,Renal agenesis,Morphological anomaly,Disorder,Prevalence at birth,Class only,1-5 / 10 000,0.0,Worldwide,Validated,24370773[PMID]
23031,411709,Renal agenesis,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_24370773[PMID]
23030,411703,Pulmonary non-tuberculous mycobacterial infection,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.0,Europe,Validated,European Medicines Agency 2014[INST]
22539,371428,Multicentric osteolysis-nodulosis-arthropathy spectrum,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,[EXPERT]
22539,371428,Multicentric osteolysis-nodulosis-arthropathy spectrum,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
22538,371364,Hypotonia-speech impairment-severe cognitive delay syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,23749988[PMID]_24075186[PMID]
22640,391673,Necrotizing enterocolitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,45.0,Worldwide,Validated,European Medicines Agency 2015[INST]
22641,391677,Short stature-optic atrophy-Pelger-Huët anomaly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,39.0,Worldwide,Validated,20577004[PMID]_26286438[PMID]_29955634[PMID]_27789416[PMID]
22641,391677,Short stature-optic atrophy-Pelger-Huët anomaly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20577004[PMID]_29955634[PMID]_27789416[PMID]
22625,391474,Frontorhiny,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
22631,391504,Transient neonatal myasthenia gravis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
22630,391497,Juvenile myasthenia gravis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
22629,391490,Adult-onset myasthenia gravis,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-5 / 10 000,31.8,Serbia,Validated,23363926[PMID]
22629,391490,Adult-onset myasthenia gravis,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 100 000,1.33,Serbia,Validated,23363926[PMID]
22629,391490,Adult-onset myasthenia gravis,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-5 / 10 000,17.0,United States,Validated,[EXPERT]_ORPHANET
22629,391490,Adult-onset myasthenia gravis,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-5 / 10 000,28.0,United Kingdom,Validated,[EXPERT]_ORPHANET
22629,391490,Adult-onset myasthenia gravis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Validated,ORPHANET
22628,391487,STAT1-related autoimmune enteropathy and endocrinopathy-susceptibility to chronic infections syndrome,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,23534974[PMID]
22628,391487,STAT1-related autoimmune enteropathy and endocrinopathy-susceptibility to chronic infections syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,ORPHANET_23534974[PMID]
22635,391646,Feingold syndrome type 2,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,28159702[PMID]
22635,391646,Feingold syndrome type 2,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28159702[PMID]
22634,391641,Feingold syndrome type 1,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,120.0,Worldwide,Validated,[EXPERT]
22634,391641,Feingold syndrome type 1,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22639,391665,Homozygous familial hypercholesterolemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.5842,Japan,Validated,21146822[PMID]
22639,391665,Homozygous familial hypercholesterolemia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.3194,Worldwide,Validated,31947532[PMID]_32439005[PMID]_ORPHANET
22639,391665,Homozygous familial hypercholesterolemia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.22,Spain,Validated,27784735[PMID]
22639,391665,Homozygous familial hypercholesterolemia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.625,Denmark,Validated,23956253[PMID]
22639,391665,Homozygous familial hypercholesterolemia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.33,Netherlands,Validated,24585268[PMID]
22639,391665,Homozygous familial hypercholesterolemia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.125,Germany,Validated,23662069[PMID]
22637,391655,Off-periods in Parkinson disease not responding to oral treatment,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.15,Europe,Validated,European Medicines Agency 2004[INST]
22608,391343,Fatal post-viral neurodegenerative disorder,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,23443029[PMID]
22608,391343,Fatal post-viral neurodegenerative disorder,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22609,391348,Growth and developmental delay-hypotonia-vision impairment-lactic acidosis syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,24119684[PMID]
22609,391348,Growth and developmental delay-hypotonia-vision impairment-lactic acidosis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22610,391351,SURF1-related Charcot-Marie-Tooth disease type 4,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,24027061[PMID]
22610,391351,SURF1-related Charcot-Marie-Tooth disease type 4,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22611,391366,Growth retardation-mild developmental delay-chronic hepatitis syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,23908464[PMID]
22611,391366,Growth retardation-mild developmental delay-chronic hepatitis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22612,391372,FOXP1 Syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,48.0,Worldwide,Validated,28735298[PMID]
22612,391372,FOXP1 Syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28735298[PMID]
22613,391376,Congenital microcephaly-severe encephalopathy-progressive cerebral atrophy syndrome,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,28776279[PMID]
22613,391376,Congenital microcephaly-severe encephalopathy-progressive cerebral atrophy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28776279[PMID]
22615,391384,Familial episodic pain syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
22616,391389,Familial episodic pain syndrome with predominantly upper body involvement,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,21.0,Worldwide,Validated,24207120[PMID]_23115331[PMID]_20547126[PMID]
22616,391389,Familial episodic pain syndrome with predominantly upper body involvement,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22617,391392,Familial episodic pain syndrome with predominantly lower limb involvement,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,28.0,Worldwide,Validated,21698661[PMID]
22617,391392,Familial episodic pain syndrome with predominantly lower limb involvement,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22618,391397,Hereditary sensory and autonomic neuropathy type 7,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,24036948[PMID]_24813307[PMID]
22618,391397,Hereditary sensory and autonomic neuropathy type 7,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22619,391408,Primary microcephaly-mild intellectual disability-young-onset diabetes syndrome,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,25053765[PMID]_26159176[PMID]
22619,391408,Primary microcephaly-mild intellectual disability-young-onset diabetes syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25053765[PMID]_26159176[PMID]
22620,391411,Atypical juvenile parkinsonism,Disease,Disorder,Cases/families,Family(ies),,6.0,Worldwide,Validated,25085748[PMID]
22620,391411,Atypical juvenile parkinsonism,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22621,391417,HSD10 disease,Disease,Disorder,Cases/families,Case(s),,37.0,Worldwide,Validated,27306202[PMID]_27295195[PMID]
22621,391417,HSD10 disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27306202[PMID]_27295195[PMID]
22623,391457,"HSD10 disease, neonatal type",Clinical subtype,Subtype of disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,22127393[PMID]
22623,391457,"HSD10 disease, neonatal type",Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22601,391307,Severe intellectual disability-short stature-behavioral abnormalities-facial dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,23956177[PMID]
22601,391307,Severe intellectual disability-short stature-behavioral abnormalities-facial dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22603,391316,Infantile-onset mesial temporal lobe epilepsy with severe cognitive regression,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,23686771[PMID]
22603,391316,Infantile-onset mesial temporal lobe epilepsy with severe cognitive regression,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22605,391327,X-linked calvarial hyperostosis,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,24145306[PMID]
22605,391327,X-linked calvarial hyperostosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
22604,391320,East Texas bleeding disorder,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,23979162[PMID]_25634741[PMID]
22604,391320,East Texas bleeding disorder,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25634741[PMID]
22606,391330,X-linked osteoporosis with fractures,Disease,Disorder,Cases/families,Family(ies),,8.0,Worldwide,Validated,24088043[PMID]_24616189[PMID]_25209159[PMID]
22606,391330,X-linked osteoporosis with fractures,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24088043[PMID]_24616189[PMID]_25209159[PMID]
22719,398063,Refractory celiac disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,23609613[PMID]
22718,398058,Squamous cell carcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.57,Europe,Validated,22119351[PMID]_RARECARE Surveillance of Rare Cancers in Europe 2003[REG]
22718,398058,Squamous cell carcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.612,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22718,398058,Squamous cell carcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.491,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22718,398058,Squamous cell carcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.605,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22718,398058,Squamous cell carcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.516,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22718,398058,Squamous cell carcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.423,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22718,398058,Squamous cell carcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.684,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22718,398058,Squamous cell carcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.6,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22718,398058,Squamous cell carcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.426,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22718,398058,Squamous cell carcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.638,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22718,398058,Squamous cell carcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.682,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22718,398058,Squamous cell carcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.475,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22718,398058,Squamous cell carcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.606,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22718,398058,Squamous cell carcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.552,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22718,398058,Squamous cell carcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.517,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22718,398058,Squamous cell carcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.628,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22718,398058,Squamous cell carcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.744,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22718,398058,Squamous cell carcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.396,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22718,398058,Squamous cell carcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.745,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22718,398058,Squamous cell carcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.499,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22718,398058,Squamous cell carcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.45,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22718,398058,Squamous cell carcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.791,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22718,398058,Squamous cell carcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.597,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22718,398058,Squamous cell carcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.691,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22717,398053,Adenocarcinoma of the penis,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,22119351[PMID]_RARECARE Surveillance of Rare Cancers in Europe 2003[REG]
22717,398053,Adenocarcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22717,398053,Adenocarcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22717,398053,Adenocarcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22717,398053,Adenocarcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22717,398053,Adenocarcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.004,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22717,398053,Adenocarcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22717,398053,Adenocarcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22717,398053,Adenocarcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22717,398053,Adenocarcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.004,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22717,398053,Adenocarcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22717,398053,Adenocarcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.012,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22717,398053,Adenocarcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22717,398053,Adenocarcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22717,398053,Adenocarcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.025,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22717,398053,Adenocarcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.004,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22717,398053,Adenocarcinoma of the penis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22716,398043,Malignant tumor of penis,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.85,Brazil,Validated,26076979[PMID]_18986562[PMID]
22716,398043,Malignant tumor of penis,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.5,Uganda,Validated,26076979[PMID]_10789729[PMID]
22716,398043,Malignant tumor of penis,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.075,Europe,Validated,26076979[PMID]_IARC International Agency for research on cancer 2002[INST]
22716,398043,Malignant tumor of penis,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.21,United Kingdom,Validated,26076979[PMID]_24101363[PMID]
22716,398043,Malignant tumor of penis,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.58,United States,Validated,26076979[PMID]_17826651[PMID]
22715,397973,Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,11746007[PMID]
22715,397973,Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11746007[PMID]
22714,397968,Charcot-Marie-Tooth disease type 2R,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,23562820[PMID]
22714,397968,Charcot-Marie-Tooth disease type 2R,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23562820[PMID]
22713,397964,Combined immunodeficiency due to MALT1 deficiency,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,23727036[PMID]_24332264[PMID]
22713,397964,Combined immunodeficiency due to MALT1 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23727036[PMID]_24332264[PMID]
22712,397959,TCR-alpha-beta-positive T-cell deficiency,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,21206088[PMID]
22712,397959,TCR-alpha-beta-positive T-cell deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21206088[PMID]
22711,397951,Microcephaly-thin corpus callosum-intellectual disability syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,24084144[PMID]
22711,397951,Microcephaly-thin corpus callosum-intellectual disability syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24084144[PMID]
22710,397946,Autosomal spastic paraplegia type 58,Disease,Disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,24482476[PMID]_24319291[PMID]_24482476[PMID]_24808017[PMID]
22710,397946,Autosomal spastic paraplegia type 58,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24482476[PMID]
22709,397941,MAN1B1-CDG,Disease,Disorder,Cases/families,Case(s),,25.0,Worldwide,Validated,21763484[PMID]_24348268[PMID]_26307094[PMID]
22709,397941,MAN1B1-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21763484[PMID]_24348268[PMID]_26307094[PMID]
22708,397937,Polyglucosan body myopathy type 1,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,23798481[PMID]
22708,397937,Polyglucosan body myopathy type 1,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23798481[PMID]
22707,397933,Severe intellectual disability-progressive postnatal microcephaly-midline stereotypic hand movements syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,23674175[PMID]
22707,397933,Severe intellectual disability-progressive postnatal microcephaly-midline stereotypic hand movements syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23674175[PMID]
22705,397927,Sacral agenesis-abnormal ossification of the vertebral bodies-persistent notochordal canal syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,24369075[PMID]
22705,397927,Sacral agenesis-abnormal ossification of the vertebral bodies-persistent notochordal canal syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24369075[PMID]
22704,397922,Ferro-cerebro-cutaneous syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,24259288[PMID]
22704,397922,Ferro-cerebro-cutaneous syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24259288[PMID]
22702,397787,Combined immunodeficiency due to IKK2 deficiency,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,25139357[PMID]
22702,397787,Combined immunodeficiency due to IKK2 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25139357[PMID]
22700,397755,Periodic paralysis with transient compartment-like syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,24240197[PMID]
22700,397755,Periodic paralysis with transient compartment-like syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24240197[PMID]
22701,397758,Retinal dystrophy with inner retinal dysfunction and ganglion cell anomalies,Disease,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,24026677[PMID]
22701,397758,Retinal dystrophy with inner retinal dysfunction and ganglion cell anomalies,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24026677[PMID]
22698,397744,Peripheral neuropathy-myopathy-hoarseness-hearing loss syndrome,Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,21480433[PMID]
22698,397744,Peripheral neuropathy-myopathy-hoarseness-hearing loss syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21480433[PMID]
22699,397750,Periodic paralysis with later-onset distal motor neuropathy,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,24153443[PMID]
22699,397750,Periodic paralysis with later-onset distal motor neuropathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24153443[PMID]
22696,397725,COASY protein-associated neurodegeneration,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,24360804[PMID]
22696,397725,COASY protein-associated neurodegeneration,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24360804[PMID]
22697,397735,Autosomal dominant Charcot-Marie-Tooth disease type 2U,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,23729695[PMID]
22697,397735,Autosomal dominant Charcot-Marie-Tooth disease type 2U,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23729695[PMID]
22694,397709,Intellectual disability-coarse face-macrocephaly-cerebellar hypotrophy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27913285[PMID]
22694,397709,Intellectual disability-coarse face-macrocephaly-cerebellar hypotrophy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,27913285[PMID]
22695,397715,Joubert syndrome with Jeune asphyxiating thoracic dystrophy,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,24360808[PMID]_20503315[PMID]
22695,397715,Joubert syndrome with Jeune asphyxiating thoracic dystrophy,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24360808[PMID]_20503315[PMID]
22692,397692,Hereditary isolated aplastic anemia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
22693,397695,3q27.3 microdeletion syndrome,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,24133203[PMID]
22693,397695,3q27.3 microdeletion syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24133203[PMID]
22690,397623,Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,24290375[PMID]
22690,397623,Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24290375[PMID]
22691,397685,Familial hyperprolactinemia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
22688,397615,Obesity due to CEP19 deficiency,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,24268657[PMID]
22688,397615,Obesity due to CEP19 deficiency,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24268657[PMID]
22689,397618,Foveal hypoplasia-optic nerve decussation defect-anterior segment dysgenesis syndrome,Disease,Disorder,Cases/families,Family(ies),,7.0,Worldwide,Validated,24290379[PMID]
22689,397618,Foveal hypoplasia-optic nerve decussation defect-anterior segment dysgenesis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24290379[PMID]
22685,397596,Activated PI3K-delta syndrome,Disease,Disorder,Cases/families,Case(s),,250.0,Worldwide,Validated,34052541[PMID]
22685,397596,Activated PI3K-delta syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,34052541[PMID]_31111319[PMID]_ORPHANET
22684,397593,Severe neonatal lactic acidosis due to NFS1-ISD11 complex deficiency,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,23814038[PMID]_24498631[PMID]
22684,397593,Severe neonatal lactic acidosis due to NFS1-ISD11 complex deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23814038[PMID]_24498631[PMID]
22687,397612,Macrocephaly-developmental delay syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,24239382[PMID]
22687,397612,Macrocephaly-developmental delay syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24239382[PMID]
22686,397606,PrP systemic amyloidosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25623792[PMID]
22686,397606,PrP systemic amyloidosis,Disease,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,25623792[PMID]
22683,397590,Silver-Russell syndrome due to a point mutation,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,24065356[PMID]
22683,397590,Silver-Russell syndrome due to a point mutation,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24065356[PMID]
22682,397587,Deep dermatophytosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
22760,399329,Epiphysiolysis of the hip,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
22754,399180,Secondary non-traumatic avascular necrosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
22745,399058,Alpha-B crystallin-related late-onset myopathy,Disease,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,21920752[PMID]_9731540[PMID]_14681890[PMID]_20171888[PMID]
22745,399058,Alpha-B crystallin-related late-onset myopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21920752[PMID]_9731540[PMID]_14681890[PMID]_20171888[PMID]
22744,398987,Malignant teratoma of ovary,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
22744,398987,Malignant teratoma of ovary,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.07,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22744,398987,Malignant teratoma of ovary,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.051,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22744,398987,Malignant teratoma of ovary,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.052,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22744,398987,Malignant teratoma of ovary,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.043,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22744,398987,Malignant teratoma of ovary,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.056,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22744,398987,Malignant teratoma of ovary,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.034,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22744,398987,Malignant teratoma of ovary,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.074,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22744,398987,Malignant teratoma of ovary,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.053,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22744,398987,Malignant teratoma of ovary,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.042,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22744,398987,Malignant teratoma of ovary,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.052,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22744,398987,Malignant teratoma of ovary,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.039,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22744,398987,Malignant teratoma of ovary,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.027,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22744,398987,Malignant teratoma of ovary,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.017,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22744,398987,Malignant teratoma of ovary,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.031,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22744,398987,Malignant teratoma of ovary,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.084,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22744,398987,Malignant teratoma of ovary,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.048,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22744,398987,Malignant teratoma of ovary,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.045,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22744,398987,Malignant teratoma of ovary,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.045,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22744,398987,Malignant teratoma of ovary,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.075,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22744,398987,Malignant teratoma of ovary,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.063,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22744,398987,Malignant teratoma of ovary,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.084,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22744,398987,Malignant teratoma of ovary,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.082,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22744,398987,Malignant teratoma of ovary,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.056,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22747,399086,Finnish upper limb-onset distal myopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12847162[PMID]
22747,399086,Finnish upper limb-onset distal myopathy,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,12847162[PMID]
22746,399081,KLHL9-related early-onset distal myopathy,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,20554658[PMID]
22746,399081,KLHL9-related early-onset distal myopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20554658[PMID]
22749,399103,Distal nebulin myopathy,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,29070751[PMID]_25205138[PMID]
22749,399103,Distal nebulin myopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29070751[PMID]_25205138[PMID]
22748,399096,Distal anoctaminopathy,Disease,Disorder,Cases/families,Case(s),,24.0,Worldwide,Validated,9673985[PMID]_17132147[PMID]_22402862[PMID]_25864073[PMID]_23663589[PMID]_23606453[PMID]
22748,399096,Distal anoctaminopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9673985[PMID]_25864073[PMID]
22739,398934,Malignant epithelial tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,9.39,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22741,398961,Mucinous adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.85,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22741,398961,Mucinous adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.497,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22741,398961,Mucinous adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.883,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22741,398961,Mucinous adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.815,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22741,398961,Mucinous adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.995,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22741,398961,Mucinous adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.666,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22741,398961,Mucinous adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.469,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22741,398961,Mucinous adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.706,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22741,398961,Mucinous adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.666,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22741,398961,Mucinous adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.503,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22741,398961,Mucinous adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.567,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22741,398961,Mucinous adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.717,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22741,398961,Mucinous adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.665,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22741,398961,Mucinous adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.49,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22741,398961,Mucinous adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.945,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22741,398961,Mucinous adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.601,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22741,398961,Mucinous adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.695,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22741,398961,Mucinous adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.563,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22741,398961,Mucinous adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.76,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22741,398961,Mucinous adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.815,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22741,398961,Mucinous adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.154,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22741,398961,Mucinous adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.108,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22741,398961,Mucinous adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.062,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22741,398961,Mucinous adenocarcinoma of ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.162,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22740,398940,Malignant non-epithelial tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.43,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22742,398971,Clear cell adenocarcinoma of the ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.32,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22742,398971,Clear cell adenocarcinoma of the ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.112,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22742,398971,Clear cell adenocarcinoma of the ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.361,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22742,398971,Clear cell adenocarcinoma of the ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.201,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22742,398971,Clear cell adenocarcinoma of the ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.147,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22742,398971,Clear cell adenocarcinoma of the ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.165,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22742,398971,Clear cell adenocarcinoma of the ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.24,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22742,398971,Clear cell adenocarcinoma of the ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.359,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22742,398971,Clear cell adenocarcinoma of the ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.182,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22742,398971,Clear cell adenocarcinoma of the ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.383,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22742,398971,Clear cell adenocarcinoma of the ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.395,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22742,398971,Clear cell adenocarcinoma of the ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.227,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22742,398971,Clear cell adenocarcinoma of the ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.162,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22742,398971,Clear cell adenocarcinoma of the ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.166,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22742,398971,Clear cell adenocarcinoma of the ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.534,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22742,398971,Clear cell adenocarcinoma of the ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.425,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22742,398971,Clear cell adenocarcinoma of the ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.118,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22742,398971,Clear cell adenocarcinoma of the ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.119,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22742,398971,Clear cell adenocarcinoma of the ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.273,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22742,398971,Clear cell adenocarcinoma of the ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.388,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22742,398971,Clear cell adenocarcinoma of the ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.343,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22742,398971,Clear cell adenocarcinoma of the ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.282,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22742,398971,Clear cell adenocarcinoma of the ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.342,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22742,398971,Clear cell adenocarcinoma of the ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.451,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
22728,398124,Neonatal lupus erythematosus,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.0,United States,Validated,9061661[PMID]
22728,398124,Neonatal lupus erythematosus,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,5.0,United States,Validated,30252317[PMID]_ORPHANET
22729,398127,Neonatal scleroderma,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,16887444[PMID]
22729,398127,Neonatal scleroderma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16887444[PMID]
22730,398147,Persistent idiopathic facial pain,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
22730,398147,Persistent idiopathic facial pain,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.4,Netherlands,Validated,19783099[PMID]
22730,398147,Persistent idiopathic facial pain,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.0,Germany,Validated,12911872[PMID]
22730,398147,Persistent idiopathic facial pain,Disease,Disorder,Lifetime Prevalence,Value and class,1-5 / 10 000,30.0,Germany,Validated,21960648[PMID]
22731,398156,Oculoauriculofrontonasal syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,41.0,Worldwide,Validated,23637006[PMID]
22731,398156,Oculoauriculofrontonasal syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23637006[PMID]
22732,398166,Focal facial dermal dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21931173[PMID]
22732,398166,Focal facial dermal dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,147.0,Worldwide,Validated,21931173[PMID]
22733,398173,Focal facial dermal dysplasia type II,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,21931173[PMID]
22733,398173,Focal facial dermal dysplasia type II,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21931173[PMID]
22734,398189,Focal facial dermal dysplasia type IV,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,21.0,Worldwide,Validated,23161670[PMID]
22734,398189,Focal facial dermal dysplasia type IV,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23161670[PMID]
22720,398069,Schaaf-Yang syndrome,Disease,Disorder,Cases/families,Case(s),,28.0,Worldwide,Validated,27195816[PMID]
22720,398069,Schaaf-Yang syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27195816[PMID]
22721,398073,Prader-Willi-like syndrome,Clinical group,Group of disorders,Cases/families,Case(s),,117.0,Worldwide,Validated,24737477[PMID]
22721,398073,Prader-Willi-like syndrome,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_24737477[PMID]
22722,398079,SIM1-related Prader-Willi-like syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,23778136[PMID]
22722,398079,SIM1-related Prader-Willi-like syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23778136[PMID]
22723,398088,Hereditary cryohydrocytosis with normal stomatin,Disease,Disorder,Cases/families,Case(s),,53.0,Worldwide,Validated,16227998[PMID]
22723,398088,Hereditary cryohydrocytosis with normal stomatin,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16227998[PMID]
22725,398097,Neonatal antiphospholipid syndrome,Disease,Disorder,Cases/families,Case(s),,34.0,Worldwide,Validated,24830792[PMID]
22725,398097,Neonatal antiphospholipid syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24830792[PMID]
22726,398109,Neonatal autoimmune hemolytic anemia,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,12819171[PMID]
22726,398109,Neonatal autoimmune hemolytic anemia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12819171[PMID]
22727,398117,Neonatal dermatomyositis,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,3508696[PMID]_8888050[PMID]_3508696[PMID]
22727,398117,Neonatal dermatomyositis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3508696[PMID]_8888050[PMID]_3508696[PMID]
23306,435628,Keppen-Lubinsky syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,25620207[PMID]
23306,435628,Keppen-Lubinsky syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25620207[PMID]
23310,435660,LIPE-related familial partial lipodystrophy,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,24848981[PMID]_27862896[PMID]
23310,435660,LIPE-related familial partial lipodystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24848981[PMID]_27862896[PMID]
23309,435651,CIDEC-related familial partial lipodystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20049731[PMID]
23309,435651,CIDEC-related familial partial lipodystrophy,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,20049731[PMID]
23308,435638,3p25.3 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,25256099[PMID]
23308,435638,3p25.3 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25256099[PMID]
23314,435804,Short stature-advanced bone age-early-onset osteoarthritis syndrome,Disease,Disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,24762113[PMID]
23314,435804,Short stature-advanced bone age-early-onset osteoarthritis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24762113[PMID]
23318,435845,Lethal neonatal spasticity-epileptic encephalopathy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,25500575[PMID]
23318,435845,Lethal neonatal spasticity-epileptic encephalopathy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25500575[PMID]
23319,435930,Colobomatous optic disc-macular atrophy-chorioretinopathy syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,24702266[PMID]
23319,435930,Colobomatous optic disc-macular atrophy-chorioretinopathy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24702266[PMID]
23317,435819,Autosomal dominant Charcot-Marie-Tooth disease type 2 due to TFG mutation,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,25098539[PMID]
23317,435819,Autosomal dominant Charcot-Marie-Tooth disease type 2 due to TFG mutation,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25098539[PMID]
23322,435953,Progeroid features-hepatocellular carcinoma predisposition syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,25261934[PMID]
23322,435953,Progeroid features-hepatocellular carcinoma predisposition syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25261934[PMID]
23323,435988,Chronic atrial and intestinal dysrhythmia syndrome,Disease,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,25282101[PMID]
23323,435988,Chronic atrial and intestinal dysrhythmia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25282101[PMID]
23320,435934,COG2-CDG,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,24784932[PMID]
23320,435934,COG2-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24784932[PMID]
23321,435938,X-linked microcephaly-growth retardation-prognathism-cryptorchidism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,25316788[PMID]
23321,435938,X-linked microcephaly-growth retardation-prognathism-cryptorchidism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25316788[PMID]
23326,436141,HIDEA syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,25078763[PMID]
23326,436141,HIDEA syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25078763[PMID]
23327,436144,Intrauterine growth restriction-short stature-early adult-onset diabetes syndrome,Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,25057881[PMID]
23327,436144,Intrauterine growth restriction-short stature-early adult-onset diabetes syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25057881[PMID]
23324,435998,Autosomal recessive intermediate Charcot-Marie-Tooth disease type D,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,25152455[PMID]_26302975[PMID]
23324,435998,Autosomal recessive intermediate Charcot-Marie-Tooth disease type D,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25152455[PMID]_26302975[PMID]
23325,436003,Contractures-developmental delay-Pierre Robin syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,25195018[PMID]
23325,436003,Contractures-developmental delay-Pierre Robin syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25195018[PMID]
23329,436159,Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency,Disease,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,25213377[PMID]_25329329[PMID]
23329,436159,Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25213377[PMID]_25329329[PMID]
23331,436169,Thrombomodulin-related bleeding disorder,Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,25049278[PMID]_25564403[PMID]
23331,436169,Thrombomodulin-related bleeding disorder,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25049278[PMID]_25564403[PMID]
23330,436166,Periodic fever-infantile enterocolitis-autoinflammatory syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,25217959[PMID]_25217960[PMID]
23330,436166,Periodic fever-infantile enterocolitis-autoinflammatory syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25217959[PMID]_25217960[PMID]
23333,436182,Microcephalic primordial dwarfism-insulin resistance syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,25105364 [PMID]
23333,436182,Microcephalic primordial dwarfism-insulin resistance syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25105364[PMID]
23332,436174,Cataract-growth hormone deficiency-sensory neuropathy-sensorineural hearing loss-skeletal dysplasia syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,25130867[PMID]
23332,436174,Cataract-growth hormone deficiency-sensory neuropathy-sensorineural hearing loss-skeletal dysplasia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25130867[PMID]
23335,436245,Retinitis pigmentosa-juvenile cataract-short stature-intellectual disability syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,24916380[PMID]
23335,436245,Retinitis pigmentosa-juvenile cataract-short stature-intellectual disability syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24916380[PMID]
23334,436242,Familial atrial tachyarrhythmia-infra-Hisian cardiac conduction disease,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,24925317[PMID]
23334,436242,Familial atrial tachyarrhythmia-infra-Hisian cardiac conduction disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24925317[PMID]
23338,436274,Pseudoxanthoma elasticum-like skin manifestations with retinitis pigmentosa,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,24739904[PMID]
23338,436274,Pseudoxanthoma elasticum-like skin manifestations with retinitis pigmentosa,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24739904[PMID]
23351,437552,Autosomal recessive primary immunodeficiency with defective spontaneous natural killer cell cytotoxicity,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,23006327[PMID]
23351,437552,Autosomal recessive primary immunodeficiency with defective spontaneous natural killer cell cytotoxicity,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23006327[PMID]
23367,438178,Fatty acyl-CoA reductase 1 deficiency,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,25439727[PMID]
23367,438178,Fatty acyl-CoA reductase 1 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25439727[PMID]
23366,438159,STAT3-related early-onset multisystem autoimmune disease,Disease,Disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,26574998[PMID]
23366,438159,STAT3-related early-onset multisystem autoimmune disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26574998[PMID]
23365,438134,PCNA-related progressive neurodegenerative photosensitivity syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,24911150[PMID]
23365,438134,PCNA-related progressive neurodegenerative photosensitivity syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24911150[PMID]
23364,438117,Steel syndrome,Disease,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,8423186[PMID]_20357596[PMID]_24986830[PMID]
23364,438117,Steel syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8423186[PMID]_20357596[PMID]_24986830[PMID]
23363,438114,RARS-related autosomal recessive hypomyelinating leukodystrophy,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,24777941[PMID]
23363,438114,RARS-related autosomal recessive hypomyelinating leukodystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24777941[PMID]
23361,438075,Ketoacidosis due to monocarboxylate transporter-1 deficiency,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,25390740[PMID]
23361,438075,Ketoacidosis due to monocarboxylate transporter-1 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25390740[PMID]
23374,438279,Human infection by orthopoxvirus,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,European Medicines Agency 2010[INST]
23373,438274,GCGR-related hyperglucagonemia,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,25914784[PMID]
23373,438274,GCGR-related hyperglucagonemia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25914784[PMID]
23371,438266,Progressive encephalomyelitis with rigidity and myoclonus,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
23370,438216,PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome due to a point mutation,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,24.0,Worldwide,Validated,25533962[PMID]_DOI: 10.1101/mcs.a000356[OTHER]
23370,438216,PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome due to a point mutation,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25533962[PMID]_DOI: 10.1101/mcs.a000356[OTHER]
23369,438213,PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome,Disease,Disorder,Cases/families,Case(s),,24.0,Worldwide,Validated,27148565[PMID]_25533962[PMID]
23369,438213,PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27148565[PMID]_25533962[PMID]
23368,438207,Severe autosomal recessive macrothrombocytopenia,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,25061177[PMID]
23368,438207,Severe autosomal recessive macrothrombocytopenia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25061177[PMID]
23383,439232,AApoAIV amyloidosis,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,11467836[PMID]_21900878[PMID]
23383,439232,AApoAIV amyloidosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11467836[PMID]_21900878[PMID]
23380,439212,Early-onset myopathy-areflexia-respiratory distress-dysphagia syndrome,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,29128256[PMID]
23380,439212,Early-onset myopathy-areflexia-respiratory distress-dysphagia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29128256[PMID]
23381,439218,KCNQ2-related epileptic encephalopathy,Disease,Disorder,Cases/families,Family(ies),,11.0,Worldwide,Validated,20437616[PMID]
23381,439218,KCNQ2-related epileptic encephalopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20437616[PMID]
23378,439196,Zinc-responsive necrolytic acral erythema,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
23376,439167,Placental insufficiency,Clinical syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,33.0,Worldwide,Validated,European Medicines Agency 2015[INST]
23391,439822,PDE4D haploinsufficiency syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,24203977[PMID]_21594994[PMID]
23391,439822,PDE4D haploinsufficiency syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24203977[PMID]_21594994[PMID]
23385,439254,ITM2B amyloidosis,Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,24473189[PMID]
23385,439254,ITM2B amyloidosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24473189[PMID]
23393,439854,Fatal congenital hypertrophic cardiomyopathy due to glycogen storage disease,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,10368461[PMID]_15877279[PMID]
23393,439854,Fatal congenital hypertrophic cardiomyopathy due to glycogen storage disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10368461[PMID]_15877279[PMID]
23395,439897,Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,24128419[PMID]
23395,439897,Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24128419[PMID]
23394,439881,Plastic bronchitis,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
23401,440354,Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25091507[PMID]
23401,440354,Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,25091507[PMID]
23412,440713,Isolated sedoheptulokinase deficiency,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,25647543[PMID]
23412,440713,Isolated sedoheptulokinase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25647543[PMID]
23414,440727,Combined hamartoma of the retina and retinal pigment epithelium,Disease,Disorder,Cases/families,Case(s),,120.0,Worldwide,Validated,23960997[PMID]
23414,440727,Combined hamartoma of the retina and retinal pigment epithelium,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23960997[PMID]
23415,440731,L-ferritin deficiency,Biological anomaly,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,23940258[PMID]_15173247[PMID]
23415,440731,L-ferritin deficiency,Biological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23940258[PMID]_15173247[PMID]
23411,440706,Ribose-5-P isomerase deficiency,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,14988808[PMID]
23411,440706,Ribose-5-P isomerase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_14988808[PMID]
23439,443084,Baroreflex failure,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
23437,443073,Charcot-Marie-Tooth disease type 2S,Disease,Disorder,Cases/families,Case(s),,35.0,Worldwide,Validated,28065684[PMID]_28202949[PMID]
23437,443073,Charcot-Marie-Tooth disease type 2S,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28065684[PMID]_28202949[PMID]
23427,442835,Non-specific early-onset epileptic encephalopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
23424,442582,AH amyloidosis,Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,20876678[PMID]_23302715[PMID]_23446254[PMID]
23424,442582,AH amyloidosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20876678[PMID]_23302715[PMID]_23446254[PMID]
23451,443197,X-linked erythropoietic protoporphyria,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,24131146[PMID]
23451,443197,X-linked erythropoietic protoporphyria,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24131146[PMID]
8026,3008,Pyruvate carboxylase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.4,Europe,Validated,ISBN:79130356[OTHER]
8026,3008,Pyruvate carboxylase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
23450,443192,Classic stiff person syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
8027,595,Centronuclear myopathy,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
8030,298,Mitochondrial neurogastrointestinal encephalomyopathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,European Medicines Agency[INST]
8030,298,Mitochondrial neurogastrointestinal encephalomyopathy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.3,Israel,Validated,33239050[PMID]
8030,298,Mitochondrial neurogastrointestinal encephalomyopathy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Specific population,Validated,33239050[PMID]
8031,396,Chronic hiccup,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,[EXPERT]
23453,443236,Postural orthostatic tachycardia syndrome due to NET deficiency,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,10684912[PMID]
23453,443236,Postural orthostatic tachycardia syndrome due to NET deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10684912[PMID]
8028,552,MODY,Disease,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Validated,ORPHANET
8028,552,MODY,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,United Kingdom,Validated,20499044[PMID]
8029,854,Non-malignant and non-cirrhotic portal vein thrombosis,Clinical syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.7,Sweden,Validated,21039677[PMID]
8029,854,Non-malignant and non-cirrhotic portal vein thrombosis,Clinical syndrome,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.7,Sweden,Validated,21039677[PMID]
8029,854,Non-malignant and non-cirrhotic portal vein thrombosis,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
8029,854,Non-malignant and non-cirrhotic portal vein thrombosis,Clinical syndrome,Disorder,Annual incidence,Value and class,,2.75,Italy,Validated,28180235[PMID]
8029,854,Non-malignant and non-cirrhotic portal vein thrombosis,Clinical syndrome,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.72,Europe,Validated,21039677[PMID]_28180235[PMID]
23443,443098,Hyperostosis cranialis interna,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,20140965[PMID]
23443,443098,Hyperostosis cranialis interna,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20140965[PMID]
23440,443087,"46,XY difference of sex development due to testicular 17,20-desmolase deficiency",Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,21802064[PMID]
23440,443087,"46,XY difference of sex development due to testicular 17,20-desmolase deficiency",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21802064[PMID]
8022,130,Brugada syndrome,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.0,Europe,Not yet validated,ORPHANET
8022,130,Brugada syndrome,Disease,Disorder,Point prevalence,Value and class,6-9 / 10 000,75.0,South East Asia,Not yet validated,15898165[PMID]_23916535[PMID]
8023,277,Severe combined immunodeficiency due to adenosine deaminase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.3,Europe,Validated,20301656[PMID]_ ORPHANET_[EXPERT]
8023,277,Severe combined immunodeficiency due to adenosine deaminase deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2,Europe,Validated,European Medicines Agency[INST]
23446,443162,NDE1-related microhydranencephaly,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,22526350[PMID]
23446,443162,NDE1-related microhydranencephaly,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22526350[PMID]
23467,443804,Focal stiff limb syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
23467,443804,Focal stiff limb syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
23468,443811,PGM3-CDG,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,24698316[PMID]_24589341[PMID]_24931394[PMID]
23468,443811,PGM3-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24698316[PMID]_24589341[PMID]_24931394[PMID]
23470,443950,DNAJB2-related Charcot-Marie-Tooth disease type 2,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,25274842[PMID]
23470,443950,DNAJB2-related Charcot-Marie-Tooth disease type 2,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25274842[PMID]
23471,443988,Ventriculomegaly-cystic kidney disease,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,25557780[PMID]_2478019[PMID]
23471,443988,Ventriculomegaly-cystic kidney disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25557780[PMID]_2478019[PMID]
23481,444092,Autoimmune interstitial lung disease-arthritis syndrome,Disease,Disorder,Cases/families,Family(ies),,5.0,Worldwide,Validated,25894502[PMID]
23481,444092,Autoimmune interstitial lung disease-arthritis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25894502[PMID]
23482,444099,Autosomal dominant spastic paraplegia type 73,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,25751282[PMID]
23482,444099,Autosomal dominant spastic paraplegia type 73,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25751282[PMID]
23486,444138,Peeling skin-leukonychia-acral punctate keratoses-cheilitis-knuckle pads syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,25683118[PMID]
23486,444138,Peeling skin-leukonychia-acral punctate keratoses-cheilitis-knuckle pads syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25683118[PMID]
23473,444002,11q22.2q22.3 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,25735893[PMID]
23473,444002,11q22.2q22.3 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25735893[PMID]
23472,443995,Mandibulofacial dysostosis with alopecia,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,25772936[PMID]
23472,443995,Mandibulofacial dysostosis with alopecia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25772936[PMID]
23475,444048,"46,XX ovarian dysgenesis-short stature syndrome",Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,25480036[PMID]
23475,444048,"46,XX ovarian dysgenesis-short stature syndrome",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25480036[PMID]
23474,444013,Combined oxidative phosphorylation defect type 23,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,25434004[PMID]
23474,444013,Combined oxidative phosphorylation defect type 23,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25434004[PMID]
23477,444069,Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,25564561[PMID]
23477,444069,Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25564561[PMID]
23476,444051,20q11.2 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,25572454[PMID]
23476,444051,20q11.2 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25572454[PMID]
23479,444077,Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,31058441[PMID]
23479,444077,Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_31058441[PMID]
23478,444072,Cerebellar-facial-dental syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,25561519[PMID]
23478,444072,Cerebellar-facial-dental syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25561519[PMID]
23490,444463,Autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome due to TPP2 deficiency,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,25414442[PMID]_25525876[PMID]
23490,444463,Autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome due to TPP2 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25414442[PMID]_25525876[PMID]
23491,444490,Familial chylomicronemia syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,United States,Validated,15758547[PMID]
23491,444490,Familial chylomicronemia syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.97,Europe,Validated,European Medicines Agency 2014[INST]
23489,444458,Combined oxidative phosphorylation defect type 24,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,25629079[PMID]_25385316[PMID]
23489,444458,Combined oxidative phosphorylation defect type 24,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25629079[PMID]_25385316[PMID]
23519,445110,Limb-girdle muscular dystrophy due to POMK deficiency,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,24925318[PMID]
23519,445110,Limb-girdle muscular dystrophy due to POMK deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24925318[PMID]
23517,445062,Juvenile-onset diabetes mellitus-central and peripheral neurodegeneration syndrome,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,25466870[PMID]
23517,445062,Juvenile-onset diabetes mellitus-central and peripheral neurodegeneration syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25466870[PMID]
23516,445038,3-methylglutaconic aciduria-neonatal cataract-neurologic involvement-congenital neutropenia syndrome,Disease,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,25650066[PMID]_25597511[PMID]_25597510[PMID]
23516,445038,3-methylglutaconic aciduria-neonatal cataract-neurologic involvement-congenital neutropenia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25650066[PMID]_25597511[PMID]_25597510[PMID]
23515,445018,Combined immunodeficiency due to LRBA deficiency,Disease,Disorder,Cases/families,Case(s),,23.0,Worldwide,Validated,22721650[PMID]_22981790[PMID]_25468195[PMID]_26206937[PMID]_22608502[PMID]
23515,445018,Combined immunodeficiency due to LRBA deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22721650[PMID]_22981790[PMID]_25468195[PMID]_26206937[PMID]_22608502[PMID]
23533,447731,NIK deficiency,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,25406581[PMID]
23533,447731,NIK deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25406581[PMID]
23534,447737,Combined immunodeficiency due to DOCK2 deficiency,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,26083206[PMID]
23534,447737,Combined immunodeficiency due to DOCK2 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26083206[PMID]
23549,447881,Idiopathic dropped head syndrome,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
23551,447896,Tremor-ataxia-central hypomyelination syndrome,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,20640464[PMID]_22384513[PMID]
23551,447896,Tremor-ataxia-central hypomyelination syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20640464[PMID]
23550,447893,Hypomyelination-cerebellar atrophy-hypoplasia of the corpus callosum syndrome,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,18851904[PMID]_22036171[PMID]
23550,447893,Hypomyelination-cerebellar atrophy-hypoplasia of the corpus callosum syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18851904[PMID]_22036171[PMID]
23544,447788,Cerebral visual impairment,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
23546,447795,Lipoyl transferase 2 deficiency,Biological anomaly,Disorder,Point prevalence,Class only,Not yet documented,0.0,Worldwide,Validated,ORPHANET
23543,447784,Mitochondrial pyruvate carrier deficiency,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,22628558[PMID]_12649063[PMID]
23543,447784,Mitochondrial pyruvate carrier deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22628558[PMID]_12649063[PMID]
23537,447757,Autosomal dominant spastic paraplegia type 9B,Disease,Disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,26026163[PMID]
23537,447757,Autosomal dominant spastic paraplegia type 9B,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26026163[PMID]
23536,447753,Autosomal dominant spastic paraplegia type 9A,Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,8779323[PMID]_9973297[PMID]
23536,447753,Autosomal dominant spastic paraplegia type 9A,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8779323[PMID]_9973297[PMID]
23538,447760,Autosomal recessive spastic paraplegia type 9B,Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,26026163[PMID]
23538,447760,Autosomal recessive spastic paraplegia type 9B,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26026163[PMID]
23041,412066,PRKAR1B-related neurodegenerative dementia with intermediate filaments,Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,24722252[PMID]_25108559[PMID]
23041,412066,PRKAR1B-related neurodegenerative dementia with intermediate filaments,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24722252[PMID]_25108559[PMID]
23040,412057,Autosomal recessive cerebellar ataxia due to STUB1 deficiency,Disease,Disorder,Cases/families,Family(ies),,10.0,Worldwide,Validated,24312598[PMID]_24742043[PMID]_25258038[PMID]_25592071[PMID]_24719489[PMID]
23040,412057,Autosomal recessive cerebellar ataxia due to STUB1 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24312598[PMID]_24742043[PMID]_25258038[PMID]_25592071[PMID]_24719489[PMID]
23043,412181,Epidermolysis bullosa simplex due to BP230 deficiency,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,20164846[PMID]_22113475[PMID]_24690439[PMID]
23043,412181,Epidermolysis bullosa simplex due to BP230 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20164846[PMID]_22113475[PMID]_24690439[PMID]
23042,412069,AHDC1-related intellectual disability-obstructive sleep apnea-mild dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,24791903[PMID]
23042,412069,AHDC1-related intellectual disability-obstructive sleep apnea-mild dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24791903[PMID]
23044,412189,Epidermolysis bullosa simplex due to exophilin 5 deficiency,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,24690439[PMID]_23176819[PMID]
23044,412189,Epidermolysis bullosa simplex due to exophilin 5 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24690439[PMID]_23176819[PMID]
23047,412217,Dystonia-aphonia syndrome,Disease,Disorder,Cases/families,Case(s),,32.0,Worldwide,Validated,24359844[PMID]_26924602[PMID]
23047,412217,Dystonia-aphonia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26924602[PMID]
23090,418959,Squamous cell carcinoma of the stomach,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
23090,418959,Squamous cell carcinoma of the stomach,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.115,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23090,418959,Squamous cell carcinoma of the stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.063,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23090,418959,Squamous cell carcinoma of the stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.025,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23090,418959,Squamous cell carcinoma of the stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.08,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23090,418959,Squamous cell carcinoma of the stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.034,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23090,418959,Squamous cell carcinoma of the stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.092,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23090,418959,Squamous cell carcinoma of the stomach,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.176,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23090,418959,Squamous cell carcinoma of the stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.065,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23090,418959,Squamous cell carcinoma of the stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.08,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23090,418959,Squamous cell carcinoma of the stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.079,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23090,418959,Squamous cell carcinoma of the stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.043,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23090,418959,Squamous cell carcinoma of the stomach,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.207,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23090,418959,Squamous cell carcinoma of the stomach,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23090,418959,Squamous cell carcinoma of the stomach,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.401,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23090,418959,Squamous cell carcinoma of the stomach,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.137,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23090,418959,Squamous cell carcinoma of the stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.031,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23090,418959,Squamous cell carcinoma of the stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.046,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23090,418959,Squamous cell carcinoma of the stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.04,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23090,418959,Squamous cell carcinoma of the stomach,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.115,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23090,418959,Squamous cell carcinoma of the stomach,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.111,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23090,418959,Squamous cell carcinoma of the stomach,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23090,418959,Squamous cell carcinoma of the stomach,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.128,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23090,418959,Squamous cell carcinoma of the stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.051,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23090,418959,Squamous cell carcinoma of the stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.053,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23090,418959,Squamous cell carcinoma of the stomach,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.18,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23088,418945,"Carcinoma of esophagus, salivary gland type",Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.004,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23088,418945,"Carcinoma of esophagus, salivary gland type",Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23088,418945,"Carcinoma of esophagus, salivary gland type",Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.017,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23088,418945,"Carcinoma of esophagus, salivary gland type",Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23088,418945,"Carcinoma of esophagus, salivary gland type",Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.007,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23088,418945,"Carcinoma of esophagus, salivary gland type",Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.009,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23088,418945,"Carcinoma of esophagus, salivary gland type",Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23088,418945,"Carcinoma of esophagus, salivary gland type",Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.004,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23088,418945,"Carcinoma of esophagus, salivary gland type",Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.009,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23088,418945,"Carcinoma of esophagus, salivary gland type",Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.001,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23088,418945,"Carcinoma of esophagus, salivary gland type",Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23088,418945,"Carcinoma of esophagus, salivary gland type",Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.013,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23088,418945,"Carcinoma of esophagus, salivary gland type",Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23088,418945,"Carcinoma of esophagus, salivary gland type",Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23088,418945,"Carcinoma of esophagus, salivary gland type",Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23088,418945,"Carcinoma of esophagus, salivary gland type",Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23088,418945,"Carcinoma of esophagus, salivary gland type",Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.008,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23088,418945,"Carcinoma of esophagus, salivary gland type",Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.004,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23089,418951,Undifferentiated carcinoma of esophagus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.044,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23089,418951,Undifferentiated carcinoma of esophagus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.029,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23089,418951,Undifferentiated carcinoma of esophagus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.077,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23089,418951,Undifferentiated carcinoma of esophagus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.027,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23089,418951,Undifferentiated carcinoma of esophagus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23089,418951,Undifferentiated carcinoma of esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.115,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23089,418951,Undifferentiated carcinoma of esophagus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.037,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23089,418951,Undifferentiated carcinoma of esophagus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23089,418951,Undifferentiated carcinoma of esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.118,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23089,418951,Undifferentiated carcinoma of esophagus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.042,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23089,418951,Undifferentiated carcinoma of esophagus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.085,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23089,418951,Undifferentiated carcinoma of esophagus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.012,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23089,418951,Undifferentiated carcinoma of esophagus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.041,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23089,418951,Undifferentiated carcinoma of esophagus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.087,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23089,418951,Undifferentiated carcinoma of esophagus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.021,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23089,418951,Undifferentiated carcinoma of esophagus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.038,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23089,418951,Undifferentiated carcinoma of esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.101,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23089,418951,Undifferentiated carcinoma of esophagus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.021,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23089,418951,Undifferentiated carcinoma of esophagus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.082,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23089,418951,Undifferentiated carcinoma of esophagus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.013,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23089,418951,Undifferentiated carcinoma of esophagus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.051,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23089,418951,Undifferentiated carcinoma of esophagus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.023,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23089,418951,Undifferentiated carcinoma of esophagus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.025,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23089,418951,Undifferentiated carcinoma of esophagus,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.039,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23101,420179,Malan overgrowth syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,25118028[PMID]
23101,420179,Malan overgrowth syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25118028[PMID]
23081,415286,Bilirubin encephalopathy,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,15254556[PMID]
23125,420789,Autoimmune encephalopathy with parasomnia and obstructive sleep apnea,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,2623676[PMID]
23125,420789,Autoimmune encephalopathy with parasomnia and obstructive sleep apnea,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2623676[PMID]
23126,420794,Cono-spondylar dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,24975242[PMID]
23126,420794,Cono-spondylar dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24975242[PMID]
23120,420702,Autosomal recessive severe congenital neutropenia due to CSF3R deficiency,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,24753537[PMID]
23120,420702,Autosomal recessive severe congenital neutropenia due to CSF3R deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24753537[PMID]
23121,420728,Combined oxidative phosphorylation defect type 20,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,24958846[PMID]_25058219[PMID]
23121,420728,Combined oxidative phosphorylation defect type 20,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24958846[PMID]_25058219[PMID]
23122,420733,Combined oxidative phosphorylation defect type 21,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,24827421[PMID]
23122,420733,Combined oxidative phosphorylation defect type 21,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24827421[PMID]
23123,420741,RIDDLE syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,17940005[PMID]_21394101[PMID]
23123,420741,RIDDLE syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17940005[PMID]_21394101[PMID]
23109,420492,"Adult-onset cervical dystonia, DYT23 type",Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,8232359[PMID]_21370267[PMID]
23109,420492,"Adult-onset cervical dystonia, DYT23 type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8232359[PMID]_21370267[PMID]
23104,420402,Semicircular canal dehiscence syndrome,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
23106,420429,"Glycogen storage disease due to acid maltase deficiency, late-onset",Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.75,Worldwide,Validated,6789760[PMID]
23116,420584,Postaxial polydactyly-anterior pituitary anomalies-facial dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,112.0,Worldwide,Validated,24744436[PMID]
23116,420584,Postaxial polydactyly-anterior pituitary anomalies-facial dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24744436[PMID]
23119,420699,Autosomal recessive severe congenital neutropenia due to CXCR2 deficiency,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,24777453[PMID]
23119,420699,Autosomal recessive severe congenital neutropenia due to CXCR2 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24777453[PMID]
23118,420686,Woolly hair-palmoplantar keratoderma syndrome,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,24671081[PMID]
23118,420686,Woolly hair-palmoplantar keratoderma syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Not yet validated,ORPHANET_24671081[PMID]
23113,420561,Temple-Baraitser syndrome,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,27282200[PMID]
23113,420561,Temple-Baraitser syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27282200[PMID]
23115,420573,Severe combined immunodeficiency due to CTPS1 deficiency,Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,29942301[PMID]
23115,420573,Severe combined immunodeficiency due to CTPS1 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29942301[PMID]
23114,420566,Bleeding disorder due to CalDAG-GEFI deficiency,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,24958846[PMID]
23114,420566,Bleeding disorder due to CalDAG-GEFI deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24958846[PMID]
23158,423461,Mucolipidosis type III alpha/beta,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-5 / 10 000,13.0,Worldwide,Validated,20301730[PMID]
23159,423470,Mucolipidosis type III gamma,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_20301784[PMID]
23157,423454,Nail and teeth abnormalities-marginal palmoplantar keratoderma-oral hyperpigmentation syndrome,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,25152456[PMID]
23157,423454,Nail and teeth abnormalities-marginal palmoplantar keratoderma-oral hyperpigmentation syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25152456[PMID]
23154,423384,Severe congenital neutropenia due to JAGN1 deficiency,Disease,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,25129144[PMID]
23154,423384,Severe congenital neutropenia due to JAGN1 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25129144[PMID]
23152,423296,Spinocerebellar ataxia type 38,Disease,Disorder,Cases/families,Family(ies),,4.0,Worldwide,Validated,25065913[PMID]
23152,423296,Spinocerebellar ataxia type 38,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25065913[PMID]
23153,423306,Microcephaly-short stature-intellectual disability-facial dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,24709618[PMID]
23153,423306,Microcephaly-short stature-intellectual disability-facial dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24709618[PMID]
23160,423479,X-linked intellectual disability-limb spasticity-retinal dystrophy-arginine vasopressin deficiency,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,24961627[PMID]
23160,423479,X-linked intellectual disability-limb spasticity-retinal dystrophy-arginine vasopressin deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24961627[PMID]
23138,422526,Hereditary clear cell renal cell carcinoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
23151,423275,Spinocerebellar ataxia type 40,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,25062847[PMID]
23151,423275,Spinocerebellar ataxia type 40,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25062847[PMID]
23193,424065,Solid pseudopapillary carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23193,424065,Solid pseudopapillary carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23193,424065,Solid pseudopapillary carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.008,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23193,424065,Solid pseudopapillary carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23193,424065,Solid pseudopapillary carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.011,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23193,424065,Solid pseudopapillary carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23193,424065,Solid pseudopapillary carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.004,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23193,424065,Solid pseudopapillary carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23193,424065,Solid pseudopapillary carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23193,424065,Solid pseudopapillary carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.009,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23193,424065,Solid pseudopapillary carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23193,424065,Solid pseudopapillary carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.001,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23192,424058,Intraductal papillary mucinous carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.011,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23192,424058,Intraductal papillary mucinous carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.017,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23192,424058,Intraductal papillary mucinous carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.028,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23192,424058,Intraductal papillary mucinous carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.031,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23192,424058,Intraductal papillary mucinous carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.048,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23192,424058,Intraductal papillary mucinous carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23192,424058,Intraductal papillary mucinous carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23192,424058,Intraductal papillary mucinous carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.041,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23192,424058,Intraductal papillary mucinous carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23192,424058,Intraductal papillary mucinous carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.018,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23192,424058,Intraductal papillary mucinous carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.028,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23192,424058,Intraductal papillary mucinous carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.016,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23192,424058,Intraductal papillary mucinous carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.001,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23195,424080,Undifferentiated carcinoma with osteoclast-like giant cells of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23195,424080,Undifferentiated carcinoma with osteoclast-like giant cells of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23195,424080,Undifferentiated carcinoma with osteoclast-like giant cells of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23195,424080,Undifferentiated carcinoma with osteoclast-like giant cells of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.001,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23195,424080,Undifferentiated carcinoma with osteoclast-like giant cells of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.043,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23195,424080,Undifferentiated carcinoma with osteoclast-like giant cells of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.001,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23195,424080,Undifferentiated carcinoma with osteoclast-like giant cells of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.004,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23195,424080,Undifferentiated carcinoma with osteoclast-like giant cells of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.004,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23195,424080,Undifferentiated carcinoma with osteoclast-like giant cells of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.001,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23194,424073,Serous cystadenocarcinoma of pancreas,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23194,424073,Serous cystadenocarcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23194,424073,Serous cystadenocarcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23194,424073,Serous cystadenocarcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.001,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23197,424107,Congenital myopathy with myasthenic-like onset,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,24951453[PMID]
23197,424107,Congenital myopathy with myasthenic-like onset,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24951453[PMID]
23196,424099,Colobomatous microphthalmia-rhizomelic dysplasia syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,5.0,Worldwide,Validated,24906020[PMID]
23196,424099,Colobomatous microphthalmia-rhizomelic dysplasia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24906020[PMID]
23198,424261,TOR1AIP1-related limb-girdle muscular dystrophy,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,24856141[PMID]
23198,424261,TOR1AIP1-related limb-girdle muscular dystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24856141[PMID]
23185,424016,Adenocarcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.253,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23185,424016,Adenocarcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.238,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23185,424016,Adenocarcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.226,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23185,424016,Adenocarcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.485,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23185,424016,Adenocarcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.076,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23185,424016,Adenocarcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.269,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23185,424016,Adenocarcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.24,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23185,424016,Adenocarcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.105,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23185,424016,Adenocarcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.09,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23185,424016,Adenocarcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23185,424016,Adenocarcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.256,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23185,424016,Adenocarcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.299,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23185,424016,Adenocarcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.499,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23185,424016,Adenocarcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.287,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23185,424016,Adenocarcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.215,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23185,424016,Adenocarcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.144,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23185,424016,Adenocarcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.217,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23185,424016,Adenocarcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.406,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23185,424016,Adenocarcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.382,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23185,424016,Adenocarcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.343,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23185,424016,Adenocarcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.135,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23185,424016,Adenocarcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23185,424016,Adenocarcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.26,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23187,424027,Progressive myoclonic epilepsy type 8,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,24782409[PMID]
23187,424027,Progressive myoclonic epilepsy type 8,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24782409[PMID]
23186,424019,Squamous cell carcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.81,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23186,424019,Squamous cell carcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.923,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23186,424019,Squamous cell carcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.707,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23186,424019,Squamous cell carcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.268,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23186,424019,Squamous cell carcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.251,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23186,424019,Squamous cell carcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.568,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23186,424019,Squamous cell carcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.6,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23186,424019,Squamous cell carcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.464,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23186,424019,Squamous cell carcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.096,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23186,424019,Squamous cell carcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.307,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23186,424019,Squamous cell carcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.809,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23186,424019,Squamous cell carcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.416,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23186,424019,Squamous cell carcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.872,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23186,424019,Squamous cell carcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.238,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23186,424019,Squamous cell carcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.153,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23186,424019,Squamous cell carcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.071,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23186,424019,Squamous cell carcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.411,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23186,424019,Squamous cell carcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.603,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23186,424019,Squamous cell carcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.194,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23186,424019,Squamous cell carcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.331,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23186,424019,Squamous cell carcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.712,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23186,424019,Squamous cell carcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.621,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23186,424019,Squamous cell carcinoma of the anal canal,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.038,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23189,424039,Squamous cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.023,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23189,424039,Squamous cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.044,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23189,424039,Squamous cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23189,424039,Squamous cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.027,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23189,424039,Squamous cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.028,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23189,424039,Squamous cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.045,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23189,424039,Squamous cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.028,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23189,424039,Squamous cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.012,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23189,424039,Squamous cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.015,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23189,424039,Squamous cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.032,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23189,424039,Squamous cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.034,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23189,424039,Squamous cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.019,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23189,424039,Squamous cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.06,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23189,424039,Squamous cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.058,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23189,424039,Squamous cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23189,424039,Squamous cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.008,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23189,424039,Squamous cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.016,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23189,424039,Squamous cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23189,424039,Squamous cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.027,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23189,424039,Squamous cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23189,424039,Squamous cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.011,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23189,424039,Squamous cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.023,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23191,424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23191,424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,RARECARE
23191,424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23191,424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23191,424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23191,424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.012,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23191,424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23191,424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.012,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23191,424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.019,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23191,424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.004,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23191,424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.024,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23191,424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23191,424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.019,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23191,424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.004,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23190,424046,Acinar cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.029,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23190,424046,Acinar cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.049,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23190,424046,Acinar cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.039,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23190,424046,Acinar cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.034,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23190,424046,Acinar cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23190,424046,Acinar cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.044,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23190,424046,Acinar cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.083,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23190,424046,Acinar cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.024,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23190,424046,Acinar cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23190,424046,Acinar cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.058,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23190,424046,Acinar cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.028,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23190,424046,Acinar cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.039,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23190,424046,Acinar cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.07,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23190,424046,Acinar cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.027,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23190,424046,Acinar cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23190,424046,Acinar cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23190,424046,Acinar cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.05,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23190,424046,Acinar cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.024,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23190,424046,Acinar cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.039,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23190,424046,Acinar cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.017,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23190,424046,Acinar cell carcinoma of pancreas,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.016,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23176,423968,Squamous cell carcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.008,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23176,423968,Squamous cell carcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.008,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23176,423968,Squamous cell carcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.008,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23176,423968,Squamous cell carcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23176,423968,Squamous cell carcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23176,423968,Squamous cell carcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.013,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23176,423968,Squamous cell carcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23176,423968,Squamous cell carcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.008,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23176,423968,Squamous cell carcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.004,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23176,423968,Squamous cell carcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.012,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23176,423968,Squamous cell carcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.007,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23176,423968,Squamous cell carcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.022,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23176,423968,Squamous cell carcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23176,423968,Squamous cell carcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23176,423968,Squamous cell carcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23176,423968,Squamous cell carcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23176,423968,Squamous cell carcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.027,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23176,423968,Squamous cell carcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.011,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23176,423968,Squamous cell carcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23176,423968,Squamous cell carcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.012,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23180,423994,Squamous cell carcinoma of the colon,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.026,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23180,423994,Squamous cell carcinoma of the colon,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.072,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23180,423994,Squamous cell carcinoma of the colon,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.014,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23180,423994,Squamous cell carcinoma of the colon,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.035,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23180,423994,Squamous cell carcinoma of the colon,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.008,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23180,423994,Squamous cell carcinoma of the colon,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.022,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23180,423994,Squamous cell carcinoma of the colon,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.009,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23180,423994,Squamous cell carcinoma of the colon,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.014,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23180,423994,Squamous cell carcinoma of the colon,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.026,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23180,423994,Squamous cell carcinoma of the colon,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.028,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23180,423994,Squamous cell carcinoma of the colon,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.025,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23180,423994,Squamous cell carcinoma of the colon,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.041,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23180,423994,Squamous cell carcinoma of the colon,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.13,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23180,423994,Squamous cell carcinoma of the colon,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.037,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23180,423994,Squamous cell carcinoma of the colon,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23180,423994,Squamous cell carcinoma of the colon,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23180,423994,Squamous cell carcinoma of the colon,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.035,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23180,423994,Squamous cell carcinoma of the colon,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.027,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23180,423994,Squamous cell carcinoma of the colon,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.024,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23180,423994,Squamous cell carcinoma of the colon,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.017,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23180,423994,Squamous cell carcinoma of the colon,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23180,423994,Squamous cell carcinoma of the colon,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.021,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23182,424002,Squamous cell carcinoma of the rectum,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.113,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23182,424002,Squamous cell carcinoma of the rectum,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.126,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23182,424002,Squamous cell carcinoma of the rectum,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.052,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23182,424002,Squamous cell carcinoma of the rectum,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.088,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23182,424002,Squamous cell carcinoma of the rectum,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.017,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23182,424002,Squamous cell carcinoma of the rectum,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.26,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23182,424002,Squamous cell carcinoma of the rectum,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.157,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23182,424002,Squamous cell carcinoma of the rectum,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.045,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23182,424002,Squamous cell carcinoma of the rectum,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.074,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23182,424002,Squamous cell carcinoma of the rectum,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.083,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23182,424002,Squamous cell carcinoma of the rectum,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.128,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23182,424002,Squamous cell carcinoma of the rectum,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.096,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23182,424002,Squamous cell carcinoma of the rectum,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.149,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23182,424002,Squamous cell carcinoma of the rectum,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.346,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23182,424002,Squamous cell carcinoma of the rectum,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.116,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23182,424002,Squamous cell carcinoma of the rectum,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.071,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23182,424002,Squamous cell carcinoma of the rectum,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.111,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23182,424002,Squamous cell carcinoma of the rectum,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.119,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23182,424002,Squamous cell carcinoma of the rectum,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.05,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23182,424002,Squamous cell carcinoma of the rectum,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.042,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23182,424002,Squamous cell carcinoma of the rectum,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.084,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23182,424002,Squamous cell carcinoma of the rectum,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.028,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23182,424002,Squamous cell carcinoma of the rectum,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.143,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23170,423786,Undifferentiated carcinoma of stomach,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.211,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23170,423786,Undifferentiated carcinoma of stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.086,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23170,423786,Undifferentiated carcinoma of stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.077,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23170,423786,Undifferentiated carcinoma of stomach,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.764,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23170,423786,Undifferentiated carcinoma of stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.068,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23170,423786,Undifferentiated carcinoma of stomach,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.328,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23170,423786,Undifferentiated carcinoma of stomach,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.743,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23170,423786,Undifferentiated carcinoma of stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23170,423786,Undifferentiated carcinoma of stomach,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23170,423786,Undifferentiated carcinoma of stomach,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.221,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23170,423786,Undifferentiated carcinoma of stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.085,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23170,423786,Undifferentiated carcinoma of stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.009,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23170,423786,Undifferentiated carcinoma of stomach,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.399,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23170,423786,Undifferentiated carcinoma of stomach,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.571,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23170,423786,Undifferentiated carcinoma of stomach,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.877,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23170,423786,Undifferentiated carcinoma of stomach,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.251,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23170,423786,Undifferentiated carcinoma of stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.087,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23170,423786,Undifferentiated carcinoma of stomach,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.386,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23170,423786,Undifferentiated carcinoma of stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.072,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23170,423786,Undifferentiated carcinoma of stomach,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.456,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23170,423786,Undifferentiated carcinoma of stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.013,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23170,423786,Undifferentiated carcinoma of stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.098,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23170,423786,Undifferentiated carcinoma of stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.045,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23170,423786,Undifferentiated carcinoma of stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23170,423786,Undifferentiated carcinoma of stomach,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.032,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23174,423894,Microcephaly-complex motor and sensory axonal neuropathy syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,24126608[PMID]
23174,423894,Microcephaly-complex motor and sensory axonal neuropathy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24126608[PMID]
23231,431140,X-linked colobomatous microphthalmia-microcephaly-intellectual disability-short stature syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,4998085[PMID]_24993872[PMID]
23231,431140,X-linked colobomatous microphthalmia-microcephaly-intellectual disability-short stature syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4998085[PMID]_24993872[PMID]
23209,425120,STING-associated vasculopathy with onset in infancy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25401470[PMID]_25029335[PMID]
23209,425120,STING-associated vasculopathy with onset in infancy,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,25401470[PMID]_25029335[PMID]
23202,424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.412,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23202,424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.715,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23202,424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.201,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23202,424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.219,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23202,424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.659,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23202,424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.471,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23202,424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.309,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23202,424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.262,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23202,424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.582,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23202,424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.256,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23202,424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.642,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23202,424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.426,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23202,424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.267,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23202,424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.481,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23202,424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.365,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23202,424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.154,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23202,424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.471,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23202,424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.377,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23202,424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.753,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23202,424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.157,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23202,424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.206,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23202,424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.467,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23202,424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.118,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23203,424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.015,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23203,424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.011,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23203,424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.056,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23203,424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.046,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23203,424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23203,424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23203,424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.03,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23203,424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.043,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23203,424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23203,424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.019,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23203,424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.049,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23203,424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.033,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23203,424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.011,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23203,424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.013,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23203,424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.016,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23203,424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.098,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23203,424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.015,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23203,424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.028,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23203,424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23206,424991,Adenocarcinoma of the gallbladder and extrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.62,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23207,424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.032,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23207,424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.026,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23207,424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23207,424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.027,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23207,424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.025,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23207,424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.124,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23207,424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.037,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23207,424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.026,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23207,424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.018,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23207,424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.055,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23207,424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.043,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23207,424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.018,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23207,424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.037,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23207,424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23207,424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.033,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23207,424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.016,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23207,424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.015,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23207,424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23207,424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.077,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23207,424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.042,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23207,424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.051,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23207,424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.014,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23207,424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.021,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23204,424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.009,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23204,424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.009,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23204,424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23204,424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.018,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23204,424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.009,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23204,424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.007,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23204,424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.008,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23204,424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.004,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23204,424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.019,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23204,424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.016,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23204,424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.004,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23204,424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23204,424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23204,424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23204,424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23204,424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.017,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23204,424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23204,424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.014,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23205,424982,Biliary cystadenocarcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23205,424982,Biliary cystadenocarcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23205,424982,Biliary cystadenocarcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23205,424982,Biliary cystadenocarcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23205,424982,Biliary cystadenocarcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23205,424982,Biliary cystadenocarcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.009,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23205,424982,Biliary cystadenocarcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23205,424982,Biliary cystadenocarcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23205,424982,Biliary cystadenocarcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23205,424982,Biliary cystadenocarcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23205,424982,Biliary cystadenocarcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23205,424982,Biliary cystadenocarcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23205,424982,Biliary cystadenocarcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.009,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23205,424982,Biliary cystadenocarcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23205,424982,Biliary cystadenocarcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.001,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
23249,431361,Progressive encephalopathy with leukodystrophy due to DECR deficiency,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,24847004[PMID]_2332510[PMID]
23249,431361,Progressive encephalopathy with leukodystrophy due to DECR deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24847004[PMID]_2332510[PMID]
23248,431353,Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.015,France,Validated,20456932[PMID]
23245,431341,Patent urachus,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.75,United States,Validated,3404578[PMID]
23245,431341,Patent urachus,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
23246,431344,Urachal sinus,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
23241,431272,X-linked scapuloperoneal muscular dystrophy,Disease,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,18179901[PMID]_20633900[PMID]
23241,431272,X-linked scapuloperoneal muscular dystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18179901[PMID]_20633900[PMID]
23243,431329,Autosomal recessive spastic paraplegia type 57,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,23479643[PMID]
23243,431329,Autosomal recessive spastic paraplegia type 57,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23479643[PMID]
23238,431255,Scapuloperoneal spinal muscular atrophy,Disease,Disorder,Cases/families,Case(s),,31.0,Worldwide,Validated,26948711[PMID]
23238,431255,Scapuloperoneal spinal muscular atrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26948711[PMID]
23233,431149,Combined immunodeficiency due to OX40 deficiency,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,23897980[PMID]
23233,431149,Combined immunodeficiency due to OX40 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23897980[PMID]
23235,431166,Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,26424569[PMID]
23235,431166,Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26424569[PMID]
23295,435438,Progressive myoclonic epilepsy type 7,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,25401298[PMID]
23295,435438,Progressive myoclonic epilepsy type 7,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25401298[PMID]
23294,435387,Autosomal dominant Charcot-Marie-Tooth disease type 2Y,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,25125609[PMID]_25125609[PMID]
23294,435387,Autosomal dominant Charcot-Marie-Tooth disease type 2Y,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25125609[PMID]_25125609[PMID]
23291,435329,Familial ossifying fibroma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
23271,434179,Orofaciodigital syndrome type 14,Malformation syndrome,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,24997988[PMID]
23271,434179,Orofaciodigital syndrome type 14,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24997988[PMID]
26292,504476,Cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25564090[PMID]_30926972[PMID]
26292,504476,Cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,25564090[PMID]_30926972[PMID]
26293,504523,Severe combined immunodeficiency due to LAT deficiency,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,27522155[PMID]
26293,504523,Severe combined immunodeficiency due to LAT deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27522155[PMID]
26294,504530,Combined immunodeficiency due to Moesin deficiency,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,27405666[PMID]
26294,504530,Combined immunodeficiency due to Moesin deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27405666[PMID]
8768,26793,Very long chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
8768,26793,Very long chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.2,Australia,Validated,16488171[PMID]
8768,26793,Very long chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.8,United States,Validated,22766612[PMID]
8768,26793,Very long chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Germany,Validated,20547398[PMID]
8768,26793,Very long chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.3,Israel,Validated,33239050[PMID]
8768,26793,Very long chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.3,Specific population,Validated,33239050[PMID]
8768,26793,Very long chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.45,Czech Republic,Validated,31241292[PMID]
8775,29072,Hereditary pheochromocytoma-paraganglioma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.3,Worldwide,Not yet validated,20301715[PMID]_23162105[PMID]
8775,29072,Hereditary pheochromocytoma-paraganglioma,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
8772,28378,Tyrosinemia type 2,Disease,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,8912606[PMID]
8772,28378,Tyrosinemia type 2,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
8778,29207,Reactive arthritis,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Worldwide,Validated,ORPHANET
8776,29073,Multiple myeloma,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.8,United States,Validated,National Cancer Institute 2005[INST]
8776,29073,Multiple myeloma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,6.0,Worldwide,Validated,[EXPERT]
8776,29073,Multiple myeloma,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,11.9,Europe,Validated,World Health Organization 2008[INST]
8776,29073,Multiple myeloma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,7.7,France,Validated,Institut National du Cancer 2013[INST]
8776,29073,Multiple myeloma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.4,Europe,Validated,World Health Organization 2008[INST]
8776,29073,Multiple myeloma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.6,United States,Validated,National Cancer Institute 2005[INST]
8776,29073,Multiple myeloma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.0,"Iran, Islamic Republic of",Validated,23725136[PMID]
8776,29073,Multiple myeloma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.1,Australia,Validated,Cancer Institute New South Wales 2008[INST]
8776,29073,Multiple myeloma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,6.2,Denmark,Validated,36413106[PMID]
8780,29822,Spontaneous periodic hypothermia,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,21166673[PMID]_15990200[PMID]
8780,29822,Spontaneous periodic hypothermia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
8781,30391,Isolated biliary atresia,Morphological anomaly,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.6,Specific population,Validated,4824812[PMID]
8781,30391,Isolated biliary atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.9,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
8781,30391,Isolated biliary atresia,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
8781,30391,Isolated biliary atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.9,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
8781,30391,Isolated biliary atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.9,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
8781,30391,Isolated biliary atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.9,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
8781,30391,Isolated biliary atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.2,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
8781,30391,Isolated biliary atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,16.6,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
8781,30391,Isolated biliary atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.6,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
8781,30391,Isolated biliary atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.9,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
8781,30391,Isolated biliary atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,12.6,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
8781,30391,Isolated biliary atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.3,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
8781,30391,Isolated biliary atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,12.7,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
8781,30391,Isolated biliary atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,18.5,Worldwide,Validated,[EXPERT]
8781,30391,Isolated biliary atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.4,Japan,Validated,Japanese biliary atresia registry[REG]
8781,30391,Isolated biliary atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.0,United States,Not yet validated,9041292[PMID]_7069535[PMID]
8781,30391,Isolated biliary atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,32.0,French Polynesia,Validated,7987462[PMID]
8781,30391,Isolated biliary atresia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.0,Australia,Validated,559475[PMID]
8740,320,Apparent mineralocorticoid excess,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
8741,724,Idiopathic acute eosinophilic pneumonia,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,12403693[PMID]
8741,724,Idiopathic acute eosinophilic pneumonia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
8743,230,Dopamine beta-hydroxylase deficiency,Disease,Disorder,Cases/families,Case(s),,25.0,Worldwide,Validated,33034372[PMID]
8743,230,Dopamine beta-hydroxylase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,33034372[PMID]
8736,725,Developmental and epileptic encephalopathy with spike-wave activation in sleep,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
8737,590,Congenital myasthenic syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.3,Europe,Validated,[EXPERT]
8737,590,Congenital myasthenic syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.92,United Kingdom,Validated,24500997[PMID]
8738,404,Familial hyperaldosteronism type II,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
8739,756,Pseudohypoaldosteronism type 1,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.12,United Kingdom,Validated,24616761[PMID]
8739,756,Pseudohypoaldosteronism type 1,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
8748,162,Congenital cataract-anterior segment dysgenesis syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,15665340[PMID]
8748,162,Congenital cataract-anterior segment dysgenesis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15665340[PMID]
8749,544,Diffuse large B-cell lymphoma,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,43.0,Europe,Validated,European Medicines Agency 2018[INST]
8749,544,Diffuse large B-cell lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,6.5,France,Validated,Institut National du Cancer 2013[INST]
8749,544,Diffuse large B-cell lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.79,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8749,544,Diffuse large B-cell lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.765,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8749,544,Diffuse large B-cell lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.298,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8749,544,Diffuse large B-cell lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.227,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8749,544,Diffuse large B-cell lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.51,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8749,544,Diffuse large B-cell lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.229,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8749,544,Diffuse large B-cell lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.304,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8749,544,Diffuse large B-cell lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.815,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8749,544,Diffuse large B-cell lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.244,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8749,544,Diffuse large B-cell lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.586,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8749,544,Diffuse large B-cell lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.559,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8749,544,Diffuse large B-cell lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.458,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8749,544,Diffuse large B-cell lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,6.47,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8749,544,Diffuse large B-cell lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.984,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8749,544,Diffuse large B-cell lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.827,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8749,544,Diffuse large B-cell lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.115,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8749,544,Diffuse large B-cell lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.673,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8749,544,Diffuse large B-cell lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.635,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8749,544,Diffuse large B-cell lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.259,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8749,544,Diffuse large B-cell lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.773,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8749,544,Diffuse large B-cell lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.78,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8749,544,Diffuse large B-cell lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,6.328,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8749,544,Diffuse large B-cell lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,6.478,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8749,544,Diffuse large B-cell lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.931,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8750,545,Follicular lymphoma,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,37.0,Europe,Validated,European Medicines Agency 2018[INST]
8750,545,Follicular lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.95,France,Validated,Institut National du Cancer 2013[INST]
8750,545,Follicular lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.192,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8750,545,Follicular lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.348,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8750,545,Follicular lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.72,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8750,545,Follicular lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.579,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8750,545,Follicular lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.363,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8750,545,Follicular lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.277,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8750,545,Follicular lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.368,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8750,545,Follicular lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.52,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8750,545,Follicular lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.04,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8750,545,Follicular lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.665,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8750,545,Follicular lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.687,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8750,545,Follicular lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.456,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8750,545,Follicular lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.769,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8750,545,Follicular lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.08,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8750,545,Follicular lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.541,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8750,545,Follicular lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.759,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8750,545,Follicular lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.298,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8750,545,Follicular lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.364,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8750,545,Follicular lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.046,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8750,545,Follicular lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.389,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8750,545,Follicular lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.375,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8750,545,Follicular lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.916,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8750,545,Follicular lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.977,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8750,545,Follicular lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.766,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8751,88,Idiopathic aplastic anemia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.4,Europe,Not yet validated,ORPHANET
8751,88,Idiopathic aplastic anemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.27,Brazil,Validated,35209917[PMID]
8744,102,Multiple system atrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.7,Europe,Not yet validated,ORPHANET
8744,102,Multiple system atrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.5,Worldwide,Validated,[EXPERT]
8744,102,Multiple system atrophy,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.8,Worldwide,Validated,[EXPERT]
8744,102,Multiple system atrophy,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.7,Iceland,Validated,23192520[PMID]
8744,102,Multiple system atrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.4,Iceland,Validated,23192520[PMID]
8744,102,Multiple system atrophy,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.1,Sweden,Validated,20108376[PMID]
8744,102,Multiple system atrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.4,United Kingdom,Validated,10577638[PMID]
8744,102,Multiple system atrophy,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.6,United States,Validated,9371909[PMID]
8744,102,Multiple system atrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.9,France,Validated,10841152[PMID]_15272223[PMID]
8744,102,Multiple system atrophy,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.11,Russian Federation,Validated,20108378[PMID]
8744,102,Multiple system atrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.9,Italy,Validated,9613728[PMID]
8744,102,Multiple system atrophy,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.3,Japan,Validated,20880268[PMID]_19169038[PMID]
8744,102,Multiple system atrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.3,Faroe Islands,Validated,9270572[PMID]
8745,824,Primary myelofibrosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.0,Europe,Validated,[EXPERT]
8745,824,Primary myelofibrosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.0,Europe,Validated,European Medicines Agency[INST]
8746,748,Mendelian susceptibility to mycobacterial diseases,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8747,729,Polycythemia vera,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.9,Europe,Validated,[EXPERT]
8747,729,Polycythemia vera,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,30.0,Europe,Validated,[EXPERT]_European Medicines Agency 2014[INST]
8747,729,Polycythemia vera,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,30.0,Italy,Validated,13679323[PMID]
8756,25980,X-linked myopathy with excessive autophagy,Disease,Disorder,Cases/families,Family(ies),,18.0,Worldwide,Validated,25809233[PMID]
8756,25980,X-linked myopathy with excessive autophagy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25809233[PMID]
8759,26137,Juvenile temporal arteritis,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,ORPHANET
8759,26137,Juvenile temporal arteritis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
8758,26106,Hereditary diffuse gastric cancer,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.5,Europe,Not yet validated,ORPHANET
8758,26106,Hereditary diffuse gastric cancer,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
26354,505395,Ventilator-induced diaphragmatic dysfunction,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_28887062[PMID]
8755,25968,Self-limited childhood occipital epilepsy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
8765,26790,Pseudomyxoma peritonei,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Worldwide,Validated,19838447[PMID]_17524597[PMID]_16678994[PMID]_[EXPERT]
8765,26790,Pseudomyxoma peritonei,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.2,Netherlands,Validated,17524597[PMID]
8765,26790,Pseudomyxoma peritonei,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8765,26790,Pseudomyxoma peritonei,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Europe,Validated,European Medicines Agency 2018[INST]
8767,26792,Short chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
8767,26792,Short chain acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.0,Netherlands,Validated,21500142[PMID]_22608595[PMID]_22241096[PMID]
8766,26791,Multiple acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.47,United States,Not yet validated,ORPHANET_24190796[PMID]
8766,26791,Multiple acyl-CoA dehydrogenase deficiency,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
8766,26791,Multiple acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Israel,Validated,33239050[PMID]
8766,26791,Multiple acyl-CoA dehydrogenase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Specific population,Validated,33239050[PMID]
8708,49,Penile agenesis,Morphological anomaly,Disorder,Cases/families,Case(s),,80.0,Worldwide,Validated,25786436[PMID]
8708,49,Penile agenesis,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25786436[PMID]
8709,227,Diphallia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.02,Worldwide,Not yet validated,23056729[PMID]
8709,227,Diphallia,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Not yet validated,23056729[PMID]
8707,674,Accessory pancreas,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
8718,266,Autosomal dominant limb-girdle muscular dystrophy type 1A,Disease,Disorder,Cases/families,Family(ies),,4.0,Worldwide,Validated,21336781[PMID]
8718,266,Autosomal dominant limb-girdle muscular dystrophy type 1A,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21336781[PMID]
8716,353,Gamma-sarcoglycan-related limb-girdle muscular dystrophy R5,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2,Europe,Validated,European Medicines Agency 2011[INST]
8716,353,Gamma-sarcoglycan-related limb-girdle muscular dystrophy R5,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.13,United Kingdom,Validated,19767415[PMID]
8716,353,Gamma-sarcoglycan-related limb-girdle muscular dystrophy R5,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.18,Japan,Validated,20350330[PMID]
8717,219,Delta-sarcoglycan-related limb-girdle muscular dystrophy R6,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.3,Europe,Validated,European Medicines Agency 2011[INST]
8714,641,Multifocal motor neuropathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.5,Worldwide,Validated,17075524[PMID]_11282149[PMID]_23623583[PMID]
8714,641,Multifocal motor neuropathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.16,Japan,Validated,23196468[PMID]
8715,119,Beta-sarcoglycan-related limb-girdle muscular dystrophy R4,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.07,United Kingdom,Validated,19767415[PMID]
8715,119,Beta-sarcoglycan-related limb-girdle muscular dystrophy R4,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,European Medicines Agency 2011[INST]
8727,603,"Distal myopathy, Welander type",Disease,Disorder,Point prevalence,Value and class,>1 / 1000,100.0,Sweden,Validated,DOI:https://doi.org/10.1016/S0960-8966(02)00116-5[OTHER]_ [EXPERT]
8727,603,"Distal myopathy, Welander type",Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
26326,505227,Combined immunodeficiency due to GINS1 deficiency,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,28414293[PMID]
26326,505227,Combined immunodeficiency due to GINS1 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28414293[PMID]
26327,505237,Early-onset seizures-distal limb anomalies-facial dysmorphism-global developmental delay syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,28343629[PMID]
26327,505237,Early-onset seizures-distal limb anomalies-facial dysmorphism-global developmental delay syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28343629[PMID]
8726,588,Muscle-eye-brain disease,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8725,899,Walker-Warburg syndrome,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.03,United Kingdom,Validated,19767415[PMID]
8725,899,Walker-Warburg syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.65,Europe,Validated,[EXPERT]
8725,899,Walker-Warburg syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,[EXPERT]
8725,899,Walker-Warburg syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.2,Italy,Validated,8786062[PMID]
26324,505216,3-methylglutaconic aciduria type 9,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,27573165[PMID]
26324,505216,3-methylglutaconic aciduria type 9,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27573165[PMID]
8724,272,"Congenital muscular dystrophy, Fukuyama type",Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.8,Japan,Validated,20301385[PMID]
8724,272,"Congenital muscular dystrophy, Fukuyama type",Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,20301385[PMID]_ORPHANET
26323,505208,3-methylglutaconic aciduria type 8,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,27208207[PMID]_27696117[PMID]
26323,505208,3-methylglutaconic aciduria type 8,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27208207[PMID]_27696117[PMID]
8720,268,Dysferlin-related limb-girdle muscular dystrophy R2,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.13,United Kingdom,Validated,19767415[PMID]
8720,268,Dysferlin-related limb-girdle muscular dystrophy R2,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
8734,263,Limb-girdle muscular dystrophy,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.81,Netherlands,Validated,8931572[PMID]
8734,263,Limb-girdle muscular dystrophy,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,2.27,United Kingdom,Validated,19767415[PMID]
8734,263,Limb-girdle muscular dystrophy,Clinical group,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
8734,263,Limb-girdle muscular dystrophy,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.55,Japan,Validated,1745328[PMID]
8734,263,Limb-girdle muscular dystrophy,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,2.32,Worldwide,Validated,25532075[PMID]
8734,263,Limb-girdle muscular dystrophy,Clinical group,Group of disorders,Lifetime Prevalence,Value and class,1-9 / 100 000,5.7,Egypt,Validated,16210862[PMID]
8734,263,Limb-girdle muscular dystrophy,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,6.9,Spain,Validated,9762961[PMID]
8734,263,Limb-girdle muscular dystrophy,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.1,Ireland,Validated,8845721[PMID]
8731,600,Vocal cord and pharyngeal distal myopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25952333[PMID]_29628183[PMID]
26330,505248,Mucopolysaccharidosis-like syndrome with congenital heart defects and hematopoietic disorders,Malformation syndrome,Disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,28013294[PMID]
26330,505248,Mucopolysaccharidosis-like syndrome with congenital heart defects and hematopoietic disorders,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28013294[PMID]
8730,609,Tibial muscular dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.0,Europe,Validated,24395473[PMID]
8730,609,Tibial muscular dystrophy,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.0,Finland,Validated,24395473[PMID]
8729,602,GNE myopathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Worldwide,Validated,25002140[PMID]
8729,602,GNE myopathy,Disease,Disorder,Point prevalence,Value and class,6-9 / 10 000,66.7,Specific population,Validated,12743242[PMID]
26329,505242,Psychomotor regression-oculomotor apraxia-movement disorder-nephropathy syndrome,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,28334855[PMID]
26329,505242,Psychomotor regression-oculomotor apraxia-movement disorder-nephropathy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28334855[PMID]
26544,508093,MEPAN syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,27817865[PMID]
26544,508093,MEPAN syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27817865[PMID]
26576,508533,Skeletal dysplasia-T-cell immunodeficiency-developmental delay syndrome,Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,28132690[PMID]_28148688[PMID]
26576,508533,Skeletal dysplasia-T-cell immunodeficiency-developmental delay syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28132690[PMID]_28148688[PMID]
26578,508542,Congenital progressive bone marrow failure-B-cell immunodeficiency-skeletal dysplasia syndrome,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,28115216[PMID]
26578,508542,Congenital progressive bone marrow failure-B-cell immunodeficiency-skeletal dysplasia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28115216[PMID]
26573,508512,Intrauterine growth restriction-congenital multiple café-au-lait macules-increased sister chromatid exchange syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,27977684[PMID]
26573,508512,Intrauterine growth restriction-congenital multiple café-au-lait macules-increased sister chromatid exchange syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27977684[PMID]
26575,508529,Intermediate epidermolysis bullosa simplex with cardiomyopathy,Disease,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,27889062[PMID]
26575,508529,Intermediate epidermolysis bullosa simplex with cardiomyopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27889062[PMID]
26574,508523,Hyperphenylalaninemia due to DNAJC12 deficiency,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,28132689[PMID]
26574,508523,Hyperphenylalaninemia due to DNAJC12 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28132689[PMID]
26569,508488,8q24.3 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,27804958[PMID]
26569,508488,8q24.3 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27804958[PMID]
26568,508476,Cleft lip and palate-craniofacial dysmorphism-congenital heart defect-hearing loss syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,28081210[PMID]
26568,508476,Cleft lip and palate-craniofacial dysmorphism-congenital heart defect-hearing loss syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28081210[PMID]
26571,508501,Oral-facial-digital syndrome with short stature and brachymesophalangy,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,27060890[PMID]
26571,508501,Oral-facial-digital syndrome with short stature and brachymesophalangy,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27060890[PMID]
26570,508498,Intellectual disability-cardiac anomalies-short stature-joint laxity syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,28327570[PMID]
26570,508498,Intellectual disability-cardiac anomalies-short stature-joint laxity syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28327570[PMID]
26390,505652,CDKL5-deficiency disorder,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_22872100[PMID]_24564546[PMID]
26390,505652,CDKL5-deficiency disorder,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.21,Australia,Validated,29264392[PMID]
26390,505652,CDKL5-deficiency disorder,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.36,United Kingdom,Validated,31302675[PMID]
26390,505652,CDKL5-deficiency disorder,Disease,Disorder,Prevalence at birth,Class only,1-9 / 100 000,0.0,Europe,Validated,EpiCARE[EXPERT]_31302675[PMID]
26448,506307,Stromme syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,18203155[PMID]_26820108[PMID]_28407396[PMID]
26448,506307,Stromme syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28407396[PMID]
26451,506358,Gabriele-de Vries syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,28575647[PMID]
26451,506358,Gabriele-de Vries syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28575647[PMID]
26450,506353,Autosomal recessive complex spastic paraplegia due to Kennedy pathway dysfunction,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,28052917[PMID]
26450,506353,Autosomal recessive complex spastic paraplegia due to Kennedy pathway dysfunction,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28052917[PMID]
25773,495274,Charcot-Marie-Tooth disease type 2T,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,26991897[PMID]
25773,495274,Charcot-Marie-Tooth disease type 2T,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26991897[PMID]
25803,495844,C11ORF73-related autosomal recessive hypomyelinating leukodystrophy,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,26545878[PMID]
25803,495844,C11ORF73-related autosomal recessive hypomyelinating leukodystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26545878[PMID]
25800,495818,9q33.3q34.11 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,26395556[PMID]
25800,495818,9q33.3q34.11 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26395556[PMID]
25805,495879,Congenital agenesis of the scrotum,Morphological anomaly,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,23374822[PMID]
25805,495879,Congenital agenesis of the scrotum,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23374822[PMID]
25804,495875,Congenital labioscrotal agenesis-cerebellar malformation-corneal dystrophy-facial dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,27075597[PMID]_27103078[PMID]
25804,495875,Congenital labioscrotal agenesis-cerebellar malformation-corneal dystrophy-facial dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27075597[PMID]_27103078[PMID]
25813,495930,Familial monosomy 7 syndrome,Disease,Disorder,Cases/families,Family(ies),,14.0,Worldwide,Validated,20614583[PMID]
25813,495930,Familial monosomy 7 syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20614583[PMID]
25835,496641,Early-onset progressive diffuse brain atrophy-microcephaly-muscle weakness-optic atrophy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,39.0,Worldwide,Validated,27807845[PMID]_27666374[PMID]_27666370[PMID]_27928163[PMID]
25835,496641,Early-onset progressive diffuse brain atrophy-microcephaly-muscle weakness-optic atrophy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27807845[PMID]_27666374[PMID]_27666370[PMID]_27928163[PMID]
25841,496686,Kyphosis-lateral tongue atrophy-myofibrillar myopathy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27484770[PMID]_27485408[PMID]
25841,496686,Kyphosis-lateral tongue atrophy-myofibrillar myopathy syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,27484770[PMID]_27485408[PMID]
25842,496689,Kyphoscoliosis-lateral tongue atrophy-hereditary spastic paraplegia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28488683[PMID]
25842,496689,Kyphoscoliosis-lateral tongue atrophy-hereditary spastic paraplegia syndrome,Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,28488683[PMID]
25843,496693,Omphalocele-diaphragmatic hernia-cardiovascular anomalies-radial ray defect syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,26639892[PMID]
25843,496693,Omphalocele-diaphragmatic hernia-cardiovascular anomalies-radial ray defect syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26639892[PMID]
25846,496751,EVEN-plus syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,26598328[PMID]
25846,496751,EVEN-plus syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26598328[PMID]
25847,496756,Early-onset progressive encephalopathy-spastic ataxia-distal spinal muscular atrophy syndrome,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,27666369[PMID]
25847,496756,Early-onset progressive encephalopathy-spastic ataxia-distal spinal muscular atrophy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27666369[PMID]
25849,496790,Ocular anomalies-axonal neuropathy-developmental delay syndrome,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,27640307[PMID]
25849,496790,Ocular anomalies-axonal neuropathy-developmental delay syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27640307[PMID]
25674,494433,MIRAGE syndrome,Disease,Disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,27182967[PMID]_28346228[PMID]
25674,494433,MIRAGE syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27182967[PMID]_28346228[PMID]
25675,494439,Retinitis pigmentosa-hearing loss-premature aging-short stature-facial dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,26843489[PMID]
25675,494439,Retinitis pigmentosa-hearing loss-premature aging-short stature-facial dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26843489[PMID]
25672,494424,Extracranial carotid artery aneurysm,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_26116488[PMID]
25673,494428,Idiopathic pleuroparenchymal fibroelastosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27141432[PMID]_28344924[PMID]
25673,494428,Idiopathic pleuroparenchymal fibroelastosis,Disease,Disorder,Cases/families,Case(s),,37.0,Worldwide,Validated,27141432[PMID]
25676,494444,DIAPH1-related sensorineural hearing loss-thrombocytopenia syndrome,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,27808407[PMID]
25676,494444,DIAPH1-related sensorineural hearing loss-thrombocytopenia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27808407[PMID]
25667,494344,RERE-related neurodevelopmental syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,27087320[PMID]
25667,494344,RERE-related neurodevelopmental syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27087320[PMID]
25683,494547,Squamous cell carcinoma of the hypopharynx,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.27,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]_28687376[PMID]
25682,494541,Childhood-onset benign chorea with striatal involvement,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,27058447[PMID]
25682,494541,Childhood-onset benign chorea with striatal involvement,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27058447[PMID]
25681,494526,Infantile-onset generalized dyskinesia with orofacial involvement,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,27058446[PMID]
25681,494526,Infantile-onset generalized dyskinesia with orofacial involvement,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27058446[PMID]
25684,494550,Squamous cell carcinoma of the larynx,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.61,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]_28687376[PMID]
26004,500180,Childhood-onset motor and cognitive regression syndrome with extrapyramidal movement disorder,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,28777933[PMID]
26004,500180,Childhood-onset motor and cognitive regression syndrome with extrapyramidal movement disorder,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28777933[PMID]
26005,500188,X-linked external auditory canal atresia-dilated internal auditory canal-facial dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,28096187[PMID]
26005,500188,X-linked external auditory canal atresia-dilated internal auditory canal-facial dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28096187[PMID]
8535,68,Amoebiasis due to free-living amoebae,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,[EXPERT]
8529,781,Q fever,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.03,United States,Validated,23535757[PMID]_Center for Diseases Control and Prevention[INST]
8529,781,Q fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.0,Australia,Validated,16503466[PMID]
8529,781,Q fever,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
8529,781,Q fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.16,Europe,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
8529,781,Q fever,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.08,Belgium,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
8529,781,Q fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.26,Bulgaria,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
8529,781,Q fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.4,Croatia,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
8529,781,Q fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.32,Cyprus,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
8529,781,Q fever,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.04,Finland,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
8529,781,Q fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.26,France,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
8529,781,Q fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.26,Germany,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
8529,781,Q fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Greece,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
8529,781,Q fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.64,Hungary,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
8529,781,Q fever,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.06,Ireland,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
8529,781,Q fever,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.07,Latvia,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
8529,781,Q fever,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.04,Luxembourg,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
8529,781,Q fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Malta,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
8529,781,Q fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.18,Netherlands,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
8529,781,Q fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.2,Portugal,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
8529,781,Q fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Romania,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
8529,781,Q fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Slovenia,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
8529,781,Q fever,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Sweden,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
8529,781,Q fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,United Kingdom,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
8529,781,Q fever,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.05,Norway,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
26000,500150,Brain malformations-musculoskeletal abnormalities-facial dysmorphism-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,33.0,Worldwide,Validated,PMID: 32926520: 27545680: 27545676: 27256762
26000,500150,Brain malformations-musculoskeletal abnormalities-facial dysmorphism-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27545680[PMID]_27545676[PMID]_27256762[PMID]
26001,500159,Microcephaly-corpus callosum and cerebellar vermis hypoplasia-facial dysmorphism-intellectual disability syndrom,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,28886345[PMID]
26001,500159,Microcephaly-corpus callosum and cerebellar vermis hypoplasia-facial dysmorphism-intellectual disability syndrom,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28886345[PMID]
26002,500163,Witteveen-Kolk syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,PMID: 27399968 & EXPERT
26002,500163,Witteveen-Kolk syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27399968[PMID]
8531,302,Inherited epidermodysplasia verruciformis,Disease,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,ORPHANET
8531,302,Inherited epidermodysplasia verruciformis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
8530,297,Tick-borne encephalitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8541,182,Chromomycosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8540,128,Diphyllobothriasis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.88,France,Not yet validated,ORPHANET
8540,128,Diphyllobothriasis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
8542,210,Cyclosporiasis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8537,76,Strongyloidiasis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
8537,76,Strongyloidiasis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.06,Spain,Validated,29284005[PMID]
8536,74,Angiostrongyliasis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8539,108,Babesiosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,emedicine[OTHER]
8538,78,Ankylostomiasis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
25997,500135,Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,28264986[PMID]
25997,500135,Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28264986[PMID]
25998,500144,Early-onset progressive encephalopathy-hearing loss-pons hypoplasia-brain atrophy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,28777934[PMID]_32347653[PMID]_32369837[PMID]
25998,500144,Early-onset progressive encephalopathy-hearing loss-pons hypoplasia-brain atrophy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28777934[PMID]
25993,500055,Hao-Fountain syndrome due to 16p13.2 microdeletion,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,26365382[PMID]
25993,500055,Hao-Fountain syndrome due to 16p13.2 microdeletion,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26365382[PMID]
25995,500095,Tall stature-intellectual disability-renal anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,26660953[PMID]_27183861[PMID]
25995,500095,Tall stature-intellectual disability-renal anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26660953[PMID]_27183861[PMID]
25994,500062,Infantile-onset periodic fever-panniculitis-dermatosis syndrome,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,27523608[PMID]_27559085[PMID]
25994,500062,Infantile-onset periodic fever-panniculitis-dermatosis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27523608[PMID]_27559085[PMID]
8567,129,Pseudopelade of Brocq,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8566,123,Björnstad syndrome,Disease,Disorder,Cases/families,Case(s),,33.0,Worldwide,Validated,11807445[PMID]
8566,123,Björnstad syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
8564,898,Wagner disease,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,ORPHANET
8564,898,Wagner disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
26034,500478,Squamous cell carcinoma of the oropharynx,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.12,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]_28687376[PMID]
8563,518,Acute megakaryoblastic leukemia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
8563,518,Acute megakaryoblastic leukemia,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8562,318,Acute erythroid leukemia,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,[WHO Classification of Tumours]
8562,318,Acute erythroid leukemia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[WHO Classification of Tumours]
8561,514,Acute monoblastic/monocytic leukemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.13,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8561,514,Acute monoblastic/monocytic leukemia,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
8560,517,Acute myelomonocytic leukemia,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
8560,517,Acute myelomonocytic leukemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.17,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8575,505,Graham Little-Piccardi-Lassueur syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8574,346,Quinquaud folliculitis decalvans,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8573,222,Erosive pustular dermatosis of the scalp,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8572,202,Crandall syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8571,170,Woolly hair,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
26042,500548,Osteosclerotic metaphyseal dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,27829680[PMID]
26042,500548,Osteosclerotic metaphyseal dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27829680[PMID]
8570,169,Ringed hair disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
26040,500533,Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome,Disease,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,27170158[PMID]
26040,500533,Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27170158[PMID]
8569,168,Loose anagen syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
26041,500545,Severe neurodevelopmental disorder with feeding difficulties-stereotypic hand movement-bilateral cataract,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,28132692[PMID]
26041,500545,Severe neurodevelopmental disorder with feeding difficulties-stereotypic hand movement-bilateral cataract,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28132692[PMID]
8568,345,Dissecting cellulitis of the scalp,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8550,591,Furuncular myiasis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
8551,723,Pneumocystosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
8548,472,Isosporiasis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
8546,401,Hymenolepiasis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
8545,400,Cystic echinococcosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.0,Europe,Validated,[EXPERT]
8545,400,Cystic echinococcosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
26030,500464,Squamous cell carcinoma of the nasal cavity and paranasal sinuses,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.35,Worldwide,Validated,RARECARE surveillance of rare cancers in Europe[REG]_28687376[PMID]
8559,520,Acute promyelocytic leukemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.28,United States,Validated,22707337[PMID]_21653939[PMID]_ ORPHANET
8559,520,Acute promyelocytic leukemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.11,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8559,520,Acute promyelocytic leukemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.3,France,Validated,Institut National du Cancer 2013[INST]
8559,520,Acute promyelocytic leukemia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8556,450,Heterotaxia,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,10.0,United States,Validated,11256661[PMID]
8556,450,Heterotaxia,Category,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
8554,529,Roch-Leri mesosomatous lipomatosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8555,224,Neonatal diabetes mellitus,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.1,Europe,Not yet validated,21953423[PMID]_19499210[PMID]_20546293[PMID]
8555,224,Neonatal diabetes mellitus,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.1,Italy,Validated,21953423[PMID]
8555,224,Neonatal diabetes mellitus,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.12,Germany,Validated,20546293[PMID]
8555,224,Neonatal diabetes mellitus,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.62,Austria,Validated,19496964[PMID]
8555,224,Neonatal diabetes mellitus,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8552,826,Sporotrichosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_25526781[PMID]
8552,826,Sporotrichosis,Disease,Disorder,Point prevalence,Value and class,>1 / 1000,2500.0,Mexico,Validated,25526781[PMID]
8552,826,Sporotrichosis,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,54.0,Peru,Validated,10619735[PMID]
8553,879,Tungiasis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,22941398[PMID]
26073,502363,Squamous cell carcinoma of the oral cavity,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.51,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]_28687376[PMID]
26074,502366,Squamous cell carcinoma of the lip,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.02,Worldwide,Validated,RARECARE surveillance of rare cancers in Europe[REG]_28687376[PMID]
26076,502423,Mitochondrial myopathy-cerebellar ataxia-pigmentary retinopathy syndrome,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,28544275[PMID]_28554942[PMID]_29339779[PMID]
26076,502423,Mitochondrial myopathy-cerebellar ataxia-pigmentary retinopathy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28544275[PMID]_28554942[PMID]_29339779[PMID]
26077,502430,Weiss-Kruszka Syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,28513610[PMID]
26077,502430,Weiss-Kruszka Syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28513610[PMID]
26078,502434,STAG1-related intellectual disability-facial dysmorphism-gastroesophageal reflux syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,28119487[PMID]
26078,502434,STAG1-related intellectual disability-facial dysmorphism-gastroesophageal reflux syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28119487[PMID]
26079,502437,4q25 proximal deletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,27587989[PMID]
26079,502437,4q25 proximal deletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27587989[PMID]
26080,502444,Alkaline ceramidase 3 deficiency,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,26792856[PMID]
26080,502444,Alkaline ceramidase 3 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26792856[PMID]
8670,91,Aromatase deficiency,Disease,Disorder,Cases/families,Case(s),,38.0,Worldwide,Validated,27256151[PMID]_27693882[PMID]_29324451[PMID]_29553041[PMID]
8670,91,Aromatase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27256151[PMID]_27693882[PMID]_29324451[PMID]_29553041[PMID]
8671,785,Estrogen resistance syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8090165[PMID]_23841731[PMID]
8671,785,Estrogen resistance syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8090165[PMID]_23841731[PMID]
8665,873,Desmoid tumor,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.3,Europe,Validated,[EXPERT]
8665,873,Desmoid tumor,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.33,Finland,Not yet validated,3946757[PMID]
8665,873,Desmoid tumor,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8660,679,Malignant atrophic papulosis,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,[EXPERT]
8660,679,Malignant atrophic papulosis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
8662,901,Wells syndrome,Disease,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,23730155[PMID]
8662,901,Wells syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23730155[PMID]
8663,703,Bullous pemphigoid,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.17,France,Validated,22418872[PMID]_23237497[PMID]
8663,703,Bullous pemphigoid,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.34,Germany,Validated,19170813[PMID]
8663,703,Bullous pemphigoid,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.3,United Kingdom,Validated,18614511[PMID]
8663,703,Bullous pemphigoid,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.21,Switzerland,Validated,19566661[PMID]
8663,703,Bullous pemphigoid,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,25.0,Europe,Validated,European Medicines Agency 2018[INST]
8663,703,Bullous pemphigoid,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,25.93,Germany,Validated,27456755[PMID]
8656,841,Sebocystomatosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8657,817,Peeling skin syndrome,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8659,867,Familial multiple trichoepithelioma,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8653,735,Porokeratosis of Mibelli,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_Pr KANITAKIS Jean[EXPERT]
25868,497906,Childhood-onset basal ganglia degeneration syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,27292112[PMID]
25868,497906,Childhood-onset basal ganglia degeneration syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27292112[PMID
8652,659,Mutilating palmoplantar keratoderma with periorificial keratotic plaques,Disease,Disorder,Cases/families,Case(s),,73.0,Worldwide,Validated,25886873[PMID]
8652,659,Mutilating palmoplantar keratoderma with periorificial keratotic plaques,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
8655,737,Porokeratosis plantaris palmaris et disseminata,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_Pr KANITAKIS Jean[EXPERT]
25864,497623,C12ORF65-related combined oxidative phosphorylation defect,Clinical group,Group of disorders,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27858754[PMID]
25864,497623,C12ORF65-related combined oxidative phosphorylation defect,Clinical group,Group of disorders,Cases/families,Case(s),,30.0,Worldwide,Validated,27858754[PMID]_28091420[PMID]_28804760[PMID]
8649,523,Hereditary leiomyomatosis and renal cell cancer,Disease,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,ORPHANET
8649,523,Hereditary leiomyomatosis and renal cell cancer,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
25866,497757,MME-related autosomal dominant Charcot Marie Tooth disease type 2,Disease,Disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,27588448[PMID]
25866,497757,MME-related autosomal dominant Charcot Marie Tooth disease type 2,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27588448[PMID]
25867,497764,Spinocerebellar ataxia type 43,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,27583304[PMID]
25867,497764,Spinocerebellar ataxia type 43,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27583304[PMID]
8650,530,Lipoid proteinosis,Malformation syndrome,Disorder,Cases/families,Case(s),,500.0,Worldwide,Validated,26803878[PMID]
8650,530,Lipoid proteinosis,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_26803878[PMID]
25861,497188,Diffuse intrinsic pontine glioma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.056,Netherlands,Validated,25435089[PMID]
8640,454,Acquired ichthyosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8700,617,Congenital primary megaureter,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8701,488,Urachal cyst,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8698,105,Atresia of urethra,Morphological anomaly,Disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
8698,105,Atresia of urethra,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
8699,237,Duplication of urethra,Morphological anomaly,Disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,19231292[PMID]
8699,237,Duplication of urethra,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_19231292[PMID]
8697,721,Gray platelet syndrome,Disease,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,[EXPERT]
8697,721,Gray platelet syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
8694,722,Hypoplasminogenemia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.16,Europe,Validated,32001536[PMID]
8692,853,Fetal and neonatal alloimmune thrombocytopenia,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,39.6307,Worldwide,Validated,23384054[PMID]_ORPHANET
8692,853,Fetal and neonatal alloimmune thrombocytopenia,Disease,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,66.6667,Worldwide,Validated,23384054[PMID]_ORPHANET
25908,498359,Aquagenic palmoplantar keratoderma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_24283504[PMID]
8691,465,Congenital plasminogen activator inhibitor type 1 deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
8688,310,Reflex epilepsy,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
25902,498251,Menstrual cycle-dependent periodic fever,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,7684743[PMID]_16006734[PMID]_21990073[PMID]_21501330[PMID]
25902,498251,Menstrual cycle-dependent periodic fever,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7684743[PMID]_16006734[PMID]_21990073[PMID]_21501330[PMID]
8686,1332,Medullary thyroid carcinoma,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.0,Europe,Validated,European Medicines Agency 2018[INST]
8686,1332,Medullary thyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.17,United States,Validated,21186939[PMID]_National Cancer Institute 1992-2006[INST]
8686,1332,Medullary thyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.22,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2011[REG]
8685,877,Neuroendocrine neoplasm,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.2,Norway,Validated,18853416[PMID]
8685,877,Neuroendocrine neoplasm,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.25,United States,Validated,18565894[PMID]_National Cancer Institute[INST]
8685,877,Neuroendocrine neoplasm,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.53,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8685,877,Neuroendocrine neoplasm,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,35.0,United States,Validated,18565894[PMID]
8685,877,Neuroendocrine neoplasm,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8684,73,Gorham-Stout disease,Malformation syndrome,Disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,[EXPERT]_20972870[PMID]_23897792[PMID]_25227772[PMID]
8684,73,Gorham-Stout disease,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_20972870[PMID]_23897792[PMID]_25227772[PMID]
25898,498228,Phyllodes tumor of the prostate,Disease,Disorder,Cases/families,Case(s),,90.0,Worldwide,Validated,25210561[PMID]
8682,728,Relapsing polychondritis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.35,United States,Validated,21962557[PMID]_14673390[PMID]
8682,728,Relapsing polychondritis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.35,Worldwide,Validated,21962557[PMID]_14673390[PMID]
8682,728,Relapsing polychondritis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
8682,728,Relapsing polychondritis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.071,United Kingdom,Validated,26187053[PMID]
8682,728,Relapsing polychondritis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.52,United Kingdom,Validated,26187053[PMID]
8680,467,Non-acquired combined pituitary hormone deficiency,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,29.0,Europe,Validated,[EXPERT]
8680,467,Non-acquired combined pituitary hormone deficiency,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Validated,[EXPERT]
8676,142,Anaplastic thyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.17,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2011[REG]
8676,142,Anaplastic thyroid carcinoma,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,European Medicines Agency 2004[INST]
8675,143,Parathyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2011[REG]
8675,143,Parathyroid carcinoma,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8675,143,Parathyroid carcinoma,Disease,Disorder,Lifetime Prevalence,Value and class,1-9 / 1 000 000,0.28,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8675,143,Parathyroid carcinoma,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,United States,Validated,26708847[PMID]_17372919[PMID]_SEER Surveillance Epidemiology and End Results Program 2003[REG]
8675,143,Parathyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.015,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8675,143,Parathyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.027,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8675,143,Parathyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.013,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8675,143,Parathyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.037,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8675,143,Parathyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.015,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8675,143,Parathyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.009,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8675,143,Parathyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.045,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8675,143,Parathyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.017,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8675,143,Parathyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.043,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8675,143,Parathyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.031,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8675,143,Parathyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.052,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8675,143,Parathyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.011,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8675,143,Parathyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.008,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8675,143,Parathyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.031,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8675,143,Parathyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.016,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8675,143,Parathyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8675,143,Parathyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.008,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8675,143,Parathyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8675,143,Parathyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8675,143,Parathyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.045,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8675,143,Parathyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.011,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8675,143,Parathyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.015,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8675,143,Parathyroid carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.037,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8672,786,Generalized glucocorticoid resistance syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,23392096[PMID]
8602,1461,Criss-cross heart,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.8,Europe,Validated,ISBN:9781416023906[OTHER]_22555779[PMID]
8602,1461,Criss-cross heart,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
8607,875,Primary pediatric heart tumor,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8593,615,Familial atrial myxoma,Disease,Disorder,Cases/families,Family(ies),,17.0,Worldwide,Validated,1540058[PMID]
8593,615,Familial atrial myxoma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1540058[PMID]
8594,874,Primary adult heart tumor,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
25941,499009,Congenital syphilis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.3,Europe,Validated,European Centre for Disease prevention and Control 2013-2017[INST]_ORPHANET
25941,499009,Congenital syphilis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,15.7,United States,Validated,CDC Centers for disease Control and prevention 2016[INST]_ORPHANET
25941,499009,Congenital syphilis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,15.7,United States,Validated,CDC Centers for disease Control and prevention 2016[INST]
25941,499009,Congenital syphilis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.3,Europe,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
25941,499009,Congenital syphilis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,26.6,Bulgaria,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
25941,499009,Congenital syphilis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.3,Czech Republic,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
25941,499009,Congenital syphilis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.04,Denmark,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
25941,499009,Congenital syphilis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.1,Greece,Validated,European Centre for Disease prevention and Control 2013-2015[INST]
25941,499009,Congenital syphilis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.7,Hungary,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
25941,499009,Congenital syphilis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.1,Italy,Validated,European Centre for Disease prevention and Control 2013-2015[INST]
25941,499009,Congenital syphilis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.6,Lithuania,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
25941,499009,Congenital syphilis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.9,Poland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
25941,499009,Congenital syphilis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.4,Portugal,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
25941,499009,Congenital syphilis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.5,Romania,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
25941,499009,Congenital syphilis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.3,Sweden,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
25941,499009,Congenital syphilis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.3,Germany,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
25941,499009,Congenital syphilis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.8,Spain,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
8597,1330,Partial atrioventricular septal defect,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,20.0,Europe,Not yet validated,23040494[PMID]
8597,1330,Partial atrioventricular septal defect,Morphological anomaly,Disorder,Point prevalence,Value and class,1-5 / 10 000,30.0,Europe,Validated,[EXPERT]_17341403[PMID]_12084585[PMID]
8599,1677,Familial idiopathic dilatation of the right atrium,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
25928,498497,Short rib-polydactyly syndrome type 5,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,17935248[PMID]
25928,498497,Short rib-polydactyly syndrome type 5,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17935248[PMID]
8585,720,Pili bifurcati,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8584,671,Primary cutis verticis gyrata,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8587,864,Trichofolliculoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
25930,498602,Sugarman brachydactyly,Morphological anomaly,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,4469972[PMID]_7083610[PMID]
25930,498602,Sugarman brachydactyly,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4469972[PMID]_7083610[PMID]
8591,247,Inherited arrhythmogenic cardiomyopathy,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,43.5,Italy,Validated,16585401[PMID]_Pr Cristina BASSO_Dr Kalliopi PILICHOU_Pr Domenico CORRADO_Pr Gaetano THIENE[EXPERT]
8591,247,Inherited arrhythmogenic cardiomyopathy,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,20.0,Worldwide,Validated,23736219[PMID]
25934,498693,MYBPC1-related autosomal recessive non-lethal arthrogryposis multiplex congenita syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,26661508[PMID]
25934,498693,MYBPC1-related autosomal recessive non-lethal arthrogryposis multiplex congenita syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26661508[PMID]
8577,444,Marie Unna hereditary hypotrichosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8576,2221,Acquired hypertrichosis lanuginosa,Disease,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,ORPHANET
8576,2221,Acquired hypertrichosis lanuginosa,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
25921,498474,Hyaline fibromatosis syndrome,Disease,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,25186005[PMID]
25921,498474,Hyaline fibromatosis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25186005[PMID]
8578,499,Kerion celsi,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
25924,498485,Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,15214018[PMID]_17618504[PMID]
25924,498485,Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15214018[PMID]_17618504[PMID]
8581,573,Monilethrix,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
25925,498488,Overgrowth syndrome with 2q37 translocation,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,25728306[PMID]
25925,498488,Overgrowth syndrome with 2q37 translocation,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25728306[PMID]
8580,525,Lichen planopilaris,Disease,Disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,ORPHANET
8580,525,Lichen planopilaris,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
8583,700,Alopecia totalis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.5,Europe,Not yet validated,ORPHANET
8582,840,Syringocystadenoma papilliferum,Disease,Disorder,Cases/families,Case(s),,730.0,Worldwide,Validated,16418676[PMID]_EXPERT
8582,840,Syringocystadenoma papilliferum,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,16418676[PMID]_EXPERT_ORPHANET
8632,315,Erythrokeratoderma ''en cocardes'',Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
8638,409,Hyperkeratosis lenticularis perstans,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8626,41,Dyschromatosis symmetrica hereditaria,Disease,Disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,ORPHANET
8626,41,Dyschromatosis symmetrica hereditaria,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
8626,41,Dyschromatosis symmetrica hereditaria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.5,Japan,Validated,12916015[PMID]
8627,122,Birt-Hogg-Dubé syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Europe,Not yet validated,ORPHANET
8624,38,Acrokeratoelastoidosis of Costa,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8625,39,Acromelanosis,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,ORPHANET
8625,39,Acromelanosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
8631,316,Progressive symmetric erythrokeratodermia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8618,658,Non-histaminic angioedema,Clinical group,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
8617,3282,Multifocal atrial tachycardia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.67,Worldwide,Validated,ORPHANET
8617,3282,Multifocal atrial tachycardia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
8616,188,Systemic capillary leak syndrome,Disease,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,[EXPERT]
8616,188,Systemic capillary leak syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
8623,303,Dystrophic epidermolysis bullosa,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.572,Europe,Validated,ORPHANET
8623,303,Dystrophic epidermolysis bullosa,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.6,Spain,Validated,23809583[PMID]
8623,303,Dystrophic epidermolysis bullosa,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.39,Australia,Validated,20566927[PMID]
8623,303,Dystrophic epidermolysis bullosa,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.14,United States,Validated,27463098[PMID]
8623,303,Dystrophic epidermolysis bullosa,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.28,Romania,Validated,25201089[PMID]
8623,303,Dystrophic epidermolysis bullosa,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.83,Netherlands,Validated,33095945[PMID]
8623,303,Dystrophic epidermolysis bullosa,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.41,Netherlands,Validated,33095945[PMID]
8622,305,Junctional epidermolysis bullosa,Clinical group,Group of disorders,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Not yet validated,ORPHANET
8622,305,Junctional epidermolysis bullosa,Clinical group,Group of disorders,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
8622,305,Junctional epidermolysis bullosa,Clinical group,Group of disorders,Point prevalence,Value and class,<1 / 1 000 000,0.08,Sweden,Validated,ISBN:443048517[OTHER]
8622,305,Junctional epidermolysis bullosa,Clinical group,Group of disorders,Point prevalence,Value and class,<1 / 1 000 000,0.07,Ireland,Validated,1419751[PMID]
8622,305,Junctional epidermolysis bullosa,Clinical group,Group of disorders,Point prevalence,Value and class,<1 / 1 000 000,0.02,Finland,Validated,6203284[PMID]
8622,305,Junctional epidermolysis bullosa,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 1 000 000,0.38,Italy,Validated,[EXPERT]
8622,305,Junctional epidermolysis bullosa,Clinical group,Group of disorders,Point prevalence,Value and class,<1 / 1 000 000,0.07,Australia,Validated,20566927[PMID]
8622,305,Junctional epidermolysis bullosa,Clinical group,Group of disorders,Point prevalence,Value and class,<1 / 1 000 000,0.02,Japan,Validated,2601109[PMID]
8622,305,Junctional epidermolysis bullosa,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 1 000 000,0.22,United States,Validated,ISBN:801860245[OTHER]
8622,305,Junctional epidermolysis bullosa,Clinical group,Group of disorders,Point prevalence,Value and class,<1 / 1 000 000,0.04,United States,Validated,ISBN:801860245[OTHER]
8622,305,Junctional epidermolysis bullosa,Clinical group,Group of disorders,Point prevalence,Value and class,<1 / 1 000 000,0.07,South Africa,Validated,ISBN:951563203[OTHER]
8622,305,Junctional epidermolysis bullosa,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.93,Netherlands,Validated,33095945[PMID]
8622,305,Junctional epidermolysis bullosa,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.21,Netherlands,Validated,33095945[PMID]
8621,3406,Ulerythema ophryogenesis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8620,2908,Kindler epidermolysis bullosa,Disease,Disorder,Cases/families,Case(s),,250.0,Worldwide,Validated,26937547[PMID]
8620,2908,Kindler epidermolysis bullosa,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_26937547[PMID]
8611,81,Antisynthetase syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.5,Worldwide,Validated,[EXPERT]
8610,563,Peripartum cardiomyopathy,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,30.0,Worldwide,Not yet validated,10703781[PMID]
8610,563,Peripartum cardiomyopathy,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,36.0,United States,Not yet validated,23090517[PMID]_10703781[PMID]_16765131[PMID]
8610,563,Peripartum cardiomyopathy,Disease,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,89.0,Singapore,Validated,23338912[PMID]
8610,563,Peripartum cardiomyopathy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.0,Japan,Validated,21617320[PMID]
8610,563,Peripartum cardiomyopathy,Disease,Disorder,Prevalence at birth,Value and class,>1 / 1000,334.0,Haiti,Validated,16342653[PMID]
8610,563,Peripartum cardiomyopathy,Disease,Disorder,Prevalence at birth,Value and class,>1 / 1000,100.0,South Africa,Validated,16920474[PMID]
8610,563,Peripartum cardiomyopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8609,764,Pyomyositis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8608,779,Reynolds syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
8614,838,Susac syndrome,Disease,Disorder,Cases/families,Case(s),,304.0,Worldwide,Validated,23628737[PMID]
8614,838,Susac syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
8613,889,Cutaneous small vessel vasculitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.7,Norway,Validated,9805179[PMID]
8613,889,Cutaneous small vessel vasculitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
8612,482,Kimura disease,Disease,Disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,18808562[PMID]
8612,482,Kimura disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
25329,486811,Prenatal-onset spinal muscular atrophy with congenital bone fractures,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26924529[PMID]_28218388[PMID]
25329,486811,Prenatal-onset spinal muscular atrophy with congenital bone fractures,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,26924529[PMID]_28218388[PMID]
25330,486815,Congenital muscular dystrophy-respiratory failure-skin abnormalities-joint hyperlaxity syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,27008887[PMID]
25330,486815,Congenital muscular dystrophy-respiratory failure-skin abnormalities-joint hyperlaxity syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27008887[PMID]
25310,485418,EMILIN-1-related connective tissue disease,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,26462740[PMID]
25310,485418,EMILIN-1-related connective tissue disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26462740[PMID]
25311,485421,MFF-related encephalopathy due to mitochondrial and peroxisomal fission defect,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,26783368[PMID]
25311,485421,MFF-related encephalopathy due to mitochondrial and peroxisomal fission defect,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26783368[PMID]
25309,485405,16p12.1p12.3 triplication syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,26647099[PMID]
25309,485405,16p12.1p12.3 triplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26647099[PMID]
25306,485350,CLCN4-related X-linked intellectual disability syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27550844[PMID]
25306,485350,CLCN4-related X-linked intellectual disability syndrome,Disease,Disorder,Cases/families,Case(s),,38.0,Worldwide,Validated,27550844[PMID]
25307,485358,Propylthiouracil embryofetopathy,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET_25974033[PMID]
25256,482606,X-linked keloid scarring-reduced joint mobility-increased optic cup-to-disc ratio syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,26804200[PMID]_26686323[PMID]
25256,482606,X-linked keloid scarring-reduced joint mobility-increased optic cup-to-disc ratio syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26804200[PMID]_26686323[PMID]
25255,482601,Adenylosuccinate synthetase-like 1-related distal myopathy,Disease,Disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,26506222[PMID]_27868399[PMID]_28268051[PMID]
25255,482601,Adenylosuccinate synthetase-like 1-related distal myopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26506222[PMID]_27868399[PMID]_28268051[PMID]
9800,31828,Digitalis poisoning,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
25224,480864,Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome,Disease,Disorder,Cases/families,Case(s),,24.0,Worldwide,Validated,26805781[PMID]_26805782[PMID]
25224,480864,Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26805781[PMID]_26805782[PMID]
9801,31837,Pulmonary venoocclusive disease,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.015,France,Validated,21510732[PMID]_16456139[PMID]
9801,31837,Pulmonary venoocclusive disease,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.015,Europe,Validated,16456139[PMID]_21510732[PMID]_ [EXPERT]
9801,31837,Pulmonary venoocclusive disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
25230,480907,X-linked intellectual disability-global development delay-facial dysmorphism-sacral caudal remnant syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,26637982[PMID]
25230,480907,X-linked intellectual disability-global development delay-facial dysmorphism-sacral caudal remnant syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26637982[PMID]
25229,480898,Global developmental delay-visual anomalies-progressive cerebellar atrophy-truncal hypotonia syndrome,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,26942288[PMID]
25229,480898,Global developmental delay-visual anomalies-progressive cerebellar atrophy-truncal hypotonia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26942288[PMID]
25228,480880,X-linked female restricted facial dysmorphism-short stature-choanal atresia-intellectual disability,Malformation syndrome,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,26833328[PMID]
25228,480880,X-linked female restricted facial dysmorphism-short stature-choanal atresia-intellectual disability,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26833328[PMID]
9794,31740,Hypersensitivity pneumonitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
25219,480556,Isolated neonatal sclerosing cholangitis,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,27319779[PMID]_27469900[PMID]
25219,480556,Isolated neonatal sclerosing cholangitis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27319779[PMID]_27469900[PMID]
9793,31709,Infantile convulsions and choreoathetosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
9798,31826,Ethylene glycol poisoning,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
25223,480851,Hereditary thrombocytopenia with early-onset myelofibrosis,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,26936507[PMID]
25223,480851,Hereditary thrombocytopenia with early-onset myelofibrosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26936507[PMID]
9799,31827,Paraquat poisoning,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
9796,31824,Colchicine poisoning,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,European Medicines Agency 2011[INST]
25220,480682,POGLUT1-related limb-girdle muscular dystrophy R21,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,27807076[PMID]
25220,480682,POGLUT1-related limb-girdle muscular dystrophy R21,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27807076[PMID]
9797,31825,Methanol poisoning,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
25240,481665,USP18 deficiency,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,27821552[PMID]_2732588[PMID]
25240,481665,USP18 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27821552[PMID]_2732588[PMID]
25247,482077,HTRA1-related autosomal dominant cerebral small vessel disease,Disease,Disorder,Cases/families,Case(s),,21.0,Worldwide,Validated,26063658[PMID]
25247,482077,HTRA1-related autosomal dominant cerebral small vessel disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26063658[PMID]
25232,481152,PYCR2-related microcephaly-progressive leukoencephalopathy,Malformation syndrome,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,25865492[PMID]_27130255[PMID]
25232,481152,PYCR2-related microcephaly-progressive leukoencephalopathy,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25865492[PMID]_27130255[PMID]
25239,481662,Familial Chilblain lupus,Disease,Disorder,Cases/families,Family(ies),,10.0,Worldwide,Validated,27566796[PMID]
25239,481662,Familial Chilblain lupus,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27566796[PMID]
25205,480476,Progressive familial intrahepatic cholestasis type 5,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,26888176[PMID]
25205,480476,Progressive familial intrahepatic cholestasis type 5,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26888176[PMID]
25207,480491,MYO5B-related progressive familial intrahepatic cholestasis,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,27532546[PMID]
25207,480491,MYO5B-related progressive familial intrahepatic cholestasis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27532546[PMID]
25206,480483,Progressive familial intrahepatic cholestasis type 4,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,26983395[PMID]_24614073[PMID]
25206,480483,Progressive familial intrahepatic cholestasis type 4,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26983395[PMID]_24614073[PMID]
25213,480528,Lethal hydranencephaly-diaphragmatic hernia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27417437[PMID]
25213,480528,Lethal hydranencephaly-diaphragmatic hernia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,27417437[PMID]
25215,480536,MSH3-related attenuated familial adenomatous polyposis,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,27476653[PMID]
25215,480536,MSH3-related attenuated familial adenomatous polyposis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27476653[PMID]
25211,480520,Caroli syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_17461493[PMID]
25159,477814,Progressive microcephaly-seizures-cortical blindness-developmental delay syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,24781755[PMID]_26463574[PMID]
25159,477814,Progressive microcephaly-seizures-cortical blindness-developmental delay syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24781755[PMID]_26463574[PMID]
25152,477781,Primary condylar hyperplasia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_26629479[PMID]
25153,477787,Cytosolic phospholipase-A2 alpha deficiency associated bleeding disorder,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,25102815[PMID]_18451993[PMID]
25153,477787,Cytosolic phospholipase-A2 alpha deficiency associated bleeding disorder,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25102815[PMID]_18451993[PMID]
25166,478029,Combined oxidative phosphorylation defect type 29,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,26626369[PMID]
25166,478029,Combined oxidative phosphorylation defect type 29,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26626369[PMID]
25167,478042,Combined oxidative phosphorylation defect type 30,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,27132592[PMID]
25167,478042,Combined oxidative phosphorylation defect type 30,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27132592[PMID]
25164,477993,Palatal anomalies-widely spaced teeth-facial dysmorphism-developmental delay syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,24838796[PMID]_26656649[PMID]
25164,477993,Palatal anomalies-widely spaced teeth-facial dysmorphism-developmental delay syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24838796[PMID]_26656649[PMID]
25162,477857,Mendelian susceptibility to mycobacterial diseases due to complete RORgamma receptor deficiency,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,26160376[PMID]
25162,477857,Mendelian susceptibility to mycobacterial diseases due to complete RORgamma receptor deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26160376[PMID]
25160,477817,PMP22-RAI1 contiguous gene duplication syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,23.0,Worldwide,Validated,26544804[PMID]
25160,477817,PMP22-RAI1 contiguous gene duplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26544804[PMID]
25161,477831,Kosaki overgrowth syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,25454926[PMID]_26455322[PMID]
25161,477831,Kosaki overgrowth syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25454926[PMID]_26455322
25168,478049,Lethal left ventricular non-compaction-seizures-hypotonia-cataract-developmental delay syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,27799064[PMID]_25778941[PMID]
25168,478049,Lethal left ventricular non-compaction-seizures-hypotonia-cataract-developmental delay syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27799064[PMID]_25778941[PMID]
25178,478664,Hereditary sensory and autonomic neuropathy type 8,Disease,Disorder,Cases/families,Family(ies),,11.0,Worldwide,Validated,26005867[PMID]_26975306[PMID]_28050684[PMID]
25178,478664,Hereditary sensory and autonomic neuropathy type 8,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26005867[PMID]_26975306[PMID]_28050684[PMID]
25135,477650,Fibroblastic rheumatism,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,25545215[PMID]
25135,477650,Fibroblastic rheumatism,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25545215[PMID]
25136,477661,IL21-related infantile inflammatory bowel disease,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,19890111[PMID]_24746753[PMID]
25136,477661,IL21-related infantile inflammatory bowel disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19890111[PMID]_24746753[PMID]
25139,477684,Combined oxidative phosphorylation defect type 26,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,26189817[PMID]_2544623[PMID]
25139,477684,Combined oxidative phosphorylation defect type 26,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26189817[PMID]_2544623[PMID]
25138,477673,Postnatal microcephaly-infantile hypotonia-spastic diplegia-dysarthria-intellectual disability syndrome,Disease,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,25758935[PMID]_27601654[PMID]
25138,477673,Postnatal microcephaly-infantile hypotonia-spastic diplegia-dysarthria-intellectual disability syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25758935[PMID]_27601654[PMID]
25143,477749,Pontine autosomal dominant microangiopathy with leukoencephalopathy,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,19187480[PMID]_27666438[PMID]
25143,477749,Pontine autosomal dominant microangiopathy with leukoencephalopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19187480[PMID]_27666438[PMID]
25142,477742,Nodular fasciitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
25150,477774,Combined oxidative phosphorylation defect type 27,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,25361775[PMID]_25787132[PMID]
25150,477774,Combined oxidative phosphorylation defect type 27,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25361775[PMID]_25787132[PMID]
25091,476119,Autosomal dominant preaxial polydactyly-upperback hypertrichosis syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,25782671[PMID]
25091,476119,Autosomal dominant preaxial polydactyly-upperback hypertrichosis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25782671[PMID]
25089,476113,Combined immunodeficiency due to TFRC deficiency,Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,26642240[PMID]
25089,476113,Combined immunodeficiency due to TFRC deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26642240[PMID]
25093,476126,Micrognathia-recurrent infections-behavioral abnormalities-mild intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,26721934[PMID]
25093,476126,Micrognathia-recurrent infections-behavioral abnormalities-mild intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26721934[PMID]
25102,476406,Congenital generalized hypercontractile muscle stiffness syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,26418456[PMID]
25102,476406,Congenital generalized hypercontractile muscle stiffness syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26418456[PMID]
25100,476394,PMP2-related Charcot-Marie-Tooth disease type 1,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,26828946[PMID]
25100,476394,PMP2-related Charcot-Marie-Tooth disease type 1,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26828946[PMID]
25553,493342,Vibratory urticaria,Disease,Disorder,Cases/families,Case(s),,37.0,Worldwide,Validated,26841242[PMID]
25553,493342,Vibratory urticaria,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26841242[PMID]
25412,488642,TELO2-related intellectual disability-neurodevelopmental disorder,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,27132593[PMID]
25412,488642,TELO2-related intellectual disability-neurodevelopmental disorder,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27132593[PMID]
25413,488647,DDX41-related hematologic malignancy predisposition syndrome,Disease,Disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,26712909[PMID]
25413,488647,DDX41-related hematologic malignancy predisposition syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26712909[PMID]
25414,488650,"Distal myopathy, Tateyama type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11805270[PMID]_15580566[PMID]_18930476[PMID]
25414,488650,"Distal myopathy, Tateyama type",Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,11805270[PMID]_15580566[PMID]_18930476[PMID]
25408,488618,Transketolase deficiency,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,27259054[PMID]
25408,488618,Transketolase deficiency,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27259054[PMID]
25409,488627,Severe growth deficiency-strabismus-extensive dermal melanocytosis-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,27055666[PMID]
25409,488627,Severe growth deficiency-strabismus-extensive dermal melanocytosis-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27055666[PMID]
25410,488632,TBCK-related intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,25.0,Worldwide,Validated,27748029[PMID]
25410,488632,TBCK-related intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27748029[PMID]
25411,488635,Early-onset epilepsy-intellectual disability-brain anomalies syndrome,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,26996948[PMID]
25411,488635,Early-onset epilepsy-intellectual disability-brain anomalies syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26996948[PMID]
25393,488239,Acute macular neuroretinopathy,Disease,Disorder,Cases/families,Case(s),,101.0,Worldwide,Validated,26973287[PMID]
25393,488239,Acute macular neuroretinopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26973287[PMID]
25392,488232,Split-foot malformation-mesoaxial polydactyly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,26755636[PMID]
25392,488232,Split-foot malformation-mesoaxial polydactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26755636[PMID]
25399,488333,Autosomal dominant Charcot-Marie-Tooth disease type 2W,Disease,Disorder,Cases/families,Case(s),,24.0,Worldwide,Validated,26072516[PMID]
25399,488333,Autosomal dominant Charcot-Marie-Tooth disease type 2W,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26072516[PMID]
25397,488280,14q32 duplication syndrome,Disease,Disorder,Cases/families,Case(s),,33.0,Worldwide,Validated,26280900[PMID]
25397,488280,14q32 duplication syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26280900[PMID]
25401,488437,SIX2-related frontonasal dysplasia,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,26581443[PMID]
25401,488437,SIX2-related frontonasal dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26581443[PMID]
25400,488434,"Camptodactyly syndrome, Guadalajara type 3",Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,12401988[PMID]
25400,488434,"Camptodactyly syndrome, Guadalajara type 3",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12401988[PMID]
25407,488613,Global developmental delay-neuro-ophthalmological abnormalities-seizures-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,26.0,Worldwide,Validated,28087732[PMID]
25407,488613,Global developmental delay-neuro-ophthalmological abnormalities-seizures-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28087732[PMID]
25404,488594,Autosomal recessive spastic paraplegia type 76,Disease,Disorder,Cases/families,Family(ies),,7.0,Worldwide,Validated,27153400[PMID]_27320912[PMID]
25404,488594,Autosomal recessive spastic paraplegia type 76,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27153400[PMID]_27320912[PMID]
25390,488197,Familial progressive retinal dystrophy-iris coloboma-congenital cataract syndrome,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,26056285[PMID]
25390,488197,Familial progressive retinal dystrophy-iris coloboma-congenital cataract syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26056285[PMID]
25388,488168,Microcephaly-congenital cataract-psoriasiform dermatitis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,28673550[PMID]
25388,488168,Microcephaly-congenital cataract-psoriasiform dermatitis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28673550[PMID]
25389,488191,Female infertility due to oocyte meiotic arrest,Disease,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,27273344[PMID]
25389,488191,Female infertility due to oocyte meiotic arrest,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_27273344[PMID]
25364,487796,Takenouchi-Kosaki syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,26708094[PMID]
25364,487796,Takenouchi-Kosaki syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26708094[PMID]
25369,487814,Autosomal dominant Charcot-Marie-Tooth disease type 2 due to DGAT2 mutation,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,26786738[PMID]
25369,487814,Autosomal dominant Charcot-Marie-Tooth disease type 2 due to DGAT2 mutation,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26786738[PMID]
25368,487809,Pediatric collagenous gastritis,Disease,Disorder,Cases/families,Case(s),,24.0,Worldwide,Validated,23538318[PMID]_25789098[PMID]
25368,487809,Pediatric collagenous gastritis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25789098[PMID]
25371,487825,Pierpont syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,28562391[PMID]
25371,487825,Pierpont syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28562391[PMID]
9294,31205,Rat-bite fever,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
9293,31204,Nocardiosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
9291,31202,Melioidosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
9291,31202,Melioidosis,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,50.0,Australia,Validated,22970946[PMID]
9291,31202,Melioidosis,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,50.0,Thailand,Validated,22970946[PMID]
9288,31150,Tangier disease,Disease,Disorder,Cases/families,Case(s),,185.0,Worldwide,Validated,27565770[PMID]
9288,31150,Tangier disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22913675[PMID]
9284,31043,Primary hypomagnesemia with hypercalciuria and nephrocalcinosis without severe ocular involvement,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,110.0,Worldwide,Validated,ORPHANET
9284,31043,Primary hypomagnesemia with hypercalciuria and nephrocalcinosis without severe ocular involvement,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
9285,31112,Dermatofibrosarcoma protuberans,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,Europe,Validated,[EXPERT]_European Medicines Agency[INST]
9282,30924,Primary hypomagnesemia with secondary hypocalcemia,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,ORPHANET
9282,30924,Primary hypomagnesemia with secondary hypocalcemia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
9283,30925,Hereditary arginine vasopressin deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
25083,476084,BVES-related limb-girdle muscular dystrophy,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,26642364[PMID]
25083,476084,BVES-related limb-girdle muscular dystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26642364[PMID]
25086,476096,Erythrokeratodermia-cardiomyopathy syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,26604139[PMID]_27408699[PMID]
25086,476096,Erythrokeratodermia-cardiomyopathy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26604139[PMID]_27408699[PMID]
25085,476093,Autosomal dominant distal axonal motor neuropathy-myofibrillar myopathy syndrome,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,26718575[PMID]
25085,476093,Autosomal dominant distal axonal motor neuropathy-myofibrillar myopathy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26718575[PMID]
11000,71278,Congenital brain dysgenesis due to glutamine synthetase deficiency,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,21353613[PMID]
11000,71278,Congenital brain dysgenesis due to glutamine synthetase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21353613[PMID]
11001,71279,CANOMAD syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
11001,71279,CANOMAD syndrome,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,[EXPERT]
10993,71271,Split hand-split foot-deafness syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,ORPHANET
10993,71271,Split hand-split foot-deafness syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10994,71272,Sandifer syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10995,71273,Renal nutcracker syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10996,71274,Disseminated peritoneal leiomyomatosis,Disease,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,[EXPERT]
10996,71274,Disseminated peritoneal leiomyomatosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10997,71275,Rh deficiency syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10998,71276,Silent sinus syndrome,Disease,Disorder,Cases/families,Case(s),,558.0,Worldwide,Validated,37219052[PMID]
10998,71276,Silent sinus syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,37219052[PMID]_ORPHANET
10999,71277,Classic glucose transporter type 1 deficiency syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.26,Norway,Validated,32913944[PMID]
10999,71277,Classic glucose transporter type 1 deficiency syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.11,Australia,Validated,16712556[PMID]
10999,71277,Classic glucose transporter type 1 deficiency syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.538,Worldwide,Validated,ORPHANET_32913944[PMID]
10999,71277,Classic glucose transporter type 1 deficiency syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.2,Denmark,Validated,26537434[PMID]
10987,71212,Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,ORPHANET
10987,71212,Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.73,Martinique,Validated,33310876[PMID]
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.054,Austria,Validated,33310876[PMID]
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1877,Worldwide,Validated,33310876[PMID]
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.071,Worldwide,Validated,33310876[PMID]
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.7,Austria,Validated,33310876[PMID]
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.08,United Kingdom,Validated,33310876[PMID]
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.43,United Kingdom,Validated,33310876[PMID]
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.09,Netherlands,Validated,33310876[PMID]
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.063,Spain,Validated,33310876[PMID]
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.89,Spain,Validated,33310876[PMID]
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.07,Denmark,Validated,33310876[PMID]
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.09,Denmark,Validated,33310876[PMID]
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.079,Sweden,Validated,PMID: 33310876
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.04,Sweden,Validated,PMID: 33310876
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.132,Hungary,Validated,PMID: 33310876
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.91,Hungary,Validated,PMID: 33310876
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.037,Australia,Validated,PMID: 33310876
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.7,Australia,Validated,PMID: 33310876
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.07,United States,Validated,PMID: 33310876
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.9,United States,Validated,PMID: 33310876
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.495,India,Validated,PMID: 33310876
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.495,Canada,Validated,PMID: 33310876
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.6,India,Validated,PMID: 33310876
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.42,Japan,Validated,PMID: 33310876
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.39,Malaysia,Validated,PMID: 33310876
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.94,Malaysia,Validated,PMID: 33310876
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.51,"Iran, Islamic Republic of",Validated,PMID: 33310876
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.053,Cuba,Validated,PMID: 33310876
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.52,Cuba,Validated,PMID: 33310876
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,Martinique,Validated,PMID: 33310876
10986,71211,Neuromyelitis optica spectrum disorder,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.285,Costa rica,Validated,PMID: 33310876
10989,71267,Dentinogenesis imperfecta-short stature-hearing loss-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,16011615[PMID]
10989,71267,Dentinogenesis imperfecta-short stature-hearing loss-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16011615[PMID]
10988,71213,Retinal capillary malformation,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10976,71198,Rare pulmonary hypertension,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_25385937[PMID]
28179,558411,Idiopathic gastroparesis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,11.4,Specific population,Validated,ORPHANET_30396519[PMID]
10962,70591,Chronic thromboembolic pulmonary hypertension,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,EXPERT
10962,70591,Chronic thromboembolic pulmonary hypertension,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.2,Europe,Validated,28356407[PMID]
10962,70591,Chronic thromboembolic pulmonary hypertension,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.1,United States,Validated,28356407[PMID]
10962,70591,Chronic thromboembolic pulmonary hypertension,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.9,Japan,Validated,28356407[PMID]
10963,70592,Transient predisposition to invasive pyogenic bacterial infection,Disease,Disorder,Cases/families,Case(s),,49.0,Worldwide,Validated,21734245[PMID]
10963,70592,Transient predisposition to invasive pyogenic bacterial infection,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21734245[PMID]
10960,70589,Bronchopulmonary dysplasia,Malformation syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,13.0,Europe,Validated,European Medicines Agency[INST]
10966,70595,Sensory ataxic neuropathy-dysarthria-ophthalmoparesis syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10967,70596,Congenital Epstein-Barr virus infection,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10964,70593,Immunodeficiency due to selective anti-polysaccharide antibody deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_28588580[PMID]
10965,70594,Dopa-responsive dystonia due to sepiapterin reductase deficiency,Disease,Disorder,Cases/families,Case(s),,43.0,Worldwide,Validated,22522443[PMID]
10965,70594,Dopa-responsive dystonia due to sepiapterin reductase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10954,70578,Adult acute respiratory distress syndrome,Disease,Disorder,Annual incidence,Value and class,6-9 / 10 000,64.0,United States,Validated,16236739[PMID]
10954,70578,Adult acute respiratory distress syndrome,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,51.0,United States,Not yet validated,ORPHANET
10954,70578,Adult acute respiratory distress syndrome,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,11.5,Iceland,Not yet validated,23216361[PMID]_10351930[PMID]_ ORPHANET
10954,70578,Adult acute respiratory distress syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,7.2,Spain,Validated,21997128[PMID]
10954,70578,Adult acute respiratory distress syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.9,Finland,Validated,10579250[PMID]
10954,70578,Adult acute respiratory distress syndrome,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,13.5,Sweden,Validated,10351930[PMID]
10954,70578,Adult acute respiratory distress syndrome,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,13.5,Denmark,Validated,10351930[PMID]
10954,70578,Adult acute respiratory distress syndrome,Disease,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Validated,European Medicines Agency 2008[INST]
10953,70573,Small cell lung cancer,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,12.0,Europe,Validated,European Medicines Agency 2018[INST]
10952,70568,Post-transplant lymphoproliferative disease,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,26.2,Europe,Validated,European Medicines Agency[INST]
10959,70588,Meconium aspiration syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.44,Europe,Validated,European Medicines Agency[INST]
10945,70472,"Congenital lactic acidosis, Saguenay-Lac-Saint-Jean type",Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10951,70567,Cholangiocarcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.2,Worldwide,Validated,[EXPERT]_emedicine 2011[OTHER]
10951,70567,Cholangiocarcinoma,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.1,Worldwide,Validated,[EXPERT]
10951,70567,Cholangiocarcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.0,United States,Validated,15765398[PMID]_19245868[PMID]_24140396[PMID]
10951,70567,Cholangiocarcinoma,Disease,Disorder,Annual incidence,Value and class,>1 / 1000,113.0,Thailand,Validated,18408464[PMID]
10951,70567,Cholangiocarcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.5,Japan,Not yet validated,emedicine 2011[OTHER]
10951,70567,Cholangiocarcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Australia,Validated,15192785[PMID]
10951,70567,Cholangiocarcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.0,Europe,Not yet validated,emedicine 2011[OTHER]_22895392[PMID]
10951,70567,Cholangiocarcinoma,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,European Medicines Agency 2004[INST]_22173164[PMID]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,7.0,Worldwide,Validated,World Health Organization 2008[INST]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,7.1,Europe,Validated,World Health Organization 2008[INST]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,6.67,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Lifetime Prevalence,Value and class,1-5 / 10 000,12.2,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]_[EXPERT]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.5,United States,Validated,National Cancer Institute 2012[INST]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,9.8,Worldwide,Validated,World Health Organization 2008[INST]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,6.873,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,10.82,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.9,India,Validated,World Health Organization 2008[INST]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,20.0,China,Validated,World Health Organization 2008[INST]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.3,Africa,Validated,World Health Organization 2008[INST]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,9.0,Japan,Validated,ISBN:443075956[OTHER]_14530066[PMID]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.9,Canada,Not yet validated,23061066[PMID]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,8.0,Russian Federation,Validated,ISBN:443075956[OTHER]_14530066[PMID]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,13.0,Latin America,Validated,ISBN:443075956[OTHER]_14530066[PMID]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.34,"Iran, Islamic Republic of",Validated,23120941[PMID]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.293,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,7.892,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.194,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.281,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.718,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.473,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.83,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.854,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.772,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,7.2,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.612,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.372,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.468,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.575,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.592,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.414,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.592,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.54,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.904,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.777,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,6.413,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10950,70482,Carcinoma of esophagus,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,8.362,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10949,70476,Vernal keratoconjunctivitis,Disease,Disorder,Point prevalence,Value and class,>1 / 1000,151.0,Italy,Validated,18356259[PMID]
10949,70476,Vernal keratoconjunctivitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,45.5,Finland,Validated,18356259[PMID]
10949,70476,Vernal keratoconjunctivitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,49.5,Sweden,Validated,18356259[PMID]
10949,70476,Vernal keratoconjunctivitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,26.0,Netherlands,Validated,18356259[PMID]
10949,70476,Vernal keratoconjunctivitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.0,France,Validated,18356259[PMID]
10949,70476,Vernal keratoconjunctivitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,11.0,Norway,Validated,18356259[PMID]
10949,70476,Vernal keratoconjunctivitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,32.0,Europe,Not yet validated,18356259[PMID]
10948,70475,Radiation proctitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,35.0,Europe,Validated,European Medicines Agency[INST]
10941,69744,Circumscribed palmoplantar hypokeratosis,Disease,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,16700830[PMID]
10941,69744,Circumscribed palmoplantar hypokeratosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10942,69745,Warty dyskeratoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10936,69735,Hypotrichosis-lymphedema-telangiectasia-renal defect syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,ORPHANET_12740761[PMID]
10936,69735,Hypotrichosis-lymphedema-telangiectasia-renal defect syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10937,69736,Bilateral acute depigmentation of the iris,Disease,Disorder,Cases/families,Case(s),,62.0,Worldwide,Validated,23812527[PMID]
10937,69736,Bilateral acute depigmentation of the iris,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23812527[PMID]
10938,69737,Bosley-Salih-Alorainy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,16155570[PMID]_17875913[PMID]_18412118[PMID]
10938,69737,Bosley-Salih-Alorainy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16155570[PMID]_17875913[PMID]_18412118[PMID]
10939,69739,Athabaskan brainstem dysgenesis syndrome,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,12833395[PMID]_18412118[PMID]
10939,69739,Athabaskan brainstem dysgenesis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12833395[PMID]_18412118[PMID]
10932,69663,Low phospholipid-associated cholelithiasis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10933,69665,Intrahepatic cholestasis of pregnancy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET_22892336[PMID]
10935,69723,Tyrosinemia type 3,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,ORPHANET
10935,69723,Tyrosinemia type 3,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10924,69126,PAPA syndrome,Disease,Disorder,Cases/families,Case(s),,53.0,Worldwide,Validated,DOI:10.1007/978-3-319-96929-9_4[OTHER]
10924,69126,PAPA syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_DOI:10.1007/978-3-319-96929-9_4[OTHER]
10921,69087,Naegeli-Franceschetti-Jadassohn syndrome,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.035,Europe,Not yet validated,ORPHANET
10923,69125,Anonychia with flexural pigmentation,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,1156563[PMID]
10923,69125,Anonychia with flexural pigmentation,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1156563[PMID]
10922,69088,Anhidrotic ectodermal dysplasia-immunodeficiency-osteopetrosis-lymphedema syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,11242109[PMID]
10922,69088,Anhidrotic ectodermal dysplasia-immunodeficiency-osteopetrosis-lymphedema syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11242109[PMID]
10917,69083,"Ectodermal dysplasia with natal teeth, Turnpenny type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8574423[PMID]
10917,69083,"Ectodermal dysplasia with natal teeth, Turnpenny type",Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,8574423[PMID]
10916,69082,Odonto-tricho-ungual-digito-palmar syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,21.0,Worldwide,Validated,9217212[PMID]
10916,69082,Odonto-tricho-ungual-digito-palmar syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9217212[PMID]
10919,69085,Limb-mammary syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,38.0,Worldwide,Validated,Pr MANOUVRIER-HANU Sylvie[EXPERT]_26075610[PMID]_9973291[PMID]_20410354[PMID]
10919,69085,Limb-mammary syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26075610[PMID]_9973291[PMID]_20410354[PMID]
10918,69084,Pure hair and nail ectodermal dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,ORPHANET
10918,69084,Pure hair and nail ectodermal dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10913,69077,Rhabdoid tumor,Disease,Disorder,Cases/families,Case(s),,500.0,Worldwide,Validated,ORPHANET
10913,69077,Rhabdoid tumor,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10913,69077,Rhabdoid tumor,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10912,69076,Familial renal glucosuria,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10914,69078,Liposarcoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.0,Europe,Validated,22517534[PMID]_[EXPERT]
10914,69078,Liposarcoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.59,United States,Validated,17013893[PMID]
10914,69078,Liposarcoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10910,69061,Idiopathic steroid-sensitive nephrotic syndrome,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
10911,69063,Congenital membranous nephropathy due to fetomaternal anti-neutral endopeptidase alloimmunization,Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,19154696[PMID]_15464186[PMID]
10911,69063,Congenital membranous nephropathy due to fetomaternal anti-neutral endopeptidase alloimmunization,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10908,67048,3-methylglutaconic aciduria type 4,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10909,69028,Dysostosis with brachydactyly,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10906,67046,3-methylglutaconic aciduria type 1,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,ORPHANET
10906,67046,3-methylglutaconic aciduria type 1,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10907,67047,3-methylglutaconic aciduria type 3,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10904,67044,Thrombocytopenia with congenital dyserythropoietic anemia,Disease,Disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,20301538[PMID]
10904,67044,Thrombocytopenia with congenital dyserythropoietic anemia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10905,67045,X-linked intellectual disability with isolated growth hormone deficiency,Clinical subtype,Subtype of disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,9508246[PMID]_8826446[PMID]
10905,67045,X-linked intellectual disability with isolated growth hormone deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9508246[PMID]_8826446[PMID]
10902,67042,Late-onset retinal degeneration,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10903,67043,Amoebic keratitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,European Medicines Agency[INST]
10900,67039,Segmental odontomaxillary dysplasia,Disease,Disorder,Cases/families,Case(s),,32.0,Worldwide,Validated,ORPHANET
10900,67039,Segmental odontomaxillary dysplasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10901,67041,Hyaluronidase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
10899,67038,B-cell chronic lymphocytic leukemia,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,48.0,Europe,Validated,European Medicines Agency 2015[INST]
10899,67038,B-cell chronic lymphocytic leukemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,7.05,France,Validated,Institut National du Cancer 2013[INST]
10897,67036,Autosomal dominant optic atrophy and cataract,Disease,Disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,22797356[PMID]
10897,67036,Autosomal dominant optic atrophy and cataract,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22797356[PMID]
10894,66646,Cutaneous mastocytosis,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10893,66637,Diaphanospondylodysostosis,Malformation syndrome,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,26467725[PMID]_21990102[PMID]_22581610[PMID]
10893,66637,Diaphanospondylodysostosis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26467725[PMID]_21990102[PMID]_22581610[PMID]
10892,66634,Dilated cardiomyopathy with ataxia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10891,66633,Sensorineural hearing loss-early graying-essential tremor syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,16025060[PMID]
10891,66633,Sensorineural hearing loss-early graying-essential tremor syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16025060[PMID]
10889,66631,CEDNIK syndrome,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,25958742[PMID]
10889,66631,CEDNIK syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10888,66630,Congenital pseudoarthrosis of the clavicle,Disease,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,ORPHANET
10888,66630,Congenital pseudoarthrosis of the clavicle,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10887,66629,Goldberg-Shprintzen megacolon syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,24.0,Worldwide,Validated,[EXPERT]_28277559[PMID]_23427148[PMID]
10887,66629,Goldberg-Shprintzen megacolon syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
10886,66628,Obesity due to congenital leptin deficiency,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
10886,66628,Obesity due to congenital leptin deficiency,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10885,66627,Tenosynovial giant cell tumor,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.0,Europe,Validated,European Medicines Agency 2015[INST]
10884,66625,Cerebrooculonasal syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,21.0,Worldwide,Validated,19206156[PMID]
10884,66625,Cerebrooculonasal syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19206156[PMID]
10883,66624,PANDAS,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10882,66529,Tako-Tsubo cardiomyopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
10882,66529,Tako-Tsubo cardiomyopathy,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.98,France,Validated,23623669[PMID]
10881,66518,Short fifth metacarpals-insulin resistance syndrome,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,16132981[PMID]_12786688[PMID]
10881,66518,Short fifth metacarpals-insulin resistance syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10865,65283,Timothy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,56.0,Worldwide,Validated,33987151[PMID]_34079780[PMID]_34844894[PMID]_36336572[PMID]_36347939[PMID]
10865,65283,Timothy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10864,65282,Carvajal syndrome,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,22795705[PMID]_20940358[PMID]_16628197[PMID]
10864,65282,Carvajal syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22795705[PMID]_20940358[PMID]_16628197[PMID]
28337,562639,Primary biliary cholangitis/primary sclerosing cholangitis and autoimmune hepatitis overlap syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10867,65285,Lhermitte-Duclos disease,Disease,Disorder,Cases/families,Case(s),,220.0,Worldwide,Validated,16459996[PMID]
10867,65285,Lhermitte-Duclos disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10869,65287,Beta-ureidopropionase deficiency,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,17964839[PMID]
10869,65287,Beta-ureidopropionase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17964839[PMID]
10868,65286,3q29 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10871,65681,Vaginal atresia,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10870,65288,Permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,24212882[PMID]
10870,65288,Permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10873,65683,Isolated focal cortical dysplasia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_24649472[PMID]
10872,65682,Benign recurrent intrahepatic cholestasis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10875,65720,Arthrogryposis-severe scoliosis syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,3565478[PMID]_7039311[PMID]
10875,65720,Arthrogryposis-severe scoliosis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3565478[PMID]_7039311[PMID]
10874,65684,Monomelic amyotrophy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10877,65748,Multiple self-healing squamous epithelioma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_24747516[PMID]
10877,65748,Multiple self-healing squamous epithelioma,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,24747516[PMID]
10876,65743,Autosomal dominant multiple pterygium syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,2831369[PMID]
10876,65743,Autosomal dominant multiple pterygium syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10879,65759,Carpenter syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,70.0,Worldwide,Validated,23063620[PMID]
10879,65759,Carpenter syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10878,65753,Charcot-Marie-Tooth disease type 1,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,17.5,Worldwide,Validated,20301384[PMID]
10848,64744,IgG4-related thyroid disease,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 100 000,1.06,United States,Validated,3906289[PMID]_21832114[PMID]
10848,64744,IgG4-related thyroid disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10849,64745,Pruritic urticarial papules and plaques of pregnancy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_27960565[PMID]
10850,64746,Autosomal dominant Charcot-Marie-Tooth disease type 2,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET
10851,64747,X-linked Charcot-Marie-Tooth disease,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.6,Europe,Not yet validated,ORPHANET
10852,64748,Dejerine-Sottas syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12090401[PMID]
10853,64749,Charcot-Marie-Tooth disease type 4,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Validated,ORPHANET
28329,562509,Heme oxygenase-1 deficiency,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,9884342[PMID]_21088618[PMID]_22023467[PMID]
28329,562509,Heme oxygenase-1 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22023467[PMID]
10856,64752,Hereditary sensory and autonomic neuropathy type 5,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
10856,64752,Hereditary sensory and autonomic neuropathy type 5,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.035,Japan,Not yet validated,23495212[PMID]
10857,64753,Spinocerebellar ataxia with axonal neuropathy type 2,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.11,France,Validated,19440741[PMID]
10858,64754,Nevus comedonicus syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_23888253[PMID]
28331,562528,Congenital limbs-face contractures-hypotonia-developmental delay syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,25683120[PMID]
28331,562528,Congenital limbs-face contractures-hypotonia-developmental delay syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25683120[PMID]_28133733[PMID]
10859,64755,Becker nevus syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_26265883[PMID]
28333,562559,Anterior maxillary protrusion-strabismus-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,17618476[PMID]_21035105[PMID]
28333,562559,Anterior maxillary protrusion-strabismus-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17618476[PMID]_21035105[PMID]
28334,562569,TMEM94-associated congenital heart defect-facial dysmorphism-developmental delay syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,30526868[PMID]
28334,562569,TMEM94-associated congenital heart defect-facial dysmorphism-developmental delay syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30526868[PMID]
10833,64542,"Acrofacial dysostosis, Kennedy-Teebi type",Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,15266620[PMID]
10833,64542,"Acrofacial dysostosis, Kennedy-Teebi type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15266620[PMID]
10832,64280,Childhood absence epilepsy,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.0,United States,Validated,24668022[PMID]
10832,64280,Childhood absence epilepsy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
10838,64720,Leiomyosarcoma,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,[WHO Classification of Tumours]
10838,64720,Leiomyosarcoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[WHO Classification of Tumours]
10843,64739,Ovarian hyperstimulation syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10841,64734,Iridocorneal endothelial syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10847,64743,Hepatoportal sclerosis,Histopathological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10846,64742,Pleuropulmonary blastoma,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,[EXPERT]
10846,64742,Pleuropulmonary blastoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10845,64741,Pulmonary blastoma,Disease,Disorder,Cases/families,Case(s),,350.0,Worldwide,Validated,[EXPERT]
10845,64741,Pulmonary blastoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10845,64741,Pulmonary blastoma,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10845,64741,Pulmonary blastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10845,64741,Pulmonary blastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10845,64741,Pulmonary blastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.001,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10845,64741,Pulmonary blastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10845,64741,Pulmonary blastoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10816,63259,Iniencephaly,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,50.0,Europe,Validated,ORPHANET
10816,63259,Iniencephaly,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10823,63442,Angel-shaped phalango-epiphyseal dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,15173244[PMID]
10823,63442,Angel-shaped phalango-epiphyseal dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10820,63273,Distal myopathy with posterior leg and anterior hand involvement,Disease,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,15824355[PMID]_21620354[PMID]
10820,63273,Distal myopathy with posterior leg and anterior hand involvement,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15824355[PMID]_21620354[PMID]
10821,63275,Pemphigoid gestationis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.2,Germany,Validated,19170813[PMID]
10821,63275,Pemphigoid gestationis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.05,France,Validated,7826096[PMID]_23237497[PMID]
10821,63275,Pemphigoid gestationis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.18,Kuwait,Validated,15569006[PMID]
10821,63275,Pemphigoid gestationis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.693,Germany,Validated,27456755[PMID]
10826,63454,Pattern dystrophy,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10827,63455,Paraneoplastic pemphigus,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,31536300[PMID]
10824,63443,Rare epithelial tumor of stomach,Category,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,18.6,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10824,63443,Rare epithelial tumor of stomach,Category,Group of disorders,Lifetime Prevalence,Value and class,1-5 / 10 000,49.17,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
10824,63443,Rare epithelial tumor of stomach,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,7.5,United States,Validated,National Cancer Institute 2010[INST]
10824,63443,Rare epithelial tumor of stomach,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,24.0,United States,Validated,National Cancer Institute 2010[INST]
10824,63443,Rare epithelial tumor of stomach,Category,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,11.2,United Kingdom,Validated,National Cancer Intelligence Network 2006[OTHER]
10824,63443,Rare epithelial tumor of stomach,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,3.9,United Kingdom,Validated,National Cancer Intelligence Network 2006[OTHER]
10824,63443,Rare epithelial tumor of stomach,Category,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET
10825,63446,Acrocapitofemoral dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
10829,63862,Schisis association,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10805,60040,Megalencephaly-capillary malformation-polymicrogyria syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,170.0,Worldwide,Validated,15712320[PMID]
10805,60040,Megalencephaly-capillary malformation-polymicrogyria syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10804,60039,Pudendal nerve entrapment syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,20071246[PMID]
10804,60039,Pudendal nerve entrapment syndrome,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,16.67,France,Validated,[EXPERT]
10806,60041,Congenital heart block,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.54,Worldwide,Validated,4273004[PMID]
10806,60041,Congenital heart block,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10801,60032,Recurrent respiratory papillomatosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.0,Netherlands,Validated,EXPERT_ORPHANET
10801,60032,Recurrent respiratory papillomatosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.16,Netherlands,Validated,EXPERT_ORPHANET
10801,60032,Recurrent respiratory papillomatosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.34,United States,Validated,7488368[PMID]_20553527[PMID]
10801,60032,Recurrent respiratory papillomatosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.76,Denmark,Validated,2350888[PMID]_20553527[PMID]
10801,60032,Recurrent respiratory papillomatosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.42,United Kingdom,Validated,27208548[PMID]
10801,60032,Recurrent respiratory papillomatosis,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET_27208548[PMID]
10802,60033,Idiopathic bronchiectasis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.8,Finland,Validated,9787927[PMID]
10802,60033,Idiopathic bronchiectasis,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,29.0,Finland,Validated,9787927[PMID]
10788,59303,Neonatal ichthyosis-sclerosing cholangitis syndrome,Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,22030598[PMID]
10788,59303,Neonatal ichthyosis-sclerosing cholangitis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22030598[PMID]
10790,59305,Gestational trophoblastic neoplasm,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10790,59305,Gestational trophoblastic neoplasm,Clinical group,Group of disorders,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10791,59306,McLeod neuroacanthocytosis syndrome,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,22027213[PMID]
10791,59306,McLeod neuroacanthocytosis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10785,59298,Schilder disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10796,60015,Enlarged parietal foramina,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.3,Europe,Validated,23543411[PMID]
10796,60015,Enlarged parietal foramina,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.7,Worldwide,Validated,23543411[PMID]
28397,564003,Osteochondrosis of the metatarsal bone,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10797,60025,Pulmonary alveolar microlithiasis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
28396,563991,Osteochondrosis of the tarsal bone,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10798,60026,Pulmonary nodular lymphoid hyperplasia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
28399,564178,Primary hypomagnesemia-refractory seizures-intellectual disability syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30388404[PMID]
28399,564178,Primary hypomagnesemia-refractory seizures-intellectual disability syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,30388404[PMID]
10799,60030,Loeys-Dietz syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,52.0,Worldwide,Validated,16928994[PMID]
10799,60030,Loeys-Dietz syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_16928994[PMID
10792,59315,Rhombencephalosynapsis,Malformation syndrome,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,25816977[PMID]
10792,59315,Rhombencephalosynapsis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25816977[PMID]
10795,60014,Argyria,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10774,57196,Medial condensing osteitis of the clavicle,Disease,Disorder,Cases/families,Case(s),,58.0,Worldwide,Validated,27622150[PMID]
10774,57196,Medial condensing osteitis of the clavicle,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27622150[PMID]
28372,563690,Furuncular myiasis due to Cordylobia rodhaini,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_29090455[PMID]
10771,57145,SUNCT syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.7,Europe,Validated,[EXPERT]
10771,57145,SUNCT syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.7,Australia,Validated,18325769[PMID]
28370,563684,Furuncular myiasis due to Dermatobia hominis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_29090455[PMID]
28371,563687,Furuncular myiasis due to Cordylobia anthropophaga,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_29090455[PMID]
10770,56970,Human prion disease,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.15,Europe,Not yet validated,ORPHANET
10770,56970,Human prion disease,Category,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.3,Europe,Not yet validated,ORPHANET
10768,56425,Cold agglutinin disease,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
10783,59181,Sorsby pseudoinflammatory fundus dystrophy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10782,59135,Laing distal myopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10778,58017,Classic hairy cell leukemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.29,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10778,58017,Classic hairy cell leukemia,Disease,Disorder,Lifetime Prevalence,Value and class,1-9 / 100 000,3.12,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
10778,58017,Classic hairy cell leukemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.33,United States,Validated,16150940[PMID]_National Cancer Institute[INST]
10778,58017,Classic hairy cell leukemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.29,United Kingdom,Validated,7918034[PMID]
10778,58017,Classic hairy cell leukemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.24,Israel,Not yet validated,17044834[PMID]
10778,58017,Classic hairy cell leukemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.47,Iceland,Validated,12111650[PMID]
10778,58017,Classic hairy cell leukemia,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.035,Hong Kong,Validated,11135356[PMID]
10778,58017,Classic hairy cell leukemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.37,Denmark,Validated,21122460[PMID]
10778,58017,Classic hairy cell leukemia,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
10777,57782,Mazabraud syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,54.0,Worldwide,Validated,ORPHANET
10777,57782,Mazabraud syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10758,55595,TNP03-related limb-girdle muscular dystrophy D2,Disease,Disorder,Cases/families,Case(s),,64.0,Worldwide,Validated,23667635[PMID]
10758,55595,TNP03-related limb-girdle muscular dystrophy D2,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23667635[PMID]
10759,55596,HNRNPDL-related limb-girdle muscular dystrophy D3,Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,24647604[PMID]
10759,55596,HNRNPDL-related limb-girdle muscular dystrophy D3,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24647604[PMID]
10756,54595,Craniopharyngioma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.0,Worldwide,Not yet validated,17825241[PMID]_22969141[PMID]
10756,54595,Craniopharyngioma,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Europe,Validated,17425791[PMID]_European Medicines Agency 2015[INST]
10756,54595,Craniopharyngioma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.19,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
10756,54595,Craniopharyngioma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.17,Sweden,Validated,25375987[PMID]_Swedish national Health registries 1987-2011[REG]
10754,54368,Sarcocystosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10755,54370,Primary membranoproliferative glomerulonephritis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,16.0,Europe,Validated,European Medicines Agency 2012[INST]
10752,54272,Hepatocellular adenoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_21175790[PMID]
10766,56304,Atelosteogenesis type II,Malformation syndrome,Disorder,Cases/families,Case(s),,25.0,Worldwide,Validated,ORPHANET
10766,56304,Atelosteogenesis type II,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10767,56305,Atelosteogenesis type III,Malformation syndrome,Disorder,Cases/families,Case(s),,25.0,Worldwide,Validated,ORPHANET
10767,56305,Atelosteogenesis type III,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10765,56044,Carcinoma of gallbladder and extrahepatic biliary tract,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,12.0,Worldwide,Validated,ORPHANET
10765,56044,Carcinoma of gallbladder and extrahepatic biliary tract,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.3,Japan,Not yet validated,ORPHANET
10765,56044,Carcinoma of gallbladder and extrahepatic biliary tract,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.5,United States,Not yet validated,13835134[PMID]_17857545[PMID]_13425293[PMID]_22570746[PMID]
10765,56044,Carcinoma of gallbladder and extrahepatic biliary tract,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,14.0,Poland,Validated,16397865[PMID]
10765,56044,Carcinoma of gallbladder and extrahepatic biliary tract,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.27,France,Not yet validated,10951337[PMID]
10765,56044,Carcinoma of gallbladder and extrahepatic biliary tract,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET
10765,56044,Carcinoma of gallbladder and extrahepatic biliary tract,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.37,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10762,55880,Chondrosarcoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.24,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10762,55880,Chondrosarcoma,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
10762,55880,Chondrosarcoma,Disease,Disorder,Lifetime Prevalence,Value and class,1-9 / 100 000,3.55,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
10763,55881,Adamantinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10763,55881,Adamantinoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10763,55881,Adamantinoma,Disease,Disorder,Lifetime Prevalence,Value and class,1-9 / 1 000 000,0.11,Worldwide,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
10760,55654,Hypotrichosis simplex,Disease,Disorder,Cases/families,Case(s),,38.0,Worldwide,Validated,ORPHANET
10760,55654,Hypotrichosis simplex,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
28451,565858,Craniosynostosis-microretrognathia-severe intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,29432562[PMID]_30254215[PMID]
28451,565858,Craniosynostosis-microretrognathia-severe intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29432562[PMID]_30254215[PMID]
28448,565788,Infantile inflammatory bowel disease with neurological involvement,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,29483653[PMID]
28448,565788,Infantile inflammatory bowel disease with neurological involvement,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29483653[PMID]
11239,79213,Mucopolysaccharidosis,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,4.5,Netherlands,Validated,10480370[PMID]_26586959[PMID]
11239,79213,Mucopolysaccharidosis,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,3.9,Australia,Validated,ORPHANET_9918480[PMID]_14608657[PMID]_26586959[PMID]
11239,79213,Mucopolysaccharidosis,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,4.8,Portugal,Validated,14685153[PMID]_26586959[PMID]
11239,79213,Mucopolysaccharidosis,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,3.53,Germany,Validated,16435194[PMID]_26586959[PMID]
11239,79213,Mucopolysaccharidosis,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,2.22,Sweden,Validated,18681890[PMID]_25274184[PMID]
11239,79213,Mucopolysaccharidosis,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,3.08,Norway,Validated,18681890[PMID]_26586959[PMID]
11239,79213,Mucopolysaccharidosis,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.77,Denmark,Validated,18681890[PMID]_26586959[PMID]
11239,79213,Mucopolysaccharidosis,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.81,Poland,Validated,25472774[PMID]_26586959[PMID]
11239,79213,Mucopolysaccharidosis,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,3.72,Czech Republic,Validated,14685153[PMID]_26586959[PMID]
11239,79213,Mucopolysaccharidosis,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,2.29,Tunisia,Validated,20209839[PMID]_26586959[PMID]
11239,79213,Mucopolysaccharidosis,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,2.04,"Taiwan, Province of China",Validated,19396827[PMID]_26586959[PMID]
11239,79213,Mucopolysaccharidosis,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,4.05,Estonia,Validated,22480138[PMID]_26586959[PMID]
11239,79213,Mucopolysaccharidosis,Category,Group of disorders,Prevalence at birth,Class only,1-9 / 100 000,0.0,Worldwide,Validated,ORPHANET_28595941[PMID]
11239,79213,Mucopolysaccharidosis,Category,Group of disorders,Prevalence at birth,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET_28595941[PMID]
11239,79213,Mucopolysaccharidosis,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.53,Japan,Validated,28595941[PMID]
11239,79213,Mucopolysaccharidosis,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.56,Switzerland,Validated,28595941[PMID]
11239,79213,Mucopolysaccharidosis,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.25,Brazil,Validated,PMID: 31926052
11239,79213,Mucopolysaccharidosis,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,16.9,Saudi Arabia,Validated,20626343[PMID]_28595941[PMID]
11239,79213,Mucopolysaccharidosis,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.35,"Korea, Republic of",Validated,25364648[PMID]_28595941[PMID]
11239,79213,Mucopolysaccharidosis,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 1 000 000,0.98,United States,Validated,34051828[PMID]
11239,79213,Mucopolysaccharidosis,Category,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.267,United States,Validated,34051828[PMID]
11239,79213,Mucopolysaccharidosis,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.04,Brazil,Validated,35209917[PMID]
28452,565899,POMGNT2-related limb-girdle muscular dystrophy R24,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,27066570[PMID]
28452,565899,POMGNT2-related limb-girdle muscular dystrophy R24,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27066570[PMID]
28453,565909,Calpain-3-related limb-girdle muscular dystrophy D4,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27259757[PMID]_28881388[PMID]_30055862[PMID]
28453,565909,Calpain-3-related limb-girdle muscular dystrophy D4,Disease,Disorder,Cases/families,Case(s),,47.0,Worldwide,Validated,27259757[PMID]_28881388[PMID]
11259,79233,Hypoxanthine guanine phosphoribosyltransferase partial deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11256,79230,HJV or HAMP-related hemochromatosis,Disease,Disorder,Cases/families,Case(s),,74.0,Worldwide,Validated,ORPHANET
11256,79230,HJV or HAMP-related hemochromatosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11263,79237,Galactokinase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
28477,566067,CEBPE-associated autoinflammation-immunodeficiency-neutrophil dysfunction syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,31201888[PMID]
28477,566067,CEBPE-associated autoinflammation-immunodeficiency-neutrophil dysfunction syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_31201888[PMID]
11260,79234,Crigler-Najjar syndrome type 1,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11261,79235,Crigler-Najjar syndrome type 2,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11215,79189,Peroxisome biogenesis disorder,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,2.0,United States,Validated,20301621[PMID]
11215,79189,Peroxisome biogenesis disorder,Clinical group,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,United States,Not yet validated,20301621[PMID]
11215,79189,Peroxisome biogenesis disorder,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 1 000 000,0.2,Japan,Validated,12794690[PMID]
11215,79189,Peroxisome biogenesis disorder,Clinical group,Group of disorders,Point prevalence,Class only,1-9 / 1 000 000,0.0,Japan,Not yet validated,12794690[PMID]
11215,79189,Peroxisome biogenesis disorder,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
28443,565624,Combined oxidative phosphorylation defect type 39,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,22700954[PMID]_26016410[PMID]_29075935[PMID]
28443,565624,Combined oxidative phosphorylation defect type 39,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22700954[PMID]_26016410[PMID]_29075935[PMID]
28442,565612,Primary triglyceride deposit cardiomyovasculopathy,Disease,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,[EXPERT]
28442,565612,Primary triglyceride deposit cardiomyovasculopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]_31186072[PMID]
11227,79201,Glycogen storage disease,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.51,China,Validated,34103049[PMID]
28446,565782,Methotrexate toxicity,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.0,Europe,Validated,European Medicines Agency 2015[INST]
11183,79157,2-methylbutyryl-CoA dehydrogenase deficiency,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
11183,79157,2-methylbutyryl-CoA dehydrogenase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11182,79156,Seizures-intellectual disability due to hydroxylysinuria syndrome,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,DOI:10.1007/978-3-642-55878-8_18[OTHER]
11182,79156,Seizures-intellectual disability due to hydroxylysinuria syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_DOI:10.1007/978-3-642-55878-8_18[OTHER]
11181,79155,Hydroxykynureninuria,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
11181,79155,Hydroxykynureninuria,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11180,79154,2-aminoadipic 2-oxoadipic aciduria,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,23141293[PMID]
11180,79154,2-aminoadipic 2-oxoadipic aciduria,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11179,79153,Idiopathic trachyonychia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11178,79152,Disseminated superficial actinic porokeratosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_Pr KANITAKIS Jean[EXPERT]
11177,79151,Acrokeratosis verruciformis of Hopf,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11175,79149,Dermochondrocorneal dystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26440764[PMID]
11175,79149,Dermochondrocorneal dystrophy,Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,26440764[PMID]
11174,79148,Elastosis perforans serpiginosa,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_27881947[PMID]
11173,79147,Familial reactive perforating collagenosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17567305[PMID]_20101333[PMID]
11173,79147,Familial reactive perforating collagenosis,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,17567305[PMID]_20101333[PMID]
11171,79145,Dowling-Degos disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11170,79144,Isolated congenital onychodysplasia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_26509026[PMID]
11169,79143,Isolated congenital anonychia,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,ORPHANET
11169,79143,Isolated congenital anonychia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11198,79172,Creatine deficiency syndrome,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11194,79168,Disorder of bile acid synthesis,Category,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.6,Europe,Validated,European Medicines Agency[INST]
11184,79158,Cerebral organic aciduria,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11185,79159,Isobutyryl-CoA dehydrogenase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11149,79107,Developmental malformations-deafness-dystonia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,12325076[PMID]
11149,79107,Developmental malformations-deafness-dystonia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12325076[PMID]
28493,566231,Resistance to thyroid hormone due to a mutation in thyroid hormone receptor alpha,Disease,Disorder,Cases/families,Case(s),,35.0,Worldwide,Validated,30842990[PMID]
28493,566231,Resistance to thyroid hormone due to a mutation in thyroid hormone receptor alpha,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30842990[PMID]
11148,79106,Eiken syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,15525660[PMID]
11148,79106,Eiken syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15525660[PMID]
28494,566243,Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,United States,Validated,ORPHANET
28494,566243,Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Japan,Validated,ORPHANET
28494,566243,Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.47,United States,Validated,14517508[PMID]_31149222[PMID]
28494,566243,Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.4,Japan,Validated,ORPHANET_19542904[PMID]_31149222[PMID]
11151,79118,Neonatal diabetes-congenital hypothyroidism-congenital glaucoma-hepatic fibrosis-polycystic kidneys syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,12966531[PMID]_16715098[PMID]
11151,79118,Neonatal diabetes-congenital hypothyroidism-congenital glaucoma-hepatic fibrosis-polycystic kidneys syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12966531[PMID]_16715098[PMID]
11150,79113,Mandibulofacial dysostosis-microcephaly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,107.0,Worldwide,Validated,PMID: 26507355
11150,79113,Mandibulofacial dysostosis-microcephaly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26507355[PMID]
11144,79102,Thyrotoxic periodic paralysis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
11147,79105,Myxofibrosarcoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11141,79099,Interstitial granulomatous dermatitis with arthritis,Disease,Disorder,Cases/families,Case(s),,53.0,Worldwide,Validated,22059717[PMID]
11141,79099,Interstitial granulomatous dermatitis with arthritis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11140,79098,Sympathetic ophthalmia,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.03,United Kingdom,Validated,10684834[PMID]
11140,79098,Sympathetic ophthalmia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.6,Europe,Not yet validated,ORPHANET
11143,79101,Hyperprolinemia type 2,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
28487,566192,Congenital autosomal recessive small-platelet thrombocytopenia,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,25876182[PMID]
28487,566192,Congenital autosomal recessive small-platelet thrombocytopenia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25876182[PMID]
11142,79100,Atrophoderma vermiculata,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11137,79095,Congenital bile acid synthesis defect type 4,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,10655068[PMID]_12512044[PMID]_ [EXPERT]
11137,79095,Congenital bile acid synthesis defect type 4,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11136,79094,Grange syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,22987684[PMID]
11136,79094,Grange syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
28482,566175,Complement hyperactivation-angiopathic thrombosis-protein-losing enteropathy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30565236[PMID]_28657829[PMID]_28657861[PMID]
11139,79097,Folinic acid-responsive seizures,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11138,79096,Pyridoxal phosphate-responsive seizures,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11138,79096,Pyridoxal phosphate-responsive seizures,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,European Medicines Agency 2018[INST]
11164,79138,Bickerstaff brainstem encephalitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11165,79139,Japanese encephalitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.65,Europe,Not yet validated,ORPHANET
11165,79139,Japanese encephalitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11166,79140,Cutaneous neuroendocrine carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.27,Worldwide,Not yet validated,ORPHANET
11166,79140,Cutaneous neuroendocrine carcinoma,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.0,Europe,Validated,European Medicines Agency[INST]
11166,79140,Cutaneous neuroendocrine carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.13,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11166,79140,Cutaneous neuroendocrine carcinoma,Disease,Disorder,Lifetime Prevalence,Value and class,1-9 / 1 000 000,0.86,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
11166,79140,Cutaneous neuroendocrine carcinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.06,Finland,Not yet validated,21729823[PMID]
11166,79140,Cutaneous neuroendocrine carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.7,United States,Validated,33932460[PMID]
11166,79140,Cutaneous neuroendocrine carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.22,Denmark,Validated,20424236[PMID]
11166,79140,Cutaneous neuroendocrine carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.378,France,Validated,12951176[PMID]
11166,79140,Cutaneous neuroendocrine carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.13,United Kingdom,Validated,16764197[PMID]
11166,79140,Cutaneous neuroendocrine carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.8,Australia,Validated,33932460[PMID]
11166,79140,Cutaneous neuroendocrine carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.0,New Zealand,Validated,33932460[PMID]
11166,79140,Cutaneous neuroendocrine carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.0,Norway,Validated,33932460[PMID]
11167,79141,Hereditary painful callosities,Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,646376[PMID]_3812560[PMID]
11167,79141,Hereditary painful callosities,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_646376[PMID]_3812560[PMID]
11160,79134,DEND syndrome,Disease,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,16670688[PMID]
11160,79134,DEND syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11161,79135,Episodic ataxia type 3,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,11673600[PMID]
11161,79135,Episodic ataxia type 3,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11673600[PMID]
11162,79136,Episodic ataxia type 4,Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,8929156[PMID]
11162,79136,Episodic ataxia type 4,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8929156[PMID]
11163,79137,Generalized epilepsy-paroxysmal dyskinesia syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11156,79129,Trichodysplasia-amelogenesis imperfecta syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,8419879[PMID]
11156,79129,Trichodysplasia-amelogenesis imperfecta syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8419879[PMID]
11159,79133,Focal facial dermal dysplasia type I,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,81.0,Worldwide,Validated,21931173[PMID]
11159,79133,Focal facial dermal dysplasia type I,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11152,79124,Hepatic veno-occlusive disease-immunodeficiency syndrome,Disease,Disorder,Cases/families,Case(s),,28.0,Worldwide,Validated,20301448[PMID]_22621957[PMID]_16648851[PMID]
11152,79124,Hepatic veno-occlusive disease-immunodeficiency syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20301448[PMID]
11153,79126,Acute interstitial pneumonia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.8,Europe,Validated,ORPHANET
11154,79127,Respiratory bronchiolitis-interstitial lung disease syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11155,79128,Lymphoid interstitial pneumonia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11106,77293,Chronic visceral acid sphingomyelinase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.4,Europe,Not yet validated,23412609[PMID]
11106,77293,Chronic visceral acid sphingomyelinase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
11107,77295,Odontoleukodystrophy,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,12605447[PMID]
11107,77295,Odontoleukodystrophy,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12605447[PMID]
11104,77261,Gaucher disease type 3,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.05,Europe,Validated,[EXPERT]
11105,77292,Infantile neurovisceral acid sphingomyelinase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.25,Europe,Not yet validated,ORPHANET
11105,77292,Infantile neurovisceral acid sphingomyelinase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
11110,77298,Anophthalmia/microphthalmia-esophageal atresia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,15578584[PMID]_16543359[PMID]
11110,77298,Anophthalmia/microphthalmia-esophageal atresia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11111,77299,Microphthalmia-brain atrophy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,16566018[PMID]
11111,77299,Microphthalmia-brain atrophy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16566018[PMID]
11108,77296,Morgagni-Stewart-Morel syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11109,77297,Majeed syndrome,Disease,Disorder,Cases/families,Family(ies),,4.0,Worldwide,Validated,20301735[PMID]
11109,77297,Majeed syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20301735[PMID]
28585,567502,B-cell immunodeficiency-limb anomaly-urogenital malformation syndrome,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,31409799[PMID]
28585,567502,B-cell immunodeficiency-limb anomaly-urogenital malformation syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_31409799[PMID]
11112,77300,Auricular abnormalities-cleft lip with or without cleft palate-ocular abnormalities syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,16317305[PMID]
11112,77300,Auricular abnormalities-cleft lip with or without cleft palate-ocular abnormalities syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16317305[PMID]
11113,77301,Monosomy 9q22.3 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,42.0,Worldwide,Validated,21850767[PMID]
11113,77301,Monosomy 9q22.3 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21850767[PMID]
28591,567550,Idiopathic multidrug-resistant nephrotic syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
28590,567548,Idiopathic steroid-resistant nephrotic syndrome,Clinical syndrome,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.2582,Worldwide,Validated,30552564[PMID]_ORPHANET
28590,567548,Idiopathic steroid-resistant nephrotic syndrome,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
28589,567546,Idiopathic steroid-sensitive nephrotic syndrome with secondary steroid resistance,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
28588,567544,Idiopathic non-lupus full-house nephropathy,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11127,79083,PPARG-related familial partial lipodystrophy,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,16409151[PMID]
11127,79083,PPARG-related familial partial lipodystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11126,79078,IgG4-related dacryoadenitis and sialadenitis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11125,79076,Juvenile polyposis of infancy,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,ORPHANET
11125,79076,Juvenile polyposis of infancy,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11131,79087,Acquired partial lipodystrophy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11131,79087,Acquired partial lipodystrophy,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,European Medicines Agency 2015[INST]
11130,79086,Acquired generalized lipodystrophy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11130,79086,Acquired generalized lipodystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,European Medicines Agency 2012[INST]
11129,79085,AKT2-related familial partial lipodystrophy,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,16409151[PMID]
11129,79085,AKT2-related familial partial lipodystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11128,79084,"Familial partial lipodystrophy, Köbberling type",Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,16409151[PMID]
11128,79084,"Familial partial lipodystrophy, Köbberling type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
28606,567983,Parenteral nutrition-associated cholestasis,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11135,79093,Foix-Alajouanine syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11134,79091,Hereditary inclusion body myopathy-joint contractures-ophthalmoplegia syndrome,Disease,Disorder,Cases/families,Case(s),,21.0,Worldwide,Validated,9708547[PMID]_23489661[PMID]_25529940[PMID]
11134,79091,Hereditary inclusion body myopathy-joint contractures-ophthalmoplegia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9708547[PMID]_23489661[PMID]_25529940[PMID]
11132,79088,Localized lipodystrophy,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11072,75327,North Carolina macular dystrophy,Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,21310494[PMID]_5100467[PMID]
11072,75327,North Carolina macular dystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21310494[PMID]_5100467[PMID]
11073,75373,Progressive bifocal chorioretinal atrophy,Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,5686965[PMID]_8541856[PMID]
11073,75373,Progressive bifocal chorioretinal atrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5686965[PMID]_8541856[PMID]
11074,75374,Bradyopsia,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,14702087[PMID]
11074,75374,Bradyopsia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_14702087[PMID]
11075,75376,Familial drusen,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11076,75377,Central areolar choroidal dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.33,France,Not yet validated,ORPHANET
11076,75377,Central areolar choroidal dystrophy,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
11077,75378,Oligocone trichromacy,Disease,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,14736794[PMID]_17090894[PMID]_ [EXPERT]
11077,75378,Oligocone trichromacy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11078,75381,Cystoid macular dystrophy,Disease,Disorder,Cases/families,Case(s),,97.0,Worldwide,Validated,25267528[PMID]
11078,75381,Cystoid macular dystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25267528[PMID]
11079,75382,Oguchi disease,Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,ORPHANET
11079,75382,Oguchi disease,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11080,75389,Brain malformation-congenital heart disease-postaxial polydactyly syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,16531731[PMID]
11080,75389,Brain malformation-congenital heart disease-postaxial polydactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
28552,566841,Liver adenomatosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_26011213[PMID]
11081,75391,Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,22354167[PMID]
11081,75391,Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22354167[PMID]
11082,75392,Periodontal Ehlers-Danlos syndrome,Disease,Disorder,Cases/families,Case(s),,62.0,Worldwide,Validated,22739343[PMID]
11082,75392,Periodontal Ehlers-Danlos syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11083,75496,B4GALT7-related spondylodysplastic Ehlers-Danlos syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26940150[PMID]
11083,75496,B4GALT7-related spondylodysplastic Ehlers-Danlos syndrome,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,34.0,Worldwide,Validated,26940150[PMID]
11084,75497,X-linked Ehlers-Danlos syndrome,Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,4006272[PMID]
11084,75497,X-linked Ehlers-Danlos syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4006272[PMID]
11086,75508,Angioosteohypotrophic syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11087,75563,X-linked sideroblastic anemia,Disease,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,ORPHANET
11087,75563,X-linked sideroblastic anemia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
28560,566943,Mueller-Weiss syndrome,Disease,Disorder,Cases/families,Case(s),,277.0,Worldwide,Validated,27145453[PMID]
28560,566943,Mueller-Weiss syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_27145453[PMID]
11089,75565,Tropical endomyocardial fibrosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11088,75564,Acquired idiopathic sideroblastic anemia,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
11088,75564,Acquired idiopathic sideroblastic anemia,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.09,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11091,75567,Primary progressive freezing gait,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11090,75566,Loeffler endocarditis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11095,75857,6q terminal deletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,16329114[PMID]
11095,75857,6q terminal deletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11094,75840,Ullrich congenital muscular dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.13,United Kingdom,Validated,19767415[PMID]
11094,75840,Ullrich congenital muscular dystrophy,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
11097,77240,Primary lymphedema,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,16.7,Europe,Validated,[EXPERT]_24212289[PMID]
11096,75858,MORM syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11101,77258,Trichorhinophalangeal syndrome type 1,Malformation syndrome,Disorder,Cases/families,Case(s),,250.0,Worldwide,Validated,[EXPERT]
11101,77258,Trichorhinophalangeal syndrome type 1,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]_ORPHANET
11103,77260,Gaucher disease type 2,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.01,Europe,Validated,[EXPERT]
11102,77259,Gaucher disease type 1,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,[EXPERT]
11102,77259,Gaucher disease type 1,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.48,Italy,Validated,11953730[PMID]
11047,73271,Bleeding diathesis due to a collagen receptor defect,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,7687896[PMID]
11047,73271,Bleeding diathesis due to a collagen receptor defect,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11044,73263,Zygomycosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11045,73267,Non-24-hour sleep-wake syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11042,73256,Central neurocytoma,Disease,Disorder,Cases/families,Case(s),,500.0,Worldwide,Validated,23810386[PMID]
11042,73256,Central neurocytoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11043,73260,Paracoccidioidomycosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11040,73246,Visceral neuropathy-brain anomalies-facial dysmorphism-developmental delay syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,16378921[PMID]
11040,73246,Visceral neuropathy-brain anomalies-facial dysmorphism-developmental delay syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16378921[PMID]
28655,569821,Congenital primary lymphedema of Gordon,Disease,Disorder,Cases/families,Case(s),,23.0,Worldwide,Validated,30071673[PMID]
28655,569821,Congenital primary lymphedema of Gordon,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30071673[PMID]
11054,73423,Acute ackee fruit intoxication,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
28654,569816,CELSR1-related late-onset primary lymphedema,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_31215153[PMID]_31403174[PMID]
28654,569816,CELSR1-related late-onset primary lymphedema,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,31215153[PMID]_31403174[PMID]
11048,73272,Growth delay due to insulin-like growth factor type 1 deficiency,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,24389050[PMID]
11048,73272,Growth delay due to insulin-like growth factor type 1 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24389050[PMID]
11049,73273,Growth delay due to insulin-like growth factor I resistance,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11071,75326,Familial isolated retinal arteriolar tortuosity,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,12745002[PMID]
11071,75326,Familial isolated retinal arteriolar tortuosity,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11070,75325,Osteosclerosis-ichthyosis-premature ovarian failure syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,15995452[PMID]
11070,75325,Osteosclerosis-ichthyosis-premature ovarian failure syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11069,75249,Familial isolated restrictive cardiomyopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,[EXPERT]
11068,75234,Cholesteryl ester storage disease,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.5,Germany,Validated,17634524[PMID]
11068,75234,Cholesteryl ester storage disease,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.8,Specific population,Validated,23424026[PMID]
11068,75234,Cholesteryl ester storage disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11067,75233,Wolman disease,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.19,Australia,Validated,9918480[PMID]
11067,75233,Wolman disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
28613,568065,EPHB4-related lymphatic-related hydrops fetalis,Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,27400125[PMID]
28613,568065,EPHB4-related lymphatic-related hydrops fetalis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27400125[PMID]
28612,568062,PIEZO1-related generalized lymphatic dysplasia with non-immune hydrops fetalis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26333996[PMID]
28612,568062,PIEZO1-related generalized lymphatic dysplasia with non-immune hydrops fetalis,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,26333996[PMID]
11014,71493,Familial thrombocytosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Not yet validated,23736217[PMID]
11015,71505,Cancer-associated retinopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
28611,568056,Warts-immunodeficiency-lymphedema-anogenital dysplasia syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,18347293[PMID]
28611,568056,Warts-immunodeficiency-lymphedema-anogenital dysplasia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18347293[PMID]
28610,568051,GJC2-related late-onset primary lymphedema,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_29906362[PMID]
11011,71289,Radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,ORPHANET
11011,71289,Radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11020,71526,Obesity due to pro-opiomelanocortin deficiency,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,16150380[PMID]
11020,71526,Obesity due to pro-opiomelanocortin deficiency,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11021,71528,Obesity due to prohormone convertase I deficiency,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,23562752[PMID]
11021,71528,Obesity due to prohormone convertase I deficiency,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11022,71529,Obesity due to melanocortin 4 receptor deficiency,Etiological subtype,Subtype of disorder,Point prevalence,Value and class,1-5 / 10 000,50.0,France,Validated,[EXPERT]
11022,71529,Obesity due to melanocortin 4 receptor deficiency,Etiological subtype,Subtype of disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET
28622,569164,Angiomatoid fibrous histiocytoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11017,71517,Rapid-onset dystonia-parkinsonism,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,17282997[PMID]_15260953[PMID]
11017,71517,Rapid-onset dystonia-parkinsonism,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11018,71518,Benign paroxysmal torticollis of infancy,Disease,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,[EXPERT]_19182151[PMID]_29956301[PMID]_29656928[PMID]
11018,71518,Benign paroxysmal torticollis of infancy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
11019,71519,Psychogenic movement disorders,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
28629,569274,Multiple mitochondrial dysfunctions syndrome type 5,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,29767723[PMID]_30105122[PMID]
28629,569274,Multiple mitochondrial dysfunctions syndrome type 5,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29767723[PMID]_30105122[PMID]
28631,569290,Multiple mitochondrial dysfunctions syndrome type 6,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,29576218[PMID]
28631,569290,Multiple mitochondrial dysfunctions syndrome type 6,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29576218[PMID]
28626,569248,Microcystic stromal tumor,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11037,73229,HANAC syndrome,Disease,Disorder,Cases/families,Family(ies),,6.0,Worldwide,Validated,20818663[PMID]
11037,73229,HANAC syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20818663[PMID]
11036,73224,Kidney tubulopathy-dilated cardiomyopathy syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,15769815[PMID]
11036,73224,Kidney tubulopathy-dilated cardiomyopathy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15769815[PMID]
11039,73245,Spinal muscular atrophy-Dandy-Walker malformation-cataracts syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,16024908[PMID]
11039,73245,Spinal muscular atrophy-Dandy-Walker malformation-cataracts syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16024908[PMID]
11038,73230,Ossification anomalies-psychomotor developmental delay syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,16086393[PMID]
11038,73230,Ossification anomalies-psychomotor developmental delay syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16086393[PMID]
11033,73217,Müllerian aplasia,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Finland,Not yet validated,ORPHANET_11570363[PMID]
11033,73217,Müllerian aplasia,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,10.0,Finland,Validated,11570363[PMID]
11033,73217,Müllerian aplasia,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET
11035,73223,Global developmental delay-osteopenia-ectodermal defect syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,16368207[PMID]
11035,73223,Global developmental delay-osteopenia-ectodermal defect syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16368207[PMID]
10462,40366,Acitretin/etretinate embryopathy,Malformation syndrome,Disorder,Cases/families,Case(s),,26.0,Worldwide,Validated,18410980[PMID]
10462,40366,Acitretin/etretinate embryopathy,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10463,40923,Eales disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10460,39812,Graft versus host disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.0,Europe,Validated,European Medicines Agency 2018[INST]
27672,530849,Familial apolipoprotein A5 deficiency,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25732519[PMID]
27672,530849,Familial apolipoprotein A5 deficiency,Etiological subtype,Subtype of disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,25732519[PMID]
10452,39041,Omenn syndrome,Disease,Disorder,Cases/families,Case(s),,25.0,Worldwide,Validated,ORPHANET
10452,39041,Omenn syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
27669,530838,KRT1-related diffuse nonepidermolytic keratoderma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_30452289[PMID]
10453,39044,Uveal melanoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,17498805[PMID]_22119735[PMID]_EUROCARE Survival of cancer patients in Europe[REG]
10453,39044,Uveal melanoma,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,22119735[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
10453,39044,Uveal melanoma,Disease,Disorder,Lifetime Prevalence,Value and class,1-9 / 100 000,6.0,Europe,Validated,22119735[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
10453,39044,Uveal melanoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.03,Africa,Not yet validated,19704035[PMID]
27668,530792,RELA fusion-positive ependymoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10451,38874,Dihydropyrimidinuria,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26771602[PMID]
10447,37748,Schnitzler syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,ORPHANET
10447,37748,Schnitzler syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10444,37612,Episodic ataxia type 1,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10442,37553,Andersen-Tawil syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Europe,Not yet validated,ORPHANET
10442,37553,Andersen-Tawil syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10442,37553,Andersen-Tawil syndrome,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.08,United Kingdom,Validated,23516313[PMID]
10442,37553,Andersen-Tawil syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Netherlands,Validated,29606556[PMID]
10441,37202,Interstitial cystitis,Disease,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET_1137336[PMID]
10441,37202,Interstitial cystitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.6,Finland,Validated,1137336[PMID]
10441,37202,Interstitial cystitis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,30.0,United States,Validated,ISBN:978-4471-3295-0[OTHER]
10441,37202,Interstitial cystitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.66,Finland,Validated,1137336[PMID]
10440,37042,Immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome,Disease,Disorder,Cases/families,Case(s),,195.0,Worldwide,Validated,32234571[PMID]
10440,37042,Immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,32234571[PMID]_ORPHANET
10438,36913,Autoimmune hypoparathyroidism,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10438,36913,Autoimmune hypoparathyroidism,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10438,36913,Autoimmune hypoparathyroidism,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.013,"Korea, Republic of",Not yet validated,32384131[PMID]
10438,36913,Autoimmune hypoparathyroidism,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.023,Denmark,Not yet validated,25753591 [PMID]
10437,36899,Myoclonus-dystonia syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,ORPHANET
27690,531151,9q21.13 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,23279911[PMID]_24355400[PMID]
27690,531151,9q21.13 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23279911[PMID]_24355400[PMID]
27685,530983,Lamb-Shaffer syndrome,Disease,Disorder,Cases/families,Case(s),,70.0,Worldwide,Validated,29477873[PMID]
27685,530983,Lamb-Shaffer syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29477873[PMID]
27686,530995,Mixed phenotype acute leukemia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10464,41751,Bietti crystalline dystrophy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10466,42062,Iminoglycinuria,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.67,Europe,Not yet validated,ORPHANET
10466,42062,Iminoglycinuria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.68,Europe,Not yet validated,ORPHANET
10394,35705,Neurometabolic disorder due to serine deficiency,Category,Group of disorders,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
10394,35705,Neurometabolic disorder due to serine deficiency,Category,Group of disorders,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10395,35706,Glutaric acidemia type 3,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10393,35704,L-Arginine:glycine amidinotransferase deficiency,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,20301745[PMID]_20625172[PMID]
10393,35704,L-Arginine:glycine amidinotransferase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10398,35710,Glucose-galactose malabsorption,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_22843301[PMID]
10398,35710,Glucose-galactose malabsorption,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.22,France,Validated,23107089[PMID]
10399,35737,Morning glory disc anomaly,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10397,35708,Aromatic L-amino acid decarboxylase deficiency,Disease,Disorder,Cases/families,Case(s),,140.0,Worldwide,Validated,30689738[PMID]
10397,35708,Aromatic L-amino acid decarboxylase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30689738[PMID]
10385,35689,Primary lateral sclerosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.5,Europe,Validated,ORPHANET
10391,35701,3-hydroxy-3-methylglutaryl-CoA synthase deficiency,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,23751782[PMID]
10391,35701,3-hydroxy-3-methylglutaryl-CoA synthase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10388,35698,Mitochondrial DNA depletion syndrome,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10388,35698,Mitochondrial DNA depletion syndrome,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Israel,Validated,33239050[PMID]
10388,35698,Mitochondrial DNA depletion syndrome,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.1,Specific population,Validated,33239050[PMID]
10378,35612,Nanophthalmos,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10376,35173,X-linked dominant chondrodysplasia punctata,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.25,Europe,Validated,21634086[PMID]
10376,35173,X-linked dominant chondrodysplasia punctata,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
10383,35687,Erdheim-Chester disease,Disease,Disorder,Cases/families,Case(s),,500.0,Worldwide,Validated,20724540[PMID]
10383,35687,Erdheim-Chester disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10381,35664,ALDH18A1-related De Barsy syndrome,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,32.0,Worldwide,Validated,ORPHANET
10381,35664,ALDH18A1-related De Barsy syndrome,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10380,35656,Coenzyme Q10 deficiency,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10370,35107,Desmosterolosis,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,29175559[PMID]
10370,35107,Desmosterolosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29175559[PMID]
10375,35125,Epidermal nevus syndrome,Disease,Disorder,Cases/families,Case(s),,400.0,Worldwide,Validated,ORPHANET
10375,35125,Epidermal nevus syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10373,35122,Congenital sucrase-isomaltase deficiency,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.0,Europe,Not yet validated,ORPHANET
10372,35121,Lysosomal acid phosphatase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
10424,36387,Genetic epilepsy with febrile seizure plus,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10425,36388,Paraneoplastic neurologic syndrome,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10426,36397,Adiposis dolorosa,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10428,36412,Hypocomplementemic urticarial vasculitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10430,36426,Stevens-Johnson syndrome,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.36,Europe,Not yet validated,23866878[PMID]
10430,36426,Stevens-Johnson syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
10417,36355,Bleeding disorder due to P2Y12 defect,Disease,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,15852220[PMID]_19229056[PMID]
10417,36355,Bleeding disorder due to P2Y12 defect,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10423,36386,Hereditary sensory and autonomic neuropathy type 1,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,18348718[PMID]
10409,36234,Bacterial toxic-shock syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.0,Worldwide,Not yet validated,15264985[PMID]
10411,36236,Staphylococcal scalded skin syndrome,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Germany,Not yet validated,15816826[PMID]
10411,36236,Staphylococcal scalded skin syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10413,36238,Staphylococcal necrotizing pneumonia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10412,36237,Bullous impetigo,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10415,36273,Gastric linitis plastica,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10414,36258,Buerger disease,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,16.0,Worldwide,Validated,[EXPERT]
10414,36258,Buerger disease,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,Europe,Validated,European Medicines Agency 2015[INST]
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.85,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.13,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.1,United States,Validated,15863154[PMID]
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.05,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.043,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.074,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.069,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.094,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.045,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.063,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.039,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.073,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.093,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.089,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.133,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.102,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.367,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.152,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.314,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.296,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.135,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.401,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.236,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.232,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10401,35808,Malignant sex cord stromal tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.212,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.08,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Lifetime Prevalence,Value and class,1-9 / 100 000,2.3,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.2,United States,Validated,15863154[PMID]
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.072,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.07,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.089,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.093,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.087,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.062,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.065,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.085,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.065,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.065,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.081,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.095,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.09,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.098,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.064,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.075,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.072,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.051,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.061,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.064,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.157,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.126,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10400,35807,Malignant germ cell tumor of ovary,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.141,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10403,35878,Hyperinsulinism-hyperammonemia syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
10402,35858,Imerslund-Gräsbeck syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Finland,Validated,Pr Ralph GRÄSBECK[EXPERT]
10402,35858,Imerslund-Gräsbeck syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Norway,Validated,Pr Ralph GRÄSBECK[EXPERT]
10402,35858,Imerslund-Gräsbeck syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10402,35858,Imerslund-Gräsbeck syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,Pr Ralph GRÄSBECK[EXPERT]_ORPHANET
10405,35909,Combined deficiency of factor V and factor VIII,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,[EXPERT]
10405,35909,Combined deficiency of factor V and factor VIII,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,"Iran, Islamic Republic of",Validated,9531348[PMID]
10404,35889,Acute opioid intoxication,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10407,36204,Intestinal lymphangiectasia,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10406,35981,Polymicrogyria,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10327,33572,5-oxoprolinase deficiency,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,ORPHANET
10327,33572,5-oxoprolinase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10326,33543,Kleine-Levin syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
10326,33543,Kleine-Levin syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.18,France,Validated,25559212[PMID]
10324,33475,Meningococcal meningitis,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,European Medicines Agency 2006[INST]
10324,33475,Meningococcal meningitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.3,France,Validated,Institut de Veille Sanitaire 2010[INST]
10324,33475,Meningococcal meningitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.7,New Zealand,Validated,Institute of Environmental Science and Research 2011[INST]
10324,33475,Meningococcal meningitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.8,United States,Validated,Center for Diseases Control and Prevention[INST]
10323,33445,Neuroectodermal melanolysosomal disease,Malformation syndrome,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,474620[PMID]_10052404[PMID]_11170073[PMID]_17710870[PMID]
10323,33445,Neuroectodermal melanolysosomal disease,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10321,33408,Bullous lichen planus,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
27792,535458,Familial GPIHBP1 deficiency,Etiological subtype,Subtype of disorder,Cases/families,Family(ies),,10.0,Worldwide,Validated,25732519[PMID]
27792,535458,Familial GPIHBP1 deficiency,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25732519[PMID]
10320,33402,Pediatric hepatocellular carcinoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,24439603[PMID]
10320,33402,Pediatric hepatocellular carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.15,Europe,Validated,[EXPERT]
10320,33402,Pediatric hepatocellular carcinoma,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,United States,Validated,24439603[PMID]
10333,34217,Naxos disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,15210133[PMID]_34926342[PMID]_ORPHANET
10330,33577,Nodular non-suppurative panniculitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10329,33574,Glutamate-cysteine ligase deficiency,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,18024385[PMID]
10329,33574,Glutamate-cysteine ligase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18024385[PMID]
10328,33573,Gamma-glutamyl transpeptidase deficiency,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,15702405[PMID]
10328,33573,Gamma-glutamyl transpeptidase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15702405[PMID]
10310,33110,Autosomal agammaglobulinemia,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,[EXPERT]
10310,33110,Autosomal agammaglobulinemia,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
10311,33111,Granulomatous slack skin,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,14726855[PMID]
10311,33111,Granulomatous slack skin,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10308,33108,Lethal multiple pterygium syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,28.0,Worldwide,Validated,ORPHANET
10308,33108,Lethal multiple pterygium syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10306,33067,"Metaphyseal chondrodysplasia, Jansen type",Disease,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,ORPHANET
10306,33067,"Metaphyseal chondrodysplasia, Jansen type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10307,33069,Dravet syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.3,Europe,Validated,22719002[PMID]_25772213[PMID]_ 31302675[PMID]
10307,33069,Dravet syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
10305,33001,Lymphedema-distichiasis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET_24215208[PMID]
10318,33355,Reticular dysgenesis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.03,Europe,Validated,[EXPERT]
10318,33355,Reticular dysgenesis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
27791,535453,Familial lipase maturation factor 1 deficiency,Etiological subtype,Subtype of disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,25732519[PMID]
27791,535453,Familial lipase maturation factor 1 deficiency,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25732519[PMID]
10319,33364,Trichothiodystrophy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10319,33364,Trichothiodystrophy,Disease,Disorder,Cases/families,Case(s),,201.0,Worldwide,Validated,18603627[PMID]_18329345[PMID]_19681155[PMID]
10319,33364,Trichothiodystrophy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.12,Europe,Validated,18329345[PMID]
10316,33276,Kaposi sarcoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.34,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
10316,33276,Kaposi sarcoma,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
10316,33276,Kaposi sarcoma,Disease,Disorder,Lifetime Prevalence,Value and class,1-9 / 100 000,2.11,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
10316,33276,Kaposi sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.051,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10316,33276,Kaposi sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.075,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10316,33276,Kaposi sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.099,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10316,33276,Kaposi sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.092,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10316,33276,Kaposi sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.065,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10316,33276,Kaposi sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.014,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10316,33276,Kaposi sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.076,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10316,33276,Kaposi sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.027,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10316,33276,Kaposi sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.043,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10316,33276,Kaposi sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.05,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10316,33276,Kaposi sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.056,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10316,33276,Kaposi sarcoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.133,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10316,33276,Kaposi sarcoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.111,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10316,33276,Kaposi sarcoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.108,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10316,33276,Kaposi sarcoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.112,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10316,33276,Kaposi sarcoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.597,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10316,33276,Kaposi sarcoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.915,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10316,33276,Kaposi sarcoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.546,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10316,33276,Kaposi sarcoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.163,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10316,33276,Kaposi sarcoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.278,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10316,33276,Kaposi sarcoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.192,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10316,33276,Kaposi sarcoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.363,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10316,33276,Kaposi sarcoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.142,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10317,33314,Jessner lymphocytic infiltration of the skin,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10312,33208,Idiopathic hypersomnia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10312,33208,Idiopathic hypersomnia,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,30.0,Europe,Validated,European Medicines Agency 2015[INST]
10313,33226,Waldenström macroglobulinemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.81,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10313,33226,Waldenström macroglobulinemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.05,France,Validated,Institut National du Cancer 2013[INST]
10313,33226,Waldenström macroglobulinemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.38,United States,Validated,22139816[PMID]
10313,33226,Waldenström macroglobulinemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.55,United Kingdom,Validated,17416416[PMID]
10313,33226,Waldenström macroglobulinemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.31,Spain,Validated,11736938[PMID]
10313,33226,Waldenström macroglobulinemia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10313,33226,Waldenström macroglobulinemia,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,European Medicines Agency 2014[INST]
10365,35069,Infantile neuroaxonal dystrophy,Disease,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,ORPHANET
10365,35069,Infantile neuroaxonal dystrophy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10367,35093,Non-syndromic sagittal craniosynostosis,Morphological anomaly,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.7,Australia,Validated,34626670[PMID]_ORPHANET
10367,35093,Non-syndromic sagittal craniosynostosis,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,20.7,Australia,Validated,34626670[PMID]
10366,35078,T-B+ severe combined immunodeficiency due to JAK3 deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10360,35062,Severe disseminated cytomegalovirus infection in immunocompetent patients,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10342,34520,Congenital muscular dystrophy with integrin alpha-7 deficiency,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.03,Europe,Not yet validated,ORPHANET
10336,34514,Telethonin-related limb-girdle muscular dystrophy R7,Disease,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,12921790[PMID]_18948002[PMID]_25298746[PMID]
10336,34514,Telethonin-related limb-girdle muscular dystrophy R7,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12921790[PMID]_18948002[PMID]_25298746[PMID]
10337,34515,FKRP-related limb-girdle muscular dystrophy R9,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,19767415[PMID]_20961759[PMID]_ORPHANET
10337,34515,FKRP-related limb-girdle muscular dystrophy R9,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.43,United Kingdom,Validated,19767415[PMID]
10337,34515,FKRP-related limb-girdle muscular dystrophy R9,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.85,Norway,Validated,20961759[PMID]
10338,34516,DNAJB6-related limb-girdle muscular dystrophy D1,Disease,Disorder,Cases/families,Family(ies),,6.0,Worldwide,Validated,26847086[PMID]
10338,34516,DNAJB6-related limb-girdle muscular dystrophy D1,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26847086[PMID]
10348,34587,Danon disease,Disease,Disorder,Cases/families,Case(s),,84.0,Worldwide,Validated,ORPHANET
10348,34587,Danon disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10348,34587,Danon disease,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.05,Sweden,Validated,25274184[PMID]
10349,34592,Immunodeficiency by defective expression of MHC class I,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,25001848[PMID]
10349,34592,Immunodeficiency by defective expression of MHC class I,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25001848[PMID]
10346,34528,Autosomal dominant primary hypomagnesemia with hypocalciuria,Disease,Disorder,Cases/families,Case(s),,28.0,Worldwide,Validated,25765846[PMID]
10346,34528,Autosomal dominant primary hypomagnesemia with hypocalciuria,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25765846[PMID]
10347,34533,Corneal dystrophy,Category,Group of disorders,Point prevalence,Value and class,>1 / 1000,110.0,United States,Not yet validated,21791583[PMID]
10347,34533,Corneal dystrophy,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
27851,536516,Myopathic Ehlers-Danlos syndrome,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,28306225[PMID]
27851,536516,Myopathic Ehlers-Danlos syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28306225[PMID]
27850,536471,Spondylodysplastic Ehlers-Danlos syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29931299[PMID]_26940150[PMID]_18513683[PMID]_18985159[PMID]
27850,536471,Spondylodysplastic Ehlers-Danlos syndrome,Disease,Disorder,Cases/families,Family(ies),,24.0,Worldwide,Validated,29931299[PMID]_26940150[PMID]_18513683[PMID]_18985159[PMID]
27849,536467,B3GALT6-related spondylodysplastic Ehlers-Danlos syndrome,Clinical subtype,Subtype of disorder,Cases/families,Family(ies),,41.0,Worldwide,Validated,23664117[PMID]_29931299[PMID]_23664118[PMID]
27849,536467,B3GALT6-related spondylodysplastic Ehlers-Danlos syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29931299[PMID]
27853,536545,Kyphoscoliotic Ehlers-Danlos syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_28306225[PMID]
27852,536532,Classical-like Ehlers-Danlos syndrome type 2,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,30759870[PMID]
27852,536532,Classical-like Ehlers-Danlos syndrome type 2,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30759870[PMID]
27892,537072,PLG-related hereditary angioedema with normal C1Inh,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,105.0,Worldwide,Validated,30809376[PMID]
27892,537072,PLG-related hereditary angioedema with normal C1Inh,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30809376[PMID]
10303,32960,Tumor necrosis factor receptor 1 associated periodic syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10303,32960,Tumor necrosis factor receptor 1 associated periodic syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,European Medicines Agency 2012[INST]
10700,52530,Pseudo-von Willebrand disease,Disease,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,23327637[PMID]_21301777[PMID]_23934752[PMID]
10700,52530,Pseudo-von Willebrand disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10703,52688,Myelodysplastic syndrome,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.5,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10703,52688,Myelodysplastic syndrome,Clinical group,Group of disorders,Lifetime Prevalence,Value and class,1-9 / 100 000,5.02,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
10703,52688,Myelodysplastic syndrome,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.15,Germany,Validated,21708407[PMID]
10703,52688,Myelodysplastic syndrome,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,7.0,Germany,Validated,21708407[PMID]
10703,52688,Myelodysplastic syndrome,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,6.4,France,Validated,Institut National du Cancer 2013[INST]
10703,52688,Myelodysplastic syndrome,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.35,Japan,Not yet validated,7718765[PMID]
10703,52688,Myelodysplastic syndrome,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.35,United States,Validated,18443215[PMID]_17345612[PMID]_National Cancer Institute[INST]_ORPHANET
10703,52688,Myelodysplastic syndrome,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.4,Greece,Not yet validated,23572136[PMID]
10703,52688,Myelodysplastic syndrome,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,8.5,United Kingdom,Not yet validated,7986716[PMID]_7819118[PMID]_ ORPHANET
10703,52688,Myelodysplastic syndrome,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.5,Sweden,Not yet validated,7720834[PMID]
10703,52688,Myelodysplastic syndrome,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.5,Romania,Validated,19411107[PMID]
10703,52688,Myelodysplastic syndrome,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,8.1,Spain,Validated,14555322[PMID]
10703,52688,Myelodysplastic syndrome,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,15.0,United States,Not yet validated,emedicine 2009[OTHER]
10703,52688,Myelodysplastic syndrome,Clinical group,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
10703,52688,Myelodysplastic syndrome,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.95,Poland,Validated,27699872[PMID]
10703,52688,Myelodysplastic syndrome,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,6.2,Poland,Validated,27699872[PMID]
10703,52688,Myelodysplastic syndrome,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.8,Switzerland,Validated,28056392[PMID]
27913,538096,Autosomal recessive lethal neonatal axonal sensorimotor polyneuropathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
27913,538096,Autosomal recessive lethal neonatal axonal sensorimotor polyneuropathy,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,22971091[PMID]_9771672[PMID]
10699,52503,X-linked creatine transporter deficiency,Disease,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,23644449[PMID]
10699,52503,X-linked creatine transporter deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_23644449[PMID]
27914,538101,Congenital axonal neuropathy with encephalopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18358405[PMID]
27914,538101,Congenital axonal neuropathy with encephalopathy,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,18358405[PMID]
10698,52430,Inclusion body myopathy with Paget disease of bone and frontotemporal dementia,Disease,Disorder,Cases/families,Family(ies),,26.0,Worldwide,Validated,20301649[PMID]
10698,52430,Inclusion body myopathy with Paget disease of bone and frontotemporal dementia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20301649[PMID]
10693,52416,Mantle cell lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.8,United States,Validated,28444739[PMID]_SEER Surveillance Epidemiology and End Results 2007-2013[INST]
10693,52416,Mantle cell lymphoma,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.5,Europe,Validated,[EXPERT]_European Medicines Agency 2015[INST]
10693,52416,Mantle cell lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.05,France,Validated,Institut National du Cancer 2013[INST]
10695,52427,Retinitis punctata albescens,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.125,Worldwide,Validated,23929416[PMID]
10695,52427,Retinitis punctata albescens,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.175,Europe,Validated,ORPHANET_European Medecines Agency 2016[INST]
10694,52417,MALT lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.3,Europe,Validated,[EXPERT]_RARECARE surveillance of rare cancers in Europe[REG]
10694,52417,MALT lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.59,United States,Validated,22893605[PMID]_National Cancer Institute[INST]
10694,52417,MALT lymphoma,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.0,Europe,Validated,European Medicines Agency 2013[INST]
10689,52056,Ulnar/fibula ray defect-brachydactyly syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,14564152[PMID]
10689,52056,Ulnar/fibula ray defect-brachydactyly syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_14564152[PMID]
10688,52055,Corpus callosum agenesis-intellectual disability-coloboma-micrognathia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,14556245[PMID]
10688,52055,Corpus callosum agenesis-intellectual disability-coloboma-micrognathia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_14556245[PMID]
10691,52368,Mohr-Tranebjaerg syndrome,Disease,Disorder,Cases/families,Case(s),,91.0,Worldwide,Validated,20301395[PMID]
10691,52368,Mohr-Tranebjaerg syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20301395[PMID]
10716,53271,Muenke syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.33,Worldwide,Validated,15241680[PMID]
10716,53271,Muenke syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10716,53271,Muenke syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.3,Australia,Validated,34626670[PMID]
10718,53296,Familial cutaneous collagenoma,Disease,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,5657391[PMID]_486326[PMID]_22028557[PMID]
10718,53296,Familial cutaneous collagenoma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5657391[PMID]_486326[PMID]_22028557[PMID]
10719,53347,Brody myopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_32040565[PMID]_22704959[PMID]
10714,52994,Orbital leiomyoma,Disease,Disorder,Cases/families,Case(s),,26.0,Worldwide,Validated,23562416[PMID]
10714,52994,Orbital leiomyoma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23562416[PMID]
10715,53035,Caroli disease,Malformation syndrome,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Worldwide,Validated,14696493[PMID]
10715,53035,Caroli disease,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_15559623[PMID]
10704,52759,Vasculitis,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,6.3,Europe,Not yet validated,ORPHANET
10706,52901,Isolated follicle stimulating hormone deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
27951,538863,Classic pyoderma gangrenosum,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_25213386[PMID]
27951,538863,Classic pyoderma gangrenosum,Clinical subtype,Subtype of disorder,Annual incidence,Class only,1-9 / 1 000 000,0.0,Italy,Validated,ORPHANET_29877043[PMID]
27945,538756,Familial multiple discoid fibromas,Disease,Disorder,Cases/families,Case(s),,44.0,Worldwide,Validated,29067220[PMID]
27945,538756,Familial multiple discoid fibromas,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29067220[PMID]
27942,538574,Palmoplantar keratoderma-hereditary motor and sensory neuropathy syndrome,Disease,Disorder,Cases/families,Case(s),,23.0,Worldwide,Validated,6446889[PMID]_2976839[PMID]_27639257[PMID]
27942,538574,Palmoplantar keratoderma-hereditary motor and sensory neuropathy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6446889[PMID]_2976839[PMID]_27639257[PMID]
10724,53583,Paroxysmal dystonic choreathetosis with episodic ataxia and spasticity,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,21832227[PMID]
10724,53583,Paroxysmal dystonic choreathetosis with episodic ataxia and spasticity,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21832227[PMID]
10723,53540,Goldmann-Favre syndrome,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,ORPHANET
10723,53540,Goldmann-Favre syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10721,53372,Hereditary geniospasm,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10720,53351,X-linked dystonia-parkinsonism,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,15390042[PMID]
10720,53351,X-linked dystonia-parkinsonism,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.31,Philippines,Validated,21047175[PMID]_20301662[PMID]_ [EXPERT]
10748,54247,Posterior cortical atrophy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
27964,538934,X-linked lymphoproliferative disease due to XIAP deficiency,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,29942301[PMID]
27964,538934,X-linked lymphoproliferative disease due to XIAP deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29942301[PMID]
10749,54251,Aseptic abscess syndrome,Disease,Disorder,Cases/families,Case(s),,49.0,Worldwide,Validated,ORPHANET
10749,54251,Aseptic abscess syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
27963,538931,X-linked lymphoproliferative disease due to SAP deficiency,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,29942301[PMID]
27963,538931,X-linked lymphoproliferative disease due to SAP deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29942301[PMID]
10746,54057,Thrombotic thrombocytopenic purpura,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10746,54057,Thrombotic thrombocytopenic purpura,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.35,Worldwide,Validated,18637802[PMID]_23729372[PMID]_31730475[PMID]
10745,54028,Plummer-Vinson syndrome,Disease,Disorder,Cases/families,Case(s),,25.0,Worldwide,Validated,ORPHANET
10745,54028,Plummer-Vinson syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10742,53719,Wyburn-Mason syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_ISBN:3211695001[OTHER]
10742,53719,Wyburn-Mason syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,90.0,Worldwide,Validated,ISBN:3211695001[OTHER]
10743,53721,Spinal arteriovenous metameric syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,45.0,Worldwide,Validated,26130930[PMID]
10743,53721,Spinal arteriovenous metameric syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26130930[PMID]
10741,53715,Familial tumoral calcinosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10738,53696,Arthrogryposis-anterior horn cell disease syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,7821908[PMID]
10738,53696,Arthrogryposis-anterior horn cell disease syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,7821908[PMID]_ORPHANET
27954,538872,Vegetative pyoderma gangrenosum,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_25213386[PMID]
27954,538872,Vegetative pyoderma gangrenosum,Clinical subtype,Subtype of disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Italy,Validated,ORPHANET_29877043[PMID]
10739,53697,Gnathodiaphyseal dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27068316[PMID]
27953,538869,Bullous pyoderma gangrenosum,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_25213386[PMID]
27953,538869,Bullous pyoderma gangrenosum,Clinical subtype,Subtype of disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Italy,Validated,ORPHANET_29877043[PMID]
27952,538866,Pustular pyoderma gangrenosum,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_25213386[PMID]
27952,538866,Pustular pyoderma gangrenosum,Clinical subtype,Subtype of disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Italy,Validated,ORPHANET_29877043[PMID]
10737,53693,GRACILE syndrome,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.0,Finland,Validated,22970607[PMID]
10737,53693,GRACILE syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Finland,Not yet validated,22970607[PMID]
10737,53693,GRACILE syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
10633,48818,Aceruloplasminemia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Japan,Validated,10449129[PMID]
10633,48818,Aceruloplasminemia,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.09,Worldwide,Validated,ORPHANET
10637,49041,IgG4-related retroperitoneal fibrosis,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.35,Europe,Validated,[EXPERT]
10637,49041,IgG4-related retroperitoneal fibrosis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Finland,Not yet validated,16427494[PMID]
10637,49041,IgG4-related retroperitoneal fibrosis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
10636,48918,Focal myositis,Disease,Disorder,Cases/families,Case(s),,115.0,Worldwide,Validated,15546587[PMID]
10636,48918,Focal myositis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10639,49382,Achromatopsia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.7,Worldwide,Validated,ISBN:521590531[OTHER]
10638,49042,Dentinogenesis imperfecta,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,14.5,Europe,Validated,[EXPERT]
27968,538958,Combined immunodeficiency due to CD70 deficiency,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,29942301[PMID]
27968,538958,Combined immunodeficiency due to CD70 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29942301[PMID]
10625,48431,Congenital cataracts-facial dysmorphism-neuropathy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,170.0,Worldwide,Validated,20301787[PMID]
10625,48431,Congenital cataracts-facial dysmorphism-neuropathy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_20301787[PMID]
27969,538963,Combined immunodeficiency due to ITK deficiency,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,29942301[PMID]
27969,538963,Combined immunodeficiency due to ITK deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29942301[PMID]
10626,48435,Postinfectious vasculitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10631,48686,Primary effusion lymphoma,Disease,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,[EXPERT]
10631,48686,Primary effusion lymphoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10630,48652,Phelan-McDermid syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,ORPHANET
10630,48652,Phelan-McDermid syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10648,50809,Talo-patello-scaphoid osteolysis,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,12910489[PMID]
10648,50809,Talo-patello-scaphoid osteolysis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12910489[PMID]
10649,50810,Microlissencephaly-micromelia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,12749064[PMID]
10649,50810,Microlissencephaly-micromelia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12749064[PMID]
10650,50811,Lipodystrophy-intellectual disability-deafness syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,12923870[PMID]
10650,50811,Lipodystrophy-intellectual disability-deafness syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12923870[PMID]
10651,50812,Zellweger-like syndrome without peroxisomal anomalies,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,12784304[PMID]
10651,50812,Zellweger-like syndrome without peroxisomal anomalies,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12784304[PMID]
10653,50814,Craniolenticulosutural dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,28.0,Worldwide,Validated,ORPHANET
10653,50814,Craniolenticulosutural dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10654,50815,Branchiogenic deafness syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,12833414[PMID]
10654,50815,Branchiogenic deafness syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12833414[PMID]
10640,49566,Acquired purpura fulminans,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10640,49566,Acquired purpura fulminans,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10643,49827,Thiamine-responsive megaloblastic anemia syndrome,Disease,Disorder,Cases/families,Case(s),,80.0,Worldwide,Validated,[EXPERT]
10643,49827,Thiamine-responsive megaloblastic anemia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10645,50251,Pleural mesothelioma,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.1,Europe,Validated,European Medicines Agency[INST]
10645,50251,Pleural mesothelioma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.9,Europe,Not yet validated,22406029[PMID]
10645,50251,Pleural mesothelioma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.8,France,Validated,19569174[PMID]
10665,50945,Blomstrand lethal chondrodysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,27353973[PMID]
10665,50945,Blomstrand lethal chondrodysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27353973[PMID]
10664,50944,Schöpf-Schulz-Passarge syndrome,Disease,Disorder,Cases/families,Case(s),,25.0,Worldwide,Validated,ORPHANET
10664,50944,Schöpf-Schulz-Passarge syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10670,51083,Familial short QT syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,23916535[PMID]_[EXPERT]
10670,51083,Familial short QT syndrome,Disease,Disorder,Cases/families,Family(ies),,80.0,Worldwide,Validated,[EXPERT]
10658,50839,Cat-scratch disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.6,Europe,Validated,[EXPERT]
10660,50918,Kikuchi-Fujimoto disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_25500707[PMID]
10660,50918,Kikuchi-Fujimoto disease,Disease,Disorder,Cases/families,Case(s),,1052.0,Worldwide,Validated,25500707[PMID]
10660,50918,Kikuchi-Fujimoto disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.278,Martinique,Validated,27015112[PMID]
10687,52054,Craniosynostosis-intracranial calcifications syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,14564206[PMID]
10687,52054,Craniosynostosis-intracranial calcifications syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_14564206[PMID]
10684,52022,Potocki-Shaffer syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,23239541[PMID]_15852040[PMID]
10684,52022,Potocki-Shaffer syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23239541[PMID]
10685,52047,Braddock syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,14556254[PMID]
10685,52047,Braddock syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_14556254[PMID]
10674,51577,Cobblestone lissencephaly,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Europe,Validated,ORPHANET
10674,51577,Cobblestone lissencephaly,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10675,51608,Generalized arterial calcification of infancy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_25392903[PMID]
10675,51608,Generalized arterial calcification of infancy,Disease,Disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,[EXPERT]_25392903[PMID]
10672,51188,Ethylmalonic encephalopathy,Disease,Disorder,Cases/families,Case(s),,80.0,Worldwide,Validated,28933811[PMID]
10672,51188,Ethylmalonic encephalopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28933811[PMID]
28017,541423,Growth delay-intellectual disability-hepatopathy syndrome,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,29052218[PMID]_30431579[PMID]
28017,541423,Growth delay-intellectual disability-hepatopathy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29052218[PMID]_30431579[PMID]
10673,51208,Formiminoglutamic aciduria,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10676,51636,WHIM syndrome,Disease,Disorder,Cases/families,Case(s),,65.0,Worldwide,Validated,23009155[PMID]_24492099[PMID]
10676,51636,WHIM syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10676,51636,WHIM syndrome,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.023,France,Validated,23009155[PMID]_[EXPERT]
10677,51890,Anterior cutaneous nerve entrapment syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10677,51890,Anterior cutaneous nerve entrapment syndrome,Disease,Disorder,Annual incidence,Value and class,6-9 / 10 000,55.6,Netherlands,Validated,[EXPERT]_25887961[PMID]_72957[PMID]
28037,542306,GNB5-related intellectual disability-cardiac arrhythmia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
28037,542306,GNB5-related intellectual disability-cardiac arrhythmia syndrome,Disease,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,27523599[PMID]_27677260[PMID]_28697420[PMID]_29368331[PMID]_30631341[PMID]
28036,542301,Combined immunodeficiency due to CARMIL2 deficiency,Disease,Disorder,Cases/families,Case(s),,21.0,Worldwide,Validated,27896283[PMID]_27647349[PMID]_28112205[PMID]_29479355[PMID]
28036,542301,Combined immunodeficiency due to CARMIL2 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27896283[PMID]_27647349[PMID]_28112205[PMID]_29479355[PMID]
28038,542310,Leukoencephalopathy with calcifications and cysts,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,27571260[PMID]
28038,542310,Leukoencephalopathy with calcifications and cysts,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27571260[PMID]
10573,42642,PFAPA syndrome,Disease,Disorder,Cases/families,Case(s),,500.0,Worldwide,Validated,24505122[PMID]_24677969[PMID]
10573,42642,PFAPA syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10575,42665,Tietz syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,23020089[PMID]
10575,42665,Tietz syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23020089[PMID]
28040,542323,CAR T cell therapy-associated cytokine release syndrome,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10581,43117,Acute tricyclic antidepressant poisoning,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
28052,542585,Auditory neuropathy-optic atrophy syndrome,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,28965846[PMID]
28052,542585,Auditory neuropathy-optic atrophy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28965846[PMID]
10580,43116,Serotonin syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
28053,542592,Necrobiosis lipoidica,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_29184811[PMID]
10583,43393,Lambert-Eaton myasthenic syndrome,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.06,Netherlands,Validated,22094130[PMID]_23690300[PMID]
10583,43393,Lambert-Eaton myasthenic syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,European Medicines Agency[INST]
10583,43393,Lambert-Eaton myasthenic syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.35,Worldwide,Validated,22094130[PMID]
10582,43119,Acute poisoning by drugs with membrane-stabilizing effect,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
28055,542643,Livedoid vasculopathy,Clinical syndrome,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.0,United States,Validated,4830097[PMID]_21184847[PMID]
28055,542643,Livedoid vasculopathy,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10577,42775,PHACE syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,26564079[PMID]
10577,42775,PHACE syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26564079[PMID]
10576,42738,Severe congenital neutropenia,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 1 000 000,0.4,Europe,Validated,[EXPERT]
10576,42738,Severe congenital neutropenia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.4,Europe,Validated,[EXPERT]
10576,42738,Severe congenital neutropenia,Clinical group,Group of disorders,Point prevalence,Value and class,<1 / 1 000 000,0.07,Worldwide,Not yet validated,12555210[PMID]
10576,42738,Severe congenital neutropenia,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Sweden,Validated,22624626[PMID]
10576,42738,Severe congenital neutropenia,Clinical group,Group of disorders,Point prevalence,Class only,1-9 / 1 000 000,0.0,Sweden,Not yet validated,22624626[PMID]
10576,42738,Severe congenital neutropenia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.6,France,Validated,20399414[PMID]
10576,42738,Severe congenital neutropenia,Clinical group,Group of disorders,Point prevalence,Value and class,<1 / 1 000 000,0.077,"Iran, Islamic Republic of",Validated,17024564[PMID]
10576,42738,Severe congenital neutropenia,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,25.7,China,Validated,34103049[PMID]
10579,43115,Hereditary myopathy with lactic acidosis due to ISCU deficiency,Disease,Disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,20301757[PMID]
10579,43115,Hereditary myopathy with lactic acidosis due to ISCU deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20301757[PMID]
10589,45448,Miyoshi myopathy,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.22,Japan,Validated,[EXPERT]
10589,45448,Miyoshi myopathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.26,United Kingdom,Validated,19767415[PMID]
10589,45448,Miyoshi myopathy,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
28061,543470,Optic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome,Disease,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,29040572[PMID]
28061,543470,Optic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29040572[PMID]
10591,45453,Incessant infant ventricular tachycardia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.5,Europe,Validated,[EXPERT]
10591,45453,Incessant infant ventricular tachycardia,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,[EXPERT]
10591,45453,Incessant infant ventricular tachycardia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.3,United Kingdom,Validated,23551862[PMID]
10591,45453,Incessant infant ventricular tachycardia,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,United Kingdom,Validated,23551862[PMID]
10590,45452,Idiopathic neonatal atrial flutter,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.5,Europe,Validated,[EXPERT]_23551862[PMID]
10590,45452,Idiopathic neonatal atrial flutter,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.1,United Kingdom,Validated,23551862[PMID]
10590,45452,Idiopathic neonatal atrial flutter,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
28056,542657,Isolated hyperchlorhidrosis,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,21035102[PMID]_26911677[PMID]_21184099[PMID]
28056,542657,Isolated hyperchlorhidrosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21035102[PMID]_26911677[PMID]_21184099[PMID]
10584,44890,Gastrointestinal stromal tumor,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,13.0,Europe,Validated,European Medicines Agency[INST]_23623056[PMID]
10584,44890,Gastrointestinal stromal tumor,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.0,Europe,Not yet validated,21420965[PMID]_23623056[PMID]
10584,44890,Gastrointestinal stromal tumor,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.0,Worldwide,Not yet validated,23177515[PMID]
10584,44890,Gastrointestinal stromal tumor,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.9,"Korea, Republic of",Not yet validated,20514305[PMID]
10584,44890,Gastrointestinal stromal tumor,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,14.5,Hong Kong,Not yet validated,16610025[PMID]
10584,44890,Gastrointestinal stromal tumor,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.82,Hong Kong,Not yet validated,16610025[PMID]
10584,44890,Gastrointestinal stromal tumor,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.5,United States,Not yet validated,11213830[PMID]_23079473[PMID]
10584,44890,Gastrointestinal stromal tumor,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,12.9,Sweden,Validated,15648083[PMID]
10586,45358,Congenital fibrosis of extraocular muscles,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,ORPHANET_9797671[PMID]
10586,45358,Congenital fibrosis of extraocular muscles,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.43,United Kingdom,Validated,9797671[PMID]
10598,46487,Epidermolysis bullosa acquisita,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.03,Europe,Not yet validated,7826096[PMID]_19170813[PMID]_7669112[PMID]
10598,46487,Epidermolysis bullosa acquisita,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,France,Not yet validated,7826096[PMID]_23237497[PMID]
10598,46487,Epidermolysis bullosa acquisita,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.05,Germany,Validated,19170813[PMID]_7669112[PMID]
10598,46487,Epidermolysis bullosa acquisita,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.05,Singapore,Validated,12207586[PMID]_23237497[PMID]
10598,46487,Epidermolysis bullosa acquisita,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
10598,46487,Epidermolysis bullosa acquisita,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.008,Serbia,Validated,27767273[PMID]
10598,46487,Epidermolysis bullosa acquisita,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.284,Germany,Validated,27456755[PMID]
28070,544254,SYNGAP1-related developmental and epileptic encephalopathy,Disease,Disorder,Cases/families,Case(s),,57.0,Worldwide,Validated,30541864[PMID]
28070,544254,SYNGAP1-related developmental and epileptic encephalopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30541864[PMID]
10599,46488,Linear IgA dermatosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Germany,Validated,19170813[PMID]
10599,46488,Linear IgA dermatosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.069,Kuwait,Validated,15569006[PMID]
10599,46488,Linear IgA dermatosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.026,Singapore,Validated,12207586[PMID]_23237497[PMID]
10599,46488,Linear IgA dermatosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.3,Germany,Validated,19170813[PMID]_30252369[PMID]_ORPHANET
10599,46488,Linear IgA dermatosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.207,Kuwait,Validated,15569006[PMID]_30252369[PMID]_ORPHANET
10599,46488,Linear IgA dermatosis,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.078,Singapore,Validated,12207586[PMID]_23237497[PMID]_30252369[PMID]_ORPHANET
10596,46485,Superficial pemphigus,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.2,Europe,Validated,[EXPERT]
10597,46486,Mucous membrane pemphigoid,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.13,France,Validated,7826096[PMID]_23237497[PMID]
10597,46486,Mucous membrane pemphigoid,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.2,Germany,Validated,19170813[PMID]_23237497[PMID]
10597,46486,Mucous membrane pemphigoid,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
10597,46486,Mucous membrane pemphigoid,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.456,Germany,Validated,27456755[PMID]
10594,46348,Paroxysmal extreme pain disorder,Disease,Disorder,Cases/families,Family(ies),,4.0,Worldwide,Validated,8778439[PMID]
10594,46348,Paroxysmal extreme pain disorder,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10595,46484,Oligodendroglial tumor,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.35,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
10595,46484,Oligodendroglial tumor,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10595,46484,Oligodendroglial tumor,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.24,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
10592,46059,Lathosterolosis,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,24142275[PMID]
10592,46059,Lathosterolosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
10593,46135,Primary central nervous system lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.44,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
10593,46135,Primary central nervous system lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.26,Sweden,Validated,28983970[PMID]
10604,46724,Cerebral arteriovenous malformation,Morphological anomaly,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.0,Europe,Not yet validated,ORPHANET
10602,46627,Char syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,109.0,Worldwide,Validated,[EXPERT]_31012281[PMID]
10602,46627,Char syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
10601,46532,Hereditary persistence of fetal hemoglobin-beta-thalassemia syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10615,48372,Nodular regenerative hyperplasia of the liver,Histopathological subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.34,Spain,Validated,2586240[PMID]
10615,48372,Nodular regenerative hyperplasia of the liver,Histopathological subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,3.1,Spain,Validated,2586240[PMID]
10615,48372,Nodular regenerative hyperplasia of the liver,Histopathological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
10614,48162,Lewis-Sumner syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.9,Europe,Not yet validated,19260065[PMID]
28084,544493,Streptococcus pneumoniae-associated hemolytic uremic syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10613,48104,Pyoderma gangrenosum,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.0,United States,Validated,ISBN:978-1-60831-581-9[OTHER]
10613,48104,Pyoderma gangrenosum,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.91,United Kingdom,Validated,22534879[PMID]
10613,48104,Pyoderma gangrenosum,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_25213386[PMID]
10613,48104,Pyoderma gangrenosum,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.33,Spain,Validated,21782147[PMID]
10613,48104,Pyoderma gangrenosum,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.74,Worldwide,Validated,ORPHANET_21782147[PMID]_22534879[PMID]_ISBN:978-1-60831-581-9[OTHER]
10613,48104,Pyoderma gangrenosum,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.517,Italy,Validated,29877043[PMID]
28085,544503,RNF13-related severe early-onset epileptic encephalopathy,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,30595371[PMID]
28085,544503,RNF13-related severe early-onset epileptic encephalopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30595371[PMID]
10611,47612,Felty syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
28082,544482,Infection-related hemolytic uremic syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
10610,47159,Proximal renal tubular acidosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
28083,544488,Global developmental delay-alopecia-macrocephaly-facial dysmorphism-structural brain anomalies syndrome,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,30239107[PMID]_30475435[PMID]
28083,544488,Global developmental delay-alopecia-macrocephaly-facial dysmorphism-structural brain anomalies syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30239107[PMID]_30475435[PMID]
28080,544469,PRUNE1-related neurological syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,48.0,Worldwide,Validated,30556349[PMID]
28080,544469,PRUNE1-related neurological syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30556349[PMID]
28081,544472,Atypical hemolytic uremic syndrome with complement gene abnormality,Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
10608,47045,Familial cold urticaria,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Europe,Not yet validated,24262697[PMID]
10608,47045,Familial cold urticaria,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
28092,544628,Atypical Fanconi syndrome-neonatal hyperinsulinism syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24285859[PMID]
28092,544628,Atypical Fanconi syndrome-neonatal hyperinsulinism syndrome,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,24285859[PMID]
28091,544602,Congenital myopathy with reduced type 2 muscle fibers,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,30215711[PMID]
28091,544602,Congenital myopathy with reduced type 2 muscle fibers,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30215711[PMID]
10616,48377,Subcorneal pustular dermatosis,Disease,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,ORPHANET
10616,48377,Subcorneal pustular dermatosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
28089,544578,"Congenital primary megaureter, refluxing and obstructed form",Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
28103,555402,NAD(P)HX dehydratase deficiency,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,30576410[PMID]
28103,555402,NAD(P)HX dehydratase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30576410[PMID]
28105,555434,Fibrohistiocytic inflammatory pseudotumor of the liver,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_17571078[PMID]
28104,555407,NAD(P)HX epimerase deficiency,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,27616477[PMID]_27122014[PMID]
28104,555407,NAD(P)HX epimerase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27616477[PMID]_27122014[PMID]
10507,68367,Rare inborn errors of metabolism,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,3.3,Germany,Validated,21689452[PMID]
28106,555437,Lymphoplasmacytic inflammatory pseudotumor of the liver,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_17571078[PMID]
28118,555874,Congenital tricuspid valve dysplasia,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
28119,555877,FLNA-related X-linked myxomatous valvular dysplasia,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29146485[PMID]
28120,555905,IgA pemphigus,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_30085605[PMID]
28123,556030,Early-onset familial hypoaldosteronism,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
28124,556037,Late-onset familial hypoaldosteronism,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
28139,556985,Early-onset calcifying leukoencephalopathy-skeletal dysplasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30982608[PMID]_30982609[PMID]_28383543[PMID]
28139,556985,Early-onset calcifying leukoencephalopathy-skeletal dysplasia,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,30982608[PMID]_30982609[PMID]_28383543[PMID]
28138,556955,Pancreatic agenesis-holoprosencephaly syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,31006513[PMID]_28525974[PMID]
28138,556955,Pancreatic agenesis-holoprosencephaly syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_31006513[PMID]_28525974[PMID]
28142,557064,Neonatal epileptic encephalopathy due to glutaminase deficiency,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,30575854[PMID]
28142,557064,Neonatal epileptic encephalopathy due to glutaminase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30575854[PMID]
28141,557056,Spastic ataxia-dysarthria due to glutaminase deficiency,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,29468182[PMID]_30987386[PMID]
28141,557056,Spastic ataxia-dysarthria due to glutaminase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29468182[PMID]_30987386[PMID]
28140,557003,Oculoskeletodental syndrome,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,31034465[PMID]
28140,557003,Oculoskeletodental syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_31034465[PMID]
11956,90065,Acquired aneurysmal subarachnoid hemorrhage,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,Europe,Validated,European Medicines Agency 2015[INST]
11957,90066,Pneumonia caused by Pseudomonas aeruginosa infection,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,50.0,Europe,Validated,European Medicines Agency[INST]
11959,90068,Cocaine intoxication,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,European Medicines Agency 2011[INST]
11952,90061,Non-infectious posterior uveitis,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,18.0,Europe,Validated,European Medicines Agency[INST]
11953,90062,Acute liver failure,Clinical syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.0,Europe,Validated,European Medicines Agency[INST]
27251,519388,Autosomal recessive anterior segment dysgenesis,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,27839872[PMID]_29556725[PMID]
27251,519388,Autosomal recessive anterior segment dysgenesis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27839872[PMID]_29556725[PMID]
11955,90064,Acute peripheral arterial occlusion,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,16.0,Europe,Validated,European Medicines Agency[INST]
11964,90073,Hepatitis B reinfection following liver transplantation,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Europe,Validated,European Medicines Agency 2004[INST]
11967,90076,Partial deep dermal and full thickness burns,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,Europe,Validated,European Medicines Agency[INST]
11960,90069,Systemic monochloroacetate poisoning,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,European Medicines Agency 2004[INST]
11941,90050,Retinopathy of prematurity,Disease,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET
11940,90045,Hereditary folate malabsorption,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
11940,90045,Hereditary folate malabsorption,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11943,90052,Recurrent hepatitis C virus induced liver disease in liver transplant recipients,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.0,Europe,Validated,European Medicines Agency[INST]
11942,90051,Sepsis in premature infants,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,32.0,Europe,Validated,European Medicines Agency[INST]
11937,90041,Gaisböck syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11936,90039,Hemoglobin D disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11939,90044,Familial pseudohyperkalemia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
11938,90042,Primary familial polycythemia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11949,90058,Spinal cord injury,Particular clinical situation in a disease or syndrome,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.57,Canada,Validated,22337075[PMID]
11949,90058,Spinal cord injury,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,32.0,Europe,Validated,European Medicines Agency[INST]
11951,90060,Diffuse alveolar hemorrhage,Clinical syndrome,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,European Medicines Agency[INST]
11950,90059,Sudden sensorineural hearing loss,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,40.0,Europe,Validated,European Medicines Agency 2018[INST]
11944,90053,Complications after hematopoietic stem cell transplantation,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.65,Europe,Validated,European Medicines Agency[INST]
11947,90056,Moderate and severe traumatic brain injury,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,37.8,Europe,Validated,European Medicines Agency[INST]
11926,90024,"Deafness with labyrinthine aplasia, microtia, and microdontia",Malformation syndrome,Disorder,Cases/families,Case(s),,56.0,Worldwide,Validated,22993869[PMID]
11926,90024,"Deafness with labyrinthine aplasia, microtia, and microdontia",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22993869[PMID]
11925,90023,Primary immunodeficiency syndrome due to P14/LAMTOR2 deficiency,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,17195838[PMID]
11925,90023,Primary immunodeficiency syndrome due to P14/LAMTOR2 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17195838[PMID]
11921,90003,Inflammatory pseudotumor of the liver,Disease,Disorder,Cases/families,Case(s),,140.0,Worldwide,Validated,ORPHANET
11921,90003,Inflammatory pseudotumor of the liver,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11934,90037,Drug-induced autoimmune hemolytic anemia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
11935,90038,Shiga toxin-associated hemolytic uremic syndrome,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 100 000,2.1,United States,Validated,ISBN:0123864577[OTHER]
11935,90038,Shiga toxin-associated hemolytic uremic syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
11932,90035,Paroxysmal cold hemoglobinuria,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
11933,90036,Mixed-type autoimmune hemolytic anemia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
11930,90031,Non-spherocytic hemolytic anemia due to hexokinase deficiency,Disease,Disorder,Cases/families,Family(ies),,17.0,Worldwide,Validated,ORPHANET
11930,90031,Non-spherocytic hemolytic anemia due to hexokinase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11931,90033,"Autoimmune hemolytic anemia, warm type",Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
11928,90026,Primary erythromelalgia,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.1,United States,Validated,18713229[PMID]
11928,90026,Primary erythromelalgia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11929,90030,Hemolytic anemia due to glutathione reductase deficiency,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,947404[PMID]
11929,90030,Hemolytic anemia due to glutathione reductase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_947404[PMID]
11911,89936,X-linked hypophosphatemia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.89,Norway,Validated,PMID: 26543054
11911,89936,X-linked hypophosphatemia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.54,United Kingdom,Validated,PMID: 31730177
11911,89936,X-linked hypophosphatemia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.66,Europe,Validated,PMID: 26543054 ; 31730177
11911,89936,X-linked hypophosphatemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.5,Worldwide,Validated,34009447[PMID]_ORPHANET
11911,89936,X-linked hypophosphatemia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.14,Worldwide,Validated,34009447[PMID]_ORPHANET
11909,89844,"Lissencephaly syndrome, Norman-Roberts type",Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11908,89843,Dystrophic epidermolysis bullosa pruriginosa,Disease,Disorder,Cases/families,Family(ies),,100.0,Worldwide,Validated,ORPHANET
11908,89843,Dystrophic epidermolysis bullosa pruriginosa,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11907,89842,"Autosomal recessive generalized dystrophic epidermolysis bullosa, intermediate form",Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11919,90001,X-linked cone dysfunction syndrome with myopia,Disease,Disorder,Cases/families,Family(ies),,10.0,Worldwide,Validated,ORPHANET
11919,90001,X-linked cone dysfunction syndrome with myopia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11918,90000,Erythema elevatum diutinum,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11913,89938,Bartter syndrome type 4,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET_[EXPERT]
11912,89937,Autosomal dominant hypophosphatemic rickets,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,ORPHANET
11912,89937,Autosomal dominant hypophosphatemic rickets,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12018,90340,Blau syndrome,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.06,Denmark,Validated,[EXPERT]
12018,90340,Blau syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
12020,90342,Xeroderma pigmentosum variant,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,[EXPERT]
12020,90342,Xeroderma pigmentosum variant,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12024,90348,Autosomal dominant cutis laxa,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,ORPHANET
12024,90348,Autosomal dominant cutis laxa,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12025,90349,Autosomal recessive cutis laxa type 1,Disease,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,ORPHANET
12025,90349,Autosomal recessive cutis laxa type 1,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12026,90350,Autosomal recessive cutis laxa type 2,Clinical group,Group of disorders,Cases/families,Case(s),,40.0,Worldwide,Validated,ORPHANET
12026,90350,Autosomal recessive cutis laxa type 2,Clinical group,Group of disorders,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12028,90354,Brittle cornea syndrome,Disease,Disorder,Cases/families,Case(s),,65.0,Worldwide,Validated,14679583[PMID]_17122114[PMID]
12028,90354,Brittle cornea syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12030,90362,Primary intestinal lymphangiectasia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12000,90289,Localized scleroderma,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,[EXPERT]
12003,90301,Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,6997748[PMID]_6587221[PMID]
12003,90301,Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12002,90291,Systemic sclerosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,15.4,Europe,Validated,[EXPERT]
12002,90291,Systemic sclerosis,Disease,Disorder,Annual incidence,Value and class,>1 / 1000,230.0,Spain,Validated,18794710[PMID]
12002,90291,Systemic sclerosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,27.7,Spain,Validated,18794710[PMID]
12002,90291,Systemic sclerosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.8,United Kingdom,Validated,14872101[PMID]
12002,90291,Systemic sclerosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,17.3,France,Validated,ORPHANET_15213329[PMID]_23290691[PMID]_26816302[PMID]
12002,90291,Systemic sclerosis,Disease,Disorder,Annual incidence,Value and class,>1 / 1000,110.0,Greece,Validated,15846586[PMID]
12002,90291,Systemic sclerosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,15.4,Greece,Validated,15846586[PMID]
12002,90291,Systemic sclerosis,Disease,Disorder,Annual incidence,Value and class,6-9 / 10 000,72.0,Japan,Validated,1796818[PMID]
12002,90291,Systemic sclerosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.6,Japan,Not yet validated,1796818[PMID]
12002,90291,Systemic sclerosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,30.0,United States,Validated,18430269[PMID]
12002,90291,Systemic sclerosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,44.3,Canada,Validated,19248123[PMID]
12002,90291,Systemic sclerosis,Disease,Disorder,Annual incidence,Value and class,>1 / 1000,204.0,Australia,Validated,11456035[PMID]
12002,90291,Systemic sclerosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,23.3,Australia,Validated,11456035[PMID]
12002,90291,Systemic sclerosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.09,"Taiwan, Province of China",Validated,21388247[PMID]
12002,90291,Systemic sclerosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.63,"Taiwan, Province of China",Validated,21388247[PMID]
12002,90291,Systemic sclerosis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,22.2,Italy,Validated,33596949[PMID]
12002,90291,Systemic sclerosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.7,Italy,Validated,33596949[PMID]
12005,90308,Klippel-Trénaunay syndrome,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.007,United States,Validated,20301304[PMID]
12005,90308,Klippel-Trénaunay syndrome,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.007,Europe,Validated,[EXPERT]
11994,90280,Chilblain lupus,Disease,Disorder,Cases/families,Case(s),,70.0,Worldwide,Validated,18543054[PMID]
11994,90280,Chilblain lupus,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18543054[PMID]
11995,90281,Discoid lupus erythematosus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.56,United States,Validated,19289752[PMID]
11995,90281,Discoid lupus erythematosus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.2,Sweden,Validated,21574972[PMID]
11993,90186,Meige disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11998,90285,Lupus erythematosus panniculitis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.07,United States,Validated,19289752[PMID]
11998,90285,Lupus erythematosus panniculitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.315,United States,Validated,9918242[PMID]_19289752[PMID]_30658703[PMID]_ORPHANET
11997,90283,Lupus erythematosus tumidus,Disease,Disorder,Cases/families,Case(s),,250.0,Worldwide,Validated,21798482[PMID]
11997,90283,Lupus erythematosus tumidus,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_21798482[PMID]
11971,90080,Scarring in glaucoma filtration surgical procedures,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,22.0,Europe,Validated,European Medicines Agency[INST]
11969,90078,Invasive infections due to vancomycin-resistant enterococci,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11973,90103,Charcot-Marie-Tooth disease-deafness-intellectual disability syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,9475604[PMID]
11973,90103,Charcot-Marie-Tooth disease-deafness-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9475604[PMID]
27140,514980,ATP13A2-related parkinsonism,Clinical group,Group of disorders,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22388936[PMID]_29112700[PMID]
11972,90081,AIDS wasting syndrome,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.0,Europe,Validated,European Medicines Agency[INST]
11978,90117,"Hereditary motor and sensory neuropathy, Okinawa type",Disease,Disorder,Cases/families,Case(s),,120.0,Worldwide,Validated,22883144[PMID]
11978,90117,"Hereditary motor and sensory neuropathy, Okinawa type",Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11977,90114,Autosomal dominant intermediate Charcot-Marie-Tooth disease,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,6.2,United States,Validated,25142309[PMID]_SEER Surveillance Epidemiology and End Results 1973-2011[INST]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,15.0,Europe,Validated,European Medicines Agency 2017[INST]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,6.264,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.106,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.129,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.212,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,9.266,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,15.0,Greece,Validated,22537432[PMID]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.0,Canada,Validated,22537432[PMID]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.0,Oceania,Validated,22537432[PMID]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,12.5,Latin America,Validated,22537432[PMID]_18666317[PMID]_ ORPHANET
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,35.0,China,Validated,12095924[PMID]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,29.0,Japan,Validated,12095924[PMID]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,49.0,"Korea, Republic of",Validated,12095924[PMID]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,6-9 / 10 000,99.0,Mongolia,Validated,12095924[PMID]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,16.0,Africa,Validated,18666317[PMID]_20616577[PMID]_22537432[PMID]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.221,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.296,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.275,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.697,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.762,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.979,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.487,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.382,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.278,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.045,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.933,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.146,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.627,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.925,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.345,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.762,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,6.649,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11824,88673,Hepatocellular carcinoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.127,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11820,88644,"Autosomal recessive ataxia, Beauce type",Disease,Disorder,Cases/families,Case(s),,57.0,Worldwide,Validated,ORPHANET
11820,88644,"Autosomal recessive ataxia, Beauce type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11821,88659,Autosomal dominant progressive nephropathy with hypertension,Disease,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,10930359 [PMID]
11821,88659,Autosomal dominant progressive nephropathy with hypertension,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10930359 [PMID]
11823,88661,Amelogenesis imperfecta,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.1,United States,Validated,13469154[PMID]
11823,88661,Amelogenesis imperfecta,Disease,Disorder,Point prevalence,Value and class,6-9 / 10 000,90.0,India,Validated,21712629[PMID]
11823,88661,Amelogenesis imperfecta,Disease,Disorder,Point prevalence,Value and class,>1 / 1000,142.0,Sweden,Validated,3169793[PMID]
11823,88661,Amelogenesis imperfecta,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11816,88637,Hypomyelination-hypogonadotropic hypogonadism-hypodontia syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29618326[PMID]
11817,88639,Neurodegeneration due to 3-hydroxyisobutyryl-CoA hydrolase deficiency,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,29703962[PMID]
11817,88639,Neurodegeneration due to 3-hydroxyisobutyryl-CoA hydrolase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29703962[PMID]
11818,88642,Congenital insensitivity to pain-anosmia-neuropathic arthropathy,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,ORPHANET
11818,88642,Congenital insensitivity to pain-anosmia-neuropathic arthropathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11819,88643,Obesity-colitis-hypothyroidism-cardiac hypertrophy-developmental delay syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,17163533[PMID]
11819,88643,Obesity-colitis-hypothyroidism-cardiac hypertrophy-developmental delay syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17163533[PMID]
11814,88635,Vacuolar myopathy with sarcoplasmic reticulum protein aggregates,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,16714317[PMID]
11814,88635,Vacuolar myopathy with sarcoplasmic reticulum protein aggregates,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16714317[PMID]
11808,88621,Ichthyosis-prematurity syndrome,Disease,Disorder,Cases/families,Family(ies),,16.0,Worldwide,Validated,ORPHANET
11808,88621,Ichthyosis-prematurity syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11809,88628,Posterior column ataxia-retinitis pigmentosa syndrome,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,[EXPERT]
11809,88628,Posterior column ataxia-retinitis pigmentosa syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11810,88629,Tritanopia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.8,Europe,Not yet validated,ORPHANET
11811,88630,Terminal osseous dysplasia-pigmentary defects syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26059211[PMID]
11807,88620,Isolated congenital anosmia,Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,ORPHANET
11807,88620,Isolated congenital anosmia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11806,88619,Familial acute necrotizing encephalopathy,Disease,Disorder,Cases/families,Family(ies),,14.0,Worldwide,Validated,12874403[PMID]_19118815[PMID]_21205700[PMID]
11806,88619,Familial acute necrotizing encephalopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12874403[PMID]_19118815[PMID]_21205700[PMID]
11805,88618,S-adenosylhomocysteine hydrolase deficiency,Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,2380820[PMID]_15024124[PMID]
11805,88618,S-adenosylhomocysteine hydrolase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2380820[PMID]_15024124[PMID]
11802,87884,Non-syndromic genetic deafness,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11801,87876,Sialidosis type 2,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
11801,87876,Sialidosis type 2,Disease,Disorder,Prevalence at birth,Class only,<1 / 1 000 000,0.0,Europe,Validated,ORPHANET
11800,87503,Mal de Meleda,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Worldwide,Validated,9887370[PMID]
11796,86923,"Hereditary palmoplantar keratoderma, Gamborg-Nielsen type",Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11793,86920,Dermatopathia pigmentosa reticularis,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,27512211[PMID]
11793,86920,Dermatopathia pigmentosa reticularis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27512211[PMID]
11792,86919,Keratosis palmaris et plantaris-clinodactyly syndrome,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,ORPHANET
11792,86919,Keratosis palmaris et plantaris-clinodactyly syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11791,86918,Diffuse palmoplantar keratoderma-acrocyanosis syndrome,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,2564235[PMID]_8578969[PMID]
11791,86918,Diffuse palmoplantar keratoderma-acrocyanosis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2564235[PMID]_8578969[PMID]
11788,86915,Lymphedema-atrial septal defects-facial changes syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,19533797[PMID]
11788,86915,Lymphedema-atrial septal defects-facial changes syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19533797[PMID]
27340,522077,Infantile hypotonia-oculomotor anomalies-hyperkinetic movements-developmental delay syndrome,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,30107533[PMID]
27340,522077,Infantile hypotonia-oculomotor anomalies-hyperkinetic movements-developmental delay syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30107533[PMID]
11786,86913,Myoclonic epilepsy in non-progressive encephalopathies,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_25266964[PMID]
11787,86914,Lymphedema-cerebral arteriovenous anomaly-primary pulmonary hypertension syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,5718986[PMID]
11787,86914,Lymphedema-cerebral arteriovenous anomaly-primary pulmonary hypertension syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5718986[PMID]
11784,86909,Myoclonic epilepsy of infancy,Disease,Disorder,Cases/families,Case(s),,106.0,Worldwide,Validated,ORPHANET
11784,86909,Myoclonic epilepsy of infancy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
27333,521450,LAMA5-related multisystemic syndrome,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,28735299[PMID]
27333,521450,LAMA5-related multisystemic syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28735299[PMID]
27332,521445,Microcephaly-facial dysmorphism-ocular anomalies-multiple congenital anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,28722276[PMID]
27332,521445,Microcephaly-facial dysmorphism-ocular anomalies-multiple congenital anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28722276[PMID]
27331,521438,Congenital vertebral-cardiac-renal anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28792876[PMID]
27331,521438,Congenital vertebral-cardiac-renal anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,28792876[PMID]
11778,86900,Interdigitating dendritic cell sarcoma,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
27330,521432,Congenital cataract-severe neonatal hepatopathy-global developmental delay syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27878435[PMID]
27330,521432,Congenital cataract-severe neonatal hepatopathy-global developmental delay syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,27878435[PMID]
11779,86902,Follicular dendritic cell sarcoma,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
27329,521426,PLAA-associated neurodevelopmental disorder,Malformation syndrome,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,28007986[PMID]_28413018[PMID]
27329,521426,PLAA-associated neurodevelopmental disorder,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28007986[PMID]_28413018[PMID]
11776,86896,Histiocytic sarcoma,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
27328,521414,Autosomal dominant Charcot-Marie-Tooth disease type 2DD,Disease,Disorder,Cases/families,Case(s),,51.0,Worldwide,Validated,29499166[PMID]
27328,521414,Autosomal dominant Charcot-Marie-Tooth disease type 2DD,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29499166[PMID]
27320,521258,Xq25 microduplication syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,28.0,Worldwide,Validated,26443594[PMID]
27320,521258,Xq25 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26443594[PMID]
27322,521305,Proximal myopathy with focal depletion of mitochondria,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,26782016[PMID]_27169979[PMID]
27322,521305,Proximal myopathy with focal depletion of mitochondria,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26782016[PMID]_27169979[PMID]
27323,521308,Frontonasal dysplasia-bifid nose-upper limb anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,29136349[PMID]
27323,521308,Frontonasal dysplasia-bifid nose-upper limb anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29136349[PMID]
27324,521390,Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,27005418[PMID]
27324,521390,Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27005418[PMID]
27326,521406,Dystonia-parkinsonism-hypermanganesemia syndrome,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,29382362[PMID]_29685658[PMID]_27231142[PMID]
27326,521406,Dystonia-parkinsonism-hypermanganesemia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29382362[PMID]_29685658[PMID]_27231142[PMID]
11903,89838,Autosomal recessive generalized epidermolysis bullosa simplex,Disease,Disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,[EXPERT]
11903,89838,Autosomal recessive generalized epidermolysis bullosa simplex,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
27327,521411,Autosomal recessive axonal Charcot-Marie-Tooth disease due to copper metabolism defect,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,29351582[PMID]
27327,521411,Autosomal recessive axonal Charcot-Marie-Tooth disease due to copper metabolism defect,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29351582[PMID]
27317,521219,Mirizzi syndrome,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_29494098[PMID]
11881,88949,MUC1-related autosomal dominant tubulointerstitial kidney disease,Clinical subtype,Subtype of disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11881,88949,MUC1-related autosomal dominant tubulointerstitial kidney disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11881,88949,MUC1-related autosomal dominant tubulointerstitial kidney disease,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.07,United States,Validated,31488840[PMID]
11881,88949,MUC1-related autosomal dominant tubulointerstitial kidney disease,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.4,Ireland,Validated,31488840[PMID]
11882,88950,UMOD-related autosomal dominant tubulointerstitial kidney disease,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,1.7,Austria,Validated,22740033[PMID]
11882,88950,UMOD-related autosomal dominant tubulointerstitial kidney disease,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,9.0,United Kingdom,Validated,30376835[PMID]
11882,88950,UMOD-related autosomal dominant tubulointerstitial kidney disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_21868615[PMID]
11884,88991,Rare congenital non-syndromic heart malformation,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,7.8,Europe,Not yet validated,21321151[PMID]
11884,88991,Rare congenital non-syndromic heart malformation,Category,Group of disorders,Prevalence at birth,Value and class,>1 / 1000,223.0,Canada,Validated,23812182[PMID]
11856,88924,Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
11856,88924,Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11849,88917,X-linked Alport syndrome,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.25,Sweden,Validated,16114783[PMID]
11849,88917,X-linked Alport syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
12199,93256,Fragile X-associated tremor/ataxia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,United States,Validated,15000674[PMID]_17166801[PMID]_ [EXPERT]
12199,93256,Fragile X-associated tremor/ataxia syndrome,Malformation syndrome,Disorder,Lifetime Prevalence,Value and class,1-9 / 100 000,6.3,United States,Validated,15000674[PMID]_17166801[PMID]_ [EXPERT]
12199,93256,Fragile X-associated tremor/ataxia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
27494,528105,Hypohidrosis-electrolyte imbalance-lacrimal gland dysfunction-ichthyosis-xerostomia syndrome,Disease,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,DOI: https://doi.org/10.1053/j.ajkd.2018.08.015[OTHER]
27494,528105,Hypohidrosis-electrolyte imbalance-lacrimal gland dysfunction-ichthyosis-xerostomia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_DOI: https://doi.org/10.1053/j.ajkd.2018.08.015[OTHER]
27492,528091,Hydrops-lactic acidosis-sideroblastic anemia-multisystemic failure syndrome,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,26537577[PMID]
27492,528091,Hydrops-lactic acidosis-sideroblastic anemia-multisystemic failure syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26537577[PMID]
27491,528084,Non-specific syndromic intellectual disability,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
12205,93262,Crouzon syndrome-acanthosis nigricans syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.1,Worldwide,Validated,23986840[PMID]_ISBN:019511843X[OTHER]
12205,93262,Crouzon syndrome-acanthosis nigricans syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
12203,93260,Pfeiffer syndrome type 3,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
12202,93259,Pfeiffer syndrome type 2,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
12201,93258,Pfeiffer syndrome type 1,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
12214,93271,"Short rib-polydactyly syndrome, Verma-Naumoff type",Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.2,United Arab Emirates,Validated,12769508[PMID]
12214,93271,"Short rib-polydactyly syndrome, Verma-Naumoff type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,United Arab Emirates,Validated,ORPHANET
12212,93269,"Short rib-polydactyly syndrome, Majewski type",Malformation syndrome,Disorder,Cases/families,Case(s),,34.0,Worldwide,Validated,20607029[PMID]
12212,93269,"Short rib-polydactyly syndrome, Majewski type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20607029[PMID]
12210,93267,Cloverleaf skull-multiple congenital anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,12081722[PMID]
12210,93267,Cloverleaf skull-multiple congenital anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12081722[PMID]
12222,93282,"Spondyloepimetaphyseal dysplasia, PAPSS2 type",Disease,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,ORPHANET
12222,93282,"Spondyloepimetaphyseal dysplasia, PAPSS2 type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12223,93283,"Spondyloepiphyseal dysplasia, Kimberley type",Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,1978986[PMID]
12223,93283,"Spondyloepiphyseal dysplasia, Kimberley type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12220,93279,Mild spondyloepiphyseal dysplasia due to COL2A1 mutation with early-onset osteoarthritis,Disease,Disorder,Cases/families,Family(ies),,4.0,Worldwide,Validated,7757086[PMID]
12220,93279,Mild spondyloepiphyseal dysplasia due to COL2A1 mutation with early-onset osteoarthritis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7757086[PMID]
12216,93274,Thanatophoric dysplasia type 2,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12165,93108,Renal dysplasia,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
12165,93108,Renal dysplasia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,43.5,Europe,Validated,EUROCAT European surveillance of congenital anomalies[REG]_21381187[PMID]
27460,527497,NKX6-2-related autosomal recessive hypomyelinating leukodystrophy,Disease,Disorder,Cases/families,Case(s),,25.0,Worldwide,Validated,29388673[PMID]_30285346[PMID]
27460,527497,NKX6-2-related autosomal recessive hypomyelinating leukodystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29388673[PMID]_30285346[PMID]
12164,93101,Renal hypoplasia,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
12167,93110,Posterior urethral valve,Morphological anomaly,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Europe,Validated,[EXPERT]
12167,93110,Posterior urethral valve,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.125,Europe,Validated,[EXPERT]_19838598[PMID]
12167,93110,Posterior urethral valve,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.4,Australia,Validated,25198372[PMID]
12166,93109,Congenital megacalycosis,Morphological anomaly,Disorder,Cases/families,Case(s),,25.0,Worldwide,Validated,23252475[PMID]
12166,93109,Congenital megacalycosis,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23252475[PMID]
27457,527450,Severe myopia-generalized joint laxity-short stature syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,28475863[PMID]
27457,527450,Severe myopia-generalized joint laxity-short stature syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28475863[PMID]
12160,91547,Relapsing fever,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12163,93100,"Renal agenesis, unilateral",Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
12163,93100,"Renal agenesis, unilateral",Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-5 / 10 000,50.0,Worldwide,Validated,23449343[PMID]
27458,527468,Diaphragmatic hernia-short bowel-asplenia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,28898547[PMID]
27458,527468,Diaphragmatic hernia-short bowel-asplenia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28898547[PMID]
12162,92050,Congenital tufting enteropathy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,Dr Julie Salomon_Dr Olivier Goulet[EXPERT]
12162,92050,Congenital tufting enteropathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_17448233[PMID]
12173,93160,Hypocalcemic vitamin D-resistant rickets,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12174,93164,Transient pseudohypoaldosteronism,Disease,Disorder,Cases/families,Case(s),,152.0,Worldwide,Validated,36090572[PMID]
12174,93164,Transient pseudohypoaldosteronism,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,36090572[PMID]_ORPHANET
12169,93114,Autosomal dominant intermediate Charcot-Marie-Tooth disease type E,Disease,Disorder,Cases/families,Case(s),,21.0,Worldwide,Validated,22187985[PMID]_24174593[PMID]
12169,93114,Autosomal dominant intermediate Charcot-Marie-Tooth disease type E,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12168,93111,HNF1B-related autosomal dominant tubulointerstitial kidney disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
12170,93126,Pauci-immune glomerulonephritis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_Dr Laure-Hélène NOEL[EXPERT]
12177,93172,"Renal dysplasia, unilateral",Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Validated,EUROCAT European surveillance of congenital anomalies[REG]_ORPHANET
12177,93172,"Renal dysplasia, unilateral",Clinical subtype,Subtype of disorder,Prevalence at birth,Class only,1-5 / 10 000,0.0,Europe,Validated,EUROCAT European surveillance of congenital anomalies[REG]_[EXPERT]
12178,93173,"Renal dysplasia, bilateral",Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,[EXPERT]
12259,93322,Isolated tibial hemimelia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,16224672[PMID]
12259,93322,Isolated tibial hemimelia,Morphological anomaly,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,ORPHANET
12258,93321,Isolated radial hemimelia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.5,Worldwide,Validated,28669420[PMID]_34452798[PMID]_ORPHANET
12258,93321,Isolated radial hemimelia,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 100 000,2.5,Worldwide,Validated,28669420[PMID]_34452798[PMID]_ORPHANET
12257,93320,Isolated ulnar hemimelia,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
12260,93323,Isolated fibular hemimelia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.1033,Worldwide,Validated,20498623[PMID]_27909861[PMID]
12260,93323,Isolated fibular hemimelia,Morphological anomaly,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.1033,Worldwide,Validated,20498623[PMID]_27909861[PMID]_ORPHANET
12265,93329,Autosomal recessive omodysplasia,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,23.0,Worldwide,Validated,19481194[PMID]
12265,93329,Autosomal recessive omodysplasia,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12270,93335,Postaxial polydactyly type B,Morphological anomaly,Disorder,Point prevalence,Value and class,1-5 / 10 000,43.5,Mexico,Validated,31091006[PMID]_ORPHANET
12270,93335,Postaxial polydactyly type B,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,43.5,Mexico,Validated,31091006[PMID]
12269,93334,Postaxial polydactyly type A,Morphological anomaly,Disorder,Point prevalence,Value and class,1-5 / 10 000,15.7,Mexico,Validated,31091006[PMID]_ORPHANET
12269,93334,Postaxial polydactyly type A,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,15.7,Mexico,Validated,31091006[PMID]
12268,93333,Pelviscapular dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,19068278[PMID]
12268,93333,Pelviscapular dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19068278[PMID]
12272,93337,Polydactyly of an index finger,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
27441,527276,Encephalopathy due to mitochondrial and peroxisomal fission defect,Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,17460227[PMID]_26825290[PMID]_26992161[PMID]_26604000[PMID]_27145208[PMID]_30109270[PMID]_27328748[PMID]_26783368[PMID]
27441,527276,Encephalopathy due to mitochondrial and peroxisomal fission defect,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17460227[PMID]_26825290[PMID]_26992161[PMID]_26604000[PMID]_27145208[PMID]_30109270[PMID]_27328748[PMID]_26783368[PMID]
12280,93346,"Spondyloepimetaphyseal dysplasia congenita, Strudwick type",Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,[EXPERT]
12280,93346,"Spondyloepimetaphyseal dysplasia congenita, Strudwick type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12281,93347,Anauxetic dysplasia,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,27380734[PMID]
12281,93347,Anauxetic dysplasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27380734[PMID]
12287,93356,"Spondyloepimetaphyseal dysplasia, Missouri type",Disease,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,9258750[PMID]
12287,93356,"Spondyloepimetaphyseal dysplasia, Missouri type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12284,93351,"Spondyloepimetaphyseal dysplasia, Irapa type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6772027[PMID]
12285,93352,"Spondyloepimetaphyseal dysplasia, Shohat type",Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,8357004[PMID]_8074146[PMID]_28263186[PMID]
12285,93352,"Spondyloepimetaphyseal dysplasia, Shohat type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28263186[PMID]
12224,93284,Spondyloepiphyseal dysplasia tarda,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Worldwide,Not yet validated,ORPHANET
12233,93296,Achondrogenesis type 2,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12235,93298,Achondrogenesis type 1B,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_20301689[PMID]
12234,93297,Hypochondrogenesis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12236,93299,Achondrogenesis type 1A,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12239,93302,"Brachyolmia, Maroteaux type",Malformation syndrome,Disorder,Cases/families,Family(ies),,4.0,Worldwide,Validated,2669482[PMID]_20503319[PMID]
12239,93302,"Brachyolmia, Maroteaux type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2669482[PMID]
12244,93307,Multiple epiphyseal dysplasia type 4,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_18328978[PMID]
12245,93308,Multiple epiphyseal dysplasia type 1,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_18328978[PMID]
12248,93311,Multiple epiphyseal dysplasia type 5,Disease,Disorder,Cases/families,Family(ies),,18.0,Worldwide,Validated,15948199[PMID]
12248,93311,Multiple epiphyseal dysplasia type 5,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15948199[PMID]
12251,93314,"Spondylometaphyseal dysplasia, Kozlowski type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,[EXPERT]
12252,93315,"Spondylometaphyseal dysplasia, 'corner fracture' type",Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,[EXPERT]
12252,93315,"Spondylometaphyseal dysplasia, 'corner fracture' type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29100092[PMID]
12253,93316,"Spondylometaphyseal dysplasia, Schmidt type",Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,23653587[PMID]_[EXPERT]
12253,93316,"Spondylometaphyseal dysplasia, Schmidt type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12254,93317,"Spondylometaphyseal dysplasia, Sedaghatian type",Malformation syndrome,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,[EXPERT]
12254,93317,"Spondylometaphyseal dysplasia, Sedaghatian type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
27631,529962,17q24.2 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28465847[PMID]_29696806[PMID]
27631,529962,17q24.2 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,29696806[PMID]
27630,529864,Secondary erythromelalgia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
27630,529864,Secondary erythromelalgia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.2,United States,Validated,18713229[PMID]
27629,529852,Combined hepatocellular carcinoma and cholangiocarcinoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_23034166[PMID]
12074,90673,Hypothyroidism due to TSH receptor mutations,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12075,90674,Isolated thyroid-stimulating hormone deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
27624,529831,Letrozole toxicity,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
27620,529808,Chronic bilirubin encephalopathy,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Canada,Validated,22966025[PMID]_ORPHANET
27620,529808,Chronic bilirubin encephalopathy,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Denmark,Validated,15858962[PMID]_ORPHANET
27620,529808,Chronic bilirubin encephalopathy,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,United States,Validated,15466085[PMID]_ORPHANET
27620,529808,Chronic bilirubin encephalopathy,Clinical syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.49,Canada,Validated,22966025[PMID]
27620,529808,Chronic bilirubin encephalopathy,Clinical syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.4,Denmark,Validated,15858962[PMID]
27620,529808,Chronic bilirubin encephalopathy,Clinical syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,United States,Validated,15466085[PMID]
12066,90658,Charcot-Marie-Tooth disease type 1E,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_23224996[PMID]
27619,529799,Acute bilirubin encephalopathy,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,United Kingdom,Validated,32021624[PMID]_ORPHANET
27619,529799,Acute bilirubin encephalopathy,Clinical syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.87,United Kingdom,Validated,17074786[PMID]
12095,90791,Congenital adrenal hyperplasia due to 3-beta-hydroxysteroid dehydrogenase deficiency,Disease,Disorder,Cases/families,Case(s),,68.0,Worldwide,Validated,12428206[PMID]_15671104[PMID]_17496421[PMID]_15448795[PMID]_15559435[PMID]
12095,90791,Congenital adrenal hyperplasia due to 3-beta-hydroxysteroid dehydrogenase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12094,90790,Congenital lipoid adrenal hyperplasia due to STAR deficency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
27636,529980,Inflammatory bowel disease-recurrent sinopulmonary infections syndrome,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,25667416[PMID]
27636,529980,Inflammatory bowel disease-recurrent sinopulmonary infections syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25667416[PMID]
27635,529977,Immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections-lymphopenia syndrome,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,30026316[PMID]
27635,529977,Immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections-lymphopenia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30026316[PMID]
27632,529965,Intellectual disability-autism-speech apraxia-craniofacial dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,28866611[PMID]
27632,529965,Intellectual disability-autism-speech apraxia-craniofacial dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28866611[PMID]
27633,529970,Male infertility due to acephalic spermatozoa,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_27640305[PMID]_30032984[PMID]
12044,90400,Scleromyxedema without monoclonal gammopathy,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,ORPHANET
12044,90400,Scleromyxedema without monoclonal gammopathy,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12045,90625,Rare X-linked non-syndromic sensorineural deafness type DFN,Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12046,90635,Rare autosomal dominant non-syndromic sensorineural deafness type DFNA,Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12047,90636,Rare autosomal recessive non-syndromic sensorineural deafness type DFNB,Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
27593,529468,Monoclonal mast cell activation syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_24745674[PMID]
27595,529574,Duane retraction syndrome with congenital deafness,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,27181683[PMID]
27595,529574,Duane retraction syndrome with congenital deafness,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27181683[PMID
12042,90398,Localized lichen myxedematosus with mixed features of different subtypes,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,ORPHANET
12042,90398,Localized lichen myxedematosus with mixed features of different subtypes,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12043,90399,Localized lichen myxedematosus with monoclonal gammopathy or systemic symptoms,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,22235972[PMID]
12043,90399,Localized lichen myxedematosus with monoclonal gammopathy or systemic symptoms,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12032,90368,Hypotrichosis simplex of the scalp,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12034,90390,Anonychia-onychodystrophy syndrome,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,15200512[PMID]
12034,90390,Anonychia-onychodystrophy syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12060,90652,Otopalatodigital syndrome type 2,Malformation syndrome,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,17431908[PMID]
12060,90652,Otopalatodigital syndrome type 2,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17431908[PMID]
27609,529665,Neurodevelopmental delay-seizures-ophthalmic anomalies-osteopenia-cerebellar atrophy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,29100095[PMID]
27609,529665,Neurodevelopmental delay-seizures-ophthalmic anomalies-osteopenia-cerebellar atrophy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29100095[PMID]
12056,90647,Jervell and Lange-Nielsen syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.3,Worldwide,Validated,[EXPERT]
12050,90641,Rare mitochondrial non-syndromic sensorineural deafness,Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12138,91387,Familial thoracic aortic aneurysm and aortic dissection,Disease,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,ORPHANET
12138,91387,Familial thoracic aortic aneurysm and aortic dissection,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Not yet validated,ORPHANET
12139,91396,Isolated cryptophthalmia,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16352480[PMID]
12139,91396,Isolated cryptophthalmia,Morphological anomaly,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,16352480[PMID]
12136,91378,Hereditary angioedema,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,5.0,Europe,Validated,23662043[PMID]_European Medicines Agency 2018[INST]
12136,91378,Hereditary angioedema,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.4,Denmark,Validated,19709101[PMID]
12136,91378,Hereditary angioedema,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.51,Norway,Validated,11202238[PMID]
12136,91378,Hereditary angioedema,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.09,Spain,Validated,15875532[PMID]
12137,91385,Acquired angioedema,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.11,Denmark,Validated,23921495[PMID]
12137,91385,Acquired angioedema,Clinical group,Group of disorders,Cases/families,Case(s),,200.0,Worldwide,Validated,23921495[PMID]
12137,91385,Acquired angioedema,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
12142,91412,Marcus-Gunn syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12140,91397,Isolated ankyloblepharon filiforme adnatum,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
12141,91411,Congenital ptosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12129,91355,Sheehan syndrome,Malformation syndrome,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
12129,91355,Sheehan syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
12133,91359,Chronic pneumonitis of infancy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12155,91496,Snowflake vitreoretinal degeneration,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,ORPHANET
12155,91496,Snowflake vitreoretinal degeneration,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12154,91495,Persistent hyperplastic primary vitreous,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12153,91494,Macular coloboma-cleft palate-hallux valgus syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,4977272[PMID]
12153,91494,Macular coloboma-cleft palate-hallux valgus syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4977272[PMID]
12159,91546,Lyme disease,Disease,Disorder,Annual incidence,Value and class,>1 / 1000,177.5,Europe,Validated,[EXPERT]
12159,91546,Lyme disease,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,16.6,France,Validated,[EXPERT]
12159,91546,Lyme disease,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,21.9,Worldwide,Not yet validated,emedicine[OTHER]
12159,91546,Lyme disease,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,12.37,Hungary,Validated,23428090[PMID]
12159,91546,Lyme disease,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,36.0,Sweden,Not yet validated,ORPHANET
12159,91546,Lyme disease,Disease,Disorder,Annual incidence,Value and class,>1 / 1000,100.0,United States,Validated,24045727[PMID]
12159,91546,Lyme disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
12158,91500,Tubulointerstitial nephritis and uveitis syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_28709457[PMID]
12157,91498,Familial congenital palsy of trochlear nerve,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,3985833[PMID]
12157,91498,Familial congenital palsy of trochlear nerve,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3985833[PMID]
12147,91481,Ring dermoid of cornea,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
12147,91481,Ring dermoid of cornea,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12146,91416,Isolated congenital alacrima,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12144,91414,Pilomatrixoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12104,91127,Adenovirus infection in immunocompromised patients,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,18.0,Europe,Validated,European Medicines Agency 2003[INST]
12107,91130,Cardiomyopathy-hypotonia-lactic acidosis syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,17273968[PMID]
12107,91130,Cardiomyopathy-hypotonia-lactic acidosis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17273968[PMID]
12108,91131,DK1-CDG,Disease,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,23890587[PMID]
12108,91131,DK1-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23890587[PMID]
12109,91132,Ichthyosis-hypotrichosis syndrome,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,26596219[PMID]
12109,91132,Ichthyosis-hypotrichosis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26596219[PMID]
12096,90793,Congenital adrenal hyperplasia due to 17-alpha-hydroxylase deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,[EXPERT]
12097,90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.0,Europe,Validated,[EXPERT]
12097,90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,7.0,Worldwide,Not yet validated,3259306[PMID]_15964450[PMID]
12097,90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.4,France,Validated,22312171[PMID]
12097,90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.2,Italy,Not yet validated,ORPHANET
12097,90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,8.7,Sweden,Validated,2321478[PMID]
12097,90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.2,United States,Validated,9521938[PMID]_22692165[PMID]
12097,90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.2,New Zealand,Validated,7815200[PMID]
12097,90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.4,Croatia,Validated,19844117[PMID]
12097,90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.2,Estonia,Validated,18204270[PMID]
12097,90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.5,Singapore,Validated,12008686[PMID]
12097,90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.5,Switzerland,Validated,6967865[PMID]
12098,90795,Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.75,Europe,Validated,[EXPERT]
12098,90795,Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.47,Europe,Not yet validated,ORPHANET
12099,90796,"46,XY difference of sex development due to isolated 17,20-lyase deficiency",Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,22170710[PMID]
12099,90796,"46,XY difference of sex development due to isolated 17,20-lyase deficiency",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22170710[PMID]
12100,90797,Partial androgen insensitivity syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12101,90970,Primary lipodystrophy,Category,Group of disorders,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,ORPHANET
12121,91347,TSH-secreting pituitary adenoma,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.28,Sweden,Validated,23295463[PMID]
12123,91349,Non-functioning pituitary adenoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.05,Worldwide,Validated,25946030[PMID]_20534753[PMID]_10770176[PMID]
12123,91349,Non-functioning pituitary adenoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.55,Europe,Not yet validated,ORPHANET_25946030[PMID]_20534753[PMID]_10770176[PMID]
12123,91349,Non-functioning pituitary adenoma,Disease,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Validated,ORPHANET_26072284[PMID]
12123,91349,Non-functioning pituitary adenoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.0,Finland,Validated,20534753[PMID]
12123,91349,Non-functioning pituitary adenoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.1,Sweden,Validated,10770176[PMID]
12123,91349,Non-functioning pituitary adenoma,Disease,Disorder,Point prevalence,Value and class,6-9 / 10 000,94.0,Belgium,Validated,16968795[PMID]
12123,91349,Non-functioning pituitary adenoma,Disease,Disorder,Point prevalence,Value and class,6-9 / 10 000,80.5,Switzerland,Validated,19968031[PMID]
12123,91349,Non-functioning pituitary adenoma,Disease,Disorder,Point prevalence,Value and class,6-9 / 10 000,77.6,United Kingdom,Validated,19650784[PMID]
12123,91349,Non-functioning pituitary adenoma,Disease,Disorder,Point prevalence,Value and class,6-9 / 10 000,68.0,Finland,Validated,20534753[PMID]
12124,91350,Pituitary deficiency due to Rathke cleft cysts,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_21951110[PMID]
12113,91136,Acquired monoclonal Ig light chain-associated Fanconi syndrome,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,[EXPERT]
12113,91136,Acquired monoclonal Ig light chain-associated Fanconi syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
12112,91135,Body skin hyperlaxity due to vitamin K-dependent coagulation factor deficiency,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,25151188[PMID]
12112,91135,Body skin hyperlaxity due to vitamin K-dependent coagulation factor deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25151188[PMID]
12115,91138,Cryoglobulinemic vasculitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,United States,Validated,6996482[PMID]
12115,91138,Cryoglobulinemic vasculitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12114,91137,Immunotactoid or fibrillary glomerulopathy,Clinical group,Group of disorders,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
12116,91139,Simple cryoglobulinemia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11422,79396,"Autosomal dominant generalized epidermolysis bullosa simplex, severe form",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
11423,79397,Epidermolysis bullosa simplex with mottled pigmentation,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11420,79394,Congenital ichthyosiform erythroderma,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Spain,Validated,22000705[PMID]
11420,79394,Congenital ichthyosiform erythroderma,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.3,Europe,Validated,[EXPERT]
11421,79395,Keratoderma hereditarium mutilans with ichthyosis,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,24346921[PMID]
11421,79395,Keratoderma hereditarium mutilans with ichthyosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24346921[PMID]
11399,79373,Ectodermal dysplasia syndrome,Category,Group of disorders,Point prevalence,Class only,6-9 / 10 000,0.0,Worldwide,Validated,15468153[PMID]
11425,79399,"Autosomal dominant generalized epidermolysis bullosa simplex, intermediate form",Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11427,79401,PLEC-related intermediate epidermolysis bullosa simplex without extracutaneous involvement,Disease,Disorder,Cases/families,Family(ies),,6.0,Worldwide,Validated,22854623[PMID]_23774525[PMID]
11427,79401,PLEC-related intermediate epidermolysis bullosa simplex without extracutaneous involvement,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11426,79400,Localized epidermolysis bullosa simplex,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
11429,79403,Junctional epidermolysis bullosa with pyloric atresia,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,20301336[PMID]
11429,79403,Junctional epidermolysis bullosa with pyloric atresia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20301336[PMID]
11428,79402,Intermediate generalized junctional epidermolysis bullosa,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11431,79405,Junctional epidermolysis bullosa inversa,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,[EXPERT]
11431,79405,Junctional epidermolysis bullosa inversa,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11430,79404,Severe generalized junctional epidermolysis bullosa,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.17,Worldwide,Validated,ORPHANET
11430,79404,Severe generalized junctional epidermolysis bullosa,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.04,United States,Validated,[EXPERT]
11430,79404,Severe generalized junctional epidermolysis bullosa,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.4,Netherlands,Validated,21801158[PMID]
11430,79404,Severe generalized junctional epidermolysis bullosa,Disease,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.07,Italy,Validated,[EXPERT]
11430,79404,Severe generalized junctional epidermolysis bullosa,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
11432,79406,Late-onset junctional epidermolysis bullosa,Disease,Disorder,Cases/families,Case(s),,37.0,Worldwide,Validated,[EXPERT]_24005051[PMID]
11432,79406,Late-onset junctional epidermolysis bullosa,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11435,79409,Recessive dystrophic epidermolysis bullosa inversa,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,ORPHANET
11435,79409,Recessive dystrophic epidermolysis bullosa inversa,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11434,79408,"Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form",Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.3,United States,Validated,31920360[PMID]
11434,79408,"Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form",Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.3,Europe,Validated,31920360[PMID]
11434,79408,"Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form",Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.963,Europe,Validated,31920360[PMID]_ORPHANET
11434,79408,"Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form",Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2222,United States,Validated,31920360[PMID]_ORPHANET
11437,79411,Self-improving dystrophic epidermolysis bullosa,Disease,Disorder,Cases/families,Case(s),,52.0,Worldwide,Validated,ORPHANET
11437,79411,Self-improving dystrophic epidermolysis bullosa,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11436,79410,"Localized dystrophic epidermolysis bullosa, pretibial form",Clinical subtype,Subtype of disorder,Cases/families,Family(ies),,40.0,Worldwide,Validated,ORPHANET
11436,79410,"Localized dystrophic epidermolysis bullosa, pretibial form",Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11478,79452,Milroy disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
11478,79452,Milroy disease,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.0,Israel,Validated,12224079[PMID]
11473,79447,X-linked lethal multiple pterygium syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,6.0,Worldwide,Validated,9916854[PMID]
11473,79447,X-linked lethal multiple pterygium syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9916854[PMID]
11482,79456,Diffuse cutaneous mastocytosis,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,20678092[PMID]
11482,79456,Diffuse cutaneous mastocytosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11483,79457,Maculopapular cutaneous mastocytosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET_25662299[PMID]
11481,79455,Cutaneous mastocytoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11461,79435,Oculocutaneous albinism type 4,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Worldwide,Validated,20301683[PMID]
11460,79434,Oculocutaneous albinism type 1B,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,1.3,Worldwide,Validated,18463683[PMID]
11459,79433,Oculocutaneous albinism type 3,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,30347088[PMID]_ORPHANET
11459,79433,Oculocutaneous albinism type 3,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,11.7647,Africa,Validated,30347088[PMID]_ORPHANET
11458,79432,Oculocutaneous albinism type 2,Disease,Disorder,Point prevalence,Value and class,6-9 / 10 000,58.34,Specific population,Validated,12469324[PMID]_ORPHANET_[EXPERT]
11458,79432,Oculocutaneous albinism type 2,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.55,Worldwide,Validated,[EXPERT]_20301410[PMID]
11458,79432,Oculocutaneous albinism type 2,Disease,Disorder,Point prevalence,Value and class,6-9 / 10 000,71.43,"Tanzania, United Republic of",Validated,3978567[PMID]
11458,79432,Oculocutaneous albinism type 2,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.78,United States,Validated,2667743[PMID]
11458,79432,Oculocutaneous albinism type 2,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,48.52,Africa,Validated,ORPHANET_7887411[PMID]_3978567[PMID]
11457,79431,Oculocutaneous albinism type 1A,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,1.3,Worldwide,Validated,18463683[PMID]
11456,79430,Hermansky-Pudlak syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.15,Worldwide,Not yet validated,ORPHANET
11456,79430,Hermansky-Pudlak syndrome,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,55.0,Puerto rico,Validated,7573033[PMID]
11471,79445,Pseudopseudohypoparathyroidism,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
11470,79444,Pseudohypoparathyroidism type 1C,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
11469,79443,Pseudohypoparathyroidism type 1A,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11504,79478,Griscelli syndrome type 3,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,26337734[PMID]
11504,79478,Griscelli syndrome type 3,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26337734[PMID]
11505,79479,Pemphigus vegetans,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.391,Germany,Validated,PMID: 27456755
11507,79481,Pemphigus foliaceus,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.001,Germany,Validated,27456755[PMID]
11519,79493,Brooke-Spiegler syndrome,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,Dr Neil RAJAN[EXPERT]
11519,79493,Brooke-Spiegler syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_Dr Neil RAJAN[EXPERT]
11503,79477,Griscelli syndrome type 2,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,102.0,Worldwide,Validated,26960655[PMID]
11503,79477,Griscelli syndrome type 2,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26960655[PMID]
11502,79476,Griscelli syndrome type 1,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,22711375[PMID]
11502,79476,Griscelli syndrome type 1,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22711375[PMID]
11499,79473,Variegate porphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.008,Europe,Not yet validated,23114748[PMID]
11499,79473,Variegate porphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.32,Europe,Not yet validated,23114748[PMID]
11499,79473,Variegate porphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.012,France,Validated,23114748[PMID]
11499,79473,Variegate porphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.48,France,Validated,23114748[PMID]
11499,79473,Variegate porphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Finland,Validated,23114748[PMID]
11499,79473,Variegate porphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.24,Finland,Validated,23114748[PMID]
11499,79473,Variegate porphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.016,Ireland,Validated,23114748[PMID]
11499,79473,Variegate porphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.64,Ireland,Validated,23114748[PMID]
11499,79473,Variegate porphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Italy,Validated,23114748[PMID]
11499,79473,Variegate porphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.24,Netherlands,Validated,23114748[PMID]
11499,79473,Variegate porphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.24,Italy,Validated,23114748[PMID]
11499,79473,Variegate porphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Netherlands,Validated,23114748[PMID]
11499,79473,Variegate porphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.007,Norway,Validated,23114748[PMID]
11499,79473,Variegate porphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.28,Norway,Validated,23114748[PMID]
11499,79473,Variegate porphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.004,Spain,Validated,23114748[PMID]
11499,79473,Variegate porphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.16,Spain,Validated,23114748[PMID]
11499,79473,Variegate porphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.011,Sweden,Validated,23114748[PMID]
11499,79473,Variegate porphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.44,Sweden,Validated,23114748[PMID]
11499,79473,Variegate porphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.026,Switzerland,Validated,23114748[PMID]
11499,79473,Variegate porphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.04,Switzerland,Validated,23114748[PMID]
11499,79473,Variegate porphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.008,United Kingdom,Validated,23114748[PMID]
11499,79473,Variegate porphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.32,United Kingdom,Validated,23114748[PMID]
11295,79269,Sanfilippo syndrome type A,Etiological subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.32,Europe,Validated,European Medicines Agency 2014[INST]
11295,79269,Sanfilippo syndrome type A,Etiological subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.16,Netherlands,Validated,10480370[PMID]
11295,79269,Sanfilippo syndrome type A,Etiological subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.88,Australia,Validated,9918480[PMID]
11295,79269,Sanfilippo syndrome type A,Etiological subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.47,Czech Republic,Validated,20490927[PMID]
11295,79269,Sanfilippo syndrome type A,Etiological subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.62,Estonia,Validated,22480138[PMID]
11295,79269,Sanfilippo syndrome type A,Etiological subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.4,Worldwide,Validated,[EXPERT]
11295,79269,Sanfilippo syndrome type A,Etiological subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.62,Sweden,Validated,25274184[PMID]
11295,79269,Sanfilippo syndrome type A,Etiological subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.052,United States,Validated,34051828[PMID]
11295,79269,Sanfilippo syndrome type A,Etiological subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.19,United States,Validated,34051828[PMID]
11283,79257,GM1 gangliosidosis type 3,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,70.0,Worldwide,Validated,ORPHANET
11283,79257,GM1 gangliosidosis type 3,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11282,79256,GM1 gangliosidosis type 2,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,ORPHANET
11282,79256,GM1 gangliosidosis type 2,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11281,79255,GM1 gangliosidosis type 1,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,ORPHANET
11281,79255,GM1 gangliosidosis type 1,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11280,79254,Classic phenylketonuria,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,6.0,Worldwide,Validated,32024337[PMID]_ORPHANET
11280,79254,Classic phenylketonuria,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,6.34,Europe,Validated,32024337[PMID]_ORPHANET
11280,79254,Classic phenylketonuria,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.0,Worldwide,Validated,32024337[PMID]
11280,79254,Classic phenylketonuria,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.34,Europe,Validated,32024337[PMID]
11285,79259,Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,23351985[PMID]
11285,79259,Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11285,79259,Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.1,Israel,Validated,33239050[PMID]
11285,79259,Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,8.0,Specific population,Validated,33239050[PMID]
11284,79258,Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Europe,Validated,[EXPERT]
11284,79258,Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.7,Italy,Validated,11953730[PMID]
11284,79258,Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11284,79258,Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.5,Israel,Validated,33239050[PMID]
11272,79246,Pyruvate dehydrogenase phosphatase deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11279,79253,Mild phenylketonuria,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11266,79240,Glycogen storage disease due to liver and muscle phosphorylase kinase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11267,79241,Biotinidase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.6,Worldwide,Not yet validated,1779651[PMID]
11267,79241,Biotinidase deficiency,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Worldwide,Not yet validated,1779651[PMID]
11267,79241,Biotinidase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.5,United States,Validated,2314964[PMID]
11267,79241,Biotinidase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.6,Brazil,Validated,9713119[PMID]
11267,79241,Biotinidase deficiency,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.6,Europe,Validated,[EXPERT]
11267,79241,Biotinidase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.0,Sweden,Validated,20224900[PMID]
11267,79241,Biotinidase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.2,Italy,Validated,11953730[PMID]_3391228[PMID]
11267,79241,Biotinidase deficiency,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Italy,Validated,11953730[PMID]_3391228[PMID]
11267,79241,Biotinidase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.4,Austria,Validated,11388594[PMID]
11267,79241,Biotinidase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.0,Hungary,Validated,17185019[PMID]
11267,79241,Biotinidase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.0,Turkey,Validated,20333870[PMID]
11267,79241,Biotinidase deficiency,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.0069,China,Validated,34103049[PMID]
11267,79241,Biotinidase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.58,Czech Republic,Validated,31241292[PMID]
11264,79238,Galactose epimerase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11265,79239,Classic galactosemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.1,Europe,Validated,[EXPERT]
11265,79239,Classic galactosemia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.0,Netherlands,Validated,15841485[PMID]
11265,79239,Classic galactosemia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.3,United Kingdom,Validated,8215542[PMID]
11265,79239,Classic galactosemia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.3,Ireland,Validated,8215542[PMID]
11265,79239,Classic galactosemia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.13,Japan,Validated,6468444[PMID]
11265,79239,Classic galactosemia,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.25,China,Validated,10457302[PMID]
11265,79239,Classic galactosemia,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,20.8,"Iran, Islamic Republic of",Validated,23113108[PMID]
11265,79239,Classic galactosemia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11270,79244,Pyruvate dehydrogenase E2 deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11268,79242,Holocarboxylase synthetase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,[EXPERT]
11268,79242,Holocarboxylase synthetase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
11269,79243,Pyruvate dehydrogenase E1-alpha deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11324,79298,Diazoxide-resistant focal hyperinsulinism,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
11327,79301,Congenital bile acid synthesis defect type 1,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11319,79293,Familial LCAT deficiency,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,70.0,Worldwide,Validated,[EXPERT]
11319,79293,Familial LCAT deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11318,79292,Fish-eye disease,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
11318,79292,Fish-eye disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11304,79278,Autosomal erythropoietic protoporphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.012,Europe,Validated,23114748[PMID]
11304,79278,Autosomal erythropoietic protoporphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.92,Europe,Validated,23114748[PMID]
11304,79278,Autosomal erythropoietic protoporphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,France,Validated,23114748[PMID]
11304,79278,Autosomal erythropoietic protoporphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.46,France,Validated,23114748[PMID]
11304,79278,Autosomal erythropoietic protoporphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.007,Italy,Validated,23114748[PMID]
11304,79278,Autosomal erythropoietic protoporphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.62,Ireland,Validated,23114748[PMID]
11304,79278,Autosomal erythropoietic protoporphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.018,Netherlands,Validated,23114748[PMID]
11304,79278,Autosomal erythropoietic protoporphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.54,Italy,Validated,23114748[PMID]
11304,79278,Autosomal erythropoietic protoporphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.036,Norway,Validated,23114748[PMID]
11304,79278,Autosomal erythropoietic protoporphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.39,Netherlands,Validated,23114748[PMID]
11304,79278,Autosomal erythropoietic protoporphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Poland,Validated,23114748[PMID]
11304,79278,Autosomal erythropoietic protoporphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.77,Norway,Validated,23114748[PMID]
11304,79278,Autosomal erythropoietic protoporphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.003,Spain,Validated,23114748[PMID]
11304,79278,Autosomal erythropoietic protoporphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.15,Poland,Validated,23114748[PMID]
11304,79278,Autosomal erythropoietic protoporphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.018,Sweden,Validated,23114748[PMID]
11304,79278,Autosomal erythropoietic protoporphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.23,Spain,Validated,23114748[PMID]
11304,79278,Autosomal erythropoietic protoporphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.035,Switzerland,Validated,23114748[PMID]
11304,79278,Autosomal erythropoietic protoporphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.39,Sweden,Validated,23114748[PMID]
11304,79278,Autosomal erythropoietic protoporphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.033,United Kingdom,Validated,17994169[PMID]
11304,79278,Autosomal erythropoietic protoporphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.7,Switzerland,Validated,23114748[PMID]
11304,79278,Autosomal erythropoietic protoporphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.54,United Kingdom,Validated,17994169[PMID]
11304,79278,Autosomal erythropoietic protoporphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.75,Slovenia,Validated,23114748[PMID]
11305,79279,Alpha-N-acetylgalactosaminidase deficiency type 1,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,ORPHANET
11305,79279,Alpha-N-acetylgalactosaminidase deficiency type 1,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11306,79280,Alpha-N-acetylgalactosaminidase deficiency type 2,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,ORPHANET
11306,79280,Alpha-N-acetylgalactosaminidase deficiency type 2,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11307,79281,Alpha-N-acetylgalactosaminidase deficiency type 3,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,ORPHANET
11307,79281,Alpha-N-acetylgalactosaminidase deficiency type 3,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11308,79282,"Methylmalonic acidemia with homocystinuria, type cblC",Clinical subtype,Subtype of disorder,Cases/families,Case(s),,500.0,Worldwide,Validated,ORPHANET
11308,79282,"Methylmalonic acidemia with homocystinuria, type cblC",Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11309,79283,"Methylmalonic acidemia with homocystinuria, type cblD",Clinical subtype,Subtype of disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,ORPHANET
11309,79283,"Methylmalonic acidemia with homocystinuria, type cblD",Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11310,79284,Methylmalonic acidemia with homocystinuria type cblF,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,ORPHANET
11310,79284,Methylmalonic acidemia with homocystinuria type cblF,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11296,79270,Sanfilippo syndrome type B,Etiological subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2,Europe,Validated,European Medicines Agency 2013[INST]
11296,79270,Sanfilippo syndrome type B,Etiological subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.42,Netherlands,Validated,10480370[PMID]
11296,79270,Sanfilippo syndrome type B,Etiological subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.72,Portugal,Validated,14685153[PMID]
11296,79270,Sanfilippo syndrome type B,Etiological subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.47,Australia,Validated,9918480[PMID]
11296,79270,Sanfilippo syndrome type B,Etiological subtype,Subtype of disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.02,Czech Republic,Validated,20490927[PMID]
11296,79270,Sanfilippo syndrome type B,Etiological subtype,Subtype of disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.05,Sweden,Validated,25274184[PMID]
11296,79270,Sanfilippo syndrome type B,Etiological subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.014,United States,Validated,34051828[PMID]
11296,79270,Sanfilippo syndrome type B,Etiological subtype,Subtype of disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.05,United States,Validated,34051828[PMID]
11297,79271,Sanfilippo syndrome type C,Etiological subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.21,Netherlands,Validated,10480370[PMID]
11297,79271,Sanfilippo syndrome type C,Etiological subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.12,Portugal,Validated,14685153[PMID]
11297,79271,Sanfilippo syndrome type C,Etiological subtype,Subtype of disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.07,Australia,Validated,9918480[PMID]
11297,79271,Sanfilippo syndrome type C,Etiological subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.42,Czech Republic,Validated,20490927[PMID]
11297,79271,Sanfilippo syndrome type C,Etiological subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,5.0,Europe,Validated,European Medicines Agency 2015[INST]
11297,79271,Sanfilippo syndrome type C,Etiological subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.34,Sweden,Validated,25274184[PMID]
11297,79271,Sanfilippo syndrome type C,Etiological subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,4.0E-4,United States,Validated,34051828[PMID]
11297,79271,Sanfilippo syndrome type C,Etiological subtype,Subtype of disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.015,United States,Validated,34051828[PMID]
11298,79272,Sanfilippo syndrome type D,Etiological subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.1,Netherlands,Validated,10480370[PMID]
11298,79272,Sanfilippo syndrome type D,Etiological subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.1,Australia,Validated,9918480[PMID]
11299,79273,Hereditary coproporphyria,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
11302,79276,Acute intermittent porphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.013,Europe,Validated,23114748[PMID]
11302,79276,Acute intermittent porphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.54,Europe,Validated,23114748[PMID]
11302,79276,Acute intermittent porphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.012,France,Validated,23114748[PMID]
11302,79276,Acute intermittent porphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.55,France,Validated,23114748[PMID]
11302,79276,Acute intermittent porphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.011,Italy,Validated,23114748[PMID]
11302,79276,Acute intermittent porphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Italy,Validated,23114748[PMID]
11302,79276,Acute intermittent porphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.013,Finland,Validated,23114748[PMID]
11302,79276,Acute intermittent porphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.59,Finland,Validated,23114748[PMID]
11302,79276,Acute intermittent porphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.018,Netherlands,Validated,23114748[PMID]
11302,79276,Acute intermittent porphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.81,Netherlands,Validated,23114748[PMID]
11302,79276,Acute intermittent porphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.014,Norway,Validated,23114748[PMID]
11302,79276,Acute intermittent porphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.63,Norway,Validated,23114748[PMID]
11302,79276,Acute intermittent porphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.016,Poland,Validated,23114748[PMID]
11302,79276,Acute intermittent porphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.72,Poland,Validated,23114748[PMID]
11302,79276,Acute intermittent porphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.014,Spain,Validated,23114748[PMID]
11302,79276,Acute intermittent porphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.63,Spain,Validated,23114748[PMID]
11302,79276,Acute intermittent porphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.051,Sweden,Validated,23114748[PMID]
11302,79276,Acute intermittent porphyria,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,Sweden,Validated,12372055[PMID]
11302,79276,Acute intermittent porphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.022,Switzerland,Validated,23114748[PMID]
11302,79276,Acute intermittent porphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.99,Switzerland,Validated,23114748[PMID]
11302,79276,Acute intermittent porphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.016,United Kingdom,Validated,23114748[PMID]
11302,79276,Acute intermittent porphyria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.72,United Kingdom,Validated,23114748[PMID]
11303,79277,Congenital erythropoietic porphyria,Disease,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,ORPHANET
11303,79277,Congenital erythropoietic porphyria,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.065,Europe,Not yet validated,23114748[PMID]
11303,79277,Congenital erythropoietic porphyria,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11359,79333,COG7-CDG,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,19577670[PMID]
11359,79333,COG7-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19577670[PMID]
11358,79332,B4GALT1-CDG,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,11930273[PMID]
11358,79332,B4GALT1-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11930273[PMID]
11356,79330,MOGS-CDG,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,24716661[PMID]
11356,79330,MOGS-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24716661[PMID]
11355,79329,MGAT2-CDG,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,22105986[PMID]
11355,79329,MGAT2-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22105986[PMID]
11354,79328,ALG9-CDG,Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,26453364[PMID]_28122681[PMID]_28932688[PMID)
11354,79328,ALG9-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28122681[PMID]_28932688[PMID]
11353,79327,ALG1-CDG,Disease,Disorder,Cases/families,Case(s),,57.0,Worldwide,Validated,26931382[PMID]
11353,79327,ALG1-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26931382[PMID]
11352,79326,ALG2-CDG,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,12684507[PMID]
11352,79326,ALG2-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12684507[PMID]
11351,79325,ALG8-CDG,Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,26066342[PMID]
11351,79325,ALG8-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26066342[PMID]
11350,79324,ALG12-CDG,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,22516080[PMID]
11350,79324,ALG12-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22516080[PMID]
11349,79323,MPDU1-CDG,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,28122681[PMID]_28940310[PMID]
11349,79323,MPDU1-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28122681[PMID]_28940310[PMID]
11348,79322,DPM1-CDG,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,27481510[PMID]
11348,79322,DPM1-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27481510[PMID]
11347,79321,ALG3-CDG,Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,28122681[PMID]
11347,79321,ALG3-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28122681[PMID]
11346,79320,ALG6-CDG,Disease,Disorder,Cases/families,Case(s),,54.0,Worldwide,Validated,25052310[PMID]
11346,79320,ALG6-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25052310[PMID]
11345,79319,MPI-CDG,Disease,Disorder,Cases/families,Case(s),,25.0,Worldwide,Validated,19862844[PMID]
11345,79319,MPI-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19862844[PMID]
11344,79318,PMM2-CDG,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.73,Italy,Validated,11953730[PMID]
11344,79318,PMM2-CDG,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_19862844[PMID]
11344,79318,PMM2-CDG,Disease,Disorder,Prevalence at birth,Class only,1-9 / 100 000,0.0,Europe,Validated,10854097[PMID]_11953730[PMID]
11340,79314,L-2-hydroxyglutaric aciduria,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11340,79314,L-2-hydroxyglutaric aciduria,Disease,Disorder,Cases/families,Case(s),,140.0,Worldwide,Validated,[EXPERT]
11341,79315,D-2-hydroxyglutaric aciduria,Disease,Disorder,Cases/families,Case(s),,80.0,Worldwide,Validated,[EXPERT]
11341,79315,D-2-hydroxyglutaric aciduria,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11338,79312,Vitamin B12-unresponsive methylmalonic acidemia type mut-,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,450.0,Worldwide,Validated,ORPHANET
11338,79312,Vitamin B12-unresponsive methylmalonic acidemia type mut-,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11336,79310,Vitamin B12-responsive methylmalonic acidemia type cblA,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,ORPHANET
11336,79310,Vitamin B12-responsive methylmalonic acidemia type cblA,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11332,79306,Progressive familial intrahepatic cholestasis type 1,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
11330,79304,Progressive familial intrahepatic cholestasis type 2,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
11331,79305,Progressive familial intrahepatic cholestasis type 3,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
11328,79302,Congenital bile acid synthesis defect type 3,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,9802883[PMID]
11328,79302,Congenital bile acid synthesis defect type 3,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9802883[PMID]
11329,79303,Congenital bile acid synthesis defect type 2,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11387,79361,Inherited epidermolysis bullosa,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.9,Europe,Validated,20507631[PMID]
11387,79361,Inherited epidermolysis bullosa,Category,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.8,Europe,Validated,20507631[PMID]
11387,79361,Inherited epidermolysis bullosa,Category,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.96,Croatia,Validated,2359725[PMID]
11387,79361,Inherited epidermolysis bullosa,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.9,United States,Validated,20507631[PMID]
11387,79361,Inherited epidermolysis bullosa,Category,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.8,United States,Validated,20507631[PMID]
11387,79361,Inherited epidermolysis bullosa,Category,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.59,China,Validated,34103049[PMID]
11377,79351,"3-phosphoglycerate dehydrogenase deficiency, infantile/juvenile form",Etiological subtype,Subtype of disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,23564319[PMID]
11377,79351,"3-phosphoglycerate dehydrogenase deficiency, infantile/juvenile form",Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23564319[PMID]
11376,79350,"3-phosphoserine phosphatase deficiency, infantile/juvenile form",Etiological subtype,Subtype of disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,9222972[PMID]_14673469[PMID]
11376,79350,"3-phosphoserine phosphatase deficiency, infantile/juvenile form",Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9222972[PMID]_14673469[PMID]
11373,79347,"Chondrodysplasia punctata, Toriello type",Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,8267015[PMID]_9450859[PMID]
11373,79347,"Chondrodysplasia punctata, Toriello type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8267015[PMID]_9450859[PMID]
11371,79345,Brachytelephalangic chondrodysplasia punctata,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_Dr BAUJAT Geneviève[EXPERT]
11649,85191,Singleton-Merten dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,23322711[PMID]_25620203[PMID]
11649,85191,Singleton-Merten dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23322711[PMID]_25620203[PMID]
11648,85188,"Metaphyseal dysplasia, Braun-Tinschert type",Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11651,85193,Idiopathic juvenile osteoporosis,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11650,85192,Calvarial doughnut lesions-bone fragility syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,ORPHANET
11650,85192,Calvarial doughnut lesions-bone fragility syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11652,85194,Spondylo-ocular syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,11260210[PMID]_16470687[PMID]
11652,85194,Spondylo-ocular syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11260210[PMID]_16470687[PMID]
11655,85197,Genochondromatosis type 1,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
11657,85199,Craniosynostosis-anal anomalies-porokeratosis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,15924278[PMID]_24095818[PMID]_[EXPERT]
11657,85199,Craniosynostosis-anal anomalies-porokeratosis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11656,85198,Dysspondyloenchondromatosis,Malformation syndrome,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,24357493[PMID]_26250472[PMID]
11656,85198,Dysspondyloenchondromatosis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
11656,85198,Dysspondyloenchondromatosis,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24357493[PMID]_26250472[PMID]
11659,85201,Genitopatellar syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,22265014[PMID]_22265017[PMID]
11659,85201,Genitopatellar syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22265014[PMID]_22265017[PMID]
11661,85203,Acropectoral syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,25.0,Worldwide,Validated,22183091[PMID]
11661,85203,Acropectoral syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22183091[PMID]
11660,85202,Keutel syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,[EXPERT]
11660,85202,Keutel syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11663,85273,"X-linked intellectual disability, Abidi type",Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,10398233[PMID]
11663,85273,"X-linked intellectual disability, Abidi type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10398233[PMID]
11662,85212,Fetal Gaucher disease,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,ORPHANET
11662,85212,Fetal Gaucher disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11664,85274,Syndromic X-linked intellectual disability 7,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,10573017[PMID]
11664,85274,Syndromic X-linked intellectual disability 7,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10573017[PMID]
11665,85275,Microphthalmia-ankyloblepharon-intellectual disability syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11666,85276,"X-linked intellectual disability, Armfield type",Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,10398235[PMID]
11666,85276,"X-linked intellectual disability, Armfield type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10398235[PMID]
11667,85277,"X-linked intellectual disability, Cantagrel type",Malformation syndrome,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,27358180[PMID]_27568816[PMID]
11667,85277,"X-linked intellectual disability, Cantagrel type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27358180[PMID]_27568816[PMID]
11668,85278,Christianson syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,1.7241,Worldwide,Validated,25044251[PMID]
11669,85279,KDM5C-related syndromic X-linked intellectual disability,Malformation syndrome,Disorder,Cases/families,Family(ies),,10.0,Worldwide,Validated,ORPHANET
11669,85279,KDM5C-related syndromic X-linked intellectual disability,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11670,85280,X-linked intellectual disability-cubitus valgus-dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,14556244[PMID]
11670,85280,X-linked intellectual disability-cubitus valgus-dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_14556244[PMID]
11672,85282,MEHMO syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,12032729[PMID]
11672,85282,MEHMO syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12032729[PMID]
11673,85283,"X-linked intellectual disability, Miles-Carpenter type",Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,2018061[PMID]
11673,85283,"X-linked intellectual disability, Miles-Carpenter type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2018061[PMID]
11674,85284,BRESEK syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,24090718[PMID]
11674,85284,BRESEK syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11675,85285,"X-linked intellectual disability, Schimke type",Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,6538752[PMID]
11675,85285,"X-linked intellectual disability, Schimke type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6538752[PMID]
11676,85286,"X-linked intellectual disability, Shashi type",Malformation syndrome,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,12605440[PMID]
11676,85286,"X-linked intellectual disability, Shashi type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12605440[PMID]
11677,85287,"X-linked intellectual disability, Siderius type",Malformation syndrome,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,16199551[PMID]
11677,85287,"X-linked intellectual disability, Siderius type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16199551[PMID]
11678,85288,"X-linked intellectual disability, Stocco Dos Santos type",Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,2063914[PMID]
11678,85288,"X-linked intellectual disability, Stocco Dos Santos type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2063914[PMID]
11683,85293,"X-linked intellectual disability, Cabezas type",Malformation syndrome,Disorder,Cases/families,Family(ies),,24.0,Worldwide,Validated,25385192[PMID]
11683,85293,"X-linked intellectual disability, Cabezas type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25385192[PMID]
11682,85292,X-linked spinocerebellar ataxia type 4,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,3470628[PMID]
11682,85292,X-linked spinocerebellar ataxia type 4,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11680,85290,"X-linked intellectual disability, Wilson type",Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,1357179[PMID]
11680,85290,"X-linked intellectual disability, Wilson type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1357179[PMID]
11687,85317,X-linked intellectual disability-hypogammaglobulinemia-progressive neurological deterioration syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,10398239[PMID]
11687,85317,X-linked intellectual disability-hypogammaglobulinemia-progressive neurological deterioration syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10398239[PMID]
11686,85297,X-linked spinocerebellar ataxia type 3,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,3614654[PMID]
11686,85297,X-linked spinocerebellar ataxia type 3,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3614654[PMID]
11685,85295,"HSD10 disease, atypical type",Clinical subtype,Subtype of disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,27306202[PMID]
11685,85295,"HSD10 disease, atypical type",Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_ 27306202[PMID]
11684,85294,X-linked epilepsy-learning disabilities-behavior disorders syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11691,85321,"Deafness-intellectual disability syndrome, Martin-Probst type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,11073537[PMID]
11691,85321,"Deafness-intellectual disability syndrome, Martin-Probst type",Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,ORPHANET_11073537[PMID]
11690,85320,X-linked intellectual disability-macrocephaly-macroorchidism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9863601[PMID]
11690,85320,X-linked intellectual disability-macrocephaly-macroorchidism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,9863601[PMID]
11689,85319,X-linked intellectual disability-epilepsy-progressive joint contractures-dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,8574418[PMID]
11689,85319,X-linked intellectual disability-epilepsy-progressive joint contractures-dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8574418[PMID]
11695,85325,"X-linked intellectual disability, Stevenson type",Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,9192265[PMID]
11695,85325,"X-linked intellectual disability, Stevenson type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9192265[PMID]
11694,85324,"X-linked intellectual disability, Shrimpton type",Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,10331611[PMID]
11694,85324,"X-linked intellectual disability, Shrimpton type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10331611[PMID]
11693,85323,"X-linked intellectual disability, Seemanova type",Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,8958326[PMID]
11693,85323,"X-linked intellectual disability, Seemanova type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8958326[PMID]
11692,85322,"X-linked intellectual disability, Pai type",Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,9222958[PMID]
11692,85322,"X-linked intellectual disability, Pai type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9222958[PMID]
11699,85329,X-linked intellectual disability-hypotonia-facial dysmorphism-aggressive behavior syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,12599187[PMID]
11699,85329,X-linked intellectual disability-hypotonia-facial dysmorphism-aggressive behavior syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12599187[PMID]
11696,85326,"X-linked intellectual disability, Stoll type",Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,1877628[PMID]
11696,85326,"X-linked intellectual disability, Stoll type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1877628[PMID]
11697,85327,X-linked intellectual disability-acromegaly-hyperactivity syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,2018059[PMID]
11697,85327,X-linked intellectual disability-acromegaly-hyperactivity syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2018059[PMID]
11702,85332,X-linked intellectual disability-retinitis pigmentosa syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
11706,85336,"X-linked neurodegenerative syndrome, Hamel type",Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,10051014[PMID]
11706,85336,"X-linked neurodegenerative syndrome, Hamel type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10051014[PMID]
11704,85334,"X-linked neurodegenerative syndrome, Bertini type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1605224[PMID]
11704,85334,"X-linked neurodegenerative syndrome, Bertini type",Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,1605224[PMID]
11705,85335,Fried syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_5054319[PMID]
11705,85335,Fried syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,5054319[PMID]
11710,85410,Oligoarticular juvenile idiopathic arthritis,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.5,Europe,Not yet validated,ORPHANET
11711,85414,Systemic-onset juvenile idiopathic arthritis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.1,Worldwide,Validated,24210707[PMID]
11711,85414,Systemic-onset juvenile idiopathic arthritis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.6,Worldwide,Validated,24210707[PMID]
11708,85338,X-linked intellectual disability-ataxia-apraxia syndrome,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,1605232[PMID]
11708,85338,X-linked intellectual disability-ataxia-apraxia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1605232[PMID]
11709,85408,Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.0,Europe,Not yet validated,ORPHANET
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.459,Germany,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.127,Worldwide,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.044,Worldwide,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.5311,Europe,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.1177,Europe,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.77,Austria,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.166,Austria,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,5.54,Belgium,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.122,Belgium,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.892,Bulgaria,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.174,Bulgaria,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.801,Croatia,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.156,Croatia,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.299,Cyprus,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.894,Cyprus,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.462,Czech Republic,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.109,Czech Republic,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.568,Denmark,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.124,Denmark,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.51,Estonia,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.107,Estonia,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.885,Finland,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.187,Finland,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.692,France,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.152,France,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.294,Germany,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.219,Greece,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.254,Greece,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.418,Hungary,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.088,Hungary,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.643,Iceland,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.948,Iceland,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.448,Ireland,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.913,Ireland,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.538,Italy,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.329,Italy,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.71,Latvia,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.123,Latvia,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.809,Liechtenstein,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.174,Liechtenstein,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.61,Lithuania,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.109,Lithuania,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.653,Luxembourg,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.968,Luxembourg,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.641,Malta,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.147,Malta,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.672,Netherlands,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.146,Netherlands,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.977,Norway,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.018,Norway,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.134,Poland,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.044,Poland,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.216,Portugal,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.25,Portugal,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.537,Romania,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.107,Romania,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.76,Slovakia,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.968,Slovakia,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.756,Slovenia,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.167,Slovenia,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.864,Spain,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.193,Spain,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.667,Sweden,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.141,Sweden,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.316,United Kingdom,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.078,United Kingdom,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.222,Brazil,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.672,Brazil,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.215,Canada,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.076,Canada,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.108,Japan,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.43,Japan,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.569,Russian Federation,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.93,Russian Federation,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.822,"Korea, Republic of",Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.997,"Korea, Republic of",Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.852,"Taiwan, Province of China",Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.001,"Taiwan, Province of China",Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.842,United States,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.991,United States,Validated,35854312[PMID]
11717,85443,AL amyloidosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,6.0,Argentina,Validated,31343332[PMID]
11716,85442,Short stature-pituitary and cerebellar defects-small sella turcica syndrome,Disease,Disorder,Cases/families,Family(ies),,5.0,Worldwide,Validated,11567216[PMID]_17527005[PMID]_18073311[PMID]
11716,85442,Short stature-pituitary and cerebellar defects-small sella turcica syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11567216[PMID]_17527005[PMID]_18073311[PMID]
11719,85446,Wild type ABeta2M amyloidosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.5,Europe,Validated,European Medicines Agency 2012[INST]
11718,85445,AA amyloidosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11713,85436,Psoriasis-related juvenile idiopathic arthritis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,24210707[PMID]
11712,85435,Rheumatoid factor-positive polyarticular juvenile idiopathic arthritis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.2,Europe,Not yet validated,ORPHANET
11715,85438,Enthesitis-related juvenile idiopathic arthritis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.7,Europe,Not yet validated,ORPHANET
11725,85458,Cerebral Amyloid Angiopathy,Disease,Disorder,Cases/families,Case(s),,350.0,Worldwide,Validated,[EXPERT]
11725,85458,Cerebral Amyloid Angiopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11724,85453,X-linked reticulate pigmentary disorder,Disease,Disorder,Cases/families,Family(ies),,6.0,Worldwide,Validated,ORPHANET
11724,85453,X-linked reticulate pigmentary disorder,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Not yet validated,ORPHANET
11727,86788,X-linked severe congenital neutropenia,Disease,Disorder,Cases/families,Case(s),,45.0,Worldwide,Validated,16804117[PMID]_11242115[PMID]
11727,86788,X-linked severe congenital neutropenia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11726,86309,DPAGT1-CDG,Disease,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,26033833 [PMID]
11726,86309,DPAGT1-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26033833 [PMID]
11721,85448,AGel amyloidosis,Disease,Disorder,Cases/families,Case(s),,475.0,Worldwide,Validated,9547007[PMID]_17097682[PMID]_14639586[PMID]_20229579[PMID]_22068858[PMID]_2262277[PMID]_10729296[PMID]_[EXPERT]
11721,85448,AGel amyloidosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11720,85447,ATTRV30M amyloidosis,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,6-9 / 10 000,90.0,Portugal,Validated,8825887[PMID]_24572009[PMID]
11720,85447,ATTRV30M amyloidosis,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Japan,Validated,[EXPERT]_23425518[PMID]
11720,85447,ATTRV30M amyloidosis,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 100 000,3.75,Sweden,Not yet validated,8406517[PMID]
11720,85447,ATTRV30M amyloidosis,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,6-9 / 10 000,97.5,Sweden,Not yet validated,8406517[PMID]
11720,85447,ATTRV30M amyloidosis,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.69,Cyprus,Validated,19291512[PMID]
11720,85447,ATTRV30M amyloidosis,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,3.7,Cyprus,Validated,19291512[PMID]
11720,85447,ATTRV30M amyloidosis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11720,85447,ATTRV30M amyloidosis,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,3.0,Spain,Validated,3210815[PMID]_12855135[PMID]_24572009[PMID]
11723,85451,ATTRV122I amyloidosis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11722,85450,Hereditary amyloidosis with primary renal involvement,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11732,86812,POMT1-related limb-girdle muscular dystrophy R11,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
11733,86813,Helicoid peripapillary chorioretinal degeneration,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,ORPHANET
11733,86813,Helicoid peripapillary chorioretinal degeneration,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11734,86814,Benign adult familial myoclonic epilepsy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.8,Japan,Validated,15508931[PMID]
11734,86814,Benign adult familial myoclonic epilepsy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11728,86789,Isolated patella aplasia/hypoplasia,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11857555[PMID]
11728,86789,Isolated patella aplasia/hypoplasia,Morphological anomaly,Disorder,Cases/families,Family(ies),,5.0,Worldwide,Validated,11857555[PMID]
11731,86797,Atypical lichen myxedematosus,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,[EXPERT]
11731,86797,Atypical lichen myxedematosus,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11740,86820,Familial avascular necrosis of femoral head,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.0,United States,Validated,[EXPERT]
11740,86820,Familial avascular necrosis of femoral head,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11741,86821,Lissencephaly type 3-familial fetal akinesia sequence syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,8779318[PMID]
11741,86821,Lissencephaly type 3-familial fetal akinesia sequence syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8779318[PMID]
11742,86822,Lissencephaly type 3-metacarpal bone dysplasia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,11170088[PMID]
11742,86822,Lissencephaly type 3-metacarpal bone dysplasia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11170088[PMID]
11743,86823,Lissencephaly with cerebellar hypoplasia,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,18521588[PMID]
11736,86816,Congenital analbuminemia,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,ORPHANET
11736,86816,Congenital analbuminemia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11737,86817,Hemolytic anemia due to adenylate kinase deficiency,Disease,Disorder,Cases/families,Family(ies),,7.0,Worldwide,Validated,10233365[PMID]
11737,86817,Hemolytic anemia due to adenylate kinase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10233365[PMID]
11738,86818,Alport syndrome-intellectual disability-midface hypoplasia-elliptocytosis syndrome,Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,7923864[PMID]_9598718[PMID]
11738,86818,Alport syndrome-intellectual disability-midface hypoplasia-elliptocytosis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
26906,512034,Large granular lymphocyte leukemia,Clinical group,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.02,United States,Validated,27494824[PMID]
11751,86843,Acute panmyelosis with myelofibrosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.06,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11750,86841,Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11749,86839,Myelodysplastic neoplasm with increased blasts,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11749,86839,Myelodysplastic neoplasm with increased blasts,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.15,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11748,86836,Refractory cytopenia with multilineage dysplasia,Clinical group,Group of disorders,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11747,86834,Juvenile myelomonocytic leukemia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,European Medicines Agency[INST]
11745,86830,"Chronic myeloproliferative disease, unclassifiable",Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.53,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11744,86829,Chronic neutrophilic leukemia,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11759,86855,Plasmacytoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11759,86855,Plasmacytoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.34,United States,Validated,19016727[PMID]_SEER Surveillance Epidemiology and End Results 1992-2004[INST]
26926,512260,Congenital cerebellar ataxia due to RNU12 mutation,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,27863452[PMID]
26926,512260,Congenital cerebellar ataxia due to RNU12 mutation,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27863452[PMID]
11758,86854,Splenic marginal zone lymphoma,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,European Medecines Agency 2013[INST]
11757,86852,B-cell prolymphocytic leukemia,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.05,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11755,86850,Myeloid sarcoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11755,86850,Myeloid sarcoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11754,86849,Acute basophilic leukemia,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11753,86846,Therapy related acute myeloid leukemia and myelodysplastic syndrome,Category,Group of disorders,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11752,86845,Acute myeloid leukaemia with myelodysplasia-related features,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11766,86872,T-cell large granular lymphocyte leukemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.4,Europe,Validated,[EXPERT]
11766,86872,T-cell large granular lymphocyte leukemia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11767,86873,Aggressive NK-cell leukemia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
11764,86870,Blastic plasmacytoid dendritic cell neoplasm,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,12.0,Europe,Validated,European Medicines Agency 2015[INST]
11764,86870,Blastic plasmacytoid dendritic cell neoplasm,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.03,United States,Validated,36946176[PMID]
11765,86871,T-cell prolymphocytic leukemia,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,[WHO Classification of Tumours ]
11765,86871,T-cell prolymphocytic leukemia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[WHO Classification of Tumours ]
11762,86867,Nodal marginal zone B-cell lymphoma,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,European Medecines Agency 2013[INST]
11761,86864,Heavy chain disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11761,86864,Heavy chain disease,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11774,86886,Angioimmunoblastic T-cell lymphoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.05,United States,Validated,16150940[PMID]
11775,86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Worldwide,Validated,[EXPERT]
11775,86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.095,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11775,86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11775,86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.041,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11775,86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.006,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11775,86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.099,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11775,86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.037,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11775,86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.097,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11775,86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.074,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11775,86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.038,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11775,86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.008,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11775,86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.013,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11775,86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.055,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11775,86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.053,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11775,86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.056,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11775,86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.092,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11775,86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.128,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11775,86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.285,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11775,86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.124,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11775,86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.226,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11775,86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.14,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11775,86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.135,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11775,86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.133,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11772,86884,Subcutaneous panniculitis-like T-cell lymphoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11770,86880,Enteropathy-associated T-cell lymphoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.0111,United States,Validated,26104061[PMID]
11770,86880,Enteropathy-associated T-cell lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Netherlands,Validated,18618372[PMID]
11771,86882,Hepatosplenic T-cell lymphoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.03,United States,Validated,21823196[PMID]
11771,86882,Hepatosplenic T-cell lymphoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11768,86875,Adult T-cell leukemia/lymphoma,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.0,Europe,Validated,European Medicines Agency 2014[INST]
11769,86879,Extranodal nasal NK/T cell lymphoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.25,France,Validated,Institut National du Cancer 2013[INST]
11528,79502,Punctate palmoplantar keratoderma type 2,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,2525006[PMID]
11528,79502,Punctate palmoplantar keratoderma type 2,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2525006[PMID]
11529,79503,Ichthyosis hystrix of Curth-Macklin,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,28405559[PMID]_26538731[PMID]
11529,79503,Ichthyosis hystrix of Curth-Macklin,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28405559[PMID]_26538731[PMID]
11533,79507,Hypotonia-failure to thrive-microcephaly syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,10896305[PMID]
11533,79507,Hypotonia-failure to thrive-microcephaly syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10896305[PMID]
11525,79499,Autosomal dominant deafness-onychodystrophy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,[EXPERT]
11525,79499,Autosomal dominant deafness-onychodystrophy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,[EXPERT]
11526,79500,DOORS syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,[EXPERT]
11526,79500,DOORS syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11527,79501,Punctate palmoplantar keratoderma type 1,Disease,Disorder,Cases/families,Case(s),,437.0,Worldwide,Validated,34535911[PMID]_EXPERT
11527,79501,Punctate palmoplantar keratoderma type 1,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.17,Croatia,Validated,8349860[PMID]
11527,79501,Punctate palmoplantar keratoderma type 1,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.3,Slovenia,Validated,19784524[PMID]
11544,79665,Gardner syndrome,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.1,Worldwide,Not yet validated,17517313[PMID]_24858982[PMID]
11543,79651,Mild hyperphenylalaninemia,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11542,79644,Autosomal recessive hyperinsulinism due to Kir6.2 deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
11562,83317,Scrub typhus,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.2,"Korea, Republic of",Validated,18362409[PMID]
11562,83317,Scrub typhus,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.3,Japan,Validated,18362409[PMID]
11562,83317,Scrub typhus,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11563,83330,Proximal spinal muscular atrophy type 1,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.26,Europe,Not yet validated,ORPHANET
11563,83330,Proximal spinal muscular atrophy type 1,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
11560,83315,Murine typhus,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11561,83316,Pseudotyphus of California,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11566,83419,Proximal spinal muscular atrophy type 3,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.6623,Italy,Validated,1483045[PMID]
11566,83419,Proximal spinal muscular atrophy type 3,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 1 000 000,0.61,Europe,Validated,28676062[PMID]_ORPHANET
11567,83420,Proximal spinal muscular atrophy type 4,Clinical subtype,Subtype of disorder,Annual incidence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
11567,83420,Proximal spinal muscular atrophy type 4,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
11565,83418,Proximal spinal muscular atrophy type 2,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.0,Europe,Validated,10677857[PMID]_1483045[PMID]
11565,83418,Proximal spinal muscular atrophy type 2,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 100 000,2.0322,Worldwide,Validated,28676062[PMID]_ORPHANET
11558,83313,Boutonneuse fever,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,24.2,France,Not yet validated,ORPHANET
11558,83313,Boutonneuse fever,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,9.8,Portugal,Not yet validated,ORPHANET
11558,83313,Boutonneuse fever,Disease,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET
11559,83314,Epidemic typhus,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11556,83311,Rocky Mountain spotted fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.24,United States,Not yet validated,ORPHANET
11556,83311,Rocky Mountain spotted fever,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11557,83312,Rickettsialpox,Disease,Disorder,Cases/families,Case(s),,800.0,Worldwide,Validated,15577753[PMID]
11557,83312,Rickettsialpox,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11579,83469,Desmoplastic small round cell tumor,Disease,Disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,15557784[PMID]
11579,83469,Desmoplastic small round cell tumor,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
11579,83469,Desmoplastic small round cell tumor,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11578,83468,Solitary bone cyst,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11577,83467,Morvan syndrome,Disease,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,27698847[PMID]
11577,83467,Morvan syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27698847[PMID]
11576,83465,Narcolepsy type 2,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11576,83465,Narcolepsy type 2,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,20.3,United States,Validated,11902429[PMID]
11583,83476,West-Nile encephalitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.92,United States,Validated,23013055[PMID]_Center for Diseases Control and Prevention 2012[INST]
11583,83476,West-Nile encephalitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11583,83476,West-Nile encephalitis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.036,Europe,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
11583,83476,West-Nile encephalitis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Austria,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
11583,83476,West-Nile encephalitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.17,Croatia,Validated,European Centre for Disease prevention and Control 2012-2015[INST]
11583,83476,West-Nile encephalitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.66,Greece,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
11583,83476,West-Nile encephalitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.16,Hungary,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
11583,83476,West-Nile encephalitis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.07,Italy,Validated,European Centre for Disease prevention and Control 2011-2013[INST]
11583,83476,West-Nile encephalitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Romania,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
11582,83473,Megalencephaly-polymicrogyria-postaxial polydactyly-hydrocephalus syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,62.0,Worldwide,Validated,27854409[PMID]
11582,83473,Megalencephaly-polymicrogyria-postaxial polydactyly-hydrocephalus syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27854409[PMID]
11581,83472,CAMOS syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,11391656[PMID]
11581,83472,CAMOS syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11391656[PMID]
11580,83471,T-cell immunodeficiency with thymic aplasia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11571,83452,Complex regional pain syndrome,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,26.2,Netherlands,Validated,17084977[PMID]_24161450[PMID]
11571,83452,Complex regional pain syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11570,83451,Florid cemento-osseous dysplasia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11569,83450,Regional odontodysplasia,Disease,Disorder,Cases/families,Case(s),,140.0,Worldwide,Validated,ORPHANET
11569,83450,Regional odontodysplasia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11575,83463,Microtia,Morphological anomaly,Disorder,Point prevalence,Value and class,1-5 / 10 000,38.0,Specific population,Validated,16359491[PMID]
11575,83463,Microtia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,13.0,Europe,Not yet validated,ORPHANET
11575,83463,Microtia,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET
11575,83463,Microtia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,15.5,Worldwide,Not yet validated,21656661[PMID]
11575,83463,Microtia,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Worldwide,Not yet validated,21656661[PMID]
11575,83463,Microtia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.7,France,Validated,8933331[PMID]
11575,83463,Microtia,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,France,Validated,8933331[PMID]
11575,83463,Microtia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.2,Italy,Validated,7666397[PMID]
11575,83463,Microtia,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Italy,Not yet validated,7666397[PMID]
11575,83463,Microtia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.1,Sweden,Validated,8933331[PMID]
11575,83463,Microtia,Morphological anomaly,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Sweden,Validated,8933331[PMID]
11575,83463,Microtia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,22.0,United States,Validated,8933331[PMID]_19760683[PMID]
11575,83463,Microtia,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,United States,Validated,8933331[PMID]_19760683[PMID]
11575,83463,Microtia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,43.4,Finland,Validated,17548114[PMID]
11575,83463,Microtia,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Finland,Validated,17548114[PMID]
11575,83463,Microtia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,>1 / 1000,174.0,Ecuador,Validated,3771073[PMID]
11575,83463,Microtia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,6-9 / 10 000,83.0,Chile,Validated,17186100[PMID]
11574,83461,Congenital primary aphakia,Malformation syndrome,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET
11573,83454,Glomuvenous malformation,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11572,83453,Vulvovaginal gingival syndrome,Disease,Disorder,Cases/families,Case(s),,380.0,Worldwide,Validated,20373919[PMID]
11572,83453,Vulvovaginal gingival syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
27125,514352,Congenital brachyesophagus-intrathoracic stomach-vertebral anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,27836748[PMID]
27125,514352,Congenital brachyesophagus-intrathoracic stomach-vertebral anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27836748[PMID]
11597,83619,Macrostomia-preauricular tags-external ophthalmoplegia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,16854200[PMID]
11597,83619,Macrostomia-preauricular tags-external ophthalmoplegia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16854200[PMID]
11598,83620,Enteric anendocrinosis,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,24134759[PMID]
11598,83620,Enteric anendocrinosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24134759[PMID]
11599,83628,LUMBAR syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,54.0,Worldwide,Validated,24259379[PMID]
11599,83628,LUMBAR syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11592,83601,Steroid-responsive encephalopathy associated with autoimmune thyroiditis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
11594,83616,Rubella panencephalitis,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,9103895[PMID]
11594,83616,Rubella panencephalitis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11595,83617,Agammaglobulinemia-microcephaly-craniosynostosis-severe dermatitis syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,16691627[PMID]
11595,83617,Agammaglobulinemia-microcephaly-craniosynostosis-severe dermatitis syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16691627[PMID]
11588,83594,Eastern equine encephalitis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,United States,Validated,Center for Diseases Control and Prevention 1989-1996[INST]
11588,83594,Eastern equine encephalitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11589,83595,Colorado tick fever,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11590,83597,Acute disseminated encephalomyelitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.6,Europe,Validated,[EXPERT]
11590,83597,Acute disseminated encephalomyelitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
11591,83600,Encephalitis lethargica,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
11584,83482,Mycoplasma encephalitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11585,83483,La Crosse encephalitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.91,Canada,Validated,Canada Public Health Agency[INST]
11585,83483,La Crosse encephalitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11586,83484,St. Louis encephalitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.38,Europe,Not yet validated,ORPHANET
11586,83484,St. Louis encephalitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11587,83593,Western equine encephalitis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,United States,Validated,Center for Diseases Control and Prevention[INST]
11587,83593,Western equine encephalitis,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
11613,84085,Hinman syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11612,84081,Senior-Boichis syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11615,84090,Fibronectin glomerulopathy,Disease,Disorder,Cases/families,Family(ies),,16.0,Worldwide,Validated,ORPHANET
11615,84090,Fibronectin glomerulopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11605,84064,Syndromic diarrhea,Disease,Disorder,Cases/families,Case(s),,116.0,Worldwide,Validated,[EXPERT]_29527791[PMID]_29868001[PMID]_30397475[PMID]
11605,84064,Syndromic diarrhea,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_[EXPERT]_30397475[PMID]
11605,84064,Syndromic diarrhea,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.1,France,Validated,23302111[PMID]
27024,513436,Autosomal recessive spastic paraplegia type 78,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,28137957[PMID]_29112700[PMID]_27217339[PMID]
27024,513436,Autosomal recessive spastic paraplegia type 78,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29112700[PMID]
11601,83639,Hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency,Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,16767100[PMID]
11601,83639,Hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16767100[PMID]
11600,83629,Leukoencephalopathy-spondyloepimetaphyseal dysplasia syndrome,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,16924009[PMID]_10486082[PMID]_27102849[PMID]
11600,83629,Leukoencephalopathy-spondyloepimetaphyseal dysplasia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16924009[PMID]_10486082[PMID]_27102849[PMID]
27025,513456,Intellectual disability-seizures-abnormal gait-facial dysmorphism syndrome,Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,28686853[PMID]
27025,513456,Intellectual disability-seizures-abnormal gait-facial dysmorphism syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28686853[PMID]
11602,83642,Microcytic anemia with liver iron overload,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,16439678[PMID]
11602,83642,Microcytic anemia with liver iron overload,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16439678[PMID]
11630,85163,Hypomyelination-congenital cataract syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,ORPHANET
11630,85163,Hypomyelination-congenital cataract syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11631,85164,Camptodactyly-tall stature-scoliosis-hearing loss syndrome,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,ORPHANET
11631,85164,Camptodactyly-tall stature-scoliosis-hearing loss syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11628,85146,"Neurogenic scapuloperoneal syndrome, Kaeser type",Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,17439987[PMID]
11628,85146,"Neurogenic scapuloperoneal syndrome, Kaeser type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17439987[PMID]
11629,85162,Facial onset sensory and motor neuronopathy,Disease,Disorder,Cases/families,Case(s),,47.0,Worldwide,Validated,29781209[PMID]
11629,85162,Facial onset sensory and motor neuronopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29781209[PMID]
11626,85138,Addison disease,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,54.0,Specific population,Validated,12788587[PMID]
11626,85138,Addison disease,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,12.5,Europe,Validated,21164269[PMID]_12788587[PMID]_ [EXPERT]
11626,85138,Addison disease,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,14.0,Norway,Validated,12072049[PMID]
11626,85138,Addison disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,9.3,United Kingdom,Validated,919670[PMID]
11624,85128,Bothnia retinal dystrophy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_10102298[PMID]
11625,85136,Cystic leukoencephalopathy without megalencephaly,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,[EXPERT]
11625,85136,Cystic leukoencephalopathy without megalencephaly,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11622,85110,Familial encephalopathy with neuroserpin inclusion bodies,Disease,Disorder,Cases/families,Family(ies),,6.0,Worldwide,Validated,18591508[PMID]
11622,85110,Familial encephalopathy with neuroserpin inclusion bodies,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18591508[PMID]
11623,85112,Palmoplantar keratoderma-XX sex reversal-predisposition to squamous cell carcinoma syndrome,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,16227098[PMID]_10733237[PMID]
11623,85112,Palmoplantar keratoderma-XX sex reversal-predisposition to squamous cell carcinoma syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16227098[PMID]_10733237[PMID]
11618,84132,Desmin-related myopathy with Mallory body-like inclusions,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,PMID: 7224095 & 15122708
11618,84132,Desmin-related myopathy with Mallory body-like inclusions,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET; PMID: 7224095 & 15122708
11619,84142,Isaacs syndrome,Disease,Disorder,Cases/families,Case(s),,150.0,Worldwide,Validated,[EXPERT]
11619,84142,Isaacs syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11616,84093,Hereditary thermosensitive neuropathy,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,9191787[PMID]
11616,84093,Hereditary thermosensitive neuropathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9191787[PMID]
11647,85186,Endosteal sclerosis-cerebellar hypoplasia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,15672385[PMID]
11647,85186,Endosteal sclerosis-cerebellar hypoplasia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15672385[PMID]
11646,85184,"Craniometadiaphyseal dysplasia, wormian bone type",Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,20684007[PMID]
11646,85184,"Craniometadiaphyseal dysplasia, wormian bone type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20684007[PMID]
11644,85179,Infantile osteopetrosis with neuroaxonal dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
11642,85175,Astley-Kendall dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,9643294[PMID]
11642,85175,Astley-Kendall dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9643294[PMID]
11641,85174,Pseudodiastrophic dysplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,26754439[PMID]
11641,85174,Pseudodiastrophic dysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26754439[PMID]
11640,85173,IMAGe syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,28.0,Worldwide,Validated,24624461[PMID]
11640,85173,IMAGe syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24624461[PMID]
11639,85172,"Microcephalic osteodysplastic dysplasia, Saul-Wilson type",Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,8074143[PMID]
11639,85172,"Microcephalic osteodysplastic dysplasia, Saul-Wilson type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8074143[PMID]
11637,85170,"Mesomelic dysplasia, Savarirayan type",Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11636,85169,Familial digital arthropathy-brachydactyly,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11635,85168,Craniofacial conodysplasia,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,7593576[PMID]
11635,85168,Craniofacial conodysplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7593576[PMID]
11634,85167,Spondylometaphyseal dysplasia-cone-rod dystrophy syndrome,Disease,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,24387990[PMID]
11634,85167,Spondylometaphyseal dysplasia-cone-rod dystrophy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
11633,85166,"Platyspondylic dysplasia, Torrance type",Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
11632,85165,Severe achondroplasia-developmental delay-acanthosis nigricans syndrome,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,10053006[PMID]_18076102[PMID]
11632,85165,Severe achondroplasia-developmental delay-acanthosis nigricans syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10053006[PMID]_18076102[PMID]
30613,603448,Cerebellar hypoplasia-intellectual disability-congenital microcephaly-dystonia-anemia-growth retardation syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,33186543[PMID]_33186545[PMID]_33460484[PMID]
30613,603448,Cerebellar hypoplasia-intellectual disability-congenital microcephaly-dystonia-anemia-growth retardation syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,33186543[PMID]_33186545[PMID]_33460484[PMID]_ORPHANET
30615,603515,Isolated female hypospadias,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,31105404[PMID]
30614,603494,Coloboma-osteopetrosis-microphthalmia-macrocephaly-albinism-deafness syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,27889061[PMID]
30614,603494,Coloboma-osteopetrosis-microphthalmia-macrocephaly-albinism-deafness syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,27889061[PMID]_ORPHANET
30617,603689,KLHL7-related Bohring-Opitz-like syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,29074562[PMID]_31953236[PMID]
30617,603689,KLHL7-related Bohring-Opitz-like syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,29074562[PMID]_31953236[PMID]_ORPHANET
30616,603684,KLHL7-related Bohring-Opitz-like and Crisponi/Cold-induced sweating-like overlap syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,30300710[PMID]_30142437[PMID]
30616,603684,KLHL7-related Bohring-Opitz-like and Crisponi/Cold-induced sweating-like overlap syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,30300710[PMID]_30142437[PMID]_ORPHANET
30684,610573,CLCN6-related childhood-onset progressive neurodegeneration-peripheral neuropathy syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,33217309[PMID]
30684,610573,CLCN6-related childhood-onset progressive neurodegeneration-peripheral neuropathy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,33217309[PMID]_ORPHANET
30683,610569,KIAA1109-related early lethal congenital brain malformations-arthrogryposis syndrome,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,29290337[PMID]
30683,610569,KIAA1109-related early lethal congenital brain malformations-arthrogryposis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,29290337[PMID]_ORPHANET
30663,604680,Symptomatic form of X-linked centronuclear myopathy in female carriers,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,28685322[PMID]_34011573[PMID]_ORPHANET
30663,604680,Symptomatic form of X-linked centronuclear myopathy in female carriers,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,28685322[PMID]_34011573[PMID]_ORPHANET
30694,611256,Pontocerebellar hypoplasia type 12,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,30089828[PMID]
30694,611256,Pontocerebellar hypoplasia type 12,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,30089828[PMID]_ORPHANET
30692,611237,Parkinsonism with polyneuropathy,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,33141179[PMID]
30692,611237,Parkinsonism with polyneuropathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,33141179[PMID]_ORPHANET
30693,611247,Pontocerebellar hypoplasia type 11,Malformation syndrome,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,28823707[PMID]_28823706[PMID]
30693,611247,Pontocerebellar hypoplasia type 11,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,28823707[PMID]_28823706[PMID]_ORPHANET
30690,611216,Aplastic anemia-intellectual disability-dwarfism syndrome,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,33355142[PMID]
30690,611216,Aplastic anemia-intellectual disability-dwarfism syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,33355142[PMID]_ORPHANET
30691,611223,EN1-related dorsoventral syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,33568816[PMID]
30691,611223,EN1-related dorsoventral syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,33568816[PMID]_ORPHANET
30688,611201,Oculogastrointestinal-neurodevelopmental syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,32885237[PMID]_33410501[PMID]
30688,611201,Oculogastrointestinal-neurodevelopmental syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,32885237[PMID]_33410501[PMID]_ORPHANET
30702,613267,Pontocerebellar hypoplasia type 13,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,30624672[PMID]_31207318[PMID]
30702,613267,Pontocerebellar hypoplasia type 13,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,30624672[PMID]_31207318[PMID]_ORPHANET
13103,98085,"46,XY difference of sex development",Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.06,Denmark,Validated,27603905[PMID]
13103,98085,"46,XY difference of sex development",Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,6.4,Denmark,Validated,27603905[PMID]
30703,613274,Pontocerebellar hypoplasia type 14,Malformation syndrome,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,33220177[PMID]
30703,613274,Pontocerebellar hypoplasia type 14,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,33220177[PMID]_ORPHANET
13266,98249,Ehlers-Danlos syndrome,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 1 000 000,0.9,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
13266,98249,Ehlers-Danlos syndrome,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
30475,600668,CCNK-related neurodevelopmental disorder-severe intellectual disability-facial dysmorphism syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,30122539[PMID]
30475,600668,CCNK-related neurodevelopmental disorder-severe intellectual disability-facial dysmorphism syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,30122539[PMID]_ORPHANET
30474,600663,NRXN1-related severe neurodevelopmental disorder-motor stereotypies-chronic constipation-sleep-wake cycle disturbance,Malformation syndrome,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,30873608[PMID]
30474,600663,NRXN1-related severe neurodevelopmental disorder-motor stereotypies-chronic constipation-sleep-wake cycle disturbance,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,30873608[PMID]_ORPHANET
30477,600691,Combined deficiency of factor VII and factor X,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,28164683[PMID]
30477,600691,Combined deficiency of factor VII and factor X,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,28164683[PMID]_ORPHANET
30478,600731,Clark-Baraitser syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,ORPHANET
30478,600731,Clark-Baraitser syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
13304,98287,Histiocytic and dendritic cell tumor,Category,Group of disorders,Annual incidence,Value and class,<1 / 1 000 000,0.05,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
13310,98293,Hodgkin lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.4,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
13310,98293,Hodgkin lymphoma,Clinical group,Group of disorders,Lifetime Prevalence,Value and class,1-5 / 10 000,46.9,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
13310,98293,Hodgkin lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.8,United States,Validated,National Cancer Institute 2008[INST]_22835602[PMID]
13310,98293,Hodgkin lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.25,Japan,Not yet validated,emedicine[OTHER]
13310,98293,Hodgkin lymphoma,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.25,China,Not yet validated,emedicine[OTHER]
13309,98292,Mastocytosis,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,3.0,Europe,Validated,European Medicines Agency 2018[INST]
13309,98292,Mastocytosis,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,9.59,Denmark,Validated,24761987[PMID]
13309,98292,Mastocytosis,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,10.0,Worldwide,Validated,[EXPERT]_24745674[PMID]
13291,98274,Myeloproliferative neoplasm,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.07,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
13294,98277,Acute myeloid leukemia with recurrent genetic anomaly,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.11,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
13292,98275,Myelodysplastic/myeloproliferative disease,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.29,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
13284,98267,Genetic non-syndromic obesity,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
13284,98267,Genetic non-syndromic obesity,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
30552,601028,Non-syndromic anorectal malformation with rectovaginal fistula,Morphological anomaly,Disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
30552,601028,Non-syndromic anorectal malformation with rectovaginal fistula,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
30553,601033,Non-syndromic anorectal malformation with H-type fistula,Morphological anomaly,Disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
30553,601033,Non-syndromic anorectal malformation with H-type fistula,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
30548,601008,Non-syndromic anorectal malformation with anal stenosis,Morphological anomaly,Disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
30548,601008,Non-syndromic anorectal malformation with anal stenosis,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
30549,601013,Non-syndromic anorectal malformation with pouch colon,Morphological anomaly,Disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
30549,601013,Non-syndromic anorectal malformation with pouch colon,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
30550,601018,Non-syndromic anorectal malformation with rectal atresia,Morphological anomaly,Disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
30550,601018,Non-syndromic anorectal malformation with rectal atresia,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
30551,601023,Non-syndromic anorectal malformation with rectal stenosis,Morphological anomaly,Disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
30551,601023,Non-syndromic anorectal malformation with rectal stenosis,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
30544,600984,Non-syndromic anorectal malformation with rectovesical fistula,Morphological anomaly,Disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
30544,600984,Non-syndromic anorectal malformation with rectovesical fistula,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
30545,600993,Non-syndromic anorectal malformation with vestibular fistula,Morphological anomaly,Disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
30545,600993,Non-syndromic anorectal malformation with vestibular fistula,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
30546,600998,Non-syndromic cloacal malformation,Morphological anomaly,Disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
30546,600998,Non-syndromic cloacal malformation,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
30547,601002,Non-syndromic anorectal malformation without fistula,Morphological anomaly,Disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
30547,601002,Non-syndromic anorectal malformation without fistula,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
30541,600961,Non-syndromic anorectal malformation with rectourethral fistula,Morphological anomaly,Disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
30541,600961,Non-syndromic anorectal malformation with rectourethral fistula,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
30540,600952,Non-syndromic anorectal malformation with perineal fistula,Morphological anomaly,Disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
30540,600952,Non-syndromic anorectal malformation with perineal fistula,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
12867,97245,Congenital myopathy,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,3.8,United States,Validated,22028225[PMID]
12866,97244,Rigid spine syndrome,Disease,Disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
12866,97244,Rigid spine syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
12866,97244,Rigid spine syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.13,United Kingdom,Validated,19767415[PMID]
12865,97242,Congenital muscular dystrophy,Category,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET
12865,97242,Congenital muscular dystrophy,Category,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.563,Italy,Validated,25653289[PMID]
12871,97261,GRFoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
12870,97253,Neuroendocrine tumor of pancreas,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.22,United States,Validated,18515795[PMID]_National Cancer Institute[INST]
12870,97253,Neuroendocrine tumor of pancreas,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,1.27,Japan,Validated,24499825[PMID]
12870,97253,Neuroendocrine tumor of pancreas,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,2.69,Japan,Validated,24499825[PMID]
12870,97253,Neuroendocrine tumor of pancreas,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.21,France,Validated,15016750[PMID]
12870,97253,Neuroendocrine tumor of pancreas,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.21,Europe,Validated,15016750[PMID]
12870,97253,Neuroendocrine tumor of pancreas,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,27.5,United States,Validated,23237225[PMID]_[EXPERT]
12870,97253,Neuroendocrine tumor of pancreas,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET
12868,97249,Pontocerebellar hypoplasia type 3,Malformation syndrome,Disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,[EXPERT]
12868,97249,Pontocerebellar hypoplasia type 3,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12875,97279,Insulinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Ireland,Validated,2575263[PMID]
12875,97279,Insulinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.25,Worldwide,Validated,23430217[PMID]
12875,97279,Insulinoma,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.56,Japan,Validated,24499825[PMID]
12875,97279,Insulinoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
12874,97278,PPoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
12879,97285,Thyroid lymphoma,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Not yet validated,23714679[PMID]
12878,97283,Somatostatinoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.0025,Europe,Validated,[EXPERT]_17645474[PMID]
12878,97283,Somatostatinoma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,ORPHANET
12877,97282,VIPoma,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,[EXPERT]
12877,97282,VIPoma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,ORPHANET
12876,97280,Glucagonoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,Europe,Validated,9113318[PMID]
12876,97280,Glucagonoma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,ORPHANET
12883,97290,Familial papillary thyroid carcinoma with renal papillary neoplasia,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,10843148[PMID]
12880,97286,Carney-Stratakis syndrome,Disease,Disorder,Cases/families,Family(ies),,20.0,Worldwide,Validated,ORPHANET
12880,97286,Carney-Stratakis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12885,97292,Cardiogenic shock,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,40.0,Europe,Validated,European Medicines Agency 2008[INST]
12891,97335,Osgood-Schlatter disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12888,97297,Bohring-Opitz syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,46.0,Worldwide,Validated,29446906[PMID]
12888,97297,Bohring-Opitz syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12889,97330,Thoracic outlet syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12895,97339,Dural sinus malformation,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12892,97336,Panner disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12893,97337,Sinding-Larsen-Johansson disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12897,97341,Persistent placoid maculopathy,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,17471331[PMID]_[EXPERT]
12897,97341,Persistent placoid maculopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12896,97340,Hunter-McAlpine syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,[EXPERT]
12896,97340,Hunter-McAlpine syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12911,97360,Robinow syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,[EXPERT]
12911,97360,Robinow syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
12910,97355,Caribbean parkinsonism,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12912,97361,"Renal hypoplasia, unilateral",Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
12913,97362,"Renal hypoplasia, bilateral",Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
12914,97363,Unilateral multicystic dysplastic kidney,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-5 / 10 000,23.2,Worldwide,Validated,19171687[PMID]_[EXPERT]
12914,97363,Unilateral multicystic dysplastic kidney,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-5 / 10 000,14.8,Europe,Validated,16053904[PMID]_[EXPERT]
12914,97363,Unilateral multicystic dysplastic kidney,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-5 / 10 000,45.4,United Kingdom,Validated,18278521[PMID]
12914,97363,Unilateral multicystic dysplastic kidney,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-5 / 10 000,25.0,Japan,Validated,11967035[PMID]
12914,97363,Unilateral multicystic dysplastic kidney,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,>1 / 1000,108.0,Saudi Arabia,Validated,12415373[PMID]
12914,97363,Unilateral multicystic dysplastic kidney,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-5 / 10 000,24.4,Finland,Validated,12532949[PMID]
12914,97363,Unilateral multicystic dysplastic kidney,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-5 / 10 000,41.0,United States,Validated,7776710[PMID]
12914,97363,Unilateral multicystic dysplastic kidney,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,6-9 / 10 000,60.3,Switzerland,Validated,11683078[PMID]
12914,97363,Unilateral multicystic dysplastic kidney,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET_[EXPERT]
12915,97364,Bilateral multicystic dysplastic kidney,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
12922,97548,Right sided atrial isomerism,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,France,Validated,9562017[PMID]_25752370[PMID]_34631807[PMID]_ORPHANET
12922,97548,Right sided atrial isomerism,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,16.67,France,Validated,8308205[PMID]
12927,97560,Primary membranous glomerulonephritis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.8103,Worldwide,Validated,21068142[PMID]_ORPHANET
12927,97560,Primary membranous glomerulonephritis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.9194,Europe,Validated,21068142[PMID]_ORPHANET
12927,97560,Primary membranous glomerulonephritis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,21068142[PMID]_34593809[PMID]_ORPHANET
12805,96181,Maternal uniparental disomy of chromosome 6 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,27922284[PMID]
12805,96181,Maternal uniparental disomy of chromosome 6 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27922284[PMID]
12802,96178,Ring chromosome 16 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,23705081[PMID]
12802,96178,Ring chromosome 16 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23705081[PMID]
12801,96177,Ring chromosome 15 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,16267671[PMID]
12801,96177,Ring chromosome 15 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16267671[PMID]
12800,96176,Ring chromosome 13 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.72,United Kingdom,Validated,7129419[PMID]
12812,96188,Maternal uniparental disomy of chromosome 22 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,ISBN:978-3-642-55287-8[OTHER]
12812,96188,Maternal uniparental disomy of chromosome 22 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_ISBN:978-3-642-55287-8[OTHER]
12811,96187,Maternal uniparental disomy of chromosome 21 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,ISBN:978-3-642-55287-8[OTHER]
12811,96187,Maternal uniparental disomy of chromosome 21 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_ISBN:978-3-642-55287-8[OTHER]
12810,96186,Maternal uniparental disomy of chromosome 20 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,26248010[PMID]
12810,96186,Maternal uniparental disomy of chromosome 20 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26248010[PMID]
12808,96184,Temple syndrome due to maternal uniparental disomy of chromosome 14,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,64.0,Worldwide,Validated,28640239[PMID]_24891339[PMID]
12808,96184,Temple syndrome due to maternal uniparental disomy of chromosome 14,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28640239[PMID]_24891339[PMID]
12816,96192,Paternal uniparental disomy of chromosome 7 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,17935233[PMID]
12816,96192,Paternal uniparental disomy of chromosome 7 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17935233[PMID]
12827,96253,Cushing disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.0,Europe,Validated,European Medicines Agency[INST]
12827,96253,Cushing disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.2,Europe,Not yet validated,22710101[PMID]
12833,96264,"49,XXXXY syndrome",Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.55,Europe,Validated,7567329[PMID]_[EXPERT]_ ORPHANET
12833,96264,"49,XXXXY syndrome",Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12832,96263,"48,XXXY syndrome",Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Europe,Validated,[EXPERT]
12832,96263,"48,XXXY syndrome",Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,[EXPERT]_ORPHANET
12843,96334,Kagami-Ogata syndrome due to paternal uniparental disomy of chromosome 14,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26377239[PMID]
12843,96334,Kagami-Ogata syndrome due to paternal uniparental disomy of chromosome 14,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,37.0,Worldwide,Validated,26377239[PMID]
12855,97214,Eisenmenger syndrome,Malformation syndrome,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2,Belgium,Validated,19725436[PMID]
12855,97214,Eisenmenger syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,ORPHANET
12860,97234,Glycogen storage disease due to phosphoglycerate mutase deficiency,Disease,Disorder,Cases/families,Case(s),,24.0,Worldwide,Validated,34237446[PMID]_ORPHANET
12860,97234,Glycogen storage disease due to phosphoglycerate mutase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,34237446[PMID]_ORPHANET
12862,97239,Reducing body myopathy,Disease,Disorder,Cases/families,Family(ies),,4.0,Worldwide,Validated,ORPHANET
12862,97239,Reducing body myopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12863,97240,Zebra body myopathy,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,[EXPERT]
12863,97240,Zebra body myopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12856,97229,Riboflavin transporter deficiency,Malformation syndrome,Disorder,Cases/families,Case(s),,109.0,Worldwide,Validated,30793323[PMID]_[EXPERT]
12856,97229,Riboflavin transporter deficiency,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30793323[PMID]
12857,97230,Solar urticaria,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.1,United Kingdom,Validated,12975156[PMID]_[EXPERT]
12857,97230,Solar urticaria,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_30585308[PMID]_27793344[PMID]_[EXPERT]
12859,97232,Fingerprint body myopathy,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,[EXPERT]
12859,97232,Fingerprint body myopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
30241,600194,Factor V Atlanta bleeding disorder,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,33773040[PMID]
30241,600194,Factor V Atlanta bleeding disorder,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,33773040[PMID]_ORPHANET
12942,97678,Maternal uniparental disomy of chromosome 13 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,ISBN:978-3-642-55287-8[OTHER]
12942,97678,Maternal uniparental disomy of chromosome 13 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_ISBN:978-3-642-55287-8[OTHER]
12935,97593,Pseudohypoparathyroidism,Category,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.67,Italy,Validated,[EXPERT]
12935,97593,Pseudohypoparathyroidism,Category,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.34,Japan,Validated,10695258[PMID]
12935,97593,Pseudohypoparathyroidism,Category,Group of disorders,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,ORPHANET_[EXPERT]
12930,97564,Pauci-immune glomerulonephritis without ANCA,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_Dr Laure-Hélène NOEL[EXPERT]
12929,97563,Pauci-immune glomerulonephritis with ANCA,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_Dr Laure-Hélène NOEL[EXPERT]
12945,97685,17q11 microdeletion syndrome,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,170.0,Worldwide,Validated,16467218[PMID]
12945,97685,17q11 microdeletion syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
12662,95707,Idiopathic isolated micropenis,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_21527236[PMID]
12661,95706,Non-syndromic posterior hypospadias,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,19.25,Europe,Validated,25712311[PMID]_26810252[PMID]
12661,95706,Non-syndromic posterior hypospadias,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
12657,95702,X-linked adrenal hypoplasia congenita,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.0,Worldwide,Validated,20301604[PMID]_ORPHANET
12657,95702,X-linked adrenal hypoplasia congenita,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,8.0,Worldwide,Validated,20301604[PMID]
12670,95715,Congenital hypothyroidism due to transplacental passage of TSH-binding inhibitory antibodies,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,[EXPERT]
12671,95716,Familial thyroid dyshormonogenesis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.67,Worldwide,Validated,[EXPERT]_emedicine[OTHER]
12671,95716,Familial thyroid dyshormonogenesis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.0,Europe,Validated,[EXPERT]
12671,95716,Familial thyroid dyshormonogenesis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.0,Finland,Validated,2919526[PMID]
12668,95713,Athyreosis,Morphological anomaly,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.5,Europe,Validated,[EXPERT]
12669,95714,Primary congenital hypothyroidism without thyroid developmental anomaly,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12666,95711,Congenital hypothyroidism due to developmental anomaly,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,21.3,Europe,Validated,[EXPERT]
12667,95712,Thyroid ectopia,Morphological anomaly,Disorder,Point prevalence,Value and class,1-5 / 10 000,14.3,Europe,Validated,[EXPERT]
12640,95613,Pituitary apoplexy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12655,95700,Familial adrenal hypoplasia with absent pituitary luteinizing hormone,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,2906226[PMID]
12655,95700,Familial adrenal hypoplasia with absent pituitary luteinizing hormone,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2906226[PMID]
12654,95699,Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.75,Europe,Validated,[EXPERT]
12654,95699,Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12650,95626,Acquired arginine vasopressin deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12630,95506,Primary hypophysitis,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12620,95496,Pituitary stalk interruption syndrome,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12618,95494,"Combined pituitary hormone deficiencies, genetic forms",Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12592,95433,Autosomal recessive spinocerebellar ataxia-blindness-deafness syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,11175288[PMID]_4154794[PMID]
12592,95433,Autosomal recessive spinocerebellar ataxia-blindness-deafness syndrome,Disease,Disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,ORPHANET_11175288[PMID]_4154794[PMID]
12593,95434,Autosomal recessive cerebellar ataxia-movement disorder syndrome,Disease,Disorder,Cases/families,Case(s),,27.0,Worldwide,Validated,29518282[PMID]_29604224[PMID]_31876103[PMID]
12593,95434,Autosomal recessive cerebellar ataxia-movement disorder syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,29518282[PMID]_29604224[PMID]_31876103[PMID]_ORPHANET
12597,95455,Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.19,Worldwide,Not yet validated,21162721[PMID]
12597,95455,Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12597,95455,Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.8,"Taiwan, Province of China",Validated,15057820[PMID]
12597,95455,Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.189,Germany,Validated,15057820[PMID]
12597,95455,Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.19,United States,Not yet validated,ORPHANET
12578,95157,Acute hepatic porphyria,Clinical group,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET
12580,95159,Hepatoerythropoietic porphyria,Disease,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,[EXPERT]
12580,95159,Hepatoerythropoietic porphyria,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12587,95428,COG8-CDG,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,17331980[PMID]_17220172[PMID]
12587,95428,COG8-CDG,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17331980[PMID]_17220172[PMID]
12586,95427,Secondary short bowel syndrome,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,30725620[PMID]_ORPHANET
12586,95427,Secondary short bowel syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,30725620[PMID]_ORPHANET
12584,95409,Acute adrenal insufficiency,Clinical syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12591,95432,Primary progressive aphasia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,7.0,Worldwide,Not yet validated,24108322[PMID]
12589,95430,Congenital tracheomalacia,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
12588,95429,Angioma serpiginosum,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
12560,94091,Mills syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.12,United Kingdom,Validated,30631918[PMID]
12561,94093,Neuroleptic malignant syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
12563,94122,"Cerebellar ataxia, Cayman type",Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12564,94124,Spinocerebellar ataxia with axonal neuropathy type 1,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12244316[PMID]
12564,94124,Spinocerebellar ataxia with axonal neuropathy type 1,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,12244316[PMID]
12566,94145,Autosomal dominant cerebellar ataxia type I,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12567,94147,Spinocerebellar ataxia type 7,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Worldwide,Validated,24374739[PMID]
12568,94148,Autosomal dominant cerebellar ataxia type III,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,24225362[PMID]
12545,94064,Deafness-infertility syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,26011646[PMID]
12545,94064,Deafness-infertility syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26011646[PMID]
12544,94063,12q14 microdeletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,28407409[PMID]_29501611[PMID]
12544,94063,12q14 microdeletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28407409[PMID]_29501611[PMID]
12547,94066,Severe intellectual disability-epilepsy-anal anomalies-distal phalangeal hypoplasia,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,17351347[PMID]
12547,94066,Severe intellectual disability-epilepsy-anal anomalies-distal phalangeal hypoplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17351347[PMID]
12546,94065,15q24 microdeletion syndrome,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,22359776[PMID]
12546,94065,15q24 microdeletion syndrome,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22359776[PMID]
12548,94068,Spondyloepiphyseal dysplasia congenita,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Europe,Validated,[EXPERT]
12548,94068,Spondyloepiphyseal dysplasia congenita,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12553,94083,Partington syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,3177452[PMID]_12376949[PMID]
12553,94083,Partington syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3177452[PMID]_12376949[PMID]
12555,94086,Blue diaper syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12557,94088,Hereditary renal hypouricemia,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
12556,94087,Cytophagic histiocytic panniculitis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12556,94087,Cytophagic histiocytic panniculitis,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,ORPHANET
12559,94090,Pseudohypoparathyroidism type 2,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
12558,94089,Pseudohypoparathyroidism type 1B,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
12799,96175,Ring chromosome 11 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,26576288[PMID]
12799,96175,Ring chromosome 11 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26576288[PMID]
12797,96173,Ring chromosome 9 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,31.0,Worldwide,Validated,25722017[PMID]
12797,96173,Ring chromosome 9 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25722017[PMID]
12796,96172,Ring chromosome 3 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,11491310[PMID]_27984612[PMID]
12796,96172,Ring chromosome 3 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11491310[PMID]_27984612[PMID]
12795,96171,Ring chromosome 2 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,25997743[PMID]
12795,96171,Ring chromosome 2 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25997743[PMID]
12794,96170,Emanuel syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,350.0,Worldwide,Validated,26076791[PMID]_20301440[PMID]
12794,96170,Emanuel syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_26076791[PMID]_20301440[PMID]
12793,96169,Koolen-De Vries syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]_26306646[PMID]
12792,96168,Monosomy 13q34 syndrome,Malformation syndrome,Disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
12792,96168,Monosomy 13q34 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
12791,96167,Recombinant 8 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12772,96148,Distal deletion 10q syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,ORPHANET
12772,96148,Distal deletion 10q syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12771,96147,Kleefstra syndrome due to 9q34 microdeletion,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,86.0,Worldwide,Validated,22670141[PMID]
12771,96147,Kleefstra syndrome due to 9q34 microdeletion,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12749,96125,Distal deletion 6p syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,35.0,Worldwide,Validated,23686687[PMID]
12749,96125,Distal deletion 6p syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12745,96121,7q11.23 microduplication syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,163.0,Worldwide,Validated,27617154[PMID]
12745,96121,7q11.23 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_27617154[PMID]
12726,96102,Distal duplication 10q syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,ORPHANET
12726,96102,Distal duplication 10q syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12719,96095,3q26 microduplication syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,27549440[PMID]
12719,96095,3q26 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27549440[PMID]
12716,96092,8p inverted duplication/deletion syndrome,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.9,Italy,Validated,11231899[PMID]
12716,96092,8p inverted duplication/deletion syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,[EXPERT]
12716,96092,8p inverted duplication/deletion syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,[EXPERT]_ORPHANET
12702,96078,16p13.3 microduplication syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,27.0,Worldwide,Validated,26873618[PMID]
12702,96078,16p13.3 microduplication syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26873618[PMID]
12685,96061,Mosaic trisomy 8 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
12672,95717,Idiopathic congenital hypothyroidism,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12674,95719,Thyroid hemiagenesis,Morphological anomaly,Disorder,Point prevalence,Value and class,1-5 / 10 000,25.0,Worldwide,Not yet validated,19016002[PMID]
12675,95720,Thyroid hypoplasia,Morphological anomaly,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.5,Worldwide,Validated,[EXPERT]
12679,96055,Tetrasomy 21 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,18372039[PMID]
12679,96055,Tetrasomy 21 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18372039[PMID]
29860,597623,IRF2BPL-related regressive neurodevelopmental disorder-dystonia-seizures syndrome,Disease,Disorder,Cases/families,Case(s),,19.0,Worldwide,Validated,31432588[PMID]
29860,597623,IRF2BPL-related regressive neurodevelopmental disorder-dystonia-seizures syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,31432588[PMID]_ORPHANET
29862,597733,Oculocutaneous albinism type 8,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,33100333[PMID]
29862,597733,Oculocutaneous albinism type 8,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,33100333[PMID]
29863,597738,Luscan-Lumish syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,31643139[PMID]_33248444[PMID]
29863,597738,Luscan-Lumish syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,31643139[PMID]_33248444[PMID]
29868,597887,ALPI-related inflammatory bowel disease,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,29567797[PMID]
29868,597887,ALPI-related inflammatory bowel disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,29567797[PMID]_ORPHANET
12397,93555,Mixed cryoglobulinemia type III,Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12396,93554,Mixed cryoglobulinemia type II,Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
29871,597939,Euthyroid dysprealbuminemic hyperthyroxinemia,Disease,Disorder,Cases/families,Case(s),,23.0,Worldwide,Validated,8784093[PMID]_15833783[PMID]_1979335[PMID]_31590893[PMID]
29871,597939,Euthyroid dysprealbuminemic hyperthyroxinemia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,8784093[PMID]_15833783[PMID]_1979335[PMID]_31590893[PMID]_ORPHANET
29864,597743,SETD2-related microcephaly-severe intellectual disability-multiple congenital anomalies syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,32710489[PMID]
29864,597743,SETD2-related microcephaly-severe intellectual disability-multiple congenital anomalies syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,32710489[PMID]
29865,597746,Blepharophimosis-intellectual disability syndrome/genitopatellar overlap syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,122.0,Worldwide,Validated,32424177[PMID]
29865,597746,Blepharophimosis-intellectual disability syndrome/genitopatellar overlap syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,32424177[PMID]
12394,93552,Pediatric systemic lupus erythematosus,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.1,United States,Validated,34825516[PMID]
12394,93552,Pediatric systemic lupus erythematosus,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.7,United States,Validated,34825516[PMID]
29867,597874,MTHFS-related developmental delay-microcephaly-short stature-epilepsy syndrome,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,30031689[PMID]_31844630[PMID]
29867,597874,MTHFS-related developmental delay-microcephaly-short stature-epilepsy syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,30031689[PMID]_31844630[PMID]_ORPHANET
29876,598216,Upper tract urothelial carcinoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
29876,598216,Upper tract urothelial carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.5,Worldwide,Validated,28543959[PMID]_32593530[PMID]
29879,598603,Facial dysmorphism-hypertrichosis-epilepsy-intellectual disability/developmental delay-gingival overgrowth syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,30290154[PMID]_32981868[PMID]
29879,598603,Facial dysmorphism-hypertrichosis-epilepsy-intellectual disability/developmental delay-gingival overgrowth syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,30290154[PMID]_32981868[PMID]_ORPHANET
29878,598363,Multisystem inflammatory syndrome in children and adults,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,33640145[PMID]
29878,598363,Multisystem inflammatory syndrome in children and adults,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,33640145[PMID]
12403,93561,ALys amyloidosis,Clinical subtype,Subtype of disorder,Cases/families,Family(ies),,7.0,Worldwide,Validated,21988333[PMID]
12403,93561,ALys amyloidosis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21988333[PMID]
12413,93571,Dense deposit disease,Histopathological subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.25,Worldwide,Validated,20301598[PMID]
29831,597201,TRIM22-related inflammatory bowel disease,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,26836588[PMID]_32463623[PMID]
29831,597201,TRIM22-related inflammatory bowel disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,26836588[PMID]_32463623[PMID]_ORPHANET
12382,93474,Scheie syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2,Canada,Validated,4250044[PMID]_ORPHANET
12382,93474,Scheie syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.07,United Kingdom,Validated,18796143[PMID]_ORPHANET
12382,93474,Scheie syndrome,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.2,Canada,Validated,4250044[PMID]
12382,93474,Scheie syndrome,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.07,United Kingdom,Validated,18796143[PMID]
12383,93476,Hurler-Scheie syndrome,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.24,United Kingdom,Validated,18796143[PMID]
12383,93476,Hurler-Scheie syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,ORPHANET
12381,93473,Hurler syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,[EXPERT]
12381,93473,Hurler syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.76,United Kingdom,Validated,18796143[PMID]
12381,93473,Hurler syndrome,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.64,Germany,Validated,16435194[PMID]
12381,93473,Hurler syndrome,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.38,Denmark,Validated,18681890[PMID]
12381,93473,Hurler syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Denmark,Validated,18681890[PMID]
12381,93473,Hurler syndrome,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.05,Portugal,Validated,14685153[PMID]
12381,93473,Hurler syndrome,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.06,"Taiwan, Province of China",Validated,19396827[PMID]
12381,93473,Hurler syndrome,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.93,Australia,Validated,14608657[PMID]
12381,93473,Hurler syndrome,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.7,Europe,Validated,ORPHANET_16435194[PMID]_14685153[PMID]_18681890[PMID]_18796143[PMID]
12381,93473,Hurler syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,<1 / 1 000 000,0.07,United States,Validated,34051828[PMID]
12381,93473,Hurler syndrome,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.26,United States,Validated,34051828[PMID]
12320,93398,Genochondromatosis type 2,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,17632779[PMID]
12320,93398,Genochondromatosis type 2,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17632779[PMID]
29924,599373,STXBP1-related encephalopathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0885,Denmark,Validated,26865513[PMID]
29924,599373,STXBP1-related encephalopathy,Disease,Disorder,Cases/families,Case(s),,282.0,Worldwide,Validated,32643187[PMID]
29924,599373,STXBP1-related encephalopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
12325,93403,Syndactyly type 2,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
29925,599376,Hypomyelination of early myelinating structures,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,26125040[PMID]_33450882[PMID]
29925,599376,Hypomyelination of early myelinating structures,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,26125040[PMID]_33450882[PMID]_ORPHANET
12324,93402,Syndactyly type 1,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,25.0,Europe,Validated,[EXPERT]
12324,93402,Syndactyly type 1,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Validated,[EXPERT]
12327,93405,Syndactyly type 4,Morphological anomaly,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,22448207[PMID]
12327,93405,Syndactyly type 4,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22448207[PMID]
12326,93404,Syndactyly type 3,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
29927,599480,Acquired hemophilia A,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,36331704[PMID]_ORPHANET
29927,599480,Acquired hemophilia A,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1505,Europe,Validated,14675412[PMID]_17047148 [PMID]_32937680 [PMID]_36331704 [PMID]_37021783[PMID]
29927,599480,Acquired hemophilia A,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,United Kingdom,Validated,14675412[PMID]_17047148 [PMID]_ORPHANET
29927,599480,Acquired hemophilia A,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,0.141,United Kingdom,Validated,14675412[PMID]_17047148 [PMID]_ORPHANET
29927,599480,Acquired hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.3063,Spain,Validated,34521101[PMID]_ORPHANET
29927,599480,Acquired hemophilia A,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.0829,Spain,Validated,34521101[PMID]_ORPHANET
29927,599480,Acquired hemophilia A,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Germany,Validated,32937680[PMID]
29927,599480,Acquired hemophilia A,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.6,Germany,Validated,32937680[PMID]
29927,599480,Acquired hemophilia A,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Australia,Validated,20169513[PMID]
29927,599480,Acquired hemophilia A,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Australia,Validated,20169513[PMID]
29927,599480,Acquired hemophilia A,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Japan,Validated,28299631[PMID]_36331704[PMID]_ORPHANET
29927,599480,Acquired hemophilia A,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.097,Japan,Validated,28299631[PMID]_36331704[PMID]_ORPHANET
29927,599480,Acquired hemophilia A,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Switzerland,Validated,37021783[PMID]
29927,599480,Acquired hemophilia A,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.45,Switzerland,Validated,37021783[PMID]
29928,599485,Acquired hemophilia B,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
29928,599485,Acquired hemophilia B,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
12328,93406,Syndactyly type 5,Morphological anomaly,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,ORPHANET
12328,93406,Syndactyly type 5,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
29929,599490,Acquired factor V deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,27428013[PMID]_36713339[PMID]_ORPHANET
29929,599490,Acquired factor V deficiency,Disease,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,27428013[PMID]_36713339[PMID]_ORPHANET
29929,599490,Acquired factor V deficiency,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.029,Australia,Validated,15613918[PMID]
29929,599490,Acquired factor V deficiency,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.009,Singapore,Validated,19404538[PMID]
12331,93409,"Brachydactyly-syndactyly, Zhao type",Malformation syndrome,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,17236141[PMID]
12331,93409,"Brachydactyly-syndactyly, Zhao type",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17236141[PMID]
29930,599495,Acquired factor VII deficiency,Disease,Disorder,Cases/families,Case(s),,83.0,Worldwide,Validated,36546749[PMID]
29930,599495,Acquired factor VII deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,36546749[PMID]_ORPHANET
29931,599501,Acquired factor X deficiency,Disease,Disorder,Cases/families,Case(s),,77.0,Worldwide,Validated,37587057[PMID]
29931,599501,Acquired factor X deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,37587057[PMID]_ORPHANET
29932,599507,Acquired factor XI deficiency,Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,18519152[PMID]_29027258[PMID]
29932,599507,Acquired factor XI deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,18519152[PMID]_29027258[PMID]_ORPHANET
29933,599513,Acquired factor XIII deficiency,Disease,Disorder,Cases/families,Case(s),,95.0,Worldwide,Validated,30446212[PMID]
29933,599513,Acquired factor XIII deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,30446212[PMID]_ORPHANET
29934,599519,Factor V short isoforms-related bleeding disorder,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,25634741[PMID]_33773040[PMID]
29934,599519,Factor V short isoforms-related bleeding disorder,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,25634741[PMID]_33773040[PMID]_ORPHANET
12334,93420,FGFR3-related chondrodysplasia,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,8.1,United States,Validated,22461456[PMID]
29935,599579,Factor V Amsterdam bleeding disorder,Etiological subtype,Subtype of disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,25634741[PMID]
29935,599579,Factor V Amsterdam bleeding disorder,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,25634741[PMID]_ORPHANET
12291,93360,"Spondyloepimetaphyseal dysplasia with joint laxity, leptodactylic type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
12289,93358,Spondyloepimetaphyseal dysplasia-short limb-abnormal calcification syndrome,Disease,Disorder,Cases/families,Case(s),,27.0,Worldwide,Validated,26463668[PMID]
12289,93358,Spondyloepimetaphyseal dysplasia-short limb-abnormal calcification syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26463668[PMID]
12288,93357,SPONASTRIME dysplasia,Disease,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,18203204[PMID]
12288,93357,SPONASTRIME dysplasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18203204[PMID]
29899,599082,CHD3-related developmental delay-speech delay-intellectual disability-abnormalities of vision-facial dysmorphism syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,PMID: 30397230 ;  32483341 ;  34535214
29899,599082,CHD3-related developmental delay-speech delay-intellectual disability-abnormalities of vision-facial dysmorphism syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12300,93372,Familial hypocalciuric hypercalcemia type 1,Etiological subtype,Subtype of disorder,Point prevalence,Value and class,6-9 / 10 000,74.1,United States,Validated,32386559[PMID]
12300,93372,Familial hypocalciuric hypercalcemia type 1,Etiological subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,5.5,Worldwide,Validated,21986511[PMID]
12300,93372,Familial hypocalciuric hypercalcemia type 1,Etiological subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,1.3,United Kingdom,Validated,11353947[PMID]
12306,93382,Brachydactyly type A6,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,4073128[PMID]
12306,93382,Brachydactyly type A6,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_4073128[PMID]
12307,93383,Brachydactyly type B,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET_18554391[PMID]
12307,93383,Brachydactyly type B,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12310,93387,Brachydactyly type E,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET_18554391[PMID]
12311,93388,Brachydactyly type A1,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_18554391[PMID]
12308,93384,Brachydactyly type C,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET_18554391[PMID]
12318,93396,Brachydactyly type A2,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
12318,93396,Brachydactyly type A2,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_18554391[PMID]
12319,93397,Brachydactyly type A7,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,2714013[PMID]
12319,93397,Brachydactyly type A7,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_2714013[PMID]
12316,93394,Brachydactyly type A4,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_18554391[PMID]
29740,595356,Localized dystrophic epidermolysis bullosa,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,32017015[PMID]_ORPHANET
29740,595356,Localized dystrophic epidermolysis bullosa,Disease,Disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,32017015[PMID]_ORPHANET
12540,94059,Uremic pruritus,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,35.0,Europe,Validated,European Medicines Agency 2010[INST]
12539,94058,Neovascular glaucoma,Particular clinical situation in a disease or syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,24.4,Europe,Validated,European Medicines Agency 2003[INST]
12538,94056,Isolated humero-ulnar synostosis,Morphological anomaly,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,ORPHANET
12538,94056,Isolated humero-ulnar synostosis,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12534,93976,Anotia,Morphological anomaly,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.03,Specific population,Validated,16359491[PMID]
12534,93976,Anotia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.028,Europe,Not yet validated,ORPHANET
12534,93976,Anotia,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
12534,93976,Anotia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.04,France,Validated,8933331[PMID]
12534,93976,Anotia,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,France,Validated,8933331[PMID]
12534,93976,Anotia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.03,Italy,Validated,7666397[PMID]
12534,93976,Anotia,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Italy,Not yet validated,7666397[PMID]
12534,93976,Anotia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.02,Sweden,Validated,8933331[PMID]
12534,93976,Anotia,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Sweden,Validated,8933331[PMID]
12534,93976,Anotia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.02,United States,Validated,8933331[PMID]_19760683[PMID]
12534,93976,Anotia,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,United States,Validated,8933331[PMID]_19760683[PMID]
12534,93976,Anotia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.02,Finland,Validated,17548114[PMID]
12534,93976,Anotia,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Finland,Validated,17548114[PMID]
12534,93976,Anotia,Morphological anomaly,Disorder,Prevalence at birth,Value and class,<1 / 1 000 000,0.05,Chile,Validated,17186100[PMID]
12534,93976,Anotia,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Chile,Not yet validated,17186100[PMID]
12492,93932,FG syndrome type 1,Disease,Disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,17574621[PMID]_ORPHANET
12492,93932,FG syndrome type 1,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,17574621[PMID]_ORPHANET
12490,93930,Bladder exstrophy,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.8,Spain,Validated,11251990[PMID]
12490,93930,Bladder exstrophy,Clinical subtype,Subtype of disorder,Prevalence at birth,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
12490,93930,Bladder exstrophy,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
12490,93930,Bladder exstrophy,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.8,United States,Not yet validated,8013895[PMID]_15821570[PMID]_17990338[PMID]
12490,93930,Bladder exstrophy,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.05,Worldwide,Not yet validated,19878548[PMID]_ORPHANET
12488,93928,Isolated epispadias,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.4,Europe,Not yet validated,19878548[PMID]
12488,93928,Isolated epispadias,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,19878548[PMID]
12489,93929,Cloacal exstrophy,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.75,Europe,Not yet validated,19878548[PMID]
12489,93929,Cloacal exstrophy,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,19878548[PMID]
12489,93929,Cloacal exstrophy,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.6,United States,Validated,17990338[PMID]
12489,93929,Cloacal exstrophy,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Spain,Validated,11251990[PMID]
12489,93929,Cloacal exstrophy,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.54,Worldwide,Not yet validated,22002951[PMID]
12486,93926,Midline interhemispheric variant of holoprosencephaly,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,31063520[PMID]_ORPHANET
12486,93926,Midline interhemispheric variant of holoprosencephaly,Clinical subtype,Subtype of disorder,Prevalence at birth,Class only,1-9 / 100 000,0.0,Worldwide,Validated,31063520[PMID]_ORPHANET
12486,93926,Midline interhemispheric variant of holoprosencephaly,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.778,Romania,Validated,31063520[PMID]
12484,93924,Lobar holoprosencephaly,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
12485,93925,Alobar holoprosencephaly,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
12482,93921,Full schwannomatosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET_ISBN:3211695001[OTHER]
12482,93921,Full schwannomatosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.058,Finland,Validated,ISBN:3211695001[OTHER]_10636128[PMID]
12511,93953,Familial thyroglossal duct cyst,Morphological anomaly,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,16012840[PMID]_19344886[PMID]_17457484[PMID]
12511,93953,Familial thyroglossal duct cyst,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16012840[PMID]_19344886[PMID]_17457484[PMID]
12510,93952,"X-linked intellectual disability, Hedera type",Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,26467484[PMID]_11782983[PMID]
12510,93952,"X-linked intellectual disability, Hedera type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26467484[PMID]_11782983[PMID]
29725,595133,Perivascular epithelioid cell neoplasm,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
12507,93947,"X-linked intellectual disability, Golabi-Ito-Hall type",Clinical subtype,Subtype of disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,[EXPERT]
12507,93947,"X-linked intellectual disability, Golabi-Ito-Hall type",Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12506,93946,Hamel cerebro-palato-cardiac syndrome,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,[EXPERT]
12506,93946,Hamel cerebro-palato-cardiac syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12501,93941,Laryngotracheoesophageal cleft type 4,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,[EXPERT]
12501,93941,Laryngotracheoesophageal cleft type 4,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12500,93940,Laryngotracheoesophageal cleft type 3,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,[EXPERT]
12500,93940,Laryngotracheoesophageal cleft type 3,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12499,93939,Laryngotracheoesophageal cleft type 2,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12498,93938,Laryngotracheoesophageal cleft type 1,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12449,93616,Hemoglobin H disease,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,8.7,United States,Not yet validated,21167500[PMID]_22766612[PMID]
12449,93616,Hemoglobin H disease,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,United States,Validated,21167500[PMID]_[EXPERT]
12449,93616,Hemoglobin H disease,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,>1 / 1000,1200.0,South East Asia,Not yet validated,20301608[PMID]_ORPHANET
12453,93622,Dent disease type 1,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12454,93623,Dent disease type 2,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
12464,93672,Juvenile dermatomyositis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.295,Worldwide,Validated,12794783[PMID]_7551657[PMID]
12464,93672,Juvenile dermatomyositis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
12466,93685,Unicentric Castleman disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_29157611[PMID]
12466,93685,Unicentric Castleman disease,Clinical subtype,Subtype of disorder,Annual incidence,Class only,1-9 / 100 000,0.0,United States,Validated,ORPHANET_25120049[PMID]
12469,93890,Rare developmental defect during embryogenesis,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,3.3,France,Validated,22939647[PMID]
12469,93890,Rare developmental defect during embryogenesis,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,2.42,France,Validated,22939647[PMID]
12426,93591,Infantile nephronophthisis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,European Rare Kidney Diseases Reference Network[EXPERT]
12431,93598,Primary hyperoxaluria type 1,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.015,Netherlands,Validated,12543880[PMID]
12431,93598,Primary hyperoxaluria type 1,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.29,Netherlands,Validated,12543880[PMID]
12431,93598,Primary hyperoxaluria type 1,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Switzerland,Validated,8808215[PMID]
12431,93598,Primary hyperoxaluria type 1,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2,Switzerland,Validated,8808215[PMID]
12431,93598,Primary hyperoxaluria type 1,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.83,France,Validated,[EXPERT]
12431,93598,Primary hyperoxaluria type 1,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,France,Validated,8592622[PMID]_[EXPERT]
12422,93583,Congenital thrombotic thrombocytopenic purpura,Clinical subtype,Subtype of disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,[EXPERT]_19847791[PMID]
12422,93583,Congenital thrombotic thrombocytopenic purpura,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,[EXPERT]_ORPHANET
12422,93583,Congenital thrombotic thrombocytopenic purpura,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,123.0,Worldwide,Validated,PMID:30792199
12423,93585,Immune-mediated thrombotic thrombocytopenic purpura,Clinical subtype,Subtype of disorder,Annual incidence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,ORPHANET
12423,93585,Immune-mediated thrombotic thrombocytopenic purpura,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
12443,93610,Distal renal tubular acidosis with anemia,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
29784,596759,Combined immunodeficiency due to RELA haploinsufficiency,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,28600438[PMID]_29305315[PMID]
29784,596759,Combined immunodeficiency due to RELA haploinsufficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,28600438[PMID]_29305315[PMID]_ORPHANET
12441,93608,Autosomal dominant distal renal tubular acidosis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
12440,93607,Autosomal recessive proximal renal tubular acidosis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
29788,596937,Portosinusoidal vascular disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,30957754[PMID]_36606618[PMID]
29788,596937,Portosinusoidal vascular disease,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,30957754[PMID]_36606618[PMID]
29776,596448,IgG4-related systemic disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
29776,596448,IgG4-related systemic disease,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
29776,596448,IgG4-related systemic disease,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Japan,Validated,21881964[PMID]_25360299[PMID]_ORPHANET
29776,596448,IgG4-related systemic disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.026,Japan,Validated,21881964[PMID]_33906357[PMID]_ORPHANET
29776,596448,IgG4-related systemic disease,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.576,Denmark,Validated,30931680[PMID]
29776,596448,IgG4-related systemic disease,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.6885,Denmark,Validated,30931680[PMID]
12433,93600,Primary hyperoxaluria type 3,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,23167815[PMID]
12433,93600,Primary hyperoxaluria type 3,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
12432,93599,Primary hyperoxaluria type 2,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,23167815[PMID]
12432,93599,Primary hyperoxaluria type 2,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
12439,93606,Nephrogenic syndrome of inappropriate antidiuresis,Disease,Disorder,Cases/families,Case(s),,21.0,Worldwide,Validated,22722264[PMID]_[EXPERT]
12439,93606,Nephrogenic syndrome of inappropriate antidiuresis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
29783,596753,VEXAS syndrome,Disease,Disorder,Cases/families,Case(s),,37.0,Worldwide,Validated,PMID: 34489099
29783,596753,VEXAS syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
12438,93605,Bartter syndrome type 3,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET_[EXPERT]
14111,99094,Laubry-Pezzi syndrome,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
14080,99063,Shone complex,Malformation syndrome,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,DOI: 10.5530/jcdr.2016.3.8[OTHER]
14080,99063,Shone complex,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_DOI: 10.5530/jcdr.2016.3.8[OTHER]
14142,99125,Congenital total pulmonary venous return anomaly,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,8.0,United States,Validated,18657826[PMID]
14142,99125,Congenital total pulmonary venous return anomaly,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.0,Worldwide,Validated,12084585[PMID]
14142,99125,Congenital total pulmonary venous return anomaly,Morphological anomaly,Disorder,Point prevalence,Value and class,1-9 / 100 000,9.0,Worldwide,Validated,12084585[PMID]_ORPHANET
14142,99125,Congenital total pulmonary venous return anomaly,Morphological anomaly,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.0,United States,Validated,18657826[PMID]_ORPHANET
14112,99095,Congenital Gerbode defect,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
14164,99147,Acquired von Willebrand syndrome,Disease,Disorder,Cases/families,Case(s),,300.0,Worldwide,Validated,ORPHANET
14164,99147,Acquired von Willebrand syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
29579,592873,Acute transverse myelitis with anti-MOG antibodies,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
29579,592873,Acute transverse myelitis with anti-MOG antibodies,Clinical subtype,Subtype of disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
14158,99141,Lymphedema-posterior choanal atresia syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,20826270[PMID] _DOI:10.1016/j.mgene.2017.07.006[OTHER]
14158,99141,Lymphedema-posterior choanal atresia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20826270[PMID]
14202,99329,"48,XYYY syndrome",Malformation syndrome,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,28137251[PMID]
14202,99329,"48,XYYY syndrome",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28137251[PMID]
14203,99330,"49,XYYYY syndrome",Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,28137251[PMID]
14203,99330,"49,XYYYY syndrome",Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28137251[PMID]
14230,99657,"Primary dystonia, DYT2 type",Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14212,99429,Complete androgen insensitivity syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.0,Europe,Not yet validated,ORPHANET
14212,99429,Complete androgen insensitivity syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.83,Worldwide,Not yet validated,ORPHANET_22698698[PMID]
14215,99642,"Spondyloepimetaphyseal dysplasia, Handigodu type",Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_7886470[PMID]
14215,99642,"Spondyloepimetaphyseal dysplasia, Handigodu type",Disease,Disorder,Cases/families,Case(s),,234.0,Worldwide,Validated,7886470[PMID]
14219,99646,Metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14261,99688,Dermotrichic syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_14708109[PMID]
29566,592574,Menke-Hennekam syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,27.0,Worldwide,Validated,PMID: 27311832; 29460469; 30892814
29566,592574,Menke-Hennekam syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
29564,592564,GNAO1-related developmental delay-seizures-movement disorder spectrum,Disease,Disorder,Cases/families,Case(s),,75.0,Worldwide,Validated,PMID: 26060304 ; 29758257 ; 30682224 ; 34122306
29564,592564,GNAO1-related developmental delay-seizures-movement disorder spectrum,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
29565,592570,TRAF7-associated heart defect-digital anomalies-facial dysmorphism-motor and speech delay syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,55.0,Worldwide,Validated,PMID: 29961569 ;  32376980 ;  32459067 ;  34088006
29565,592570,TRAF7-associated heart defect-digital anomalies-facial dysmorphism-motor and speech delay syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
14245,99672,Fried's tooth and nail syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,856958[PMID]_9450885[PMID]
14245,99672,Fried's tooth and nail syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_856958[PMID]_9450885[PMID]
14291,99718,Leber plus disease,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.04,Europe,Validated,ORPHANET
29460,590539,Isolated melanotic schwannoma,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,PMID: 33088497
29460,590539,Isolated melanotic schwannoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,PMID: 33088497
14298,99725,Pituitary gigantism,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]_26187128[PMID]
29441,589821,Congenital-onset Steinert myotonic dystrophy,Clinical subtype,Subtype of disorder,Prevalence at birth,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
29441,589821,Congenital-onset Steinert myotonic dystrophy,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.1,Canada,Validated,PMID: 23415617
29441,589821,Congenital-onset Steinert myotonic dystrophy,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.94,Italy,Validated,PMID: 26882032
29441,589821,Congenital-onset Steinert myotonic dystrophy,Clinical subtype,Subtype of disorder,Prevalence at birth,Value and class,1-5 / 10 000,47.6,United States,Validated,PMID: 33472919
29441,589821,Congenital-onset Steinert myotonic dystrophy,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
29443,589827,Juvenile-onset Steinert myotonic dystrophy,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
29443,589827,Juvenile-onset Steinert myotonic dystrophy,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,1.64,Italy,Validated,PMID: 26882032
29442,589824,Childhood-onset Steinert myotonic dystrophy,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
29442,589824,Childhood-onset Steinert myotonic dystrophy,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,1.29,Italy,Validated,26882032[PMID]
29445,589833,Late-onset Steinert myotonic dystrophy,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
29445,589833,Late-onset Steinert myotonic dystrophy,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,8.14,Italy,Validated,PMID: 26882032
29444,589830,Adult-onset Steinert myotonic dystrophy,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
29444,589830,Adult-onset Steinert myotonic dystrophy,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-5 / 10 000,12.54,Italy,Validated,PMID: 26882032
29447,589905,PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome,Disease,Disorder,Cases/families,Case(s),,35.0,Worldwide,Validated,PMID:27900362 ;  29209020 ; 31167805
29447,589905,PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,PMID:27900362 ; 29209020 ; 31167805
29446,589856,Choanal atresia-athelia-hypothyroidism-delayed puberty-short stature syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,PMID: 34369642
29446,589856,Choanal atresia-athelia-hypothyroidism-delayed puberty-short stature syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,PMID: 34369642
14283,99710,Punctate acrokeratoderma freckle-like pigmentation,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,8338755[PMID]
14283,99710,Punctate acrokeratoderma freckle-like pigmentation,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8338755[PMID]
14323,99750,Atypical progressive supranuclear palsy syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,[EXPERT]
14322,99749,Kostmann syndrome,Disease,Disorder,Cases/families,Case(s),,45.0,Worldwide,Validated,23351985[PMID]
14322,99749,Kostmann syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
14322,99749,Kostmann syndrome,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.0425,Brazil,Validated,35209917[PMID]
14321,99748,Pontiac fever,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14330,99757,Embryonal rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.048,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14330,99757,Embryonal rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.091,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14330,99757,Embryonal rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.034,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14330,99757,Embryonal rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.054,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14330,99757,Embryonal rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.011,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14330,99757,Embryonal rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.055,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14330,99757,Embryonal rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14330,99757,Embryonal rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.046,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14330,99757,Embryonal rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.089,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14330,99757,Embryonal rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.045,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14330,99757,Embryonal rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.032,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14330,99757,Embryonal rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.046,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14330,99757,Embryonal rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.057,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14330,99757,Embryonal rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.035,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14330,99757,Embryonal rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.051,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14330,99757,Embryonal rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.074,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14330,99757,Embryonal rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.088,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14330,99757,Embryonal rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.051,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14330,99757,Embryonal rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.051,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14330,99757,Embryonal rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.093,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14330,99757,Embryonal rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.053,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14330,99757,Embryonal rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.128,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14330,99757,Embryonal rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.126,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14329,99756,Alveolar rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.018,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14329,99756,Alveolar rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.054,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14329,99756,Alveolar rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.03,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14329,99756,Alveolar rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.017,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14329,99756,Alveolar rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14329,99756,Alveolar rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.009,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14329,99756,Alveolar rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.002,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14329,99756,Alveolar rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.033,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14329,99756,Alveolar rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.085,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14329,99756,Alveolar rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.062,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14329,99756,Alveolar rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.039,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14329,99756,Alveolar rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.005,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14329,99756,Alveolar rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.021,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14329,99756,Alveolar rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.063,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14329,99756,Alveolar rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.035,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14329,99756,Alveolar rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14329,99756,Alveolar rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14329,99756,Alveolar rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.029,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14329,99756,Alveolar rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.044,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14329,99756,Alveolar rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.027,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14329,99756,Alveolar rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.045,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14329,99756,Alveolar rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.036,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14329,99756,Alveolar rhabdomyosarcoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.039,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14307,99734,Myotonia fluctuans,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14304,99731,Isolated sulfite oxidase deficiency,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,28933809[PMID]
14304,99731,Isolated sulfite oxidase deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28933809[PMID]
14308,99735,Myotonia permanens,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14309,99736,Acetazolamide-responsive myotonia,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
14314,99741,King-Denborough syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,12738133[PMID]_18765655[PMID]
14314,99741,King-Denborough syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12738133[PMID]_18765655[PMID]
14315,99742,Amish lethal microcephaly,Malformation syndrome,Disorder,Prevalence at birth,Value and class,>1 / 1000,200.0,Specific population,Validated,12376931[PMID]
14315,99742,Amish lethal microcephaly,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20301539[PMID]
14318,99745,Typhoid,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.0,Europe,Validated,15298225[PMID]_[EXPERT]_World Health Organization[INST]
14318,99745,Typhoid,Disease,Disorder,Annual incidence,Value and class,>1 / 1000,274.0,South East Asia,Validated,15298225[PMID]_World Health Organization[INST]
14318,99745,Typhoid,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,53.0,Latin America,Validated,15298225[PMID]_World Health Organization[INST]
14318,99745,Typhoid,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,50.0,Africa,Validated,15298225[PMID]_World Health Organization[INST]
14318,99745,Typhoid,Disease,Disorder,Annual incidence,Class only,1-9 / 1 000 000,0.0,North America,Validated,15298225[PMID]_World Health Organization[INST]
14318,99745,Typhoid,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,15.0,Oceania,Validated,15298225[PMID]_World Health Organization[INST]
14318,99745,Typhoid,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.2,France,Validated,Institut Pasteur[INST]
14318,99745,Typhoid,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
13835,98818,Landau-Kleffner syndrome,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.4,Japan,Validated,23706409[PMID]
13832,98815,Self-limited epilepsy with autonomic seizures,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.8,United Kingdom,Validated,DOI:10.1136/archdischild-2016-310863.98[OTHER]
13830,98813,Hypohidrotic ectodermal dysplasia with immunodeficiency,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.2,Europe,Validated,[EXPERT]
13830,98813,Hypohidrotic ectodermal dysplasia with immunodeficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
13828,98811,Paroxysmal exertion-induced dyskinesia,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,18577546[PMID]
13828,98811,Paroxysmal exertion-induced dyskinesia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
13827,98810,Paroxysmal non-kinesigenic dyskinesia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Worldwide,Validated,19289562[PMID]_[EXPERT]
13826,98809,Paroxysmal kinesigenic dyskinesia,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.6,Worldwide,Validated,20301633[PMID]
13825,98808,Autosomal dominant dopa-responsive dystonia,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,ORPHANET
13824,98807,"Primary dystonia, DYT13 type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9120448[PMID]
13824,98807,"Primary dystonia, DYT13 type",Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,9120448[PMID]
13855,98838,Primary mediastinal large B-cell lymphoma,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.0,Europe,Validated,European Medicines Agency 2018[INST]
13850,98833,Acute myeloblastic leukemia without maturation,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
13851,98834,Acute myeloblastic leukemia with maturation,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
13848,98831,Acute myeloid leukemia with 11q23 abnormalities,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
13849,98832,Acute myeloid leukemia with minimal differentiation,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.01,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
13846,98829,Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22),Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
13844,98827,Unclassified myelodysplastic syndrome,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,WHO Tumour classification
13844,98827,Unclassified myelodysplastic syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,WHO Tumour classification
13843,98826,Myelodysplastic neoplasm with low blasts,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
13840,98823,Chronic myelomonocytic leukemia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.68,Worldwide,Validated,30690330[PMID]_32501529[PMID]
13841,98824,Atypical chronic myeloid leukemia,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
13868,98851,Mast cell leukemia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
13868,98851,Mast cell leukemia,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
13865,98848,Indolent systemic mastocytosis,Disease,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Validated,ORPHANET
13867,98850,Aggressive systemic mastocytosis,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,[EXPERT]_ORPHANET
13866,98849,Systemic mastocytosis with associated hematologic neoplasm,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,[EXPERT]
13861,98844,"Classic Hodgkin lymphoma, mixed cellularity type",Histopathological subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.42,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
13860,98843,"Classic Hodgkin lymphoma, nodular sclerosis type",Histopathological subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 100 000,1.28,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
13863,98846,"Classic Hodgkin lymphoma, lymphocyte-depleted type",Histopathological subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.04,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
13862,98845,"Classic Hodgkin lymphoma, lymphocyte-rich type",Histopathological subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
13859,98842,Lymphomatoid papulosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
13858,98841,Anaplastic large cell lymphoma,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Europe,Validated,European Medicines Agency 2011[INST]
29437,589608,"Linear hypopigmentation and craniofacial asymmetry with acral, ocular and brain anomalies",Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,PMID: 31570889
29437,589608,"Linear hypopigmentation and craniofacial asymmetry with acral, ocular and brain anomalies",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
29436,589595,Mixed phenotype acute leukemia with t(v;11q23.3),Etiological subtype,Subtype of disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,WHO Classification of Tumour_ORPHANET
29436,589595,Mixed phenotype acute leukemia with t(v;11q23.3),Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,WHO Classification of Tumour_ORPHANET
13885,98868,Southeast Asian ovalocytosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
13886,98869,Congenital dyserythropoietic anemia type I,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,20665989[PMID]_[EXPERT]
13886,98869,Congenital dyserythropoietic anemia type I,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
29438,589618,Dystonia 28,Disease,Disorder,Cases/families,Case(s),,160.0,Worldwide,Validated,ORPHANET
29438,589618,Dystonia 28,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
13887,98870,Congenital dyserythropoietic anemia type III,Disease,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,23570799[PMID]
13887,98870,Congenital dyserythropoietic anemia type III,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23570799[PMID]
29433,589534,Mixed phenotype acute leukemia with t(9;22)(q34.1;q11.2),Etiological subtype,Subtype of disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
29433,589534,Mixed phenotype acute leukemia with t(9;22)(q34.1;q11.2),Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
13880,98863,X-linked Emery-Dreifuss muscular dystrophy,Etiological subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.13,United Kingdom,Validated,19767415[PMID]
13880,98863,X-linked Emery-Dreifuss muscular dystrophy,Etiological subtype,Subtype of disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.0,Worldwide,Not yet validated,20301609[PMID]_Association Française contre les Myopathies[Patient organisation]
13880,98863,X-linked Emery-Dreifuss muscular dystrophy,Etiological subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Worldwide,Not yet validated,20301609[PMID]_Association Française contre les Myopathies[Patient organisation]
29432,589527,Spinocerebellar ataxia type 45,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,PMID: 29053796 ; 29847346
29432,589527,Spinocerebellar ataxia type 45,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,PMID: 29053796 ; 29847346
29435,589547,"GRIN2B-related developmental delay, intellectual disability and autism spectrum disorder",Disease,Disorder,Cases/families,Case(s),,98.0,Worldwide,Validated,PMID: 28377535 ; 31085877 ; 34568804 ; 34615535
29435,589547,"GRIN2B-related developmental delay, intellectual disability and autism spectrum disorder",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
29434,589542,Myeloid/lymphoid neoplasm associated with JAK2 rearrangement,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
29434,589542,Myeloid/lymphoid neoplasm associated with JAK2 rearrangement,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
29429,589442,Short stature-skeletal dysplasia-retinal degeneration-intellectual disability-sensorineural hearing loss syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,PMID: 30488656 ; 31263216
29429,589442,Short stature-skeletal dysplasia-retinal degeneration-intellectual disability-sensorineural hearing loss syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
29428,589435,Spondylometaphyseal dysplasia-corneal dystrophy syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,PMID: 29122926
29428,589435,Spondylometaphyseal dysplasia-corneal dystrophy syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,PMID: 29122926
29431,589522,Spinocerebellar ataxia type 46,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,PMID: 8595484 ; 29847346
29431,589522,Spinocerebellar ataxia type 46,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,PMID: 8595484 ; 29847346
29430,589515,PUM1-associated developmental disability-ataxia-seizure syndrome,Disease,Disorder,Cases/families,Case(s),,14.0,Worldwide,Validated,"PMID reference: 29474920, 31859446, 30903679"
29430,589515,PUM1-associated developmental disability-ataxia-seizure syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,"PMID reference: 29474920, 31859446, 30903679"
13873,98856,Charcot-Marie-Tooth disease type 2B1,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
13898,98881,Familial dysfibrinogenemia,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.0,Europe,Validated,21649801[PMID]_European Medicines Agency 2018[INST]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Albania,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.44,Algeria,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.54,Argentina,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2,Armenia,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.665,Austria,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.16,Azerbaijan,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.015,Bangladesh,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.84,Belarus,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.32,Belgium,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.155,Belize,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.045,Bolivia,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.265,Bosnia and Herzegovina,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.535,Brazil,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.775,Bulgaria,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.795,Chile,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.405,Colombia,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.645,Costa rica,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.625,Croatia,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.49,Cuba,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.195,Cyprus,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.045,Czech Republic,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.56,Denmark,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.165,Dominican Republic,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.25,Ecuador,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.955,Egypt,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.31,El Salvador,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.065,Eritrea,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.24,Estonia,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.235,Finland,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Georgia,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.885,Germany,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.075,Greece,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.075,Guatemala,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.17,Honduras,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.115,Hungary,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.695,Iceland,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.095,India,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.01,Indonesia,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.98,"Iran, Islamic Republic of",Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.545,Iraq,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.06,Italy,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.495,"Korea, Republic of",Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.76,Latvia,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.57,Lithuania,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.235,Luxembourg,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.205,North Macedonia,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Malaysia,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.77,Malta,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.29,Mexico,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.37,"Moldova, Republic of",Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.15,Mongolia,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2,Morocco,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.065,Nepal,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.035,Netherlands,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.855,New Zealand,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.005,Nigeria,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.975,Norway,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.24,Pakistan,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.84,"Palestinian Territory, occupied",Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.24,Peru,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Philippines,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.85,Poland,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.93,Portugal,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.265,Qatar,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.73,Russian Federation,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.15,Saudi Arabia,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.04,Senegal,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.715,Serbia,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.045,Sierra leone,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.545,Singapore,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.995,Israel,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.32,Jamaica,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.745,Jordan,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.13,Kenya,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.33,Lebanon,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.33,Nicaragua,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.585,Panama,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.375,Paraguay,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.76,Romania,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.28,Slovakia,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.82,Slovenia,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.525,South Africa,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.765,Spain,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.065,Sri Lanka,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.115,Sudan,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.85,Sweden,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.375,Switzerland,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.085,Thailand,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.02,Togo,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.37,Tunisia,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.31,Turkey,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.01,Ukraine,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.08,United Kingdom,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.36,Uruguay,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.285,Uzbekistan,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.18,Venezuela,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.14,Viet Nam,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.35,Zimbabwe,Validated,21649801[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.665,Worldwide,Validated,20301668[PMID]
13896,98879,Hemophilia B,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.44,France,Validated,https://www.francecoag.org/SiteWebPublic/public/stats/stats_page.jsp?stat3=on
13890,98873,Congenital dyserythropoietic anemia type II,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,20665989[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.85,Worldwide,Not yet validated,19845775[PMID]_ORPHANET
13895,98878,Hemophilia A,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,11.25,Worldwide,Not yet validated,20301578[PMID]_ORPHANET
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.5,France,Validated,https://www.francecoag.org/SiteWebPublic/public/stats/stats_page.jsp?stat2=on
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.0,United States,Validated,20301578[PMID]_19845775[PMID]_ ORPHANET
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.0,Europe,Validated,European Medicines Agency 2018[INST]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.58,Africa,Validated,19845775[PMID]_ORPHANET
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.6,Albania,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.8,Algeria,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.5,Argentina,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.0,Armenia,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.8,Australia,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.3,Austria,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.0,Azerbaijan,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2,Bangladesh,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.1,Belarus,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.0,Belgium,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.2,Belize,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Bolivia,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.6,Bosnia and Herzegovina,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.7,Brazil,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.8,Bulgaria,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.3,Canada,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.3,Chile,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.2,China,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.6,Colombia,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.0,Costa rica,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.5,Croatia,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.7,Cuba,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.2,Cyprus,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.1,Czech Republic,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.2,Denmark,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.8,Dominican Republic,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.5,Ecuador,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.4,Egypt,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.0,El Salvador,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.7,Eritrea,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.8,Estonia,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.6,Finland,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.0,Germany,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.5,Greece,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Guatemala,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.6,Honduras,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.3,Hungary,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,19.3,Iceland,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.7,India,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Indonesia,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.6,"Iran, Islamic Republic of",Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.8,Iraq,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,9.2,Ireland,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.4,Israel,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.7,Italy,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.6,Jamaica,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.3,Japan,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.5,Jordan,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.1,Kenya,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.0,"Korea, Republic of",Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.9,Latvia,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.5,Lebanon,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.7,Lesotho,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.1,Lithuania,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.4,Luxembourg,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.1,North Macedonia,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.3,Malaysia,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.3,Malta,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.2,Mexico,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.7,"Moldova, Republic of",Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.4,Mongolia,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Morocco,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.6,Nepal,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,9.3,Netherlands,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,11.0,New Zealand,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.7,Nicaragua,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.025,Nigeria,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.1,Norway,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.8,Pakistan,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.7,"Palestinian Territory, occupied",Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.6,Panama,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.2,Paraguay,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.6,Peru,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.9,Philippines,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.6,Poland,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.9,Portugal,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.9,Qatar,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,6.4,Romania,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.3,Russian Federation,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Saudi Arabia,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.8,Senegal,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.7,Serbia,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Sierra leone,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.0,Singapore,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.6,Slovakia,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.2,Slovenia,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.0,South Africa,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.8,Spain,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.6,Sri Lanka,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.85,Sudan,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.7,Sweden,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,7.1,Switzerland,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.8,Thailand,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.02,Togo,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.2,Tunisia,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.1,Turkey,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.35,Ukraine,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.4,United Kingdom,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.9,Uruguay,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.8,Uzbekistan,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.9,Venezuela,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Viet Nam,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.3,Zimbabwe,Validated,19845775[PMID]
13895,98878,Hemophilia A,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.4,Georgia,Validated,19845775[PMID]
13912,98895,Becker muscular dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Europe,Validated,European Medicines Agency 2018[INST]
13912,98895,Becker muscular dystrophy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.7,United Kingdom,Validated,1673177[PMID]
13912,98895,Becker muscular dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.64,United Kingdom,Validated,19767415[PMID]_24780148[PMID]_ORPHANET
13912,98895,Becker muscular dystrophy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.5,United States,Validated,12495984[PMID]
13912,98895,Becker muscular dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.4,United States,Not yet validated,emedicine[OTHER]
13912,98895,Becker muscular dystrophy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.2,Europe,Validated,[EXPERT]
13912,98895,Becker muscular dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.53,Worldwide,Not yet validated,24780148[PMID]
13912,98895,Becker muscular dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.47,Italy,Validated,10466417[PMID]_24780148[PMID]
13912,98895,Becker muscular dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.94,Egypt,Validated,16210862[PMID]_24780148[PMID]
13912,98895,Becker muscular dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.91,Japan,Validated,1745328[PMID]_24780148[PMID]_ORPHANET
13912,98895,Becker muscular dystrophy,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.07,South Africa,Validated,7825085[PMID]_24780148[PMID]_ORPHANET
13912,98895,Becker muscular dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.59,Ireland,Validated,8845721[PMID]_24780148[PMID]
13912,98895,Becker muscular dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.42,Puerto rico,Validated,DOI:10.3233/JND-160147[OTHER]
13913,98896,Duchenne muscular dystrophy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.9,Worldwide,Validated,PMID: 32503598
13913,98896,Duchenne muscular dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.14,United Kingdom,Validated,19767415[PMID]_24780148[PMID]_ORPHANET
13913,98896,Duchenne muscular dystrophy,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,14.0,United States,Validated,12495984[PMID]
13913,98896,Duchenne muscular dystrophy,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,12.0,Netherlands,Validated,1733827[PMID]
13913,98896,Duchenne muscular dystrophy,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,10.5,Canada,Validated,20080524[PMID]
13913,98896,Duchenne muscular dystrophy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,9.7,United Kingdom,Validated,23340516[PMID]
13913,98896,Duchenne muscular dystrophy,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,8.2,Ireland,Validated,8845721[PMID]_24780148[PMID]
13913,98896,Duchenne muscular dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.7,Italy,Validated,10466417[PMID]_24780148[PMID]
13913,98896,Duchenne muscular dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.26,Ireland,Validated,8845721[PMID]_24780148[PMID]
13913,98896,Duchenne muscular dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.8,Worldwide,Validated,PMID: 32503598
13913,98896,Duchenne muscular dystrophy,Disease,Disorder,Lifetime Prevalence,Value and class,1-9 / 100 000,7.66,Egypt,Validated,16210862[PMID]_24780148[PMID]
13913,98896,Duchenne muscular dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.56,Japan,Validated,1745328[PMID]_24780148[PMID]_ORPHANET
13913,98896,Duchenne muscular dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.47,South Africa,Validated,7825085[PMID]_24780148[PMID]_ORPHANET
13913,98896,Duchenne muscular dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.75,Denmark,Validated,14678803[PMID]_24780148[PMID]_ORPHANET
13913,98896,Duchenne muscular dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.59,Puerto rico,Validated,DOI:10.3233/JND-160147[OTHER]
13919,98902,Amish nemaline myopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
13919,98902,Amish nemaline myopathy,Disease,Disorder,Prevalence at birth,Value and class,>1 / 1000,200.0,Specific population,Validated,10952871[PMID]
13907,98890,Early-onset X-linked optic atrophy,Disease,Disorder,Cases/families,Family(ies),,4.0,Worldwide,Validated,16969871[PMID]
13907,98890,Early-onset X-linked optic atrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16969871[PMID]
13910,98893,Congenital muscular dystrophy type 1B,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,10677302[PMID]
13910,98893,Congenital muscular dystrophy type 1B,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10677302[PMID]
13909,98892,Periventricular nodular heterotopia,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
13929,98912,"Late-onset distal myopathy, Markesbery-Griggs type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15668942[PMID]
13929,98912,"Late-onset distal myopathy, Markesbery-Griggs type",Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,15668942[PMID]
13933,98916,Acute inflammatory demyelinating polyradiculoneuropathy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.1,Europe,Validated,[EXPERT]_European Medicines Agency[INST]
13925,98908,Neutral lipid storage disease with myopathy,Disease,Disorder,Cases/families,Case(s),,36.0,Worldwide,Validated,26600210[PMID]_28499397[PMID]
13925,98908,Neutral lipid storage disease with myopathy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26600210[PMID]_28499397[PMID]
13924,98907,Neutral lipid storage disease with ichthyosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
13926,98909,Desminopathy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
13950,98933,"Multiple system atrophy, parkinsonian type",Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,2.4,Europe,Not yet validated,ORPHANET
13951,98934,Huntington disease-like 2,Disease,Disorder,Cases/families,Family(ies),,50.0,Worldwide,Validated,20301701[PMID]_[EXPERT]
13951,98934,Huntington disease-like 2,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
13936,98919,Miller Fisher syndrome,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,[EXPERT]
13936,98919,Miller Fisher syndrome,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
13937,98920,Spinal muscular atrophy with respiratory distress type 1,Disease,Disorder,Cases/families,Case(s),,128.0,Worldwide,Validated,26709713[PMID]
13937,98920,Spinal muscular atrophy with respiratory distress type 1,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26709713[PMID]
13955,98938,Colobomatous microphthalmia,Malformation syndrome,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,19.0,United Kingdom,Validated,11826019[PMID]
13955,98938,Colobomatous microphthalmia,Malformation syndrome,Disorder,Point prevalence,Value and class,1-5 / 10 000,19.0,United Kingdom,Validated,11826019[PMID]_ORPHANET
13966,98949,Complete cryptophthalmia,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16352480[PMID]
13966,98949,Complete cryptophthalmia,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,16352480[PMID]
13967,98950,Partial cryptophthalmia,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3099574[PMID]
13965,98948,Congenital symblepharon,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3099574[PMID]
13974,98957,Gelatinous drop-like corneal dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.33,Japan,Validated,[EXPERT]
13974,98957,Gelatinous drop-like corneal dystrophy,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
13972,98955,Lisch epithelial corneal dystrophy,Disease,Disorder,Cases/families,Case(s),,36.0,Worldwide,Validated,ORPHANET
13972,98955,Lisch epithelial corneal dystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
13971,98954,Meesmann corneal dystrophy,Disease,Disorder,Cases/families,Case(s),,250.0,Worldwide,Validated,ORPHANET
13971,98954,Meesmann corneal dystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
13981,98964,Lattice corneal dystrophy type I,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
13980,98963,Granular corneal dystrophy type II,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
13979,98962,Granular corneal dystrophy type I,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
13978,98961,Reis-Bücklers corneal dystrophy,Disease,Disorder,Cases/families,Case(s),,81.0,Worldwide,Validated,ORPHANET
13978,98961,Reis-Bücklers corneal dystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
13977,98960,Thiel-Behnke corneal dystrophy,Disease,Disorder,Cases/families,Case(s),,173.0,Worldwide,Validated,ORPHANET
13977,98960,Thiel-Behnke corneal dystrophy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
13976,98959,Subepithelial mucinous corneal dystrophy,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,8352693[PMID]_[EXPERT]
13976,98959,Subepithelial mucinous corneal dystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
13988,98971,Posterior amorphous corneal dystrophy,Disease,Disorder,Cases/families,Family(ies),,11.0,Worldwide,Validated,301356[PMID]_2314832[PMID]_1582220[PMID]_7573302[PMID]_8600425[PMID]_17273695[PMID]_17300585[PMID]_11862100[PMID]
13988,98971,Posterior amorphous corneal dystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
13989,98972,Central cloudy dystrophy of François,Disease,Disorder,Cases/families,Case(s),,24.0,Worldwide,Validated,5305046[PMID]_1083619[PMID]_15734014[PMID]_15534129[PMID]_9258229[PMID]_8776559[PMID]_20337272[PMID]
13989,98972,Central cloudy dystrophy of François,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
13990,98973,Posterior polymorphous corneal dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Czech Republic,Validated,23049806[PMID]
13990,98973,Posterior polymorphous corneal dystrophy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
13991,98974,Fuchs endothelial corneal dystrophy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
13984,98967,Schnyder corneal dystrophy,Disease,Disorder,Cases/families,Case(s),,115.0,Worldwide,Validated,19398911[PMID]
13984,98967,Schnyder corneal dystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
13986,98969,Macular corneal dystrophy,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,United States,Not yet validated,21791583[PMID]
13986,98969,Macular corneal dystrophy,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
13987,98970,Fleck corneal dystrophy,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,139144[PMID]_7950337[PMID]_141212[PMID]_14078376[PMID]_10660318[PMID]_19948560[PMID]_22065932[PMID]
13987,98970,Fleck corneal dystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
13993,98976,Congenital glaucoma,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.2,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
13993,98976,Congenital glaucoma,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.9,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
13993,98976,Congenital glaucoma,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.6,France,Validated,EUROCAT European surveillance of congenital anomalies 2000-2010[REG]
13993,98976,Congenital glaucoma,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.8,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
13993,98976,Congenital glaucoma,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.6,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
13993,98976,Congenital glaucoma,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,5.6,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
13993,98976,Congenital glaucoma,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.8,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
13993,98976,Congenital glaucoma,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.9,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
13993,98976,Congenital glaucoma,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,6.5,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
13993,98976,Congenital glaucoma,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.2,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
13993,98976,Congenital glaucoma,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.0,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2000-2004[REG]
13993,98976,Congenital glaucoma,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
13993,98976,Congenital glaucoma,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.5,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
13993,98976,Congenital glaucoma,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.4,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
13993,98976,Congenital glaucoma,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.1,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
13993,98976,Congenital glaucoma,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,4.1,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
13993,98976,Congenital glaucoma,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,2.8,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
13993,98976,Congenital glaucoma,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,3.4,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
13994,98977,Juvenile glaucoma,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,United States,Validated,18214788[PMID]
14017,99000,Adult-onset foveomacular vitelliform dystrophy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
14030,99013,Spastic paraplegia type 7,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
14031,99014,X-linked Charcot-Marie-Tooth disease type 5,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_17701900[PMID]_20301731[PMID]
14031,99014,X-linked Charcot-Marie-Tooth disease type 5,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,17701900[PMID]_20301731[PMID]
14032,99015,Spastic paraplegia type 2,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,ORPHANET
14032,99015,Spastic paraplegia type 2,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
29204,585867,Acute myeloid leukemia with t(9;22)(q34.1;q11.2),Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.0,Worldwide,Validated,PMID: 29340131; 29090343; 31101526
29205,585877,B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormality,Etiological subtype,Subtype of disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_WHO Classification of Tumours
29205,585877,B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormality,Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_WHO Classification of Tumours
29211,585909,B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2),Etiological subtype,Subtype of disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_WHO Classification of Tumours
29211,585909,B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2),Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_WHO Classification of Tumours
29214,585936,B-lymphoblastic leukemia/lymphoma with hyperdiploidy,Etiological subtype,Subtype of disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
29214,585936,B-lymphoblastic leukemia/lymphoma with hyperdiploidy,Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
29215,585942,B-lymphoblastic leukemia/lymphoma with hypodiploidy,Etiological subtype,Subtype of disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
29215,585942,B-lymphoblastic leukemia/lymphoma with hypodiploidy,Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
29212,585918,B-lymphoblastic leukemia/lymphoma with t(v;11q23.3),Etiological subtype,Subtype of disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
29212,585918,B-lymphoblastic leukemia/lymphoma with t(v;11q23.3),Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
29213,585929,B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1),Etiological subtype,Subtype of disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
29213,585929,B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1),Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
14044,99027,Adult-onset autosomal dominant leukodystrophy,Disease,Disorder,Cases/families,Family(ies),,20.0,Worldwide,Validated,[EXPERT]
14044,99027,Adult-onset autosomal dominant leukodystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Not yet validated,ORPHANET
29217,585956,B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3),Etiological subtype,Subtype of disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
29217,585956,B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3),Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
29216,585948,B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3),Etiological subtype,Subtype of disorder,Annual incidence,Class only,Unknown,0.0,Western Asia,Validated,WHO Classification of Tumours_ORPHANET
29216,585948,B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3),Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
29226,586130,Sporadic fatal insomnia,Disease,Disorder,Cases/families,Case(s),,27.0,Worldwide,Validated,PMID: 30048013
29226,586130,Sporadic fatal insomnia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,PMID: 30048013
14059,99042,Congenitally uncorrected transposition of the great arteries with coarctation,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14067,99050,Abnormal origin of right or left pulmonary artery from the aorta,Morphological anomaly,Disorder,Cases/families,Case(s),,200.0,Worldwide,Validated,24182510[PMID]
14067,99050,Abnormal origin of right or left pulmonary artery from the aorta,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,[EXPERT]
13623,98606,Syndromic orbital border hypoplasia,Malformation syndrome,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,14359373[PMID]
13623,98606,Syndromic orbital border hypoplasia,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_14359373[PMID]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,8.3,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,2.9,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,9.8,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2008[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2008[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,36.4,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2008[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2008[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,7.3,France,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,France,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,5.8,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,17.7,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,3.6,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,11.0,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,25.9,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2005[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2005[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,11.1,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,6.4,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,2.4,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,13.1,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2008[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2008[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,14.4,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,12.3,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,3.9,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,12.9,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,5.2,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2008[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2008[REG]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,18.0,United States,Validated,8921488[PMID]_8179669[PMID]_16007635[PMID]_Center for Diseases Control and Prevention 2004-2006[INST]
13572,98555,Microphthalmia-anophthalmia-coloboma,Category,Group of disorders,Point prevalence,Class only,1-5 / 10 000,0.0,United States,Validated,8921488[PMID]_8179669[PMID]_16007635[PMID]_Center for Diseases Control and Prevention 2004-2006[INST]
13693,98676,Autosomal recessive isolated optic atrophy,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,14508503[PMID]
13693,98676,Autosomal recessive isolated optic atrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_14508503[PMID]
13690,98673,"Autosomal dominant optic atrophy, classic form",Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.0,Worldwide,Not yet validated,ORPHANET_20301426[PMID]
13690,98673,"Autosomal dominant optic atrophy, classic form",Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,Denmark,Validated,8689476[PMID]
13690,98673,"Autosomal dominant optic atrophy, classic form",Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.86,United Kingdom,Validated,20417570[PMID]
13690,98673,"Autosomal dominant optic atrophy, classic form",Disease,Disorder,Point prevalence,Value and class,6-9 / 10 000,83.33,Specific population,Validated,21745197[PMID]
13689,98672,Autosomal dominant optic atrophy,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,10.0,Denmark,Validated,22776096[PMID]
13689,98672,Autosomal dominant optic atrophy,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,2.5,United Kingdom,Not yet validated,20417570[PMID]_ORPHANET
13689,98672,Autosomal dominant optic atrophy,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,3.3,Worldwide,Not yet validated,22776096[PMID]
13689,98672,Autosomal dominant optic atrophy,Clinical group,Group of disorders,Point prevalence,Value and class,6-9 / 10 000,83.0,Specific population,Validated,21745197[PMID]
13644,98627,Posterior corneal dystrophy,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
13643,98626,Stromal corneal dystrophy,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
13642,98625,Superficial corneal dystrophy,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,13.8,United States,Not yet validated,21791583[PMID]
13642,98625,Superficial corneal dystrophy,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
29050,583856,Isolated splenic vein thrombosis,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
29050,583856,Isolated splenic vein thrombosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
29051,583861,Isolated mesenteric vein thrombosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.6,Europe,Validated,18720461[PMID]_25917534[PMID]
29051,583861,Isolated mesenteric vein thrombosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.5,Finland,Validated,25917534[PMID]
29051,583861,Isolated mesenteric vein thrombosis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.7,Sweden,Validated,18720461[PMID]
29051,583861,Isolated mesenteric vein thrombosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,18720461[PMID]_25917534[PMID]_ORPHANET
13732,98715,Uveitis,Category,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,17.0,Europe,Not yet validated,8407119[PMID]
13732,98715,Uveitis,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,38.0,Europe,Not yet validated,8407119[PMID]
13740,98723,Hypoplastic right heart syndrome,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,3.3,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13740,98723,Hypoplastic right heart syndrome,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,2.9,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
13740,98723,Hypoplastic right heart syndrome,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,19.8,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13740,98723,Hypoplastic right heart syndrome,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,2.0,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
13740,98723,Hypoplastic right heart syndrome,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,5.8,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
13740,98723,Hypoplastic right heart syndrome,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,3.3,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13740,98723,Hypoplastic right heart syndrome,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,3.6,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
13740,98723,Hypoplastic right heart syndrome,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.4,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13740,98723,Hypoplastic right heart syndrome,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,24.1,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
13740,98723,Hypoplastic right heart syndrome,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,5.8,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
13740,98723,Hypoplastic right heart syndrome,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,6.5,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
13740,98723,Hypoplastic right heart syndrome,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 1 000 000,0.5,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13740,98723,Hypoplastic right heart syndrome,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-5 / 10 000,12.6,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
13740,98723,Hypoplastic right heart syndrome,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,3.9,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
13740,98723,Hypoplastic right heart syndrome,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,9.5,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
13740,98723,Hypoplastic right heart syndrome,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 1 000 000,0.6,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
13740,98723,Hypoplastic right heart syndrome,Clinical group,Group of disorders,Prevalence at birth,Value and class,1-9 / 100 000,1.68,United States,Validated,28009100[PMID]
29004,583097,Congenital infiltrating lipomatosis of the face,Disease,Disorder,Cases/families,Case(s),,59.0,Worldwide,Validated,PMID: 31280031; 25860506; 28846548
29004,583097,Congenital infiltrating lipomatosis of the face,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,PMID: 31280031; 25860506; 28846548
13808,98791,Alpha-thalassemia-intellectual disability syndrome linked to chromosome 16,Malformation syndrome,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,[EXPERT]
13808,98791,Alpha-thalassemia-intellectual disability syndrome linked to chromosome 16,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
13823,98806,"Primary dystonia, DYT6 type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19345147[PMID]_21110056[PMID]
13823,98806,"Primary dystonia, DYT6 type",Disease,Disorder,Cases/families,Case(s),,53.0,Worldwide,Validated,19345147[PMID]_21110056[PMID]
13822,98805,"Primary dystonia, DYT4 type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21956287[PMID]
13822,98805,"Primary dystonia, DYT4 type",Disease,Disorder,Cases/families,Case(s),,22.0,Worldwide,Validated,21956287[PMID]
13801,98784,Autosomal dominant nocturnal frontal lobe epilepsy,Disease,Disorder,Cases/families,Family(ies),,100.0,Worldwide,Validated,20301348[PMID]
13801,98784,Autosomal dominant nocturnal frontal lobe epilepsy,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
13781,98764,Spinocerebellar ataxia type 27A,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,[EXPERT]
13781,98764,Spinocerebellar ataxia type 27A,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
13780,98763,Spinocerebellar ataxia type 14,Disease,Disorder,Cases/families,Family(ies),,20.0,Worldwide,Validated,20301573[PMID]_[EXPERT]
13780,98763,Spinocerebellar ataxia type 14,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
13783,98766,Spinocerebellar ataxia type 5,Disease,Disorder,Cases/families,Family(ies),,5.0,Worldwide,Validated,25142508[PMID]
13783,98766,Spinocerebellar ataxia type 5,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_[EXPERT]_25142508[PMID]
13782,98765,Spinocerebellar ataxia type 4,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
13777,98760,Spinocerebellar ataxia type 8,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
13776,98759,Spinocerebellar ataxia type 17,Disease,Disorder,Cases/families,Family(ies),,100.0,Worldwide,Validated,[EXPERT]
13776,98759,Spinocerebellar ataxia type 17,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
13776,98759,Spinocerebellar ataxia type 17,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.047,Japan,Validated,12116198[PMID]_[EXPERT]
13776,98759,Spinocerebellar ataxia type 17,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.16,United Kingdom,Validated,16223509[PMID]_[EXPERT]
13779,98762,Spinocerebellar ataxia type 12,Disease,Disorder,Cases/families,Family(ies),,40.0,Worldwide,Validated,20301381[PMID]_[EXPERT]
13779,98762,Spinocerebellar ataxia type 12,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
13778,98761,Spinocerebellar ataxia type 10,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
13789,98772,Spinocerebellar ataxia type 19/22,Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,[EXPERT]
13789,98772,Spinocerebellar ataxia type 19/22,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
13788,98771,Spinocerebellar ataxia type 18,Disease,Disorder,Cases/families,Case(s),,26.0,Worldwide,Validated,[EXPERT]
13788,98771,Spinocerebellar ataxia type 18,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
13790,98773,Spinocerebellar ataxia type 21,Disease,Disorder,Cases/families,Case(s),,35.0,Worldwide,Validated,26813285[PMID]
13790,98773,Spinocerebellar ataxia type 21,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_26813285[PMID]
13785,98768,Spinocerebellar ataxia type 13,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,[EXPERT]
13785,98768,Spinocerebellar ataxia type 13,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
13784,98767,Spinocerebellar ataxia type 11,Disease,Disorder,Cases/families,Case(s),,51.0,Worldwide,Validated,21827911[PMID]
13784,98767,Spinocerebellar ataxia type 11,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_21827911[PMID]
13786,98769,Spinocerebellar ataxia type 15/16,Disease,Disorder,Cases/families,Case(s),,80.0,Worldwide,Validated,Dr Shinsuke FUJIOKA_Dr Nathaniel WHALEY_Dr Zbigniew WSZOLEK[EXPERT]
13786,98769,Spinocerebellar ataxia type 15/16,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_[EXPERT]
28931,580933,Lethal brain and heart developmental defects,Malformation syndrome,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,PMID: 29555651
28931,580933,Lethal brain and heart developmental defects,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,PMID: 29555651
13772,98755,Spinocerebellar ataxia type 1,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.5,Worldwide,Validated,20301363[PMID]_[EXPERT]
13773,98756,Spinocerebellar ataxia type 2,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.5,Worldwide,Validated,[EXPERT]
13774,98757,Spinocerebellar ataxia type 3,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.5,Worldwide,Validated,[EXPERT]
13774,98757,Spinocerebellar ataxia type 3,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Portugal,Validated,21635785[PMID]
13774,98757,Spinocerebellar ataxia type 3,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,5.5,Japan,Validated,19169038[PMID]
13775,98758,Spinocerebellar ataxia type 6,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Worldwide,Validated,23331413[PMID]
13775,98758,Spinocerebellar ataxia type 6,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.7,Japan,Validated,19169038[PMID]
28919,580572,Intraductal tubulopapillary neoplasm of pancreas,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,28529742[PMID]_26464736[PMID]
13323,98306,Familial partial lipodystrophy,Clinical group,Group of disorders,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,European Medicines Agency 2016[INST]_29066925[PMID]
28850,576278,SATB2-associated syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,171.0,Worldwide,Validated,ORPHANET
28850,576278,SATB2-associated syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
28815,573253,Split cord malformation type II,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
28824,574957,Mendelian susceptibility to mycobacterial diseases due to partial JAK1 deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
28823,574918,Predisposition to severe viral infection due to IRF7 deficiency,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,25814066[PMID]
28823,574918,Predisposition to severe viral infection due to IRF7 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25814066[PMID]
13392,98375,Autoimmune hemolytic anemia,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.02,Europe,Validated,[EXPERT]_ORPHANET
13392,98375,Autoimmune hemolytic anemia,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.02,United States,Validated,[EXPERT]_ORPHANET
13392,98375,Autoimmune hemolytic anemia,Clinical group,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,11.0,Denmark,Validated,20066507[PMID]
13392,98375,Autoimmune hemolytic anemia,Clinical group,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
28816,573278,Split cord malformation,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
13499,98482,Idiopathic inflammatory myopathy,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_30073460[PMID]
28738,572385,Brachydactyly type B1,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
28736,572361,Blepharophimosis-ptosis-epicanthus inversus syndrome type 2,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
13445,98428,Secondary polycythemia,Category,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
28746,572428,Infantile-onset pulmonary alveolar proteinosis-hypogammaglobulinemia,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,29455859[PMID]
28746,572428,Infantile-onset pulmonary alveolar proteinosis-hypogammaglobulinemia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29455859[PMID]
13451,98434,Hereditary combined deficiency of vitamin K-dependent clotting factors,Disease,Disorder,Cases/families,Family(ies),,30.0,Worldwide,Validated,20630065[PMID]
13451,98434,Hereditary combined deficiency of vitamin K-dependent clotting factors,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20630065[PMID]
28754,572543,RFVT2-related riboflavin transporter deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
28755,572550,RFVT3-related riboflavin transporter deficiency,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
28766,572773,Microcephaly-short stature-limb abnormalities syndrome,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,29.0,Worldwide,Validated,28191891[PMID]_31320746[PMID]
28766,572773,Microcephaly-short stature-limb abnormalities syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28191891[PMID]_31320746[PMID]
28767,572798,WARS2-related combined oxidative phosphorylation defect,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,29783990[PMID]
28767,572798,WARS2-related combined oxidative phosphorylation defect,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_29783990[PMID]
28764,572761,DONSON-related microcephaly-short stature-limb abnormalities spectrum,Malformation syndrome,Disorder,Cases/families,Case(s),,51.0,Worldwide,Validated,PMID: 31191207 & EXPERT
28764,572761,DONSON-related microcephaly-short stature-limb abnormalities spectrum,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
28765,572768,Microcephaly-micromelia syndrome,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,32.0,Worldwide,Validated,7468660[PMID]_28630177[PMID]_31191207[PMID]
28765,572768,Microcephaly-micromelia syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_31191207[PMID]
13540,98523,Non-syndromic pontocerebellar hypoplasia,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
28726,572013,Posterior-predominant lissencephaly-broad flat pons and medulla-midline crossing defects syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,30471716[PMID]
28726,572013,Posterior-predominant lissencephaly-broad flat pons and medulla-midline crossing defects syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30471716[PMID]
28732,572333,Blepharophimosis-ptosis-epicanthus inversus syndrome plus,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
28735,572354,Blepharophimosis-ptosis-epicanthus inversus syndrome type 1,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
28678,570762,Infective endocarditis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
28678,570762,Infective endocarditis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.38,France,Validated,22492317[PMID]
28678,570762,Infective endocarditis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.8,Denmark,Validated,3433553[PMID]
28678,570762,Infective endocarditis,Disease,Disorder,Annual incidence,Class only,1-9 / 100 000,0.0,Europe,Validated,ORPHANET_25432123[PMID]
28677,570491,QRSL1-related combined oxidative phosphorylation defect,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_30459337[PMID]
28676,570470,Ricin poisoning,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
28676,570470,Ricin poisoning,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,European Medicines Agency 2018[INST]
28675,570438,HHV-8-associated multicentric Castleman disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
28674,570431,Idiopathic multicentric Castleman disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_29157611[PMID]
28674,570431,Idiopathic multicentric Castleman disease,Clinical subtype,Subtype of disorder,Annual incidence,Class only,1-9 / 1 000 000,0.0,United States,Validated,ORPHANET_25120049[PMID]
28673,570422,Galactose mutarotase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
28673,570422,Galactose mutarotase deficiency,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.4,Worldwide,Validated,30451973[PMID]
28673,570422,Galactose mutarotase deficiency,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.2,Japan,Validated,30451973[PMID]
28672,570371,Bartter syndrome type 5,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27120771[PMID]
28672,570371,Bartter syndrome type 5,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,27120771[PMID]_9630034[PMID]
13514,98497,Genetic peripheral neuropathy,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,40.0,Worldwide,Not yet validated,22961002[PMID]
15005,104075,Adenocarcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.588,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
15005,104075,Adenocarcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.517,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
15005,104075,Adenocarcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.734,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
15005,104075,Adenocarcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.174,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
15005,104075,Adenocarcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.308,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
15005,104075,Adenocarcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.464,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
15005,104075,Adenocarcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.36,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
15005,104075,Adenocarcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.574,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
15005,104075,Adenocarcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.657,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
15005,104075,Adenocarcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.551,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
15005,104075,Adenocarcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.724,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
15005,104075,Adenocarcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.564,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
15005,104075,Adenocarcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.79,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
15005,104075,Adenocarcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.265,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
15005,104075,Adenocarcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.277,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
15005,104075,Adenocarcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.377,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
15005,104075,Adenocarcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.788,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
15005,104075,Adenocarcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.219,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
15005,104075,Adenocarcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.743,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
15005,104075,Adenocarcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.462,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
15005,104075,Adenocarcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.4,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
15005,104075,Adenocarcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.477,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
15005,104075,Adenocarcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.76,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
15005,104075,Adenocarcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.626,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
15005,104075,Adenocarcinoma of the small intestine,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.679,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14999,104008,Short bowel syndrome,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,2.0,Europe,Validated,European Medicines Agency 2019[INST]
14991,103918,Tropical pancreatitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14986,103910,Congenital enterocyte heparan sulfate deficiency,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,8622507[PMID]
14986,103910,Congenital enterocyte heparan sulfate deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8622507[PMID]
14984,103908,Congenital sodium diarrhea,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,26835907[PMID]
14984,103908,Congenital sodium diarrhea,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,26835907[PMID]_ORPHANET
14985,103909,Trehalase deficiency,Disease,Disorder,Annual incidence,Value and class,>1 / 1000,7700.0,Greenland,Validated,[EXPERT]
14985,103909,Trehalase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14983,103907,Chronic diarrhea due to glucoamylase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14981,102724,Acute myeloid leukemia with t(8;21)(q22;q22) translocation,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14933,101997,Primary immunodeficiency,Category,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,22288591[PMID]
14933,101997,Primary immunodeficiency,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,6.8,Norway,Validated,11202238[PMID]
14933,101997,Primary immunodeficiency,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,11.0,France,Validated,28732644[PMID]
14933,101997,Primary immunodeficiency,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,3.6,Spain,Validated,22288591[PMID]
14933,101997,Primary immunodeficiency,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,2.6,Netherlands,Validated,22288591[PMID]
14933,101997,Primary immunodeficiency,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.84,United Kingdom,Validated,22288591[PMID]
14933,101997,Primary immunodeficiency,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.79,Italy,Validated,22288591[PMID]
14933,101997,Primary immunodeficiency,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.38,Germany,Validated,22288591[PMID]
14933,101997,Primary immunodeficiency,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,2.0,Turkey,Validated,22288591[PMID]
14933,101997,Primary immunodeficiency,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.33,Poland,Validated,22288591[PMID]
14933,101997,Primary immunodeficiency,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,5.6,Australia,Not yet validated,17588141[PMID]
14933,101997,Primary immunodeficiency,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,4.9,New Zealand,Validated,17588141[PMID]
14933,101997,Primary immunodeficiency,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.1,"Korea, Republic of",Validated,22787376[PMID]
14933,101997,Primary immunodeficiency,Category,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,4.5,Oman,Validated,23268475[PMID]
14865,101685,Rare non-syndromic intellectual disability,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
14865,101685,Rare non-syndromic intellectual disability,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
14895,101959,Chronic primary adrenal insufficiency,Category,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.4,Europe,Validated,[EXPERT]
14895,101959,Chronic primary adrenal insufficiency,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,14.0,Europe,Validated,12788587[PMID]_[EXPERT]
14826,101150,Autosomal recessive dopa-responsive dystonia,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,ORPHANET
14826,101150,Autosomal recessive dopa-responsive dystonia,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,ORPHANET
14822,101111,Spinocerebellar ataxia type 25,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,[EXPERT]
14822,101111,Spinocerebellar ataxia type 25,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
14823,101112,Spinocerebellar ataxia type 26,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,15732118[PMID]
14823,101112,Spinocerebellar ataxia type 26,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15732118[PMID]
14820,101109,Spinocerebellar ataxia type 28,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14821,101110,Spinocerebellar ataxia type 20,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,[EXPERT]
14821,101110,Spinocerebellar ataxia type 20,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
14819,101108,Spinocerebellar ataxia type 23,Disease,Disorder,Cases/families,Family(ies),,4.0,Worldwide,Validated,[EXPERT]
14819,101108,Spinocerebellar ataxia type 23,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
14841,101330,Porphyria cutanea tarda,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.6,Europe,Validated,19233912[PMID]_9516680[PMID]_[EXPERT]_ORPHANET
14841,101330,Porphyria cutanea tarda,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,4.0,Europe,Validated,[EXPERT]
14841,101330,Porphyria cutanea tarda,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.0,Norway,Validated,19233912[PMID]
14841,101330,Porphyria cutanea tarda,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,Sweden,Validated,16191856[PMID]
14796,101085,Charcot-Marie-Tooth disease type 1F,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_20301366[PMID]
14792,101081,Charcot-Marie-Tooth disease type 1A,Disease,Disorder,Point prevalence,Value and class,6-9 / 10 000,82.37,Norway,Validated,20482598[PMID]_24646194[PMID]
14792,101081,Charcot-Marie-Tooth disease type 1A,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,15.2,United Kingdom,Validated,21984771[PMID]
14792,101081,Charcot-Marie-Tooth disease type 1A,Disease,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Worldwide,Validated,ORPHANET_20301384[PMID]
14793,101082,Charcot-Marie-Tooth disease type 1B,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Worldwide,Validated,ORPHANET_20301384[PMID]
14794,101083,Charcot-Marie-Tooth disease type 1C,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
14788,101077,X-linked Charcot-Marie-Tooth disease type 3,Disease,Disorder,Cases/families,Family(ies),,4.0,Worldwide,Validated,18458969[PMID]
14788,101077,X-linked Charcot-Marie-Tooth disease type 3,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18458969[PMID]
14789,101078,X-linked Charcot-Marie-Tooth disease type 4,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,23217327[PMID]
14789,101078,X-linked Charcot-Marie-Tooth disease type 4,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23217327[PMID]
14786,101075,X-linked Charcot-Marie-Tooth disease type 1,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,20301548[PMID]
14787,101076,X-linked Charcot-Marie-Tooth disease type 2,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,1557086[PMID]_1674639[PMID]
14787,101076,X-linked Charcot-Marie-Tooth disease type 2,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_1557086[PMID]_1674639[PMID]
14813,101102,Charcot-Marie-Tooth disease type 2H,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,11166163[PMID]
14813,101102,Charcot-Marie-Tooth disease type 2H,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11166163[PMID]
14812,101101,Charcot-Marie-Tooth disease type 2B2,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,11112660[PMID]
14812,101101,Charcot-Marie-Tooth disease type 2B2,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11112660[PMID]
14808,101097,Autosomal recessive Charcot-Marie-Tooth disease with hoarseness,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14752,101041,Familial hypofibrinogenemia,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14757,101046,Autosomal dominant epilepsy with auditory features,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_20301709[PMID]
14779,101068,Congenital stromal corneal dystrophy,Disease,Disorder,Cases/families,Family(ies),,6.0,Worldwide,Validated,24413633[PMID]_20301741[PMID]
14779,101068,Congenital stromal corneal dystrophy,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24413633[PMID]_20301741[PMID]
14720,101009,Autosomal dominant spastic paraplegia type 29,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,16130112[PMID]
14720,101009,Autosomal dominant spastic paraplegia type 29,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16130112[PMID]
14721,101010,Autosomal spastic paraplegia type 30,Disease,Disorder,Cases/families,Family(ies),,3.0,Worldwide,Validated,22258533[PMID]
14721,101010,Autosomal spastic paraplegia type 30,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22258533[PMID]
14722,101011,Autosomal dominant spastic paraplegia type 31,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14727,101016,Romano-Ward syndrome,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,40.0,Europe,Validated,[EXPERT]
14750,101039,Female restricted epilepsy with intellectual disability,Disease,Disorder,Cases/families,Family(ies),,5.0,Worldwide,Validated,18234694[PMID]_20830798[PMID]
14750,101039,Female restricted epilepsy with intellectual disability,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18234694[PMID]_20830798[PMID]
14739,101028,Transaldolase deficiency,Disease,Disorder,Cases/families,Case(s),,23.0,Worldwide,Validated,23315216[PMID]
14739,101028,Transaldolase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23315216[PMID]
14695,100984,Autosomal dominant spastic paraplegia type 3,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.14,Portugal,Validated,23609960[PMID]
14695,100984,Autosomal dominant spastic paraplegia type 3,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,20862796[PMID]_8649538[PMID]_23609960[PMID]
14691,100980,Autosomal dominant pure spastic paraplegia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,4.4,Norway,Not yet validated,22554690[PMID]_ORPHANET
14691,100980,Autosomal dominant pure spastic paraplegia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 1 000 000,0.9,Ireland,Validated,22554690[PMID]
14691,100980,Autosomal dominant pure spastic paraplegia,Clinical group,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
14690,100979,Autosomal dominant complex spastic paraplegia,Clinical group,Group of disorders,Point prevalence,Value and class,1-9 / 100 000,1.0,Norway,Validated,19339254[PMID]
14690,100979,Autosomal dominant complex spastic paraplegia,Clinical group,Group of disorders,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
14689,100978,Cloverleaf skull-asphyxiating thoracic dysplasia syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3499843[PMID]
14702,100991,Autosomal dominant spastic paraplegia type 10,Disease,Disorder,Cases/families,Family(ies),,10.0,Worldwide,Validated,ORPHANET
14702,100991,Autosomal dominant spastic paraplegia type 10,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
14700,100989,Autosomal dominant spastic paraplegia type 8,Disease,Disorder,Cases/families,Family(ies),,10.0,Worldwide,Validated,ORPHANET
14700,100989,Autosomal dominant spastic paraplegia type 8,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
14699,100988,Autosomal dominant spastic paraplegia type 6,Disease,Disorder,Cases/families,Family(ies),,10.0,Worldwide,Validated,ORPHANET
14699,100988,Autosomal dominant spastic paraplegia type 6,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
14697,100986,Autosomal recessive spastic paraplegia type 5A,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
14696,100985,Autosomal dominant spastic paraplegia type 4,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.91,Portugal,Validated,23609960[PMID]
14710,100999,Autosomal dominant spastic paraplegia type 19,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,12112072[PMID]
14710,100999,Autosomal dominant spastic paraplegia type 19,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12112072[PMID]
14711,101000,Autosomal recessive spastic paraplegia type 20,Disease,Disorder,Cases/families,Case(s),,36.0,Worldwide,Validated,28679690[PMID]
14711,101000,Autosomal recessive spastic paraplegia type 20,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28679690[PMID]
14708,100997,X-linked spastic paraplegia type 16,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,9254866[PMID]
14708,100997,X-linked spastic paraplegia type 16,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9254866[PMID]
14709,100998,Autosomal dominant spastic paraplegia type 17,Disease,Disorder,Cases/families,Family(ies),,20.0,Worldwide,Validated,ORPHANET
14709,100998,Autosomal dominant spastic paraplegia type 17,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
14706,100995,Autosomal recessive spastic paraplegia type 14,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,10877981[PMID]
14706,100995,Autosomal recessive spastic paraplegia type 14,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10877981[PMID]
14707,100996,Autosomal recessive spastic paraplegia type 15,Disease,Disorder,Cases/families,Family(ies),,10.0,Worldwide,Validated,ORPHANET
14707,100996,Autosomal recessive spastic paraplegia type 15,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
14704,100993,Autosomal dominant spastic paraplegia type 12,Disease,Disorder,Cases/families,Case(s),,27.0,Worldwide,Validated,22232211[PMID]
14704,100993,Autosomal dominant spastic paraplegia type 12,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22232211[PMID]
14705,100994,Autosomal dominant spastic paraplegia type 13,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,10677329[PMID]
14705,100994,Autosomal dominant spastic paraplegia type 13,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10677329[PMID]
14718,101007,Autosomal recessive spastic paraplegia type 27,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,15455396[PMID]_16511635[PMID]_20301682[PMID]
14718,101007,Autosomal recessive spastic paraplegia type 27,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15455396[PMID]_16511635[PMID]
14719,101008,Autosomal recessive spastic paraplegia type 28,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,27216551[PMID]
14719,101008,Autosomal recessive spastic paraplegia type 28,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27216551[PMID]
14716,101005,Autosomal recessive spastic paraplegia type 25,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,12070243[PMID]
14716,101005,Autosomal recessive spastic paraplegia type 25,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12070243[PMID]
14717,101006,Autosomal recessive spastic paraplegia type 26,Disease,Disorder,Cases/families,Family(ies),,10.0,Worldwide,Validated,24103911[PMID]_23746551[PMID]_24283893[PMID]
14717,101006,Autosomal recessive spastic paraplegia type 26,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24103911[PMID]_23746551[PMID]_24283893[PMID]
14714,101003,Autosomal recessive spastic paraplegia type 23,Disease,Disorder,Cases/families,Family(ies),,5.0,Worldwide,Validated,7294071[PMID]_6264350[PMID]_6886718[PMID]_4061404[PMID]_12868479[PMID]
14714,101003,Autosomal recessive spastic paraplegia type 23,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_7294071[PMID]_6264350[PMID]_6886718[PMID]_4061404[PMID]_12868479[PMID]
14715,101004,Autosomal recessive spastic paraplegia type 24,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,12499481[PMID]
14715,101004,Autosomal recessive spastic paraplegia type 24,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12499481[PMID]
14712,101001,Autosomal recessive spastic paraplegia type 21,Disease,Disorder,Cases/families,Case(s),,35.0,Worldwide,Validated,6024251[PMID]_6024251[PMID]_14564668[PMID]_24451228[PMID]
14712,101001,Autosomal recessive spastic paraplegia type 21,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_6024251[PMID]_14564668[PMID]_24451228[PMID]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.65,Europe,Not yet validated,22033323[PMID]_23894154[PMID]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Lifetime Prevalence,Value and class,6-9 / 10 000,61.7,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,12.2,United States,Validated,National Cancer Institute 2010[INST]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.1,Worldwide,Validated,World Health Organization 2008[INST]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Point prevalence,Value and class,1-5 / 10 000,12.7,Worldwide,Validated,World Health Organization 2008[INST]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.733,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Annual incidence,Value and class,1-5 / 10 000,12.86,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,7.679,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.74,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.921,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,8.329,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,6.382,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.803,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,6.375,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.526,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.45,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.563,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,7.905,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,6.344,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.472,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,4.488,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,8.628,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.991,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.649,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.162,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,6.39,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14660,100088,Rare thyroid carcinoma,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,2.373,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14657,100085,Primary hepatic neuroendocrine carcinoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.2,Worldwide,Validated,8227395[PMID]_24944650[PMID]_ [EXPERT]
14657,100085,Primary hepatic neuroendocrine carcinoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
14659,100087,Rare thyroid tumor,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,3.2,Worldwide,Not yet validated,21513910[PMID]_ORPHANET
14659,100087,Rare thyroid tumor,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.0,Europe,Not yet validated,21513910[PMID]
14659,100087,Rare thyroid tumor,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.7,Italy,Not yet validated,23518150[PMID]_ORPHANET
14659,100087,Rare thyroid tumor,Category,Group of disorders,Annual incidence,Value and class,1-9 / 100 000,5.35,France,Not yet validated,21513910[PMID]_ORPHANET
14678,100924,Porphyria due to ALA dehydratase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
14684,100973,FRAXE intellectual disability,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
14685,100974,FRAXF syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14687,100976,Bathing suit ichthyosis,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,[EXPERT]
14687,100976,Bathing suit ichthyosis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
14627,100054,F12-related hereditary angioedema with normal C1Inh,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14624,100051,Hereditary angioedema type 2,Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
14630,100057,Renin-angiotensin-aldosterone system-blocker-induced angioedema,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14643,100070,Progressive non-fluent aphasia,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,2.5,Europe,Validated,22608668[PMID]_European Medicines Agency 2010[INST]
14643,100070,Progressive non-fluent aphasia,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.7,Europe,Not yet validated,22608668[PMID]
14646,100073,Neurogenic thoracic outlet syndrome,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14647,100075,Neuroendocrine tumor of stomach,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,3.2,Europe,Validated,25480460[PMID]
14647,100075,Neuroendocrine tumor of stomach,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.7,United States,Validated,25480460[PMID]
14647,100075,Neuroendocrine tumor of stomach,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.7,United Kingdom,Validated,25480460[PMID]
14647,100075,Neuroendocrine tumor of stomach,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.5,Japan,Validated,25480460[PMID]
14644,100071,Mosaic trisomy 3 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,15386452[PMID]
14644,100071,Mosaic trisomy 3 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15386452[PMID]
14593,100020,Myelodysplastic neoplasm with increased blasts type 2,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14592,100019,Myelodysplastic neoplasm with increased blasts type 1,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14595,100022,Extramedullary soft tissue plasmacytoma,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,United States,Validated,19016727[PMID]_SEER Surveillance Epidemiology and End Results 1992-2004[INST]
14594,100021,Primary plasmacytoma of the bone,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.15,United States,Validated,19016727[PMID]_SEER Surveillance Epidemiology and End Results 1992-2004[INST]
14597,100024,Mu-heavy chain disease,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,35.0,Worldwide,Validated,[EXPERT]
14597,100024,Mu-heavy chain disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
14599,100026,Gamma-heavy chain disease,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,120.0,Worldwide,Validated,[EXPERT]
14599,100026,Gamma-heavy chain disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
14598,100025,Alpha-heavy chain disease,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,400.0,Worldwide,Validated,[EXPERT]
14598,100025,Alpha-heavy chain disease,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
14616,100043,Autosomal dominant intermediate Charcot-Marie-Tooth disease type A,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,11533914[PMID]
14616,100043,Autosomal dominant intermediate Charcot-Marie-Tooth disease type A,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11533914[PMID]
14617,100044,Autosomal dominant intermediate Charcot-Marie-Tooth disease type B,Disease,Disorder,Cases/families,Case(s),,37.0,Worldwide,Validated,19502294[PMID]
14617,100044,Autosomal dominant intermediate Charcot-Marie-Tooth disease type B,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_19502294[PMID]
14618,100045,Autosomal dominant intermediate Charcot-Marie-Tooth disease type C,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16429158[PMID]_24354524[PMID]
14618,100045,Autosomal dominant intermediate Charcot-Marie-Tooth disease type C,Disease,Disorder,Cases/families,Case(s),,35.0,Worldwide,Validated,16429158[PMID]_24354524[PMID]
14619,100046,Autosomal dominant intermediate Charcot-Marie-Tooth disease type D,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10406984[PMID]
14619,100046,Autosomal dominant intermediate Charcot-Marie-Tooth disease type D,Disease,Disorder,Cases/families,Case(s),,12.0,Worldwide,Validated,10406984[PMID]
14623,100050,Hereditary angioedema type 1,Etiological subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,1.54,Italy,Validated,25758562[PMID]_[EXPERT]
14623,100050,Hereditary angioedema type 1,Etiological subtype,Subtype of disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
14585,100012,Lissencephaly with cerebellar hypoplasia type B,Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,11748497[PMID]
14585,100012,Lissencephaly with cerebellar hypoplasia type B,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11748497[PMID]
14586,100013,Lissencephaly with cerebellar hypoplasia type C,Malformation syndrome,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,10594886[PMID]_11748497[PMID]
14586,100013,Lissencephaly with cerebellar hypoplasia type C,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11748497[PMID]
14581,100008,ACys amyloidosis,Clinical subtype,Subtype of disorder,Cases/families,Family(ies),,9.0,Worldwide,Validated,[EXPERT]
14581,100008,ACys amyloidosis,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
14579,100006,"ABeta amyloidosis, Dutch type",Clinical subtype,Subtype of disorder,Cases/families,Case(s),,250.0,Worldwide,Validated,[EXPERT]
14579,100006,"ABeta amyloidosis, Dutch type",Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
14568,99995,Complex regional pain syndrome type 1,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 100 000,5.46,United States,Validated,12749974[PMID]
14568,99995,Complex regional pain syndrome type 1,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-5 / 10 000,20.57,United States,Validated,12749974[PMID]
14567,99994,Complex regional pain syndrome type 2,Clinical subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.82,United States,Validated,12749974[PMID]
14567,99994,Complex regional pain syndrome type 2,Clinical subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
14562,99989,Intermediate DEND syndrome,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14554,99981,Apnea of prematurity,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,8.5,Europe,Validated,European Medicines Agency 2003[INST]
14551,99978,Klatskin tumor,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.5,United States,Not yet validated,19638920[PMID]_ORPHANET
14551,99978,Klatskin tumor,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Not yet validated,ORPHANET
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.357,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,22033323[PMID]_[EXPERT]_RARECARE surveillance of rare cancers in Europe[REG]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Lifetime Prevalence,Value and class,1-9 / 100 000,5.42,Europe,Validated,22033323[PMID]_[EXPERT]_RARECARE surveillance of rare cancers in Europe[REG]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.2,Worldwide,Validated,25320104[PMID]_WHO World Health Organization (GLOBOCAN 2012)[INST]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.026,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.881,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.801,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.79,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.315,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.122,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.325,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.069,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.172,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.215,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.443,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.623,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.896,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.922,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.256,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.706,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.996,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.734,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.866,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.234,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.544,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.778,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.139,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14550,99977,Squamous cell carcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,4.186,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.264,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,22033323[PMID]_[EXPERT]_RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Lifetime Prevalence,Value and class,1-9 / 100 000,5.55,Europe,Validated,22033323[PMID]_[EXPERT]_RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.7,Worldwide,Validated,25320104[PMID]_WHO World Health Organization (GLOBOCAN 2012)[INST]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.235,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.918,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.364,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.485,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.28,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.305,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.5,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.681,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.636,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.471,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,3.736,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.947,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.39,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.526,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.319,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.315,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.829,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.578,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.651,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.612,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,5.196,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,6.592,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.848,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14549,99976,Adenocarcinoma of the esophagus,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.178,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14544,99971,Well-differentiated liposarcoma,Histopathological subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.51,Europe,Validated,22517534[PMID]_[EXPERT]
14544,99971,Well-differentiated liposarcoma,Histopathological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14542,99969,Pleomorphic liposarcoma,Histopathological subtype,Subtype of disorder,Annual incidence,Value and class,<1 / 1 000 000,0.05,Europe,Validated,22517534[PMID]_[EXPERT]
14542,99969,Pleomorphic liposarcoma,Histopathological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14543,99970,Dedifferentiated liposarcoma,Histopathological subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.27,Europe,Validated,22517534[PMID]_[EXPERT]
14543,99970,Dedifferentiated liposarcoma,Histopathological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14540,99967,Myxoid/round cell liposarcoma,Histopathological subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,22517534[PMID]_[EXPERT]
14540,99967,Myxoid/round cell liposarcoma,Histopathological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14539,99966,Atypical teratoid rhabdoid tumor,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,20737418[PMID]_19707161[PMID]_22988546[PMID]
14539,99966,Atypical teratoid rhabdoid tumor,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.38,Austria,Validated,[EXPERT]
31747,643549,Hao-Fountain syndrome,Disease,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,26365382[PMID]_30679821[PMID]_35627274[PMID]
31747,643549,Hao-Fountain syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,26365382[PMID]_30679821[PMID]_35627274[PMID]_ORPHANET
14528,99955,Charcot-Marie-Tooth disease type 4B1,Disease,Disorder,Cases/families,Family(ies),,11.0,Worldwide,Validated,20301641[PMID]_DOI: 10.1016/j.nmd.2015.06.356[OTHER]
14528,99955,Charcot-Marie-Tooth disease type 4B1,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_20301641[PMID]_DOI: 10.1016/j.nmd.2015.06.356[OTHER]
14529,99956,Charcot-Marie-Tooth disease type 4B2,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14521,99948,Charcot-Marie-Tooth disease type 4A,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14520,99947,Autosomal dominant Charcot-Marie-Tooth disease type 2A2,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,21715711[PMID]_21715704[PMID]
14523,99950,Charcot-Marie-Tooth disease type 4D,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
14522,99949,Charcot-Marie-Tooth disease type 4C,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14525,99952,Charcot-Marie-Tooth disease type 4F,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
14527,99954,Charcot-Marie-Tooth disease type 4H,Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,23770104[PMID]_26400421[PMID]
14527,99954,Charcot-Marie-Tooth disease type 4H,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_23770104[PMID]_26400421[PMID]
14526,99953,Charcot-Marie-Tooth disease type 4G,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14526,99953,Charcot-Marie-Tooth disease type 4G,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,10.0,Czech Republic,Validated,26822750[PMID]
14513,99940,Autosomal dominant Charcot-Marie-Tooth disease type 2F,Disease,Disorder,Cases/families,Family(ies),,5.0,Worldwide,Validated,16087758[PMID]
14513,99940,Autosomal dominant Charcot-Marie-Tooth disease type 2F,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_16087758[PMID]
14512,99939,Autosomal dominant Charcot-Marie-Tooth disease type 2E,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_20301366[PMID]
14514,99941,Autosomal dominant Charcot-Marie-Tooth disease type 2G,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,3022865[PMID]
14514,99941,Autosomal dominant Charcot-Marie-Tooth disease type 2G,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_3022865[PMID]
14517,99944,Autosomal dominant Charcot-Marie-Tooth disease type 2K,Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,18231710[PMID]_19089472[PMID]_20685671[PMID]_21753178[PMID]
14517,99944,Autosomal dominant Charcot-Marie-Tooth disease type 2K,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_18231710[PMID]_19089472[PMID]_20685671[PMID]_21753178[PMID]
14519,99946,Autosomal dominant Charcot-Marie-Tooth disease type 2A1,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,9409358[PMID]
14519,99946,Autosomal dominant Charcot-Marie-Tooth disease type 2A1,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9409358[PMID]
14518,99945,Autosomal dominant Charcot-Marie-Tooth disease type 2L,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,15021985[PMID]
14518,99945,Autosomal dominant Charcot-Marie-Tooth disease type 2L,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15021985[PMID]
14504,99931,Idiopathic pulmonary hemosiderosis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.0425,Europe,Validated,[EXPERT]
14504,99931,Idiopathic pulmonary hemosiderosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
14511,99938,Autosomal dominant Charcot-Marie-Tooth disease type 2D,Disease,Disorder,Cases/families,Case(s),,44.0,Worldwide,Validated,8872480[PMID]_10732809[PMID]_9879677[PMID]_19329989[PMID]
14511,99938,Autosomal dominant Charcot-Marie-Tooth disease type 2D,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_8872480[PMID]_10732809[PMID]_9879677[PMID]_19329989[PMID]
14498,99925,Invasive mole,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14499,99926,Gestational choriocarcinoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
14499,99926,Gestational choriocarcinoma,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
14499,99926,Gestational choriocarcinoma,Disease,Disorder,Lifetime Prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
14500,99927,Hydatidiform mole,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
14500,99927,Hydatidiform mole,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
14501,99928,Placental site trophoblastic tumor,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.02,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14501,99928,Placental site trophoblastic tumor,Disease,Disorder,Lifetime Prevalence,Value and class,1-9 / 1 000 000,0.86,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
14501,99928,Placental site trophoblastic tumor,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
14491,99918,Streptococcal toxic-shock syndrome,Etiological subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,France,Validated,21976764[PMID]_Dr Lina Gérard[EXPERT]
14491,99918,Streptococcal toxic-shock syndrome,Etiological subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.2,United States,Validated,22534148[PMID]_Dr Lina Gérard[EXPERT]
14491,99918,Streptococcal toxic-shock syndrome,Etiological subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.33,Sweden,Validated,17638193[PMID]_Dr Lina Gérard[EXPERT]
14491,99918,Streptococcal toxic-shock syndrome,Etiological subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.23,Denmark,Validated,15815000[PMID]
14490,99917,"Theca steroid-producing cell malignant tumor of ovary, not further specified",Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14489,99916,Malignant Sertoli-Leydig cell tumor of the ovary,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14488,99915,Malignant granulosa cell tumor of the ovary,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.12,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14492,99919,Staphylococcal toxic-shock syndrome,Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14492,99919,Staphylococcal toxic-shock syndrome,Etiological subtype,Subtype of disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.58,United States,Validated,21860665[PMID]_24188357[PMID]
14485,99912,Ovarian dysgerminoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
14485,99912,Ovarian dysgerminoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.04,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14474,99901,Acyl-CoA dehydrogenase 9 deficiency,Disease,Disorder,Cases/families,Case(s),,23.0,Worldwide,Validated,24158852[PMID]_26669660[PMID]
14474,99901,Acyl-CoA dehydrogenase 9 deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_26669660[PMID]
14478,99905,Streptobacillary rat-bite fever,Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14476,99903,Spirillary rat-bite fever,Etiological subtype,Subtype of disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14465,99892,ACTH-dependent Cushing syndrome,Clinical group,Group of disorders,Annual incidence,Value and class,1-9 / 1 000 000,0.55,Worldwide,Not yet validated,20829610[PMID]_18226430[PMID]_15903005[PMID]
14465,99892,ACTH-dependent Cushing syndrome,Clinical group,Group of disorders,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14471,99898,Mendelian susceptibility to mycobacterial diseases due to complete IFNgammaR1 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25453225[PMID]
14471,99898,Mendelian susceptibility to mycobacterial diseases due to complete IFNgammaR1 deficiency,Disease,Disorder,Cases/families,Case(s),,31.0,Worldwide,Validated,25453225[PMID]
14452,99879,Familial isolated hyperparathyroidism,Disease,Disorder,Cases/families,Family(ies),,100.0,Worldwide,Validated,18084346[PMID]
14452,99879,Familial isolated hyperparathyroidism,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET_18084346[PMID]
14453,99880,Hyperparathyroidism-jaw tumor syndrome,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,25511968[PMID]
14453,99880,Hyperparathyroidism-jaw tumor syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_25511968[PMID]
14462,99889,Cushing syndrome due to ectopic ACTH secretion,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14458,99885,Isolated permanent neonatal diabetes mellitus,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.38,Europe,Validated,19499210[PMID]
14458,99885,Isolated permanent neonatal diabetes mellitus,Disease,Disorder,Point prevalence,Class only,1-9 / 1 000 000,0.0,Europe,Validated,19499210[PMID]_ORPHANET
14458,99885,Isolated permanent neonatal diabetes mellitus,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.38,United Kingdom,Validated,19499210[PMID]
14458,99885,Isolated permanent neonatal diabetes mellitus,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.38,Poland,Validated,19499210[PMID]
14458,99885,Isolated permanent neonatal diabetes mellitus,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.38,Netherlands,Validated,19499210[PMID]
14458,99885,Isolated permanent neonatal diabetes mellitus,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.46,Slovakia,Validated,17213273[PMID]
14458,99885,Isolated permanent neonatal diabetes mellitus,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.4,United States,Validated,23050777[PMID]
14458,99885,Isolated permanent neonatal diabetes mellitus,Disease,Disorder,Prevalence at birth,Value and class,1-5 / 10 000,18.0,Oman,Validated,10798084[PMID]
14459,99886,Transient neonatal diabetes mellitus,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 1 000 000,0.3,Europe,Validated,[EXPERT]
14459,99886,Transient neonatal diabetes mellitus,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,ORPHANET
14438,99865,Spermatocytic seminoma,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.03,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
14438,99865,Spermatocytic seminoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Not yet validated,ORPHANET
14441,99868,Thymic carcinoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
14440,99867,Thymoma,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.14,Europe,Validated,[EXPERT]_RARECARE surveillance of rare cancers in Europe 2011[REG]
14440,99867,Thymoma,Disease,Disorder,Lifetime Prevalence,Value and class,1-9 / 100 000,1.22,Europe,Validated,22033323[PMID]_[EXPERT]_RARECARE surveillance of rare cancers in Europe[REG]
14440,99867,Thymoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14442,99869,Thymic neuroendocrine carcinoma,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
14422,99849,Glycogen storage disease due to muscle beta-enolase deficiency,Disease,Disorder,Cases/families,Case(s),,1.0,Worldwide,Validated,11506403[PMID]
14422,99849,Glycogen storage disease due to muscle beta-enolase deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_11506403[PMID]
14418,99845,Genetic recurrent myoglobinuria,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14419,99846,Autosomal dominant myoglobinuria,Disease,Disorder,Cases/families,Family(ies),,2.0,Worldwide,Validated,9098484[PMID]
14419,99846,Autosomal dominant myoglobinuria,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_9098484[PMID]
14416,99843,Leukocyte adhesion deficiency type II,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,24403049[PMID]
14416,99843,Leukocyte adhesion deficiency type II,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24403049[PMID]
14417,99844,Leukocyte adhesion deficiency type III,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,40.0,Worldwide,Validated,28827066[PMID]
14417,99844,Leukocyte adhesion deficiency type III,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_28827066[PMID]
14426,99853,Ovarioleukodystrophy,Clinical subtype,Subtype of disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,24808023[PMID]_12707859[PMID]_9153528[PMID]
14426,99853,Ovarioleukodystrophy,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_24808023[PMID]_12707859[PMID]_9153528[PMID]
14425,99852,Ravine syndrome,Disease,Disorder,Cases/families,Case(s),,38.0,Worldwide,Validated,10429812[PMID]
14425,99852,Ravine syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_10429812[PMID]
14405,99832,Resistance to thyrotropin-releasing hormone syndrome,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,19213692[PMID]
14405,99832,Resistance to thyrotropin-releasing hormone syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,19213692[PMID]
14402,99829,Yellow fever,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14402,99829,Yellow fever,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Europe,Validated,European Centre for Disease prevention and Control 2017[INST]
14401,99828,Dengue fever,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14401,99828,Dengue fever,Disease,Disorder,Annual incidence,Value and class,>1 / 1000,714.0,Worldwide,Validated,22494122[PMID]
14401,99828,Dengue fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.5,Europe,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
14401,99828,Dengue fever,Disease,Disorder,Point prevalence,Class only,1-9 / 100 000,0.0,Europe,Validated,European Medicines Agency 2015[INST]
14401,99828,Dengue fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.14,Austria,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
14401,99828,Dengue fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.98,Belgium,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
14401,99828,Dengue fever,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.033,Croatia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
14401,99828,Dengue fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.58,Estonia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
14401,99828,Dengue fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.98,Finland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
14401,99828,Dengue fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.36,France,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
14401,99828,Dengue fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.96,Germany,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
14401,99828,Dengue fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.14,Hungary,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
14401,99828,Dengue fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.32,Ireland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
14401,99828,Dengue fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.14,Italy,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
14401,99828,Dengue fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.34,Latvia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
14401,99828,Dengue fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.15,Lithuania,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
14401,99828,Dengue fever,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.04,Luxembourg,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
14401,99828,Dengue fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.22,Malta,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
14401,99828,Dengue fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.1,Portugal,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
14401,99828,Dengue fever,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.07,Slovakia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
14401,99828,Dengue fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.22,Slovenia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
14401,99828,Dengue fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.26,Spain,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
14401,99828,Dengue fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.7,Sweden,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
14401,99828,Dengue fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.72,United Kingdom,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
14401,99828,Dengue fever,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.26,Norway,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
14401,99828,Dengue fever,Disease,Disorder,Annual incidence,Class only,<1 / 1 000 000,0.0,Greece,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
14400,99827,Crimean-Congo hemorrhagic fever,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14400,99827,Crimean-Congo hemorrhagic fever,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,European Medicines Agency 2018[INST]
14415,99842,Leukocyte adhesion deficiency type I,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1,Europe,Validated,[EXPERT]
14385,99812,LIG4 syndrome,Disease,Disorder,Cases/families,Case(s),,28.0,Worldwide,Validated,27717373[PMID]
14385,99812,LIG4 syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_27717373[PMID]
14397,99824,Lassa fever,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14397,99824,Lassa fever,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Validated,European Medicines Agency 2018[INST]
14398,99825,Nipah virus disease,Disease,Disorder,Cases/families,Case(s),,556.0,Worldwide,Validated,[EXPERT]_World Health Organization[INST]
14398,99825,Nipah virus disease,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
14399,99826,Marburg hemorrhagic fever,Disease,Disorder,Cases/families,Case(s),,500.0,Worldwide,Validated,[EXPERT]
14399,99826,Marburg hemorrhagic fever,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
14371,99798,Oligodontia,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14375,99802,Hemimegalencephaly,Malformation syndrome,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
14376,99803,Haddad syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,ORPHANET
14376,99803,Haddad syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
14379,99806,Oculootodental syndrome,Malformation syndrome,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,12147582[PMID]
14379,99806,Oculootodental syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_12147582[PMID]
14380,99807,PEHO-like syndrome,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,8723564[PMID]_12868478[PMID]_12949965[PMID]_15968934[PMID]_22408680[PMID]_12818526[PMID
14380,99807,PEHO-like syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_15968934[PMID]_22408680[PMID]
14383,99810,Familial porencephaly,Etiological subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Europe,Not yet validated,ORPHANET
14362,99789,Dentin dysplasia type I,Clinical subtype,Subtype of disorder,Point prevalence,Value and class,1-9 / 100 000,1.0,Europe,Validated,17452557[PMID]_[EXPERT]
14364,99791,Dentin dysplasia type II,Clinical subtype,Subtype of disorder,Cases/families,Family(ies),,19.0,Worldwide,Validated,10397672[PMID]
14364,99791,Dentin dysplasia type II,Clinical subtype,Subtype of disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
14365,99792,Dentin dysplasia-sclerotic bones syndrome,Disease,Disorder,Cases/families,Family(ies),,1.0,Worldwide,Validated,264650[PMID]
14365,99792,Dentin dysplasia-sclerotic bones syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_264650[PMID]
14345,99772,Cleft velum,Morphological anomaly,Disorder,Point prevalence,Class only,1-5 / 10 000,0.0,Europe,Not yet validated,ORPHANET
14344,99771,Bifid uvula,Morphological anomaly,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Not yet validated,ORPHANET
14349,99776,Mosaic trisomy 9 syndrome,Malformation syndrome,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,22249800[PMID]
14349,99776,Mosaic trisomy 9 syndrome,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET_22249800[PMID]
31580,631073,Autosomal recessive spastic paraplegia type 82,Disease,Disorder,Cases/families,Case(s),,5.0,Worldwide,Validated,31637422[PMID]
31580,631073,Autosomal recessive spastic paraplegia type 82,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,31637422[PMID]_ORPHANET
31581,631076,Autosomal recessive spastic paraplegia type 83,Disease,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,32707086[PMID]_33188300[PMID]_33970200[PMID]
31581,631076,Autosomal recessive spastic paraplegia type 83,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,32707086[PMID]_33188300[PMID]_33970200[PMID]_ORPHANET
31582,631079,Autosomal recessive spastic paraplegia type 84,Disease,Disorder,Cases/families,Case(s),,2.0,Worldwide,Validated,34415322[PMID]
31582,631079,Autosomal recessive spastic paraplegia type 84,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,34415322[PMID]_ORPHANET
31583,631082,Autosomal recessive spastic paraplegia type 85,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,31636353[PMID]
31583,631082,Autosomal recessive spastic paraplegia type 85,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,31636353[PMID]_ORPHANET
31579,631068,Autosomal dominant spastic paraplegia type 80,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,30929741[PMID]_ 31203368[PMID]
31579,631068,Autosomal dominant spastic paraplegia type 80,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,30929741[PMID]_ 31203368[PMID]_ORPHANET
31591,631106,Spinocerebellar ataxia type 49,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,35310830[PMID]
31591,631106,Spinocerebellar ataxia type 49,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,35310830[PMID]_ORPHANET
31590,631103,Spinocerebellar ataxia type 48,Disease,Disorder,Cases/families,Case(s),,50.0,Worldwide,Validated,34070858[PMID]
31590,631103,Spinocerebellar ataxia type 48,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,34070858[PMID]_ORPHANET
31588,631095,Spinocerebellar ataxia type 44,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,28886343[PMID]
31588,631095,Spinocerebellar ataxia type 44,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,28886343[PMID]_ORPHANET
31585,631088,Autosomal recessive spastic paraplegia type 87,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,35718349[PMID]
31585,631088,Autosomal recessive spastic paraplegia type 87,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,35718349[PMID]_ORPHANET
31584,631085,Autosomal recessive spastic paraplegia type 86,Disease,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,34866177[PMID]_34489854[PMID]_34587489[PMID]
31584,631085,Autosomal recessive spastic paraplegia type 86,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,34866177[PMID]_34489854[PMID]_34587489[PMID]_ORPHANET
31592,631248,Mitchell Syndrome,Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,32169171[PMID]
31592,631248,Mitchell Syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,32169171[PMID] _ORPHANET
31692,634475,Mosaic NF2-related schwannomatosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,35674741[PMID]_ORPHANET
31693,634492,Mosaic schwannomatosis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,29909380[PMID]_ORPHANET
31693,634492,Mosaic schwannomatosis,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.7928,United Kingdom,Validated,29909380[PMID]
31693,634492,Mosaic schwannomatosis,Disease,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.4502,United Kingdom,Validated,29909380[PMID]
31691,634461,Mosaic neurofibromatosis type 1,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,20301288[PMID]_29215653[PMID]
31691,634461,Mosaic neurofibromatosis type 1,Disease,Disorder,Point prevalence,Value and class,1-5 / 10 000,24.4618,Finland,Validated,29215653[PMID]_ORPHANET
31680,633228,Isolated proximal femoral focal deficiency,Morphological anomaly,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.55,Worldwide,Validated,32019581[PMID]_ORPHANET
31680,633228,Isolated proximal femoral focal deficiency,Morphological anomaly,Disorder,Prevalence at birth,Value and class,1-9 / 100 000,1.55,Worldwide,Validated,32019581[PMID]_ORPHANET
31705,637064,Isolated optic nerve aplasia,Morphological anomaly,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,29676329[PMID]
31705,637064,Isolated optic nerve aplasia,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,29676329[PMID]_ORPHANET
31704,637061,Isolated optic nerve hypoplasia,Morphological anomaly,Disorder,Cases/families,Case(s),,25.0,Worldwide,Validated,24082663[PMID]
31704,637061,Isolated optic nerve hypoplasia,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,24082663[PMID]_ORPHANET
31703,637051,Borna virus encephalitis,Disease,Disorder,Cases/families,Case(s),,18.0,Worldwide,Validated,31924550[PMID]
31703,637051,Borna virus encephalitis,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,31924550[PMID]_ORPHANET
31697,636945,Invasive candidiasis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,27394927[PMID]_32809459[PMID]_ORPHANET
31697,636945,Invasive candidiasis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,2.5,France,Validated,27394927[PMID]
31696,636941,Vascular Ehlers-Danlos-polymicrogyria syndrome,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,29499446[PMID]
31696,636941,Vascular Ehlers-Danlos-polymicrogyria syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,29499446[PMID]_ORPHANET
31699,636955,Endemic pemphigus foliaceus,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,34909708[PMID]
31699,636955,Endemic pemphigus foliaceus,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.4,Tunisia,Validated,34909708[PMID]
31698,636950,Glaucomatocyclitic crisis disease,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,35015437[PMID]_ORPHANET
31727,641829,Neonatal compartment syndrome,Clinical syndrome,Disorder,Cases/families,Case(s),,60.0,Worldwide,Validated,35415493[PMID]
31727,641829,Neonatal compartment syndrome,Clinical syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,35415493[PMID]_ORPHANET
31725,641496,Childhood-onset schizophrenia,Disease,Disorder,Annual incidence,Class only,1-5 / 10 000,0.0,Europe,Validated,22906158[PMID]_ORPHANET
31725,641496,Childhood-onset schizophrenia,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,22906158[PMID]_ORPHANET
31722,641390,PsAPASH syndrome,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,32942279[PMID]_ORPHANET
31722,641390,PsAPASH syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,32942279[PMID]_ORPHANET
31720,641380,PAPASH syndrome,Disease,Disorder,Cases/families,Case(s),,20.0,Worldwide,Validated,32942279[PMID]_35034021[PMID]
31720,641380,PAPASH syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,32942279[PMID]_35034021[PMID]_ORPHANET
31721,641385,PASS syndrome,Disease,Disorder,Cases/families,Case(s),,16.0,Worldwide,Validated,32942279[PMID]_ORPHANET
31721,641385,PASS syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,32942279[PMID]_ORPHANET
31716,641368,Autosomal recessive hyper-IgE syndrome due to ZNF341 deficiency,Disease,Disorder,Cases/families,Case(s),,61.0,Worldwide,Validated,30264496[PMID]
31716,641368,Autosomal recessive hyper-IgE syndrome due to ZNF341 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,30264496[PMID]_ORPHANET
31714,641353,Infantile neurodegeneration-progressive spasticity-intellectual disability-white matter lesions syndrome,Disease,Disorder,Cases/families,Case(s),,32.0,Worldwide,Validated,35985664[PMID]
31714,641353,Infantile neurodegeneration-progressive spasticity-intellectual disability-white matter lesions syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,35985664[PMID]_ORPHANET
31715,641361,Neurodevelopmental delay-hypotonia-cerebellar ataxia-cardiac conduction defects syndrome,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,34089229[PMID]
31715,641361,Neurodevelopmental delay-hypotonia-cerebellar ataxia-cardiac conduction defects syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,34089229[PMID]_ORPHANET
31713,641350,Immunotherapy induced hypophysitis,Disease,Disorder,Annual incidence,Value and class,1-5 / 10 000,12.8074,Europe,Validated,28702249[PMID]_34430146[PMID]
31713,641350,Immunotherapy induced hypophysitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Europe,Validated,28702249[PMID]_34430146[PMID]_ORPHANET
31731,642099,"Spondyloepimetaphyseal dysplasia with joint laxity, Beighton type",Disease,Disorder,Cases/families,Case(s),,30.0,Worldwide,Validated,27245527[PMID]
31731,642099,"Spondyloepimetaphyseal dysplasia with joint laxity, Beighton type",Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,27245527[PMID]_ORPHANET
31730,642085,EXOC6B-related spondyloepimetaphyseal dysplasia with joint laxity,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,36150098[PMID]
31730,642085,EXOC6B-related spondyloepimetaphyseal dysplasia with joint laxity,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,36150098[PMID]_ORPHANET
31660,633004,KDM3B-related intellectual disability-facial dysmorphism-short stature syndrome,Disease,Disorder,Cases/families,Case(s),,17.0,Worldwide,Validated,30929739[PMID]
31660,633004,KDM3B-related intellectual disability-facial dysmorphism-short stature syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,30929739[PMID]_ORPHANET
31661,633014,SLC12A2-related developmental delay-intellectual disability-sensorineural deafness syndrome,Disease,Disorder,Cases/families,Case(s),,13.0,Worldwide,Validated,34797034[PMID]
31661,633014,SLC12A2-related developmental delay-intellectual disability-sensorineural deafness syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,34797034[PMID]_ORPHANET
31676,633124,Invasive scopulariopsis infection,Disease,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.05,Europe,Validated,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2563
31664,633028,CPE-related Prader-Willi-like syndrome,Disease,Disorder,Cases/families,Case(s),,8.0,Worldwide,Validated,26120850[PMID]_32936766[PMID]_34383079[PMID]
31664,633028,CPE-related Prader-Willi-like syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,26120850[PMID]_32936766[PMID]_34383079[PMID]_ORPHANET
31322,615970,Chronic intervillositis of unknown etiology,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,32841927[PMID]_ORPHANET
31346,617408,Classic eosinophilic pustular folliculitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,37983361[PMID]_ORPHANET
31340,617304,Amniotic fluid embolism,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,United Kingdom,Validated,31714909[PMID]_ORPHANET
31337,617294,Twin anemia-polycythemia sequence,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,27068715[PMID]_ORPHANET
31339,617301,Selective intrauterine growth restriction,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,28532678[PMID]_ORPHANET
31338,617297,Twin-reversed arterial perfusion sequence,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,20522408[PMID]_ORPHANET
31449,621758,Fibrosis-neurodegeneration-cerebral angiomatosis syndrome,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,34165204[PMID]
31449,621758,Fibrosis-neurodegeneration-cerebral angiomatosis syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,34165204[PMID]_ORPHANET
31442,620371,Gitelman-like kidney tubulopathy due to mitochondrial DNA mutation,Disease,Disorder,Cases/families,Family(ies),,14.0,Worldwide,Validated,15498972[PMID]_34607911[PMID]
31442,620371,Gitelman-like kidney tubulopathy due to mitochondrial DNA mutation,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,15498972[PMID]_34607911[PMID]_ORPHANET
31441,620368,EGF-related primary hypomagnesemia with intellectual disability,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,33600043[PMID]
31441,620368,EGF-related primary hypomagnesemia with intellectual disability,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,33600043[PMID]_ORPHANET
31440,620363,Primary hypomagnesemia-generalized seizures-intellectual disability-obesity syndrome,Disease,Disorder,Cases/families,Case(s),,11.0,Worldwide,Validated,33600043[PMID]
31440,620363,Primary hypomagnesemia-generalized seizures-intellectual disability-obesity syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,33600043[PMID]_ORPHANET
31436,620205,Non-syndromic bicoronal and sagittal craniosynostosis,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
31437,620212,Non-syndromic pansynostosis,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
31434,620192,Non-syndromic metopic and sagittal craniosynostosis,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
31435,620198,Non-syndromic bicoronal and metopic craniosynostosis,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
31432,620178,Non-syndromic bilambdoid craniosynostosis,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
31433,620186,Non-syndromic unicoronal and sagittal craniosynostosis,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
31431,620158,Non-syndromic non-specific multisutural craniosynostosis,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
31428,620139,Non-syndromic unifrontosphenoidal craniosynostosis,Morphological anomaly,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.0136,Worldwide,Validated,29065043[PMID]_ORPHANET
31429,620146,Non-syndromic unisquamosal craniosynostosis,Morphological anomaly,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,ORPHANET
31426,620102,Non-syndromic unicoronal craniosynostosis,Morphological anomaly,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.1049,Worldwide,Validated,35636659[PMID]_38348760[PMID]_ORPHANET
31427,620113,Non-syndromic unilambdoid craniosynostosis,Morphological anomaly,Disorder,Point prevalence,Value and class,<1 / 1 000 000,0.0442,Worldwide,Validated,35636659[PMID]_ORPHANET
31477,624268,Non-specific autoimmune cerebellar ataxia without characteristic antibodies,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
31473,624199,Non-specific autoimmune brainstem encephalitis with characteristic antibodies,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
31472,624190,Paraneoplastic isolated brainstem encephalitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,34827413[PMID]_ORPHANET
31475,624244,Postinfectious cerebellitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,31515702[PMID]_ORPHANET
31475,624244,Postinfectious cerebellitis,Disease,Disorder,Annual incidence,Class only,Unknown,0.0,Worldwide,Validated,31515702[PMID]_ORPHANET
31474,624216,Non-specific autoimmune brainstem encephalitis without characteristic antibodies,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
31468,623789,Body integrity dysphoria,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.11,Worldwide,Validated,25108391[PMID] _34237024[PMID]
31469,623801,Acute flaccid myelitis,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,36268734[PMID]_ORPHANET
31469,623801,Acute flaccid myelitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 100 000,1.12,Australia,Validated,37817313[PMID]
31469,623801,Acute flaccid myelitis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.06,Netherlands,Validated,32628734[PMID]
31469,623801,Acute flaccid myelitis,Disease,Disorder,Annual incidence,Value and class,<1 / 1 000 000,0.04,United States,Validated,36268734[PMID]
31470,624166,Non-specific autoimmune supratentorial encephalitis with characteristic antibodies,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
31471,624178,Non-specific autoimmune supratentorial encephalitis without characteristic antibodies,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,ORPHANET
31464,623615,Autoimmune limbic encephalitis,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.7,Europe,Validated,31552550[PMID]_ORPHANET
31464,623615,Autoimmune limbic encephalitis,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.25,Europe,Validated,31552550[PMID]_ORPHANET
31465,623626,Paraneoplastic cerebellar degeneration,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.9553,Europe,Validated,31552550[PMID]_32847939[PMID]_ORPHANET
31465,623626,Paraneoplastic cerebellar degeneration,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.2225,Europe,Validated,31552550[PMID]_32847939[PMID]_ORPHANET
31465,623626,Paraneoplastic cerebellar degeneration,Disease,Disorder,Point prevalence,Value and class,1-9 / 1 000 000,0.6869,France,Validated,32847939[PMID]_ORPHANET
31465,623626,Paraneoplastic cerebellar degeneration,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.16,France,Validated,32847939[PMID]_ORPHANET
31465,623626,Paraneoplastic cerebellar degeneration,Disease,Disorder,Point prevalence,Value and class,1-9 / 100 000,1.2236,Italy,Validated,31552550[PMID]
31465,623626,Paraneoplastic cerebellar degeneration,Disease,Disorder,Annual incidence,Value and class,1-9 / 1 000 000,0.285,Italy,Validated,31552550[PMID]
31460,622925,X-linked severe syndromic thoracic aortic aneurysm and dissection,Malformation syndrome,Disorder,Cases/families,Case(s),,32.0,Worldwide,Validated,27632686[PMID]_34807424[PMID]
31460,622925,X-linked severe syndromic thoracic aortic aneurysm and dissection,Malformation syndrome,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,27632686[PMID]_34807424[PMID]_ORPHANET
31388,618891,Chronic neurovisceral acid sphingomyelinase deficiency,Disease,Disorder,Point prevalence,Class only,Unknown,0.0,Worldwide,Validated,20301544[PMID]_ORPHANET
31370,617910,Conjunctival malignant melanoma,Disease,Disorder,Cases/families,Case(s),,32.0,Worldwide,Validated,31768361[PMID]
31370,617910,Conjunctival malignant melanoma,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,31768361[PMID]_ORPHANET
31371,617916,Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia,Disease,Disorder,Cases/families,Case(s),,100.0,Worldwide,Validated,30593169[PMID]
31371,617916,Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,30593169[PMID]_ORPHANET
31372,617919,F12-associated cold autoinflammatory syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,31924766[PMID]
31372,617919,F12-associated cold autoinflammatory syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,31924766[PMID]_ORPHANET
31417,619941,Congenital neutropenia-combined immunodeficiency due to MKL1 deficiency,Disease,Disorder,Cases/families,Case(s),,3.0,Worldwide,Validated,32128589[PMID]
31417,619941,Congenital neutropenia-combined immunodeficiency due to MKL1 deficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,32128589[PMID]_ORPHANET
31416,619367,SAMD9L-associated autoinflammatory syndrome,Disease,Disorder,Cases/families,Case(s),,6.0,Worldwide,Validated,31874111[PMID]
31416,619367,SAMD9L-associated autoinflammatory syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,31874111[PMID]_ORPHANET
31419,619953,Familial hyperinflammatory lymphoproliferative immunodeficiency,Disease,Disorder,Cases/families,Case(s),,7.0,Worldwide,Validated,32646852[PMID]_32647003[PMID]_32766723[PMID]
31419,619953,Familial hyperinflammatory lymphoproliferative immunodeficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,32646852[PMID]_32647003[PMID]_32766723[PMID]_ORPHANET
31418,619948,Early-onset autoimmunity-autoinflammation-immunodeficiency syndrome due to SOCS1 haploinsufficiency,Disease,Disorder,Cases/families,Case(s),,10.0,Worldwide,Validated,34421895[PMID]
31418,619948,Early-onset autoimmunity-autoinflammation-immunodeficiency syndrome due to SOCS1 haploinsufficiency,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,34421895[PMID]_ORPHANET
31423,619979,Developmental delay-immunodeficiency-leukoencephalopathy-hypohomocysteinemia syndrome,Disease,Disorder,Cases/families,Case(s),,4.0,Worldwide,Validated,29018201[PMID]
31423,619979,Developmental delay-immunodeficiency-leukoencephalopathy-hypohomocysteinemia syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,29018201[PMID]_ORPHANET
31415,619363,NOCARH syndrome,Disease,Disorder,Cases/families,Case(s),,15.0,Worldwide,Validated,31271789[PMID]_37741518[PMID]
31415,619363,NOCARH syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,31271789[PMID]_37741518[PMID]_ORPHANET
31405,619233,Hereditary persistence of fetal hemoglobin-intellectual disability syndrome,Disease,Disorder,Cases/families,Case(s),,9.0,Worldwide,Validated,27453576[PMID]
31405,619233,Hereditary persistence of fetal hemoglobin-intellectual disability syndrome,Disease,Disorder,Point prevalence,Class only,<1 / 1 000 000,0.0,Worldwide,Validated,27453576[PMID]_ORPHANET
